Province, Autonomous City and Community of hospitalization;Main diagnosis (ICD-9-CM) reduced list;Sex;Total TOTAL NATIONAL;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;4.719.667 TOTAL NATIONAL;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;2.223.772 TOTAL NATIONAL;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;2.495.895 TOTAL NATIONAL;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;98.875 TOTAL NATIONAL;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;54.718 TOTAL NATIONAL;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;44.157 TOTAL NATIONAL;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;15.065 TOTAL NATIONAL;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;7.883 TOTAL NATIONAL;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;7.182 TOTAL NATIONAL;Group 0102 Imprecise intestinal infections 009;Both sexes;8.245 TOTAL NATIONAL;Group 0102 Imprecise intestinal infections 009;Men;3.980 TOTAL NATIONAL;Group 0102 Imprecise intestinal infections 009;Women;4.266 TOTAL NATIONAL;Group 0103 Tuberculosis 010-018, 137;Both sexes;3.711 TOTAL NATIONAL;Group 0103 Tuberculosis 010-018, 137;Men;2.374 TOTAL NATIONAL;Group 0103 Tuberculosis 010-018, 137;Women;1.337 TOTAL NATIONAL;Group 0104 Septicaemia 038;Both sexes;38.149 TOTAL NATIONAL;Group 0104 Septicaemia 038;Men;20.525 TOTAL NATIONAL;Group 0104 Septicaemia 038;Women;17.623 TOTAL NATIONAL;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;3.022 TOTAL NATIONAL;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;2.205 TOTAL NATIONAL;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;817 TOTAL NATIONAL;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;30.683 TOTAL NATIONAL;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;17.751 TOTAL NATIONAL;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;12.932 TOTAL NATIONAL;Group 0200 Neoplasms 140-239;Both sexes;453.632 TOTAL NATIONAL;Group 0200 Neoplasms 140-239;Men;238.329 TOTAL NATIONAL;Group 0200 Neoplasms 140-239;Women;215.302 TOTAL NATIONAL;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;46.296 TOTAL NATIONAL;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;27.941 TOTAL NATIONAL;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;18.355 TOTAL NATIONAL;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;34.201 TOTAL NATIONAL;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;27.060 TOTAL NATIONAL;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;7.141 TOTAL NATIONAL;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;8.741 TOTAL NATIONAL;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;5.055 TOTAL NATIONAL;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;3.686 TOTAL NATIONAL;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;34.831 TOTAL NATIONAL;Group 0204 Malignant neoplasm of breast 174-175;Men;295 TOTAL NATIONAL;Group 0204 Malignant neoplasm of breast 174-175;Women;34.535 TOTAL NATIONAL;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;9.185 TOTAL NATIONAL;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. TOTAL NATIONAL;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;9.185 TOTAL NATIONAL;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;5.041 TOTAL NATIONAL;Group 0206 Malignant neoplasm of ovary 1830;Men;.. TOTAL NATIONAL;Group 0206 Malignant neoplasm of ovary 1830;Women;5.041 TOTAL NATIONAL;Group 0207 Malignant neoplasm of prostate 185;Both sexes;17.477 TOTAL NATIONAL;Group 0207 Malignant neoplasm of prostate 185;Men;17.477 TOTAL NATIONAL;Group 0207 Malignant neoplasm of prostate 185;Women;.. TOTAL NATIONAL;Group 0208 Malignant neoplasm of bladder 188;Both sexes;41.509 TOTAL NATIONAL;Group 0208 Malignant neoplasm of bladder 188;Men;34.767 TOTAL NATIONAL;Group 0208 Malignant neoplasm of bladder 188;Women;6.742 TOTAL NATIONAL;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;159.368 TOTAL NATIONAL;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;93.231 TOTAL NATIONAL;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;66.137 TOTAL NATIONAL;Group 0210 Carcinoma in situ 230-234;Both sexes;7.579 TOTAL NATIONAL;Group 0210 Carcinoma in situ 230-234;Men;2.757 TOTAL NATIONAL;Group 0210 Carcinoma in situ 230-234;Women;4.822 TOTAL NATIONAL;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;5.268 TOTAL NATIONAL;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;3.196 TOTAL NATIONAL;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;2.072 TOTAL NATIONAL;Grupo 0212 Leiomyoma of uterus 218;Both sexes;22.395 TOTAL NATIONAL;Grupo 0212 Leiomyoma of uterus 218;Men;.. TOTAL NATIONAL;Grupo 0212 Leiomyoma of uterus 218;Women;22.395 TOTAL NATIONAL;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;61.742 TOTAL NATIONAL;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;26.549 TOTAL NATIONAL;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;35.193 TOTAL NATIONAL;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;42.532 TOTAL NATIONAL;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;20.959 TOTAL NATIONAL;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;21.573 TOTAL NATIONAL;Group 0301 Anaemias 280-285;Both sexes;24.892 TOTAL NATIONAL;Group 0301 Anaemias 280-285;Men;11.898 TOTAL NATIONAL;Group 0301 Anaemias 280-285;Women;12.994 TOTAL NATIONAL;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;17.640 TOTAL NATIONAL;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;9.061 TOTAL NATIONAL;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;8.579 TOTAL NATIONAL;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;85.507 TOTAL NATIONAL;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;33.875 TOTAL NATIONAL;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;51.631 TOTAL NATIONAL;Group 0401 Diabetes mellitus 249-250;Both sexes;26.681 TOTAL NATIONAL;Group 0401 Diabetes mellitus 249-250;Men;15.382 TOTAL NATIONAL;Group 0401 Diabetes mellitus 249-250;Women;11.299 TOTAL NATIONAL;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;58.826 TOTAL NATIONAL;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;18.494 TOTAL NATIONAL;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;40.332 TOTAL NATIONAL;Group 0500 Mental disorders 290-319;Both sexes;117.965 TOTAL NATIONAL;Group 0500 Mental disorders 290-319;Men;60.939 TOTAL NATIONAL;Group 0500 Mental disorders 290-319;Women;57.027 TOTAL NATIONAL;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;4.560 TOTAL NATIONAL;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;1.996 TOTAL NATIONAL;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;2.564 TOTAL NATIONAL;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;8.578 TOTAL NATIONAL;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;6.374 TOTAL NATIONAL;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;2.204 TOTAL NATIONAL;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;7.169 TOTAL NATIONAL;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;5.273 TOTAL NATIONAL;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;1.896 TOTAL NATIONAL;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;33.780 TOTAL NATIONAL;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;20.818 TOTAL NATIONAL;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;12.961 TOTAL NATIONAL;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;27.351 TOTAL NATIONAL;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;10.671 TOTAL NATIONAL;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;16.680 TOTAL NATIONAL;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;36.527 TOTAL NATIONAL;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;15.806 TOTAL NATIONAL;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;20.721 TOTAL NATIONAL;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;107.107 TOTAL NATIONAL;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;54.020 TOTAL NATIONAL;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;53.087 TOTAL NATIONAL;Group 0601 Alzheimer's disease 3310;Both sexes;3.373 TOTAL NATIONAL;Group 0601 Alzheimer's disease 3310;Men;1.150 TOTAL NATIONAL;Group 0601 Alzheimer's disease 3310;Women;2.223 TOTAL NATIONAL;Group 0602 Multiple sclerosis 340;Both sexes;2.454 TOTAL NATIONAL;Group 0602 Multiple sclerosis 340;Men;800 TOTAL NATIONAL;Group 0602 Multiple sclerosis 340;Women;1.655 TOTAL NATIONAL;Group 0603 Epilepsy 345;Both sexes;17.969 TOTAL NATIONAL;Group 0603 Epilepsy 345;Men;9.604 TOTAL NATIONAL;Group 0603 Epilepsy 345;Women;8.364 TOTAL NATIONAL;Group 0604 Transient cerebral ischemia 435;Both sexes;16.026 TOTAL NATIONAL;Group 0604 Transient cerebral ischemia 435;Men;8.037 TOTAL NATIONAL;Group 0604 Transient cerebral ischemia 435;Women;7.989 TOTAL NATIONAL;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;67.285 TOTAL NATIONAL;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;34.429 TOTAL NATIONAL;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;32.856 TOTAL NATIONAL;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;29.505 TOTAL NATIONAL;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;15.256 TOTAL NATIONAL;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;14.250 TOTAL NATIONAL;Grupo 0701 Cataract 366;Both sexes;5.815 TOTAL NATIONAL;Grupo 0701 Cataract 366;Men;2.772 TOTAL NATIONAL;Grupo 0701 Cataract 366;Women;3.043 TOTAL NATIONAL;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;23.690 TOTAL NATIONAL;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;12.483 TOTAL NATIONAL;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;11.207 TOTAL NATIONAL;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;23.375 TOTAL NATIONAL;Group 0800 Diseases of the ear and the mastoid 380-389;Men;11.325 TOTAL NATIONAL;Group 0800 Diseases of the ear and the mastoid 380-389;Women;12.049 TOTAL NATIONAL;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;607.575 TOTAL NATIONAL;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;339.103 TOTAL NATIONAL;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;268.472 TOTAL NATIONAL;Group 0901 Hypertensive disease 401-405;Both sexes;31.523 TOTAL NATIONAL;Group 0901 Hypertensive disease 401-405;Men;13.434 TOTAL NATIONAL;Group 0901 Hypertensive disease 401-405;Women;18.090 TOTAL NATIONAL;Group 0902 Angina pectoris 4111, 413;Both sexes;25.804 TOTAL NATIONAL;Group 0902 Angina pectoris 4111, 413;Men;16.103 TOTAL NATIONAL;Group 0902 Angina pectoris 4111, 413;Women;9.701 TOTAL NATIONAL;Group 0903 Acute myocardial infarction 410;Both sexes;53.435 TOTAL NATIONAL;Group 0903 Acute myocardial infarction 410;Men;37.750 TOTAL NATIONAL;Group 0903 Acute myocardial infarction 410;Women;15.685 TOTAL NATIONAL;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;42.666 TOTAL NATIONAL;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;32.460 TOTAL NATIONAL;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;10.207 TOTAL NATIONAL;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;19.577 TOTAL NATIONAL;Group 0905 Diseases of the lungs circulation 415-417;Men;8.885 TOTAL NATIONAL;Group 0905 Diseases of the lungs circulation 415-417;Women;10.692 TOTAL NATIONAL;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;77.626 TOTAL NATIONAL;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;42.215 TOTAL NATIONAL;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;35.411 TOTAL NATIONAL;Grupo 0907 Heart failure 428;Both sexes;121.240 TOTAL NATIONAL;Grupo 0907 Heart failure 428;Men;56.432 TOTAL NATIONAL;Grupo 0907 Heart failure 428;Women;64.807 TOTAL NATIONAL;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;102.120 TOTAL NATIONAL;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;54.689 TOTAL NATIONAL;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;47.431 TOTAL NATIONAL;Grupo 0909 Atherosclerosis 440;Both sexes;20.630 TOTAL NATIONAL;Grupo 0909 Atherosclerosis 440;Men;15.244 TOTAL NATIONAL;Grupo 0909 Atherosclerosis 440;Women;5.386 TOTAL NATIONAL;Group 0910 Varicose veins of lower extremities 454;Both sexes;16.762 TOTAL NATIONAL;Group 0910 Varicose veins of lower extremities 454;Men;6.008 TOTAL NATIONAL;Group 0910 Varicose veins of lower extremities 454;Women;10.754 TOTAL NATIONAL;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;96.192 TOTAL NATIONAL;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;55.883 TOTAL NATIONAL;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;40.308 TOTAL NATIONAL;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;531.141 TOTAL NATIONAL;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;302.411 TOTAL NATIONAL;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;228.729 TOTAL NATIONAL;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;25.520 TOTAL NATIONAL;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;13.528 TOTAL NATIONAL;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;11.992 TOTAL NATIONAL;Group 1002 Pneumonia 480-486;Both sexes;115.723 TOTAL NATIONAL;Group 1002 Pneumonia 480-486;Men;68.055 TOTAL NATIONAL;Group 1002 Pneumonia 480-486;Women;47.668 TOTAL NATIONAL;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;49.336 TOTAL NATIONAL;Group 1003 Acute bronchitis and bronchiolitis 466;Men;24.068 TOTAL NATIONAL;Group 1003 Acute bronchitis and bronchiolitis 466;Women;25.269 TOTAL NATIONAL;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;26.813 TOTAL NATIONAL;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;14.135 TOTAL NATIONAL;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;12.678 TOTAL NATIONAL;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;42.159 TOTAL NATIONAL;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;26.132 TOTAL NATIONAL;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;16.028 TOTAL NATIONAL;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;84.780 TOTAL NATIONAL;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;64.338 TOTAL NATIONAL;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;20.442 TOTAL NATIONAL;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;21.616 TOTAL NATIONAL;Group 1007 Asthma 4930-4931,4938-4939;Men;6.855 TOTAL NATIONAL;Group 1007 Asthma 4930-4931,4938-4939;Women;14.761 TOTAL NATIONAL;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;165.193 TOTAL NATIONAL;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;85.301 TOTAL NATIONAL;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;79.891 TOTAL NATIONAL;Group 1100 Diseases of the digestive system 520-579;Both sexes;576.156 TOTAL NATIONAL;Group 1100 Diseases of the digestive system 520-579;Men;320.174 TOTAL NATIONAL;Group 1100 Diseases of the digestive system 520-579;Women;255.981 TOTAL NATIONAL;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;9.794 TOTAL NATIONAL;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;4.535 TOTAL NATIONAL;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;5.259 TOTAL NATIONAL;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;8.146 TOTAL NATIONAL;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;4.497 TOTAL NATIONAL;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;3.649 TOTAL NATIONAL;Group 1103 Diseases of the esophagus 530;Both sexes;11.041 TOTAL NATIONAL;Group 1103 Diseases of the esophagus 530;Men;6.598 TOTAL NATIONAL;Group 1103 Diseases of the esophagus 530;Women;4.443 TOTAL NATIONAL;Group 1104 Peptic ulcer 531-534;Both sexes;10.967 TOTAL NATIONAL;Group 1104 Peptic ulcer 531-534;Men;7.630 TOTAL NATIONAL;Group 1104 Peptic ulcer 531-534;Women;3.337 TOTAL NATIONAL;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;14.177 TOTAL NATIONAL;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;6.926 TOTAL NATIONAL;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;7.251 TOTAL NATIONAL;Group 1106 Appendicitis 540-543;Both sexes;48.585 TOTAL NATIONAL;Group 1106 Appendicitis 540-543;Men;27.594 TOTAL NATIONAL;Group 1106 Appendicitis 540-543;Women;20.991 TOTAL NATIONAL;Group 1107 Inguinal hernia 550;Both sexes;59.881 TOTAL NATIONAL;Group 1107 Inguinal hernia 550;Men;53.098 TOTAL NATIONAL;Group 1107 Inguinal hernia 550;Women;6.784 TOTAL NATIONAL;Group 1108 Other abdominal hernia 551-553;Both sexes;47.490 TOTAL NATIONAL;Group 1108 Other abdominal hernia 551-553;Men;22.499 TOTAL NATIONAL;Group 1108 Other abdominal hernia 551-553;Women;24.992 TOTAL NATIONAL;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;11.251 TOTAL NATIONAL;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;5.709 TOTAL NATIONAL;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;5.543 TOTAL NATIONAL;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;31.749 TOTAL NATIONAL;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;14.934 TOTAL NATIONAL;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;16.815 TOTAL NATIONAL;Group 1111 Intestinal obstruction without hernia 560;Both sexes;27.247 TOTAL NATIONAL;Group 1111 Intestinal obstruction without hernia 560;Men;13.806 TOTAL NATIONAL;Group 1111 Intestinal obstruction without hernia 560;Women;13.441 TOTAL NATIONAL;Group 1112 Intestinal diverticulosis 562;Both sexes;23.978 TOTAL NATIONAL;Group 1112 Intestinal diverticulosis 562;Men;11.898 TOTAL NATIONAL;Group 1112 Intestinal diverticulosis 562;Women;12.079 TOTAL NATIONAL;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;33.783 TOTAL NATIONAL;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;21.596 TOTAL NATIONAL;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;12.187 TOTAL NATIONAL;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;19.160 TOTAL NATIONAL;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;8.722 TOTAL NATIONAL;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;10.438 TOTAL NATIONAL;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;10.017 TOTAL NATIONAL;Group 1115 Alcoholic hepatitis 5710-5713;Men;8.503 TOTAL NATIONAL;Group 1115 Alcoholic hepatitis 5710-5713;Women;1.514 TOTAL NATIONAL;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;20.224 TOTAL NATIONAL;Group 1116 Other diseases of the liver 570,5714-573;Men;12.168 TOTAL NATIONAL;Group 1116 Other diseases of the liver 570,5714-573;Women;8.055 TOTAL NATIONAL;Group 1117 Cholelithiasis 574;Both sexes;105.339 TOTAL NATIONAL;Group 1117 Cholelithiasis 574;Men;44.013 TOTAL NATIONAL;Group 1117 Cholelithiasis 574;Women;61.326 TOTAL NATIONAL;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;28.016 TOTAL NATIONAL;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;14.994 TOTAL NATIONAL;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;13.021 TOTAL NATIONAL;Group 1119 Pancreatic diseases 577;Both sexes;31.711 TOTAL NATIONAL;Group 1119 Pancreatic diseases 577;Men;17.587 TOTAL NATIONAL;Group 1119 Pancreatic diseases 577;Women;14.125 TOTAL NATIONAL;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;23.599 TOTAL NATIONAL;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;12.867 TOTAL NATIONAL;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;10.732 TOTAL NATIONAL;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;48.303 TOTAL NATIONAL;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;26.145 TOTAL NATIONAL;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;22.158 TOTAL NATIONAL;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;30.158 TOTAL NATIONAL;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;17.760 TOTAL NATIONAL;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;12.398 TOTAL NATIONAL;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;2.234 TOTAL NATIONAL;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;1.161 TOTAL NATIONAL;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;1.073 TOTAL NATIONAL;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;15.911 TOTAL NATIONAL;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;7.224 TOTAL NATIONAL;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;8.688 TOTAL NATIONAL;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;352.112 TOTAL NATIONAL;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;167.441 TOTAL NATIONAL;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;184.670 TOTAL NATIONAL;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. TOTAL NATIONAL;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. TOTAL NATIONAL;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. TOTAL NATIONAL;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. TOTAL NATIONAL;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. TOTAL NATIONAL;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. TOTAL NATIONAL;Group 1303 Internal derangement of knee 717;Both sexes;48.791 TOTAL NATIONAL;Group 1303 Internal derangement of knee 717;Men;32.911 TOTAL NATIONAL;Group 1303 Internal derangement of knee 717;Women;15.880 TOTAL NATIONAL;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;129.913 TOTAL NATIONAL;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;54.955 TOTAL NATIONAL;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;74.959 TOTAL NATIONAL;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;6.210 TOTAL NATIONAL;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;2.205 TOTAL NATIONAL;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;4.005 TOTAL NATIONAL;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;17.730 TOTAL NATIONAL;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;8.502 TOTAL NATIONAL;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;9.228 TOTAL NATIONAL;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;32.883 TOTAL NATIONAL;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;17.520 TOTAL NATIONAL;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;15.363 TOTAL NATIONAL;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;8.855 TOTAL NATIONAL;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;3.932 TOTAL NATIONAL;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;4.922 TOTAL NATIONAL;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;52.302 TOTAL NATIONAL;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;26.830 TOTAL NATIONAL;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;25.473 TOTAL NATIONAL;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;55.428 TOTAL NATIONAL;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;20.586 TOTAL NATIONAL;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;34.841 TOTAL NATIONAL;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;311.049 TOTAL NATIONAL;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;142.809 TOTAL NATIONAL;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;168.239 TOTAL NATIONAL;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;31.944 TOTAL NATIONAL;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;11.393 TOTAL NATIONAL;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;20.551 TOTAL NATIONAL;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;27.306 TOTAL NATIONAL;Group 1402 Renal failure 5836-5837, 584-586;Men;15.696 TOTAL NATIONAL;Group 1402 Renal failure 5836-5837, 584-586;Women;11.610 TOTAL NATIONAL;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;40.254 TOTAL NATIONAL;Group 1403 Urolithiasis 592, 594, 7880;Men;23.951 TOTAL NATIONAL;Group 1403 Urolithiasis 592, 594, 7880;Women;16.303 TOTAL NATIONAL;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;82.896 TOTAL NATIONAL;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;40.380 TOTAL NATIONAL;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;42.517 TOTAL NATIONAL;Group 1405 Prostatic hyperplasia 600;Both sexes;26.555 TOTAL NATIONAL;Group 1405 Prostatic hyperplasia 600;Men;26.555 TOTAL NATIONAL;Group 1405 Prostatic hyperplasia 600;Women;.. TOTAL NATIONAL;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;22.323 TOTAL NATIONAL;Group 1406 Other diseases of the male genital organs 601-608;Men;22.323 TOTAL NATIONAL;Group 1406 Other diseases of the male genital organs 601-608;Women;.. TOTAL NATIONAL;Group 1407 Disorders of breast 610-612;Both sexes;20.396 TOTAL NATIONAL;Group 1407 Disorders of breast 610-612;Men;1.809 TOTAL NATIONAL;Group 1407 Disorders of breast 610-612;Women;18.587 TOTAL NATIONAL;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;8.251 TOTAL NATIONAL;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. TOTAL NATIONAL;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;8.251 TOTAL NATIONAL;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;4.016 TOTAL NATIONAL;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. TOTAL NATIONAL;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;4.016 TOTAL NATIONAL;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;47.107 TOTAL NATIONAL;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;702 TOTAL NATIONAL;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;46.405 TOTAL NATIONAL;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;492.723 TOTAL NATIONAL;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. TOTAL NATIONAL;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;492.723 TOTAL NATIONAL;Group 1501 Legally induced abortion 635;Both sexes;2.098 TOTAL NATIONAL;Group 1501 Legally induced abortion 635;Men;.. TOTAL NATIONAL;Group 1501 Legally induced abortion 635;Women;2.098 TOTAL NATIONAL;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;27.798 TOTAL NATIONAL;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. TOTAL NATIONAL;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;27.798 TOTAL NATIONAL;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;292.630 TOTAL NATIONAL;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. TOTAL NATIONAL;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;292.630 TOTAL NATIONAL;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;83.868 TOTAL NATIONAL;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. TOTAL NATIONAL;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;83.868 TOTAL NATIONAL;Group 1505 Single spontaneous delivery 650;Both sexes;31.864 TOTAL NATIONAL;Group 1505 Single spontaneous delivery 650;Men;.. TOTAL NATIONAL;Group 1505 Single spontaneous delivery 650;Women;31.864 TOTAL NATIONAL;Group 1506 Other deliveries 6695-6697;Both sexes;15.948 TOTAL NATIONAL;Group 1506 Other deliveries 6695-6697;Men;.. TOTAL NATIONAL;Group 1506 Other deliveries 6695-6697;Women;15.948 TOTAL NATIONAL;Group 1507 Complications related to the puerperium 670-676;Both sexes;3.955 TOTAL NATIONAL;Group 1507 Complications related to the puerperium 670-676;Men;.. TOTAL NATIONAL;Group 1507 Complications related to the puerperium 670-676;Women;3.955 TOTAL NATIONAL;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;34.561 TOTAL NATIONAL;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. TOTAL NATIONAL;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;34.561 TOTAL NATIONAL;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;64.181 TOTAL NATIONAL;Group 1600 Some disorders originating in the perinatal period 760-779;Men;35.382 TOTAL NATIONAL;Group 1600 Some disorders originating in the perinatal period 760-779;Women;28.799 TOTAL NATIONAL;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;17.752 TOTAL NATIONAL;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;9.410 TOTAL NATIONAL;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;8.343 TOTAL NATIONAL;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;46.429 TOTAL NATIONAL;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;25.972 TOTAL NATIONAL;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;20.457 TOTAL NATIONAL;Grupo 1700 Congenital abnormalities 740-759;Both sexes;38.190 TOTAL NATIONAL;Grupo 1700 Congenital abnormalities 740-759;Men;21.328 TOTAL NATIONAL;Grupo 1700 Congenital abnormalities 740-759;Women;16.863 TOTAL NATIONAL;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;224.060 TOTAL NATIONAL;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;119.692 TOTAL NATIONAL;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;104.368 TOTAL NATIONAL;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;26.454 TOTAL NATIONAL;Group 1801 Pain in throat and chest 7841, 7865;Men;15.037 TOTAL NATIONAL;Group 1801 Pain in throat and chest 7841, 7865;Women;11.417 TOTAL NATIONAL;Group 1802 Abdominal pain 7890;Both sexes;24.628 TOTAL NATIONAL;Group 1802 Abdominal pain 7890;Men;9.684 TOTAL NATIONAL;Group 1802 Abdominal pain 7890;Women;14.944 TOTAL NATIONAL;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;27.392 TOTAL NATIONAL;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;13.766 TOTAL NATIONAL;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;13.626 TOTAL NATIONAL;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;145.586 TOTAL NATIONAL;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;81.205 TOTAL NATIONAL;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;64.381 TOTAL NATIONAL;Group 1900 Injuries and poisoning 800-999;Both sexes;418.002 TOTAL NATIONAL;Group 1900 Injuries and poisoning 800-999;Men;212.051 TOTAL NATIONAL;Group 1900 Injuries and poisoning 800-999;Women;205.951 TOTAL NATIONAL;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;23.073 TOTAL NATIONAL;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;13.225 TOTAL NATIONAL;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;9.848 TOTAL NATIONAL;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;11.222 TOTAL NATIONAL;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;7.849 TOTAL NATIONAL;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;3.372 TOTAL NATIONAL;Group 1903 Radius and ulna fracture 813;Both sexes;25.409 TOTAL NATIONAL;Group 1903 Radius and ulna fracture 813;Men;11.772 TOTAL NATIONAL;Group 1903 Radius and ulna fracture 813;Women;13.637 TOTAL NATIONAL;Group 1904 Femur fracture 820-821;Both sexes;68.328 TOTAL NATIONAL;Group 1904 Femur fracture 820-821;Men;19.059 TOTAL NATIONAL;Group 1904 Femur fracture 820-821;Women;49.270 TOTAL NATIONAL;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;30.220 TOTAL NATIONAL;Group 1905 Leg fracture, including the ankle 823-824;Men;15.269 TOTAL NATIONAL;Group 1905 Leg fracture, including the ankle 823-824;Women;14.950 TOTAL NATIONAL;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;120.926 TOTAL NATIONAL;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;71.576 TOTAL NATIONAL;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;49.351 TOTAL NATIONAL;Group 1907 Burns 940-949;Both sexes;3.350 TOTAL NATIONAL;Group 1907 Burns 940-949;Men;2.041 TOTAL NATIONAL;Group 1907 Burns 940-949;Women;1.309 TOTAL NATIONAL;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;11.852 TOTAL NATIONAL;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;5.426 TOTAL NATIONAL;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;6.426 TOTAL NATIONAL;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;110.400 TOTAL NATIONAL;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;58.752 TOTAL NATIONAL;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;51.648 TOTAL NATIONAL;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;1.207 TOTAL NATIONAL;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;748 TOTAL NATIONAL;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;459 TOTAL NATIONAL;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;12.015 TOTAL NATIONAL;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;6.334 TOTAL NATIONAL;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;5.681 TOTAL NATIONAL;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;97.679 TOTAL NATIONAL;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;47.814 TOTAL NATIONAL;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;49.865 TOTAL NATIONAL;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;4.850 TOTAL NATIONAL;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;2.816 TOTAL NATIONAL;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;2.034 TOTAL NATIONAL;Group 2102 Contraceptive management V25;Both sexes;1.677 TOTAL NATIONAL;Group 2102 Contraceptive management V25;Men;114 TOTAL NATIONAL;Group 2102 Contraceptive management V25;Women;1.563 TOTAL NATIONAL;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. TOTAL NATIONAL;Group 2103 Living newborns by type of delivery V30-V39;Men;.. TOTAL NATIONAL;Group 2103 Living newborns by type of delivery V30-V39;Women;.. TOTAL NATIONAL;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;31.802 TOTAL NATIONAL;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;19.260 TOTAL NATIONAL;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;12.542 TOTAL NATIONAL;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;59.350 TOTAL NATIONAL;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;25.624 TOTAL NATIONAL;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;33.726 ANDALUC═A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;694.141 ANDALUC═A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;310.756 ANDALUC═A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;383.385 ANDALUC═A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;16.129 ANDALUC═A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;9.147 ANDALUC═A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;6.982 ANDALUC═A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;1.732 ANDALUC═A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;945 ANDALUC═A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;787 ANDALUC═A;Group 0102 Imprecise intestinal infections 009;Both sexes;1.655 ANDALUC═A;Group 0102 Imprecise intestinal infections 009;Men;784 ANDALUC═A;Group 0102 Imprecise intestinal infections 009;Women;870 ANDALUC═A;Group 0103 Tuberculosis 010-018, 137;Both sexes;550 ANDALUC═A;Group 0103 Tuberculosis 010-018, 137;Men;367 ANDALUC═A;Group 0103 Tuberculosis 010-018, 137;Women;183 ANDALUC═A;Group 0104 Septicaemia 038;Both sexes;6.690 ANDALUC═A;Group 0104 Septicaemia 038;Men;3.621 ANDALUC═A;Group 0104 Septicaemia 038;Women;3.068 ANDALUC═A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;669 ANDALUC═A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;533 ANDALUC═A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;137 ANDALUC═A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;4.834 ANDALUC═A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;2.897 ANDALUC═A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;1.937 ANDALUC═A;Group 0200 Neoplasms 140-239;Both sexes;64.625 ANDALUC═A;Group 0200 Neoplasms 140-239;Men;33.237 ANDALUC═A;Group 0200 Neoplasms 140-239;Women;31.388 ANDALUC═A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;6.599 ANDALUC═A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;4.046 ANDALUC═A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;2.553 ANDALUC═A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;4.575 ANDALUC═A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;3.788 ANDALUC═A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;787 ANDALUC═A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;1.643 ANDALUC═A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;1.005 ANDALUC═A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;638 ANDALUC═A;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;5.514 ANDALUC═A;Group 0204 Malignant neoplasm of breast 174-175;Men;55 ANDALUC═A;Group 0204 Malignant neoplasm of breast 174-175;Women;5.460 ANDALUC═A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1.421 ANDALUC═A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. ANDALUC═A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1.421 ANDALUC═A;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;774 ANDALUC═A;Group 0206 Malignant neoplasm of ovary 1830;Men;.. ANDALUC═A;Group 0206 Malignant neoplasm of ovary 1830;Women;774 ANDALUC═A;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1.856 ANDALUC═A;Group 0207 Malignant neoplasm of prostate 185;Men;1.856 ANDALUC═A;Group 0207 Malignant neoplasm of prostate 185;Women;.. ANDALUC═A;Group 0208 Malignant neoplasm of bladder 188;Both sexes;5.970 ANDALUC═A;Group 0208 Malignant neoplasm of bladder 188;Men;5.024 ANDALUC═A;Group 0208 Malignant neoplasm of bladder 188;Women;947 ANDALUC═A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;22.145 ANDALUC═A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;13.073 ANDALUC═A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;9.072 ANDALUC═A;Group 0210 Carcinoma in situ 230-234;Both sexes;813 ANDALUC═A;Group 0210 Carcinoma in situ 230-234;Men;268 ANDALUC═A;Group 0210 Carcinoma in situ 230-234;Women;544 ANDALUC═A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;533 ANDALUC═A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;286 ANDALUC═A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;247 ANDALUC═A;Grupo 0212 Leiomyoma of uterus 218;Both sexes;3.635 ANDALUC═A;Grupo 0212 Leiomyoma of uterus 218;Men;.. ANDALUC═A;Grupo 0212 Leiomyoma of uterus 218;Women;3.635 ANDALUC═A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;9.147 ANDALUC═A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;3.836 ANDALUC═A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;5.312 ANDALUC═A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;6.306 ANDALUC═A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;3.092 ANDALUC═A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;3.214 ANDALUC═A;Group 0301 Anaemias 280-285;Both sexes;3.427 ANDALUC═A;Group 0301 Anaemias 280-285;Men;1.673 ANDALUC═A;Group 0301 Anaemias 280-285;Women;1.754 ANDALUC═A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;2.879 ANDALUC═A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;1.419 ANDALUC═A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;1.461 ANDALUC═A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;12.245 ANDALUC═A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;4.805 ANDALUC═A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;7.440 ANDALUC═A;Group 0401 Diabetes mellitus 249-250;Both sexes;3.711 ANDALUC═A;Group 0401 Diabetes mellitus 249-250;Men;2.175 ANDALUC═A;Group 0401 Diabetes mellitus 249-250;Women;1.536 ANDALUC═A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;8.535 ANDALUC═A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;2.631 ANDALUC═A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;5.904 ANDALUC═A;Group 0500 Mental disorders 290-319;Both sexes;13.178 ANDALUC═A;Group 0500 Mental disorders 290-319;Men;7.222 ANDALUC═A;Group 0500 Mental disorders 290-319;Women;5.956 ANDALUC═A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;271 ANDALUC═A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;120 ANDALUC═A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;150 ANDALUC═A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;552 ANDALUC═A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;431 ANDALUC═A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;121 ANDALUC═A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;761 ANDALUC═A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;592 ANDALUC═A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;169 ANDALUC═A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;4.158 ANDALUC═A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;2.763 ANDALUC═A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;1.395 ANDALUC═A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;3.075 ANDALUC═A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;1.316 ANDALUC═A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;1.759 ANDALUC═A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;4.361 ANDALUC═A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;1.999 ANDALUC═A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;2.362 ANDALUC═A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;13.630 ANDALUC═A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;6.530 ANDALUC═A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;7.100 ANDALUC═A;Group 0601 Alzheimer's disease 3310;Both sexes;301 ANDALUC═A;Group 0601 Alzheimer's disease 3310;Men;104 ANDALUC═A;Group 0601 Alzheimer's disease 3310;Women;197 ANDALUC═A;Group 0602 Multiple sclerosis 340;Both sexes;318 ANDALUC═A;Group 0602 Multiple sclerosis 340;Men;97 ANDALUC═A;Group 0602 Multiple sclerosis 340;Women;221 ANDALUC═A;Group 0603 Epilepsy 345;Both sexes;2.456 ANDALUC═A;Group 0603 Epilepsy 345;Men;1.285 ANDALUC═A;Group 0603 Epilepsy 345;Women;1.171 ANDALUC═A;Group 0604 Transient cerebral ischemia 435;Both sexes;2.458 ANDALUC═A;Group 0604 Transient cerebral ischemia 435;Men;1.245 ANDALUC═A;Group 0604 Transient cerebral ischemia 435;Women;1.213 ANDALUC═A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;8.098 ANDALUC═A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;3.800 ANDALUC═A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;4.298 ANDALUC═A;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;5.517 ANDALUC═A;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;2.981 ANDALUC═A;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;2.536 ANDALUC═A;Grupo 0701 Cataract 366;Both sexes;940 ANDALUC═A;Grupo 0701 Cataract 366;Men;497 ANDALUC═A;Grupo 0701 Cataract 366;Women;443 ANDALUC═A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;4.577 ANDALUC═A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;2.484 ANDALUC═A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;2.093 ANDALUC═A;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;3.329 ANDALUC═A;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1.636 ANDALUC═A;Group 0800 Diseases of the ear and the mastoid 380-389;Women;1.694 ANDALUC═A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;92.429 ANDALUC═A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;52.714 ANDALUC═A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;39.716 ANDALUC═A;Group 0901 Hypertensive disease 401-405;Both sexes;6.137 ANDALUC═A;Group 0901 Hypertensive disease 401-405;Men;2.537 ANDALUC═A;Group 0901 Hypertensive disease 401-405;Women;3.600 ANDALUC═A;Group 0902 Angina pectoris 4111, 413;Both sexes;5.723 ANDALUC═A;Group 0902 Angina pectoris 4111, 413;Men;3.476 ANDALUC═A;Group 0902 Angina pectoris 4111, 413;Women;2.247 ANDALUC═A;Group 0903 Acute myocardial infarction 410;Both sexes;9.951 ANDALUC═A;Group 0903 Acute myocardial infarction 410;Men;6.850 ANDALUC═A;Group 0903 Acute myocardial infarction 410;Women;3.101 ANDALUC═A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;7.682 ANDALUC═A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;5.661 ANDALUC═A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;2.021 ANDALUC═A;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;2.495 ANDALUC═A;Group 0905 Diseases of the lungs circulation 415-417;Men;1.181 ANDALUC═A;Group 0905 Diseases of the lungs circulation 415-417;Women;1.314 ANDALUC═A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;10.977 ANDALUC═A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;6.074 ANDALUC═A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;4.904 ANDALUC═A;Grupo 0907 Heart failure 428;Both sexes;15.172 ANDALUC═A;Grupo 0907 Heart failure 428;Men;7.237 ANDALUC═A;Grupo 0907 Heart failure 428;Women;7.935 ANDALUC═A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;15.626 ANDALUC═A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;8.705 ANDALUC═A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;6.921 ANDALUC═A;Grupo 0909 Atherosclerosis 440;Both sexes;3.069 ANDALUC═A;Grupo 0909 Atherosclerosis 440;Men;2.295 ANDALUC═A;Grupo 0909 Atherosclerosis 440;Women;774 ANDALUC═A;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.809 ANDALUC═A;Group 0910 Varicose veins of lower extremities 454;Men;692 ANDALUC═A;Group 0910 Varicose veins of lower extremities 454;Women;1.117 ANDALUC═A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;13.789 ANDALUC═A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;8.006 ANDALUC═A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;5.783 ANDALUC═A;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;63.274 ANDALUC═A;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;36.728 ANDALUC═A;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;26.546 ANDALUC═A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;4.118 ANDALUC═A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;2.213 ANDALUC═A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;1.905 ANDALUC═A;Group 1002 Pneumonia 480-486;Both sexes;13.435 ANDALUC═A;Group 1002 Pneumonia 480-486;Men;7.910 ANDALUC═A;Group 1002 Pneumonia 480-486;Women;5.525 ANDALUC═A;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;5.878 ANDALUC═A;Group 1003 Acute bronchitis and bronchiolitis 466;Men;3.087 ANDALUC═A;Group 1003 Acute bronchitis and bronchiolitis 466;Women;2.791 ANDALUC═A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;2.926 ANDALUC═A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1.482 ANDALUC═A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1.444 ANDALUC═A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;6.228 ANDALUC═A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;3.796 ANDALUC═A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;2.432 ANDALUC═A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;7.390 ANDALUC═A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;5.874 ANDALUC═A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1.516 ANDALUC═A;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1.890 ANDALUC═A;Group 1007 Asthma 4930-4931,4938-4939;Men;609 ANDALUC═A;Group 1007 Asthma 4930-4931,4938-4939;Women;1.282 ANDALUC═A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;21.408 ANDALUC═A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;11.757 ANDALUC═A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;9.651 ANDALUC═A;Group 1100 Diseases of the digestive system 520-579;Both sexes;87.738 ANDALUC═A;Group 1100 Diseases of the digestive system 520-579;Men;47.433 ANDALUC═A;Group 1100 Diseases of the digestive system 520-579;Women;40.305 ANDALUC═A;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;1.455 ANDALUC═A;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;684 ANDALUC═A;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;771 ANDALUC═A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;1.382 ANDALUC═A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;729 ANDALUC═A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;653 ANDALUC═A;Group 1103 Diseases of the esophagus 530;Both sexes;1.931 ANDALUC═A;Group 1103 Diseases of the esophagus 530;Men;1.115 ANDALUC═A;Group 1103 Diseases of the esophagus 530;Women;816 ANDALUC═A;Group 1104 Peptic ulcer 531-534;Both sexes;1.779 ANDALUC═A;Group 1104 Peptic ulcer 531-534;Men;1.258 ANDALUC═A;Group 1104 Peptic ulcer 531-534;Women;520 ANDALUC═A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;2.289 ANDALUC═A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;1.119 ANDALUC═A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;1.170 ANDALUC═A;Group 1106 Appendicitis 540-543;Both sexes;7.836 ANDALUC═A;Group 1106 Appendicitis 540-543;Men;4.435 ANDALUC═A;Group 1106 Appendicitis 540-543;Women;3.401 ANDALUC═A;Group 1107 Inguinal hernia 550;Both sexes;6.951 ANDALUC═A;Group 1107 Inguinal hernia 550;Men;6.079 ANDALUC═A;Group 1107 Inguinal hernia 550;Women;871 ANDALUC═A;Group 1108 Other abdominal hernia 551-553;Both sexes;7.141 ANDALUC═A;Group 1108 Other abdominal hernia 551-553;Men;3.147 ANDALUC═A;Group 1108 Other abdominal hernia 551-553;Women;3.995 ANDALUC═A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;2.201 ANDALUC═A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;1.087 ANDALUC═A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;1.114 ANDALUC═A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;4.363 ANDALUC═A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;2.038 ANDALUC═A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;2.325 ANDALUC═A;Group 1111 Intestinal obstruction without hernia 560;Both sexes;3.576 ANDALUC═A;Group 1111 Intestinal obstruction without hernia 560;Men;1.791 ANDALUC═A;Group 1111 Intestinal obstruction without hernia 560;Women;1.785 ANDALUC═A;Group 1112 Intestinal diverticulosis 562;Both sexes;3.213 ANDALUC═A;Group 1112 Intestinal diverticulosis 562;Men;1.690 ANDALUC═A;Group 1112 Intestinal diverticulosis 562;Women;1.523 ANDALUC═A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;5.412 ANDALUC═A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;3.416 ANDALUC═A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;1.996 ANDALUC═A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;2.525 ANDALUC═A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;1.228 ANDALUC═A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1.296 ANDALUC═A;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1.659 ANDALUC═A;Group 1115 Alcoholic hepatitis 5710-5713;Men;1.415 ANDALUC═A;Group 1115 Alcoholic hepatitis 5710-5713;Women;244 ANDALUC═A;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;2.945 ANDALUC═A;Group 1116 Other diseases of the liver 570,5714-573;Men;1.843 ANDALUC═A;Group 1116 Other diseases of the liver 570,5714-573;Women;1.101 ANDALUC═A;Group 1117 Cholelithiasis 574;Both sexes;17.451 ANDALUC═A;Group 1117 Cholelithiasis 574;Men;7.073 ANDALUC═A;Group 1117 Cholelithiasis 574;Women;10.378 ANDALUC═A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;4.013 ANDALUC═A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;2.059 ANDALUC═A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;1.954 ANDALUC═A;Group 1119 Pancreatic diseases 577;Both sexes;6.054 ANDALUC═A;Group 1119 Pancreatic diseases 577;Men;3.241 ANDALUC═A;Group 1119 Pancreatic diseases 577;Women;2.813 ANDALUC═A;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;3.563 ANDALUC═A;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1.985 ANDALUC═A;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1.578 ANDALUC═A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;6.411 ANDALUC═A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;3.481 ANDALUC═A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;2.930 ANDALUC═A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;3.782 ANDALUC═A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;2.290 ANDALUC═A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;1.492 ANDALUC═A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;328 ANDALUC═A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;181 ANDALUC═A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;147 ANDALUC═A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;2.301 ANDALUC═A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;1.011 ANDALUC═A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;1.290 ANDALUC═A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;45.191 ANDALUC═A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;20.612 ANDALUC═A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;24.579 ANDALUC═A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. ANDALUC═A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. ANDALUC═A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. ANDALUC═A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. ANDALUC═A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. ANDALUC═A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. ANDALUC═A;Group 1303 Internal derangement of knee 717;Both sexes;4.682 ANDALUC═A;Group 1303 Internal derangement of knee 717;Men;3.192 ANDALUC═A;Group 1303 Internal derangement of knee 717;Women;1.490 ANDALUC═A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;19.118 ANDALUC═A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;7.682 ANDALUC═A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;11.436 ANDALUC═A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;939 ANDALUC═A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;326 ANDALUC═A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;613 ANDALUC═A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;2.354 ANDALUC═A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1.137 ANDALUC═A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1.217 ANDALUC═A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;4.358 ANDALUC═A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;2.158 ANDALUC═A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;2.200 ANDALUC═A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;1.197 ANDALUC═A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;472 ANDALUC═A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;725 ANDALUC═A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;5.820 ANDALUC═A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;2.910 ANDALUC═A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;2.910 ANDALUC═A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;6.724 ANDALUC═A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;2.736 ANDALUC═A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;3.988 ANDALUC═A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;42.145 ANDALUC═A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;18.108 ANDALUC═A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;24.038 ANDALUC═A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;4.785 ANDALUC═A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;1.940 ANDALUC═A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;2.845 ANDALUC═A;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;4.350 ANDALUC═A;Group 1402 Renal failure 5836-5837, 584-586;Men;2.468 ANDALUC═A;Group 1402 Renal failure 5836-5837, 584-586;Women;1.882 ANDALUC═A;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;5.848 ANDALUC═A;Group 1403 Urolithiasis 592, 594, 7880;Men;3.378 ANDALUC═A;Group 1403 Urolithiasis 592, 594, 7880;Women;2.470 ANDALUC═A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;8.524 ANDALUC═A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;4.153 ANDALUC═A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;4.371 ANDALUC═A;Group 1405 Prostatic hyperplasia 600;Both sexes;2.904 ANDALUC═A;Group 1405 Prostatic hyperplasia 600;Men;2.904 ANDALUC═A;Group 1405 Prostatic hyperplasia 600;Women;.. ANDALUC═A;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;2.922 ANDALUC═A;Group 1406 Other diseases of the male genital organs 601-608;Men;2.922 ANDALUC═A;Group 1406 Other diseases of the male genital organs 601-608;Women;.. ANDALUC═A;Group 1407 Disorders of breast 610-612;Both sexes;3.222 ANDALUC═A;Group 1407 Disorders of breast 610-612;Men;283 ANDALUC═A;Group 1407 Disorders of breast 610-612;Women;2.939 ANDALUC═A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;1.540 ANDALUC═A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. ANDALUC═A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;1.540 ANDALUC═A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;751 ANDALUC═A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. ANDALUC═A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;751 ANDALUC═A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;7.299 ANDALUC═A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;60 ANDALUC═A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;7.240 ANDALUC═A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;97.891 ANDALUC═A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. ANDALUC═A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;97.891 ANDALUC═A;Group 1501 Legally induced abortion 635;Both sexes;162 ANDALUC═A;Group 1501 Legally induced abortion 635;Men;.. ANDALUC═A;Group 1501 Legally induced abortion 635;Women;162 ANDALUC═A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;6.269 ANDALUC═A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. ANDALUC═A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;6.269 ANDALUC═A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;61.217 ANDALUC═A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. ANDALUC═A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;61.217 ANDALUC═A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;13.323 ANDALUC═A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. ANDALUC═A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;13.323 ANDALUC═A;Group 1505 Single spontaneous delivery 650;Both sexes;6.164 ANDALUC═A;Group 1505 Single spontaneous delivery 650;Men;.. ANDALUC═A;Group 1505 Single spontaneous delivery 650;Women;6.164 ANDALUC═A;Group 1506 Other deliveries 6695-6697;Both sexes;4.002 ANDALUC═A;Group 1506 Other deliveries 6695-6697;Men;.. ANDALUC═A;Group 1506 Other deliveries 6695-6697;Women;4.002 ANDALUC═A;Group 1507 Complications related to the puerperium 670-676;Both sexes;671 ANDALUC═A;Group 1507 Complications related to the puerperium 670-676;Men;.. ANDALUC═A;Group 1507 Complications related to the puerperium 670-676;Women;671 ANDALUC═A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;6.084 ANDALUC═A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. ANDALUC═A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;6.084 ANDALUC═A;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;9.805 ANDALUC═A;Group 1600 Some disorders originating in the perinatal period 760-779;Men;5.295 ANDALUC═A;Group 1600 Some disorders originating in the perinatal period 760-779;Women;4.510 ANDALUC═A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;3.465 ANDALUC═A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;1.783 ANDALUC═A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;1.683 ANDALUC═A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;6.340 ANDALUC═A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;3.512 ANDALUC═A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;2.827 ANDALUC═A;Grupo 1700 Congenital abnormalities 740-759;Both sexes;6.518 ANDALUC═A;Grupo 1700 Congenital abnormalities 740-759;Men;3.562 ANDALUC═A;Grupo 1700 Congenital abnormalities 740-759;Women;2.955 ANDALUC═A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;35.586 ANDALUC═A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;18.290 ANDALUC═A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;17.296 ANDALUC═A;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;5.059 ANDALUC═A;Group 1801 Pain in throat and chest 7841, 7865;Men;2.723 ANDALUC═A;Group 1801 Pain in throat and chest 7841, 7865;Women;2.337 ANDALUC═A;Group 1802 Abdominal pain 7890;Both sexes;4.650 ANDALUC═A;Group 1802 Abdominal pain 7890;Men;1.707 ANDALUC═A;Group 1802 Abdominal pain 7890;Women;2.944 ANDALUC═A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;4.634 ANDALUC═A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;2.164 ANDALUC═A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;2.470 ANDALUC═A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;21.242 ANDALUC═A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;11.697 ANDALUC═A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;9.546 ANDALUC═A;Group 1900 Injuries and poisoning 800-999;Both sexes;61.111 ANDALUC═A;Group 1900 Injuries and poisoning 800-999;Men;30.805 ANDALUC═A;Group 1900 Injuries and poisoning 800-999;Women;30.306 ANDALUC═A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;2.722 ANDALUC═A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;1.662 ANDALUC═A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;1.060 ANDALUC═A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1.788 ANDALUC═A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;1.282 ANDALUC═A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;506 ANDALUC═A;Group 1903 Radius and ulna fracture 813;Both sexes;4.366 ANDALUC═A;Group 1903 Radius and ulna fracture 813;Men;2.129 ANDALUC═A;Group 1903 Radius and ulna fracture 813;Women;2.236 ANDALUC═A;Group 1904 Femur fracture 820-821;Both sexes;10.168 ANDALUC═A;Group 1904 Femur fracture 820-821;Men;2.932 ANDALUC═A;Group 1904 Femur fracture 820-821;Women;7.235 ANDALUC═A;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;5.088 ANDALUC═A;Group 1905 Leg fracture, including the ankle 823-824;Men;2.577 ANDALUC═A;Group 1905 Leg fracture, including the ankle 823-824;Women;2.510 ANDALUC═A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;16.734 ANDALUC═A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;9.591 ANDALUC═A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;7.143 ANDALUC═A;Group 1907 Burns 940-949;Both sexes;568 ANDALUC═A;Group 1907 Burns 940-949;Men;311 ANDALUC═A;Group 1907 Burns 940-949;Women;257 ANDALUC═A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;2.003 ANDALUC═A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;975 ANDALUC═A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;1.028 ANDALUC═A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;16.205 ANDALUC═A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;8.521 ANDALUC═A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;7.684 ANDALUC═A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;226 ANDALUC═A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;134 ANDALUC═A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;92 ANDALUC═A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;1.244 ANDALUC═A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;690 ANDALUC═A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;553 ANDALUC═A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;11.081 ANDALUC═A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;5.079 ANDALUC═A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;6.002 ANDALUC═A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;684 ANDALUC═A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;382 ANDALUC═A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;302 ANDALUC═A;Group 2102 Contraceptive management V25;Both sexes;157 ANDALUC═A;Group 2102 Contraceptive management V25;Men;25 ANDALUC═A;Group 2102 Contraceptive management V25;Women;132 ANDALUC═A;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. ANDALUC═A;Group 2103 Living newborns by type of delivery V30-V39;Men;.. ANDALUC═A;Group 2103 Living newborns by type of delivery V30-V39;Women;.. ANDALUC═A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;3.892 ANDALUC═A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;2.488 ANDALUC═A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1.404 ANDALUC═A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;6.349 ANDALUC═A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;2.184 ANDALUC═A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;4.165 AlmerÝa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;52.541 AlmerÝa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;23.299 AlmerÝa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;29.242 AlmerÝa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.312 AlmerÝa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;799 AlmerÝa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;513 AlmerÝa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;195 AlmerÝa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;119 AlmerÝa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;76 AlmerÝa;Group 0102 Imprecise intestinal infections 009;Both sexes;197 AlmerÝa;Group 0102 Imprecise intestinal infections 009;Men;98 AlmerÝa;Group 0102 Imprecise intestinal infections 009;Women;99 AlmerÝa;Group 0103 Tuberculosis 010-018, 137;Both sexes;80 AlmerÝa;Group 0103 Tuberculosis 010-018, 137;Men;57 AlmerÝa;Group 0103 Tuberculosis 010-018, 137;Women;23 AlmerÝa;Group 0104 Septicaemia 038;Both sexes;389 AlmerÝa;Group 0104 Septicaemia 038;Men;208 AlmerÝa;Group 0104 Septicaemia 038;Women;181 AlmerÝa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;47 AlmerÝa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;43 AlmerÝa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;4 AlmerÝa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;404 AlmerÝa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;274 AlmerÝa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;130 AlmerÝa;Group 0200 Neoplasms 140-239;Both sexes;4.285 AlmerÝa;Group 0200 Neoplasms 140-239;Men;2.268 AlmerÝa;Group 0200 Neoplasms 140-239;Women;2.017 AlmerÝa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;408 AlmerÝa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;258 AlmerÝa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;150 AlmerÝa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;402 AlmerÝa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;343 AlmerÝa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;59 AlmerÝa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;27 AlmerÝa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;19 AlmerÝa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;8 AlmerÝa;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;345 AlmerÝa;Group 0204 Malignant neoplasm of breast 174-175;Men;3 AlmerÝa;Group 0204 Malignant neoplasm of breast 174-175;Women;342 AlmerÝa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;99 AlmerÝa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. AlmerÝa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;99 AlmerÝa;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;45 AlmerÝa;Group 0206 Malignant neoplasm of ovary 1830;Men;.. AlmerÝa;Group 0206 Malignant neoplasm of ovary 1830;Women;45 AlmerÝa;Group 0207 Malignant neoplasm of prostate 185;Both sexes;110 AlmerÝa;Group 0207 Malignant neoplasm of prostate 185;Men;110 AlmerÝa;Group 0207 Malignant neoplasm of prostate 185;Women;.. AlmerÝa;Group 0208 Malignant neoplasm of bladder 188;Both sexes;471 AlmerÝa;Group 0208 Malignant neoplasm of bladder 188;Men;421 AlmerÝa;Group 0208 Malignant neoplasm of bladder 188;Women;50 AlmerÝa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.393 AlmerÝa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;819 AlmerÝa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;574 AlmerÝa;Group 0210 Carcinoma in situ 230-234;Both sexes;32 AlmerÝa;Group 0210 Carcinoma in situ 230-234;Men;10 AlmerÝa;Group 0210 Carcinoma in situ 230-234;Women;22 AlmerÝa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;28 AlmerÝa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;11 AlmerÝa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;17 AlmerÝa;Grupo 0212 Leiomyoma of uterus 218;Both sexes;324 AlmerÝa;Grupo 0212 Leiomyoma of uterus 218;Men;.. AlmerÝa;Grupo 0212 Leiomyoma of uterus 218;Women;324 AlmerÝa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;601 AlmerÝa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;274 AlmerÝa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;327 AlmerÝa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;452 AlmerÝa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;239 AlmerÝa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;213 AlmerÝa;Group 0301 Anaemias 280-285;Both sexes;266 AlmerÝa;Group 0301 Anaemias 280-285;Men;151 AlmerÝa;Group 0301 Anaemias 280-285;Women;115 AlmerÝa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;186 AlmerÝa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;88 AlmerÝa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;98 AlmerÝa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;832 AlmerÝa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;384 AlmerÝa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;448 AlmerÝa;Group 0401 Diabetes mellitus 249-250;Both sexes;315 AlmerÝa;Group 0401 Diabetes mellitus 249-250;Men;202 AlmerÝa;Group 0401 Diabetes mellitus 249-250;Women;113 AlmerÝa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;517 AlmerÝa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;182 AlmerÝa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;335 AlmerÝa;Group 0500 Mental disorders 290-319;Both sexes;960 AlmerÝa;Group 0500 Mental disorders 290-319;Men;547 AlmerÝa;Group 0500 Mental disorders 290-319;Women;413 AlmerÝa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;14 AlmerÝa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;6 AlmerÝa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;8 AlmerÝa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;24 AlmerÝa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;18 AlmerÝa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;6 AlmerÝa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;60 AlmerÝa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;49 AlmerÝa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;11 AlmerÝa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;343 AlmerÝa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;230 AlmerÝa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;113 AlmerÝa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;173 AlmerÝa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;90 AlmerÝa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;83 AlmerÝa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;346 AlmerÝa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;154 AlmerÝa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;192 AlmerÝa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;818 AlmerÝa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;394 AlmerÝa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;424 AlmerÝa;Group 0601 Alzheimer's disease 3310;Both sexes;35 AlmerÝa;Group 0601 Alzheimer's disease 3310;Men;9 AlmerÝa;Group 0601 Alzheimer's disease 3310;Women;26 AlmerÝa;Group 0602 Multiple sclerosis 340;Both sexes;11 AlmerÝa;Group 0602 Multiple sclerosis 340;Men;4 AlmerÝa;Group 0602 Multiple sclerosis 340;Women;7 AlmerÝa;Group 0603 Epilepsy 345;Both sexes;133 AlmerÝa;Group 0603 Epilepsy 345;Men;65 AlmerÝa;Group 0603 Epilepsy 345;Women;68 AlmerÝa;Group 0604 Transient cerebral ischemia 435;Both sexes;197 AlmerÝa;Group 0604 Transient cerebral ischemia 435;Men;100 AlmerÝa;Group 0604 Transient cerebral ischemia 435;Women;97 AlmerÝa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;442 AlmerÝa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;216 AlmerÝa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;226 AlmerÝa;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;377 AlmerÝa;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;216 AlmerÝa;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;161 AlmerÝa;Grupo 0701 Cataract 366;Both sexes;24 AlmerÝa;Grupo 0701 Cataract 366;Men;10 AlmerÝa;Grupo 0701 Cataract 366;Women;14 AlmerÝa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;353 AlmerÝa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;206 AlmerÝa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;147 AlmerÝa;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;272 AlmerÝa;Group 0800 Diseases of the ear and the mastoid 380-389;Men;135 AlmerÝa;Group 0800 Diseases of the ear and the mastoid 380-389;Women;137 AlmerÝa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5.841 AlmerÝa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3.395 AlmerÝa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.446 AlmerÝa;Group 0901 Hypertensive disease 401-405;Both sexes;397 AlmerÝa;Group 0901 Hypertensive disease 401-405;Men;144 AlmerÝa;Group 0901 Hypertensive disease 401-405;Women;253 AlmerÝa;Group 0902 Angina pectoris 4111, 413;Both sexes;259 AlmerÝa;Group 0902 Angina pectoris 4111, 413;Men;158 AlmerÝa;Group 0902 Angina pectoris 4111, 413;Women;101 AlmerÝa;Group 0903 Acute myocardial infarction 410;Both sexes;815 AlmerÝa;Group 0903 Acute myocardial infarction 410;Men;599 AlmerÝa;Group 0903 Acute myocardial infarction 410;Women;216 AlmerÝa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;397 AlmerÝa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;303 AlmerÝa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;94 AlmerÝa;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;176 AlmerÝa;Group 0905 Diseases of the lungs circulation 415-417;Men;87 AlmerÝa;Group 0905 Diseases of the lungs circulation 415-417;Women;89 AlmerÝa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;637 AlmerÝa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;375 AlmerÝa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;262 AlmerÝa;Grupo 0907 Heart failure 428;Both sexes;1.146 AlmerÝa;Grupo 0907 Heart failure 428;Men;540 AlmerÝa;Grupo 0907 Heart failure 428;Women;606 AlmerÝa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.175 AlmerÝa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;663 AlmerÝa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;512 AlmerÝa;Grupo 0909 Atherosclerosis 440;Both sexes;226 AlmerÝa;Grupo 0909 Atherosclerosis 440;Men;163 AlmerÝa;Grupo 0909 Atherosclerosis 440;Women;63 AlmerÝa;Group 0910 Varicose veins of lower extremities 454;Both sexes;9 AlmerÝa;Group 0910 Varicose veins of lower extremities 454;Men;4 AlmerÝa;Group 0910 Varicose veins of lower extremities 454;Women;5 AlmerÝa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;604 AlmerÝa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;359 AlmerÝa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;245 AlmerÝa;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;6.267 AlmerÝa;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3.641 AlmerÝa;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.626 AlmerÝa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;358 AlmerÝa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;196 AlmerÝa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;162 AlmerÝa;Group 1002 Pneumonia 480-486;Both sexes;1.523 AlmerÝa;Group 1002 Pneumonia 480-486;Men;907 AlmerÝa;Group 1002 Pneumonia 480-486;Women;616 AlmerÝa;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.017 AlmerÝa;Group 1003 Acute bronchitis and bronchiolitis 466;Men;475 AlmerÝa;Group 1003 Acute bronchitis and bronchiolitis 466;Women;542 AlmerÝa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;229 AlmerÝa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;109 AlmerÝa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;120 AlmerÝa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;434 AlmerÝa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;309 AlmerÝa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;125 AlmerÝa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;897 AlmerÝa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;754 AlmerÝa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;143 AlmerÝa;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;251 AlmerÝa;Group 1007 Asthma 4930-4931,4938-4939;Men;107 AlmerÝa;Group 1007 Asthma 4930-4931,4938-4939;Women;144 AlmerÝa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.558 AlmerÝa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;784 AlmerÝa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;774 AlmerÝa;Group 1100 Diseases of the digestive system 520-579;Both sexes;6.237 AlmerÝa;Group 1100 Diseases of the digestive system 520-579;Men;3.436 AlmerÝa;Group 1100 Diseases of the digestive system 520-579;Women;2.801 AlmerÝa;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;92 AlmerÝa;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;55 AlmerÝa;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;37 AlmerÝa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;140 AlmerÝa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;69 AlmerÝa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;71 AlmerÝa;Group 1103 Diseases of the esophagus 530;Both sexes;137 AlmerÝa;Group 1103 Diseases of the esophagus 530;Men;88 AlmerÝa;Group 1103 Diseases of the esophagus 530;Women;49 AlmerÝa;Group 1104 Peptic ulcer 531-534;Both sexes;139 AlmerÝa;Group 1104 Peptic ulcer 531-534;Men;107 AlmerÝa;Group 1104 Peptic ulcer 531-534;Women;32 AlmerÝa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;143 AlmerÝa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;74 AlmerÝa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;69 AlmerÝa;Group 1106 Appendicitis 540-543;Both sexes;736 AlmerÝa;Group 1106 Appendicitis 540-543;Men;424 AlmerÝa;Group 1106 Appendicitis 540-543;Women;312 AlmerÝa;Group 1107 Inguinal hernia 550;Both sexes;312 AlmerÝa;Group 1107 Inguinal hernia 550;Men;286 AlmerÝa;Group 1107 Inguinal hernia 550;Women;26 AlmerÝa;Group 1108 Other abdominal hernia 551-553;Both sexes;346 AlmerÝa;Group 1108 Other abdominal hernia 551-553;Men;162 AlmerÝa;Group 1108 Other abdominal hernia 551-553;Women;184 AlmerÝa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;155 AlmerÝa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;81 AlmerÝa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;74 AlmerÝa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;327 AlmerÝa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;151 AlmerÝa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;176 AlmerÝa;Group 1111 Intestinal obstruction without hernia 560;Both sexes;317 AlmerÝa;Group 1111 Intestinal obstruction without hernia 560;Men;160 AlmerÝa;Group 1111 Intestinal obstruction without hernia 560;Women;157 AlmerÝa;Group 1112 Intestinal diverticulosis 562;Both sexes;318 AlmerÝa;Group 1112 Intestinal diverticulosis 562;Men;159 AlmerÝa;Group 1112 Intestinal diverticulosis 562;Women;159 AlmerÝa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;285 AlmerÝa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;181 AlmerÝa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;104 AlmerÝa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;141 AlmerÝa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;75 AlmerÝa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;66 AlmerÝa;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;126 AlmerÝa;Group 1115 Alcoholic hepatitis 5710-5713;Men;111 AlmerÝa;Group 1115 Alcoholic hepatitis 5710-5713;Women;15 AlmerÝa;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;227 AlmerÝa;Group 1116 Other diseases of the liver 570,5714-573;Men;139 AlmerÝa;Group 1116 Other diseases of the liver 570,5714-573;Women;88 AlmerÝa;Group 1117 Cholelithiasis 574;Both sexes;1.314 AlmerÝa;Group 1117 Cholelithiasis 574;Men;568 AlmerÝa;Group 1117 Cholelithiasis 574;Women;746 AlmerÝa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;256 AlmerÝa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;133 AlmerÝa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;123 AlmerÝa;Group 1119 Pancreatic diseases 577;Both sexes;515 AlmerÝa;Group 1119 Pancreatic diseases 577;Men;288 AlmerÝa;Group 1119 Pancreatic diseases 577;Women;227 AlmerÝa;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;211 AlmerÝa;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;125 AlmerÝa;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;86 AlmerÝa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;448 AlmerÝa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;259 AlmerÝa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;189 AlmerÝa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;310 AlmerÝa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;194 AlmerÝa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;116 AlmerÝa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;17 AlmerÝa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;9 AlmerÝa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;8 AlmerÝa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;121 AlmerÝa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;56 AlmerÝa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;65 AlmerÝa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;3.363 AlmerÝa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.627 AlmerÝa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.736 AlmerÝa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. AlmerÝa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. AlmerÝa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. AlmerÝa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. AlmerÝa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. AlmerÝa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. AlmerÝa;Group 1303 Internal derangement of knee 717;Both sexes;444 AlmerÝa;Group 1303 Internal derangement of knee 717;Men;304 AlmerÝa;Group 1303 Internal derangement of knee 717;Women;140 AlmerÝa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.253 AlmerÝa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;496 AlmerÝa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;757 AlmerÝa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;60 AlmerÝa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;33 AlmerÝa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;27 AlmerÝa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;140 AlmerÝa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;71 AlmerÝa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;69 AlmerÝa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;300 AlmerÝa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;160 AlmerÝa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;140 AlmerÝa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;68 AlmerÝa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;35 AlmerÝa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;33 AlmerÝa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;571 AlmerÝa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;293 AlmerÝa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;278 AlmerÝa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;527 AlmerÝa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;235 AlmerÝa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;292 AlmerÝa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.215 AlmerÝa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.406 AlmerÝa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.809 AlmerÝa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;438 AlmerÝa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;191 AlmerÝa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;247 AlmerÝa;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;331 AlmerÝa;Group 1402 Renal failure 5836-5837, 584-586;Men;188 AlmerÝa;Group 1402 Renal failure 5836-5837, 584-586;Women;143 AlmerÝa;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;315 AlmerÝa;Group 1403 Urolithiasis 592, 594, 7880;Men;217 AlmerÝa;Group 1403 Urolithiasis 592, 594, 7880;Women;98 AlmerÝa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;717 AlmerÝa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;370 AlmerÝa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;347 AlmerÝa;Group 1405 Prostatic hyperplasia 600;Both sexes;216 AlmerÝa;Group 1405 Prostatic hyperplasia 600;Men;216 AlmerÝa;Group 1405 Prostatic hyperplasia 600;Women;.. AlmerÝa;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;204 AlmerÝa;Group 1406 Other diseases of the male genital organs 601-608;Men;204 AlmerÝa;Group 1406 Other diseases of the male genital organs 601-608;Women;.. AlmerÝa;Group 1407 Disorders of breast 610-612;Both sexes;269 AlmerÝa;Group 1407 Disorders of breast 610-612;Men;20 AlmerÝa;Group 1407 Disorders of breast 610-612;Women;249 AlmerÝa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;154 AlmerÝa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. AlmerÝa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;154 AlmerÝa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;47 AlmerÝa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. AlmerÝa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;47 AlmerÝa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;524 AlmerÝa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. AlmerÝa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;524 AlmerÝa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;9.635 AlmerÝa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. AlmerÝa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;9.635 AlmerÝa;Group 1501 Legally induced abortion 635;Both sexes;12 AlmerÝa;Group 1501 Legally induced abortion 635;Men;.. AlmerÝa;Group 1501 Legally induced abortion 635;Women;12 AlmerÝa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;734 AlmerÝa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. AlmerÝa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;734 AlmerÝa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6.451 AlmerÝa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. AlmerÝa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6.451 AlmerÝa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;961 AlmerÝa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. AlmerÝa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;961 AlmerÝa;Group 1505 Single spontaneous delivery 650;Both sexes;481 AlmerÝa;Group 1505 Single spontaneous delivery 650;Men;.. AlmerÝa;Group 1505 Single spontaneous delivery 650;Women;481 AlmerÝa;Group 1506 Other deliveries 6695-6697;Both sexes;347 AlmerÝa;Group 1506 Other deliveries 6695-6697;Men;.. AlmerÝa;Group 1506 Other deliveries 6695-6697;Women;347 AlmerÝa;Group 1507 Complications related to the puerperium 670-676;Both sexes;21 AlmerÝa;Group 1507 Complications related to the puerperium 670-676;Men;.. AlmerÝa;Group 1507 Complications related to the puerperium 670-676;Women;21 AlmerÝa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;628 AlmerÝa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. AlmerÝa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;628 AlmerÝa;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;855 AlmerÝa;Group 1600 Some disorders originating in the perinatal period 760-779;Men;471 AlmerÝa;Group 1600 Some disorders originating in the perinatal period 760-779;Women;384 AlmerÝa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;323 AlmerÝa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;177 AlmerÝa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;146 AlmerÝa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;532 AlmerÝa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;294 AlmerÝa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;238 AlmerÝa;Grupo 1700 Congenital abnormalities 740-759;Both sexes;438 AlmerÝa;Grupo 1700 Congenital abnormalities 740-759;Men;270 AlmerÝa;Grupo 1700 Congenital abnormalities 740-759;Women;168 AlmerÝa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.060 AlmerÝa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.105 AlmerÝa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;955 AlmerÝa;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;225 AlmerÝa;Group 1801 Pain in throat and chest 7841, 7865;Men;132 AlmerÝa;Group 1801 Pain in throat and chest 7841, 7865;Women;93 AlmerÝa;Group 1802 Abdominal pain 7890;Both sexes;241 AlmerÝa;Group 1802 Abdominal pain 7890;Men;72 AlmerÝa;Group 1802 Abdominal pain 7890;Women;169 AlmerÝa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;130 AlmerÝa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;58 AlmerÝa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;72 AlmerÝa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.464 AlmerÝa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;843 AlmerÝa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;621 AlmerÝa;Group 1900 Injuries and poisoning 800-999;Both sexes;4.185 AlmerÝa;Group 1900 Injuries and poisoning 800-999;Men;2.302 AlmerÝa;Group 1900 Injuries and poisoning 800-999;Women;1.883 AlmerÝa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;185 AlmerÝa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;119 AlmerÝa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;66 AlmerÝa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;155 AlmerÝa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;115 AlmerÝa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;40 AlmerÝa;Group 1903 Radius and ulna fracture 813;Both sexes;366 AlmerÝa;Group 1903 Radius and ulna fracture 813;Men;206 AlmerÝa;Group 1903 Radius and ulna fracture 813;Women;160 AlmerÝa;Group 1904 Femur fracture 820-821;Both sexes;726 AlmerÝa;Group 1904 Femur fracture 820-821;Men;226 AlmerÝa;Group 1904 Femur fracture 820-821;Women;500 AlmerÝa;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;387 AlmerÝa;Group 1905 Leg fracture, including the ankle 823-824;Men;219 AlmerÝa;Group 1905 Leg fracture, including the ankle 823-824;Women;168 AlmerÝa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.181 AlmerÝa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;786 AlmerÝa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;395 AlmerÝa;Group 1907 Burns 940-949;Both sexes;44 AlmerÝa;Group 1907 Burns 940-949;Men;21 AlmerÝa;Group 1907 Burns 940-949;Women;23 AlmerÝa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;139 AlmerÝa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;84 AlmerÝa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;55 AlmerÝa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;890 AlmerÝa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;463 AlmerÝa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;427 AlmerÝa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;13 AlmerÝa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;8 AlmerÝa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;5 AlmerÝa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;99 AlmerÝa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;55 AlmerÝa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;44 AlmerÝa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;689 AlmerÝa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;405 AlmerÝa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;284 AlmerÝa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;20 AlmerÝa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;10 AlmerÝa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;10 AlmerÝa;Group 2102 Contraceptive management V25;Both sexes;7 AlmerÝa;Group 2102 Contraceptive management V25;Men;.. AlmerÝa;Group 2102 Contraceptive management V25;Women;7 AlmerÝa;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. AlmerÝa;Group 2103 Living newborns by type of delivery V30-V39;Men;.. AlmerÝa;Group 2103 Living newborns by type of delivery V30-V39;Women;.. AlmerÝa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;310 AlmerÝa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;203 AlmerÝa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;107 AlmerÝa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;352 AlmerÝa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;192 AlmerÝa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;160 Cßdiz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;103.366 Cßdiz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;46.961 Cßdiz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;56.405 Cßdiz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3.891 Cßdiz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2.157 Cßdiz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.734 Cßdiz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;282 Cßdiz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;145 Cßdiz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;137 Cßdiz;Group 0102 Imprecise intestinal infections 009;Both sexes;548 Cßdiz;Group 0102 Imprecise intestinal infections 009;Men;274 Cßdiz;Group 0102 Imprecise intestinal infections 009;Women;274 Cßdiz;Group 0103 Tuberculosis 010-018, 137;Both sexes;64 Cßdiz;Group 0103 Tuberculosis 010-018, 137;Men;46 Cßdiz;Group 0103 Tuberculosis 010-018, 137;Women;18 Cßdiz;Group 0104 Septicaemia 038;Both sexes;1.872 Cßdiz;Group 0104 Septicaemia 038;Men;1.018 Cßdiz;Group 0104 Septicaemia 038;Women;854 Cßdiz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;127 Cßdiz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;98 Cßdiz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;28 Cßdiz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;998 Cßdiz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;575 Cßdiz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;423 Cßdiz;Group 0200 Neoplasms 140-239;Both sexes;8.924 Cßdiz;Group 0200 Neoplasms 140-239;Men;4.867 Cßdiz;Group 0200 Neoplasms 140-239;Women;4.057 Cßdiz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.026 Cßdiz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;619 Cßdiz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;407 Cßdiz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;686 Cßdiz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;572 Cßdiz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;114 Cßdiz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;178 Cßdiz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;107 Cßdiz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;71 Cßdiz;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;797 Cßdiz;Group 0204 Malignant neoplasm of breast 174-175;Men;12 Cßdiz;Group 0204 Malignant neoplasm of breast 174-175;Women;786 Cßdiz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;200 Cßdiz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Cßdiz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;200 Cßdiz;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;121 Cßdiz;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Cßdiz;Group 0206 Malignant neoplasm of ovary 1830;Women;121 Cßdiz;Group 0207 Malignant neoplasm of prostate 185;Both sexes;281 Cßdiz;Group 0207 Malignant neoplasm of prostate 185;Men;281 Cßdiz;Group 0207 Malignant neoplasm of prostate 185;Women;.. Cßdiz;Group 0208 Malignant neoplasm of bladder 188;Both sexes;878 Cßdiz;Group 0208 Malignant neoplasm of bladder 188;Men;757 Cßdiz;Group 0208 Malignant neoplasm of bladder 188;Women;120 Cßdiz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;3.032 Cßdiz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.912 Cßdiz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.119 Cßdiz;Group 0210 Carcinoma in situ 230-234;Both sexes;140 Cßdiz;Group 0210 Carcinoma in situ 230-234;Men;90 Cßdiz;Group 0210 Carcinoma in situ 230-234;Women;50 Cßdiz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;63 Cßdiz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;30 Cßdiz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;32 Cßdiz;Grupo 0212 Leiomyoma of uterus 218;Both sexes;439 Cßdiz;Grupo 0212 Leiomyoma of uterus 218;Men;.. Cßdiz;Grupo 0212 Leiomyoma of uterus 218;Women;439 Cßdiz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.082 Cßdiz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;485 Cßdiz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;596 Cßdiz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.154 Cßdiz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;551 Cßdiz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;603 Cßdiz;Group 0301 Anaemias 280-285;Both sexes;702 Cßdiz;Group 0301 Anaemias 280-285;Men;332 Cßdiz;Group 0301 Anaemias 280-285;Women;370 Cßdiz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;452 Cßdiz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;220 Cßdiz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;232 Cßdiz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.807 Cßdiz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;685 Cßdiz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.122 Cßdiz;Group 0401 Diabetes mellitus 249-250;Both sexes;562 Cßdiz;Group 0401 Diabetes mellitus 249-250;Men;300 Cßdiz;Group 0401 Diabetes mellitus 249-250;Women;262 Cßdiz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.245 Cßdiz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;385 Cßdiz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;860 Cßdiz;Group 0500 Mental disorders 290-319;Both sexes;1.807 Cßdiz;Group 0500 Mental disorders 290-319;Men;1.076 Cßdiz;Group 0500 Mental disorders 290-319;Women;731 Cßdiz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;76 Cßdiz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;29 Cßdiz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;47 Cßdiz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;101 Cßdiz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;85 Cßdiz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;17 Cßdiz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;129 Cßdiz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;91 Cßdiz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;38 Cßdiz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;587 Cßdiz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;433 Cßdiz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;154 Cßdiz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;359 Cßdiz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;171 Cßdiz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;188 Cßdiz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;555 Cßdiz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;267 Cßdiz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;288 Cßdiz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.296 Cßdiz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.070 Cßdiz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.226 Cßdiz;Group 0601 Alzheimer's disease 3310;Both sexes;56 Cßdiz;Group 0601 Alzheimer's disease 3310;Men;23 Cßdiz;Group 0601 Alzheimer's disease 3310;Women;33 Cßdiz;Group 0602 Multiple sclerosis 340;Both sexes;64 Cßdiz;Group 0602 Multiple sclerosis 340;Men;14 Cßdiz;Group 0602 Multiple sclerosis 340;Women;50 Cßdiz;Group 0603 Epilepsy 345;Both sexes;409 Cßdiz;Group 0603 Epilepsy 345;Men;221 Cßdiz;Group 0603 Epilepsy 345;Women;188 Cßdiz;Group 0604 Transient cerebral ischemia 435;Both sexes;544 Cßdiz;Group 0604 Transient cerebral ischemia 435;Men;247 Cßdiz;Group 0604 Transient cerebral ischemia 435;Women;297 Cßdiz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.223 Cßdiz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;566 Cßdiz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;657 Cßdiz;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;822 Cßdiz;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;412 Cßdiz;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;410 Cßdiz;Grupo 0701 Cataract 366;Both sexes;181 Cßdiz;Grupo 0701 Cataract 366;Men;96 Cßdiz;Grupo 0701 Cataract 366;Women;85 Cßdiz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;641 Cßdiz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;316 Cßdiz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;325 Cßdiz;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;420 Cßdiz;Group 0800 Diseases of the ear and the mastoid 380-389;Men;231 Cßdiz;Group 0800 Diseases of the ear and the mastoid 380-389;Women;188 Cßdiz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;14.653 Cßdiz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;8.209 Cßdiz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;6.445 Cßdiz;Group 0901 Hypertensive disease 401-405;Both sexes;785 Cßdiz;Group 0901 Hypertensive disease 401-405;Men;342 Cßdiz;Group 0901 Hypertensive disease 401-405;Women;443 Cßdiz;Group 0902 Angina pectoris 4111, 413;Both sexes;966 Cßdiz;Group 0902 Angina pectoris 4111, 413;Men;561 Cßdiz;Group 0902 Angina pectoris 4111, 413;Women;405 Cßdiz;Group 0903 Acute myocardial infarction 410;Both sexes;1.368 Cßdiz;Group 0903 Acute myocardial infarction 410;Men;920 Cßdiz;Group 0903 Acute myocardial infarction 410;Women;449 Cßdiz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.567 Cßdiz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.088 Cßdiz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;479 Cßdiz;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;297 Cßdiz;Group 0905 Diseases of the lungs circulation 415-417;Men;131 Cßdiz;Group 0905 Diseases of the lungs circulation 415-417;Women;166 Cßdiz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.825 Cßdiz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;955 Cßdiz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;869 Cßdiz;Grupo 0907 Heart failure 428;Both sexes;2.606 Cßdiz;Grupo 0907 Heart failure 428;Men;1.163 Cßdiz;Grupo 0907 Heart failure 428;Women;1.443 Cßdiz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.549 Cßdiz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.447 Cßdiz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.102 Cßdiz;Grupo 0909 Atherosclerosis 440;Both sexes;425 Cßdiz;Grupo 0909 Atherosclerosis 440;Men;307 Cßdiz;Grupo 0909 Atherosclerosis 440;Women;118 Cßdiz;Group 0910 Varicose veins of lower extremities 454;Both sexes;139 Cßdiz;Group 0910 Varicose veins of lower extremities 454;Men;60 Cßdiz;Group 0910 Varicose veins of lower extremities 454;Women;80 Cßdiz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.127 Cßdiz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.236 Cßdiz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;891 Cßdiz;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;9.603 Cßdiz;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;5.462 Cßdiz;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;4.141 Cßdiz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;701 Cßdiz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;381 Cßdiz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;320 Cßdiz;Group 1002 Pneumonia 480-486;Both sexes;1.854 Cßdiz;Group 1002 Pneumonia 480-486;Men;1.040 Cßdiz;Group 1002 Pneumonia 480-486;Women;814 Cßdiz;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.214 Cßdiz;Group 1003 Acute bronchitis and bronchiolitis 466;Men;652 Cßdiz;Group 1003 Acute bronchitis and bronchiolitis 466;Women;562 Cßdiz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;361 Cßdiz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;183 Cßdiz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;178 Cßdiz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;837 Cßdiz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;525 Cßdiz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;312 Cßdiz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.143 Cßdiz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;861 Cßdiz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;282 Cßdiz;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;321 Cßdiz;Group 1007 Asthma 4930-4931,4938-4939;Men;107 Cßdiz;Group 1007 Asthma 4930-4931,4938-4939;Women;214 Cßdiz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3.172 Cßdiz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.714 Cßdiz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.458 Cßdiz;Group 1100 Diseases of the digestive system 520-579;Both sexes;12.725 Cßdiz;Group 1100 Diseases of the digestive system 520-579;Men;6.857 Cßdiz;Group 1100 Diseases of the digestive system 520-579;Women;5.868 Cßdiz;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;150 Cßdiz;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;72 Cßdiz;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;77 Cßdiz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;176 Cßdiz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;95 Cßdiz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;81 Cßdiz;Group 1103 Diseases of the esophagus 530;Both sexes;207 Cßdiz;Group 1103 Diseases of the esophagus 530;Men;119 Cßdiz;Group 1103 Diseases of the esophagus 530;Women;88 Cßdiz;Group 1104 Peptic ulcer 531-534;Both sexes;280 Cßdiz;Group 1104 Peptic ulcer 531-534;Men;203 Cßdiz;Group 1104 Peptic ulcer 531-534;Women;77 Cßdiz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;498 Cßdiz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;222 Cßdiz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;276 Cßdiz;Group 1106 Appendicitis 540-543;Both sexes;1.087 Cßdiz;Group 1106 Appendicitis 540-543;Men;590 Cßdiz;Group 1106 Appendicitis 540-543;Women;497 Cßdiz;Group 1107 Inguinal hernia 550;Both sexes;1.079 Cßdiz;Group 1107 Inguinal hernia 550;Men;961 Cßdiz;Group 1107 Inguinal hernia 550;Women;117 Cßdiz;Group 1108 Other abdominal hernia 551-553;Both sexes;942 Cßdiz;Group 1108 Other abdominal hernia 551-553;Men;438 Cßdiz;Group 1108 Other abdominal hernia 551-553;Women;503 Cßdiz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;402 Cßdiz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;194 Cßdiz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;208 Cßdiz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;703 Cßdiz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;310 Cßdiz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;393 Cßdiz;Group 1111 Intestinal obstruction without hernia 560;Both sexes;549 Cßdiz;Group 1111 Intestinal obstruction without hernia 560;Men;290 Cßdiz;Group 1111 Intestinal obstruction without hernia 560;Women;259 Cßdiz;Group 1112 Intestinal diverticulosis 562;Both sexes;429 Cßdiz;Group 1112 Intestinal diverticulosis 562;Men;213 Cßdiz;Group 1112 Intestinal diverticulosis 562;Women;216 Cßdiz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;703 Cßdiz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;444 Cßdiz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;259 Cßdiz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;404 Cßdiz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;180 Cßdiz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;224 Cßdiz;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;317 Cßdiz;Group 1115 Alcoholic hepatitis 5710-5713;Men;277 Cßdiz;Group 1115 Alcoholic hepatitis 5710-5713;Women;40 Cßdiz;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;426 Cßdiz;Group 1116 Other diseases of the liver 570,5714-573;Men;272 Cßdiz;Group 1116 Other diseases of the liver 570,5714-573;Women;154 Cßdiz;Group 1117 Cholelithiasis 574;Both sexes;2.376 Cßdiz;Group 1117 Cholelithiasis 574;Men;903 Cßdiz;Group 1117 Cholelithiasis 574;Women;1.473 Cßdiz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;596 Cßdiz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;300 Cßdiz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;296 Cßdiz;Group 1119 Pancreatic diseases 577;Both sexes;800 Cßdiz;Group 1119 Pancreatic diseases 577;Men;429 Cßdiz;Group 1119 Pancreatic diseases 577;Women;371 Cßdiz;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;602 Cßdiz;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;344 Cßdiz;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;257 Cßdiz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.239 Cßdiz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;657 Cßdiz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;582 Cßdiz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;661 Cßdiz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;404 Cßdiz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;257 Cßdiz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;97 Cßdiz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;50 Cßdiz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;47 Cßdiz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;480 Cßdiz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;203 Cßdiz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;277 Cßdiz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;5.751 Cßdiz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.627 Cßdiz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.124 Cßdiz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Cßdiz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Cßdiz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Cßdiz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Cßdiz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Cßdiz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Cßdiz;Group 1303 Internal derangement of knee 717;Both sexes;594 Cßdiz;Group 1303 Internal derangement of knee 717;Men;426 Cßdiz;Group 1303 Internal derangement of knee 717;Women;168 Cßdiz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.473 Cßdiz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.027 Cßdiz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.446 Cßdiz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;149 Cßdiz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;54 Cßdiz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;94 Cßdiz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;231 Cßdiz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;120 Cßdiz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;111 Cßdiz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;485 Cßdiz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;252 Cßdiz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;233 Cßdiz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;240 Cßdiz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;91 Cßdiz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;149 Cßdiz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;567 Cßdiz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;301 Cßdiz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;266 Cßdiz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.012 Cßdiz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;355 Cßdiz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;657 Cßdiz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;7.261 Cßdiz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3.073 Cßdiz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4.188 Cßdiz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;719 Cßdiz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;294 Cßdiz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;425 Cßdiz;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;594 Cßdiz;Group 1402 Renal failure 5836-5837, 584-586;Men;319 Cßdiz;Group 1402 Renal failure 5836-5837, 584-586;Women;275 Cßdiz;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.220 Cßdiz;Group 1403 Urolithiasis 592, 594, 7880;Men;681 Cßdiz;Group 1403 Urolithiasis 592, 594, 7880;Women;539 Cßdiz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.832 Cßdiz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;879 Cßdiz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;953 Cßdiz;Group 1405 Prostatic hyperplasia 600;Both sexes;425 Cßdiz;Group 1405 Prostatic hyperplasia 600;Men;425 Cßdiz;Group 1405 Prostatic hyperplasia 600;Women;.. Cßdiz;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;416 Cßdiz;Group 1406 Other diseases of the male genital organs 601-608;Men;416 Cßdiz;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Cßdiz;Group 1407 Disorders of breast 610-612;Both sexes;452 Cßdiz;Group 1407 Disorders of breast 610-612;Men;47 Cßdiz;Group 1407 Disorders of breast 610-612;Women;405 Cßdiz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;248 Cßdiz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Cßdiz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;248 Cßdiz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;225 Cßdiz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Cßdiz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;225 Cßdiz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.130 Cßdiz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;12 Cßdiz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.118 Cßdiz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;13.523 Cßdiz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Cßdiz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;13.523 Cßdiz;Group 1501 Legally induced abortion 635;Both sexes;29 Cßdiz;Group 1501 Legally induced abortion 635;Men;.. Cßdiz;Group 1501 Legally induced abortion 635;Women;29 Cßdiz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;920 Cßdiz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Cßdiz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;920 Cßdiz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;7.645 Cßdiz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Cßdiz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;7.645 Cßdiz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.575 Cßdiz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Cßdiz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.575 Cßdiz;Group 1505 Single spontaneous delivery 650;Both sexes;1.407 Cßdiz;Group 1505 Single spontaneous delivery 650;Men;.. Cßdiz;Group 1505 Single spontaneous delivery 650;Women;1.407 Cßdiz;Group 1506 Other deliveries 6695-6697;Both sexes;1.219 Cßdiz;Group 1506 Other deliveries 6695-6697;Men;.. Cßdiz;Group 1506 Other deliveries 6695-6697;Women;1.219 Cßdiz;Group 1507 Complications related to the puerperium 670-676;Both sexes;58 Cßdiz;Group 1507 Complications related to the puerperium 670-676;Men;.. Cßdiz;Group 1507 Complications related to the puerperium 670-676;Women;58 Cßdiz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;672 Cßdiz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Cßdiz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;672 Cßdiz;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.511 Cßdiz;Group 1600 Some disorders originating in the perinatal period 760-779;Men;811 Cßdiz;Group 1600 Some disorders originating in the perinatal period 760-779;Women;700 Cßdiz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;509 Cßdiz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;251 Cßdiz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;258 Cßdiz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.001 Cßdiz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;560 Cßdiz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;441 Cßdiz;Grupo 1700 Congenital abnormalities 740-759;Both sexes;863 Cßdiz;Grupo 1700 Congenital abnormalities 740-759;Men;488 Cßdiz;Grupo 1700 Congenital abnormalities 740-759;Women;376 Cßdiz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;6.235 Cßdiz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3.238 Cßdiz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2.997 Cßdiz;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;886 Cßdiz;Group 1801 Pain in throat and chest 7841, 7865;Men;462 Cßdiz;Group 1801 Pain in throat and chest 7841, 7865;Women;424 Cßdiz;Group 1802 Abdominal pain 7890;Both sexes;1.149 Cßdiz;Group 1802 Abdominal pain 7890;Men;441 Cßdiz;Group 1802 Abdominal pain 7890;Women;707 Cßdiz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;233 Cßdiz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;124 Cßdiz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;109 Cßdiz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;3.967 Cßdiz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.210 Cßdiz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.758 Cßdiz;Group 1900 Injuries and poisoning 800-999;Both sexes;7.588 Cßdiz;Group 1900 Injuries and poisoning 800-999;Men;3.865 Cßdiz;Group 1900 Injuries and poisoning 800-999;Women;3.723 Cßdiz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;523 Cßdiz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;308 Cßdiz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;216 Cßdiz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;236 Cßdiz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;183 Cßdiz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;53 Cßdiz;Group 1903 Radius and ulna fracture 813;Both sexes;441 Cßdiz;Group 1903 Radius and ulna fracture 813;Men;219 Cßdiz;Group 1903 Radius and ulna fracture 813;Women;223 Cßdiz;Group 1904 Femur fracture 820-821;Both sexes;1.290 Cßdiz;Group 1904 Femur fracture 820-821;Men;372 Cßdiz;Group 1904 Femur fracture 820-821;Women;918 Cßdiz;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;639 Cßdiz;Group 1905 Leg fracture, including the ankle 823-824;Men;332 Cßdiz;Group 1905 Leg fracture, including the ankle 823-824;Women;308 Cßdiz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.964 Cßdiz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.171 Cßdiz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;793 Cßdiz;Group 1907 Burns 940-949;Both sexes;29 Cßdiz;Group 1907 Burns 940-949;Men;16 Cßdiz;Group 1907 Burns 940-949;Women;14 Cßdiz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;379 Cßdiz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;186 Cßdiz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;193 Cßdiz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.857 Cßdiz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;953 Cßdiz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;904 Cßdiz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;49 Cßdiz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;28 Cßdiz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;21 Cßdiz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;180 Cßdiz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;97 Cßdiz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;83 Cßdiz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.293 Cßdiz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;626 Cßdiz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;667 Cßdiz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;32 Cßdiz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;20 Cßdiz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;13 Cßdiz;Group 2102 Contraceptive management V25;Both sexes;17 Cßdiz;Group 2102 Contraceptive management V25;Men;2 Cßdiz;Group 2102 Contraceptive management V25;Women;15 Cßdiz;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Cßdiz;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Cßdiz;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Cßdiz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;465 Cßdiz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;323 Cßdiz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;141 Cßdiz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;779 Cßdiz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;280 Cßdiz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;499 C¾rdoba;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;70.697 C¾rdoba;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;33.117 C¾rdoba;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;37.580 C¾rdoba;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.061 C¾rdoba;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;624 C¾rdoba;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;437 C¾rdoba;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;108 C¾rdoba;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;61 C¾rdoba;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;47 C¾rdoba;Group 0102 Imprecise intestinal infections 009;Both sexes;29 C¾rdoba;Group 0102 Imprecise intestinal infections 009;Men;16 C¾rdoba;Group 0102 Imprecise intestinal infections 009;Women;13 C¾rdoba;Group 0103 Tuberculosis 010-018, 137;Both sexes;46 C¾rdoba;Group 0103 Tuberculosis 010-018, 137;Men;26 C¾rdoba;Group 0103 Tuberculosis 010-018, 137;Women;20 C¾rdoba;Group 0104 Septicaemia 038;Both sexes;369 C¾rdoba;Group 0104 Septicaemia 038;Men;200 C¾rdoba;Group 0104 Septicaemia 038;Women;169 C¾rdoba;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;60 C¾rdoba;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;48 C¾rdoba;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;12 C¾rdoba;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;449 C¾rdoba;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;273 C¾rdoba;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;176 C¾rdoba;Group 0200 Neoplasms 140-239;Both sexes;7.039 C¾rdoba;Group 0200 Neoplasms 140-239;Men;3.729 C¾rdoba;Group 0200 Neoplasms 140-239;Women;3.310 C¾rdoba;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;695 C¾rdoba;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;457 C¾rdoba;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;238 C¾rdoba;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;428 C¾rdoba;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;353 C¾rdoba;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;75 C¾rdoba;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;287 C¾rdoba;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;175 C¾rdoba;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;112 C¾rdoba;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;537 C¾rdoba;Group 0204 Malignant neoplasm of breast 174-175;Men;4 C¾rdoba;Group 0204 Malignant neoplasm of breast 174-175;Women;533 C¾rdoba;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;160 C¾rdoba;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. C¾rdoba;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;160 C¾rdoba;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;73 C¾rdoba;Group 0206 Malignant neoplasm of ovary 1830;Men;.. C¾rdoba;Group 0206 Malignant neoplasm of ovary 1830;Women;73 C¾rdoba;Group 0207 Malignant neoplasm of prostate 185;Both sexes;211 C¾rdoba;Group 0207 Malignant neoplasm of prostate 185;Men;211 C¾rdoba;Group 0207 Malignant neoplasm of prostate 185;Women;.. C¾rdoba;Group 0208 Malignant neoplasm of bladder 188;Both sexes;589 C¾rdoba;Group 0208 Malignant neoplasm of bladder 188;Men;468 C¾rdoba;Group 0208 Malignant neoplasm of bladder 188;Women;121 C¾rdoba;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.467 C¾rdoba;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.478 C¾rdoba;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;989 C¾rdoba;Group 0210 Carcinoma in situ 230-234;Both sexes;77 C¾rdoba;Group 0210 Carcinoma in situ 230-234;Men;13 C¾rdoba;Group 0210 Carcinoma in situ 230-234;Women;64 C¾rdoba;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;76 C¾rdoba;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;39 C¾rdoba;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;37 C¾rdoba;Grupo 0212 Leiomyoma of uterus 218;Both sexes;234 C¾rdoba;Grupo 0212 Leiomyoma of uterus 218;Men;.. C¾rdoba;Grupo 0212 Leiomyoma of uterus 218;Women;234 C¾rdoba;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.205 C¾rdoba;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;531 C¾rdoba;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;674 C¾rdoba;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;688 C¾rdoba;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;335 C¾rdoba;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;353 C¾rdoba;Group 0301 Anaemias 280-285;Both sexes;451 C¾rdoba;Group 0301 Anaemias 280-285;Men;230 C¾rdoba;Group 0301 Anaemias 280-285;Women;221 C¾rdoba;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;237 C¾rdoba;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;105 C¾rdoba;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;132 C¾rdoba;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.123 C¾rdoba;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;448 C¾rdoba;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;675 C¾rdoba;Group 0401 Diabetes mellitus 249-250;Both sexes;261 C¾rdoba;Group 0401 Diabetes mellitus 249-250;Men;133 C¾rdoba;Group 0401 Diabetes mellitus 249-250;Women;128 C¾rdoba;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;862 C¾rdoba;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;315 C¾rdoba;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;547 C¾rdoba;Group 0500 Mental disorders 290-319;Both sexes;1.034 C¾rdoba;Group 0500 Mental disorders 290-319;Men;552 C¾rdoba;Group 0500 Mental disorders 290-319;Women;482 C¾rdoba;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;25 C¾rdoba;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;15 C¾rdoba;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;10 C¾rdoba;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;34 C¾rdoba;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;31 C¾rdoba;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;3 C¾rdoba;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;71 C¾rdoba;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;52 C¾rdoba;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;19 C¾rdoba;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;281 C¾rdoba;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;185 C¾rdoba;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;96 C¾rdoba;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;272 C¾rdoba;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;118 C¾rdoba;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;154 C¾rdoba;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;351 C¾rdoba;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;151 C¾rdoba;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;200 C¾rdoba;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.257 C¾rdoba;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;610 C¾rdoba;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;647 C¾rdoba;Group 0601 Alzheimer's disease 3310;Both sexes;17 C¾rdoba;Group 0601 Alzheimer's disease 3310;Men;9 C¾rdoba;Group 0601 Alzheimer's disease 3310;Women;8 C¾rdoba;Group 0602 Multiple sclerosis 340;Both sexes;21 C¾rdoba;Group 0602 Multiple sclerosis 340;Men;6 C¾rdoba;Group 0602 Multiple sclerosis 340;Women;15 C¾rdoba;Group 0603 Epilepsy 345;Both sexes;175 C¾rdoba;Group 0603 Epilepsy 345;Men;98 C¾rdoba;Group 0603 Epilepsy 345;Women;77 C¾rdoba;Group 0604 Transient cerebral ischemia 435;Both sexes;211 C¾rdoba;Group 0604 Transient cerebral ischemia 435;Men;105 C¾rdoba;Group 0604 Transient cerebral ischemia 435;Women;106 C¾rdoba;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;833 C¾rdoba;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;392 C¾rdoba;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;441 C¾rdoba;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;937 C¾rdoba;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;565 C¾rdoba;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;372 C¾rdoba;Grupo 0701 Cataract 366;Both sexes;166 C¾rdoba;Grupo 0701 Cataract 366;Men;98 C¾rdoba;Grupo 0701 Cataract 366;Women;68 C¾rdoba;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;771 C¾rdoba;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;467 C¾rdoba;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;304 C¾rdoba;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;236 C¾rdoba;Group 0800 Diseases of the ear and the mastoid 380-389;Men;115 C¾rdoba;Group 0800 Diseases of the ear and the mastoid 380-389;Women;121 C¾rdoba;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;10.051 C¾rdoba;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5.863 C¾rdoba;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4.188 C¾rdoba;Group 0901 Hypertensive disease 401-405;Both sexes;401 C¾rdoba;Group 0901 Hypertensive disease 401-405;Men;188 C¾rdoba;Group 0901 Hypertensive disease 401-405;Women;213 C¾rdoba;Group 0902 Angina pectoris 4111, 413;Both sexes;693 C¾rdoba;Group 0902 Angina pectoris 4111, 413;Men;477 C¾rdoba;Group 0902 Angina pectoris 4111, 413;Women;216 C¾rdoba;Group 0903 Acute myocardial infarction 410;Both sexes;771 C¾rdoba;Group 0903 Acute myocardial infarction 410;Men;565 C¾rdoba;Group 0903 Acute myocardial infarction 410;Women;206 C¾rdoba;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;753 C¾rdoba;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;582 C¾rdoba;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;171 C¾rdoba;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;331 C¾rdoba;Group 0905 Diseases of the lungs circulation 415-417;Men;145 C¾rdoba;Group 0905 Diseases of the lungs circulation 415-417;Women;186 C¾rdoba;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.205 C¾rdoba;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;720 C¾rdoba;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;485 C¾rdoba;Grupo 0907 Heart failure 428;Both sexes;1.853 C¾rdoba;Grupo 0907 Heart failure 428;Men;868 C¾rdoba;Grupo 0907 Heart failure 428;Women;985 C¾rdoba;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.690 C¾rdoba;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;922 C¾rdoba;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;768 C¾rdoba;Grupo 0909 Atherosclerosis 440;Both sexes;277 C¾rdoba;Grupo 0909 Atherosclerosis 440;Men;218 C¾rdoba;Grupo 0909 Atherosclerosis 440;Women;59 C¾rdoba;Group 0910 Varicose veins of lower extremities 454;Both sexes;206 C¾rdoba;Group 0910 Varicose veins of lower extremities 454;Men;79 C¾rdoba;Group 0910 Varicose veins of lower extremities 454;Women;127 C¾rdoba;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.871 C¾rdoba;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.099 C¾rdoba;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;772 C¾rdoba;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7.378 C¾rdoba;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.290 C¾rdoba;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3.088 C¾rdoba;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;357 C¾rdoba;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;188 C¾rdoba;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;169 C¾rdoba;Group 1002 Pneumonia 480-486;Both sexes;1.771 C¾rdoba;Group 1002 Pneumonia 480-486;Men;1.046 C¾rdoba;Group 1002 Pneumonia 480-486;Women;725 C¾rdoba;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;277 C¾rdoba;Group 1003 Acute bronchitis and bronchiolitis 466;Men;176 C¾rdoba;Group 1003 Acute bronchitis and bronchiolitis 466;Women;101 C¾rdoba;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;108 C¾rdoba;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;54 C¾rdoba;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;54 C¾rdoba;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;407 C¾rdoba;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;251 C¾rdoba;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;156 C¾rdoba;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.188 C¾rdoba;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;963 C¾rdoba;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;225 C¾rdoba;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;137 C¾rdoba;Group 1007 Asthma 4930-4931,4938-4939;Men;27 C¾rdoba;Group 1007 Asthma 4930-4931,4938-4939;Women;110 C¾rdoba;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3.133 C¾rdoba;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.585 C¾rdoba;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.548 C¾rdoba;Group 1100 Diseases of the digestive system 520-579;Both sexes;10.457 C¾rdoba;Group 1100 Diseases of the digestive system 520-579;Men;5.781 C¾rdoba;Group 1100 Diseases of the digestive system 520-579;Women;4.676 C¾rdoba;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;190 C¾rdoba;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;93 C¾rdoba;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;97 C¾rdoba;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;185 C¾rdoba;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;105 C¾rdoba;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;80 C¾rdoba;Group 1103 Diseases of the esophagus 530;Both sexes;235 C¾rdoba;Group 1103 Diseases of the esophagus 530;Men;130 C¾rdoba;Group 1103 Diseases of the esophagus 530;Women;105 C¾rdoba;Group 1104 Peptic ulcer 531-534;Both sexes;179 C¾rdoba;Group 1104 Peptic ulcer 531-534;Men;123 C¾rdoba;Group 1104 Peptic ulcer 531-534;Women;56 C¾rdoba;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;149 C¾rdoba;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;79 C¾rdoba;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;70 C¾rdoba;Group 1106 Appendicitis 540-543;Both sexes;795 C¾rdoba;Group 1106 Appendicitis 540-543;Men;463 C¾rdoba;Group 1106 Appendicitis 540-543;Women;332 C¾rdoba;Group 1107 Inguinal hernia 550;Both sexes;999 C¾rdoba;Group 1107 Inguinal hernia 550;Men;887 C¾rdoba;Group 1107 Inguinal hernia 550;Women;112 C¾rdoba;Group 1108 Other abdominal hernia 551-553;Both sexes;1.094 C¾rdoba;Group 1108 Other abdominal hernia 551-553;Men;498 C¾rdoba;Group 1108 Other abdominal hernia 551-553;Women;596 C¾rdoba;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;196 C¾rdoba;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;107 C¾rdoba;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;89 C¾rdoba;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;438 C¾rdoba;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;209 C¾rdoba;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;229 C¾rdoba;Group 1111 Intestinal obstruction without hernia 560;Both sexes;554 C¾rdoba;Group 1111 Intestinal obstruction without hernia 560;Men;294 C¾rdoba;Group 1111 Intestinal obstruction without hernia 560;Women;260 C¾rdoba;Group 1112 Intestinal diverticulosis 562;Both sexes;395 C¾rdoba;Group 1112 Intestinal diverticulosis 562;Men;223 C¾rdoba;Group 1112 Intestinal diverticulosis 562;Women;172 C¾rdoba;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;593 C¾rdoba;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;364 C¾rdoba;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;229 C¾rdoba;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;265 C¾rdoba;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;126 C¾rdoba;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;139 C¾rdoba;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;193 C¾rdoba;Group 1115 Alcoholic hepatitis 5710-5713;Men;167 C¾rdoba;Group 1115 Alcoholic hepatitis 5710-5713;Women;26 C¾rdoba;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;393 C¾rdoba;Group 1116 Other diseases of the liver 570,5714-573;Men;240 C¾rdoba;Group 1116 Other diseases of the liver 570,5714-573;Women;153 C¾rdoba;Group 1117 Cholelithiasis 574;Both sexes;2.146 C¾rdoba;Group 1117 Cholelithiasis 574;Men;885 C¾rdoba;Group 1117 Cholelithiasis 574;Women;1.261 C¾rdoba;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;355 C¾rdoba;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;194 C¾rdoba;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;161 C¾rdoba;Group 1119 Pancreatic diseases 577;Both sexes;669 C¾rdoba;Group 1119 Pancreatic diseases 577;Men;344 C¾rdoba;Group 1119 Pancreatic diseases 577;Women;325 C¾rdoba;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;434 C¾rdoba;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;250 C¾rdoba;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;184 C¾rdoba;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;689 C¾rdoba;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;392 C¾rdoba;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;297 C¾rdoba;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;398 C¾rdoba;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;252 C¾rdoba;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;146 C¾rdoba;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;25 C¾rdoba;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;12 C¾rdoba;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;13 C¾rdoba;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;266 C¾rdoba;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;128 C¾rdoba;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;138 C¾rdoba;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;5.135 C¾rdoba;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.088 C¾rdoba;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.047 C¾rdoba;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. C¾rdoba;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. C¾rdoba;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. C¾rdoba;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. C¾rdoba;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. C¾rdoba;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. C¾rdoba;Group 1303 Internal derangement of knee 717;Both sexes;359 C¾rdoba;Group 1303 Internal derangement of knee 717;Men;256 C¾rdoba;Group 1303 Internal derangement of knee 717;Women;103 C¾rdoba;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.301 C¾rdoba;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;851 C¾rdoba;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.450 C¾rdoba;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;82 C¾rdoba;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;25 C¾rdoba;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;57 C¾rdoba;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;337 C¾rdoba;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;147 C¾rdoba;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;190 C¾rdoba;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;372 C¾rdoba;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;171 C¾rdoba;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;201 C¾rdoba;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;46 C¾rdoba;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;21 C¾rdoba;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;25 C¾rdoba;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;578 C¾rdoba;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;279 C¾rdoba;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;299 C¾rdoba;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.060 C¾rdoba;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;338 C¾rdoba;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;722 C¾rdoba;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.655 C¾rdoba;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.705 C¾rdoba;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.950 C¾rdoba;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;401 C¾rdoba;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;159 C¾rdoba;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;242 C¾rdoba;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;541 C¾rdoba;Group 1402 Renal failure 5836-5837, 584-586;Men;316 C¾rdoba;Group 1402 Renal failure 5836-5837, 584-586;Women;225 C¾rdoba;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;456 C¾rdoba;Group 1403 Urolithiasis 592, 594, 7880;Men;251 C¾rdoba;Group 1403 Urolithiasis 592, 594, 7880;Women;205 C¾rdoba;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;646 C¾rdoba;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;337 C¾rdoba;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;309 C¾rdoba;Group 1405 Prostatic hyperplasia 600;Both sexes;271 C¾rdoba;Group 1405 Prostatic hyperplasia 600;Men;271 C¾rdoba;Group 1405 Prostatic hyperplasia 600;Women;.. C¾rdoba;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;325 C¾rdoba;Group 1406 Other diseases of the male genital organs 601-608;Men;325 C¾rdoba;Group 1406 Other diseases of the male genital organs 601-608;Women;.. C¾rdoba;Group 1407 Disorders of breast 610-612;Both sexes;299 C¾rdoba;Group 1407 Disorders of breast 610-612;Men;43 C¾rdoba;Group 1407 Disorders of breast 610-612;Women;256 C¾rdoba;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;132 C¾rdoba;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. C¾rdoba;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;132 C¾rdoba;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;31 C¾rdoba;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. C¾rdoba;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;31 C¾rdoba;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;553 C¾rdoba;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;3 C¾rdoba;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;550 C¾rdoba;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;8.387 C¾rdoba;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. C¾rdoba;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;8.387 C¾rdoba;Group 1501 Legally induced abortion 635;Both sexes;3 C¾rdoba;Group 1501 Legally induced abortion 635;Men;.. C¾rdoba;Group 1501 Legally induced abortion 635;Women;3 C¾rdoba;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;339 C¾rdoba;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. C¾rdoba;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;339 C¾rdoba;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;5.021 C¾rdoba;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. C¾rdoba;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;5.021 C¾rdoba;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.061 C¾rdoba;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. C¾rdoba;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.061 C¾rdoba;Group 1505 Single spontaneous delivery 650;Both sexes;817 C¾rdoba;Group 1505 Single spontaneous delivery 650;Men;.. C¾rdoba;Group 1505 Single spontaneous delivery 650;Women;817 C¾rdoba;Group 1506 Other deliveries 6695-6697;Both sexes;551 C¾rdoba;Group 1506 Other deliveries 6695-6697;Men;.. C¾rdoba;Group 1506 Other deliveries 6695-6697;Women;551 C¾rdoba;Group 1507 Complications related to the puerperium 670-676;Both sexes;35 C¾rdoba;Group 1507 Complications related to the puerperium 670-676;Men;.. C¾rdoba;Group 1507 Complications related to the puerperium 670-676;Women;35 C¾rdoba;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;560 C¾rdoba;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. C¾rdoba;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;560 C¾rdoba;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;988 C¾rdoba;Group 1600 Some disorders originating in the perinatal period 760-779;Men;545 C¾rdoba;Group 1600 Some disorders originating in the perinatal period 760-779;Women;443 C¾rdoba;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;311 C¾rdoba;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;152 C¾rdoba;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;159 C¾rdoba;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;677 C¾rdoba;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;393 C¾rdoba;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;284 C¾rdoba;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.071 C¾rdoba;Grupo 1700 Congenital abnormalities 740-759;Men;481 C¾rdoba;Grupo 1700 Congenital abnormalities 740-759;Women;590 C¾rdoba;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.727 C¾rdoba;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.459 C¾rdoba;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.268 C¾rdoba;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;452 C¾rdoba;Group 1801 Pain in throat and chest 7841, 7865;Men;255 C¾rdoba;Group 1801 Pain in throat and chest 7841, 7865;Women;197 C¾rdoba;Group 1802 Abdominal pain 7890;Both sexes;521 C¾rdoba;Group 1802 Abdominal pain 7890;Men;192 C¾rdoba;Group 1802 Abdominal pain 7890;Women;329 C¾rdoba;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;25 C¾rdoba;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;16 C¾rdoba;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;9 C¾rdoba;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.729 C¾rdoba;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;996 C¾rdoba;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;733 C¾rdoba;Group 1900 Injuries and poisoning 800-999;Both sexes;5.985 C¾rdoba;Group 1900 Injuries and poisoning 800-999;Men;3.018 C¾rdoba;Group 1900 Injuries and poisoning 800-999;Women;2.967 C¾rdoba;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;345 C¾rdoba;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;209 C¾rdoba;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;136 C¾rdoba;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;225 C¾rdoba;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;148 C¾rdoba;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;77 C¾rdoba;Group 1903 Radius and ulna fracture 813;Both sexes;325 C¾rdoba;Group 1903 Radius and ulna fracture 813;Men;157 C¾rdoba;Group 1903 Radius and ulna fracture 813;Women;168 C¾rdoba;Group 1904 Femur fracture 820-821;Both sexes;1.134 C¾rdoba;Group 1904 Femur fracture 820-821;Men;337 C¾rdoba;Group 1904 Femur fracture 820-821;Women;797 C¾rdoba;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;385 C¾rdoba;Group 1905 Leg fracture, including the ankle 823-824;Men;199 C¾rdoba;Group 1905 Leg fracture, including the ankle 823-824;Women;186 C¾rdoba;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.205 C¾rdoba;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;721 C¾rdoba;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;484 C¾rdoba;Group 1907 Burns 940-949;Both sexes;72 C¾rdoba;Group 1907 Burns 940-949;Men;40 C¾rdoba;Group 1907 Burns 940-949;Women;32 C¾rdoba;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;211 C¾rdoba;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;87 C¾rdoba;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;124 C¾rdoba;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.938 C¾rdoba;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.032 C¾rdoba;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;906 C¾rdoba;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;2 C¾rdoba;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. C¾rdoba;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 C¾rdoba;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;143 C¾rdoba;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;88 C¾rdoba;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;55 C¾rdoba;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;799 C¾rdoba;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;517 C¾rdoba;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;282 C¾rdoba;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;78 C¾rdoba;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;38 C¾rdoba;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;40 C¾rdoba;Group 2102 Contraceptive management V25;Both sexes;8 C¾rdoba;Group 2102 Contraceptive management V25;Men;2 C¾rdoba;Group 2102 Contraceptive management V25;Women;6 C¾rdoba;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. C¾rdoba;Group 2103 Living newborns by type of delivery V30-V39;Men;.. C¾rdoba;Group 2103 Living newborns by type of delivery V30-V39;Women;.. C¾rdoba;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;465 C¾rdoba;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;343 C¾rdoba;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;122 C¾rdoba;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;248 C¾rdoba;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;134 C¾rdoba;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;114 Granada;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;73.980 Granada;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;33.336 Granada;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;40.644 Granada;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.733 Granada;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.016 Granada;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;717 Granada;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;166 Granada;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;100 Granada;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;66 Granada;Group 0102 Imprecise intestinal infections 009;Both sexes;58 Granada;Group 0102 Imprecise intestinal infections 009;Men;29 Granada;Group 0102 Imprecise intestinal infections 009;Women;29 Granada;Group 0103 Tuberculosis 010-018, 137;Both sexes;53 Granada;Group 0103 Tuberculosis 010-018, 137;Men;36 Granada;Group 0103 Tuberculosis 010-018, 137;Women;17 Granada;Group 0104 Septicaemia 038;Both sexes;893 Granada;Group 0104 Septicaemia 038;Men;490 Granada;Group 0104 Septicaemia 038;Women;403 Granada;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;50 Granada;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;40 Granada;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;10 Granada;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;513 Granada;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;321 Granada;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;192 Granada;Group 0200 Neoplasms 140-239;Both sexes;7.502 Granada;Group 0200 Neoplasms 140-239;Men;3.843 Granada;Group 0200 Neoplasms 140-239;Women;3.659 Granada;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;698 Granada;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;418 Granada;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;280 Granada;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;551 Granada;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;449 Granada;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;102 Granada;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;327 Granada;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;202 Granada;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;125 Granada;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;637 Granada;Group 0204 Malignant neoplasm of breast 174-175;Men;5 Granada;Group 0204 Malignant neoplasm of breast 174-175;Women;632 Granada;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;174 Granada;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Granada;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;174 Granada;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;79 Granada;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Granada;Group 0206 Malignant neoplasm of ovary 1830;Women;79 Granada;Group 0207 Malignant neoplasm of prostate 185;Both sexes;231 Granada;Group 0207 Malignant neoplasm of prostate 185;Men;231 Granada;Group 0207 Malignant neoplasm of prostate 185;Women;.. Granada;Group 0208 Malignant neoplasm of bladder 188;Both sexes;704 Granada;Group 0208 Malignant neoplasm of bladder 188;Men;578 Granada;Group 0208 Malignant neoplasm of bladder 188;Women;126 Granada;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.471 Granada;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.465 Granada;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.006 Granada;Group 0210 Carcinoma in situ 230-234;Both sexes;77 Granada;Group 0210 Carcinoma in situ 230-234;Men;20 Granada;Group 0210 Carcinoma in situ 230-234;Women;57 Granada;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;37 Granada;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;21 Granada;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;16 Granada;Grupo 0212 Leiomyoma of uterus 218;Both sexes;433 Granada;Grupo 0212 Leiomyoma of uterus 218;Men;.. Granada;Grupo 0212 Leiomyoma of uterus 218;Women;433 Granada;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.083 Granada;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;454 Granada;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;629 Granada;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;545 Granada;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;262 Granada;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;283 Granada;Group 0301 Anaemias 280-285;Both sexes;189 Granada;Group 0301 Anaemias 280-285;Men;82 Granada;Group 0301 Anaemias 280-285;Women;107 Granada;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;356 Granada;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;180 Granada;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;176 Granada;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.496 Granada;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;546 Granada;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;950 Granada;Group 0401 Diabetes mellitus 249-250;Both sexes;481 Granada;Group 0401 Diabetes mellitus 249-250;Men;262 Granada;Group 0401 Diabetes mellitus 249-250;Women;219 Granada;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.015 Granada;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;284 Granada;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;731 Granada;Group 0500 Mental disorders 290-319;Both sexes;1.245 Granada;Group 0500 Mental disorders 290-319;Men;668 Granada;Group 0500 Mental disorders 290-319;Women;577 Granada;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;8 Granada;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;2 Granada;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;6 Granada;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;93 Granada;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;64 Granada;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;29 Granada;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;90 Granada;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;74 Granada;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;16 Granada;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;445 Granada;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;275 Granada;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;170 Granada;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;273 Granada;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;115 Granada;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;158 Granada;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;336 Granada;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;138 Granada;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;198 Granada;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.560 Granada;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;761 Granada;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;799 Granada;Group 0601 Alzheimer's disease 3310;Both sexes;11 Granada;Group 0601 Alzheimer's disease 3310;Men;6 Granada;Group 0601 Alzheimer's disease 3310;Women;5 Granada;Group 0602 Multiple sclerosis 340;Both sexes;26 Granada;Group 0602 Multiple sclerosis 340;Men;10 Granada;Group 0602 Multiple sclerosis 340;Women;16 Granada;Group 0603 Epilepsy 345;Both sexes;246 Granada;Group 0603 Epilepsy 345;Men;120 Granada;Group 0603 Epilepsy 345;Women;126 Granada;Group 0604 Transient cerebral ischemia 435;Both sexes;197 Granada;Group 0604 Transient cerebral ischemia 435;Men;104 Granada;Group 0604 Transient cerebral ischemia 435;Women;93 Granada;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.080 Granada;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;521 Granada;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;559 Granada;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;737 Granada;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;380 Granada;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;357 Granada;Grupo 0701 Cataract 366;Both sexes;142 Granada;Grupo 0701 Cataract 366;Men;75 Granada;Grupo 0701 Cataract 366;Women;67 Granada;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;595 Granada;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;305 Granada;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;290 Granada;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;375 Granada;Group 0800 Diseases of the ear and the mastoid 380-389;Men;197 Granada;Group 0800 Diseases of the ear and the mastoid 380-389;Women;178 Granada;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;9.394 Granada;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5.396 Granada;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3.998 Granada;Group 0901 Hypertensive disease 401-405;Both sexes;503 Granada;Group 0901 Hypertensive disease 401-405;Men;197 Granada;Group 0901 Hypertensive disease 401-405;Women;306 Granada;Group 0902 Angina pectoris 4111, 413;Both sexes;527 Granada;Group 0902 Angina pectoris 4111, 413;Men;335 Granada;Group 0902 Angina pectoris 4111, 413;Women;192 Granada;Group 0903 Acute myocardial infarction 410;Both sexes;1.094 Granada;Group 0903 Acute myocardial infarction 410;Men;767 Granada;Group 0903 Acute myocardial infarction 410;Women;327 Granada;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;596 Granada;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;439 Granada;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;157 Granada;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;429 Granada;Group 0905 Diseases of the lungs circulation 415-417;Men;207 Granada;Group 0905 Diseases of the lungs circulation 415-417;Women;222 Granada;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.006 Granada;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;596 Granada;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;410 Granada;Grupo 0907 Heart failure 428;Both sexes;1.580 Granada;Grupo 0907 Heart failure 428;Men;773 Granada;Grupo 0907 Heart failure 428;Women;807 Granada;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.892 Granada;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;997 Granada;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;895 Granada;Grupo 0909 Atherosclerosis 440;Both sexes;312 Granada;Grupo 0909 Atherosclerosis 440;Men;228 Granada;Grupo 0909 Atherosclerosis 440;Women;84 Granada;Group 0910 Varicose veins of lower extremities 454;Both sexes;65 Granada;Group 0910 Varicose veins of lower extremities 454;Men;31 Granada;Group 0910 Varicose veins of lower extremities 454;Women;34 Granada;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.390 Granada;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;826 Granada;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;564 Granada;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;6.742 Granada;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.025 Granada;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.717 Granada;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;479 Granada;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;282 Granada;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;197 Granada;Group 1002 Pneumonia 480-486;Both sexes;1.580 Granada;Group 1002 Pneumonia 480-486;Men;978 Granada;Group 1002 Pneumonia 480-486;Women;602 Granada;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;593 Granada;Group 1003 Acute bronchitis and bronchiolitis 466;Men;307 Granada;Group 1003 Acute bronchitis and bronchiolitis 466;Women;286 Granada;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;327 Granada;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;166 Granada;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;161 Granada;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;578 Granada;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;380 Granada;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;198 Granada;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;717 Granada;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;633 Granada;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;84 Granada;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;356 Granada;Group 1007 Asthma 4930-4931,4938-4939;Men;111 Granada;Group 1007 Asthma 4930-4931,4938-4939;Women;245 Granada;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.112 Granada;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.168 Granada;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;944 Granada;Group 1100 Diseases of the digestive system 520-579;Both sexes;9.581 Granada;Group 1100 Diseases of the digestive system 520-579;Men;5.190 Granada;Group 1100 Diseases of the digestive system 520-579;Women;4.391 Granada;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;331 Granada;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;144 Granada;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;187 Granada;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;201 Granada;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;115 Granada;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;86 Granada;Group 1103 Diseases of the esophagus 530;Both sexes;139 Granada;Group 1103 Diseases of the esophagus 530;Men;87 Granada;Group 1103 Diseases of the esophagus 530;Women;52 Granada;Group 1104 Peptic ulcer 531-534;Both sexes;187 Granada;Group 1104 Peptic ulcer 531-534;Men;129 Granada;Group 1104 Peptic ulcer 531-534;Women;58 Granada;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;189 Granada;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;100 Granada;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;89 Granada;Group 1106 Appendicitis 540-543;Both sexes;983 Granada;Group 1106 Appendicitis 540-543;Men;554 Granada;Group 1106 Appendicitis 540-543;Women;429 Granada;Group 1107 Inguinal hernia 550;Both sexes;610 Granada;Group 1107 Inguinal hernia 550;Men;541 Granada;Group 1107 Inguinal hernia 550;Women;69 Granada;Group 1108 Other abdominal hernia 551-553;Both sexes;849 Granada;Group 1108 Other abdominal hernia 551-553;Men;357 Granada;Group 1108 Other abdominal hernia 551-553;Women;492 Granada;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;159 Granada;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;87 Granada;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;72 Granada;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;338 Granada;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;187 Granada;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;151 Granada;Group 1111 Intestinal obstruction without hernia 560;Both sexes;380 Granada;Group 1111 Intestinal obstruction without hernia 560;Men;191 Granada;Group 1111 Intestinal obstruction without hernia 560;Women;189 Granada;Group 1112 Intestinal diverticulosis 562;Both sexes;241 Granada;Group 1112 Intestinal diverticulosis 562;Men;129 Granada;Group 1112 Intestinal diverticulosis 562;Women;112 Granada;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;721 Granada;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;480 Granada;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;241 Granada;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;249 Granada;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;127 Granada;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;122 Granada;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;154 Granada;Group 1115 Alcoholic hepatitis 5710-5713;Men;130 Granada;Group 1115 Alcoholic hepatitis 5710-5713;Women;24 Granada;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;388 Granada;Group 1116 Other diseases of the liver 570,5714-573;Men;260 Granada;Group 1116 Other diseases of the liver 570,5714-573;Women;128 Granada;Group 1117 Cholelithiasis 574;Both sexes;1.934 Granada;Group 1117 Cholelithiasis 574;Men;765 Granada;Group 1117 Cholelithiasis 574;Women;1.169 Granada;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;496 Granada;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;237 Granada;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;259 Granada;Group 1119 Pancreatic diseases 577;Both sexes;711 Granada;Group 1119 Pancreatic diseases 577;Men;391 Granada;Group 1119 Pancreatic diseases 577;Women;320 Granada;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;321 Granada;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;179 Granada;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;142 Granada;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;617 Granada;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;340 Granada;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;277 Granada;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;350 Granada;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;208 Granada;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;142 Granada;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;28 Granada;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;13 Granada;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;15 Granada;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;239 Granada;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;119 Granada;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;120 Granada;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;4.179 Granada;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.954 Granada;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2.225 Granada;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Granada;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Granada;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Granada;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Granada;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Granada;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Granada;Group 1303 Internal derangement of knee 717;Both sexes;193 Granada;Group 1303 Internal derangement of knee 717;Men;134 Granada;Group 1303 Internal derangement of knee 717;Women;59 Granada;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.138 Granada;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;872 Granada;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.266 Granada;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;149 Granada;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;39 Granada;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;110 Granada;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;378 Granada;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;183 Granada;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;195 Granada;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;292 Granada;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;174 Granada;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;118 Granada;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;30 Granada;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;14 Granada;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;16 Granada;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;458 Granada;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;256 Granada;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;202 Granada;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;541 Granada;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;282 Granada;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;259 Granada;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;4.116 Granada;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.788 Granada;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2.328 Granada;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;589 Granada;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;277 Granada;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;312 Granada;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;598 Granada;Group 1402 Renal failure 5836-5837, 584-586;Men;368 Granada;Group 1402 Renal failure 5836-5837, 584-586;Women;230 Granada;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;343 Granada;Group 1403 Urolithiasis 592, 594, 7880;Men;191 Granada;Group 1403 Urolithiasis 592, 594, 7880;Women;152 Granada;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;718 Granada;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;395 Granada;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;323 Granada;Group 1405 Prostatic hyperplasia 600;Both sexes;281 Granada;Group 1405 Prostatic hyperplasia 600;Men;281 Granada;Group 1405 Prostatic hyperplasia 600;Women;.. Granada;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;255 Granada;Group 1406 Other diseases of the male genital organs 601-608;Men;255 Granada;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Granada;Group 1407 Disorders of breast 610-612;Both sexes;226 Granada;Group 1407 Disorders of breast 610-612;Men;20 Granada;Group 1407 Disorders of breast 610-612;Women;206 Granada;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;186 Granada;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Granada;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;186 Granada;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;70 Granada;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Granada;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;70 Granada;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;850 Granada;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Granada;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;849 Granada;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;10.570 Granada;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Granada;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;10.570 Granada;Group 1501 Legally induced abortion 635;Both sexes;3 Granada;Group 1501 Legally induced abortion 635;Men;.. Granada;Group 1501 Legally induced abortion 635;Women;3 Granada;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;990 Granada;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Granada;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;990 Granada;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6.558 Granada;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Granada;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6.558 Granada;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.121 Granada;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Granada;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.121 Granada;Group 1505 Single spontaneous delivery 650;Both sexes;546 Granada;Group 1505 Single spontaneous delivery 650;Men;.. Granada;Group 1505 Single spontaneous delivery 650;Women;546 Granada;Group 1506 Other deliveries 6695-6697;Both sexes;528 Granada;Group 1506 Other deliveries 6695-6697;Men;.. Granada;Group 1506 Other deliveries 6695-6697;Women;528 Granada;Group 1507 Complications related to the puerperium 670-676;Both sexes;72 Granada;Group 1507 Complications related to the puerperium 670-676;Men;.. Granada;Group 1507 Complications related to the puerperium 670-676;Women;72 Granada;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;752 Granada;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Granada;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;752 Granada;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;948 Granada;Group 1600 Some disorders originating in the perinatal period 760-779;Men;524 Granada;Group 1600 Some disorders originating in the perinatal period 760-779;Women;424 Granada;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;358 Granada;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;205 Granada;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;153 Granada;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;590 Granada;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;319 Granada;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;271 Granada;Grupo 1700 Congenital abnormalities 740-759;Both sexes;582 Granada;Grupo 1700 Congenital abnormalities 740-759;Men;354 Granada;Grupo 1700 Congenital abnormalities 740-759;Women;228 Granada;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;3.055 Granada;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.575 Granada;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.480 Granada;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;249 Granada;Group 1801 Pain in throat and chest 7841, 7865;Men;130 Granada;Group 1801 Pain in throat and chest 7841, 7865;Women;119 Granada;Group 1802 Abdominal pain 7890;Both sexes;201 Granada;Group 1802 Abdominal pain 7890;Men;77 Granada;Group 1802 Abdominal pain 7890;Women;124 Granada;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.338 Granada;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;681 Granada;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;657 Granada;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.267 Granada;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;687 Granada;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;580 Granada;Group 1900 Injuries and poisoning 800-999;Both sexes;7.810 Granada;Group 1900 Injuries and poisoning 800-999;Men;3.980 Granada;Group 1900 Injuries and poisoning 800-999;Women;3.830 Granada;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;258 Granada;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;163 Granada;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;95 Granada;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;236 Granada;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;177 Granada;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;59 Granada;Group 1903 Radius and ulna fracture 813;Both sexes;743 Granada;Group 1903 Radius and ulna fracture 813;Men;330 Granada;Group 1903 Radius and ulna fracture 813;Women;413 Granada;Group 1904 Femur fracture 820-821;Both sexes;1.245 Granada;Group 1904 Femur fracture 820-821;Men;352 Granada;Group 1904 Femur fracture 820-821;Women;893 Granada;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;677 Granada;Group 1905 Leg fracture, including the ankle 823-824;Men;362 Granada;Group 1905 Leg fracture, including the ankle 823-824;Women;315 Granada;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2.278 Granada;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.416 Granada;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;862 Granada;Group 1907 Burns 940-949;Both sexes;85 Granada;Group 1907 Burns 940-949;Men;46 Granada;Group 1907 Burns 940-949;Women;39 Granada;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;216 Granada;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;99 Granada;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;117 Granada;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.872 Granada;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;923 Granada;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;949 Granada;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;30 Granada;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;21 Granada;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;9 Granada;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;170 Granada;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;91 Granada;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;79 Granada;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.193 Granada;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;537 Granada;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;656 Granada;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;37 Granada;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;25 Granada;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;12 Granada;Group 2102 Contraceptive management V25;Both sexes;6 Granada;Group 2102 Contraceptive management V25;Men;1 Granada;Group 2102 Contraceptive management V25;Women;5 Granada;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Granada;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Granada;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Granada;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;389 Granada;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;231 Granada;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;158 Granada;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;761 Granada;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;280 Granada;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;481 Huelva;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;40.505 Huelva;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;18.156 Huelva;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;22.349 Huelva;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;741 Huelva;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;412 Huelva;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;329 Huelva;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;101 Huelva;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;47 Huelva;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;54 Huelva;Group 0102 Imprecise intestinal infections 009;Both sexes;83 Huelva;Group 0102 Imprecise intestinal infections 009;Men;31 Huelva;Group 0102 Imprecise intestinal infections 009;Women;52 Huelva;Group 0103 Tuberculosis 010-018, 137;Both sexes;54 Huelva;Group 0103 Tuberculosis 010-018, 137;Men;35 Huelva;Group 0103 Tuberculosis 010-018, 137;Women;19 Huelva;Group 0104 Septicaemia 038;Both sexes;209 Huelva;Group 0104 Septicaemia 038;Men;113 Huelva;Group 0104 Septicaemia 038;Women;96 Huelva;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;45 Huelva;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;36 Huelva;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;9 Huelva;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;249 Huelva;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;150 Huelva;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;99 Huelva;Group 0200 Neoplasms 140-239;Both sexes;3.161 Huelva;Group 0200 Neoplasms 140-239;Men;1.698 Huelva;Group 0200 Neoplasms 140-239;Women;1.463 Huelva;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;466 Huelva;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;266 Huelva;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;200 Huelva;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;210 Huelva;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;175 Huelva;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;35 Huelva;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;15 Huelva;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;9 Huelva;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;6 Huelva;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;279 Huelva;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Huelva;Group 0204 Malignant neoplasm of breast 174-175;Women;276 Huelva;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;70 Huelva;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Huelva;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;70 Huelva;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;39 Huelva;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Huelva;Group 0206 Malignant neoplasm of ovary 1830;Women;39 Huelva;Group 0207 Malignant neoplasm of prostate 185;Both sexes;104 Huelva;Group 0207 Malignant neoplasm of prostate 185;Men;104 Huelva;Group 0207 Malignant neoplasm of prostate 185;Women;.. Huelva;Group 0208 Malignant neoplasm of bladder 188;Both sexes;351 Huelva;Group 0208 Malignant neoplasm of bladder 188;Men;301 Huelva;Group 0208 Malignant neoplasm of bladder 188;Women;50 Huelva;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.012 Huelva;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;639 Huelva;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;373 Huelva;Group 0210 Carcinoma in situ 230-234;Both sexes;30 Huelva;Group 0210 Carcinoma in situ 230-234;Men;13 Huelva;Group 0210 Carcinoma in situ 230-234;Women;17 Huelva;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;36 Huelva;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;23 Huelva;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;13 Huelva;Grupo 0212 Leiomyoma of uterus 218;Both sexes;186 Huelva;Grupo 0212 Leiomyoma of uterus 218;Men;.. Huelva;Grupo 0212 Leiomyoma of uterus 218;Women;186 Huelva;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;363 Huelva;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;165 Huelva;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;198 Huelva;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;569 Huelva;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;267 Huelva;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;302 Huelva;Group 0301 Anaemias 280-285;Both sexes;361 Huelva;Group 0301 Anaemias 280-285;Men;170 Huelva;Group 0301 Anaemias 280-285;Women;191 Huelva;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;208 Huelva;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;97 Huelva;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;111 Huelva;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;669 Huelva;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;303 Huelva;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;366 Huelva;Group 0401 Diabetes mellitus 249-250;Both sexes;264 Huelva;Group 0401 Diabetes mellitus 249-250;Men;160 Huelva;Group 0401 Diabetes mellitus 249-250;Women;104 Huelva;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;405 Huelva;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;143 Huelva;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;262 Huelva;Group 0500 Mental disorders 290-319;Both sexes;893 Huelva;Group 0500 Mental disorders 290-319;Men;440 Huelva;Group 0500 Mental disorders 290-319;Women;453 Huelva;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;22 Huelva;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;18 Huelva;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;4 Huelva;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;31 Huelva;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;25 Huelva;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;6 Huelva;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;30 Huelva;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;25 Huelva;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;5 Huelva;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;296 Huelva;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;181 Huelva;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;115 Huelva;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;191 Huelva;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;67 Huelva;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;124 Huelva;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;323 Huelva;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;124 Huelva;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;199 Huelva;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;959 Huelva;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;479 Huelva;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;480 Huelva;Group 0601 Alzheimer's disease 3310;Both sexes;35 Huelva;Group 0601 Alzheimer's disease 3310;Men;12 Huelva;Group 0601 Alzheimer's disease 3310;Women;23 Huelva;Group 0602 Multiple sclerosis 340;Both sexes;17 Huelva;Group 0602 Multiple sclerosis 340;Men;5 Huelva;Group 0602 Multiple sclerosis 340;Women;12 Huelva;Group 0603 Epilepsy 345;Both sexes;180 Huelva;Group 0603 Epilepsy 345;Men;95 Huelva;Group 0603 Epilepsy 345;Women;85 Huelva;Group 0604 Transient cerebral ischemia 435;Both sexes;240 Huelva;Group 0604 Transient cerebral ischemia 435;Men;131 Huelva;Group 0604 Transient cerebral ischemia 435;Women;109 Huelva;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;487 Huelva;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;236 Huelva;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;251 Huelva;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;157 Huelva;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;83 Huelva;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;74 Huelva;Grupo 0701 Cataract 366;Both sexes;7 Huelva;Grupo 0701 Cataract 366;Men;4 Huelva;Grupo 0701 Cataract 366;Women;3 Huelva;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;150 Huelva;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;79 Huelva;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;71 Huelva;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;318 Huelva;Group 0800 Diseases of the ear and the mastoid 380-389;Men;140 Huelva;Group 0800 Diseases of the ear and the mastoid 380-389;Women;178 Huelva;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;6.066 Huelva;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3.414 Huelva;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.652 Huelva;Group 0901 Hypertensive disease 401-405;Both sexes;515 Huelva;Group 0901 Hypertensive disease 401-405;Men;203 Huelva;Group 0901 Hypertensive disease 401-405;Women;312 Huelva;Group 0902 Angina pectoris 4111, 413;Both sexes;557 Huelva;Group 0902 Angina pectoris 4111, 413;Men;321 Huelva;Group 0902 Angina pectoris 4111, 413;Women;236 Huelva;Group 0903 Acute myocardial infarction 410;Both sexes;464 Huelva;Group 0903 Acute myocardial infarction 410;Men;332 Huelva;Group 0903 Acute myocardial infarction 410;Women;132 Huelva;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;391 Huelva;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;277 Huelva;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;114 Huelva;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;137 Huelva;Group 0905 Diseases of the lungs circulation 415-417;Men;70 Huelva;Group 0905 Diseases of the lungs circulation 415-417;Women;67 Huelva;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;928 Huelva;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;496 Huelva;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;432 Huelva;Grupo 0907 Heart failure 428;Both sexes;979 Huelva;Grupo 0907 Heart failure 428;Men;492 Huelva;Grupo 0907 Heart failure 428;Women;487 Huelva;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.005 Huelva;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;585 Huelva;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;420 Huelva;Grupo 0909 Atherosclerosis 440;Both sexes;151 Huelva;Grupo 0909 Atherosclerosis 440;Men;105 Huelva;Grupo 0909 Atherosclerosis 440;Women;46 Huelva;Group 0910 Varicose veins of lower extremities 454;Both sexes;132 Huelva;Group 0910 Varicose veins of lower extremities 454;Men;62 Huelva;Group 0910 Varicose veins of lower extremities 454;Women;70 Huelva;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;807 Huelva;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;471 Huelva;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;336 Huelva;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;3.472 Huelva;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.961 Huelva;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.511 Huelva;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;231 Huelva;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;120 Huelva;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;111 Huelva;Group 1002 Pneumonia 480-486;Both sexes;698 Huelva;Group 1002 Pneumonia 480-486;Men;414 Huelva;Group 1002 Pneumonia 480-486;Women;284 Huelva;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;349 Huelva;Group 1003 Acute bronchitis and bronchiolitis 466;Men;158 Huelva;Group 1003 Acute bronchitis and bronchiolitis 466;Women;191 Huelva;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;247 Huelva;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;123 Huelva;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;124 Huelva;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;409 Huelva;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;268 Huelva;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;141 Huelva;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;434 Huelva;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;336 Huelva;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;98 Huelva;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;104 Huelva;Group 1007 Asthma 4930-4931,4938-4939;Men;19 Huelva;Group 1007 Asthma 4930-4931,4938-4939;Women;85 Huelva;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.000 Huelva;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;523 Huelva;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;477 Huelva;Group 1100 Diseases of the digestive system 520-579;Both sexes;5.111 Huelva;Group 1100 Diseases of the digestive system 520-579;Men;2.842 Huelva;Group 1100 Diseases of the digestive system 520-579;Women;2.269 Huelva;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;18 Huelva;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;10 Huelva;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;8 Huelva;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;56 Huelva;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;30 Huelva;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;26 Huelva;Group 1103 Diseases of the esophagus 530;Both sexes;122 Huelva;Group 1103 Diseases of the esophagus 530;Men;68 Huelva;Group 1103 Diseases of the esophagus 530;Women;54 Huelva;Group 1104 Peptic ulcer 531-534;Both sexes;137 Huelva;Group 1104 Peptic ulcer 531-534;Men;93 Huelva;Group 1104 Peptic ulcer 531-534;Women;44 Huelva;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;175 Huelva;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;100 Huelva;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;75 Huelva;Group 1106 Appendicitis 540-543;Both sexes;404 Huelva;Group 1106 Appendicitis 540-543;Men;235 Huelva;Group 1106 Appendicitis 540-543;Women;169 Huelva;Group 1107 Inguinal hernia 550;Both sexes;413 Huelva;Group 1107 Inguinal hernia 550;Men;368 Huelva;Group 1107 Inguinal hernia 550;Women;45 Huelva;Group 1108 Other abdominal hernia 551-553;Both sexes;363 Huelva;Group 1108 Other abdominal hernia 551-553;Men;177 Huelva;Group 1108 Other abdominal hernia 551-553;Women;186 Huelva;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;135 Huelva;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;77 Huelva;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;58 Huelva;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;287 Huelva;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;145 Huelva;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;142 Huelva;Group 1111 Intestinal obstruction without hernia 560;Both sexes;190 Huelva;Group 1111 Intestinal obstruction without hernia 560;Men;82 Huelva;Group 1111 Intestinal obstruction without hernia 560;Women;108 Huelva;Group 1112 Intestinal diverticulosis 562;Both sexes;149 Huelva;Group 1112 Intestinal diverticulosis 562;Men;70 Huelva;Group 1112 Intestinal diverticulosis 562;Women;79 Huelva;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;467 Huelva;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;301 Huelva;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;166 Huelva;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;187 Huelva;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;90 Huelva;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;97 Huelva;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;100 Huelva;Group 1115 Alcoholic hepatitis 5710-5713;Men;95 Huelva;Group 1115 Alcoholic hepatitis 5710-5713;Women;5 Huelva;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;164 Huelva;Group 1116 Other diseases of the liver 570,5714-573;Men;95 Huelva;Group 1116 Other diseases of the liver 570,5714-573;Women;69 Huelva;Group 1117 Cholelithiasis 574;Both sexes;946 Huelva;Group 1117 Cholelithiasis 574;Men;399 Huelva;Group 1117 Cholelithiasis 574;Women;547 Huelva;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;222 Huelva;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;113 Huelva;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;109 Huelva;Group 1119 Pancreatic diseases 577;Both sexes;340 Huelva;Group 1119 Pancreatic diseases 577;Men;185 Huelva;Group 1119 Pancreatic diseases 577;Women;155 Huelva;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;236 Huelva;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;109 Huelva;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;127 Huelva;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;369 Huelva;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;206 Huelva;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;163 Huelva;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;217 Huelva;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;133 Huelva;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;84 Huelva;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;26 Huelva;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;12 Huelva;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;14 Huelva;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;126 Huelva;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;61 Huelva;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;65 Huelva;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.428 Huelva;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.101 Huelva;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.327 Huelva;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Huelva;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Huelva;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Huelva;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Huelva;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Huelva;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Huelva;Group 1303 Internal derangement of knee 717;Both sexes;162 Huelva;Group 1303 Internal derangement of knee 717;Men;118 Huelva;Group 1303 Internal derangement of knee 717;Women;44 Huelva;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.053 Huelva;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;421 Huelva;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;632 Huelva;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;50 Huelva;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;24 Huelva;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;26 Huelva;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;105 Huelva;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;50 Huelva;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;55 Huelva;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;237 Huelva;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;99 Huelva;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;138 Huelva;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;123 Huelva;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;54 Huelva;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;69 Huelva;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;334 Huelva;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;190 Huelva;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;144 Huelva;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;364 Huelva;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;145 Huelva;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;219 Huelva;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.209 Huelva;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;921 Huelva;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.288 Huelva;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;233 Huelva;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;90 Huelva;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;143 Huelva;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;219 Huelva;Group 1402 Renal failure 5836-5837, 584-586;Men;122 Huelva;Group 1402 Renal failure 5836-5837, 584-586;Women;97 Huelva;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;422 Huelva;Group 1403 Urolithiasis 592, 594, 7880;Men;246 Huelva;Group 1403 Urolithiasis 592, 594, 7880;Women;176 Huelva;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;552 Huelva;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;210 Huelva;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;342 Huelva;Group 1405 Prostatic hyperplasia 600;Both sexes;124 Huelva;Group 1405 Prostatic hyperplasia 600;Men;124 Huelva;Group 1405 Prostatic hyperplasia 600;Women;.. Huelva;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;112 Huelva;Group 1406 Other diseases of the male genital organs 601-608;Men;112 Huelva;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Huelva;Group 1407 Disorders of breast 610-612;Both sexes;63 Huelva;Group 1407 Disorders of breast 610-612;Men;17 Huelva;Group 1407 Disorders of breast 610-612;Women;46 Huelva;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;71 Huelva;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Huelva;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;71 Huelva;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;33 Huelva;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Huelva;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;33 Huelva;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;380 Huelva;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Huelva;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;380 Huelva;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5.900 Huelva;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Huelva;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5.900 Huelva;Group 1501 Legally induced abortion 635;Both sexes;18 Huelva;Group 1501 Legally induced abortion 635;Men;.. Huelva;Group 1501 Legally induced abortion 635;Women;18 Huelva;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;433 Huelva;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Huelva;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;433 Huelva;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4.022 Huelva;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Huelva;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4.022 Huelva;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;396 Huelva;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Huelva;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;396 Huelva;Group 1505 Single spontaneous delivery 650;Both sexes;392 Huelva;Group 1505 Single spontaneous delivery 650;Men;.. Huelva;Group 1505 Single spontaneous delivery 650;Women;392 Huelva;Group 1506 Other deliveries 6695-6697;Both sexes;115 Huelva;Group 1506 Other deliveries 6695-6697;Men;.. Huelva;Group 1506 Other deliveries 6695-6697;Women;115 Huelva;Group 1507 Complications related to the puerperium 670-676;Both sexes;59 Huelva;Group 1507 Complications related to the puerperium 670-676;Men;.. Huelva;Group 1507 Complications related to the puerperium 670-676;Women;59 Huelva;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;465 Huelva;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Huelva;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;465 Huelva;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;464 Huelva;Group 1600 Some disorders originating in the perinatal period 760-779;Men;239 Huelva;Group 1600 Some disorders originating in the perinatal period 760-779;Women;225 Huelva;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;177 Huelva;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;78 Huelva;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;99 Huelva;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;287 Huelva;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;161 Huelva;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;126 Huelva;Grupo 1700 Congenital abnormalities 740-759;Both sexes;159 Huelva;Grupo 1700 Congenital abnormalities 740-759;Men;87 Huelva;Grupo 1700 Congenital abnormalities 740-759;Women;72 Huelva;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;3.074 Huelva;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.639 Huelva;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.435 Huelva;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;615 Huelva;Group 1801 Pain in throat and chest 7841, 7865;Men;351 Huelva;Group 1801 Pain in throat and chest 7841, 7865;Women;264 Huelva;Group 1802 Abdominal pain 7890;Both sexes;415 Huelva;Group 1802 Abdominal pain 7890;Men;174 Huelva;Group 1802 Abdominal pain 7890;Women;241 Huelva;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;243 Huelva;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;127 Huelva;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;116 Huelva;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.801 Huelva;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;987 Huelva;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;814 Huelva;Group 1900 Injuries and poisoning 800-999;Both sexes;3.282 Huelva;Group 1900 Injuries and poisoning 800-999;Men;1.645 Huelva;Group 1900 Injuries and poisoning 800-999;Women;1.637 Huelva;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;142 Huelva;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;81 Huelva;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;61 Huelva;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;74 Huelva;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;50 Huelva;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;24 Huelva;Group 1903 Radius and ulna fracture 813;Both sexes;284 Huelva;Group 1903 Radius and ulna fracture 813;Men;141 Huelva;Group 1903 Radius and ulna fracture 813;Women;143 Huelva;Group 1904 Femur fracture 820-821;Both sexes;530 Huelva;Group 1904 Femur fracture 820-821;Men;151 Huelva;Group 1904 Femur fracture 820-821;Women;379 Huelva;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;242 Huelva;Group 1905 Leg fracture, including the ankle 823-824;Men;123 Huelva;Group 1905 Leg fracture, including the ankle 823-824;Women;119 Huelva;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;970 Huelva;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;562 Huelva;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;408 Huelva;Group 1907 Burns 940-949;Both sexes;4 Huelva;Group 1907 Burns 940-949;Men;1 Huelva;Group 1907 Burns 940-949;Women;3 Huelva;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;149 Huelva;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;74 Huelva;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;75 Huelva;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;800 Huelva;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;410 Huelva;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;390 Huelva;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;15 Huelva;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;8 Huelva;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;7 Huelva;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;72 Huelva;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;44 Huelva;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;28 Huelva;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;504 Huelva;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;279 Huelva;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;225 Huelva;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;11 Huelva;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;6 Huelva;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;5 Huelva;Group 2102 Contraceptive management V25;Both sexes;8 Huelva;Group 2102 Contraceptive management V25;Men;.. Huelva;Group 2102 Contraceptive management V25;Women;8 Huelva;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Huelva;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Huelva;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Huelva;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;163 Huelva;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;114 Huelva;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;49 Huelva;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;322 Huelva;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;159 Huelva;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;163 JaÚn;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;48.370 JaÚn;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;22.066 JaÚn;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;26.304 JaÚn;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;767 JaÚn;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;417 JaÚn;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;350 JaÚn;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;98 JaÚn;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;53 JaÚn;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;45 JaÚn;Group 0102 Imprecise intestinal infections 009;Both sexes;23 JaÚn;Group 0102 Imprecise intestinal infections 009;Men;2 JaÚn;Group 0102 Imprecise intestinal infections 009;Women;21 JaÚn;Group 0103 Tuberculosis 010-018, 137;Both sexes;18 JaÚn;Group 0103 Tuberculosis 010-018, 137;Men;12 JaÚn;Group 0103 Tuberculosis 010-018, 137;Women;6 JaÚn;Group 0104 Septicaemia 038;Both sexes;276 JaÚn;Group 0104 Septicaemia 038;Men;135 JaÚn;Group 0104 Septicaemia 038;Women;141 JaÚn;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;46 JaÚn;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;31 JaÚn;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;15 JaÚn;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;306 JaÚn;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;184 JaÚn;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;122 JaÚn;Group 0200 Neoplasms 140-239;Both sexes;3.768 JaÚn;Group 0200 Neoplasms 140-239;Men;1.923 JaÚn;Group 0200 Neoplasms 140-239;Women;1.845 JaÚn;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;486 JaÚn;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;296 JaÚn;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;190 JaÚn;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;273 JaÚn;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;236 JaÚn;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;37 JaÚn;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;47 JaÚn;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;30 JaÚn;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;17 JaÚn;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;358 JaÚn;Group 0204 Malignant neoplasm of breast 174-175;Men;3 JaÚn;Group 0204 Malignant neoplasm of breast 174-175;Women;355 JaÚn;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;96 JaÚn;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. JaÚn;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;96 JaÚn;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;47 JaÚn;Group 0206 Malignant neoplasm of ovary 1830;Men;.. JaÚn;Group 0206 Malignant neoplasm of ovary 1830;Women;47 JaÚn;Group 0207 Malignant neoplasm of prostate 185;Both sexes;58 JaÚn;Group 0207 Malignant neoplasm of prostate 185;Men;58 JaÚn;Group 0207 Malignant neoplasm of prostate 185;Women;.. JaÚn;Group 0208 Malignant neoplasm of bladder 188;Both sexes;429 JaÚn;Group 0208 Malignant neoplasm of bladder 188;Men;360 JaÚn;Group 0208 Malignant neoplasm of bladder 188;Women;69 JaÚn;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.204 JaÚn;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;729 JaÚn;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;475 JaÚn;Group 0210 Carcinoma in situ 230-234;Both sexes;54 JaÚn;Group 0210 Carcinoma in situ 230-234;Men;25 JaÚn;Group 0210 Carcinoma in situ 230-234;Women;29 JaÚn;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;46 JaÚn;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;22 JaÚn;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;24 JaÚn;Grupo 0212 Leiomyoma of uterus 218;Both sexes;233 JaÚn;Grupo 0212 Leiomyoma of uterus 218;Men;.. JaÚn;Grupo 0212 Leiomyoma of uterus 218;Women;233 JaÚn;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;437 JaÚn;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;164 JaÚn;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;273 JaÚn;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;472 JaÚn;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;258 JaÚn;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;214 JaÚn;Group 0301 Anaemias 280-285;Both sexes;247 JaÚn;Group 0301 Anaemias 280-285;Men;134 JaÚn;Group 0301 Anaemias 280-285;Women;113 JaÚn;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;225 JaÚn;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;124 JaÚn;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;101 JaÚn;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;967 JaÚn;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;465 JaÚn;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;502 JaÚn;Group 0401 Diabetes mellitus 249-250;Both sexes;380 JaÚn;Group 0401 Diabetes mellitus 249-250;Men;249 JaÚn;Group 0401 Diabetes mellitus 249-250;Women;131 JaÚn;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;587 JaÚn;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;216 JaÚn;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;371 JaÚn;Group 0500 Mental disorders 290-319;Both sexes;1.130 JaÚn;Group 0500 Mental disorders 290-319;Men;584 JaÚn;Group 0500 Mental disorders 290-319;Women;546 JaÚn;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;28 JaÚn;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;10 JaÚn;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;18 JaÚn;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;38 JaÚn;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;31 JaÚn;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;7 JaÚn;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;32 JaÚn;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;26 JaÚn;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;6 JaÚn;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;282 JaÚn;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;188 JaÚn;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;94 JaÚn;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;305 JaÚn;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;128 JaÚn;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;177 JaÚn;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;445 JaÚn;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;201 JaÚn;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;244 JaÚn;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.106 JaÚn;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;523 JaÚn;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;583 JaÚn;Group 0601 Alzheimer's disease 3310;Both sexes;41 JaÚn;Group 0601 Alzheimer's disease 3310;Men;16 JaÚn;Group 0601 Alzheimer's disease 3310;Women;25 JaÚn;Group 0602 Multiple sclerosis 340;Both sexes;44 JaÚn;Group 0602 Multiple sclerosis 340;Men;13 JaÚn;Group 0602 Multiple sclerosis 340;Women;31 JaÚn;Group 0603 Epilepsy 345;Both sexes;218 JaÚn;Group 0603 Epilepsy 345;Men;117 JaÚn;Group 0603 Epilepsy 345;Women;101 JaÚn;Group 0604 Transient cerebral ischemia 435;Both sexes;237 JaÚn;Group 0604 Transient cerebral ischemia 435;Men;124 JaÚn;Group 0604 Transient cerebral ischemia 435;Women;113 JaÚn;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;566 JaÚn;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;253 JaÚn;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;313 JaÚn;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;621 JaÚn;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;347 JaÚn;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;274 JaÚn;Grupo 0701 Cataract 366;Both sexes;99 JaÚn;Grupo 0701 Cataract 366;Men;58 JaÚn;Grupo 0701 Cataract 366;Women;41 JaÚn;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;522 JaÚn;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;289 JaÚn;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;233 JaÚn;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;131 JaÚn;Group 0800 Diseases of the ear and the mastoid 380-389;Men;50 JaÚn;Group 0800 Diseases of the ear and the mastoid 380-389;Women;81 JaÚn;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;6.461 JaÚn;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3.678 JaÚn;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.783 JaÚn;Group 0901 Hypertensive disease 401-405;Both sexes;457 JaÚn;Group 0901 Hypertensive disease 401-405;Men;169 JaÚn;Group 0901 Hypertensive disease 401-405;Women;288 JaÚn;Group 0902 Angina pectoris 4111, 413;Both sexes;426 JaÚn;Group 0902 Angina pectoris 4111, 413;Men;277 JaÚn;Group 0902 Angina pectoris 4111, 413;Women;149 JaÚn;Group 0903 Acute myocardial infarction 410;Both sexes;938 JaÚn;Group 0903 Acute myocardial infarction 410;Men;651 JaÚn;Group 0903 Acute myocardial infarction 410;Women;287 JaÚn;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;268 JaÚn;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;193 JaÚn;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;75 JaÚn;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;194 JaÚn;Group 0905 Diseases of the lungs circulation 415-417;Men;94 JaÚn;Group 0905 Diseases of the lungs circulation 415-417;Women;100 JaÚn;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;744 JaÚn;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;384 JaÚn;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;360 JaÚn;Grupo 0907 Heart failure 428;Both sexes;1.101 JaÚn;Grupo 0907 Heart failure 428;Men;533 JaÚn;Grupo 0907 Heart failure 428;Women;568 JaÚn;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.227 JaÚn;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;700 JaÚn;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;527 JaÚn;Grupo 0909 Atherosclerosis 440;Both sexes;135 JaÚn;Grupo 0909 Atherosclerosis 440;Men;112 JaÚn;Grupo 0909 Atherosclerosis 440;Women;23 JaÚn;Group 0910 Varicose veins of lower extremities 454;Both sexes;67 JaÚn;Group 0910 Varicose veins of lower extremities 454;Men;27 JaÚn;Group 0910 Varicose veins of lower extremities 454;Women;40 JaÚn;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;904 JaÚn;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;538 JaÚn;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;366 JaÚn;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5.539 JaÚn;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3.314 JaÚn;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.225 JaÚn;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;385 JaÚn;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;212 JaÚn;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;173 JaÚn;Group 1002 Pneumonia 480-486;Both sexes;1.246 JaÚn;Group 1002 Pneumonia 480-486;Men;715 JaÚn;Group 1002 Pneumonia 480-486;Women;531 JaÚn;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;407 JaÚn;Group 1003 Acute bronchitis and bronchiolitis 466;Men;220 JaÚn;Group 1003 Acute bronchitis and bronchiolitis 466;Women;187 JaÚn;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;106 JaÚn;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;58 JaÚn;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;48 JaÚn;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;330 JaÚn;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;221 JaÚn;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;109 JaÚn;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;595 JaÚn;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;513 JaÚn;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;82 JaÚn;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;108 JaÚn;Group 1007 Asthma 4930-4931,4938-4939;Men;49 JaÚn;Group 1007 Asthma 4930-4931,4938-4939;Women;59 JaÚn;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.362 JaÚn;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.326 JaÚn;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.036 JaÚn;Group 1100 Diseases of the digestive system 520-579;Both sexes;6.113 JaÚn;Group 1100 Diseases of the digestive system 520-579;Men;3.393 JaÚn;Group 1100 Diseases of the digestive system 520-579;Women;2.720 JaÚn;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;63 JaÚn;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;36 JaÚn;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;27 JaÚn;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;90 JaÚn;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;41 JaÚn;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;49 JaÚn;Group 1103 Diseases of the esophagus 530;Both sexes;75 JaÚn;Group 1103 Diseases of the esophagus 530;Men;53 JaÚn;Group 1103 Diseases of the esophagus 530;Women;22 JaÚn;Group 1104 Peptic ulcer 531-534;Both sexes;178 JaÚn;Group 1104 Peptic ulcer 531-534;Men;135 JaÚn;Group 1104 Peptic ulcer 531-534;Women;43 JaÚn;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;147 JaÚn;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;73 JaÚn;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;74 JaÚn;Group 1106 Appendicitis 540-543;Both sexes;441 JaÚn;Group 1106 Appendicitis 540-543;Men;251 JaÚn;Group 1106 Appendicitis 540-543;Women;190 JaÚn;Group 1107 Inguinal hernia 550;Both sexes;374 JaÚn;Group 1107 Inguinal hernia 550;Men;328 JaÚn;Group 1107 Inguinal hernia 550;Women;46 JaÚn;Group 1108 Other abdominal hernia 551-553;Both sexes;398 JaÚn;Group 1108 Other abdominal hernia 551-553;Men;158 JaÚn;Group 1108 Other abdominal hernia 551-553;Women;240 JaÚn;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;174 JaÚn;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;106 JaÚn;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;68 JaÚn;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;268 JaÚn;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;132 JaÚn;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;136 JaÚn;Group 1111 Intestinal obstruction without hernia 560;Both sexes;256 JaÚn;Group 1111 Intestinal obstruction without hernia 560;Men;135 JaÚn;Group 1111 Intestinal obstruction without hernia 560;Women;121 JaÚn;Group 1112 Intestinal diverticulosis 562;Both sexes;190 JaÚn;Group 1112 Intestinal diverticulosis 562;Men;116 JaÚn;Group 1112 Intestinal diverticulosis 562;Women;74 JaÚn;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;518 JaÚn;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;336 JaÚn;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;182 JaÚn;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;153 JaÚn;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;75 JaÚn;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;78 JaÚn;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;134 JaÚn;Group 1115 Alcoholic hepatitis 5710-5713;Men;116 JaÚn;Group 1115 Alcoholic hepatitis 5710-5713;Women;18 JaÚn;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;207 JaÚn;Group 1116 Other diseases of the liver 570,5714-573;Men;134 JaÚn;Group 1116 Other diseases of the liver 570,5714-573;Women;73 JaÚn;Group 1117 Cholelithiasis 574;Both sexes;1.316 JaÚn;Group 1117 Cholelithiasis 574;Men;550 JaÚn;Group 1117 Cholelithiasis 574;Women;766 JaÚn;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;253 JaÚn;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;144 JaÚn;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;109 JaÚn;Group 1119 Pancreatic diseases 577;Both sexes;575 JaÚn;Group 1119 Pancreatic diseases 577;Men;307 JaÚn;Group 1119 Pancreatic diseases 577;Women;268 JaÚn;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;303 JaÚn;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;167 JaÚn;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;136 JaÚn;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;316 JaÚn;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;187 JaÚn;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;129 JaÚn;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;219 JaÚn;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;139 JaÚn;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;80 JaÚn;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;14 JaÚn;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;8 JaÚn;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;6 JaÚn;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;83 JaÚn;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;40 JaÚn;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;43 JaÚn;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.678 JaÚn;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.252 JaÚn;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.426 JaÚn;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. JaÚn;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. JaÚn;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. JaÚn;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. JaÚn;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. JaÚn;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. JaÚn;Group 1303 Internal derangement of knee 717;Both sexes;242 JaÚn;Group 1303 Internal derangement of knee 717;Men;187 JaÚn;Group 1303 Internal derangement of knee 717;Women;55 JaÚn;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.467 JaÚn;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;581 JaÚn;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;886 JaÚn;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;90 JaÚn;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;26 JaÚn;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;64 JaÚn;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;129 JaÚn;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;74 JaÚn;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;55 JaÚn;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;170 JaÚn;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;93 JaÚn;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;77 JaÚn;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;25 JaÚn;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;11 JaÚn;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;14 JaÚn;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;294 JaÚn;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;148 JaÚn;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;146 JaÚn;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;261 JaÚn;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;132 JaÚn;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;129 JaÚn;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.698 JaÚn;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.152 JaÚn;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.546 JaÚn;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;295 JaÚn;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;121 JaÚn;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;174 JaÚn;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;480 JaÚn;Group 1402 Renal failure 5836-5837, 584-586;Men;276 JaÚn;Group 1402 Renal failure 5836-5837, 584-586;Women;204 JaÚn;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;322 JaÚn;Group 1403 Urolithiasis 592, 594, 7880;Men;170 JaÚn;Group 1403 Urolithiasis 592, 594, 7880;Women;152 JaÚn;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;462 JaÚn;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;203 JaÚn;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;259 JaÚn;Group 1405 Prostatic hyperplasia 600;Both sexes;152 JaÚn;Group 1405 Prostatic hyperplasia 600;Men;152 JaÚn;Group 1405 Prostatic hyperplasia 600;Women;.. JaÚn;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;214 JaÚn;Group 1406 Other diseases of the male genital organs 601-608;Men;214 JaÚn;Group 1406 Other diseases of the male genital organs 601-608;Women;.. JaÚn;Group 1407 Disorders of breast 610-612;Both sexes;92 JaÚn;Group 1407 Disorders of breast 610-612;Men;15 JaÚn;Group 1407 Disorders of breast 610-612;Women;77 JaÚn;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;83 JaÚn;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. JaÚn;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;83 JaÚn;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;45 JaÚn;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. JaÚn;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;45 JaÚn;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;553 JaÚn;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 JaÚn;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;552 JaÚn;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;6.608 JaÚn;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. JaÚn;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;6.608 JaÚn;Group 1501 Legally induced abortion 635;Both sexes;4 JaÚn;Group 1501 Legally induced abortion 635;Men;.. JaÚn;Group 1501 Legally induced abortion 635;Women;4 JaÚn;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;383 JaÚn;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. JaÚn;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;383 JaÚn;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4.014 JaÚn;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. JaÚn;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4.014 JaÚn;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.250 JaÚn;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. JaÚn;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.250 JaÚn;Group 1505 Single spontaneous delivery 650;Both sexes;290 JaÚn;Group 1505 Single spontaneous delivery 650;Men;.. JaÚn;Group 1505 Single spontaneous delivery 650;Women;290 JaÚn;Group 1506 Other deliveries 6695-6697;Both sexes;273 JaÚn;Group 1506 Other deliveries 6695-6697;Men;.. JaÚn;Group 1506 Other deliveries 6695-6697;Women;273 JaÚn;Group 1507 Complications related to the puerperium 670-676;Both sexes;42 JaÚn;Group 1507 Complications related to the puerperium 670-676;Men;.. JaÚn;Group 1507 Complications related to the puerperium 670-676;Women;42 JaÚn;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;352 JaÚn;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. JaÚn;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;352 JaÚn;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;716 JaÚn;Group 1600 Some disorders originating in the perinatal period 760-779;Men;394 JaÚn;Group 1600 Some disorders originating in the perinatal period 760-779;Women;322 JaÚn;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;230 JaÚn;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;111 JaÚn;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;119 JaÚn;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;486 JaÚn;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;283 JaÚn;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;203 JaÚn;Grupo 1700 Congenital abnormalities 740-759;Both sexes;157 JaÚn;Grupo 1700 Congenital abnormalities 740-759;Men;79 JaÚn;Grupo 1700 Congenital abnormalities 740-759;Women;78 JaÚn;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.981 JaÚn;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.521 JaÚn;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.460 JaÚn;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;356 JaÚn;Group 1801 Pain in throat and chest 7841, 7865;Men;185 JaÚn;Group 1801 Pain in throat and chest 7841, 7865;Women;171 JaÚn;Group 1802 Abdominal pain 7890;Both sexes;243 JaÚn;Group 1802 Abdominal pain 7890;Men;92 JaÚn;Group 1802 Abdominal pain 7890;Women;151 JaÚn;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.108 JaÚn;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;551 JaÚn;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;557 JaÚn;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.274 JaÚn;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;693 JaÚn;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;581 JaÚn;Group 1900 Injuries and poisoning 800-999;Both sexes;4.290 JaÚn;Group 1900 Injuries and poisoning 800-999;Men;2.160 JaÚn;Group 1900 Injuries and poisoning 800-999;Women;2.130 JaÚn;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;188 JaÚn;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;107 JaÚn;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;81 JaÚn;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;112 JaÚn;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;86 JaÚn;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;26 JaÚn;Group 1903 Radius and ulna fracture 813;Both sexes;337 JaÚn;Group 1903 Radius and ulna fracture 813;Men;183 JaÚn;Group 1903 Radius and ulna fracture 813;Women;154 JaÚn;Group 1904 Femur fracture 820-821;Both sexes;930 JaÚn;Group 1904 Femur fracture 820-821;Men;257 JaÚn;Group 1904 Femur fracture 820-821;Women;673 JaÚn;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;372 JaÚn;Group 1905 Leg fracture, including the ankle 823-824;Men;196 JaÚn;Group 1905 Leg fracture, including the ankle 823-824;Women;176 JaÚn;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.168 JaÚn;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;729 JaÚn;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;439 JaÚn;Group 1907 Burns 940-949;Both sexes;11 JaÚn;Group 1907 Burns 940-949;Men;6 JaÚn;Group 1907 Burns 940-949;Women;5 JaÚn;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;143 JaÚn;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;69 JaÚn;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;74 JaÚn;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;923 JaÚn;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;467 JaÚn;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;456 JaÚn;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;6 JaÚn;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;1 JaÚn;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;5 JaÚn;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;100 JaÚn;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;59 JaÚn;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;41 JaÚn;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;851 JaÚn;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;369 JaÚn;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;482 JaÚn;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;45 JaÚn;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;28 JaÚn;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;17 JaÚn;Group 2102 Contraceptive management V25;Both sexes;15 JaÚn;Group 2102 Contraceptive management V25;Men;.. JaÚn;Group 2102 Contraceptive management V25;Women;15 JaÚn;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. JaÚn;Group 2103 Living newborns by type of delivery V30-V39;Men;.. JaÚn;Group 2103 Living newborns by type of delivery V30-V39;Women;.. JaÚn;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;393 JaÚn;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;228 JaÚn;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;165 JaÚn;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;398 JaÚn;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;113 JaÚn;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;285 Mßlaga;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;137.716 Mßlaga;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;61.100 Mßlaga;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;76.616 Mßlaga;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2.929 Mßlaga;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.627 Mßlaga;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.303 Mßlaga;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;324 Mßlaga;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;158 Mßlaga;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;167 Mßlaga;Group 0102 Imprecise intestinal infections 009;Both sexes;414 Mßlaga;Group 0102 Imprecise intestinal infections 009;Men;178 Mßlaga;Group 0102 Imprecise intestinal infections 009;Women;235 Mßlaga;Group 0103 Tuberculosis 010-018, 137;Both sexes;119 Mßlaga;Group 0103 Tuberculosis 010-018, 137;Men;82 Mßlaga;Group 0103 Tuberculosis 010-018, 137;Women;37 Mßlaga;Group 0104 Septicaemia 038;Both sexes;1.029 Mßlaga;Group 0104 Septicaemia 038;Men;561 Mßlaga;Group 0104 Septicaemia 038;Women;468 Mßlaga;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;167 Mßlaga;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;134 Mßlaga;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;32 Mßlaga;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;877 Mßlaga;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;513 Mßlaga;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;363 Mßlaga;Group 0200 Neoplasms 140-239;Both sexes;13.582 Mßlaga;Group 0200 Neoplasms 140-239;Men;6.680 Mßlaga;Group 0200 Neoplasms 140-239;Women;6.902 Mßlaga;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.238 Mßlaga;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;775 Mßlaga;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;463 Mßlaga;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;934 Mßlaga;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;733 Mßlaga;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;201 Mßlaga;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;396 Mßlaga;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;251 Mßlaga;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;144 Mßlaga;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.226 Mßlaga;Group 0204 Malignant neoplasm of breast 174-175;Men;13 Mßlaga;Group 0204 Malignant neoplasm of breast 174-175;Women;1.213 Mßlaga;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;271 Mßlaga;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Mßlaga;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;271 Mßlaga;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;155 Mßlaga;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Mßlaga;Group 0206 Malignant neoplasm of ovary 1830;Women;155 Mßlaga;Group 0207 Malignant neoplasm of prostate 185;Both sexes;396 Mßlaga;Group 0207 Malignant neoplasm of prostate 185;Men;396 Mßlaga;Group 0207 Malignant neoplasm of prostate 185;Women;.. Mßlaga;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.006 Mßlaga;Group 0208 Malignant neoplasm of bladder 188;Men;859 Mßlaga;Group 0208 Malignant neoplasm of bladder 188;Women;146 Mßlaga;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;4.788 Mßlaga;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2.720 Mßlaga;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2.069 Mßlaga;Group 0210 Carcinoma in situ 230-234;Both sexes;247 Mßlaga;Group 0210 Carcinoma in situ 230-234;Men;55 Mßlaga;Group 0210 Carcinoma in situ 230-234;Women;192 Mßlaga;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;93 Mßlaga;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;54 Mßlaga;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;39 Mßlaga;Grupo 0212 Leiomyoma of uterus 218;Both sexes;878 Mßlaga;Grupo 0212 Leiomyoma of uterus 218;Men;.. Mßlaga;Grupo 0212 Leiomyoma of uterus 218;Women;878 Mßlaga;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.955 Mßlaga;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;824 Mßlaga;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.130 Mßlaga;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.088 Mßlaga;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;517 Mßlaga;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;572 Mßlaga;Group 0301 Anaemias 280-285;Both sexes;444 Mßlaga;Group 0301 Anaemias 280-285;Men;213 Mßlaga;Group 0301 Anaemias 280-285;Women;231 Mßlaga;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;644 Mßlaga;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;304 Mßlaga;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;340 Mßlaga;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2.314 Mßlaga;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;882 Mßlaga;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.431 Mßlaga;Group 0401 Diabetes mellitus 249-250;Both sexes;599 Mßlaga;Group 0401 Diabetes mellitus 249-250;Men;368 Mßlaga;Group 0401 Diabetes mellitus 249-250;Women;231 Mßlaga;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.715 Mßlaga;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;515 Mßlaga;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.200 Mßlaga;Group 0500 Mental disorders 290-319;Both sexes;2.595 Mßlaga;Group 0500 Mental disorders 290-319;Men;1.389 Mßlaga;Group 0500 Mental disorders 290-319;Women;1.206 Mßlaga;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;40 Mßlaga;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;17 Mßlaga;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;23 Mßlaga;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;98 Mßlaga;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;73 Mßlaga;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;25 Mßlaga;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;161 Mßlaga;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;124 Mßlaga;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;37 Mßlaga;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;807 Mßlaga;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;526 Mßlaga;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;280 Mßlaga;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;681 Mßlaga;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;280 Mßlaga;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;402 Mßlaga;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;808 Mßlaga;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;369 Mßlaga;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;438 Mßlaga;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.475 Mßlaga;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.165 Mßlaga;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.310 Mßlaga;Group 0601 Alzheimer's disease 3310;Both sexes;43 Mßlaga;Group 0601 Alzheimer's disease 3310;Men;10 Mßlaga;Group 0601 Alzheimer's disease 3310;Women;33 Mßlaga;Group 0602 Multiple sclerosis 340;Both sexes;92 Mßlaga;Group 0602 Multiple sclerosis 340;Men;30 Mßlaga;Group 0602 Multiple sclerosis 340;Women;62 Mßlaga;Group 0603 Epilepsy 345;Both sexes;416 Mßlaga;Group 0603 Epilepsy 345;Men;221 Mßlaga;Group 0603 Epilepsy 345;Women;195 Mßlaga;Group 0604 Transient cerebral ischemia 435;Both sexes;402 Mßlaga;Group 0604 Transient cerebral ischemia 435;Men;217 Mßlaga;Group 0604 Transient cerebral ischemia 435;Women;185 Mßlaga;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.522 Mßlaga;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;687 Mßlaga;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;835 Mßlaga;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;881 Mßlaga;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;452 Mßlaga;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;429 Mßlaga;Grupo 0701 Cataract 366;Both sexes;249 Mßlaga;Grupo 0701 Cataract 366;Men;118 Mßlaga;Grupo 0701 Cataract 366;Women;131 Mßlaga;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;631 Mßlaga;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;334 Mßlaga;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;298 Mßlaga;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;736 Mßlaga;Group 0800 Diseases of the ear and the mastoid 380-389;Men;356 Mßlaga;Group 0800 Diseases of the ear and the mastoid 380-389;Women;379 Mßlaga;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;17.829 Mßlaga;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;10.469 Mßlaga;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;7.360 Mßlaga;Group 0901 Hypertensive disease 401-405;Both sexes;1.092 Mßlaga;Group 0901 Hypertensive disease 401-405;Men;449 Mßlaga;Group 0901 Hypertensive disease 401-405;Women;643 Mßlaga;Group 0902 Angina pectoris 4111, 413;Both sexes;964 Mßlaga;Group 0902 Angina pectoris 4111, 413;Men;587 Mßlaga;Group 0902 Angina pectoris 4111, 413;Women;377 Mßlaga;Group 0903 Acute myocardial infarction 410;Both sexes;2.118 Mßlaga;Group 0903 Acute myocardial infarction 410;Men;1.501 Mßlaga;Group 0903 Acute myocardial infarction 410;Women;617 Mßlaga;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.976 Mßlaga;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.464 Mßlaga;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;512 Mßlaga;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;400 Mßlaga;Group 0905 Diseases of the lungs circulation 415-417;Men;213 Mßlaga;Group 0905 Diseases of the lungs circulation 415-417;Women;187 Mßlaga;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.705 Mßlaga;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;973 Mßlaga;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;731 Mßlaga;Grupo 0907 Heart failure 428;Both sexes;2.378 Mßlaga;Grupo 0907 Heart failure 428;Men;1.192 Mßlaga;Grupo 0907 Heart failure 428;Women;1.186 Mßlaga;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.761 Mßlaga;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.599 Mßlaga;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.162 Mßlaga;Grupo 0909 Atherosclerosis 440;Both sexes;606 Mßlaga;Grupo 0909 Atherosclerosis 440;Men;450 Mßlaga;Grupo 0909 Atherosclerosis 440;Women;155 Mßlaga;Group 0910 Varicose veins of lower extremities 454;Both sexes;665 Mßlaga;Group 0910 Varicose veins of lower extremities 454;Men;232 Mßlaga;Group 0910 Varicose veins of lower extremities 454;Women;432 Mßlaga;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;3.165 Mßlaga;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.809 Mßlaga;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.357 Mßlaga;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;11.611 Mßlaga;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;6.609 Mßlaga;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;5.002 Mßlaga;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;823 Mßlaga;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;401 Mßlaga;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;422 Mßlaga;Group 1002 Pneumonia 480-486;Both sexes;2.421 Mßlaga;Group 1002 Pneumonia 480-486;Men;1.465 Mßlaga;Group 1002 Pneumonia 480-486;Women;956 Mßlaga;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;683 Mßlaga;Group 1003 Acute bronchitis and bronchiolitis 466;Men;357 Mßlaga;Group 1003 Acute bronchitis and bronchiolitis 466;Women;326 Mßlaga;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;816 Mßlaga;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;421 Mßlaga;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;395 Mßlaga;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.677 Mßlaga;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;942 Mßlaga;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;735 Mßlaga;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.191 Mßlaga;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;829 Mßlaga;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;362 Mßlaga;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;316 Mßlaga;Group 1007 Asthma 4930-4931,4938-4939;Men;82 Mßlaga;Group 1007 Asthma 4930-4931,4938-4939;Women;234 Mßlaga;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3.683 Mßlaga;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.111 Mßlaga;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.572 Mßlaga;Group 1100 Diseases of the digestive system 520-579;Both sexes;17.333 Mßlaga;Group 1100 Diseases of the digestive system 520-579;Men;9.338 Mßlaga;Group 1100 Diseases of the digestive system 520-579;Women;7.995 Mßlaga;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;250 Mßlaga;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;111 Mßlaga;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;139 Mßlaga;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;228 Mßlaga;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;124 Mßlaga;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;104 Mßlaga;Group 1103 Diseases of the esophagus 530;Both sexes;269 Mßlaga;Group 1103 Diseases of the esophagus 530;Men;143 Mßlaga;Group 1103 Diseases of the esophagus 530;Women;126 Mßlaga;Group 1104 Peptic ulcer 531-534;Both sexes;335 Mßlaga;Group 1104 Peptic ulcer 531-534;Men;231 Mßlaga;Group 1104 Peptic ulcer 531-534;Women;104 Mßlaga;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;434 Mßlaga;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;220 Mßlaga;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;214 Mßlaga;Group 1106 Appendicitis 540-543;Both sexes;1.647 Mßlaga;Group 1106 Appendicitis 540-543;Men;940 Mßlaga;Group 1106 Appendicitis 540-543;Women;707 Mßlaga;Group 1107 Inguinal hernia 550;Both sexes;1.573 Mßlaga;Group 1107 Inguinal hernia 550;Men;1.412 Mßlaga;Group 1107 Inguinal hernia 550;Women;161 Mßlaga;Group 1108 Other abdominal hernia 551-553;Both sexes;1.466 Mßlaga;Group 1108 Other abdominal hernia 551-553;Men;647 Mßlaga;Group 1108 Other abdominal hernia 551-553;Women;818 Mßlaga;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;435 Mßlaga;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;193 Mßlaga;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;242 Mßlaga;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.015 Mßlaga;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;454 Mßlaga;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;560 Mßlaga;Group 1111 Intestinal obstruction without hernia 560;Both sexes;609 Mßlaga;Group 1111 Intestinal obstruction without hernia 560;Men;292 Mßlaga;Group 1111 Intestinal obstruction without hernia 560;Women;316 Mßlaga;Group 1112 Intestinal diverticulosis 562;Both sexes;853 Mßlaga;Group 1112 Intestinal diverticulosis 562;Men;451 Mßlaga;Group 1112 Intestinal diverticulosis 562;Women;402 Mßlaga;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.035 Mßlaga;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;669 Mßlaga;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;366 Mßlaga;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;468 Mßlaga;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;216 Mßlaga;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;252 Mßlaga;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;222 Mßlaga;Group 1115 Alcoholic hepatitis 5710-5713;Men;176 Mßlaga;Group 1115 Alcoholic hepatitis 5710-5713;Women;45 Mßlaga;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;474 Mßlaga;Group 1116 Other diseases of the liver 570,5714-573;Men;310 Mßlaga;Group 1116 Other diseases of the liver 570,5714-573;Women;164 Mßlaga;Group 1117 Cholelithiasis 574;Both sexes;3.580 Mßlaga;Group 1117 Cholelithiasis 574;Men;1.430 Mßlaga;Group 1117 Cholelithiasis 574;Women;2.150 Mßlaga;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;764 Mßlaga;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;408 Mßlaga;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;356 Mßlaga;Group 1119 Pancreatic diseases 577;Both sexes;1.059 Mßlaga;Group 1119 Pancreatic diseases 577;Men;561 Mßlaga;Group 1119 Pancreatic diseases 577;Women;499 Mßlaga;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;619 Mßlaga;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;349 Mßlaga;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;270 Mßlaga;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.292 Mßlaga;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;688 Mßlaga;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;604 Mßlaga;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;830 Mßlaga;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;502 Mßlaga;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;328 Mßlaga;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;49 Mßlaga;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;25 Mßlaga;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;24 Mßlaga;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;414 Mßlaga;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;162 Mßlaga;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;252 Mßlaga;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;8.587 Mßlaga;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.175 Mßlaga;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;4.412 Mßlaga;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Mßlaga;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Mßlaga;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Mßlaga;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Mßlaga;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Mßlaga;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Mßlaga;Group 1303 Internal derangement of knee 717;Both sexes;1.016 Mßlaga;Group 1303 Internal derangement of knee 717;Men;688 Mßlaga;Group 1303 Internal derangement of knee 717;Women;327 Mßlaga;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3.296 Mßlaga;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.450 Mßlaga;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.845 Mßlaga;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;159 Mßlaga;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;67 Mßlaga;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;93 Mßlaga;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;368 Mßlaga;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;174 Mßlaga;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;194 Mßlaga;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;960 Mßlaga;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;473 Mßlaga;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;487 Mßlaga;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;290 Mßlaga;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;120 Mßlaga;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;170 Mßlaga;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.322 Mßlaga;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;693 Mßlaga;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;629 Mßlaga;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.175 Mßlaga;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;510 Mßlaga;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;665 Mßlaga;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;9.634 Mßlaga;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4.091 Mßlaga;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;5.543 Mßlaga;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.109 Mßlaga;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;429 Mßlaga;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;679 Mßlaga;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;781 Mßlaga;Group 1402 Renal failure 5836-5837, 584-586;Men;440 Mßlaga;Group 1402 Renal failure 5836-5837, 584-586;Women;341 Mßlaga;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.400 Mßlaga;Group 1403 Urolithiasis 592, 594, 7880;Men;849 Mßlaga;Group 1403 Urolithiasis 592, 594, 7880;Women;552 Mßlaga;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.774 Mßlaga;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;883 Mßlaga;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;891 Mßlaga;Group 1405 Prostatic hyperplasia 600;Both sexes;745 Mßlaga;Group 1405 Prostatic hyperplasia 600;Men;745 Mßlaga;Group 1405 Prostatic hyperplasia 600;Women;.. Mßlaga;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;676 Mßlaga;Group 1406 Other diseases of the male genital organs 601-608;Men;676 Mßlaga;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Mßlaga;Group 1407 Disorders of breast 610-612;Both sexes;1.044 Mßlaga;Group 1407 Disorders of breast 610-612;Men;56 Mßlaga;Group 1407 Disorders of breast 610-612;Women;988 Mßlaga;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;355 Mßlaga;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Mßlaga;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;355 Mßlaga;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;156 Mßlaga;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Mßlaga;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;156 Mßlaga;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.594 Mßlaga;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;13 Mßlaga;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.581 Mßlaga;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;19.453 Mßlaga;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Mßlaga;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;19.453 Mßlaga;Group 1501 Legally induced abortion 635;Both sexes;59 Mßlaga;Group 1501 Legally induced abortion 635;Men;.. Mßlaga;Group 1501 Legally induced abortion 635;Women;59 Mßlaga;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.322 Mßlaga;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Mßlaga;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.322 Mßlaga;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;12.538 Mßlaga;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Mßlaga;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;12.538 Mßlaga;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3.034 Mßlaga;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Mßlaga;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3.034 Mßlaga;Group 1505 Single spontaneous delivery 650;Both sexes;710 Mßlaga;Group 1505 Single spontaneous delivery 650;Men;.. Mßlaga;Group 1505 Single spontaneous delivery 650;Women;710 Mßlaga;Group 1506 Other deliveries 6695-6697;Both sexes;447 Mßlaga;Group 1506 Other deliveries 6695-6697;Men;.. Mßlaga;Group 1506 Other deliveries 6695-6697;Women;447 Mßlaga;Group 1507 Complications related to the puerperium 670-676;Both sexes;159 Mßlaga;Group 1507 Complications related to the puerperium 670-676;Men;.. Mßlaga;Group 1507 Complications related to the puerperium 670-676;Women;159 Mßlaga;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.184 Mßlaga;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Mßlaga;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.184 Mßlaga;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.074 Mßlaga;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.082 Mßlaga;Group 1600 Some disorders originating in the perinatal period 760-779;Women;992 Mßlaga;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;693 Mßlaga;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;357 Mßlaga;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;336 Mßlaga;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.381 Mßlaga;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;726 Mßlaga;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;656 Mßlaga;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.120 Mßlaga;Grupo 1700 Congenital abnormalities 740-759;Men;608 Mßlaga;Grupo 1700 Congenital abnormalities 740-759;Women;513 Mßlaga;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;6.820 Mßlaga;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3.488 Mßlaga;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3.332 Mßlaga;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;617 Mßlaga;Group 1801 Pain in throat and chest 7841, 7865;Men;352 Mßlaga;Group 1801 Pain in throat and chest 7841, 7865;Women;265 Mßlaga;Group 1802 Abdominal pain 7890;Both sexes;619 Mßlaga;Group 1802 Abdominal pain 7890;Men;205 Mßlaga;Group 1802 Abdominal pain 7890;Women;413 Mßlaga;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.337 Mßlaga;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;516 Mßlaga;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;821 Mßlaga;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;4.247 Mßlaga;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.414 Mßlaga;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.833 Mßlaga;Group 1900 Injuries and poisoning 800-999;Both sexes;12.712 Mßlaga;Group 1900 Injuries and poisoning 800-999;Men;6.553 Mßlaga;Group 1900 Injuries and poisoning 800-999;Women;6.159 Mßlaga;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;521 Mßlaga;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;332 Mßlaga;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;188 Mßlaga;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;367 Mßlaga;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;256 Mßlaga;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;112 Mßlaga;Group 1903 Radius and ulna fracture 813;Both sexes;772 Mßlaga;Group 1903 Radius and ulna fracture 813;Men;362 Mßlaga;Group 1903 Radius and ulna fracture 813;Women;410 Mßlaga;Group 1904 Femur fracture 820-821;Both sexes;2.117 Mßlaga;Group 1904 Femur fracture 820-821;Men;649 Mßlaga;Group 1904 Femur fracture 820-821;Women;1.468 Mßlaga;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.133 Mßlaga;Group 1905 Leg fracture, including the ankle 823-824;Men;582 Mßlaga;Group 1905 Leg fracture, including the ankle 823-824;Women;552 Mßlaga;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3.607 Mßlaga;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.127 Mßlaga;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.479 Mßlaga;Group 1907 Burns 940-949;Both sexes;165 Mßlaga;Group 1907 Burns 940-949;Men;83 Mßlaga;Group 1907 Burns 940-949;Women;82 Mßlaga;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;375 Mßlaga;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;185 Mßlaga;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;189 Mßlaga;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3.347 Mßlaga;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.804 Mßlaga;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.543 Mßlaga;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;57 Mßlaga;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;39 Mßlaga;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;18 Mßlaga;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;251 Mßlaga;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;134 Mßlaga;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;117 Mßlaga;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.650 Mßlaga;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;931 Mßlaga;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.719 Mßlaga;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;132 Mßlaga;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;81 Mßlaga;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;51 Mßlaga;Group 2102 Contraceptive management V25;Both sexes;61 Mßlaga;Group 2102 Contraceptive management V25;Men;16 Mßlaga;Group 2102 Contraceptive management V25;Women;45 Mßlaga;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Mßlaga;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Mßlaga;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Mßlaga;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;648 Mßlaga;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;371 Mßlaga;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;278 Mßlaga;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.809 Mßlaga;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;464 Mßlaga;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.345 Sevilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;166.966 Sevilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;72.721 Sevilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;94.245 Sevilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3.695 Sevilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2.095 Sevilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.600 Sevilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;457 Sevilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;262 Sevilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;195 Sevilla;Group 0102 Imprecise intestinal infections 009;Both sexes;303 Sevilla;Group 0102 Imprecise intestinal infections 009;Men;156 Sevilla;Group 0102 Imprecise intestinal infections 009;Women;147 Sevilla;Group 0103 Tuberculosis 010-018, 137;Both sexes;116 Sevilla;Group 0103 Tuberculosis 010-018, 137;Men;73 Sevilla;Group 0103 Tuberculosis 010-018, 137;Women;43 Sevilla;Group 0104 Septicaemia 038;Both sexes;1.653 Sevilla;Group 0104 Septicaemia 038;Men;896 Sevilla;Group 0104 Septicaemia 038;Women;757 Sevilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;128 Sevilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;102 Sevilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;26 Sevilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.038 Sevilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;606 Sevilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;432 Sevilla;Group 0200 Neoplasms 140-239;Both sexes;16.364 Sevilla;Group 0200 Neoplasms 140-239;Men;8.229 Sevilla;Group 0200 Neoplasms 140-239;Women;8.135 Sevilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.581 Sevilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;956 Sevilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;625 Sevilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.091 Sevilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;927 Sevilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;164 Sevilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;366 Sevilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;212 Sevilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;154 Sevilla;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.335 Sevilla;Group 0204 Malignant neoplasm of breast 174-175;Men;12 Sevilla;Group 0204 Malignant neoplasm of breast 174-175;Women;1.323 Sevilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;351 Sevilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Sevilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;351 Sevilla;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;214 Sevilla;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Sevilla;Group 0206 Malignant neoplasm of ovary 1830;Women;214 Sevilla;Group 0207 Malignant neoplasm of prostate 185;Both sexes;465 Sevilla;Group 0207 Malignant neoplasm of prostate 185;Men;465 Sevilla;Group 0207 Malignant neoplasm of prostate 185;Women;.. Sevilla;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.543 Sevilla;Group 0208 Malignant neoplasm of bladder 188;Men;1.279 Sevilla;Group 0208 Malignant neoplasm of bladder 188;Women;264 Sevilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5.778 Sevilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3.311 Sevilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2.467 Sevilla;Group 0210 Carcinoma in situ 230-234;Both sexes;156 Sevilla;Group 0210 Carcinoma in situ 230-234;Men;43 Sevilla;Group 0210 Carcinoma in situ 230-234;Women;113 Sevilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;154 Sevilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;86 Sevilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;68 Sevilla;Grupo 0212 Leiomyoma of uterus 218;Both sexes;908 Sevilla;Grupo 0212 Leiomyoma of uterus 218;Men;.. Sevilla;Grupo 0212 Leiomyoma of uterus 218;Women;908 Sevilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2.422 Sevilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;938 Sevilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.484 Sevilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.338 Sevilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;663 Sevilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;675 Sevilla;Group 0301 Anaemias 280-285;Both sexes;767 Sevilla;Group 0301 Anaemias 280-285;Men;362 Sevilla;Group 0301 Anaemias 280-285;Women;405 Sevilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;571 Sevilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;301 Sevilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;270 Sevilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;3.038 Sevilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.092 Sevilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.946 Sevilla;Group 0401 Diabetes mellitus 249-250;Both sexes;849 Sevilla;Group 0401 Diabetes mellitus 249-250;Men;501 Sevilla;Group 0401 Diabetes mellitus 249-250;Women;348 Sevilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2.189 Sevilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;591 Sevilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.598 Sevilla;Group 0500 Mental disorders 290-319;Both sexes;3.514 Sevilla;Group 0500 Mental disorders 290-319;Men;1.966 Sevilla;Group 0500 Mental disorders 290-319;Women;1.548 Sevilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;57 Sevilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;23 Sevilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;34 Sevilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;133 Sevilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;105 Sevilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;28 Sevilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;188 Sevilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;151 Sevilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;37 Sevilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.117 Sevilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;744 Sevilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;373 Sevilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;821 Sevilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;348 Sevilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;473 Sevilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.198 Sevilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;595 Sevilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;603 Sevilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3.159 Sevilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.528 Sevilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.631 Sevilla;Group 0601 Alzheimer's disease 3310;Both sexes;62 Sevilla;Group 0601 Alzheimer's disease 3310;Men;19 Sevilla;Group 0601 Alzheimer's disease 3310;Women;43 Sevilla;Group 0602 Multiple sclerosis 340;Both sexes;43 Sevilla;Group 0602 Multiple sclerosis 340;Men;15 Sevilla;Group 0602 Multiple sclerosis 340;Women;28 Sevilla;Group 0603 Epilepsy 345;Both sexes;679 Sevilla;Group 0603 Epilepsy 345;Men;348 Sevilla;Group 0603 Epilepsy 345;Women;331 Sevilla;Group 0604 Transient cerebral ischemia 435;Both sexes;430 Sevilla;Group 0604 Transient cerebral ischemia 435;Men;217 Sevilla;Group 0604 Transient cerebral ischemia 435;Women;213 Sevilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.945 Sevilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;929 Sevilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.016 Sevilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;985 Sevilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;526 Sevilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;459 Sevilla;Grupo 0701 Cataract 366;Both sexes;72 Sevilla;Grupo 0701 Cataract 366;Men;38 Sevilla;Grupo 0701 Cataract 366;Women;34 Sevilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;913 Sevilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;488 Sevilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;425 Sevilla;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;842 Sevilla;Group 0800 Diseases of the ear and the mastoid 380-389;Men;411 Sevilla;Group 0800 Diseases of the ear and the mastoid 380-389;Women;431 Sevilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;22.134 Sevilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;12.290 Sevilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;9.844 Sevilla;Group 0901 Hypertensive disease 401-405;Both sexes;1.987 Sevilla;Group 0901 Hypertensive disease 401-405;Men;845 Sevilla;Group 0901 Hypertensive disease 401-405;Women;1.142 Sevilla;Group 0902 Angina pectoris 4111, 413;Both sexes;1.331 Sevilla;Group 0902 Angina pectoris 4111, 413;Men;760 Sevilla;Group 0902 Angina pectoris 4111, 413;Women;571 Sevilla;Group 0903 Acute myocardial infarction 410;Both sexes;2.383 Sevilla;Group 0903 Acute myocardial infarction 410;Men;1.516 Sevilla;Group 0903 Acute myocardial infarction 410;Women;867 Sevilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.734 Sevilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.315 Sevilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;419 Sevilla;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;531 Sevilla;Group 0905 Diseases of the lungs circulation 415-417;Men;234 Sevilla;Group 0905 Diseases of the lungs circulation 415-417;Women;297 Sevilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.928 Sevilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.574 Sevilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.354 Sevilla;Grupo 0907 Heart failure 428;Both sexes;3.529 Sevilla;Grupo 0907 Heart failure 428;Men;1.676 Sevilla;Grupo 0907 Heart failure 428;Women;1.853 Sevilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3.327 Sevilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.792 Sevilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.535 Sevilla;Grupo 0909 Atherosclerosis 440;Both sexes;937 Sevilla;Grupo 0909 Atherosclerosis 440;Men;712 Sevilla;Grupo 0909 Atherosclerosis 440;Women;225 Sevilla;Group 0910 Varicose veins of lower extremities 454;Both sexes;526 Sevilla;Group 0910 Varicose veins of lower extremities 454;Men;197 Sevilla;Group 0910 Varicose veins of lower extremities 454;Women;329 Sevilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.921 Sevilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.669 Sevilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.252 Sevilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;12.662 Sevilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;7.426 Sevilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;5.236 Sevilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;784 Sevilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;433 Sevilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;351 Sevilla;Group 1002 Pneumonia 480-486;Both sexes;2.342 Sevilla;Group 1002 Pneumonia 480-486;Men;1.345 Sevilla;Group 1002 Pneumonia 480-486;Women;997 Sevilla;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.338 Sevilla;Group 1003 Acute bronchitis and bronchiolitis 466;Men;742 Sevilla;Group 1003 Acute bronchitis and bronchiolitis 466;Women;596 Sevilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;732 Sevilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;368 Sevilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;364 Sevilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.556 Sevilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;900 Sevilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;656 Sevilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.225 Sevilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;985 Sevilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;240 Sevilla;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;297 Sevilla;Group 1007 Asthma 4930-4931,4938-4939;Men;107 Sevilla;Group 1007 Asthma 4930-4931,4938-4939;Women;190 Sevilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;4.388 Sevilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.546 Sevilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.842 Sevilla;Group 1100 Diseases of the digestive system 520-579;Both sexes;20.181 Sevilla;Group 1100 Diseases of the digestive system 520-579;Men;10.596 Sevilla;Group 1100 Diseases of the digestive system 520-579;Women;9.585 Sevilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;362 Sevilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;163 Sevilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;199 Sevilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;307 Sevilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;150 Sevilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;157 Sevilla;Group 1103 Diseases of the esophagus 530;Both sexes;747 Sevilla;Group 1103 Diseases of the esophagus 530;Men;427 Sevilla;Group 1103 Diseases of the esophagus 530;Women;320 Sevilla;Group 1104 Peptic ulcer 531-534;Both sexes;343 Sevilla;Group 1104 Peptic ulcer 531-534;Men;237 Sevilla;Group 1104 Peptic ulcer 531-534;Women;106 Sevilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;554 Sevilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;251 Sevilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;303 Sevilla;Group 1106 Appendicitis 540-543;Both sexes;1.743 Sevilla;Group 1106 Appendicitis 540-543;Men;978 Sevilla;Group 1106 Appendicitis 540-543;Women;765 Sevilla;Group 1107 Inguinal hernia 550;Both sexes;1.591 Sevilla;Group 1107 Inguinal hernia 550;Men;1.296 Sevilla;Group 1107 Inguinal hernia 550;Women;295 Sevilla;Group 1108 Other abdominal hernia 551-553;Both sexes;1.684 Sevilla;Group 1108 Other abdominal hernia 551-553;Men;709 Sevilla;Group 1108 Other abdominal hernia 551-553;Women;975 Sevilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;545 Sevilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;243 Sevilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;302 Sevilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;987 Sevilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;450 Sevilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;537 Sevilla;Group 1111 Intestinal obstruction without hernia 560;Both sexes;721 Sevilla;Group 1111 Intestinal obstruction without hernia 560;Men;347 Sevilla;Group 1111 Intestinal obstruction without hernia 560;Women;374 Sevilla;Group 1112 Intestinal diverticulosis 562;Both sexes;638 Sevilla;Group 1112 Intestinal diverticulosis 562;Men;328 Sevilla;Group 1112 Intestinal diverticulosis 562;Women;310 Sevilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.090 Sevilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;642 Sevilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;448 Sevilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;658 Sevilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;339 Sevilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;319 Sevilla;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;413 Sevilla;Group 1115 Alcoholic hepatitis 5710-5713;Men;342 Sevilla;Group 1115 Alcoholic hepatitis 5710-5713;Women;71 Sevilla;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;666 Sevilla;Group 1116 Other diseases of the liver 570,5714-573;Men;393 Sevilla;Group 1116 Other diseases of the liver 570,5714-573;Women;273 Sevilla;Group 1117 Cholelithiasis 574;Both sexes;3.839 Sevilla;Group 1117 Cholelithiasis 574;Men;1.573 Sevilla;Group 1117 Cholelithiasis 574;Women;2.266 Sevilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1.071 Sevilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;530 Sevilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;541 Sevilla;Group 1119 Pancreatic diseases 577;Both sexes;1.384 Sevilla;Group 1119 Pancreatic diseases 577;Men;736 Sevilla;Group 1119 Pancreatic diseases 577;Women;648 Sevilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;838 Sevilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;462 Sevilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;376 Sevilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.441 Sevilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;752 Sevilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;689 Sevilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;797 Sevilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;458 Sevilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;339 Sevilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;72 Sevilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;52 Sevilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;20 Sevilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;572 Sevilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;242 Sevilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;330 Sevilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;13.070 Sevilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;5.788 Sevilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;7.282 Sevilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Sevilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Sevilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Sevilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Sevilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Sevilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Sevilla;Group 1303 Internal derangement of knee 717;Both sexes;1.672 Sevilla;Group 1303 Internal derangement of knee 717;Men;1.079 Sevilla;Group 1303 Internal derangement of knee 717;Women;593 Sevilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;5.137 Sevilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.983 Sevilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;3.154 Sevilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;200 Sevilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;58 Sevilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;142 Sevilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;665 Sevilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;317 Sevilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;348 Sevilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.541 Sevilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;736 Sevilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;805 Sevilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;375 Sevilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;126 Sevilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;249 Sevilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.696 Sevilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;750 Sevilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;946 Sevilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.784 Sevilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;739 Sevilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.045 Sevilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;9.358 Sevilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3.972 Sevilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;5.386 Sevilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.002 Sevilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;379 Sevilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;623 Sevilla;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;806 Sevilla;Group 1402 Renal failure 5836-5837, 584-586;Men;439 Sevilla;Group 1402 Renal failure 5836-5837, 584-586;Women;367 Sevilla;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.370 Sevilla;Group 1403 Urolithiasis 592, 594, 7880;Men;773 Sevilla;Group 1403 Urolithiasis 592, 594, 7880;Women;597 Sevilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.823 Sevilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;876 Sevilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;947 Sevilla;Group 1405 Prostatic hyperplasia 600;Both sexes;690 Sevilla;Group 1405 Prostatic hyperplasia 600;Men;690 Sevilla;Group 1405 Prostatic hyperplasia 600;Women;.. Sevilla;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;720 Sevilla;Group 1406 Other diseases of the male genital organs 601-608;Men;720 Sevilla;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Sevilla;Group 1407 Disorders of breast 610-612;Both sexes;777 Sevilla;Group 1407 Disorders of breast 610-612;Men;65 Sevilla;Group 1407 Disorders of breast 610-612;Women;712 Sevilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;311 Sevilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Sevilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;311 Sevilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;144 Sevilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Sevilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;144 Sevilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.715 Sevilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;30 Sevilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.685 Sevilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;23.815 Sevilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Sevilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;23.815 Sevilla;Group 1501 Legally induced abortion 635;Both sexes;34 Sevilla;Group 1501 Legally induced abortion 635;Men;.. Sevilla;Group 1501 Legally induced abortion 635;Women;34 Sevilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.148 Sevilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Sevilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.148 Sevilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;14.968 Sevilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Sevilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;14.968 Sevilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3.925 Sevilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Sevilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3.925 Sevilla;Group 1505 Single spontaneous delivery 650;Both sexes;1.520 Sevilla;Group 1505 Single spontaneous delivery 650;Men;.. Sevilla;Group 1505 Single spontaneous delivery 650;Women;1.520 Sevilla;Group 1506 Other deliveries 6695-6697;Both sexes;522 Sevilla;Group 1506 Other deliveries 6695-6697;Men;.. Sevilla;Group 1506 Other deliveries 6695-6697;Women;522 Sevilla;Group 1507 Complications related to the puerperium 670-676;Both sexes;226 Sevilla;Group 1507 Complications related to the puerperium 670-676;Men;.. Sevilla;Group 1507 Complications related to the puerperium 670-676;Women;226 Sevilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.472 Sevilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Sevilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.472 Sevilla;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.249 Sevilla;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.229 Sevilla;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1.020 Sevilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;864 Sevilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;452 Sevilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;412 Sevilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.385 Sevilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;777 Sevilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;608 Sevilla;Grupo 1700 Congenital abnormalities 740-759;Both sexes;2.127 Sevilla;Grupo 1700 Congenital abnormalities 740-759;Men;1.196 Sevilla;Grupo 1700 Congenital abnormalities 740-759;Women;931 Sevilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;8.633 Sevilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4.265 Sevilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;4.368 Sevilla;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.659 Sevilla;Group 1801 Pain in throat and chest 7841, 7865;Men;855 Sevilla;Group 1801 Pain in throat and chest 7841, 7865;Women;804 Sevilla;Group 1802 Abdominal pain 7890;Both sexes;1.262 Sevilla;Group 1802 Abdominal pain 7890;Men;453 Sevilla;Group 1802 Abdominal pain 7890;Women;809 Sevilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;219 Sevilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;90 Sevilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;129 Sevilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5.493 Sevilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.867 Sevilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.626 Sevilla;Group 1900 Injuries and poisoning 800-999;Both sexes;15.259 Sevilla;Group 1900 Injuries and poisoning 800-999;Men;7.282 Sevilla;Group 1900 Injuries and poisoning 800-999;Women;7.977 Sevilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;560 Sevilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;343 Sevilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;217 Sevilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;382 Sevilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;267 Sevilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;115 Sevilla;Group 1903 Radius and ulna fracture 813;Both sexes;1.097 Sevilla;Group 1903 Radius and ulna fracture 813;Men;532 Sevilla;Group 1903 Radius and ulna fracture 813;Women;565 Sevilla;Group 1904 Femur fracture 820-821;Both sexes;2.196 Sevilla;Group 1904 Femur fracture 820-821;Men;588 Sevilla;Group 1904 Femur fracture 820-821;Women;1.608 Sevilla;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.252 Sevilla;Group 1905 Leg fracture, including the ankle 823-824;Men;565 Sevilla;Group 1905 Leg fracture, including the ankle 823-824;Women;687 Sevilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;4.362 Sevilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.079 Sevilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2.283 Sevilla;Group 1907 Burns 940-949;Both sexes;158 Sevilla;Group 1907 Burns 940-949;Men;98 Sevilla;Group 1907 Burns 940-949;Women;60 Sevilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;391 Sevilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;190 Sevilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;201 Sevilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;4.578 Sevilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;2.469 Sevilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;2.109 Sevilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;54 Sevilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;29 Sevilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;25 Sevilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;229 Sevilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;122 Sevilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;107 Sevilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;3.102 Sevilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.415 Sevilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.687 Sevilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;328 Sevilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;174 Sevilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;154 Sevilla;Group 2102 Contraceptive management V25;Both sexes;35 Sevilla;Group 2102 Contraceptive management V25;Men;4 Sevilla;Group 2102 Contraceptive management V25;Women;31 Sevilla;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Sevilla;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Sevilla;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Sevilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1.059 Sevilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;675 Sevilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;384 Sevilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.680 Sevilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;562 Sevilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.118 ARAGËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;155.285 ARAGËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;75.756 ARAGËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;79.529 ARAGËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3.045 ARAGËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.672 ARAGËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.373 ARAGËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;575 ARAGËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;293 ARAGËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;282 ARAGËN;Group 0102 Imprecise intestinal infections 009;Both sexes;216 ARAGËN;Group 0102 Imprecise intestinal infections 009;Men;103 ARAGËN;Group 0102 Imprecise intestinal infections 009;Women;113 ARAGËN;Group 0103 Tuberculosis 010-018, 137;Both sexes;177 ARAGËN;Group 0103 Tuberculosis 010-018, 137;Men;110 ARAGËN;Group 0103 Tuberculosis 010-018, 137;Women;67 ARAGËN;Group 0104 Septicaemia 038;Both sexes;1.141 ARAGËN;Group 0104 Septicaemia 038;Men;603 ARAGËN;Group 0104 Septicaemia 038;Women;538 ARAGËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;59 ARAGËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;44 ARAGËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;15 ARAGËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;876 ARAGËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;518 ARAGËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;358 ARAGËN;Group 0200 Neoplasms 140-239;Both sexes;14.171 ARAGËN;Group 0200 Neoplasms 140-239;Men;7.326 ARAGËN;Group 0200 Neoplasms 140-239;Women;6.845 ARAGËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.293 ARAGËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;804 ARAGËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;489 ARAGËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;996 ARAGËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;811 ARAGËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;185 ARAGËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;550 ARAGËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;328 ARAGËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;222 ARAGËN;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;978 ARAGËN;Group 0204 Malignant neoplasm of breast 174-175;Men;10 ARAGËN;Group 0204 Malignant neoplasm of breast 174-175;Women;968 ARAGËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;243 ARAGËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. ARAGËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;243 ARAGËN;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;137 ARAGËN;Group 0206 Malignant neoplasm of ovary 1830;Men;.. ARAGËN;Group 0206 Malignant neoplasm of ovary 1830;Women;137 ARAGËN;Group 0207 Malignant neoplasm of prostate 185;Both sexes;536 ARAGËN;Group 0207 Malignant neoplasm of prostate 185;Men;536 ARAGËN;Group 0207 Malignant neoplasm of prostate 185;Women;.. ARAGËN;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.083 ARAGËN;Group 0208 Malignant neoplasm of bladder 188;Men;868 ARAGËN;Group 0208 Malignant neoplasm of bladder 188;Women;215 ARAGËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;4.650 ARAGËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2.733 ARAGËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.917 ARAGËN;Group 0210 Carcinoma in situ 230-234;Both sexes;701 ARAGËN;Group 0210 Carcinoma in situ 230-234;Men;242 ARAGËN;Group 0210 Carcinoma in situ 230-234;Women;459 ARAGËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;136 ARAGËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;77 ARAGËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;59 ARAGËN;Grupo 0212 Leiomyoma of uterus 218;Both sexes;721 ARAGËN;Grupo 0212 Leiomyoma of uterus 218;Men;.. ARAGËN;Grupo 0212 Leiomyoma of uterus 218;Women;721 ARAGËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2.147 ARAGËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;917 ARAGËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.230 ARAGËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.432 ARAGËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;710 ARAGËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;722 ARAGËN;Group 0301 Anaemias 280-285;Both sexes;957 ARAGËN;Group 0301 Anaemias 280-285;Men;466 ARAGËN;Group 0301 Anaemias 280-285;Women;491 ARAGËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;475 ARAGËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;244 ARAGËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;231 ARAGËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;3.040 ARAGËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.302 ARAGËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.739 ARAGËN;Group 0401 Diabetes mellitus 249-250;Both sexes;881 ARAGËN;Group 0401 Diabetes mellitus 249-250;Men;508 ARAGËN;Group 0401 Diabetes mellitus 249-250;Women;372 ARAGËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2.160 ARAGËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;793 ARAGËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.366 ARAGËN;Group 0500 Mental disorders 290-319;Both sexes;3.343 ARAGËN;Group 0500 Mental disorders 290-319;Men;1.609 ARAGËN;Group 0500 Mental disorders 290-319;Women;1.734 ARAGËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;162 ARAGËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;73 ARAGËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;90 ARAGËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;219 ARAGËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;170 ARAGËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;49 ARAGËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;115 ARAGËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;82 ARAGËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;33 ARAGËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;771 ARAGËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;456 ARAGËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;315 ARAGËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;784 ARAGËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;278 ARAGËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;505 ARAGËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.292 ARAGËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;550 ARAGËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;743 ARAGËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;4.109 ARAGËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.048 ARAGËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2.061 ARAGËN;Group 0601 Alzheimer's disease 3310;Both sexes;101 ARAGËN;Group 0601 Alzheimer's disease 3310;Men;45 ARAGËN;Group 0601 Alzheimer's disease 3310;Women;56 ARAGËN;Group 0602 Multiple sclerosis 340;Both sexes;69 ARAGËN;Group 0602 Multiple sclerosis 340;Men;25 ARAGËN;Group 0602 Multiple sclerosis 340;Women;44 ARAGËN;Group 0603 Epilepsy 345;Both sexes;367 ARAGËN;Group 0603 Epilepsy 345;Men;176 ARAGËN;Group 0603 Epilepsy 345;Women;190 ARAGËN;Group 0604 Transient cerebral ischemia 435;Both sexes;502 ARAGËN;Group 0604 Transient cerebral ischemia 435;Men;249 ARAGËN;Group 0604 Transient cerebral ischemia 435;Women;254 ARAGËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.071 ARAGËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.554 ARAGËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.517 ARAGËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1.159 ARAGËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;593 ARAGËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;566 ARAGËN;Grupo 0701 Cataract 366;Both sexes;343 ARAGËN;Grupo 0701 Cataract 366;Men;176 ARAGËN;Grupo 0701 Cataract 366;Women;167 ARAGËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;816 ARAGËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;417 ARAGËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;399 ARAGËN;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;676 ARAGËN;Group 0800 Diseases of the ear and the mastoid 380-389;Men;300 ARAGËN;Group 0800 Diseases of the ear and the mastoid 380-389;Women;376 ARAGËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;18.121 ARAGËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;9.946 ARAGËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;8.175 ARAGËN;Group 0901 Hypertensive disease 401-405;Both sexes;546 ARAGËN;Group 0901 Hypertensive disease 401-405;Men;255 ARAGËN;Group 0901 Hypertensive disease 401-405;Women;291 ARAGËN;Group 0902 Angina pectoris 4111, 413;Both sexes;773 ARAGËN;Group 0902 Angina pectoris 4111, 413;Men;503 ARAGËN;Group 0902 Angina pectoris 4111, 413;Women;270 ARAGËN;Group 0903 Acute myocardial infarction 410;Both sexes;1.330 ARAGËN;Group 0903 Acute myocardial infarction 410;Men;944 ARAGËN;Group 0903 Acute myocardial infarction 410;Women;386 ARAGËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.155 ARAGËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;871 ARAGËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;284 ARAGËN;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;595 ARAGËN;Group 0905 Diseases of the lungs circulation 415-417;Men;272 ARAGËN;Group 0905 Diseases of the lungs circulation 415-417;Women;323 ARAGËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.348 ARAGËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.263 ARAGËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.085 ARAGËN;Grupo 0907 Heart failure 428;Both sexes;4.265 ARAGËN;Grupo 0907 Heart failure 428;Men;2.014 ARAGËN;Grupo 0907 Heart failure 428;Women;2.252 ARAGËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.803 ARAGËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.473 ARAGËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.330 ARAGËN;Grupo 0909 Atherosclerosis 440;Both sexes;519 ARAGËN;Grupo 0909 Atherosclerosis 440;Men;383 ARAGËN;Grupo 0909 Atherosclerosis 440;Women;136 ARAGËN;Group 0910 Varicose veins of lower extremities 454;Both sexes;852 ARAGËN;Group 0910 Varicose veins of lower extremities 454;Men;294 ARAGËN;Group 0910 Varicose veins of lower extremities 454;Women;558 ARAGËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.935 ARAGËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.675 ARAGËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.260 ARAGËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;15.587 ARAGËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;9.106 ARAGËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6.481 ARAGËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;960 ARAGËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;512 ARAGËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;448 ARAGËN;Group 1002 Pneumonia 480-486;Both sexes;3.313 ARAGËN;Group 1002 Pneumonia 480-486;Men;1.946 ARAGËN;Group 1002 Pneumonia 480-486;Women;1.367 ARAGËN;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.386 ARAGËN;Group 1003 Acute bronchitis and bronchiolitis 466;Men;691 ARAGËN;Group 1003 Acute bronchitis and bronchiolitis 466;Women;696 ARAGËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;594 ARAGËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;337 ARAGËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;257 ARAGËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.712 ARAGËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1.093 ARAGËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;619 ARAGËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.624 ARAGËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2.079 ARAGËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;544 ARAGËN;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;466 ARAGËN;Group 1007 Asthma 4930-4931,4938-4939;Men;125 ARAGËN;Group 1007 Asthma 4930-4931,4938-4939;Women;341 ARAGËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;4.531 ARAGËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.322 ARAGËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2.209 ARAGËN;Group 1100 Diseases of the digestive system 520-579;Both sexes;18.035 ARAGËN;Group 1100 Diseases of the digestive system 520-579;Men;10.378 ARAGËN;Group 1100 Diseases of the digestive system 520-579;Women;7.658 ARAGËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;251 ARAGËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;113 ARAGËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;138 ARAGËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;226 ARAGËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;130 ARAGËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;96 ARAGËN;Group 1103 Diseases of the esophagus 530;Both sexes;304 ARAGËN;Group 1103 Diseases of the esophagus 530;Men;176 ARAGËN;Group 1103 Diseases of the esophagus 530;Women;128 ARAGËN;Group 1104 Peptic ulcer 531-534;Both sexes;403 ARAGËN;Group 1104 Peptic ulcer 531-534;Men;277 ARAGËN;Group 1104 Peptic ulcer 531-534;Women;126 ARAGËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;404 ARAGËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;183 ARAGËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;221 ARAGËN;Group 1106 Appendicitis 540-543;Both sexes;1.241 ARAGËN;Group 1106 Appendicitis 540-543;Men;705 ARAGËN;Group 1106 Appendicitis 540-543;Women;536 ARAGËN;Group 1107 Inguinal hernia 550;Both sexes;2.650 ARAGËN;Group 1107 Inguinal hernia 550;Men;2.324 ARAGËN;Group 1107 Inguinal hernia 550;Women;326 ARAGËN;Group 1108 Other abdominal hernia 551-553;Both sexes;1.596 ARAGËN;Group 1108 Other abdominal hernia 551-553;Men;783 ARAGËN;Group 1108 Other abdominal hernia 551-553;Women;813 ARAGËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;281 ARAGËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;165 ARAGËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;116 ARAGËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;937 ARAGËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;438 ARAGËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;499 ARAGËN;Group 1111 Intestinal obstruction without hernia 560;Both sexes;857 ARAGËN;Group 1111 Intestinal obstruction without hernia 560;Men;428 ARAGËN;Group 1111 Intestinal obstruction without hernia 560;Women;429 ARAGËN;Group 1112 Intestinal diverticulosis 562;Both sexes;753 ARAGËN;Group 1112 Intestinal diverticulosis 562;Men;369 ARAGËN;Group 1112 Intestinal diverticulosis 562;Women;384 ARAGËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.110 ARAGËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;681 ARAGËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;429 ARAGËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;635 ARAGËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;279 ARAGËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;356 ARAGËN;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;303 ARAGËN;Group 1115 Alcoholic hepatitis 5710-5713;Men;263 ARAGËN;Group 1115 Alcoholic hepatitis 5710-5713;Women;40 ARAGËN;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;597 ARAGËN;Group 1116 Other diseases of the liver 570,5714-573;Men;368 ARAGËN;Group 1116 Other diseases of the liver 570,5714-573;Women;229 ARAGËN;Group 1117 Cholelithiasis 574;Both sexes;3.233 ARAGËN;Group 1117 Cholelithiasis 574;Men;1.442 ARAGËN;Group 1117 Cholelithiasis 574;Women;1.791 ARAGËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;750 ARAGËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;412 ARAGËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;338 ARAGËN;Group 1119 Pancreatic diseases 577;Both sexes;788 ARAGËN;Group 1119 Pancreatic diseases 577;Men;470 ARAGËN;Group 1119 Pancreatic diseases 577;Women;318 ARAGËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;715 ARAGËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;371 ARAGËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;344 ARAGËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.576 ARAGËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;877 ARAGËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;700 ARAGËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;894 ARAGËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;545 ARAGËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;348 ARAGËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;87 ARAGËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;53 ARAGËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;34 ARAGËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;596 ARAGËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;278 ARAGËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;317 ARAGËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;12.036 ARAGËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;5.917 ARAGËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;6.119 ARAGËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. ARAGËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. ARAGËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. ARAGËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. ARAGËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. ARAGËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. ARAGËN;Group 1303 Internal derangement of knee 717;Both sexes;1.833 ARAGËN;Group 1303 Internal derangement of knee 717;Men;1.165 ARAGËN;Group 1303 Internal derangement of knee 717;Women;668 ARAGËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3.769 ARAGËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.721 ARAGËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.048 ARAGËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;192 ARAGËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;68 ARAGËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;124 ARAGËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;486 ARAGËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;255 ARAGËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;231 ARAGËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.225 ARAGËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;677 ARAGËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;548 ARAGËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;379 ARAGËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;172 ARAGËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;207 ARAGËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;2.052 ARAGËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1.134 ARAGËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;918 ARAGËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;2.100 ARAGËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;725 ARAGËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.375 ARAGËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;9.792 ARAGËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4.664 ARAGËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;5.129 ARAGËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;641 ARAGËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;247 ARAGËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;394 ARAGËN;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;795 ARAGËN;Group 1402 Renal failure 5836-5837, 584-586;Men;449 ARAGËN;Group 1402 Renal failure 5836-5837, 584-586;Women;346 ARAGËN;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.546 ARAGËN;Group 1403 Urolithiasis 592, 594, 7880;Men;922 ARAGËN;Group 1403 Urolithiasis 592, 594, 7880;Women;624 ARAGËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2.258 ARAGËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.135 ARAGËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.123 ARAGËN;Group 1405 Prostatic hyperplasia 600;Both sexes;1.098 ARAGËN;Group 1405 Prostatic hyperplasia 600;Men;1.098 ARAGËN;Group 1405 Prostatic hyperplasia 600;Women;.. ARAGËN;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;717 ARAGËN;Group 1406 Other diseases of the male genital organs 601-608;Men;717 ARAGËN;Group 1406 Other diseases of the male genital organs 601-608;Women;.. ARAGËN;Group 1407 Disorders of breast 610-612;Both sexes;613 ARAGËN;Group 1407 Disorders of breast 610-612;Men;85 ARAGËN;Group 1407 Disorders of breast 610-612;Women;528 ARAGËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;240 ARAGËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. ARAGËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;240 ARAGËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;160 ARAGËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. ARAGËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;160 ARAGËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.724 ARAGËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;11 ARAGËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.713 ARAGËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;12.879 ARAGËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. ARAGËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;12.879 ARAGËN;Group 1501 Legally induced abortion 635;Both sexes;5 ARAGËN;Group 1501 Legally induced abortion 635;Men;.. ARAGËN;Group 1501 Legally induced abortion 635;Women;5 ARAGËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;865 ARAGËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. ARAGËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;865 ARAGËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6.371 ARAGËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. ARAGËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6.371 ARAGËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3.011 ARAGËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. ARAGËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3.011 ARAGËN;Group 1505 Single spontaneous delivery 650;Both sexes;1.201 ARAGËN;Group 1505 Single spontaneous delivery 650;Men;.. ARAGËN;Group 1505 Single spontaneous delivery 650;Women;1.201 ARAGËN;Group 1506 Other deliveries 6695-6697;Both sexes;347 ARAGËN;Group 1506 Other deliveries 6695-6697;Men;.. ARAGËN;Group 1506 Other deliveries 6695-6697;Women;347 ARAGËN;Group 1507 Complications related to the puerperium 670-676;Both sexes;118 ARAGËN;Group 1507 Complications related to the puerperium 670-676;Men;.. ARAGËN;Group 1507 Complications related to the puerperium 670-676;Women;118 ARAGËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;961 ARAGËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. ARAGËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;961 ARAGËN;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.087 ARAGËN;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.161 ARAGËN;Group 1600 Some disorders originating in the perinatal period 760-779;Women;926 ARAGËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;369 ARAGËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;202 ARAGËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;167 ARAGËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.718 ARAGËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;959 ARAGËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;759 ARAGËN;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.330 ARAGËN;Grupo 1700 Congenital abnormalities 740-759;Men;708 ARAGËN;Grupo 1700 Congenital abnormalities 740-759;Women;622 ARAGËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;15.179 ARAGËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;7.872 ARAGËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;7.307 ARAGËN;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.042 ARAGËN;Group 1801 Pain in throat and chest 7841, 7865;Men;615 ARAGËN;Group 1801 Pain in throat and chest 7841, 7865;Women;427 ARAGËN;Group 1802 Abdominal pain 7890;Both sexes;882 ARAGËN;Group 1802 Abdominal pain 7890;Men;381 ARAGËN;Group 1802 Abdominal pain 7890;Women;501 ARAGËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;8.059 ARAGËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;3.944 ARAGËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;4.115 ARAGËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5.196 ARAGËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.932 ARAGËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.264 ARAGËN;Group 1900 Injuries and poisoning 800-999;Both sexes;13.725 ARAGËN;Group 1900 Injuries and poisoning 800-999;Men;7.348 ARAGËN;Group 1900 Injuries and poisoning 800-999;Women;6.377 ARAGËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;705 ARAGËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;409 ARAGËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;296 ARAGËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;366 ARAGËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;260 ARAGËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;106 ARAGËN;Group 1903 Radius and ulna fracture 813;Both sexes;771 ARAGËN;Group 1903 Radius and ulna fracture 813;Men;343 ARAGËN;Group 1903 Radius and ulna fracture 813;Women;428 ARAGËN;Group 1904 Femur fracture 820-821;Both sexes;2.297 ARAGËN;Group 1904 Femur fracture 820-821;Men;650 ARAGËN;Group 1904 Femur fracture 820-821;Women;1.647 ARAGËN;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;810 ARAGËN;Group 1905 Leg fracture, including the ankle 823-824;Men;424 ARAGËN;Group 1905 Leg fracture, including the ankle 823-824;Women;386 ARAGËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;4.914 ARAGËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;3.164 ARAGËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.750 ARAGËN;Group 1907 Burns 940-949;Both sexes;95 ARAGËN;Group 1907 Burns 940-949;Men;64 ARAGËN;Group 1907 Burns 940-949;Women;31 ARAGËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;272 ARAGËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;134 ARAGËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;138 ARAGËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3.084 ARAGËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.665 ARAGËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.419 ARAGËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;20 ARAGËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;13 ARAGËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;7 ARAGËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;390 ARAGËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;221 ARAGËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;169 ARAGËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;3.961 ARAGËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;2.219 ARAGËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.742 ARAGËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;241 ARAGËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;161 ARAGËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;80 ARAGËN;Group 2102 Contraceptive management V25;Both sexes;60 ARAGËN;Group 2102 Contraceptive management V25;Men;4 ARAGËN;Group 2102 Contraceptive management V25;Women;56 ARAGËN;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. ARAGËN;Group 2103 Living newborns by type of delivery V30-V39;Men;.. ARAGËN;Group 2103 Living newborns by type of delivery V30-V39;Women;.. ARAGËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1.049 ARAGËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;644 ARAGËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;405 ARAGËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2.611 ARAGËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1.410 ARAGËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.201 Huesca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;21.395 Huesca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;10.461 Huesca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;10.934 Huesca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;684 Huesca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;373 Huesca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;311 Huesca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;114 Huesca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;63 Huesca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;51 Huesca;Group 0102 Imprecise intestinal infections 009;Both sexes;114 Huesca;Group 0102 Imprecise intestinal infections 009;Men;56 Huesca;Group 0102 Imprecise intestinal infections 009;Women;58 Huesca;Group 0103 Tuberculosis 010-018, 137;Both sexes;28 Huesca;Group 0103 Tuberculosis 010-018, 137;Men;18 Huesca;Group 0103 Tuberculosis 010-018, 137;Women;10 Huesca;Group 0104 Septicaemia 038;Both sexes;286 Huesca;Group 0104 Septicaemia 038;Men;163 Huesca;Group 0104 Septicaemia 038;Women;123 Huesca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;13 Huesca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;11 Huesca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;2 Huesca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;129 Huesca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;62 Huesca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;67 Huesca;Group 0200 Neoplasms 140-239;Both sexes;1.654 Huesca;Group 0200 Neoplasms 140-239;Men;850 Huesca;Group 0200 Neoplasms 140-239;Women;804 Huesca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;209 Huesca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;129 Huesca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;80 Huesca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;138 Huesca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;108 Huesca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;30 Huesca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;19 Huesca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;10 Huesca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;9 Huesca;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;153 Huesca;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Huesca;Group 0204 Malignant neoplasm of breast 174-175;Women;150 Huesca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;33 Huesca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Huesca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;33 Huesca;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;18 Huesca;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Huesca;Group 0206 Malignant neoplasm of ovary 1830;Women;18 Huesca;Group 0207 Malignant neoplasm of prostate 185;Both sexes;74 Huesca;Group 0207 Malignant neoplasm of prostate 185;Men;74 Huesca;Group 0207 Malignant neoplasm of prostate 185;Women;.. Huesca;Group 0208 Malignant neoplasm of bladder 188;Both sexes;138 Huesca;Group 0208 Malignant neoplasm of bladder 188;Men;120 Huesca;Group 0208 Malignant neoplasm of bladder 188;Women;18 Huesca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;507 Huesca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;306 Huesca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;201 Huesca;Group 0210 Carcinoma in situ 230-234;Both sexes;45 Huesca;Group 0210 Carcinoma in situ 230-234;Men;17 Huesca;Group 0210 Carcinoma in situ 230-234;Women;28 Huesca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;15 Huesca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;7 Huesca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;8 Huesca;Grupo 0212 Leiomyoma of uterus 218;Both sexes;88 Huesca;Grupo 0212 Leiomyoma of uterus 218;Men;.. Huesca;Grupo 0212 Leiomyoma of uterus 218;Women;88 Huesca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;217 Huesca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;76 Huesca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;141 Huesca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;225 Huesca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;119 Huesca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;106 Huesca;Group 0301 Anaemias 280-285;Both sexes;173 Huesca;Group 0301 Anaemias 280-285;Men;90 Huesca;Group 0301 Anaemias 280-285;Women;83 Huesca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;52 Huesca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;29 Huesca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;23 Huesca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;348 Huesca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;175 Huesca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;173 Huesca;Group 0401 Diabetes mellitus 249-250;Both sexes;148 Huesca;Group 0401 Diabetes mellitus 249-250;Men;90 Huesca;Group 0401 Diabetes mellitus 249-250;Women;58 Huesca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;200 Huesca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;85 Huesca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;115 Huesca;Group 0500 Mental disorders 290-319;Both sexes;767 Huesca;Group 0500 Mental disorders 290-319;Men;402 Huesca;Group 0500 Mental disorders 290-319;Women;365 Huesca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;39 Huesca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;21 Huesca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;18 Huesca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;40 Huesca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;30 Huesca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;10 Huesca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;25 Huesca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;22 Huesca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;3 Huesca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;183 Huesca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;112 Huesca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;71 Huesca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;242 Huesca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;94 Huesca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;148 Huesca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;238 Huesca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;123 Huesca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;115 Huesca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;511 Huesca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;229 Huesca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;282 Huesca;Group 0601 Alzheimer's disease 3310;Both sexes;17 Huesca;Group 0601 Alzheimer's disease 3310;Men;11 Huesca;Group 0601 Alzheimer's disease 3310;Women;6 Huesca;Group 0602 Multiple sclerosis 340;Both sexes;5 Huesca;Group 0602 Multiple sclerosis 340;Men;4 Huesca;Group 0602 Multiple sclerosis 340;Women;1 Huesca;Group 0603 Epilepsy 345;Both sexes;75 Huesca;Group 0603 Epilepsy 345;Men;40 Huesca;Group 0603 Epilepsy 345;Women;35 Huesca;Group 0604 Transient cerebral ischemia 435;Both sexes;98 Huesca;Group 0604 Transient cerebral ischemia 435;Men;45 Huesca;Group 0604 Transient cerebral ischemia 435;Women;53 Huesca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;316 Huesca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;129 Huesca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;187 Huesca;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;232 Huesca;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;107 Huesca;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;125 Huesca;Grupo 0701 Cataract 366;Both sexes;166 Huesca;Grupo 0701 Cataract 366;Men;77 Huesca;Grupo 0701 Cataract 366;Women;89 Huesca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;66 Huesca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;30 Huesca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;36 Huesca;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;88 Huesca;Group 0800 Diseases of the ear and the mastoid 380-389;Men;40 Huesca;Group 0800 Diseases of the ear and the mastoid 380-389;Women;48 Huesca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;2.643 Huesca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1.403 Huesca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1.240 Huesca;Group 0901 Hypertensive disease 401-405;Both sexes;122 Huesca;Group 0901 Hypertensive disease 401-405;Men;52 Huesca;Group 0901 Hypertensive disease 401-405;Women;70 Huesca;Group 0902 Angina pectoris 4111, 413;Both sexes;107 Huesca;Group 0902 Angina pectoris 4111, 413;Men;69 Huesca;Group 0902 Angina pectoris 4111, 413;Women;38 Huesca;Group 0903 Acute myocardial infarction 410;Both sexes;135 Huesca;Group 0903 Acute myocardial infarction 410;Men;90 Huesca;Group 0903 Acute myocardial infarction 410;Women;45 Huesca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;64 Huesca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;49 Huesca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;15 Huesca;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;77 Huesca;Group 0905 Diseases of the lungs circulation 415-417;Men;38 Huesca;Group 0905 Diseases of the lungs circulation 415-417;Women;39 Huesca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;414 Huesca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;222 Huesca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;192 Huesca;Grupo 0907 Heart failure 428;Both sexes;706 Huesca;Grupo 0907 Heart failure 428;Men;348 Huesca;Grupo 0907 Heart failure 428;Women;358 Huesca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;448 Huesca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;247 Huesca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;201 Huesca;Grupo 0909 Atherosclerosis 440;Both sexes;60 Huesca;Grupo 0909 Atherosclerosis 440;Men;50 Huesca;Grupo 0909 Atherosclerosis 440;Women;10 Huesca;Group 0910 Varicose veins of lower extremities 454;Both sexes;179 Huesca;Group 0910 Varicose veins of lower extremities 454;Men;64 Huesca;Group 0910 Varicose veins of lower extremities 454;Women;115 Huesca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;331 Huesca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;174 Huesca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;157 Huesca;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2.641 Huesca;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.575 Huesca;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.066 Huesca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;156 Huesca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;83 Huesca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;73 Huesca;Group 1002 Pneumonia 480-486;Both sexes;517 Huesca;Group 1002 Pneumonia 480-486;Men;304 Huesca;Group 1002 Pneumonia 480-486;Women;213 Huesca;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;340 Huesca;Group 1003 Acute bronchitis and bronchiolitis 466;Men;156 Huesca;Group 1003 Acute bronchitis and bronchiolitis 466;Women;184 Huesca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;50 Huesca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;26 Huesca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;24 Huesca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;210 Huesca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;156 Huesca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;54 Huesca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;447 Huesca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;383 Huesca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;64 Huesca;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;70 Huesca;Group 1007 Asthma 4930-4931,4938-4939;Men;25 Huesca;Group 1007 Asthma 4930-4931,4938-4939;Women;45 Huesca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;851 Huesca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;442 Huesca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;409 Huesca;Group 1100 Diseases of the digestive system 520-579;Both sexes;2.894 Huesca;Group 1100 Diseases of the digestive system 520-579;Men;1.686 Huesca;Group 1100 Diseases of the digestive system 520-579;Women;1.208 Huesca;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;21 Huesca;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;8 Huesca;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;13 Huesca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;27 Huesca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;14 Huesca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;13 Huesca;Group 1103 Diseases of the esophagus 530;Both sexes;27 Huesca;Group 1103 Diseases of the esophagus 530;Men;15 Huesca;Group 1103 Diseases of the esophagus 530;Women;12 Huesca;Group 1104 Peptic ulcer 531-534;Both sexes;84 Huesca;Group 1104 Peptic ulcer 531-534;Men;60 Huesca;Group 1104 Peptic ulcer 531-534;Women;24 Huesca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;87 Huesca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;34 Huesca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;53 Huesca;Group 1106 Appendicitis 540-543;Both sexes;193 Huesca;Group 1106 Appendicitis 540-543;Men;119 Huesca;Group 1106 Appendicitis 540-543;Women;74 Huesca;Group 1107 Inguinal hernia 550;Both sexes;430 Huesca;Group 1107 Inguinal hernia 550;Men;374 Huesca;Group 1107 Inguinal hernia 550;Women;56 Huesca;Group 1108 Other abdominal hernia 551-553;Both sexes;224 Huesca;Group 1108 Other abdominal hernia 551-553;Men;110 Huesca;Group 1108 Other abdominal hernia 551-553;Women;114 Huesca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;40 Huesca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;21 Huesca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;19 Huesca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;162 Huesca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;73 Huesca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;89 Huesca;Group 1111 Intestinal obstruction without hernia 560;Both sexes;138 Huesca;Group 1111 Intestinal obstruction without hernia 560;Men;69 Huesca;Group 1111 Intestinal obstruction without hernia 560;Women;69 Huesca;Group 1112 Intestinal diverticulosis 562;Both sexes;102 Huesca;Group 1112 Intestinal diverticulosis 562;Men;56 Huesca;Group 1112 Intestinal diverticulosis 562;Women;46 Huesca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;156 Huesca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;97 Huesca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;59 Huesca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;153 Huesca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;69 Huesca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;84 Huesca;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;52 Huesca;Group 1115 Alcoholic hepatitis 5710-5713;Men;46 Huesca;Group 1115 Alcoholic hepatitis 5710-5713;Women;6 Huesca;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;113 Huesca;Group 1116 Other diseases of the liver 570,5714-573;Men;71 Huesca;Group 1116 Other diseases of the liver 570,5714-573;Women;42 Huesca;Group 1117 Cholelithiasis 574;Both sexes;558 Huesca;Group 1117 Cholelithiasis 574;Men;266 Huesca;Group 1117 Cholelithiasis 574;Women;292 Huesca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;140 Huesca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;80 Huesca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;60 Huesca;Group 1119 Pancreatic diseases 577;Both sexes;94 Huesca;Group 1119 Pancreatic diseases 577;Men;51 Huesca;Group 1119 Pancreatic diseases 577;Women;43 Huesca;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;93 Huesca;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;53 Huesca;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;40 Huesca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;268 Huesca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;140 Huesca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;128 Huesca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;178 Huesca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;104 Huesca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;74 Huesca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;10 Huesca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;8 Huesca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;2 Huesca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;80 Huesca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;28 Huesca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;52 Huesca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;1.287 Huesca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;629 Huesca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;658 Huesca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Huesca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Huesca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Huesca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Huesca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Huesca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Huesca;Group 1303 Internal derangement of knee 717;Both sexes;241 Huesca;Group 1303 Internal derangement of knee 717;Men;154 Huesca;Group 1303 Internal derangement of knee 717;Women;87 Huesca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;456 Huesca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;224 Huesca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;232 Huesca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;24 Huesca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;11 Huesca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;13 Huesca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;16 Huesca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;10 Huesca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;6 Huesca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;59 Huesca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;31 Huesca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;28 Huesca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;70 Huesca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;21 Huesca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;49 Huesca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;192 Huesca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;102 Huesca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;90 Huesca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;229 Huesca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;76 Huesca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;153 Huesca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1.379 Huesca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;677 Huesca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;702 Huesca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;105 Huesca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;33 Huesca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;72 Huesca;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;156 Huesca;Group 1402 Renal failure 5836-5837, 584-586;Men;101 Huesca;Group 1402 Renal failure 5836-5837, 584-586;Women;55 Huesca;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;198 Huesca;Group 1403 Urolithiasis 592, 594, 7880;Men;117 Huesca;Group 1403 Urolithiasis 592, 594, 7880;Women;81 Huesca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;436 Huesca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;226 Huesca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;210 Huesca;Group 1405 Prostatic hyperplasia 600;Both sexes;122 Huesca;Group 1405 Prostatic hyperplasia 600;Men;122 Huesca;Group 1405 Prostatic hyperplasia 600;Women;.. Huesca;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;70 Huesca;Group 1406 Other diseases of the male genital organs 601-608;Men;70 Huesca;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Huesca;Group 1407 Disorders of breast 610-612;Both sexes;49 Huesca;Group 1407 Disorders of breast 610-612;Men;5 Huesca;Group 1407 Disorders of breast 610-612;Women;44 Huesca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;28 Huesca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Huesca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;28 Huesca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;21 Huesca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Huesca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;21 Huesca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;194 Huesca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;3 Huesca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;191 Huesca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.755 Huesca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Huesca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.755 Huesca;Group 1501 Legally induced abortion 635;Both sexes;.. Huesca;Group 1501 Legally induced abortion 635;Men;.. Huesca;Group 1501 Legally induced abortion 635;Women;.. Huesca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;128 Huesca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Huesca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;128 Huesca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;946 Huesca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Huesca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;946 Huesca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;335 Huesca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Huesca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;335 Huesca;Group 1505 Single spontaneous delivery 650;Both sexes;85 Huesca;Group 1505 Single spontaneous delivery 650;Men;.. Huesca;Group 1505 Single spontaneous delivery 650;Women;85 Huesca;Group 1506 Other deliveries 6695-6697;Both sexes;39 Huesca;Group 1506 Other deliveries 6695-6697;Men;.. Huesca;Group 1506 Other deliveries 6695-6697;Women;39 Huesca;Group 1507 Complications related to the puerperium 670-676;Both sexes;24 Huesca;Group 1507 Complications related to the puerperium 670-676;Men;.. Huesca;Group 1507 Complications related to the puerperium 670-676;Women;24 Huesca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;198 Huesca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Huesca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;198 Huesca;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;266 Huesca;Group 1600 Some disorders originating in the perinatal period 760-779;Men;150 Huesca;Group 1600 Some disorders originating in the perinatal period 760-779;Women;116 Huesca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;61 Huesca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;37 Huesca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;24 Huesca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;205 Huesca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;113 Huesca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;92 Huesca;Grupo 1700 Congenital abnormalities 740-759;Both sexes;33 Huesca;Grupo 1700 Congenital abnormalities 740-759;Men;17 Huesca;Grupo 1700 Congenital abnormalities 740-759;Women;16 Huesca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.265 Huesca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;664 Huesca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;601 Huesca;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;137 Huesca;Group 1801 Pain in throat and chest 7841, 7865;Men;79 Huesca;Group 1801 Pain in throat and chest 7841, 7865;Women;58 Huesca;Group 1802 Abdominal pain 7890;Both sexes;210 Huesca;Group 1802 Abdominal pain 7890;Men;82 Huesca;Group 1802 Abdominal pain 7890;Women;128 Huesca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;.. Huesca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;.. Huesca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;.. Huesca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;918 Huesca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;503 Huesca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;415 Huesca;Group 1900 Injuries and poisoning 800-999;Both sexes;1.788 Huesca;Group 1900 Injuries and poisoning 800-999;Men;873 Huesca;Group 1900 Injuries and poisoning 800-999;Women;915 Huesca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;126 Huesca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;69 Huesca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;57 Huesca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;28 Huesca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;17 Huesca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;11 Huesca;Group 1903 Radius and ulna fracture 813;Both sexes;71 Huesca;Group 1903 Radius and ulna fracture 813;Men;26 Huesca;Group 1903 Radius and ulna fracture 813;Women;45 Huesca;Group 1904 Femur fracture 820-821;Both sexes;392 Huesca;Group 1904 Femur fracture 820-821;Men;118 Huesca;Group 1904 Femur fracture 820-821;Women;274 Huesca;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;139 Huesca;Group 1905 Leg fracture, including the ankle 823-824;Men;58 Huesca;Group 1905 Leg fracture, including the ankle 823-824;Women;81 Huesca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;519 Huesca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;298 Huesca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;221 Huesca;Group 1907 Burns 940-949;Both sexes;3 Huesca;Group 1907 Burns 940-949;Men;.. Huesca;Group 1907 Burns 940-949;Women;3 Huesca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;74 Huesca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;41 Huesca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;33 Huesca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;393 Huesca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;218 Huesca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;175 Huesca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Huesca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Huesca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Huesca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;43 Huesca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;28 Huesca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;15 Huesca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;667 Huesca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;352 Huesca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;315 Huesca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;27 Huesca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;20 Huesca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;7 Huesca;Group 2102 Contraceptive management V25;Both sexes;12 Huesca;Group 2102 Contraceptive management V25;Men;.. Huesca;Group 2102 Contraceptive management V25;Women;12 Huesca;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Huesca;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Huesca;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Huesca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;107 Huesca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;57 Huesca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;50 Huesca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;521 Huesca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;275 Huesca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;246 Teruel;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;14.161 Teruel;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;6.970 Teruel;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;7.191 Teruel;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;258 Teruel;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;147 Teruel;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;111 Teruel;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;113 Teruel;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;60 Teruel;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;53 Teruel;Group 0102 Imprecise intestinal infections 009;Both sexes;9 Teruel;Group 0102 Imprecise intestinal infections 009;Men;5 Teruel;Group 0102 Imprecise intestinal infections 009;Women;4 Teruel;Group 0103 Tuberculosis 010-018, 137;Both sexes;8 Teruel;Group 0103 Tuberculosis 010-018, 137;Men;4 Teruel;Group 0103 Tuberculosis 010-018, 137;Women;4 Teruel;Group 0104 Septicaemia 038;Both sexes;38 Teruel;Group 0104 Septicaemia 038;Men;25 Teruel;Group 0104 Septicaemia 038;Women;13 Teruel;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;5 Teruel;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;4 Teruel;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Teruel;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;84 Teruel;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;48 Teruel;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;36 Teruel;Group 0200 Neoplasms 140-239;Both sexes;968 Teruel;Group 0200 Neoplasms 140-239;Men;514 Teruel;Group 0200 Neoplasms 140-239;Women;454 Teruel;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;156 Teruel;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;102 Teruel;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;54 Teruel;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;72 Teruel;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;56 Teruel;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;16 Teruel;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;5 Teruel;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;4 Teruel;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;1 Teruel;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;75 Teruel;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Teruel;Group 0204 Malignant neoplasm of breast 174-175;Women;75 Teruel;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;15 Teruel;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Teruel;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;15 Teruel;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;19 Teruel;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Teruel;Group 0206 Malignant neoplasm of ovary 1830;Women;19 Teruel;Group 0207 Malignant neoplasm of prostate 185;Both sexes;29 Teruel;Group 0207 Malignant neoplasm of prostate 185;Men;29 Teruel;Group 0207 Malignant neoplasm of prostate 185;Women;.. Teruel;Group 0208 Malignant neoplasm of bladder 188;Both sexes;130 Teruel;Group 0208 Malignant neoplasm of bladder 188;Men;99 Teruel;Group 0208 Malignant neoplasm of bladder 188;Women;31 Teruel;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;313 Teruel;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;174 Teruel;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;139 Teruel;Group 0210 Carcinoma in situ 230-234;Both sexes;13 Teruel;Group 0210 Carcinoma in situ 230-234;Men;5 Teruel;Group 0210 Carcinoma in situ 230-234;Women;8 Teruel;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;13 Teruel;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;8 Teruel;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;5 Teruel;Grupo 0212 Leiomyoma of uterus 218;Both sexes;30 Teruel;Grupo 0212 Leiomyoma of uterus 218;Men;.. Teruel;Grupo 0212 Leiomyoma of uterus 218;Women;30 Teruel;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;98 Teruel;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;37 Teruel;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;61 Teruel;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;127 Teruel;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;54 Teruel;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;73 Teruel;Group 0301 Anaemias 280-285;Both sexes;85 Teruel;Group 0301 Anaemias 280-285;Men;40 Teruel;Group 0301 Anaemias 280-285;Women;45 Teruel;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;42 Teruel;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;14 Teruel;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;28 Teruel;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;159 Teruel;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;75 Teruel;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;85 Teruel;Group 0401 Diabetes mellitus 249-250;Both sexes;75 Teruel;Group 0401 Diabetes mellitus 249-250;Men;43 Teruel;Group 0401 Diabetes mellitus 249-250;Women;31 Teruel;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;85 Teruel;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;31 Teruel;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;53 Teruel;Group 0500 Mental disorders 290-319;Both sexes;341 Teruel;Group 0500 Mental disorders 290-319;Men;179 Teruel;Group 0500 Mental disorders 290-319;Women;162 Teruel;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;39 Teruel;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;19 Teruel;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;21 Teruel;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;26 Teruel;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;21 Teruel;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;5 Teruel;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;12 Teruel;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;7 Teruel;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;5 Teruel;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;98 Teruel;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;58 Teruel;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;40 Teruel;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;55 Teruel;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;22 Teruel;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;33 Teruel;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;111 Teruel;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;53 Teruel;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;58 Teruel;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;266 Teruel;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;131 Teruel;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;135 Teruel;Group 0601 Alzheimer's disease 3310;Both sexes;11 Teruel;Group 0601 Alzheimer's disease 3310;Men;1 Teruel;Group 0601 Alzheimer's disease 3310;Women;10 Teruel;Group 0602 Multiple sclerosis 340;Both sexes;3 Teruel;Group 0602 Multiple sclerosis 340;Men;.. Teruel;Group 0602 Multiple sclerosis 340;Women;3 Teruel;Group 0603 Epilepsy 345;Both sexes;48 Teruel;Group 0603 Epilepsy 345;Men;12 Teruel;Group 0603 Epilepsy 345;Women;35 Teruel;Group 0604 Transient cerebral ischemia 435;Both sexes;86 Teruel;Group 0604 Transient cerebral ischemia 435;Men;47 Teruel;Group 0604 Transient cerebral ischemia 435;Women;40 Teruel;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;119 Teruel;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;72 Teruel;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;47 Teruel;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;34 Teruel;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;18 Teruel;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;16 Teruel;Grupo 0701 Cataract 366;Both sexes;9 Teruel;Grupo 0701 Cataract 366;Men;5 Teruel;Grupo 0701 Cataract 366;Women;4 Teruel;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;25 Teruel;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;13 Teruel;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;12 Teruel;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;44 Teruel;Group 0800 Diseases of the ear and the mastoid 380-389;Men;22 Teruel;Group 0800 Diseases of the ear and the mastoid 380-389;Women;22 Teruel;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;1.712 Teruel;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;926 Teruel;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;786 Teruel;Group 0901 Hypertensive disease 401-405;Both sexes;39 Teruel;Group 0901 Hypertensive disease 401-405;Men;18 Teruel;Group 0901 Hypertensive disease 401-405;Women;21 Teruel;Group 0902 Angina pectoris 4111, 413;Both sexes;138 Teruel;Group 0902 Angina pectoris 4111, 413;Men;102 Teruel;Group 0902 Angina pectoris 4111, 413;Women;36 Teruel;Group 0903 Acute myocardial infarction 410;Both sexes;85 Teruel;Group 0903 Acute myocardial infarction 410;Men;58 Teruel;Group 0903 Acute myocardial infarction 410;Women;27 Teruel;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;49 Teruel;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;33 Teruel;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;16 Teruel;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;80 Teruel;Group 0905 Diseases of the lungs circulation 415-417;Men;39 Teruel;Group 0905 Diseases of the lungs circulation 415-417;Women;41 Teruel;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;219 Teruel;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;122 Teruel;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;97 Teruel;Grupo 0907 Heart failure 428;Both sexes;544 Teruel;Grupo 0907 Heart failure 428;Men;284 Teruel;Grupo 0907 Heart failure 428;Women;261 Teruel;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;256 Teruel;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;124 Teruel;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;132 Teruel;Grupo 0909 Atherosclerosis 440;Both sexes;19 Teruel;Grupo 0909 Atherosclerosis 440;Men;13 Teruel;Grupo 0909 Atherosclerosis 440;Women;6 Teruel;Group 0910 Varicose veins of lower extremities 454;Both sexes;41 Teruel;Group 0910 Varicose veins of lower extremities 454;Men;9 Teruel;Group 0910 Varicose veins of lower extremities 454;Women;32 Teruel;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;242 Teruel;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;125 Teruel;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;117 Teruel;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;1.893 Teruel;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.186 Teruel;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;707 Teruel;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;135 Teruel;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;81 Teruel;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;54 Teruel;Group 1002 Pneumonia 480-486;Both sexes;404 Teruel;Group 1002 Pneumonia 480-486;Men;252 Teruel;Group 1002 Pneumonia 480-486;Women;152 Teruel;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;215 Teruel;Group 1003 Acute bronchitis and bronchiolitis 466;Men;100 Teruel;Group 1003 Acute bronchitis and bronchiolitis 466;Women;116 Teruel;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;35 Teruel;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;22 Teruel;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;13 Teruel;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;126 Teruel;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;82 Teruel;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;44 Teruel;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;363 Teruel;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;309 Teruel;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;53 Teruel;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;59 Teruel;Group 1007 Asthma 4930-4931,4938-4939;Men;16 Teruel;Group 1007 Asthma 4930-4931,4938-4939;Women;43 Teruel;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;555 Teruel;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;323 Teruel;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;232 Teruel;Group 1100 Diseases of the digestive system 520-579;Both sexes;2.110 Teruel;Group 1100 Diseases of the digestive system 520-579;Men;1.245 Teruel;Group 1100 Diseases of the digestive system 520-579;Women;866 Teruel;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;5 Teruel;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;2 Teruel;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;3 Teruel;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;17 Teruel;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;10 Teruel;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;7 Teruel;Group 1103 Diseases of the esophagus 530;Both sexes;32 Teruel;Group 1103 Diseases of the esophagus 530;Men;21 Teruel;Group 1103 Diseases of the esophagus 530;Women;11 Teruel;Group 1104 Peptic ulcer 531-534;Both sexes;52 Teruel;Group 1104 Peptic ulcer 531-534;Men;32 Teruel;Group 1104 Peptic ulcer 531-534;Women;20 Teruel;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;49 Teruel;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;16 Teruel;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;33 Teruel;Group 1106 Appendicitis 540-543;Both sexes;142 Teruel;Group 1106 Appendicitis 540-543;Men;80 Teruel;Group 1106 Appendicitis 540-543;Women;62 Teruel;Group 1107 Inguinal hernia 550;Both sexes;352 Teruel;Group 1107 Inguinal hernia 550;Men;321 Teruel;Group 1107 Inguinal hernia 550;Women;31 Teruel;Group 1108 Other abdominal hernia 551-553;Both sexes;187 Teruel;Group 1108 Other abdominal hernia 551-553;Men;92 Teruel;Group 1108 Other abdominal hernia 551-553;Women;95 Teruel;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;30 Teruel;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;19 Teruel;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;11 Teruel;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;126 Teruel;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;58 Teruel;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;68 Teruel;Group 1111 Intestinal obstruction without hernia 560;Both sexes;109 Teruel;Group 1111 Intestinal obstruction without hernia 560;Men;59 Teruel;Group 1111 Intestinal obstruction without hernia 560;Women;50 Teruel;Group 1112 Intestinal diverticulosis 562;Both sexes;86 Teruel;Group 1112 Intestinal diverticulosis 562;Men;49 Teruel;Group 1112 Intestinal diverticulosis 562;Women;37 Teruel;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;86 Teruel;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;50 Teruel;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;36 Teruel;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;57 Teruel;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;20 Teruel;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;37 Teruel;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;21 Teruel;Group 1115 Alcoholic hepatitis 5710-5713;Men;17 Teruel;Group 1115 Alcoholic hepatitis 5710-5713;Women;4 Teruel;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;68 Teruel;Group 1116 Other diseases of the liver 570,5714-573;Men;42 Teruel;Group 1116 Other diseases of the liver 570,5714-573;Women;26 Teruel;Group 1117 Cholelithiasis 574;Both sexes;395 Teruel;Group 1117 Cholelithiasis 574;Men;198 Teruel;Group 1117 Cholelithiasis 574;Women;197 Teruel;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;113 Teruel;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;61 Teruel;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;52 Teruel;Group 1119 Pancreatic diseases 577;Both sexes;99 Teruel;Group 1119 Pancreatic diseases 577;Men;56 Teruel;Group 1119 Pancreatic diseases 577;Women;43 Teruel;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;83 Teruel;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;41 Teruel;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;42 Teruel;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;136 Teruel;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;72 Teruel;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;65 Teruel;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;91 Teruel;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;53 Teruel;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;37 Teruel;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;4 Teruel;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;2 Teruel;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;2 Teruel;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;42 Teruel;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;16 Teruel;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;25 Teruel;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;738 Teruel;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;347 Teruel;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;391 Teruel;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Teruel;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Teruel;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Teruel;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Teruel;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Teruel;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Teruel;Group 1303 Internal derangement of knee 717;Both sexes;109 Teruel;Group 1303 Internal derangement of knee 717;Men;66 Teruel;Group 1303 Internal derangement of knee 717;Women;43 Teruel;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;322 Teruel;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;162 Teruel;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;160 Teruel;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;21 Teruel;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;7 Teruel;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;14 Teruel;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;5 Teruel;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;2 Teruel;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;3 Teruel;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;20 Teruel;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;13 Teruel;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;7 Teruel;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;13 Teruel;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;6 Teruel;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;7 Teruel;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;115 Teruel;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;56 Teruel;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;59 Teruel;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;133 Teruel;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;35 Teruel;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;98 Teruel;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;724 Teruel;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;391 Teruel;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;334 Teruel;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;51 Teruel;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;19 Teruel;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;32 Teruel;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;91 Teruel;Group 1402 Renal failure 5836-5837, 584-586;Men;57 Teruel;Group 1402 Renal failure 5836-5837, 584-586;Women;34 Teruel;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;101 Teruel;Group 1403 Urolithiasis 592, 594, 7880;Men;64 Teruel;Group 1403 Urolithiasis 592, 594, 7880;Women;37 Teruel;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;148 Teruel;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;68 Teruel;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;80 Teruel;Group 1405 Prostatic hyperplasia 600;Both sexes;106 Teruel;Group 1405 Prostatic hyperplasia 600;Men;106 Teruel;Group 1405 Prostatic hyperplasia 600;Women;.. Teruel;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;71 Teruel;Group 1406 Other diseases of the male genital organs 601-608;Men;71 Teruel;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Teruel;Group 1407 Disorders of breast 610-612;Both sexes;20 Teruel;Group 1407 Disorders of breast 610-612;Men;6 Teruel;Group 1407 Disorders of breast 610-612;Women;14 Teruel;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;26 Teruel;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Teruel;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;26 Teruel;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;7 Teruel;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Teruel;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;7 Teruel;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;103 Teruel;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Teruel;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;103 Teruel;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.227 Teruel;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Teruel;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.227 Teruel;Group 1501 Legally induced abortion 635;Both sexes;1 Teruel;Group 1501 Legally induced abortion 635;Men;.. Teruel;Group 1501 Legally induced abortion 635;Women;1 Teruel;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;99 Teruel;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Teruel;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;99 Teruel;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;608 Teruel;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Teruel;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;608 Teruel;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;248 Teruel;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Teruel;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;248 Teruel;Group 1505 Single spontaneous delivery 650;Both sexes;150 Teruel;Group 1505 Single spontaneous delivery 650;Men;.. Teruel;Group 1505 Single spontaneous delivery 650;Women;150 Teruel;Group 1506 Other deliveries 6695-6697;Both sexes;16 Teruel;Group 1506 Other deliveries 6695-6697;Men;.. Teruel;Group 1506 Other deliveries 6695-6697;Women;16 Teruel;Group 1507 Complications related to the puerperium 670-676;Both sexes;12 Teruel;Group 1507 Complications related to the puerperium 670-676;Men;.. Teruel;Group 1507 Complications related to the puerperium 670-676;Women;12 Teruel;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;93 Teruel;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Teruel;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;93 Teruel;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;534 Teruel;Group 1600 Some disorders originating in the perinatal period 760-779;Men;267 Teruel;Group 1600 Some disorders originating in the perinatal period 760-779;Women;267 Teruel;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;23 Teruel;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;15 Teruel;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;8 Teruel;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;511 Teruel;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;252 Teruel;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;259 Teruel;Grupo 1700 Congenital abnormalities 740-759;Both sexes;27 Teruel;Grupo 1700 Congenital abnormalities 740-759;Men;8 Teruel;Grupo 1700 Congenital abnormalities 740-759;Women;19 Teruel;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.405 Teruel;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;751 Teruel;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;654 Teruel;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;75 Teruel;Group 1801 Pain in throat and chest 7841, 7865;Men;49 Teruel;Group 1801 Pain in throat and chest 7841, 7865;Women;26 Teruel;Group 1802 Abdominal pain 7890;Both sexes;92 Teruel;Group 1802 Abdominal pain 7890;Men;54 Teruel;Group 1802 Abdominal pain 7890;Women;38 Teruel;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;728 Teruel;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;350 Teruel;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;378 Teruel;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;510 Teruel;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;298 Teruel;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;212 Teruel;Group 1900 Injuries and poisoning 800-999;Both sexes;1.142 Teruel;Group 1900 Injuries and poisoning 800-999;Men;494 Teruel;Group 1900 Injuries and poisoning 800-999;Women;648 Teruel;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;71 Teruel;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;35 Teruel;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;36 Teruel;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;12 Teruel;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;9 Teruel;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;3 Teruel;Group 1903 Radius and ulna fracture 813;Both sexes;59 Teruel;Group 1903 Radius and ulna fracture 813;Men;25 Teruel;Group 1903 Radius and ulna fracture 813;Women;34 Teruel;Group 1904 Femur fracture 820-821;Both sexes;324 Teruel;Group 1904 Femur fracture 820-821;Men;76 Teruel;Group 1904 Femur fracture 820-821;Women;248 Teruel;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;72 Teruel;Group 1905 Leg fracture, including the ankle 823-824;Men;33 Teruel;Group 1905 Leg fracture, including the ankle 823-824;Women;39 Teruel;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;247 Teruel;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;148 Teruel;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;99 Teruel;Group 1907 Burns 940-949;Both sexes;2 Teruel;Group 1907 Burns 940-949;Men;1 Teruel;Group 1907 Burns 940-949;Women;1 Teruel;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;26 Teruel;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;8 Teruel;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;18 Teruel;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;219 Teruel;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;98 Teruel;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;121 Teruel;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;5 Teruel;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;3 Teruel;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 Teruel;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;104 Teruel;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;57 Teruel;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;47 Teruel;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;314 Teruel;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;142 Teruel;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;172 Teruel;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;30 Teruel;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;21 Teruel;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;9 Teruel;Group 2102 Contraceptive management V25;Both sexes;6 Teruel;Group 2102 Contraceptive management V25;Men;.. Teruel;Group 2102 Contraceptive management V25;Women;6 Teruel;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Teruel;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Teruel;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Teruel;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;39 Teruel;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;23 Teruel;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;16 Teruel;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;239 Teruel;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;98 Teruel;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;141 Zaragoza;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;119.729 Zaragoza;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;58.325 Zaragoza;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;61.404 Zaragoza;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2.103 Zaragoza;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.152 Zaragoza;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;951 Zaragoza;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;348 Zaragoza;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;170 Zaragoza;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;178 Zaragoza;Group 0102 Imprecise intestinal infections 009;Both sexes;93 Zaragoza;Group 0102 Imprecise intestinal infections 009;Men;42 Zaragoza;Group 0102 Imprecise intestinal infections 009;Women;51 Zaragoza;Group 0103 Tuberculosis 010-018, 137;Both sexes;141 Zaragoza;Group 0103 Tuberculosis 010-018, 137;Men;88 Zaragoza;Group 0103 Tuberculosis 010-018, 137;Women;53 Zaragoza;Group 0104 Septicaemia 038;Both sexes;817 Zaragoza;Group 0104 Septicaemia 038;Men;415 Zaragoza;Group 0104 Septicaemia 038;Women;402 Zaragoza;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;41 Zaragoza;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;29 Zaragoza;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;12 Zaragoza;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;663 Zaragoza;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;408 Zaragoza;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;255 Zaragoza;Group 0200 Neoplasms 140-239;Both sexes;11.549 Zaragoza;Group 0200 Neoplasms 140-239;Men;5.962 Zaragoza;Group 0200 Neoplasms 140-239;Women;5.587 Zaragoza;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;928 Zaragoza;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;573 Zaragoza;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;355 Zaragoza;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;786 Zaragoza;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;647 Zaragoza;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;139 Zaragoza;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;526 Zaragoza;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;314 Zaragoza;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;212 Zaragoza;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;750 Zaragoza;Group 0204 Malignant neoplasm of breast 174-175;Men;7 Zaragoza;Group 0204 Malignant neoplasm of breast 174-175;Women;743 Zaragoza;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;195 Zaragoza;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Zaragoza;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;195 Zaragoza;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;100 Zaragoza;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Zaragoza;Group 0206 Malignant neoplasm of ovary 1830;Women;100 Zaragoza;Group 0207 Malignant neoplasm of prostate 185;Both sexes;433 Zaragoza;Group 0207 Malignant neoplasm of prostate 185;Men;433 Zaragoza;Group 0207 Malignant neoplasm of prostate 185;Women;.. Zaragoza;Group 0208 Malignant neoplasm of bladder 188;Both sexes;815 Zaragoza;Group 0208 Malignant neoplasm of bladder 188;Men;649 Zaragoza;Group 0208 Malignant neoplasm of bladder 188;Women;166 Zaragoza;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;3.830 Zaragoza;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2.253 Zaragoza;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.577 Zaragoza;Group 0210 Carcinoma in situ 230-234;Both sexes;643 Zaragoza;Group 0210 Carcinoma in situ 230-234;Men;220 Zaragoza;Group 0210 Carcinoma in situ 230-234;Women;423 Zaragoza;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;108 Zaragoza;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;62 Zaragoza;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;46 Zaragoza;Grupo 0212 Leiomyoma of uterus 218;Both sexes;603 Zaragoza;Grupo 0212 Leiomyoma of uterus 218;Men;.. Zaragoza;Grupo 0212 Leiomyoma of uterus 218;Women;603 Zaragoza;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.832 Zaragoza;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;804 Zaragoza;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.028 Zaragoza;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.080 Zaragoza;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;537 Zaragoza;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;543 Zaragoza;Group 0301 Anaemias 280-285;Both sexes;699 Zaragoza;Group 0301 Anaemias 280-285;Men;336 Zaragoza;Group 0301 Anaemias 280-285;Women;363 Zaragoza;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;381 Zaragoza;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;201 Zaragoza;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;180 Zaragoza;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2.533 Zaragoza;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.052 Zaragoza;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.481 Zaragoza;Group 0401 Diabetes mellitus 249-250;Both sexes;658 Zaragoza;Group 0401 Diabetes mellitus 249-250;Men;375 Zaragoza;Group 0401 Diabetes mellitus 249-250;Women;283 Zaragoza;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.875 Zaragoza;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;677 Zaragoza;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.198 Zaragoza;Group 0500 Mental disorders 290-319;Both sexes;2.235 Zaragoza;Group 0500 Mental disorders 290-319;Men;1.027 Zaragoza;Group 0500 Mental disorders 290-319;Women;1.208 Zaragoza;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;84 Zaragoza;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;33 Zaragoza;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;51 Zaragoza;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;153 Zaragoza;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;119 Zaragoza;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;34 Zaragoza;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;78 Zaragoza;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;53 Zaragoza;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;25 Zaragoza;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;490 Zaragoza;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;286 Zaragoza;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;204 Zaragoza;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;487 Zaragoza;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;162 Zaragoza;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;324 Zaragoza;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;943 Zaragoza;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;374 Zaragoza;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;570 Zaragoza;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3.332 Zaragoza;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.688 Zaragoza;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.644 Zaragoza;Group 0601 Alzheimer's disease 3310;Both sexes;73 Zaragoza;Group 0601 Alzheimer's disease 3310;Men;33 Zaragoza;Group 0601 Alzheimer's disease 3310;Women;40 Zaragoza;Group 0602 Multiple sclerosis 340;Both sexes;61 Zaragoza;Group 0602 Multiple sclerosis 340;Men;21 Zaragoza;Group 0602 Multiple sclerosis 340;Women;40 Zaragoza;Group 0603 Epilepsy 345;Both sexes;244 Zaragoza;Group 0603 Epilepsy 345;Men;124 Zaragoza;Group 0603 Epilepsy 345;Women;120 Zaragoza;Group 0604 Transient cerebral ischemia 435;Both sexes;318 Zaragoza;Group 0604 Transient cerebral ischemia 435;Men;157 Zaragoza;Group 0604 Transient cerebral ischemia 435;Women;161 Zaragoza;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;2.636 Zaragoza;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.353 Zaragoza;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.283 Zaragoza;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;893 Zaragoza;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;468 Zaragoza;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;425 Zaragoza;Grupo 0701 Cataract 366;Both sexes;168 Zaragoza;Grupo 0701 Cataract 366;Men;94 Zaragoza;Grupo 0701 Cataract 366;Women;74 Zaragoza;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;725 Zaragoza;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;374 Zaragoza;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;351 Zaragoza;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;544 Zaragoza;Group 0800 Diseases of the ear and the mastoid 380-389;Men;238 Zaragoza;Group 0800 Diseases of the ear and the mastoid 380-389;Women;306 Zaragoza;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;13.766 Zaragoza;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;7.617 Zaragoza;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;6.149 Zaragoza;Group 0901 Hypertensive disease 401-405;Both sexes;385 Zaragoza;Group 0901 Hypertensive disease 401-405;Men;185 Zaragoza;Group 0901 Hypertensive disease 401-405;Women;200 Zaragoza;Group 0902 Angina pectoris 4111, 413;Both sexes;528 Zaragoza;Group 0902 Angina pectoris 4111, 413;Men;332 Zaragoza;Group 0902 Angina pectoris 4111, 413;Women;196 Zaragoza;Group 0903 Acute myocardial infarction 410;Both sexes;1.110 Zaragoza;Group 0903 Acute myocardial infarction 410;Men;796 Zaragoza;Group 0903 Acute myocardial infarction 410;Women;314 Zaragoza;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.042 Zaragoza;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;789 Zaragoza;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;253 Zaragoza;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;438 Zaragoza;Group 0905 Diseases of the lungs circulation 415-417;Men;195 Zaragoza;Group 0905 Diseases of the lungs circulation 415-417;Women;243 Zaragoza;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.715 Zaragoza;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;919 Zaragoza;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;796 Zaragoza;Grupo 0907 Heart failure 428;Both sexes;3.015 Zaragoza;Grupo 0907 Heart failure 428;Men;1.382 Zaragoza;Grupo 0907 Heart failure 428;Women;1.633 Zaragoza;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.099 Zaragoza;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.102 Zaragoza;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;997 Zaragoza;Grupo 0909 Atherosclerosis 440;Both sexes;440 Zaragoza;Grupo 0909 Atherosclerosis 440;Men;320 Zaragoza;Grupo 0909 Atherosclerosis 440;Women;120 Zaragoza;Group 0910 Varicose veins of lower extremities 454;Both sexes;632 Zaragoza;Group 0910 Varicose veins of lower extremities 454;Men;221 Zaragoza;Group 0910 Varicose veins of lower extremities 454;Women;411 Zaragoza;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.362 Zaragoza;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.376 Zaragoza;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;986 Zaragoza;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;11.053 Zaragoza;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;6.345 Zaragoza;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;4.708 Zaragoza;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;669 Zaragoza;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;348 Zaragoza;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;321 Zaragoza;Group 1002 Pneumonia 480-486;Both sexes;2.392 Zaragoza;Group 1002 Pneumonia 480-486;Men;1.390 Zaragoza;Group 1002 Pneumonia 480-486;Women;1.002 Zaragoza;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;831 Zaragoza;Group 1003 Acute bronchitis and bronchiolitis 466;Men;435 Zaragoza;Group 1003 Acute bronchitis and bronchiolitis 466;Women;396 Zaragoza;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;509 Zaragoza;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;289 Zaragoza;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;220 Zaragoza;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.376 Zaragoza;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;855 Zaragoza;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;521 Zaragoza;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.814 Zaragoza;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.387 Zaragoza;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;427 Zaragoza;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;337 Zaragoza;Group 1007 Asthma 4930-4931,4938-4939;Men;84 Zaragoza;Group 1007 Asthma 4930-4931,4938-4939;Women;253 Zaragoza;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3.125 Zaragoza;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.557 Zaragoza;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.568 Zaragoza;Group 1100 Diseases of the digestive system 520-579;Both sexes;13.031 Zaragoza;Group 1100 Diseases of the digestive system 520-579;Men;7.447 Zaragoza;Group 1100 Diseases of the digestive system 520-579;Women;5.584 Zaragoza;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;225 Zaragoza;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;103 Zaragoza;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;122 Zaragoza;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;182 Zaragoza;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;106 Zaragoza;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;76 Zaragoza;Group 1103 Diseases of the esophagus 530;Both sexes;245 Zaragoza;Group 1103 Diseases of the esophagus 530;Men;140 Zaragoza;Group 1103 Diseases of the esophagus 530;Women;105 Zaragoza;Group 1104 Peptic ulcer 531-534;Both sexes;267 Zaragoza;Group 1104 Peptic ulcer 531-534;Men;185 Zaragoza;Group 1104 Peptic ulcer 531-534;Women;82 Zaragoza;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;268 Zaragoza;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;133 Zaragoza;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;135 Zaragoza;Group 1106 Appendicitis 540-543;Both sexes;906 Zaragoza;Group 1106 Appendicitis 540-543;Men;506 Zaragoza;Group 1106 Appendicitis 540-543;Women;400 Zaragoza;Group 1107 Inguinal hernia 550;Both sexes;1.868 Zaragoza;Group 1107 Inguinal hernia 550;Men;1.629 Zaragoza;Group 1107 Inguinal hernia 550;Women;239 Zaragoza;Group 1108 Other abdominal hernia 551-553;Both sexes;1.185 Zaragoza;Group 1108 Other abdominal hernia 551-553;Men;581 Zaragoza;Group 1108 Other abdominal hernia 551-553;Women;604 Zaragoza;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;211 Zaragoza;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;125 Zaragoza;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;86 Zaragoza;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;649 Zaragoza;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;307 Zaragoza;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;342 Zaragoza;Group 1111 Intestinal obstruction without hernia 560;Both sexes;610 Zaragoza;Group 1111 Intestinal obstruction without hernia 560;Men;300 Zaragoza;Group 1111 Intestinal obstruction without hernia 560;Women;310 Zaragoza;Group 1112 Intestinal diverticulosis 562;Both sexes;565 Zaragoza;Group 1112 Intestinal diverticulosis 562;Men;264 Zaragoza;Group 1112 Intestinal diverticulosis 562;Women;301 Zaragoza;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;868 Zaragoza;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;534 Zaragoza;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;334 Zaragoza;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;425 Zaragoza;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;190 Zaragoza;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;235 Zaragoza;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;230 Zaragoza;Group 1115 Alcoholic hepatitis 5710-5713;Men;200 Zaragoza;Group 1115 Alcoholic hepatitis 5710-5713;Women;30 Zaragoza;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;416 Zaragoza;Group 1116 Other diseases of the liver 570,5714-573;Men;255 Zaragoza;Group 1116 Other diseases of the liver 570,5714-573;Women;161 Zaragoza;Group 1117 Cholelithiasis 574;Both sexes;2.280 Zaragoza;Group 1117 Cholelithiasis 574;Men;978 Zaragoza;Group 1117 Cholelithiasis 574;Women;1.302 Zaragoza;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;497 Zaragoza;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;271 Zaragoza;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;226 Zaragoza;Group 1119 Pancreatic diseases 577;Both sexes;595 Zaragoza;Group 1119 Pancreatic diseases 577;Men;363 Zaragoza;Group 1119 Pancreatic diseases 577;Women;232 Zaragoza;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;539 Zaragoza;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;277 Zaragoza;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;262 Zaragoza;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.172 Zaragoza;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;665 Zaragoza;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;507 Zaragoza;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;625 Zaragoza;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;388 Zaragoza;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;237 Zaragoza;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;73 Zaragoza;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;43 Zaragoza;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;30 Zaragoza;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;474 Zaragoza;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;234 Zaragoza;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;240 Zaragoza;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;10.011 Zaragoza;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.941 Zaragoza;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5.070 Zaragoza;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Zaragoza;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Zaragoza;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Zaragoza;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Zaragoza;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Zaragoza;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Zaragoza;Group 1303 Internal derangement of knee 717;Both sexes;1.483 Zaragoza;Group 1303 Internal derangement of knee 717;Men;945 Zaragoza;Group 1303 Internal derangement of knee 717;Women;538 Zaragoza;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.991 Zaragoza;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.335 Zaragoza;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.656 Zaragoza;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;147 Zaragoza;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;50 Zaragoza;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;97 Zaragoza;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;465 Zaragoza;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;243 Zaragoza;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;222 Zaragoza;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.146 Zaragoza;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;633 Zaragoza;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;513 Zaragoza;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;296 Zaragoza;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;145 Zaragoza;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;151 Zaragoza;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.745 Zaragoza;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;976 Zaragoza;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;769 Zaragoza;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.738 Zaragoza;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;614 Zaragoza;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.124 Zaragoza;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;7.689 Zaragoza;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3.596 Zaragoza;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4.093 Zaragoza;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;485 Zaragoza;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;195 Zaragoza;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;290 Zaragoza;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;548 Zaragoza;Group 1402 Renal failure 5836-5837, 584-586;Men;291 Zaragoza;Group 1402 Renal failure 5836-5837, 584-586;Women;257 Zaragoza;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.247 Zaragoza;Group 1403 Urolithiasis 592, 594, 7880;Men;741 Zaragoza;Group 1403 Urolithiasis 592, 594, 7880;Women;506 Zaragoza;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.674 Zaragoza;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;841 Zaragoza;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;833 Zaragoza;Group 1405 Prostatic hyperplasia 600;Both sexes;870 Zaragoza;Group 1405 Prostatic hyperplasia 600;Men;870 Zaragoza;Group 1405 Prostatic hyperplasia 600;Women;.. Zaragoza;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;576 Zaragoza;Group 1406 Other diseases of the male genital organs 601-608;Men;576 Zaragoza;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Zaragoza;Group 1407 Disorders of breast 610-612;Both sexes;544 Zaragoza;Group 1407 Disorders of breast 610-612;Men;74 Zaragoza;Group 1407 Disorders of breast 610-612;Women;470 Zaragoza;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;186 Zaragoza;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Zaragoza;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;186 Zaragoza;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;132 Zaragoza;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Zaragoza;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;132 Zaragoza;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.427 Zaragoza;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;8 Zaragoza;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.419 Zaragoza;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;9.897 Zaragoza;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Zaragoza;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;9.897 Zaragoza;Group 1501 Legally induced abortion 635;Both sexes;4 Zaragoza;Group 1501 Legally induced abortion 635;Men;.. Zaragoza;Group 1501 Legally induced abortion 635;Women;4 Zaragoza;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;638 Zaragoza;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Zaragoza;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;638 Zaragoza;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4.817 Zaragoza;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Zaragoza;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4.817 Zaragoza;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2.428 Zaragoza;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Zaragoza;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2.428 Zaragoza;Group 1505 Single spontaneous delivery 650;Both sexes;966 Zaragoza;Group 1505 Single spontaneous delivery 650;Men;.. Zaragoza;Group 1505 Single spontaneous delivery 650;Women;966 Zaragoza;Group 1506 Other deliveries 6695-6697;Both sexes;292 Zaragoza;Group 1506 Other deliveries 6695-6697;Men;.. Zaragoza;Group 1506 Other deliveries 6695-6697;Women;292 Zaragoza;Group 1507 Complications related to the puerperium 670-676;Both sexes;82 Zaragoza;Group 1507 Complications related to the puerperium 670-676;Men;.. Zaragoza;Group 1507 Complications related to the puerperium 670-676;Women;82 Zaragoza;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;670 Zaragoza;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Zaragoza;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;670 Zaragoza;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.287 Zaragoza;Group 1600 Some disorders originating in the perinatal period 760-779;Men;744 Zaragoza;Group 1600 Some disorders originating in the perinatal period 760-779;Women;543 Zaragoza;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;285 Zaragoza;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;150 Zaragoza;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;135 Zaragoza;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.002 Zaragoza;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;594 Zaragoza;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;408 Zaragoza;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.270 Zaragoza;Grupo 1700 Congenital abnormalities 740-759;Men;683 Zaragoza;Grupo 1700 Congenital abnormalities 740-759;Women;587 Zaragoza;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;12.509 Zaragoza;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;6.457 Zaragoza;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;6.052 Zaragoza;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;830 Zaragoza;Group 1801 Pain in throat and chest 7841, 7865;Men;487 Zaragoza;Group 1801 Pain in throat and chest 7841, 7865;Women;343 Zaragoza;Group 1802 Abdominal pain 7890;Both sexes;580 Zaragoza;Group 1802 Abdominal pain 7890;Men;245 Zaragoza;Group 1802 Abdominal pain 7890;Women;335 Zaragoza;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;7.331 Zaragoza;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;3.594 Zaragoza;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;3.737 Zaragoza;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;3.768 Zaragoza;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.131 Zaragoza;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.637 Zaragoza;Group 1900 Injuries and poisoning 800-999;Both sexes;10.795 Zaragoza;Group 1900 Injuries and poisoning 800-999;Men;5.981 Zaragoza;Group 1900 Injuries and poisoning 800-999;Women;4.814 Zaragoza;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;508 Zaragoza;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;305 Zaragoza;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;203 Zaragoza;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;326 Zaragoza;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;234 Zaragoza;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;92 Zaragoza;Group 1903 Radius and ulna fracture 813;Both sexes;641 Zaragoza;Group 1903 Radius and ulna fracture 813;Men;292 Zaragoza;Group 1903 Radius and ulna fracture 813;Women;349 Zaragoza;Group 1904 Femur fracture 820-821;Both sexes;1.581 Zaragoza;Group 1904 Femur fracture 820-821;Men;456 Zaragoza;Group 1904 Femur fracture 820-821;Women;1.125 Zaragoza;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;599 Zaragoza;Group 1905 Leg fracture, including the ankle 823-824;Men;333 Zaragoza;Group 1905 Leg fracture, including the ankle 823-824;Women;266 Zaragoza;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;4.148 Zaragoza;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.718 Zaragoza;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.430 Zaragoza;Group 1907 Burns 940-949;Both sexes;90 Zaragoza;Group 1907 Burns 940-949;Men;63 Zaragoza;Group 1907 Burns 940-949;Women;27 Zaragoza;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;172 Zaragoza;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;85 Zaragoza;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;87 Zaragoza;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.472 Zaragoza;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.349 Zaragoza;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.123 Zaragoza;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;15 Zaragoza;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;10 Zaragoza;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;5 Zaragoza;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;243 Zaragoza;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;136 Zaragoza;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;107 Zaragoza;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.980 Zaragoza;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.725 Zaragoza;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.255 Zaragoza;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;184 Zaragoza;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;120 Zaragoza;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;64 Zaragoza;Group 2102 Contraceptive management V25;Both sexes;42 Zaragoza;Group 2102 Contraceptive management V25;Men;4 Zaragoza;Group 2102 Contraceptive management V25;Women;38 Zaragoza;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Zaragoza;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Zaragoza;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Zaragoza;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;903 Zaragoza;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;564 Zaragoza;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;339 Zaragoza;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.851 Zaragoza;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1.037 Zaragoza;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;814 ASTURIAS, PRINCIPADO DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;116.616 ASTURIAS, PRINCIPADO DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;57.073 ASTURIAS, PRINCIPADO DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;59.543 ASTURIAS, PRINCIPADO DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2.098 ASTURIAS, PRINCIPADO DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.101 ASTURIAS, PRINCIPADO DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;997 ASTURIAS, PRINCIPADO DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;311 ASTURIAS, PRINCIPADO DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;151 ASTURIAS, PRINCIPADO DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;160 ASTURIAS, PRINCIPADO DE;Group 0102 Imprecise intestinal infections 009;Both sexes;131 ASTURIAS, PRINCIPADO DE;Group 0102 Imprecise intestinal infections 009;Men;71 ASTURIAS, PRINCIPADO DE;Group 0102 Imprecise intestinal infections 009;Women;60 ASTURIAS, PRINCIPADO DE;Group 0103 Tuberculosis 010-018, 137;Both sexes;110 ASTURIAS, PRINCIPADO DE;Group 0103 Tuberculosis 010-018, 137;Men;69 ASTURIAS, PRINCIPADO DE;Group 0103 Tuberculosis 010-018, 137;Women;41 ASTURIAS, PRINCIPADO DE;Group 0104 Septicaemia 038;Both sexes;906 ASTURIAS, PRINCIPADO DE;Group 0104 Septicaemia 038;Men;457 ASTURIAS, PRINCIPADO DE;Group 0104 Septicaemia 038;Women;449 ASTURIAS, PRINCIPADO DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;40 ASTURIAS, PRINCIPADO DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;28 ASTURIAS, PRINCIPADO DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;12 ASTURIAS, PRINCIPADO DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;600 ASTURIAS, PRINCIPADO DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;325 ASTURIAS, PRINCIPADO DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;275 ASTURIAS, PRINCIPADO DE;Group 0200 Neoplasms 140-239;Both sexes;11.019 ASTURIAS, PRINCIPADO DE;Group 0200 Neoplasms 140-239;Men;6.070 ASTURIAS, PRINCIPADO DE;Group 0200 Neoplasms 140-239;Women;4.949 ASTURIAS, PRINCIPADO DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.208 ASTURIAS, PRINCIPADO DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;724 ASTURIAS, PRINCIPADO DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;484 ASTURIAS, PRINCIPADO DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.095 ASTURIAS, PRINCIPADO DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;855 ASTURIAS, PRINCIPADO DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;240 ASTURIAS, PRINCIPADO DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;182 ASTURIAS, PRINCIPADO DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;96 ASTURIAS, PRINCIPADO DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;86 ASTURIAS, PRINCIPADO DE;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;685 ASTURIAS, PRINCIPADO DE;Group 0204 Malignant neoplasm of breast 174-175;Men;8 ASTURIAS, PRINCIPADO DE;Group 0204 Malignant neoplasm of breast 174-175;Women;677 ASTURIAS, PRINCIPADO DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;226 ASTURIAS, PRINCIPADO DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. ASTURIAS, PRINCIPADO DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;226 ASTURIAS, PRINCIPADO DE;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;117 ASTURIAS, PRINCIPADO DE;Group 0206 Malignant neoplasm of ovary 1830;Men;.. ASTURIAS, PRINCIPADO DE;Group 0206 Malignant neoplasm of ovary 1830;Women;117 ASTURIAS, PRINCIPADO DE;Group 0207 Malignant neoplasm of prostate 185;Both sexes;548 ASTURIAS, PRINCIPADO DE;Group 0207 Malignant neoplasm of prostate 185;Men;548 ASTURIAS, PRINCIPADO DE;Group 0207 Malignant neoplasm of prostate 185;Women;.. ASTURIAS, PRINCIPADO DE;Group 0208 Malignant neoplasm of bladder 188;Both sexes;869 ASTURIAS, PRINCIPADO DE;Group 0208 Malignant neoplasm of bladder 188;Men;741 ASTURIAS, PRINCIPADO DE;Group 0208 Malignant neoplasm of bladder 188;Women;128 ASTURIAS, PRINCIPADO DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;3.921 ASTURIAS, PRINCIPADO DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2.307 ASTURIAS, PRINCIPADO DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.614 ASTURIAS, PRINCIPADO DE;Group 0210 Carcinoma in situ 230-234;Both sexes;351 ASTURIAS, PRINCIPADO DE;Group 0210 Carcinoma in situ 230-234;Men;234 ASTURIAS, PRINCIPADO DE;Group 0210 Carcinoma in situ 230-234;Women;117 ASTURIAS, PRINCIPADO DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;92 ASTURIAS, PRINCIPADO DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;55 ASTURIAS, PRINCIPADO DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;37 ASTURIAS, PRINCIPADO DE;Grupo 0212 Leiomyoma of uterus 218;Both sexes;522 ASTURIAS, PRINCIPADO DE;Grupo 0212 Leiomyoma of uterus 218;Men;.. ASTURIAS, PRINCIPADO DE;Grupo 0212 Leiomyoma of uterus 218;Women;522 ASTURIAS, PRINCIPADO DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.203 ASTURIAS, PRINCIPADO DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;502 ASTURIAS, PRINCIPADO DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;701 ASTURIAS, PRINCIPADO DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;998 ASTURIAS, PRINCIPADO DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;474 ASTURIAS, PRINCIPADO DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;524 ASTURIAS, PRINCIPADO DE;Group 0301 Anaemias 280-285;Both sexes;750 ASTURIAS, PRINCIPADO DE;Group 0301 Anaemias 280-285;Men;339 ASTURIAS, PRINCIPADO DE;Group 0301 Anaemias 280-285;Women;411 ASTURIAS, PRINCIPADO DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;248 ASTURIAS, PRINCIPADO DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;135 ASTURIAS, PRINCIPADO DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;113 ASTURIAS, PRINCIPADO DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.790 ASTURIAS, PRINCIPADO DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;746 ASTURIAS, PRINCIPADO DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.044 ASTURIAS, PRINCIPADO DE;Group 0401 Diabetes mellitus 249-250;Both sexes;812 ASTURIAS, PRINCIPADO DE;Group 0401 Diabetes mellitus 249-250;Men;448 ASTURIAS, PRINCIPADO DE;Group 0401 Diabetes mellitus 249-250;Women;364 ASTURIAS, PRINCIPADO DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;978 ASTURIAS, PRINCIPADO DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;298 ASTURIAS, PRINCIPADO DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;680 ASTURIAS, PRINCIPADO DE;Group 0500 Mental disorders 290-319;Both sexes;3.073 ASTURIAS, PRINCIPADO DE;Group 0500 Mental disorders 290-319;Men;1.525 ASTURIAS, PRINCIPADO DE;Group 0500 Mental disorders 290-319;Women;1.548 ASTURIAS, PRINCIPADO DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;80 ASTURIAS, PRINCIPADO DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;36 ASTURIAS, PRINCIPADO DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;44 ASTURIAS, PRINCIPADO DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;242 ASTURIAS, PRINCIPADO DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;182 ASTURIAS, PRINCIPADO DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;60 ASTURIAS, PRINCIPADO DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;175 ASTURIAS, PRINCIPADO DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;132 ASTURIAS, PRINCIPADO DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;43 ASTURIAS, PRINCIPADO DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;728 ASTURIAS, PRINCIPADO DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;452 ASTURIAS, PRINCIPADO DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;276 ASTURIAS, PRINCIPADO DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;713 ASTURIAS, PRINCIPADO DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;227 ASTURIAS, PRINCIPADO DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;486 ASTURIAS, PRINCIPADO DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.135 ASTURIAS, PRINCIPADO DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;496 ASTURIAS, PRINCIPADO DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;639 ASTURIAS, PRINCIPADO DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.442 ASTURIAS, PRINCIPADO DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.248 ASTURIAS, PRINCIPADO DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.194 ASTURIAS, PRINCIPADO DE;Group 0601 Alzheimer's disease 3310;Both sexes;37 ASTURIAS, PRINCIPADO DE;Group 0601 Alzheimer's disease 3310;Men;16 ASTURIAS, PRINCIPADO DE;Group 0601 Alzheimer's disease 3310;Women;21 ASTURIAS, PRINCIPADO DE;Group 0602 Multiple sclerosis 340;Both sexes;105 ASTURIAS, PRINCIPADO DE;Group 0602 Multiple sclerosis 340;Men;41 ASTURIAS, PRINCIPADO DE;Group 0602 Multiple sclerosis 340;Women;64 ASTURIAS, PRINCIPADO DE;Group 0603 Epilepsy 345;Both sexes;448 ASTURIAS, PRINCIPADO DE;Group 0603 Epilepsy 345;Men;242 ASTURIAS, PRINCIPADO DE;Group 0603 Epilepsy 345;Women;206 ASTURIAS, PRINCIPADO DE;Group 0604 Transient cerebral ischemia 435;Both sexes;547 ASTURIAS, PRINCIPADO DE;Group 0604 Transient cerebral ischemia 435;Men;259 ASTURIAS, PRINCIPADO DE;Group 0604 Transient cerebral ischemia 435;Women;288 ASTURIAS, PRINCIPADO DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.305 ASTURIAS, PRINCIPADO DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;690 ASTURIAS, PRINCIPADO DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;615 ASTURIAS, PRINCIPADO DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;639 ASTURIAS, PRINCIPADO DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;278 ASTURIAS, PRINCIPADO DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;361 ASTURIAS, PRINCIPADO DE;Grupo 0701 Cataract 366;Both sexes;279 ASTURIAS, PRINCIPADO DE;Grupo 0701 Cataract 366;Men;113 ASTURIAS, PRINCIPADO DE;Grupo 0701 Cataract 366;Women;166 ASTURIAS, PRINCIPADO DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;360 ASTURIAS, PRINCIPADO DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;165 ASTURIAS, PRINCIPADO DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;195 ASTURIAS, PRINCIPADO DE;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;401 ASTURIAS, PRINCIPADO DE;Group 0800 Diseases of the ear and the mastoid 380-389;Men;191 ASTURIAS, PRINCIPADO DE;Group 0800 Diseases of the ear and the mastoid 380-389;Women;210 ASTURIAS, PRINCIPADO DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;20.059 ASTURIAS, PRINCIPADO DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;10.766 ASTURIAS, PRINCIPADO DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;9.293 ASTURIAS, PRINCIPADO DE;Group 0901 Hypertensive disease 401-405;Both sexes;1.504 ASTURIAS, PRINCIPADO DE;Group 0901 Hypertensive disease 401-405;Men;601 ASTURIAS, PRINCIPADO DE;Group 0901 Hypertensive disease 401-405;Women;903 ASTURIAS, PRINCIPADO DE;Group 0902 Angina pectoris 4111, 413;Both sexes;1.170 ASTURIAS, PRINCIPADO DE;Group 0902 Angina pectoris 4111, 413;Men;729 ASTURIAS, PRINCIPADO DE;Group 0902 Angina pectoris 4111, 413;Women;441 ASTURIAS, PRINCIPADO DE;Group 0903 Acute myocardial infarction 410;Both sexes;1.760 ASTURIAS, PRINCIPADO DE;Group 0903 Acute myocardial infarction 410;Men;1.182 ASTURIAS, PRINCIPADO DE;Group 0903 Acute myocardial infarction 410;Women;578 ASTURIAS, PRINCIPADO DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;991 ASTURIAS, PRINCIPADO DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;732 ASTURIAS, PRINCIPADO DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;259 ASTURIAS, PRINCIPADO DE;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;734 ASTURIAS, PRINCIPADO DE;Group 0905 Diseases of the lungs circulation 415-417;Men;318 ASTURIAS, PRINCIPADO DE;Group 0905 Diseases of the lungs circulation 415-417;Women;416 ASTURIAS, PRINCIPADO DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.242 ASTURIAS, PRINCIPADO DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.194 ASTURIAS, PRINCIPADO DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.048 ASTURIAS, PRINCIPADO DE;Grupo 0907 Heart failure 428;Both sexes;3.477 ASTURIAS, PRINCIPADO DE;Grupo 0907 Heart failure 428;Men;1.727 ASTURIAS, PRINCIPADO DE;Grupo 0907 Heart failure 428;Women;1.750 ASTURIAS, PRINCIPADO DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3.389 ASTURIAS, PRINCIPADO DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.754 ASTURIAS, PRINCIPADO DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.635 ASTURIAS, PRINCIPADO DE;Grupo 0909 Atherosclerosis 440;Both sexes;685 ASTURIAS, PRINCIPADO DE;Grupo 0909 Atherosclerosis 440;Men;465 ASTURIAS, PRINCIPADO DE;Grupo 0909 Atherosclerosis 440;Women;220 ASTURIAS, PRINCIPADO DE;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.479 ASTURIAS, PRINCIPADO DE;Group 0910 Varicose veins of lower extremities 454;Men;519 ASTURIAS, PRINCIPADO DE;Group 0910 Varicose veins of lower extremities 454;Women;960 ASTURIAS, PRINCIPADO DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.628 ASTURIAS, PRINCIPADO DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.545 ASTURIAS, PRINCIPADO DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.083 ASTURIAS, PRINCIPADO DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;15.456 ASTURIAS, PRINCIPADO DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;8.820 ASTURIAS, PRINCIPADO DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6.636 ASTURIAS, PRINCIPADO DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;738 ASTURIAS, PRINCIPADO DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;398 ASTURIAS, PRINCIPADO DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;340 ASTURIAS, PRINCIPADO DE;Group 1002 Pneumonia 480-486;Both sexes;3.377 ASTURIAS, PRINCIPADO DE;Group 1002 Pneumonia 480-486;Men;2.069 ASTURIAS, PRINCIPADO DE;Group 1002 Pneumonia 480-486;Women;1.308 ASTURIAS, PRINCIPADO DE;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;740 ASTURIAS, PRINCIPADO DE;Group 1003 Acute bronchitis and bronchiolitis 466;Men;377 ASTURIAS, PRINCIPADO DE;Group 1003 Acute bronchitis and bronchiolitis 466;Women;363 ASTURIAS, PRINCIPADO DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;224 ASTURIAS, PRINCIPADO DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;87 ASTURIAS, PRINCIPADO DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;137 ASTURIAS, PRINCIPADO DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;786 ASTURIAS, PRINCIPADO DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;477 ASTURIAS, PRINCIPADO DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;309 ASTURIAS, PRINCIPADO DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;3.054 ASTURIAS, PRINCIPADO DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2.412 ASTURIAS, PRINCIPADO DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;642 ASTURIAS, PRINCIPADO DE;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1.533 ASTURIAS, PRINCIPADO DE;Group 1007 Asthma 4930-4931,4938-4939;Men;556 ASTURIAS, PRINCIPADO DE;Group 1007 Asthma 4930-4931,4938-4939;Women;977 ASTURIAS, PRINCIPADO DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5.004 ASTURIAS, PRINCIPADO DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.444 ASTURIAS, PRINCIPADO DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2.560 ASTURIAS, PRINCIPADO DE;Group 1100 Diseases of the digestive system 520-579;Both sexes;13.768 ASTURIAS, PRINCIPADO DE;Group 1100 Diseases of the digestive system 520-579;Men;7.800 ASTURIAS, PRINCIPADO DE;Group 1100 Diseases of the digestive system 520-579;Women;5.968 ASTURIAS, PRINCIPADO DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;111 ASTURIAS, PRINCIPADO DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;61 ASTURIAS, PRINCIPADO DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;50 ASTURIAS, PRINCIPADO DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;161 ASTURIAS, PRINCIPADO DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;81 ASTURIAS, PRINCIPADO DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;80 ASTURIAS, PRINCIPADO DE;Group 1103 Diseases of the esophagus 530;Both sexes;224 ASTURIAS, PRINCIPADO DE;Group 1103 Diseases of the esophagus 530;Men;132 ASTURIAS, PRINCIPADO DE;Group 1103 Diseases of the esophagus 530;Women;92 ASTURIAS, PRINCIPADO DE;Group 1104 Peptic ulcer 531-534;Both sexes;215 ASTURIAS, PRINCIPADO DE;Group 1104 Peptic ulcer 531-534;Men;139 ASTURIAS, PRINCIPADO DE;Group 1104 Peptic ulcer 531-534;Women;76 ASTURIAS, PRINCIPADO DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;301 ASTURIAS, PRINCIPADO DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;180 ASTURIAS, PRINCIPADO DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;121 ASTURIAS, PRINCIPADO DE;Group 1106 Appendicitis 540-543;Both sexes;1.036 ASTURIAS, PRINCIPADO DE;Group 1106 Appendicitis 540-543;Men;589 ASTURIAS, PRINCIPADO DE;Group 1106 Appendicitis 540-543;Women;447 ASTURIAS, PRINCIPADO DE;Group 1107 Inguinal hernia 550;Both sexes;1.476 ASTURIAS, PRINCIPADO DE;Group 1107 Inguinal hernia 550;Men;1.353 ASTURIAS, PRINCIPADO DE;Group 1107 Inguinal hernia 550;Women;123 ASTURIAS, PRINCIPADO DE;Group 1108 Other abdominal hernia 551-553;Both sexes;975 ASTURIAS, PRINCIPADO DE;Group 1108 Other abdominal hernia 551-553;Men;488 ASTURIAS, PRINCIPADO DE;Group 1108 Other abdominal hernia 551-553;Women;487 ASTURIAS, PRINCIPADO DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;344 ASTURIAS, PRINCIPADO DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;185 ASTURIAS, PRINCIPADO DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;159 ASTURIAS, PRINCIPADO DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;776 ASTURIAS, PRINCIPADO DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;367 ASTURIAS, PRINCIPADO DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;409 ASTURIAS, PRINCIPADO DE;Group 1111 Intestinal obstruction without hernia 560;Both sexes;965 ASTURIAS, PRINCIPADO DE;Group 1111 Intestinal obstruction without hernia 560;Men;452 ASTURIAS, PRINCIPADO DE;Group 1111 Intestinal obstruction without hernia 560;Women;513 ASTURIAS, PRINCIPADO DE;Group 1112 Intestinal diverticulosis 562;Both sexes;675 ASTURIAS, PRINCIPADO DE;Group 1112 Intestinal diverticulosis 562;Men;321 ASTURIAS, PRINCIPADO DE;Group 1112 Intestinal diverticulosis 562;Women;354 ASTURIAS, PRINCIPADO DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;674 ASTURIAS, PRINCIPADO DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;416 ASTURIAS, PRINCIPADO DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;258 ASTURIAS, PRINCIPADO DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;537 ASTURIAS, PRINCIPADO DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;226 ASTURIAS, PRINCIPADO DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;311 ASTURIAS, PRINCIPADO DE;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;319 ASTURIAS, PRINCIPADO DE;Group 1115 Alcoholic hepatitis 5710-5713;Men;286 ASTURIAS, PRINCIPADO DE;Group 1115 Alcoholic hepatitis 5710-5713;Women;33 ASTURIAS, PRINCIPADO DE;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;458 ASTURIAS, PRINCIPADO DE;Group 1116 Other diseases of the liver 570,5714-573;Men;294 ASTURIAS, PRINCIPADO DE;Group 1116 Other diseases of the liver 570,5714-573;Women;164 ASTURIAS, PRINCIPADO DE;Group 1117 Cholelithiasis 574;Both sexes;2.341 ASTURIAS, PRINCIPADO DE;Group 1117 Cholelithiasis 574;Men;1.016 ASTURIAS, PRINCIPADO DE;Group 1117 Cholelithiasis 574;Women;1.325 ASTURIAS, PRINCIPADO DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;846 ASTURIAS, PRINCIPADO DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;470 ASTURIAS, PRINCIPADO DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;376 ASTURIAS, PRINCIPADO DE;Group 1119 Pancreatic diseases 577;Both sexes;774 ASTURIAS, PRINCIPADO DE;Group 1119 Pancreatic diseases 577;Men;448 ASTURIAS, PRINCIPADO DE;Group 1119 Pancreatic diseases 577;Women;326 ASTURIAS, PRINCIPADO DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;560 ASTURIAS, PRINCIPADO DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;296 ASTURIAS, PRINCIPADO DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;264 ASTURIAS, PRINCIPADO DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.119 ASTURIAS, PRINCIPADO DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;613 ASTURIAS, PRINCIPADO DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;506 ASTURIAS, PRINCIPADO DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;727 ASTURIAS, PRINCIPADO DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;429 ASTURIAS, PRINCIPADO DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;298 ASTURIAS, PRINCIPADO DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;45 ASTURIAS, PRINCIPADO DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;26 ASTURIAS, PRINCIPADO DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;19 ASTURIAS, PRINCIPADO DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;347 ASTURIAS, PRINCIPADO DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;158 ASTURIAS, PRINCIPADO DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;189 ASTURIAS, PRINCIPADO DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;8.619 ASTURIAS, PRINCIPADO DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.189 ASTURIAS, PRINCIPADO DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;4.430 ASTURIAS, PRINCIPADO DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. ASTURIAS, PRINCIPADO DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. ASTURIAS, PRINCIPADO DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. ASTURIAS, PRINCIPADO DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. ASTURIAS, PRINCIPADO DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. ASTURIAS, PRINCIPADO DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. ASTURIAS, PRINCIPADO DE;Group 1303 Internal derangement of knee 717;Both sexes;873 ASTURIAS, PRINCIPADO DE;Group 1303 Internal derangement of knee 717;Men;554 ASTURIAS, PRINCIPADO DE;Group 1303 Internal derangement of knee 717;Women;319 ASTURIAS, PRINCIPADO DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;4.351 ASTURIAS, PRINCIPADO DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;2.013 ASTURIAS, PRINCIPADO DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.338 ASTURIAS, PRINCIPADO DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;127 ASTURIAS, PRINCIPADO DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;46 ASTURIAS, PRINCIPADO DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;81 ASTURIAS, PRINCIPADO DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;366 ASTURIAS, PRINCIPADO DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;171 ASTURIAS, PRINCIPADO DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;195 ASTURIAS, PRINCIPADO DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;793 ASTURIAS, PRINCIPADO DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;416 ASTURIAS, PRINCIPADO DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;377 ASTURIAS, PRINCIPADO DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;258 ASTURIAS, PRINCIPADO DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;131 ASTURIAS, PRINCIPADO DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;127 ASTURIAS, PRINCIPADO DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;901 ASTURIAS, PRINCIPADO DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;473 ASTURIAS, PRINCIPADO DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;428 ASTURIAS, PRINCIPADO DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;950 ASTURIAS, PRINCIPADO DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;385 ASTURIAS, PRINCIPADO DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;565 ASTURIAS, PRINCIPADO DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;6.922 ASTURIAS, PRINCIPADO DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3.231 ASTURIAS, PRINCIPADO DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3.691 ASTURIAS, PRINCIPADO DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;512 ASTURIAS, PRINCIPADO DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;222 ASTURIAS, PRINCIPADO DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;290 ASTURIAS, PRINCIPADO DE;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;619 ASTURIAS, PRINCIPADO DE;Group 1402 Renal failure 5836-5837, 584-586;Men;343 ASTURIAS, PRINCIPADO DE;Group 1402 Renal failure 5836-5837, 584-586;Women;276 ASTURIAS, PRINCIPADO DE;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;927 ASTURIAS, PRINCIPADO DE;Group 1403 Urolithiasis 592, 594, 7880;Men;547 ASTURIAS, PRINCIPADO DE;Group 1403 Urolithiasis 592, 594, 7880;Women;380 ASTURIAS, PRINCIPADO DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2.420 ASTURIAS, PRINCIPADO DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.037 ASTURIAS, PRINCIPADO DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.383 ASTURIAS, PRINCIPADO DE;Group 1405 Prostatic hyperplasia 600;Both sexes;560 ASTURIAS, PRINCIPADO DE;Group 1405 Prostatic hyperplasia 600;Men;560 ASTURIAS, PRINCIPADO DE;Group 1405 Prostatic hyperplasia 600;Women;.. ASTURIAS, PRINCIPADO DE;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;477 ASTURIAS, PRINCIPADO DE;Group 1406 Other diseases of the male genital organs 601-608;Men;477 ASTURIAS, PRINCIPADO DE;Group 1406 Other diseases of the male genital organs 601-608;Women;.. ASTURIAS, PRINCIPADO DE;Group 1407 Disorders of breast 610-612;Both sexes;305 ASTURIAS, PRINCIPADO DE;Group 1407 Disorders of breast 610-612;Men;34 ASTURIAS, PRINCIPADO DE;Group 1407 Disorders of breast 610-612;Women;271 ASTURIAS, PRINCIPADO DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;142 ASTURIAS, PRINCIPADO DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. ASTURIAS, PRINCIPADO DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;142 ASTURIAS, PRINCIPADO DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;50 ASTURIAS, PRINCIPADO DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. ASTURIAS, PRINCIPADO DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;50 ASTURIAS, PRINCIPADO DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;910 ASTURIAS, PRINCIPADO DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;11 ASTURIAS, PRINCIPADO DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;899 ASTURIAS, PRINCIPADO DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;7.848 ASTURIAS, PRINCIPADO DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. ASTURIAS, PRINCIPADO DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;7.848 ASTURIAS, PRINCIPADO DE;Group 1501 Legally induced abortion 635;Both sexes;55 ASTURIAS, PRINCIPADO DE;Group 1501 Legally induced abortion 635;Men;.. ASTURIAS, PRINCIPADO DE;Group 1501 Legally induced abortion 635;Women;55 ASTURIAS, PRINCIPADO DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;340 ASTURIAS, PRINCIPADO DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. ASTURIAS, PRINCIPADO DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;340 ASTURIAS, PRINCIPADO DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4.813 ASTURIAS, PRINCIPADO DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. ASTURIAS, PRINCIPADO DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4.813 ASTURIAS, PRINCIPADO DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.036 ASTURIAS, PRINCIPADO DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. ASTURIAS, PRINCIPADO DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.036 ASTURIAS, PRINCIPADO DE;Group 1505 Single spontaneous delivery 650;Both sexes;718 ASTURIAS, PRINCIPADO DE;Group 1505 Single spontaneous delivery 650;Men;.. ASTURIAS, PRINCIPADO DE;Group 1505 Single spontaneous delivery 650;Women;718 ASTURIAS, PRINCIPADO DE;Group 1506 Other deliveries 6695-6697;Both sexes;426 ASTURIAS, PRINCIPADO DE;Group 1506 Other deliveries 6695-6697;Men;.. ASTURIAS, PRINCIPADO DE;Group 1506 Other deliveries 6695-6697;Women;426 ASTURIAS, PRINCIPADO DE;Group 1507 Complications related to the puerperium 670-676;Both sexes;92 ASTURIAS, PRINCIPADO DE;Group 1507 Complications related to the puerperium 670-676;Men;.. ASTURIAS, PRINCIPADO DE;Group 1507 Complications related to the puerperium 670-676;Women;92 ASTURIAS, PRINCIPADO DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;368 ASTURIAS, PRINCIPADO DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. ASTURIAS, PRINCIPADO DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;368 ASTURIAS, PRINCIPADO DE;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.041 ASTURIAS, PRINCIPADO DE;Group 1600 Some disorders originating in the perinatal period 760-779;Men;603 ASTURIAS, PRINCIPADO DE;Group 1600 Some disorders originating in the perinatal period 760-779;Women;438 ASTURIAS, PRINCIPADO DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;272 ASTURIAS, PRINCIPADO DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;149 ASTURIAS, PRINCIPADO DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;123 ASTURIAS, PRINCIPADO DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;769 ASTURIAS, PRINCIPADO DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;454 ASTURIAS, PRINCIPADO DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;315 ASTURIAS, PRINCIPADO DE;Grupo 1700 Congenital abnormalities 740-759;Both sexes;568 ASTURIAS, PRINCIPADO DE;Grupo 1700 Congenital abnormalities 740-759;Men;307 ASTURIAS, PRINCIPADO DE;Grupo 1700 Congenital abnormalities 740-759;Women;261 ASTURIAS, PRINCIPADO DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;6.849 ASTURIAS, PRINCIPADO DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3.444 ASTURIAS, PRINCIPADO DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3.405 ASTURIAS, PRINCIPADO DE;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;670 ASTURIAS, PRINCIPADO DE;Group 1801 Pain in throat and chest 7841, 7865;Men;352 ASTURIAS, PRINCIPADO DE;Group 1801 Pain in throat and chest 7841, 7865;Women;318 ASTURIAS, PRINCIPADO DE;Group 1802 Abdominal pain 7890;Both sexes;736 ASTURIAS, PRINCIPADO DE;Group 1802 Abdominal pain 7890;Men;314 ASTURIAS, PRINCIPADO DE;Group 1802 Abdominal pain 7890;Women;422 ASTURIAS, PRINCIPADO DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;374 ASTURIAS, PRINCIPADO DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;209 ASTURIAS, PRINCIPADO DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;165 ASTURIAS, PRINCIPADO DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5.069 ASTURIAS, PRINCIPADO DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.569 ASTURIAS, PRINCIPADO DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.500 ASTURIAS, PRINCIPADO DE;Group 1900 Injuries and poisoning 800-999;Both sexes;10.263 ASTURIAS, PRINCIPADO DE;Group 1900 Injuries and poisoning 800-999;Men;4.801 ASTURIAS, PRINCIPADO DE;Group 1900 Injuries and poisoning 800-999;Women;5.462 ASTURIAS, PRINCIPADO DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;408 ASTURIAS, PRINCIPADO DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;220 ASTURIAS, PRINCIPADO DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;188 ASTURIAS, PRINCIPADO DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;249 ASTURIAS, PRINCIPADO DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;175 ASTURIAS, PRINCIPADO DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;74 ASTURIAS, PRINCIPADO DE;Group 1903 Radius and ulna fracture 813;Both sexes;390 ASTURIAS, PRINCIPADO DE;Group 1903 Radius and ulna fracture 813;Men;162 ASTURIAS, PRINCIPADO DE;Group 1903 Radius and ulna fracture 813;Women;228 ASTURIAS, PRINCIPADO DE;Group 1904 Femur fracture 820-821;Both sexes;2.076 ASTURIAS, PRINCIPADO DE;Group 1904 Femur fracture 820-821;Men;502 ASTURIAS, PRINCIPADO DE;Group 1904 Femur fracture 820-821;Women;1.574 ASTURIAS, PRINCIPADO DE;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;754 ASTURIAS, PRINCIPADO DE;Group 1905 Leg fracture, including the ankle 823-824;Men;372 ASTURIAS, PRINCIPADO DE;Group 1905 Leg fracture, including the ankle 823-824;Women;382 ASTURIAS, PRINCIPADO DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2.947 ASTURIAS, PRINCIPADO DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.637 ASTURIAS, PRINCIPADO DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.310 ASTURIAS, PRINCIPADO DE;Group 1907 Burns 940-949;Both sexes;76 ASTURIAS, PRINCIPADO DE;Group 1907 Burns 940-949;Men;40 ASTURIAS, PRINCIPADO DE;Group 1907 Burns 940-949;Women;36 ASTURIAS, PRINCIPADO DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;393 ASTURIAS, PRINCIPADO DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;175 ASTURIAS, PRINCIPADO DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;218 ASTURIAS, PRINCIPADO DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.724 ASTURIAS, PRINCIPADO DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.400 ASTURIAS, PRINCIPADO DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.324 ASTURIAS, PRINCIPADO DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;21 ASTURIAS, PRINCIPADO DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;10 ASTURIAS, PRINCIPADO DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;11 ASTURIAS, PRINCIPADO DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;225 ASTURIAS, PRINCIPADO DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;108 ASTURIAS, PRINCIPADO DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;117 ASTURIAS, PRINCIPADO DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.644 ASTURIAS, PRINCIPADO DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;866 ASTURIAS, PRINCIPADO DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;778 ASTURIAS, PRINCIPADO DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;67 ASTURIAS, PRINCIPADO DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;47 ASTURIAS, PRINCIPADO DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;20 ASTURIAS, PRINCIPADO DE;Group 2102 Contraceptive management V25;Both sexes;26 ASTURIAS, PRINCIPADO DE;Group 2102 Contraceptive management V25;Men;1 ASTURIAS, PRINCIPADO DE;Group 2102 Contraceptive management V25;Women;25 ASTURIAS, PRINCIPADO DE;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. ASTURIAS, PRINCIPADO DE;Group 2103 Living newborns by type of delivery V30-V39;Men;.. ASTURIAS, PRINCIPADO DE;Group 2103 Living newborns by type of delivery V30-V39;Women;.. ASTURIAS, PRINCIPADO DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;850 ASTURIAS, PRINCIPADO DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;503 ASTURIAS, PRINCIPADO DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;347 ASTURIAS, PRINCIPADO DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;701 ASTURIAS, PRINCIPADO DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;315 ASTURIAS, PRINCIPADO DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;386 BALEARS, ILLES;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;123.621 BALEARS, ILLES;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;58.257 BALEARS, ILLES;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;65.364 BALEARS, ILLES;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2.959 BALEARS, ILLES;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.615 BALEARS, ILLES;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.344 BALEARS, ILLES;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;546 BALEARS, ILLES;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;275 BALEARS, ILLES;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;270 BALEARS, ILLES;Group 0102 Imprecise intestinal infections 009;Both sexes;561 BALEARS, ILLES;Group 0102 Imprecise intestinal infections 009;Men;255 BALEARS, ILLES;Group 0102 Imprecise intestinal infections 009;Women;306 BALEARS, ILLES;Group 0103 Tuberculosis 010-018, 137;Both sexes;102 BALEARS, ILLES;Group 0103 Tuberculosis 010-018, 137;Men;79 BALEARS, ILLES;Group 0103 Tuberculosis 010-018, 137;Women;23 BALEARS, ILLES;Group 0104 Septicaemia 038;Both sexes;846 BALEARS, ILLES;Group 0104 Septicaemia 038;Men;498 BALEARS, ILLES;Group 0104 Septicaemia 038;Women;348 BALEARS, ILLES;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;82 BALEARS, ILLES;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;55 BALEARS, ILLES;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;27 BALEARS, ILLES;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;821 BALEARS, ILLES;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;451 BALEARS, ILLES;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;370 BALEARS, ILLES;Group 0200 Neoplasms 140-239;Both sexes;8.057 BALEARS, ILLES;Group 0200 Neoplasms 140-239;Men;4.021 BALEARS, ILLES;Group 0200 Neoplasms 140-239;Women;4.036 BALEARS, ILLES;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;777 BALEARS, ILLES;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;464 BALEARS, ILLES;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;312 BALEARS, ILLES;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;675 BALEARS, ILLES;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;521 BALEARS, ILLES;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;154 BALEARS, ILLES;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;138 BALEARS, ILLES;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;83 BALEARS, ILLES;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;54 BALEARS, ILLES;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;859 BALEARS, ILLES;Group 0204 Malignant neoplasm of breast 174-175;Men;7 BALEARS, ILLES;Group 0204 Malignant neoplasm of breast 174-175;Women;852 BALEARS, ILLES;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;161 BALEARS, ILLES;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. BALEARS, ILLES;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;161 BALEARS, ILLES;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;89 BALEARS, ILLES;Group 0206 Malignant neoplasm of ovary 1830;Men;.. BALEARS, ILLES;Group 0206 Malignant neoplasm of ovary 1830;Women;89 BALEARS, ILLES;Group 0207 Malignant neoplasm of prostate 185;Both sexes;293 BALEARS, ILLES;Group 0207 Malignant neoplasm of prostate 185;Men;293 BALEARS, ILLES;Group 0207 Malignant neoplasm of prostate 185;Women;.. BALEARS, ILLES;Group 0208 Malignant neoplasm of bladder 188;Both sexes;643 BALEARS, ILLES;Group 0208 Malignant neoplasm of bladder 188;Men;515 BALEARS, ILLES;Group 0208 Malignant neoplasm of bladder 188;Women;128 BALEARS, ILLES;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.475 BALEARS, ILLES;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.441 BALEARS, ILLES;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.034 BALEARS, ILLES;Group 0210 Carcinoma in situ 230-234;Both sexes;211 BALEARS, ILLES;Group 0210 Carcinoma in situ 230-234;Men;119 BALEARS, ILLES;Group 0210 Carcinoma in situ 230-234;Women;91 BALEARS, ILLES;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;112 BALEARS, ILLES;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;66 BALEARS, ILLES;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;45 BALEARS, ILLES;Grupo 0212 Leiomyoma of uterus 218;Both sexes;408 BALEARS, ILLES;Grupo 0212 Leiomyoma of uterus 218;Men;.. BALEARS, ILLES;Grupo 0212 Leiomyoma of uterus 218;Women;408 BALEARS, ILLES;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.217 BALEARS, ILLES;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;509 BALEARS, ILLES;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;707 BALEARS, ILLES;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;872 BALEARS, ILLES;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;396 BALEARS, ILLES;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;476 BALEARS, ILLES;Group 0301 Anaemias 280-285;Both sexes;601 BALEARS, ILLES;Group 0301 Anaemias 280-285;Men;261 BALEARS, ILLES;Group 0301 Anaemias 280-285;Women;340 BALEARS, ILLES;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;271 BALEARS, ILLES;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;135 BALEARS, ILLES;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;137 BALEARS, ILLES;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.967 BALEARS, ILLES;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;879 BALEARS, ILLES;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.088 BALEARS, ILLES;Group 0401 Diabetes mellitus 249-250;Both sexes;751 BALEARS, ILLES;Group 0401 Diabetes mellitus 249-250;Men;432 BALEARS, ILLES;Group 0401 Diabetes mellitus 249-250;Women;319 BALEARS, ILLES;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.217 BALEARS, ILLES;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;447 BALEARS, ILLES;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;770 BALEARS, ILLES;Group 0500 Mental disorders 290-319;Both sexes;3.168 BALEARS, ILLES;Group 0500 Mental disorders 290-319;Men;1.564 BALEARS, ILLES;Group 0500 Mental disorders 290-319;Women;1.604 BALEARS, ILLES;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;95 BALEARS, ILLES;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;47 BALEARS, ILLES;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;48 BALEARS, ILLES;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;435 BALEARS, ILLES;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;306 BALEARS, ILLES;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;128 BALEARS, ILLES;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;153 BALEARS, ILLES;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;108 BALEARS, ILLES;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;45 BALEARS, ILLES;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;784 BALEARS, ILLES;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;450 BALEARS, ILLES;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;334 BALEARS, ILLES;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;747 BALEARS, ILLES;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;286 BALEARS, ILLES;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;460 BALEARS, ILLES;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;956 BALEARS, ILLES;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;367 BALEARS, ILLES;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;589 BALEARS, ILLES;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;4.055 BALEARS, ILLES;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.147 BALEARS, ILLES;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.908 BALEARS, ILLES;Group 0601 Alzheimer's disease 3310;Both sexes;72 BALEARS, ILLES;Group 0601 Alzheimer's disease 3310;Men;27 BALEARS, ILLES;Group 0601 Alzheimer's disease 3310;Women;45 BALEARS, ILLES;Group 0602 Multiple sclerosis 340;Both sexes;45 BALEARS, ILLES;Group 0602 Multiple sclerosis 340;Men;12 BALEARS, ILLES;Group 0602 Multiple sclerosis 340;Women;33 BALEARS, ILLES;Group 0603 Epilepsy 345;Both sexes;520 BALEARS, ILLES;Group 0603 Epilepsy 345;Men;278 BALEARS, ILLES;Group 0603 Epilepsy 345;Women;241 BALEARS, ILLES;Group 0604 Transient cerebral ischemia 435;Both sexes;375 BALEARS, ILLES;Group 0604 Transient cerebral ischemia 435;Men;198 BALEARS, ILLES;Group 0604 Transient cerebral ischemia 435;Women;177 BALEARS, ILLES;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.043 BALEARS, ILLES;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.632 BALEARS, ILLES;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.412 BALEARS, ILLES;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;576 BALEARS, ILLES;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;292 BALEARS, ILLES;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;283 BALEARS, ILLES;Grupo 0701 Cataract 366;Both sexes;44 BALEARS, ILLES;Grupo 0701 Cataract 366;Men;22 BALEARS, ILLES;Grupo 0701 Cataract 366;Women;22 BALEARS, ILLES;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;532 BALEARS, ILLES;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;270 BALEARS, ILLES;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;261 BALEARS, ILLES;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;882 BALEARS, ILLES;Group 0800 Diseases of the ear and the mastoid 380-389;Men;428 BALEARS, ILLES;Group 0800 Diseases of the ear and the mastoid 380-389;Women;454 BALEARS, ILLES;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;13.344 BALEARS, ILLES;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;7.481 BALEARS, ILLES;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;5.863 BALEARS, ILLES;Group 0901 Hypertensive disease 401-405;Both sexes;766 BALEARS, ILLES;Group 0901 Hypertensive disease 401-405;Men;344 BALEARS, ILLES;Group 0901 Hypertensive disease 401-405;Women;422 BALEARS, ILLES;Group 0902 Angina pectoris 4111, 413;Both sexes;891 BALEARS, ILLES;Group 0902 Angina pectoris 4111, 413;Men;576 BALEARS, ILLES;Group 0902 Angina pectoris 4111, 413;Women;316 BALEARS, ILLES;Group 0903 Acute myocardial infarction 410;Both sexes;1.094 BALEARS, ILLES;Group 0903 Acute myocardial infarction 410;Men;785 BALEARS, ILLES;Group 0903 Acute myocardial infarction 410;Women;310 BALEARS, ILLES;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;686 BALEARS, ILLES;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;517 BALEARS, ILLES;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;170 BALEARS, ILLES;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;299 BALEARS, ILLES;Group 0905 Diseases of the lungs circulation 415-417;Men;143 BALEARS, ILLES;Group 0905 Diseases of the lungs circulation 415-417;Women;157 BALEARS, ILLES;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.948 BALEARS, ILLES;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.075 BALEARS, ILLES;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;872 BALEARS, ILLES;Grupo 0907 Heart failure 428;Both sexes;2.632 BALEARS, ILLES;Grupo 0907 Heart failure 428;Men;1.198 BALEARS, ILLES;Grupo 0907 Heart failure 428;Women;1.434 BALEARS, ILLES;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.154 BALEARS, ILLES;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.235 BALEARS, ILLES;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;919 BALEARS, ILLES;Grupo 0909 Atherosclerosis 440;Both sexes;306 BALEARS, ILLES;Grupo 0909 Atherosclerosis 440;Men;232 BALEARS, ILLES;Grupo 0909 Atherosclerosis 440;Women;74 BALEARS, ILLES;Group 0910 Varicose veins of lower extremities 454;Both sexes;482 BALEARS, ILLES;Group 0910 Varicose veins of lower extremities 454;Men;169 BALEARS, ILLES;Group 0910 Varicose veins of lower extremities 454;Women;314 BALEARS, ILLES;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.084 BALEARS, ILLES;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.209 BALEARS, ILLES;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;875 BALEARS, ILLES;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;14.767 BALEARS, ILLES;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;8.088 BALEARS, ILLES;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6.679 BALEARS, ILLES;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;772 BALEARS, ILLES;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;407 BALEARS, ILLES;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;365 BALEARS, ILLES;Group 1002 Pneumonia 480-486;Both sexes;3.553 BALEARS, ILLES;Group 1002 Pneumonia 480-486;Men;2.011 BALEARS, ILLES;Group 1002 Pneumonia 480-486;Women;1.541 BALEARS, ILLES;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2.715 BALEARS, ILLES;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1.154 BALEARS, ILLES;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.561 BALEARS, ILLES;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;548 BALEARS, ILLES;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;277 BALEARS, ILLES;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;270 BALEARS, ILLES;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.135 BALEARS, ILLES;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;713 BALEARS, ILLES;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;422 BALEARS, ILLES;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.492 BALEARS, ILLES;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.778 BALEARS, ILLES;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;714 BALEARS, ILLES;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;591 BALEARS, ILLES;Group 1007 Asthma 4930-4931,4938-4939;Men;198 BALEARS, ILLES;Group 1007 Asthma 4930-4931,4938-4939;Women;393 BALEARS, ILLES;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.962 BALEARS, ILLES;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.550 BALEARS, ILLES;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.412 BALEARS, ILLES;Group 1100 Diseases of the digestive system 520-579;Both sexes;14.414 BALEARS, ILLES;Group 1100 Diseases of the digestive system 520-579;Men;7.827 BALEARS, ILLES;Group 1100 Diseases of the digestive system 520-579;Women;6.587 BALEARS, ILLES;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;183 BALEARS, ILLES;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;88 BALEARS, ILLES;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;94 BALEARS, ILLES;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;191 BALEARS, ILLES;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;106 BALEARS, ILLES;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;85 BALEARS, ILLES;Group 1103 Diseases of the esophagus 530;Both sexes;197 BALEARS, ILLES;Group 1103 Diseases of the esophagus 530;Men;123 BALEARS, ILLES;Group 1103 Diseases of the esophagus 530;Women;74 BALEARS, ILLES;Group 1104 Peptic ulcer 531-534;Both sexes;241 BALEARS, ILLES;Group 1104 Peptic ulcer 531-534;Men;175 BALEARS, ILLES;Group 1104 Peptic ulcer 531-534;Women;66 BALEARS, ILLES;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;578 BALEARS, ILLES;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;259 BALEARS, ILLES;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;319 BALEARS, ILLES;Group 1106 Appendicitis 540-543;Both sexes;1.294 BALEARS, ILLES;Group 1106 Appendicitis 540-543;Men;715 BALEARS, ILLES;Group 1106 Appendicitis 540-543;Women;580 BALEARS, ILLES;Group 1107 Inguinal hernia 550;Both sexes;1.296 BALEARS, ILLES;Group 1107 Inguinal hernia 550;Men;1.158 BALEARS, ILLES;Group 1107 Inguinal hernia 550;Women;139 BALEARS, ILLES;Group 1108 Other abdominal hernia 551-553;Both sexes;1.108 BALEARS, ILLES;Group 1108 Other abdominal hernia 551-553;Men;552 BALEARS, ILLES;Group 1108 Other abdominal hernia 551-553;Women;557 BALEARS, ILLES;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;286 BALEARS, ILLES;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;115 BALEARS, ILLES;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;172 BALEARS, ILLES;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.787 BALEARS, ILLES;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;757 BALEARS, ILLES;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;1.030 BALEARS, ILLES;Group 1111 Intestinal obstruction without hernia 560;Both sexes;640 BALEARS, ILLES;Group 1111 Intestinal obstruction without hernia 560;Men;307 BALEARS, ILLES;Group 1111 Intestinal obstruction without hernia 560;Women;334 BALEARS, ILLES;Group 1112 Intestinal diverticulosis 562;Both sexes;718 BALEARS, ILLES;Group 1112 Intestinal diverticulosis 562;Men;358 BALEARS, ILLES;Group 1112 Intestinal diverticulosis 562;Women;360 BALEARS, ILLES;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;741 BALEARS, ILLES;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;457 BALEARS, ILLES;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;283 BALEARS, ILLES;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;455 BALEARS, ILLES;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;206 BALEARS, ILLES;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;249 BALEARS, ILLES;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;148 BALEARS, ILLES;Group 1115 Alcoholic hepatitis 5710-5713;Men;112 BALEARS, ILLES;Group 1115 Alcoholic hepatitis 5710-5713;Women;36 BALEARS, ILLES;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;367 BALEARS, ILLES;Group 1116 Other diseases of the liver 570,5714-573;Men;225 BALEARS, ILLES;Group 1116 Other diseases of the liver 570,5714-573;Women;142 BALEARS, ILLES;Group 1117 Cholelithiasis 574;Both sexes;2.210 BALEARS, ILLES;Group 1117 Cholelithiasis 574;Men;1.018 BALEARS, ILLES;Group 1117 Cholelithiasis 574;Women;1.193 BALEARS, ILLES;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;739 BALEARS, ILLES;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;379 BALEARS, ILLES;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;360 BALEARS, ILLES;Group 1119 Pancreatic diseases 577;Both sexes;666 BALEARS, ILLES;Group 1119 Pancreatic diseases 577;Men;397 BALEARS, ILLES;Group 1119 Pancreatic diseases 577;Women;269 BALEARS, ILLES;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;569 BALEARS, ILLES;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;324 BALEARS, ILLES;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;245 BALEARS, ILLES;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.451 BALEARS, ILLES;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;782 BALEARS, ILLES;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;669 BALEARS, ILLES;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.052 BALEARS, ILLES;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;617 BALEARS, ILLES;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;435 BALEARS, ILLES;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;64 BALEARS, ILLES;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;34 BALEARS, ILLES;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;30 BALEARS, ILLES;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;335 BALEARS, ILLES;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;131 BALEARS, ILLES;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;204 BALEARS, ILLES;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;10.290 BALEARS, ILLES;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.964 BALEARS, ILLES;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5.325 BALEARS, ILLES;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. BALEARS, ILLES;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. BALEARS, ILLES;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. BALEARS, ILLES;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. BALEARS, ILLES;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. BALEARS, ILLES;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. BALEARS, ILLES;Group 1303 Internal derangement of knee 717;Both sexes;1.291 BALEARS, ILLES;Group 1303 Internal derangement of knee 717;Men;867 BALEARS, ILLES;Group 1303 Internal derangement of knee 717;Women;424 BALEARS, ILLES;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3.424 BALEARS, ILLES;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.523 BALEARS, ILLES;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.901 BALEARS, ILLES;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;134 BALEARS, ILLES;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;51 BALEARS, ILLES;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;82 BALEARS, ILLES;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;342 BALEARS, ILLES;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;162 BALEARS, ILLES;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;180 BALEARS, ILLES;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;873 BALEARS, ILLES;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;466 BALEARS, ILLES;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;407 BALEARS, ILLES;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;787 BALEARS, ILLES;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;326 BALEARS, ILLES;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;460 BALEARS, ILLES;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.844 BALEARS, ILLES;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;955 BALEARS, ILLES;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;888 BALEARS, ILLES;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.596 BALEARS, ILLES;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;613 BALEARS, ILLES;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;983 BALEARS, ILLES;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;8.616 BALEARS, ILLES;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4.119 BALEARS, ILLES;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4.497 BALEARS, ILLES;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;912 BALEARS, ILLES;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;245 BALEARS, ILLES;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;666 BALEARS, ILLES;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;459 BALEARS, ILLES;Group 1402 Renal failure 5836-5837, 584-586;Men;279 BALEARS, ILLES;Group 1402 Renal failure 5836-5837, 584-586;Women;180 BALEARS, ILLES;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.783 BALEARS, ILLES;Group 1403 Urolithiasis 592, 594, 7880;Men;1.082 BALEARS, ILLES;Group 1403 Urolithiasis 592, 594, 7880;Women;700 BALEARS, ILLES;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2.403 BALEARS, ILLES;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.147 BALEARS, ILLES;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.256 BALEARS, ILLES;Group 1405 Prostatic hyperplasia 600;Both sexes;614 BALEARS, ILLES;Group 1405 Prostatic hyperplasia 600;Men;614 BALEARS, ILLES;Group 1405 Prostatic hyperplasia 600;Women;.. BALEARS, ILLES;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;666 BALEARS, ILLES;Group 1406 Other diseases of the male genital organs 601-608;Men;666 BALEARS, ILLES;Group 1406 Other diseases of the male genital organs 601-608;Women;.. BALEARS, ILLES;Group 1407 Disorders of breast 610-612;Both sexes;378 BALEARS, ILLES;Group 1407 Disorders of breast 610-612;Men;57 BALEARS, ILLES;Group 1407 Disorders of breast 610-612;Women;321 BALEARS, ILLES;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;224 BALEARS, ILLES;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. BALEARS, ILLES;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;224 BALEARS, ILLES;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;97 BALEARS, ILLES;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. BALEARS, ILLES;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;97 BALEARS, ILLES;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.079 BALEARS, ILLES;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;27 BALEARS, ILLES;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.052 BALEARS, ILLES;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;11.381 BALEARS, ILLES;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. BALEARS, ILLES;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;11.381 BALEARS, ILLES;Group 1501 Legally induced abortion 635;Both sexes;187 BALEARS, ILLES;Group 1501 Legally induced abortion 635;Men;.. BALEARS, ILLES;Group 1501 Legally induced abortion 635;Women;187 BALEARS, ILLES;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;524 BALEARS, ILLES;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. BALEARS, ILLES;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;524 BALEARS, ILLES;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;5.053 BALEARS, ILLES;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. BALEARS, ILLES;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;5.053 BALEARS, ILLES;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2.831 BALEARS, ILLES;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. BALEARS, ILLES;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2.831 BALEARS, ILLES;Group 1505 Single spontaneous delivery 650;Both sexes;1.655 BALEARS, ILLES;Group 1505 Single spontaneous delivery 650;Men;.. BALEARS, ILLES;Group 1505 Single spontaneous delivery 650;Women;1.655 BALEARS, ILLES;Group 1506 Other deliveries 6695-6697;Both sexes;508 BALEARS, ILLES;Group 1506 Other deliveries 6695-6697;Men;.. BALEARS, ILLES;Group 1506 Other deliveries 6695-6697;Women;508 BALEARS, ILLES;Group 1507 Complications related to the puerperium 670-676;Both sexes;83 BALEARS, ILLES;Group 1507 Complications related to the puerperium 670-676;Men;.. BALEARS, ILLES;Group 1507 Complications related to the puerperium 670-676;Women;83 BALEARS, ILLES;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;540 BALEARS, ILLES;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. BALEARS, ILLES;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;540 BALEARS, ILLES;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.582 BALEARS, ILLES;Group 1600 Some disorders originating in the perinatal period 760-779;Men;914 BALEARS, ILLES;Group 1600 Some disorders originating in the perinatal period 760-779;Women;668 BALEARS, ILLES;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;313 BALEARS, ILLES;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;188 BALEARS, ILLES;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;125 BALEARS, ILLES;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.269 BALEARS, ILLES;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;726 BALEARS, ILLES;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;544 BALEARS, ILLES;Grupo 1700 Congenital abnormalities 740-759;Both sexes;754 BALEARS, ILLES;Grupo 1700 Congenital abnormalities 740-759;Men;422 BALEARS, ILLES;Grupo 1700 Congenital abnormalities 740-759;Women;332 BALEARS, ILLES;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;9.763 BALEARS, ILLES;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4.923 BALEARS, ILLES;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;4.840 BALEARS, ILLES;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.044 BALEARS, ILLES;Group 1801 Pain in throat and chest 7841, 7865;Men;586 BALEARS, ILLES;Group 1801 Pain in throat and chest 7841, 7865;Women;458 BALEARS, ILLES;Group 1802 Abdominal pain 7890;Both sexes;1.482 BALEARS, ILLES;Group 1802 Abdominal pain 7890;Men;545 BALEARS, ILLES;Group 1802 Abdominal pain 7890;Women;938 BALEARS, ILLES;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.425 BALEARS, ILLES;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;678 BALEARS, ILLES;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;747 BALEARS, ILLES;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5.812 BALEARS, ILLES;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;3.114 BALEARS, ILLES;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.697 BALEARS, ILLES;Group 1900 Injuries and poisoning 800-999;Both sexes;12.547 BALEARS, ILLES;Group 1900 Injuries and poisoning 800-999;Men;6.486 BALEARS, ILLES;Group 1900 Injuries and poisoning 800-999;Women;6.062 BALEARS, ILLES;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1.034 BALEARS, ILLES;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;586 BALEARS, ILLES;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;448 BALEARS, ILLES;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;405 BALEARS, ILLES;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;282 BALEARS, ILLES;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;123 BALEARS, ILLES;Group 1903 Radius and ulna fracture 813;Both sexes;809 BALEARS, ILLES;Group 1903 Radius and ulna fracture 813;Men;329 BALEARS, ILLES;Group 1903 Radius and ulna fracture 813;Women;480 BALEARS, ILLES;Group 1904 Femur fracture 820-821;Both sexes;1.634 BALEARS, ILLES;Group 1904 Femur fracture 820-821;Men;534 BALEARS, ILLES;Group 1904 Femur fracture 820-821;Women;1.100 BALEARS, ILLES;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;924 BALEARS, ILLES;Group 1905 Leg fracture, including the ankle 823-824;Men;433 BALEARS, ILLES;Group 1905 Leg fracture, including the ankle 823-824;Women;491 BALEARS, ILLES;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;4.955 BALEARS, ILLES;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.838 BALEARS, ILLES;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2.117 BALEARS, ILLES;Group 1907 Burns 940-949;Both sexes;104 BALEARS, ILLES;Group 1907 Burns 940-949;Men;65 BALEARS, ILLES;Group 1907 Burns 940-949;Women;39 BALEARS, ILLES;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;371 BALEARS, ILLES;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;173 BALEARS, ILLES;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;198 BALEARS, ILLES;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.811 BALEARS, ILLES;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;965 BALEARS, ILLES;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;846 BALEARS, ILLES;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;9 BALEARS, ILLES;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;1 BALEARS, ILLES;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;8 BALEARS, ILLES;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;491 BALEARS, ILLES;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;280 BALEARS, ILLES;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;211 BALEARS, ILLES;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.176 BALEARS, ILLES;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;907 BALEARS, ILLES;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.269 BALEARS, ILLES;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;168 BALEARS, ILLES;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;71 BALEARS, ILLES;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;96 BALEARS, ILLES;Group 2102 Contraceptive management V25;Both sexes;43 BALEARS, ILLES;Group 2102 Contraceptive management V25;Men;5 BALEARS, ILLES;Group 2102 Contraceptive management V25;Women;38 BALEARS, ILLES;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. BALEARS, ILLES;Group 2103 Living newborns by type of delivery V30-V39;Men;.. BALEARS, ILLES;Group 2103 Living newborns by type of delivery V30-V39;Women;.. BALEARS, ILLES;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;268 BALEARS, ILLES;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;164 BALEARS, ILLES;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;104 BALEARS, ILLES;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.696 BALEARS, ILLES;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;667 BALEARS, ILLES;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.030 CANARIAS;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;179.647 CANARIAS;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;83.329 CANARIAS;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;96.318 CANARIAS;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3.532 CANARIAS;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.924 CANARIAS;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.607 CANARIAS;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;419 CANARIAS;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;206 CANARIAS;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;213 CANARIAS;Group 0102 Imprecise intestinal infections 009;Both sexes;189 CANARIAS;Group 0102 Imprecise intestinal infections 009;Men;75 CANARIAS;Group 0102 Imprecise intestinal infections 009;Women;114 CANARIAS;Group 0103 Tuberculosis 010-018, 137;Both sexes;84 CANARIAS;Group 0103 Tuberculosis 010-018, 137;Men;61 CANARIAS;Group 0103 Tuberculosis 010-018, 137;Women;23 CANARIAS;Group 0104 Septicaemia 038;Both sexes;1.588 CANARIAS;Group 0104 Septicaemia 038;Men;847 CANARIAS;Group 0104 Septicaemia 038;Women;740 CANARIAS;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;123 CANARIAS;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;102 CANARIAS;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;21 CANARIAS;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.129 CANARIAS;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;633 CANARIAS;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;496 CANARIAS;Group 0200 Neoplasms 140-239;Both sexes;16.655 CANARIAS;Group 0200 Neoplasms 140-239;Men;8.239 CANARIAS;Group 0200 Neoplasms 140-239;Women;8.416 CANARIAS;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.506 CANARIAS;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;888 CANARIAS;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;618 CANARIAS;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.165 CANARIAS;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;848 CANARIAS;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;317 CANARIAS;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;405 CANARIAS;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;221 CANARIAS;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;184 CANARIAS;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.370 CANARIAS;Group 0204 Malignant neoplasm of breast 174-175;Men;11 CANARIAS;Group 0204 Malignant neoplasm of breast 174-175;Women;1.359 CANARIAS;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;441 CANARIAS;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CANARIAS;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;441 CANARIAS;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;165 CANARIAS;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CANARIAS;Group 0206 Malignant neoplasm of ovary 1830;Women;165 CANARIAS;Group 0207 Malignant neoplasm of prostate 185;Both sexes;692 CANARIAS;Group 0207 Malignant neoplasm of prostate 185;Men;692 CANARIAS;Group 0207 Malignant neoplasm of prostate 185;Women;.. CANARIAS;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.143 CANARIAS;Group 0208 Malignant neoplasm of bladder 188;Men;960 CANARIAS;Group 0208 Malignant neoplasm of bladder 188;Women;183 CANARIAS;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5.720 CANARIAS;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3.241 CANARIAS;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2.479 CANARIAS;Group 0210 Carcinoma in situ 230-234;Both sexes;365 CANARIAS;Group 0210 Carcinoma in situ 230-234;Men;115 CANARIAS;Group 0210 Carcinoma in situ 230-234;Women;250 CANARIAS;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;220 CANARIAS;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;131 CANARIAS;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;89 CANARIAS;Grupo 0212 Leiomyoma of uterus 218;Both sexes;926 CANARIAS;Grupo 0212 Leiomyoma of uterus 218;Men;.. CANARIAS;Grupo 0212 Leiomyoma of uterus 218;Women;926 CANARIAS;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2.537 CANARIAS;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.132 CANARIAS;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.405 CANARIAS;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.285 CANARIAS;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;590 CANARIAS;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;695 CANARIAS;Group 0301 Anaemias 280-285;Both sexes;678 CANARIAS;Group 0301 Anaemias 280-285;Men;309 CANARIAS;Group 0301 Anaemias 280-285;Women;369 CANARIAS;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;607 CANARIAS;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;281 CANARIAS;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;326 CANARIAS;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;4.337 CANARIAS;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.707 CANARIAS;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2.630 CANARIAS;Group 0401 Diabetes mellitus 249-250;Both sexes;1.240 CANARIAS;Group 0401 Diabetes mellitus 249-250;Men;707 CANARIAS;Group 0401 Diabetes mellitus 249-250;Women;533 CANARIAS;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;3.097 CANARIAS;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;1.000 CANARIAS;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;2.097 CANARIAS;Group 0500 Mental disorders 290-319;Both sexes;3.663 CANARIAS;Group 0500 Mental disorders 290-319;Men;2.016 CANARIAS;Group 0500 Mental disorders 290-319;Women;1.647 CANARIAS;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;80 CANARIAS;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;36 CANARIAS;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;44 CANARIAS;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;403 CANARIAS;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;330 CANARIAS;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;73 CANARIAS;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;429 CANARIAS;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;340 CANARIAS;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;89 CANARIAS;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.153 CANARIAS;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;669 CANARIAS;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;484 CANARIAS;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;855 CANARIAS;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;326 CANARIAS;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;529 CANARIAS;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;743 CANARIAS;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;315 CANARIAS;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;428 CANARIAS;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3.983 CANARIAS;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.106 CANARIAS;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.876 CANARIAS;Group 0601 Alzheimer's disease 3310;Both sexes;60 CANARIAS;Group 0601 Alzheimer's disease 3310;Men;19 CANARIAS;Group 0601 Alzheimer's disease 3310;Women;41 CANARIAS;Group 0602 Multiple sclerosis 340;Both sexes;204 CANARIAS;Group 0602 Multiple sclerosis 340;Men;61 CANARIAS;Group 0602 Multiple sclerosis 340;Women;143 CANARIAS;Group 0603 Epilepsy 345;Both sexes;445 CANARIAS;Group 0603 Epilepsy 345;Men;222 CANARIAS;Group 0603 Epilepsy 345;Women;223 CANARIAS;Group 0604 Transient cerebral ischemia 435;Both sexes;456 CANARIAS;Group 0604 Transient cerebral ischemia 435;Men;245 CANARIAS;Group 0604 Transient cerebral ischemia 435;Women;211 CANARIAS;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;2.817 CANARIAS;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.559 CANARIAS;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.258 CANARIAS;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1.148 CANARIAS;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;559 CANARIAS;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;589 CANARIAS;Grupo 0701 Cataract 366;Both sexes;132 CANARIAS;Grupo 0701 Cataract 366;Men;67 CANARIAS;Grupo 0701 Cataract 366;Women;65 CANARIAS;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;1.016 CANARIAS;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;492 CANARIAS;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;524 CANARIAS;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;996 CANARIAS;Group 0800 Diseases of the ear and the mastoid 380-389;Men;479 CANARIAS;Group 0800 Diseases of the ear and the mastoid 380-389;Women;517 CANARIAS;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;23.066 CANARIAS;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;13.118 CANARIAS;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;9.948 CANARIAS;Group 0901 Hypertensive disease 401-405;Both sexes;1.534 CANARIAS;Group 0901 Hypertensive disease 401-405;Men;688 CANARIAS;Group 0901 Hypertensive disease 401-405;Women;846 CANARIAS;Group 0902 Angina pectoris 4111, 413;Both sexes;830 CANARIAS;Group 0902 Angina pectoris 4111, 413;Men;508 CANARIAS;Group 0902 Angina pectoris 4111, 413;Women;322 CANARIAS;Group 0903 Acute myocardial infarction 410;Both sexes;2.686 CANARIAS;Group 0903 Acute myocardial infarction 410;Men;1.919 CANARIAS;Group 0903 Acute myocardial infarction 410;Women;767 CANARIAS;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.685 CANARIAS;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.245 CANARIAS;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;440 CANARIAS;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;528 CANARIAS;Group 0905 Diseases of the lungs circulation 415-417;Men;202 CANARIAS;Group 0905 Diseases of the lungs circulation 415-417;Women;326 CANARIAS;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.760 CANARIAS;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.595 CANARIAS;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.164 CANARIAS;Grupo 0907 Heart failure 428;Both sexes;3.390 CANARIAS;Grupo 0907 Heart failure 428;Men;1.671 CANARIAS;Grupo 0907 Heart failure 428;Women;1.719 CANARIAS;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3.661 CANARIAS;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;2.019 CANARIAS;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.642 CANARIAS;Grupo 0909 Atherosclerosis 440;Both sexes;804 CANARIAS;Grupo 0909 Atherosclerosis 440;Men;574 CANARIAS;Grupo 0909 Atherosclerosis 440;Women;230 CANARIAS;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.185 CANARIAS;Group 0910 Varicose veins of lower extremities 454;Men;380 CANARIAS;Group 0910 Varicose veins of lower extremities 454;Women;805 CANARIAS;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;4.003 CANARIAS;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;2.316 CANARIAS;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.687 CANARIAS;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;19.271 CANARIAS;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;10.456 CANARIAS;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;8.816 CANARIAS;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;894 CANARIAS;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;476 CANARIAS;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;418 CANARIAS;Group 1002 Pneumonia 480-486;Both sexes;4.705 CANARIAS;Group 1002 Pneumonia 480-486;Men;2.581 CANARIAS;Group 1002 Pneumonia 480-486;Women;2.124 CANARIAS;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2.159 CANARIAS;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1.025 CANARIAS;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.134 CANARIAS;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1.550 CANARIAS;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;791 CANARIAS;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;759 CANARIAS;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.852 CANARIAS;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1.159 CANARIAS;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;693 CANARIAS;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.137 CANARIAS;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.441 CANARIAS;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;696 CANARIAS;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;788 CANARIAS;Group 1007 Asthma 4930-4931,4938-4939;Men;295 CANARIAS;Group 1007 Asthma 4930-4931,4938-4939;Women;493 CANARIAS;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5.186 CANARIAS;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.687 CANARIAS;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2.498 CANARIAS;Group 1100 Diseases of the digestive system 520-579;Both sexes;22.932 CANARIAS;Group 1100 Diseases of the digestive system 520-579;Men;12.858 CANARIAS;Group 1100 Diseases of the digestive system 520-579;Women;10.073 CANARIAS;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;485 CANARIAS;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;210 CANARIAS;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;275 CANARIAS;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;318 CANARIAS;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;170 CANARIAS;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;148 CANARIAS;Group 1103 Diseases of the esophagus 530;Both sexes;388 CANARIAS;Group 1103 Diseases of the esophagus 530;Men;215 CANARIAS;Group 1103 Diseases of the esophagus 530;Women;173 CANARIAS;Group 1104 Peptic ulcer 531-534;Both sexes;407 CANARIAS;Group 1104 Peptic ulcer 531-534;Men;298 CANARIAS;Group 1104 Peptic ulcer 531-534;Women;109 CANARIAS;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;600 CANARIAS;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;294 CANARIAS;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;306 CANARIAS;Group 1106 Appendicitis 540-543;Both sexes;1.788 CANARIAS;Group 1106 Appendicitis 540-543;Men;1.089 CANARIAS;Group 1106 Appendicitis 540-543;Women;699 CANARIAS;Group 1107 Inguinal hernia 550;Both sexes;2.768 CANARIAS;Group 1107 Inguinal hernia 550;Men;2.516 CANARIAS;Group 1107 Inguinal hernia 550;Women;252 CANARIAS;Group 1108 Other abdominal hernia 551-553;Both sexes;2.366 CANARIAS;Group 1108 Other abdominal hernia 551-553;Men;1.281 CANARIAS;Group 1108 Other abdominal hernia 551-553;Women;1.085 CANARIAS;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;454 CANARIAS;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;222 CANARIAS;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;232 CANARIAS;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.797 CANARIAS;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;818 CANARIAS;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;979 CANARIAS;Group 1111 Intestinal obstruction without hernia 560;Both sexes;827 CANARIAS;Group 1111 Intestinal obstruction without hernia 560;Men;419 CANARIAS;Group 1111 Intestinal obstruction without hernia 560;Women;408 CANARIAS;Group 1112 Intestinal diverticulosis 562;Both sexes;1.028 CANARIAS;Group 1112 Intestinal diverticulosis 562;Men;523 CANARIAS;Group 1112 Intestinal diverticulosis 562;Women;505 CANARIAS;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.122 CANARIAS;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;743 CANARIAS;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;379 CANARIAS;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;774 CANARIAS;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;349 CANARIAS;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;425 CANARIAS;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;616 CANARIAS;Group 1115 Alcoholic hepatitis 5710-5713;Men;528 CANARIAS;Group 1115 Alcoholic hepatitis 5710-5713;Women;88 CANARIAS;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;711 CANARIAS;Group 1116 Other diseases of the liver 570,5714-573;Men;399 CANARIAS;Group 1116 Other diseases of the liver 570,5714-573;Women;312 CANARIAS;Group 1117 Cholelithiasis 574;Both sexes;3.859 CANARIAS;Group 1117 Cholelithiasis 574;Men;1.415 CANARIAS;Group 1117 Cholelithiasis 574;Women;2.444 CANARIAS;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;948 CANARIAS;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;447 CANARIAS;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;501 CANARIAS;Group 1119 Pancreatic diseases 577;Both sexes;1.057 CANARIAS;Group 1119 Pancreatic diseases 577;Men;600 CANARIAS;Group 1119 Pancreatic diseases 577;Women;457 CANARIAS;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;618 CANARIAS;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;322 CANARIAS;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;296 CANARIAS;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;2.566 CANARIAS;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1.405 CANARIAS;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1.161 CANARIAS;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.737 CANARIAS;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;1.045 CANARIAS;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;692 CANARIAS;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;94 CANARIAS;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;45 CANARIAS;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;49 CANARIAS;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;735 CANARIAS;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;315 CANARIAS;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;420 CANARIAS;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;12.846 CANARIAS;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;6.235 CANARIAS;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;6.611 CANARIAS;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CANARIAS;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CANARIAS;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CANARIAS;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CANARIAS;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CANARIAS;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CANARIAS;Group 1303 Internal derangement of knee 717;Both sexes;1.948 CANARIAS;Group 1303 Internal derangement of knee 717;Men;1.338 CANARIAS;Group 1303 Internal derangement of knee 717;Women;610 CANARIAS;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;4.513 CANARIAS;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.793 CANARIAS;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.720 CANARIAS;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;297 CANARIAS;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;70 CANARIAS;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;227 CANARIAS;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;651 CANARIAS;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;336 CANARIAS;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;315 CANARIAS;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.725 CANARIAS;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;922 CANARIAS;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;803 CANARIAS;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;376 CANARIAS;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;168 CANARIAS;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;208 CANARIAS;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.746 CANARIAS;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;955 CANARIAS;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;791 CANARIAS;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.590 CANARIAS;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;653 CANARIAS;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;937 CANARIAS;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;10.772 CANARIAS;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4.138 CANARIAS;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;6.633 CANARIAS;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;977 CANARIAS;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;373 CANARIAS;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;604 CANARIAS;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;634 CANARIAS;Group 1402 Renal failure 5836-5837, 584-586;Men;352 CANARIAS;Group 1402 Renal failure 5836-5837, 584-586;Women;282 CANARIAS;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.123 CANARIAS;Group 1403 Urolithiasis 592, 594, 7880;Men;630 CANARIAS;Group 1403 Urolithiasis 592, 594, 7880;Women;493 CANARIAS;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2.884 CANARIAS;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.224 CANARIAS;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.660 CANARIAS;Group 1405 Prostatic hyperplasia 600;Both sexes;768 CANARIAS;Group 1405 Prostatic hyperplasia 600;Men;768 CANARIAS;Group 1405 Prostatic hyperplasia 600;Women;.. CANARIAS;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;647 CANARIAS;Group 1406 Other diseases of the male genital organs 601-608;Men;647 CANARIAS;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CANARIAS;Group 1407 Disorders of breast 610-612;Both sexes;1.131 CANARIAS;Group 1407 Disorders of breast 610-612;Men;127 CANARIAS;Group 1407 Disorders of breast 610-612;Women;1.004 CANARIAS;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;422 CANARIAS;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CANARIAS;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;422 CANARIAS;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;156 CANARIAS;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CANARIAS;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;156 CANARIAS;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;2.029 CANARIAS;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;17 CANARIAS;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;2.012 CANARIAS;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;19.133 CANARIAS;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CANARIAS;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;19.133 CANARIAS;Group 1501 Legally induced abortion 635;Both sexes;182 CANARIAS;Group 1501 Legally induced abortion 635;Men;.. CANARIAS;Group 1501 Legally induced abortion 635;Women;182 CANARIAS;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;958 CANARIAS;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CANARIAS;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;958 CANARIAS;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;13.150 CANARIAS;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CANARIAS;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;13.150 CANARIAS;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3.085 CANARIAS;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CANARIAS;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3.085 CANARIAS;Group 1505 Single spontaneous delivery 650;Both sexes;412 CANARIAS;Group 1505 Single spontaneous delivery 650;Men;.. CANARIAS;Group 1505 Single spontaneous delivery 650;Women;412 CANARIAS;Group 1506 Other deliveries 6695-6697;Both sexes;129 CANARIAS;Group 1506 Other deliveries 6695-6697;Men;.. CANARIAS;Group 1506 Other deliveries 6695-6697;Women;129 CANARIAS;Group 1507 Complications related to the puerperium 670-676;Both sexes;83 CANARIAS;Group 1507 Complications related to the puerperium 670-676;Men;.. CANARIAS;Group 1507 Complications related to the puerperium 670-676;Women;83 CANARIAS;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.134 CANARIAS;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CANARIAS;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.134 CANARIAS;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.600 CANARIAS;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.492 CANARIAS;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1.108 CANARIAS;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;696 CANARIAS;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;364 CANARIAS;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;332 CANARIAS;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.904 CANARIAS;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1.128 CANARIAS;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;776 CANARIAS;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.486 CANARIAS;Grupo 1700 Congenital abnormalities 740-759;Men;880 CANARIAS;Grupo 1700 Congenital abnormalities 740-759;Women;606 CANARIAS;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;8.052 CANARIAS;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4.223 CANARIAS;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3.829 CANARIAS;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;847 CANARIAS;Group 1801 Pain in throat and chest 7841, 7865;Men;485 CANARIAS;Group 1801 Pain in throat and chest 7841, 7865;Women;362 CANARIAS;Group 1802 Abdominal pain 7890;Both sexes;694 CANARIAS;Group 1802 Abdominal pain 7890;Men;268 CANARIAS;Group 1802 Abdominal pain 7890;Women;426 CANARIAS;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.400 CANARIAS;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;689 CANARIAS;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;711 CANARIAS;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5.111 CANARIAS;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.781 CANARIAS;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.330 CANARIAS;Group 1900 Injuries and poisoning 800-999;Both sexes;17.029 CANARIAS;Group 1900 Injuries and poisoning 800-999;Men;9.066 CANARIAS;Group 1900 Injuries and poisoning 800-999;Women;7.963 CANARIAS;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1.151 CANARIAS;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;672 CANARIAS;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;479 CANARIAS;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;684 CANARIAS;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;466 CANARIAS;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;218 CANARIAS;Group 1903 Radius and ulna fracture 813;Both sexes;1.281 CANARIAS;Group 1903 Radius and ulna fracture 813;Men;541 CANARIAS;Group 1903 Radius and ulna fracture 813;Women;740 CANARIAS;Group 1904 Femur fracture 820-821;Both sexes;2.006 CANARIAS;Group 1904 Femur fracture 820-821;Men;623 CANARIAS;Group 1904 Femur fracture 820-821;Women;1.383 CANARIAS;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.612 CANARIAS;Group 1905 Leg fracture, including the ankle 823-824;Men;767 CANARIAS;Group 1905 Leg fracture, including the ankle 823-824;Women;845 CANARIAS;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;4.807 CANARIAS;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.933 CANARIAS;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.874 CANARIAS;Group 1907 Burns 940-949;Both sexes;136 CANARIAS;Group 1907 Burns 940-949;Men;86 CANARIAS;Group 1907 Burns 940-949;Women;50 CANARIAS;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;311 CANARIAS;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;151 CANARIAS;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;160 CANARIAS;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;4.588 CANARIAS;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;2.584 CANARIAS;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;2.004 CANARIAS;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;29 CANARIAS;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;22 CANARIAS;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;7 CANARIAS;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;424 CANARIAS;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;221 CANARIAS;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;203 CANARIAS;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;4.294 CANARIAS;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.836 CANARIAS;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2.458 CANARIAS;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;326 CANARIAS;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;169 CANARIAS;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;157 CANARIAS;Group 2102 Contraceptive management V25;Both sexes;248 CANARIAS;Group 2102 Contraceptive management V25;Men;5 CANARIAS;Group 2102 Contraceptive management V25;Women;243 CANARIAS;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CANARIAS;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CANARIAS;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CANARIAS;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1.402 CANARIAS;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;802 CANARIAS;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;600 CANARIAS;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2.318 CANARIAS;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;860 CANARIAS;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.458 Palmas, Las;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;84.283 Palmas, Las;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;39.118 Palmas, Las;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;45.165 Palmas, Las;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.552 Palmas, Las;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;886 Palmas, Las;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;666 Palmas, Las;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;262 Palmas, Las;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;134 Palmas, Las;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;128 Palmas, Las;Group 0102 Imprecise intestinal infections 009;Both sexes;68 Palmas, Las;Group 0102 Imprecise intestinal infections 009;Men;26 Palmas, Las;Group 0102 Imprecise intestinal infections 009;Women;42 Palmas, Las;Group 0103 Tuberculosis 010-018, 137;Both sexes;60 Palmas, Las;Group 0103 Tuberculosis 010-018, 137;Men;48 Palmas, Las;Group 0103 Tuberculosis 010-018, 137;Women;12 Palmas, Las;Group 0104 Septicaemia 038;Both sexes;613 Palmas, Las;Group 0104 Septicaemia 038;Men;328 Palmas, Las;Group 0104 Septicaemia 038;Women;285 Palmas, Las;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;62 Palmas, Las;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;51 Palmas, Las;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;11 Palmas, Las;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;487 Palmas, Las;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;299 Palmas, Las;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;188 Palmas, Las;Group 0200 Neoplasms 140-239;Both sexes;7.869 Palmas, Las;Group 0200 Neoplasms 140-239;Men;3.905 Palmas, Las;Group 0200 Neoplasms 140-239;Women;3.964 Palmas, Las;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;693 Palmas, Las;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;408 Palmas, Las;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;285 Palmas, Las;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;596 Palmas, Las;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;435 Palmas, Las;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;161 Palmas, Las;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;159 Palmas, Las;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;97 Palmas, Las;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;62 Palmas, Las;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;596 Palmas, Las;Group 0204 Malignant neoplasm of breast 174-175;Men;5 Palmas, Las;Group 0204 Malignant neoplasm of breast 174-175;Women;591 Palmas, Las;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;252 Palmas, Las;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Palmas, Las;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;252 Palmas, Las;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;76 Palmas, Las;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Palmas, Las;Group 0206 Malignant neoplasm of ovary 1830;Women;76 Palmas, Las;Group 0207 Malignant neoplasm of prostate 185;Both sexes;235 Palmas, Las;Group 0207 Malignant neoplasm of prostate 185;Men;235 Palmas, Las;Group 0207 Malignant neoplasm of prostate 185;Women;.. Palmas, Las;Group 0208 Malignant neoplasm of bladder 188;Both sexes;495 Palmas, Las;Group 0208 Malignant neoplasm of bladder 188;Men;419 Palmas, Las;Group 0208 Malignant neoplasm of bladder 188;Women;76 Palmas, Las;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.712 Palmas, Las;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.543 Palmas, Las;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.169 Palmas, Las;Group 0210 Carcinoma in situ 230-234;Both sexes;200 Palmas, Las;Group 0210 Carcinoma in situ 230-234;Men;82 Palmas, Las;Group 0210 Carcinoma in situ 230-234;Women;118 Palmas, Las;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;109 Palmas, Las;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;69 Palmas, Las;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;40 Palmas, Las;Grupo 0212 Leiomyoma of uterus 218;Both sexes;448 Palmas, Las;Grupo 0212 Leiomyoma of uterus 218;Men;.. Palmas, Las;Grupo 0212 Leiomyoma of uterus 218;Women;448 Palmas, Las;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.298 Palmas, Las;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;612 Palmas, Las;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;686 Palmas, Las;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;520 Palmas, Las;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;233 Palmas, Las;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;287 Palmas, Las;Group 0301 Anaemias 280-285;Both sexes;262 Palmas, Las;Group 0301 Anaemias 280-285;Men;120 Palmas, Las;Group 0301 Anaemias 280-285;Women;142 Palmas, Las;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;258 Palmas, Las;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;113 Palmas, Las;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;145 Palmas, Las;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2.056 Palmas, Las;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;867 Palmas, Las;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.189 Palmas, Las;Group 0401 Diabetes mellitus 249-250;Both sexes;681 Palmas, Las;Group 0401 Diabetes mellitus 249-250;Men;410 Palmas, Las;Group 0401 Diabetes mellitus 249-250;Women;271 Palmas, Las;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.375 Palmas, Las;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;457 Palmas, Las;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;918 Palmas, Las;Group 0500 Mental disorders 290-319;Both sexes;1.906 Palmas, Las;Group 0500 Mental disorders 290-319;Men;1.016 Palmas, Las;Group 0500 Mental disorders 290-319;Women;890 Palmas, Las;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;54 Palmas, Las;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;27 Palmas, Las;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;27 Palmas, Las;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;130 Palmas, Las;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;109 Palmas, Las;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;21 Palmas, Las;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;146 Palmas, Las;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;111 Palmas, Las;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;35 Palmas, Las;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;664 Palmas, Las;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;388 Palmas, Las;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;276 Palmas, Las;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;485 Palmas, Las;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;190 Palmas, Las;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;295 Palmas, Las;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;427 Palmas, Las;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;191 Palmas, Las;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;236 Palmas, Las;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.470 Palmas, Las;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;794 Palmas, Las;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;676 Palmas, Las;Group 0601 Alzheimer's disease 3310;Both sexes;20 Palmas, Las;Group 0601 Alzheimer's disease 3310;Men;10 Palmas, Las;Group 0601 Alzheimer's disease 3310;Women;10 Palmas, Las;Group 0602 Multiple sclerosis 340;Both sexes;29 Palmas, Las;Group 0602 Multiple sclerosis 340;Men;6 Palmas, Las;Group 0602 Multiple sclerosis 340;Women;23 Palmas, Las;Group 0603 Epilepsy 345;Both sexes;188 Palmas, Las;Group 0603 Epilepsy 345;Men;95 Palmas, Las;Group 0603 Epilepsy 345;Women;93 Palmas, Las;Group 0604 Transient cerebral ischemia 435;Both sexes;192 Palmas, Las;Group 0604 Transient cerebral ischemia 435;Men;107 Palmas, Las;Group 0604 Transient cerebral ischemia 435;Women;85 Palmas, Las;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.041 Palmas, Las;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;576 Palmas, Las;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;465 Palmas, Las;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;326 Palmas, Las;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;151 Palmas, Las;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;175 Palmas, Las;Grupo 0701 Cataract 366;Both sexes;25 Palmas, Las;Grupo 0701 Cataract 366;Men;16 Palmas, Las;Grupo 0701 Cataract 366;Women;9 Palmas, Las;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;301 Palmas, Las;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;135 Palmas, Las;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;166 Palmas, Las;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;521 Palmas, Las;Group 0800 Diseases of the ear and the mastoid 380-389;Men;249 Palmas, Las;Group 0800 Diseases of the ear and the mastoid 380-389;Women;272 Palmas, Las;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;11.152 Palmas, Las;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;6.334 Palmas, Las;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4.818 Palmas, Las;Group 0901 Hypertensive disease 401-405;Both sexes;766 Palmas, Las;Group 0901 Hypertensive disease 401-405;Men;357 Palmas, Las;Group 0901 Hypertensive disease 401-405;Women;409 Palmas, Las;Group 0902 Angina pectoris 4111, 413;Both sexes;437 Palmas, Las;Group 0902 Angina pectoris 4111, 413;Men;262 Palmas, Las;Group 0902 Angina pectoris 4111, 413;Women;175 Palmas, Las;Group 0903 Acute myocardial infarction 410;Both sexes;1.582 Palmas, Las;Group 0903 Acute myocardial infarction 410;Men;1.134 Palmas, Las;Group 0903 Acute myocardial infarction 410;Women;448 Palmas, Las;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;757 Palmas, Las;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;555 Palmas, Las;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;202 Palmas, Las;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;275 Palmas, Las;Group 0905 Diseases of the lungs circulation 415-417;Men;100 Palmas, Las;Group 0905 Diseases of the lungs circulation 415-417;Women;175 Palmas, Las;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.228 Palmas, Las;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;686 Palmas, Las;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;542 Palmas, Las;Grupo 0907 Heart failure 428;Both sexes;1.675 Palmas, Las;Grupo 0907 Heart failure 428;Men;807 Palmas, Las;Grupo 0907 Heart failure 428;Women;868 Palmas, Las;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.683 Palmas, Las;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;954 Palmas, Las;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;729 Palmas, Las;Grupo 0909 Atherosclerosis 440;Both sexes;400 Palmas, Las;Grupo 0909 Atherosclerosis 440;Men;285 Palmas, Las;Grupo 0909 Atherosclerosis 440;Women;115 Palmas, Las;Group 0910 Varicose veins of lower extremities 454;Both sexes;576 Palmas, Las;Group 0910 Varicose veins of lower extremities 454;Men;179 Palmas, Las;Group 0910 Varicose veins of lower extremities 454;Women;397 Palmas, Las;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.773 Palmas, Las;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.015 Palmas, Las;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;758 Palmas, Las;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;8.389 Palmas, Las;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.654 Palmas, Las;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3.735 Palmas, Las;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;374 Palmas, Las;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;199 Palmas, Las;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;175 Palmas, Las;Group 1002 Pneumonia 480-486;Both sexes;2.194 Palmas, Las;Group 1002 Pneumonia 480-486;Men;1.203 Palmas, Las;Group 1002 Pneumonia 480-486;Women;991 Palmas, Las;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;865 Palmas, Las;Group 1003 Acute bronchitis and bronchiolitis 466;Men;415 Palmas, Las;Group 1003 Acute bronchitis and bronchiolitis 466;Women;450 Palmas, Las;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;701 Palmas, Las;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;380 Palmas, Las;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;321 Palmas, Las;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;925 Palmas, Las;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;579 Palmas, Las;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;346 Palmas, Las;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;901 Palmas, Las;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;632 Palmas, Las;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;269 Palmas, Las;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;438 Palmas, Las;Group 1007 Asthma 4930-4931,4938-4939;Men;167 Palmas, Las;Group 1007 Asthma 4930-4931,4938-4939;Women;271 Palmas, Las;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.991 Palmas, Las;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.079 Palmas, Las;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;912 Palmas, Las;Group 1100 Diseases of the digestive system 520-579;Both sexes;10.332 Palmas, Las;Group 1100 Diseases of the digestive system 520-579;Men;5.921 Palmas, Las;Group 1100 Diseases of the digestive system 520-579;Women;4.411 Palmas, Las;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;167 Palmas, Las;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;83 Palmas, Las;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;84 Palmas, Las;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;119 Palmas, Las;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;61 Palmas, Las;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;58 Palmas, Las;Group 1103 Diseases of the esophagus 530;Both sexes;181 Palmas, Las;Group 1103 Diseases of the esophagus 530;Men;97 Palmas, Las;Group 1103 Diseases of the esophagus 530;Women;84 Palmas, Las;Group 1104 Peptic ulcer 531-534;Both sexes;195 Palmas, Las;Group 1104 Peptic ulcer 531-534;Men;147 Palmas, Las;Group 1104 Peptic ulcer 531-534;Women;48 Palmas, Las;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;204 Palmas, Las;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;110 Palmas, Las;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;94 Palmas, Las;Group 1106 Appendicitis 540-543;Both sexes;930 Palmas, Las;Group 1106 Appendicitis 540-543;Men;572 Palmas, Las;Group 1106 Appendicitis 540-543;Women;358 Palmas, Las;Group 1107 Inguinal hernia 550;Both sexes;1.322 Palmas, Las;Group 1107 Inguinal hernia 550;Men;1.217 Palmas, Las;Group 1107 Inguinal hernia 550;Women;105 Palmas, Las;Group 1108 Other abdominal hernia 551-553;Both sexes;1.184 Palmas, Las;Group 1108 Other abdominal hernia 551-553;Men;647 Palmas, Las;Group 1108 Other abdominal hernia 551-553;Women;537 Palmas, Las;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;235 Palmas, Las;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;122 Palmas, Las;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;113 Palmas, Las;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;617 Palmas, Las;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;291 Palmas, Las;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;326 Palmas, Las;Group 1111 Intestinal obstruction without hernia 560;Both sexes;398 Palmas, Las;Group 1111 Intestinal obstruction without hernia 560;Men;201 Palmas, Las;Group 1111 Intestinal obstruction without hernia 560;Women;197 Palmas, Las;Group 1112 Intestinal diverticulosis 562;Both sexes;463 Palmas, Las;Group 1112 Intestinal diverticulosis 562;Men;242 Palmas, Las;Group 1112 Intestinal diverticulosis 562;Women;221 Palmas, Las;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;422 Palmas, Las;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;290 Palmas, Las;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;132 Palmas, Las;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;337 Palmas, Las;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;159 Palmas, Las;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;178 Palmas, Las;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;201 Palmas, Las;Group 1115 Alcoholic hepatitis 5710-5713;Men;164 Palmas, Las;Group 1115 Alcoholic hepatitis 5710-5713;Women;37 Palmas, Las;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;315 Palmas, Las;Group 1116 Other diseases of the liver 570,5714-573;Men;186 Palmas, Las;Group 1116 Other diseases of the liver 570,5714-573;Women;129 Palmas, Las;Group 1117 Cholelithiasis 574;Both sexes;1.840 Palmas, Las;Group 1117 Cholelithiasis 574;Men;641 Palmas, Las;Group 1117 Cholelithiasis 574;Women;1.199 Palmas, Las;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;378 Palmas, Las;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;213 Palmas, Las;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;165 Palmas, Las;Group 1119 Pancreatic diseases 577;Both sexes;568 Palmas, Las;Group 1119 Pancreatic diseases 577;Men;346 Palmas, Las;Group 1119 Pancreatic diseases 577;Women;222 Palmas, Las;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;256 Palmas, Las;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;132 Palmas, Las;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;124 Palmas, Las;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.083 Palmas, Las;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;590 Palmas, Las;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;493 Palmas, Las;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;649 Palmas, Las;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;410 Palmas, Las;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;239 Palmas, Las;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;30 Palmas, Las;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;12 Palmas, Las;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;18 Palmas, Las;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;404 Palmas, Las;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;168 Palmas, Las;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;236 Palmas, Las;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;6.147 Palmas, Las;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3.047 Palmas, Las;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.100 Palmas, Las;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Palmas, Las;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Palmas, Las;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Palmas, Las;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Palmas, Las;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Palmas, Las;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Palmas, Las;Group 1303 Internal derangement of knee 717;Both sexes;865 Palmas, Las;Group 1303 Internal derangement of knee 717;Men;653 Palmas, Las;Group 1303 Internal derangement of knee 717;Women;212 Palmas, Las;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.948 Palmas, Las;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;782 Palmas, Las;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.166 Palmas, Las;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;202 Palmas, Las;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;43 Palmas, Las;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;159 Palmas, Las;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;349 Palmas, Las;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;171 Palmas, Las;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;178 Palmas, Las;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.022 Palmas, Las;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;558 Palmas, Las;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;464 Palmas, Las;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;210 Palmas, Las;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;93 Palmas, Las;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;117 Palmas, Las;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;735 Palmas, Las;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;416 Palmas, Las;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;319 Palmas, Las;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;816 Palmas, Las;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;331 Palmas, Las;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;485 Palmas, Las;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;5.158 Palmas, Las;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.025 Palmas, Las;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3.133 Palmas, Las;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;512 Palmas, Las;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;202 Palmas, Las;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;310 Palmas, Las;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;346 Palmas, Las;Group 1402 Renal failure 5836-5837, 584-586;Men;186 Palmas, Las;Group 1402 Renal failure 5836-5837, 584-586;Women;160 Palmas, Las;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;448 Palmas, Las;Group 1403 Urolithiasis 592, 594, 7880;Men;247 Palmas, Las;Group 1403 Urolithiasis 592, 594, 7880;Women;201 Palmas, Las;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.097 Palmas, Las;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;486 Palmas, Las;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;611 Palmas, Las;Group 1405 Prostatic hyperplasia 600;Both sexes;465 Palmas, Las;Group 1405 Prostatic hyperplasia 600;Men;465 Palmas, Las;Group 1405 Prostatic hyperplasia 600;Women;.. Palmas, Las;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;355 Palmas, Las;Group 1406 Other diseases of the male genital organs 601-608;Men;355 Palmas, Las;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Palmas, Las;Group 1407 Disorders of breast 610-612;Both sexes;747 Palmas, Las;Group 1407 Disorders of breast 610-612;Men;77 Palmas, Las;Group 1407 Disorders of breast 610-612;Women;670 Palmas, Las;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;155 Palmas, Las;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Palmas, Las;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;155 Palmas, Las;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;76 Palmas, Las;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Palmas, Las;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;76 Palmas, Las;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;957 Palmas, Las;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;7 Palmas, Las;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;950 Palmas, Las;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;10.024 Palmas, Las;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Palmas, Las;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;10.024 Palmas, Las;Group 1501 Legally induced abortion 635;Both sexes;94 Palmas, Las;Group 1501 Legally induced abortion 635;Men;.. Palmas, Las;Group 1501 Legally induced abortion 635;Women;94 Palmas, Las;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;445 Palmas, Las;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Palmas, Las;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;445 Palmas, Las;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6.920 Palmas, Las;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Palmas, Las;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6.920 Palmas, Las;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.771 Palmas, Las;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Palmas, Las;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.771 Palmas, Las;Group 1505 Single spontaneous delivery 650;Both sexes;211 Palmas, Las;Group 1505 Single spontaneous delivery 650;Men;.. Palmas, Las;Group 1505 Single spontaneous delivery 650;Women;211 Palmas, Las;Group 1506 Other deliveries 6695-6697;Both sexes;104 Palmas, Las;Group 1506 Other deliveries 6695-6697;Men;.. Palmas, Las;Group 1506 Other deliveries 6695-6697;Women;104 Palmas, Las;Group 1507 Complications related to the puerperium 670-676;Both sexes;36 Palmas, Las;Group 1507 Complications related to the puerperium 670-676;Men;.. Palmas, Las;Group 1507 Complications related to the puerperium 670-676;Women;36 Palmas, Las;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;443 Palmas, Las;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Palmas, Las;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;443 Palmas, Las;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.393 Palmas, Las;Group 1600 Some disorders originating in the perinatal period 760-779;Men;823 Palmas, Las;Group 1600 Some disorders originating in the perinatal period 760-779;Women;570 Palmas, Las;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;339 Palmas, Las;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;188 Palmas, Las;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;151 Palmas, Las;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.054 Palmas, Las;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;635 Palmas, Las;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;419 Palmas, Las;Grupo 1700 Congenital abnormalities 740-759;Both sexes;845 Palmas, Las;Grupo 1700 Congenital abnormalities 740-759;Men;518 Palmas, Las;Grupo 1700 Congenital abnormalities 740-759;Women;327 Palmas, Las;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;4.291 Palmas, Las;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;2.239 Palmas, Las;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2.052 Palmas, Las;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;323 Palmas, Las;Group 1801 Pain in throat and chest 7841, 7865;Men;189 Palmas, Las;Group 1801 Pain in throat and chest 7841, 7865;Women;134 Palmas, Las;Group 1802 Abdominal pain 7890;Both sexes;270 Palmas, Las;Group 1802 Abdominal pain 7890;Men;95 Palmas, Las;Group 1802 Abdominal pain 7890;Women;175 Palmas, Las;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.153 Palmas, Las;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;578 Palmas, Las;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;575 Palmas, Las;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;2.545 Palmas, Las;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.377 Palmas, Las;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.168 Palmas, Las;Group 1900 Injuries and poisoning 800-999;Both sexes;7.535 Palmas, Las;Group 1900 Injuries and poisoning 800-999;Men;4.075 Palmas, Las;Group 1900 Injuries and poisoning 800-999;Women;3.460 Palmas, Las;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;584 Palmas, Las;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;341 Palmas, Las;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;243 Palmas, Las;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;191 Palmas, Las;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;139 Palmas, Las;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;52 Palmas, Las;Group 1903 Radius and ulna fracture 813;Both sexes;454 Palmas, Las;Group 1903 Radius and ulna fracture 813;Men;202 Palmas, Las;Group 1903 Radius and ulna fracture 813;Women;252 Palmas, Las;Group 1904 Femur fracture 820-821;Both sexes;916 Palmas, Las;Group 1904 Femur fracture 820-821;Men;311 Palmas, Las;Group 1904 Femur fracture 820-821;Women;605 Palmas, Las;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;760 Palmas, Las;Group 1905 Leg fracture, including the ankle 823-824;Men;389 Palmas, Las;Group 1905 Leg fracture, including the ankle 823-824;Women;371 Palmas, Las;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2.143 Palmas, Las;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.330 Palmas, Las;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;813 Palmas, Las;Group 1907 Burns 940-949;Both sexes;64 Palmas, Las;Group 1907 Burns 940-949;Men;40 Palmas, Las;Group 1907 Burns 940-949;Women;24 Palmas, Las;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;157 Palmas, Las;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;73 Palmas, Las;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;84 Palmas, Las;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.080 Palmas, Las;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.145 Palmas, Las;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;935 Palmas, Las;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;10 Palmas, Las;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;8 Palmas, Las;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 Palmas, Las;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;176 Palmas, Las;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;97 Palmas, Las;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;79 Palmas, Las;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.714 Palmas, Las;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;791 Palmas, Las;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;923 Palmas, Las;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;166 Palmas, Las;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;86 Palmas, Las;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;80 Palmas, Las;Group 2102 Contraceptive management V25;Both sexes;101 Palmas, Las;Group 2102 Contraceptive management V25;Men;2 Palmas, Las;Group 2102 Contraceptive management V25;Women;99 Palmas, Las;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Palmas, Las;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Palmas, Las;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Palmas, Las;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;489 Palmas, Las;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;263 Palmas, Las;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;226 Palmas, Las;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;958 Palmas, Las;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;440 Palmas, Las;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;518 Santa Cruz de Tenerife;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;95.364 Santa Cruz de Tenerife;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;44.211 Santa Cruz de Tenerife;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;51.153 Santa Cruz de Tenerife;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.980 Santa Cruz de Tenerife;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.038 Santa Cruz de Tenerife;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;941 Santa Cruz de Tenerife;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;157 Santa Cruz de Tenerife;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;72 Santa Cruz de Tenerife;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;85 Santa Cruz de Tenerife;Group 0102 Imprecise intestinal infections 009;Both sexes;121 Santa Cruz de Tenerife;Group 0102 Imprecise intestinal infections 009;Men;49 Santa Cruz de Tenerife;Group 0102 Imprecise intestinal infections 009;Women;72 Santa Cruz de Tenerife;Group 0103 Tuberculosis 010-018, 137;Both sexes;24 Santa Cruz de Tenerife;Group 0103 Tuberculosis 010-018, 137;Men;13 Santa Cruz de Tenerife;Group 0103 Tuberculosis 010-018, 137;Women;11 Santa Cruz de Tenerife;Group 0104 Septicaemia 038;Both sexes;975 Santa Cruz de Tenerife;Group 0104 Septicaemia 038;Men;519 Santa Cruz de Tenerife;Group 0104 Septicaemia 038;Women;455 Santa Cruz de Tenerife;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;61 Santa Cruz de Tenerife;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;51 Santa Cruz de Tenerife;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;10 Santa Cruz de Tenerife;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;642 Santa Cruz de Tenerife;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;334 Santa Cruz de Tenerife;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;308 Santa Cruz de Tenerife;Group 0200 Neoplasms 140-239;Both sexes;8.786 Santa Cruz de Tenerife;Group 0200 Neoplasms 140-239;Men;4.334 Santa Cruz de Tenerife;Group 0200 Neoplasms 140-239;Women;4.452 Santa Cruz de Tenerife;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;813 Santa Cruz de Tenerife;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;480 Santa Cruz de Tenerife;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;333 Santa Cruz de Tenerife;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;569 Santa Cruz de Tenerife;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;413 Santa Cruz de Tenerife;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;156 Santa Cruz de Tenerife;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;246 Santa Cruz de Tenerife;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;124 Santa Cruz de Tenerife;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;122 Santa Cruz de Tenerife;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;774 Santa Cruz de Tenerife;Group 0204 Malignant neoplasm of breast 174-175;Men;6 Santa Cruz de Tenerife;Group 0204 Malignant neoplasm of breast 174-175;Women;768 Santa Cruz de Tenerife;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;189 Santa Cruz de Tenerife;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Santa Cruz de Tenerife;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;189 Santa Cruz de Tenerife;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;89 Santa Cruz de Tenerife;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Santa Cruz de Tenerife;Group 0206 Malignant neoplasm of ovary 1830;Women;89 Santa Cruz de Tenerife;Group 0207 Malignant neoplasm of prostate 185;Both sexes;457 Santa Cruz de Tenerife;Group 0207 Malignant neoplasm of prostate 185;Men;457 Santa Cruz de Tenerife;Group 0207 Malignant neoplasm of prostate 185;Women;.. Santa Cruz de Tenerife;Group 0208 Malignant neoplasm of bladder 188;Both sexes;648 Santa Cruz de Tenerife;Group 0208 Malignant neoplasm of bladder 188;Men;541 Santa Cruz de Tenerife;Group 0208 Malignant neoplasm of bladder 188;Women;107 Santa Cruz de Tenerife;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;3.008 Santa Cruz de Tenerife;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.698 Santa Cruz de Tenerife;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.310 Santa Cruz de Tenerife;Group 0210 Carcinoma in situ 230-234;Both sexes;165 Santa Cruz de Tenerife;Group 0210 Carcinoma in situ 230-234;Men;33 Santa Cruz de Tenerife;Group 0210 Carcinoma in situ 230-234;Women;132 Santa Cruz de Tenerife;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;111 Santa Cruz de Tenerife;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;62 Santa Cruz de Tenerife;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;49 Santa Cruz de Tenerife;Grupo 0212 Leiomyoma of uterus 218;Both sexes;478 Santa Cruz de Tenerife;Grupo 0212 Leiomyoma of uterus 218;Men;.. Santa Cruz de Tenerife;Grupo 0212 Leiomyoma of uterus 218;Women;478 Santa Cruz de Tenerife;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.239 Santa Cruz de Tenerife;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;520 Santa Cruz de Tenerife;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;719 Santa Cruz de Tenerife;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;765 Santa Cruz de Tenerife;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;357 Santa Cruz de Tenerife;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;408 Santa Cruz de Tenerife;Group 0301 Anaemias 280-285;Both sexes;416 Santa Cruz de Tenerife;Group 0301 Anaemias 280-285;Men;189 Santa Cruz de Tenerife;Group 0301 Anaemias 280-285;Women;227 Santa Cruz de Tenerife;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;349 Santa Cruz de Tenerife;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;168 Santa Cruz de Tenerife;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;181 Santa Cruz de Tenerife;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2.281 Santa Cruz de Tenerife;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;840 Santa Cruz de Tenerife;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.441 Santa Cruz de Tenerife;Group 0401 Diabetes mellitus 249-250;Both sexes;559 Santa Cruz de Tenerife;Group 0401 Diabetes mellitus 249-250;Men;297 Santa Cruz de Tenerife;Group 0401 Diabetes mellitus 249-250;Women;262 Santa Cruz de Tenerife;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.722 Santa Cruz de Tenerife;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;543 Santa Cruz de Tenerife;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.179 Santa Cruz de Tenerife;Group 0500 Mental disorders 290-319;Both sexes;1.757 Santa Cruz de Tenerife;Group 0500 Mental disorders 290-319;Men;1.000 Santa Cruz de Tenerife;Group 0500 Mental disorders 290-319;Women;757 Santa Cruz de Tenerife;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;26 Santa Cruz de Tenerife;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;9 Santa Cruz de Tenerife;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;17 Santa Cruz de Tenerife;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;273 Santa Cruz de Tenerife;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;221 Santa Cruz de Tenerife;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;52 Santa Cruz de Tenerife;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;283 Santa Cruz de Tenerife;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;229 Santa Cruz de Tenerife;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;54 Santa Cruz de Tenerife;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;489 Santa Cruz de Tenerife;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;281 Santa Cruz de Tenerife;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;208 Santa Cruz de Tenerife;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;370 Santa Cruz de Tenerife;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;136 Santa Cruz de Tenerife;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;234 Santa Cruz de Tenerife;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;316 Santa Cruz de Tenerife;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;124 Santa Cruz de Tenerife;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;192 Santa Cruz de Tenerife;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.513 Santa Cruz de Tenerife;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.312 Santa Cruz de Tenerife;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.200 Santa Cruz de Tenerife;Group 0601 Alzheimer's disease 3310;Both sexes;40 Santa Cruz de Tenerife;Group 0601 Alzheimer's disease 3310;Men;9 Santa Cruz de Tenerife;Group 0601 Alzheimer's disease 3310;Women;31 Santa Cruz de Tenerife;Group 0602 Multiple sclerosis 340;Both sexes;175 Santa Cruz de Tenerife;Group 0602 Multiple sclerosis 340;Men;55 Santa Cruz de Tenerife;Group 0602 Multiple sclerosis 340;Women;120 Santa Cruz de Tenerife;Group 0603 Epilepsy 345;Both sexes;257 Santa Cruz de Tenerife;Group 0603 Epilepsy 345;Men;127 Santa Cruz de Tenerife;Group 0603 Epilepsy 345;Women;130 Santa Cruz de Tenerife;Group 0604 Transient cerebral ischemia 435;Both sexes;264 Santa Cruz de Tenerife;Group 0604 Transient cerebral ischemia 435;Men;138 Santa Cruz de Tenerife;Group 0604 Transient cerebral ischemia 435;Women;126 Santa Cruz de Tenerife;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.776 Santa Cruz de Tenerife;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;983 Santa Cruz de Tenerife;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;793 Santa Cruz de Tenerife;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;822 Santa Cruz de Tenerife;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;408 Santa Cruz de Tenerife;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;414 Santa Cruz de Tenerife;Grupo 0701 Cataract 366;Both sexes;107 Santa Cruz de Tenerife;Grupo 0701 Cataract 366;Men;51 Santa Cruz de Tenerife;Grupo 0701 Cataract 366;Women;56 Santa Cruz de Tenerife;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;715 Santa Cruz de Tenerife;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;357 Santa Cruz de Tenerife;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;358 Santa Cruz de Tenerife;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;475 Santa Cruz de Tenerife;Group 0800 Diseases of the ear and the mastoid 380-389;Men;230 Santa Cruz de Tenerife;Group 0800 Diseases of the ear and the mastoid 380-389;Women;245 Santa Cruz de Tenerife;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;11.914 Santa Cruz de Tenerife;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;6.784 Santa Cruz de Tenerife;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;5.130 Santa Cruz de Tenerife;Group 0901 Hypertensive disease 401-405;Both sexes;768 Santa Cruz de Tenerife;Group 0901 Hypertensive disease 401-405;Men;331 Santa Cruz de Tenerife;Group 0901 Hypertensive disease 401-405;Women;437 Santa Cruz de Tenerife;Group 0902 Angina pectoris 4111, 413;Both sexes;393 Santa Cruz de Tenerife;Group 0902 Angina pectoris 4111, 413;Men;246 Santa Cruz de Tenerife;Group 0902 Angina pectoris 4111, 413;Women;147 Santa Cruz de Tenerife;Group 0903 Acute myocardial infarction 410;Both sexes;1.104 Santa Cruz de Tenerife;Group 0903 Acute myocardial infarction 410;Men;785 Santa Cruz de Tenerife;Group 0903 Acute myocardial infarction 410;Women;319 Santa Cruz de Tenerife;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;928 Santa Cruz de Tenerife;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;690 Santa Cruz de Tenerife;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;238 Santa Cruz de Tenerife;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;253 Santa Cruz de Tenerife;Group 0905 Diseases of the lungs circulation 415-417;Men;102 Santa Cruz de Tenerife;Group 0905 Diseases of the lungs circulation 415-417;Women;151 Santa Cruz de Tenerife;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.532 Santa Cruz de Tenerife;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;909 Santa Cruz de Tenerife;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;622 Santa Cruz de Tenerife;Grupo 0907 Heart failure 428;Both sexes;1.715 Santa Cruz de Tenerife;Grupo 0907 Heart failure 428;Men;864 Santa Cruz de Tenerife;Grupo 0907 Heart failure 428;Women;851 Santa Cruz de Tenerife;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.978 Santa Cruz de Tenerife;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.065 Santa Cruz de Tenerife;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;913 Santa Cruz de Tenerife;Grupo 0909 Atherosclerosis 440;Both sexes;404 Santa Cruz de Tenerife;Grupo 0909 Atherosclerosis 440;Men;289 Santa Cruz de Tenerife;Grupo 0909 Atherosclerosis 440;Women;115 Santa Cruz de Tenerife;Group 0910 Varicose veins of lower extremities 454;Both sexes;609 Santa Cruz de Tenerife;Group 0910 Varicose veins of lower extremities 454;Men;201 Santa Cruz de Tenerife;Group 0910 Varicose veins of lower extremities 454;Women;408 Santa Cruz de Tenerife;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.230 Santa Cruz de Tenerife;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.301 Santa Cruz de Tenerife;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;929 Santa Cruz de Tenerife;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;10.882 Santa Cruz de Tenerife;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;5.802 Santa Cruz de Tenerife;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;5.081 Santa Cruz de Tenerife;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;520 Santa Cruz de Tenerife;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;277 Santa Cruz de Tenerife;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;243 Santa Cruz de Tenerife;Group 1002 Pneumonia 480-486;Both sexes;2.511 Santa Cruz de Tenerife;Group 1002 Pneumonia 480-486;Men;1.378 Santa Cruz de Tenerife;Group 1002 Pneumonia 480-486;Women;1.133 Santa Cruz de Tenerife;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.294 Santa Cruz de Tenerife;Group 1003 Acute bronchitis and bronchiolitis 466;Men;610 Santa Cruz de Tenerife;Group 1003 Acute bronchitis and bronchiolitis 466;Women;684 Santa Cruz de Tenerife;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;849 Santa Cruz de Tenerife;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;411 Santa Cruz de Tenerife;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;438 Santa Cruz de Tenerife;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;927 Santa Cruz de Tenerife;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;580 Santa Cruz de Tenerife;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;347 Santa Cruz de Tenerife;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.236 Santa Cruz de Tenerife;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;809 Santa Cruz de Tenerife;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;427 Santa Cruz de Tenerife;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;350 Santa Cruz de Tenerife;Group 1007 Asthma 4930-4931,4938-4939;Men;128 Santa Cruz de Tenerife;Group 1007 Asthma 4930-4931,4938-4939;Women;222 Santa Cruz de Tenerife;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3.195 Santa Cruz de Tenerife;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.608 Santa Cruz de Tenerife;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.586 Santa Cruz de Tenerife;Group 1100 Diseases of the digestive system 520-579;Both sexes;12.600 Santa Cruz de Tenerife;Group 1100 Diseases of the digestive system 520-579;Men;6.937 Santa Cruz de Tenerife;Group 1100 Diseases of the digestive system 520-579;Women;5.662 Santa Cruz de Tenerife;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;318 Santa Cruz de Tenerife;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;127 Santa Cruz de Tenerife;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;191 Santa Cruz de Tenerife;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;199 Santa Cruz de Tenerife;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;109 Santa Cruz de Tenerife;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;90 Santa Cruz de Tenerife;Group 1103 Diseases of the esophagus 530;Both sexes;207 Santa Cruz de Tenerife;Group 1103 Diseases of the esophagus 530;Men;118 Santa Cruz de Tenerife;Group 1103 Diseases of the esophagus 530;Women;89 Santa Cruz de Tenerife;Group 1104 Peptic ulcer 531-534;Both sexes;212 Santa Cruz de Tenerife;Group 1104 Peptic ulcer 531-534;Men;151 Santa Cruz de Tenerife;Group 1104 Peptic ulcer 531-534;Women;61 Santa Cruz de Tenerife;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;396 Santa Cruz de Tenerife;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;184 Santa Cruz de Tenerife;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;212 Santa Cruz de Tenerife;Group 1106 Appendicitis 540-543;Both sexes;858 Santa Cruz de Tenerife;Group 1106 Appendicitis 540-543;Men;517 Santa Cruz de Tenerife;Group 1106 Appendicitis 540-543;Women;341 Santa Cruz de Tenerife;Group 1107 Inguinal hernia 550;Both sexes;1.446 Santa Cruz de Tenerife;Group 1107 Inguinal hernia 550;Men;1.299 Santa Cruz de Tenerife;Group 1107 Inguinal hernia 550;Women;147 Santa Cruz de Tenerife;Group 1108 Other abdominal hernia 551-553;Both sexes;1.182 Santa Cruz de Tenerife;Group 1108 Other abdominal hernia 551-553;Men;634 Santa Cruz de Tenerife;Group 1108 Other abdominal hernia 551-553;Women;548 Santa Cruz de Tenerife;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;219 Santa Cruz de Tenerife;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;100 Santa Cruz de Tenerife;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;119 Santa Cruz de Tenerife;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.180 Santa Cruz de Tenerife;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;527 Santa Cruz de Tenerife;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;653 Santa Cruz de Tenerife;Group 1111 Intestinal obstruction without hernia 560;Both sexes;429 Santa Cruz de Tenerife;Group 1111 Intestinal obstruction without hernia 560;Men;218 Santa Cruz de Tenerife;Group 1111 Intestinal obstruction without hernia 560;Women;211 Santa Cruz de Tenerife;Group 1112 Intestinal diverticulosis 562;Both sexes;565 Santa Cruz de Tenerife;Group 1112 Intestinal diverticulosis 562;Men;281 Santa Cruz de Tenerife;Group 1112 Intestinal diverticulosis 562;Women;284 Santa Cruz de Tenerife;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;700 Santa Cruz de Tenerife;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;453 Santa Cruz de Tenerife;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;247 Santa Cruz de Tenerife;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;437 Santa Cruz de Tenerife;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;190 Santa Cruz de Tenerife;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;247 Santa Cruz de Tenerife;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;415 Santa Cruz de Tenerife;Group 1115 Alcoholic hepatitis 5710-5713;Men;364 Santa Cruz de Tenerife;Group 1115 Alcoholic hepatitis 5710-5713;Women;51 Santa Cruz de Tenerife;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;396 Santa Cruz de Tenerife;Group 1116 Other diseases of the liver 570,5714-573;Men;213 Santa Cruz de Tenerife;Group 1116 Other diseases of the liver 570,5714-573;Women;183 Santa Cruz de Tenerife;Group 1117 Cholelithiasis 574;Both sexes;2.019 Santa Cruz de Tenerife;Group 1117 Cholelithiasis 574;Men;774 Santa Cruz de Tenerife;Group 1117 Cholelithiasis 574;Women;1.245 Santa Cruz de Tenerife;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;570 Santa Cruz de Tenerife;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;234 Santa Cruz de Tenerife;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;336 Santa Cruz de Tenerife;Group 1119 Pancreatic diseases 577;Both sexes;489 Santa Cruz de Tenerife;Group 1119 Pancreatic diseases 577;Men;254 Santa Cruz de Tenerife;Group 1119 Pancreatic diseases 577;Women;235 Santa Cruz de Tenerife;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;362 Santa Cruz de Tenerife;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;190 Santa Cruz de Tenerife;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;172 Santa Cruz de Tenerife;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.483 Santa Cruz de Tenerife;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;815 Santa Cruz de Tenerife;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;668 Santa Cruz de Tenerife;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.088 Santa Cruz de Tenerife;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;635 Santa Cruz de Tenerife;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;453 Santa Cruz de Tenerife;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;64 Santa Cruz de Tenerife;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;33 Santa Cruz de Tenerife;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;31 Santa Cruz de Tenerife;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;331 Santa Cruz de Tenerife;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;147 Santa Cruz de Tenerife;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;184 Santa Cruz de Tenerife;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;6.699 Santa Cruz de Tenerife;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3.188 Santa Cruz de Tenerife;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.511 Santa Cruz de Tenerife;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Santa Cruz de Tenerife;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Santa Cruz de Tenerife;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Santa Cruz de Tenerife;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Santa Cruz de Tenerife;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Santa Cruz de Tenerife;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Santa Cruz de Tenerife;Group 1303 Internal derangement of knee 717;Both sexes;1.083 Santa Cruz de Tenerife;Group 1303 Internal derangement of knee 717;Men;685 Santa Cruz de Tenerife;Group 1303 Internal derangement of knee 717;Women;398 Santa Cruz de Tenerife;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.565 Santa Cruz de Tenerife;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.011 Santa Cruz de Tenerife;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.554 Santa Cruz de Tenerife;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;95 Santa Cruz de Tenerife;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;27 Santa Cruz de Tenerife;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;68 Santa Cruz de Tenerife;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;302 Santa Cruz de Tenerife;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;165 Santa Cruz de Tenerife;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;137 Santa Cruz de Tenerife;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;703 Santa Cruz de Tenerife;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;364 Santa Cruz de Tenerife;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;339 Santa Cruz de Tenerife;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;166 Santa Cruz de Tenerife;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;75 Santa Cruz de Tenerife;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;91 Santa Cruz de Tenerife;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.011 Santa Cruz de Tenerife;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;539 Santa Cruz de Tenerife;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;472 Santa Cruz de Tenerife;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;774 Santa Cruz de Tenerife;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;322 Santa Cruz de Tenerife;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;452 Santa Cruz de Tenerife;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;5.614 Santa Cruz de Tenerife;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.113 Santa Cruz de Tenerife;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3.500 Santa Cruz de Tenerife;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;465 Santa Cruz de Tenerife;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;171 Santa Cruz de Tenerife;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;294 Santa Cruz de Tenerife;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;288 Santa Cruz de Tenerife;Group 1402 Renal failure 5836-5837, 584-586;Men;166 Santa Cruz de Tenerife;Group 1402 Renal failure 5836-5837, 584-586;Women;122 Santa Cruz de Tenerife;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;675 Santa Cruz de Tenerife;Group 1403 Urolithiasis 592, 594, 7880;Men;383 Santa Cruz de Tenerife;Group 1403 Urolithiasis 592, 594, 7880;Women;292 Santa Cruz de Tenerife;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.787 Santa Cruz de Tenerife;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;738 Santa Cruz de Tenerife;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.049 Santa Cruz de Tenerife;Group 1405 Prostatic hyperplasia 600;Both sexes;303 Santa Cruz de Tenerife;Group 1405 Prostatic hyperplasia 600;Men;303 Santa Cruz de Tenerife;Group 1405 Prostatic hyperplasia 600;Women;.. Santa Cruz de Tenerife;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;292 Santa Cruz de Tenerife;Group 1406 Other diseases of the male genital organs 601-608;Men;292 Santa Cruz de Tenerife;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Santa Cruz de Tenerife;Group 1407 Disorders of breast 610-612;Both sexes;384 Santa Cruz de Tenerife;Group 1407 Disorders of breast 610-612;Men;50 Santa Cruz de Tenerife;Group 1407 Disorders of breast 610-612;Women;334 Santa Cruz de Tenerife;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;267 Santa Cruz de Tenerife;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Santa Cruz de Tenerife;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;267 Santa Cruz de Tenerife;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;80 Santa Cruz de Tenerife;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Santa Cruz de Tenerife;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;80 Santa Cruz de Tenerife;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.072 Santa Cruz de Tenerife;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;10 Santa Cruz de Tenerife;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.062 Santa Cruz de Tenerife;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;9.109 Santa Cruz de Tenerife;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Santa Cruz de Tenerife;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;9.109 Santa Cruz de Tenerife;Group 1501 Legally induced abortion 635;Both sexes;88 Santa Cruz de Tenerife;Group 1501 Legally induced abortion 635;Men;.. Santa Cruz de Tenerife;Group 1501 Legally induced abortion 635;Women;88 Santa Cruz de Tenerife;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;513 Santa Cruz de Tenerife;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Santa Cruz de Tenerife;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;513 Santa Cruz de Tenerife;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6.230 Santa Cruz de Tenerife;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Santa Cruz de Tenerife;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6.230 Santa Cruz de Tenerife;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.314 Santa Cruz de Tenerife;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Santa Cruz de Tenerife;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.314 Santa Cruz de Tenerife;Group 1505 Single spontaneous delivery 650;Both sexes;201 Santa Cruz de Tenerife;Group 1505 Single spontaneous delivery 650;Men;.. Santa Cruz de Tenerife;Group 1505 Single spontaneous delivery 650;Women;201 Santa Cruz de Tenerife;Group 1506 Other deliveries 6695-6697;Both sexes;25 Santa Cruz de Tenerife;Group 1506 Other deliveries 6695-6697;Men;.. Santa Cruz de Tenerife;Group 1506 Other deliveries 6695-6697;Women;25 Santa Cruz de Tenerife;Group 1507 Complications related to the puerperium 670-676;Both sexes;47 Santa Cruz de Tenerife;Group 1507 Complications related to the puerperium 670-676;Men;.. Santa Cruz de Tenerife;Group 1507 Complications related to the puerperium 670-676;Women;47 Santa Cruz de Tenerife;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;691 Santa Cruz de Tenerife;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Santa Cruz de Tenerife;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;691 Santa Cruz de Tenerife;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.207 Santa Cruz de Tenerife;Group 1600 Some disorders originating in the perinatal period 760-779;Men;669 Santa Cruz de Tenerife;Group 1600 Some disorders originating in the perinatal period 760-779;Women;538 Santa Cruz de Tenerife;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;357 Santa Cruz de Tenerife;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;176 Santa Cruz de Tenerife;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;181 Santa Cruz de Tenerife;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;850 Santa Cruz de Tenerife;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;493 Santa Cruz de Tenerife;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;357 Santa Cruz de Tenerife;Grupo 1700 Congenital abnormalities 740-759;Both sexes;641 Santa Cruz de Tenerife;Grupo 1700 Congenital abnormalities 740-759;Men;362 Santa Cruz de Tenerife;Grupo 1700 Congenital abnormalities 740-759;Women;279 Santa Cruz de Tenerife;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;3.761 Santa Cruz de Tenerife;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.984 Santa Cruz de Tenerife;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.777 Santa Cruz de Tenerife;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;524 Santa Cruz de Tenerife;Group 1801 Pain in throat and chest 7841, 7865;Men;296 Santa Cruz de Tenerife;Group 1801 Pain in throat and chest 7841, 7865;Women;228 Santa Cruz de Tenerife;Group 1802 Abdominal pain 7890;Both sexes;424 Santa Cruz de Tenerife;Group 1802 Abdominal pain 7890;Men;173 Santa Cruz de Tenerife;Group 1802 Abdominal pain 7890;Women;251 Santa Cruz de Tenerife;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;247 Santa Cruz de Tenerife;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;111 Santa Cruz de Tenerife;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;136 Santa Cruz de Tenerife;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;2.566 Santa Cruz de Tenerife;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.404 Santa Cruz de Tenerife;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.162 Santa Cruz de Tenerife;Group 1900 Injuries and poisoning 800-999;Both sexes;9.494 Santa Cruz de Tenerife;Group 1900 Injuries and poisoning 800-999;Men;4.991 Santa Cruz de Tenerife;Group 1900 Injuries and poisoning 800-999;Women;4.503 Santa Cruz de Tenerife;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;567 Santa Cruz de Tenerife;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;331 Santa Cruz de Tenerife;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;236 Santa Cruz de Tenerife;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;493 Santa Cruz de Tenerife;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;327 Santa Cruz de Tenerife;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;166 Santa Cruz de Tenerife;Group 1903 Radius and ulna fracture 813;Both sexes;827 Santa Cruz de Tenerife;Group 1903 Radius and ulna fracture 813;Men;339 Santa Cruz de Tenerife;Group 1903 Radius and ulna fracture 813;Women;488 Santa Cruz de Tenerife;Group 1904 Femur fracture 820-821;Both sexes;1.090 Santa Cruz de Tenerife;Group 1904 Femur fracture 820-821;Men;312 Santa Cruz de Tenerife;Group 1904 Femur fracture 820-821;Women;778 Santa Cruz de Tenerife;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;852 Santa Cruz de Tenerife;Group 1905 Leg fracture, including the ankle 823-824;Men;378 Santa Cruz de Tenerife;Group 1905 Leg fracture, including the ankle 823-824;Women;474 Santa Cruz de Tenerife;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2.664 Santa Cruz de Tenerife;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.603 Santa Cruz de Tenerife;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.061 Santa Cruz de Tenerife;Group 1907 Burns 940-949;Both sexes;72 Santa Cruz de Tenerife;Group 1907 Burns 940-949;Men;46 Santa Cruz de Tenerife;Group 1907 Burns 940-949;Women;26 Santa Cruz de Tenerife;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;154 Santa Cruz de Tenerife;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;78 Santa Cruz de Tenerife;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;76 Santa Cruz de Tenerife;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.508 Santa Cruz de Tenerife;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.439 Santa Cruz de Tenerife;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.069 Santa Cruz de Tenerife;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;19 Santa Cruz de Tenerife;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;14 Santa Cruz de Tenerife;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;5 Santa Cruz de Tenerife;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;248 Santa Cruz de Tenerife;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;124 Santa Cruz de Tenerife;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;124 Santa Cruz de Tenerife;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.580 Santa Cruz de Tenerife;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.045 Santa Cruz de Tenerife;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.535 Santa Cruz de Tenerife;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;160 Santa Cruz de Tenerife;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;83 Santa Cruz de Tenerife;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;77 Santa Cruz de Tenerife;Group 2102 Contraceptive management V25;Both sexes;147 Santa Cruz de Tenerife;Group 2102 Contraceptive management V25;Men;3 Santa Cruz de Tenerife;Group 2102 Contraceptive management V25;Women;144 Santa Cruz de Tenerife;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Santa Cruz de Tenerife;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Santa Cruz de Tenerife;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Santa Cruz de Tenerife;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;913 Santa Cruz de Tenerife;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;539 Santa Cruz de Tenerife;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;374 Santa Cruz de Tenerife;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.360 Santa Cruz de Tenerife;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;420 Santa Cruz de Tenerife;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;940 CANTABRIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;59.985 CANTABRIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;29.323 CANTABRIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;30.662 CANTABRIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.349 CANTABRIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;738 CANTABRIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;611 CANTABRIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;150 CANTABRIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;80 CANTABRIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;70 CANTABRIA;Group 0102 Imprecise intestinal infections 009;Both sexes;39 CANTABRIA;Group 0102 Imprecise intestinal infections 009;Men;23 CANTABRIA;Group 0102 Imprecise intestinal infections 009;Women;16 CANTABRIA;Group 0103 Tuberculosis 010-018, 137;Both sexes;54 CANTABRIA;Group 0103 Tuberculosis 010-018, 137;Men;31 CANTABRIA;Group 0103 Tuberculosis 010-018, 137;Women;23 CANTABRIA;Group 0104 Septicaemia 038;Both sexes;750 CANTABRIA;Group 0104 Septicaemia 038;Men;392 CANTABRIA;Group 0104 Septicaemia 038;Women;358 CANTABRIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;23 CANTABRIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;18 CANTABRIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;5 CANTABRIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;333 CANTABRIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;194 CANTABRIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;139 CANTABRIA;Group 0200 Neoplasms 140-239;Both sexes;5.617 CANTABRIA;Group 0200 Neoplasms 140-239;Men;3.003 CANTABRIA;Group 0200 Neoplasms 140-239;Women;2.614 CANTABRIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;591 CANTABRIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;380 CANTABRIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;211 CANTABRIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;421 CANTABRIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;346 CANTABRIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;75 CANTABRIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;97 CANTABRIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;45 CANTABRIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;52 CANTABRIA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;394 CANTABRIA;Group 0204 Malignant neoplasm of breast 174-175;Men;4 CANTABRIA;Group 0204 Malignant neoplasm of breast 174-175;Women;390 CANTABRIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;96 CANTABRIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CANTABRIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;96 CANTABRIA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;60 CANTABRIA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CANTABRIA;Group 0206 Malignant neoplasm of ovary 1830;Women;60 CANTABRIA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;140 CANTABRIA;Group 0207 Malignant neoplasm of prostate 185;Men;140 CANTABRIA;Group 0207 Malignant neoplasm of prostate 185;Women;.. CANTABRIA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;452 CANTABRIA;Group 0208 Malignant neoplasm of bladder 188;Men;381 CANTABRIA;Group 0208 Malignant neoplasm of bladder 188;Women;71 CANTABRIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.005 CANTABRIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.211 CANTABRIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;794 CANTABRIA;Group 0210 Carcinoma in situ 230-234;Both sexes;97 CANTABRIA;Group 0210 Carcinoma in situ 230-234;Men;39 CANTABRIA;Group 0210 Carcinoma in situ 230-234;Women;58 CANTABRIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;88 CANTABRIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;53 CANTABRIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;35 CANTABRIA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;230 CANTABRIA;Grupo 0212 Leiomyoma of uterus 218;Men;.. CANTABRIA;Grupo 0212 Leiomyoma of uterus 218;Women;230 CANTABRIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;946 CANTABRIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;404 CANTABRIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;542 CANTABRIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;689 CANTABRIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;357 CANTABRIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;332 CANTABRIA;Group 0301 Anaemias 280-285;Both sexes;459 CANTABRIA;Group 0301 Anaemias 280-285;Men;218 CANTABRIA;Group 0301 Anaemias 280-285;Women;241 CANTABRIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;230 CANTABRIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;139 CANTABRIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;91 CANTABRIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.089 CANTABRIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;443 CANTABRIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;646 CANTABRIA;Group 0401 Diabetes mellitus 249-250;Both sexes;329 CANTABRIA;Group 0401 Diabetes mellitus 249-250;Men;194 CANTABRIA;Group 0401 Diabetes mellitus 249-250;Women;135 CANTABRIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;760 CANTABRIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;249 CANTABRIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;511 CANTABRIA;Group 0500 Mental disorders 290-319;Both sexes;1.153 CANTABRIA;Group 0500 Mental disorders 290-319;Men;566 CANTABRIA;Group 0500 Mental disorders 290-319;Women;587 CANTABRIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;75 CANTABRIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;31 CANTABRIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;44 CANTABRIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;94 CANTABRIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;71 CANTABRIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;23 CANTABRIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;69 CANTABRIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;34 CANTABRIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;35 CANTABRIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;306 CANTABRIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;160 CANTABRIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;146 CANTABRIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;244 CANTABRIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;89 CANTABRIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;155 CANTABRIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;365 CANTABRIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;181 CANTABRIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;184 CANTABRIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.205 CANTABRIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;604 CANTABRIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;601 CANTABRIA;Group 0601 Alzheimer's disease 3310;Both sexes;44 CANTABRIA;Group 0601 Alzheimer's disease 3310;Men;14 CANTABRIA;Group 0601 Alzheimer's disease 3310;Women;30 CANTABRIA;Group 0602 Multiple sclerosis 340;Both sexes;12 CANTABRIA;Group 0602 Multiple sclerosis 340;Men;4 CANTABRIA;Group 0602 Multiple sclerosis 340;Women;8 CANTABRIA;Group 0603 Epilepsy 345;Both sexes;178 CANTABRIA;Group 0603 Epilepsy 345;Men;110 CANTABRIA;Group 0603 Epilepsy 345;Women;68 CANTABRIA;Group 0604 Transient cerebral ischemia 435;Both sexes;197 CANTABRIA;Group 0604 Transient cerebral ischemia 435;Men;99 CANTABRIA;Group 0604 Transient cerebral ischemia 435;Women;98 CANTABRIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;774 CANTABRIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;377 CANTABRIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;397 CANTABRIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;209 CANTABRIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;101 CANTABRIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;108 CANTABRIA;Grupo 0701 Cataract 366;Both sexes;42 CANTABRIA;Grupo 0701 Cataract 366;Men;20 CANTABRIA;Grupo 0701 Cataract 366;Women;22 CANTABRIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;167 CANTABRIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;81 CANTABRIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;86 CANTABRIA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;283 CANTABRIA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;132 CANTABRIA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;151 CANTABRIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;8.634 CANTABRIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;4.979 CANTABRIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3.655 CANTABRIA;Group 0901 Hypertensive disease 401-405;Both sexes;453 CANTABRIA;Group 0901 Hypertensive disease 401-405;Men;207 CANTABRIA;Group 0901 Hypertensive disease 401-405;Women;246 CANTABRIA;Group 0902 Angina pectoris 4111, 413;Both sexes;392 CANTABRIA;Group 0902 Angina pectoris 4111, 413;Men;235 CANTABRIA;Group 0902 Angina pectoris 4111, 413;Women;157 CANTABRIA;Group 0903 Acute myocardial infarction 410;Both sexes;647 CANTABRIA;Group 0903 Acute myocardial infarction 410;Men;445 CANTABRIA;Group 0903 Acute myocardial infarction 410;Women;202 CANTABRIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;613 CANTABRIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;459 CANTABRIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;154 CANTABRIA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;273 CANTABRIA;Group 0905 Diseases of the lungs circulation 415-417;Men;116 CANTABRIA;Group 0905 Diseases of the lungs circulation 415-417;Women;157 CANTABRIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.287 CANTABRIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;727 CANTABRIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;560 CANTABRIA;Grupo 0907 Heart failure 428;Both sexes;1.367 CANTABRIA;Grupo 0907 Heart failure 428;Men;721 CANTABRIA;Grupo 0907 Heart failure 428;Women;646 CANTABRIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.510 CANTABRIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;784 CANTABRIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;726 CANTABRIA;Grupo 0909 Atherosclerosis 440;Both sexes;453 CANTABRIA;Grupo 0909 Atherosclerosis 440;Men;355 CANTABRIA;Grupo 0909 Atherosclerosis 440;Women;98 CANTABRIA;Group 0910 Varicose veins of lower extremities 454;Both sexes;57 CANTABRIA;Group 0910 Varicose veins of lower extremities 454;Men;24 CANTABRIA;Group 0910 Varicose veins of lower extremities 454;Women;33 CANTABRIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.582 CANTABRIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;906 CANTABRIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;676 CANTABRIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7.036 CANTABRIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.004 CANTABRIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3.032 CANTABRIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;369 CANTABRIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;195 CANTABRIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;174 CANTABRIA;Group 1002 Pneumonia 480-486;Both sexes;1.335 CANTABRIA;Group 1002 Pneumonia 480-486;Men;804 CANTABRIA;Group 1002 Pneumonia 480-486;Women;531 CANTABRIA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;248 CANTABRIA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;122 CANTABRIA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;126 CANTABRIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;568 CANTABRIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;287 CANTABRIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;281 CANTABRIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;362 CANTABRIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;247 CANTABRIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;115 CANTABRIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.405 CANTABRIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.035 CANTABRIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;370 CANTABRIA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;482 CANTABRIA;Group 1007 Asthma 4930-4931,4938-4939;Men;189 CANTABRIA;Group 1007 Asthma 4930-4931,4938-4939;Women;293 CANTABRIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.267 CANTABRIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.125 CANTABRIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.142 CANTABRIA;Group 1100 Diseases of the digestive system 520-579;Both sexes;6.726 CANTABRIA;Group 1100 Diseases of the digestive system 520-579;Men;3.688 CANTABRIA;Group 1100 Diseases of the digestive system 520-579;Women;3.038 CANTABRIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;52 CANTABRIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;24 CANTABRIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;28 CANTABRIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;91 CANTABRIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;45 CANTABRIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;46 CANTABRIA;Group 1103 Diseases of the esophagus 530;Both sexes;128 CANTABRIA;Group 1103 Diseases of the esophagus 530;Men;80 CANTABRIA;Group 1103 Diseases of the esophagus 530;Women;48 CANTABRIA;Group 1104 Peptic ulcer 531-534;Both sexes;180 CANTABRIA;Group 1104 Peptic ulcer 531-534;Men;117 CANTABRIA;Group 1104 Peptic ulcer 531-534;Women;63 CANTABRIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;145 CANTABRIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;82 CANTABRIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;63 CANTABRIA;Group 1106 Appendicitis 540-543;Both sexes;650 CANTABRIA;Group 1106 Appendicitis 540-543;Men;385 CANTABRIA;Group 1106 Appendicitis 540-543;Women;265 CANTABRIA;Group 1107 Inguinal hernia 550;Both sexes;484 CANTABRIA;Group 1107 Inguinal hernia 550;Men;414 CANTABRIA;Group 1107 Inguinal hernia 550;Women;70 CANTABRIA;Group 1108 Other abdominal hernia 551-553;Both sexes;493 CANTABRIA;Group 1108 Other abdominal hernia 551-553;Men;236 CANTABRIA;Group 1108 Other abdominal hernia 551-553;Women;257 CANTABRIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;186 CANTABRIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;99 CANTABRIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;87 CANTABRIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;307 CANTABRIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;155 CANTABRIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;152 CANTABRIA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;330 CANTABRIA;Group 1111 Intestinal obstruction without hernia 560;Men;159 CANTABRIA;Group 1111 Intestinal obstruction without hernia 560;Women;171 CANTABRIA;Group 1112 Intestinal diverticulosis 562;Both sexes;346 CANTABRIA;Group 1112 Intestinal diverticulosis 562;Men;160 CANTABRIA;Group 1112 Intestinal diverticulosis 562;Women;186 CANTABRIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;276 CANTABRIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;180 CANTABRIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;96 CANTABRIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;248 CANTABRIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;108 CANTABRIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;140 CANTABRIA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;121 CANTABRIA;Group 1115 Alcoholic hepatitis 5710-5713;Men;98 CANTABRIA;Group 1115 Alcoholic hepatitis 5710-5713;Women;23 CANTABRIA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;247 CANTABRIA;Group 1116 Other diseases of the liver 570,5714-573;Men;149 CANTABRIA;Group 1116 Other diseases of the liver 570,5714-573;Women;98 CANTABRIA;Group 1117 Cholelithiasis 574;Both sexes;1.366 CANTABRIA;Group 1117 Cholelithiasis 574;Men;606 CANTABRIA;Group 1117 Cholelithiasis 574;Women;760 CANTABRIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;362 CANTABRIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;207 CANTABRIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;155 CANTABRIA;Group 1119 Pancreatic diseases 577;Both sexes;402 CANTABRIA;Group 1119 Pancreatic diseases 577;Men;228 CANTABRIA;Group 1119 Pancreatic diseases 577;Women;174 CANTABRIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;312 CANTABRIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;156 CANTABRIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;156 CANTABRIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;581 CANTABRIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;312 CANTABRIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;269 CANTABRIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;317 CANTABRIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;191 CANTABRIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;126 CANTABRIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;24 CANTABRIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;12 CANTABRIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;12 CANTABRIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;240 CANTABRIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;109 CANTABRIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;131 CANTABRIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;4.653 CANTABRIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.216 CANTABRIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2.437 CANTABRIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CANTABRIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CANTABRIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CANTABRIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CANTABRIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CANTABRIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CANTABRIA;Group 1303 Internal derangement of knee 717;Both sexes;424 CANTABRIA;Group 1303 Internal derangement of knee 717;Men;287 CANTABRIA;Group 1303 Internal derangement of knee 717;Women;137 CANTABRIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.250 CANTABRIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.060 CANTABRIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.190 CANTABRIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;88 CANTABRIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;35 CANTABRIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;53 CANTABRIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;80 CANTABRIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;46 CANTABRIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;34 CANTABRIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;197 CANTABRIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;114 CANTABRIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;83 CANTABRIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;40 CANTABRIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;21 CANTABRIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;19 CANTABRIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;584 CANTABRIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;330 CANTABRIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;254 CANTABRIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;990 CANTABRIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;323 CANTABRIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;667 CANTABRIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.204 CANTABRIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.546 CANTABRIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.658 CANTABRIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;297 CANTABRIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;125 CANTABRIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;172 CANTABRIA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;267 CANTABRIA;Group 1402 Renal failure 5836-5837, 584-586;Men;139 CANTABRIA;Group 1402 Renal failure 5836-5837, 584-586;Women;128 CANTABRIA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;400 CANTABRIA;Group 1403 Urolithiasis 592, 594, 7880;Men;259 CANTABRIA;Group 1403 Urolithiasis 592, 594, 7880;Women;141 CANTABRIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;904 CANTABRIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;427 CANTABRIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;477 CANTABRIA;Group 1405 Prostatic hyperplasia 600;Both sexes;237 CANTABRIA;Group 1405 Prostatic hyperplasia 600;Men;237 CANTABRIA;Group 1405 Prostatic hyperplasia 600;Women;.. CANTABRIA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;347 CANTABRIA;Group 1406 Other diseases of the male genital organs 601-608;Men;347 CANTABRIA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CANTABRIA;Group 1407 Disorders of breast 610-612;Both sexes;92 CANTABRIA;Group 1407 Disorders of breast 610-612;Men;11 CANTABRIA;Group 1407 Disorders of breast 610-612;Women;81 CANTABRIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;108 CANTABRIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CANTABRIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;108 CANTABRIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;79 CANTABRIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CANTABRIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;79 CANTABRIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;473 CANTABRIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 CANTABRIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;472 CANTABRIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5.340 CANTABRIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CANTABRIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5.340 CANTABRIA;Group 1501 Legally induced abortion 635;Both sexes;2 CANTABRIA;Group 1501 Legally induced abortion 635;Men;.. CANTABRIA;Group 1501 Legally induced abortion 635;Women;2 CANTABRIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;528 CANTABRIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CANTABRIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;528 CANTABRIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.488 CANTABRIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CANTABRIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.488 CANTABRIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;655 CANTABRIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CANTABRIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;655 CANTABRIA;Group 1505 Single spontaneous delivery 650;Both sexes;119 CANTABRIA;Group 1505 Single spontaneous delivery 650;Men;.. CANTABRIA;Group 1505 Single spontaneous delivery 650;Women;119 CANTABRIA;Group 1506 Other deliveries 6695-6697;Both sexes;67 CANTABRIA;Group 1506 Other deliveries 6695-6697;Men;.. CANTABRIA;Group 1506 Other deliveries 6695-6697;Women;67 CANTABRIA;Group 1507 Complications related to the puerperium 670-676;Both sexes;57 CANTABRIA;Group 1507 Complications related to the puerperium 670-676;Men;.. CANTABRIA;Group 1507 Complications related to the puerperium 670-676;Women;57 CANTABRIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;424 CANTABRIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CANTABRIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;424 CANTABRIA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;673 CANTABRIA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;372 CANTABRIA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;301 CANTABRIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;144 CANTABRIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;74 CANTABRIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;70 CANTABRIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;529 CANTABRIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;298 CANTABRIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;231 CANTABRIA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;486 CANTABRIA;Grupo 1700 Congenital abnormalities 740-759;Men;310 CANTABRIA;Grupo 1700 Congenital abnormalities 740-759;Women;176 CANTABRIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;3.167 CANTABRIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.602 CANTABRIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.565 CANTABRIA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;369 CANTABRIA;Group 1801 Pain in throat and chest 7841, 7865;Men;210 CANTABRIA;Group 1801 Pain in throat and chest 7841, 7865;Women;159 CANTABRIA;Group 1802 Abdominal pain 7890;Both sexes;188 CANTABRIA;Group 1802 Abdominal pain 7890;Men;72 CANTABRIA;Group 1802 Abdominal pain 7890;Women;116 CANTABRIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;924 CANTABRIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;452 CANTABRIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;472 CANTABRIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.686 CANTABRIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;868 CANTABRIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;818 CANTABRIA;Group 1900 Injuries and poisoning 800-999;Both sexes;6.876 CANTABRIA;Group 1900 Injuries and poisoning 800-999;Men;3.734 CANTABRIA;Group 1900 Injuries and poisoning 800-999;Women;3.142 CANTABRIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;309 CANTABRIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;178 CANTABRIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;131 CANTABRIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;135 CANTABRIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;100 CANTABRIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;35 CANTABRIA;Group 1903 Radius and ulna fracture 813;Both sexes;408 CANTABRIA;Group 1903 Radius and ulna fracture 813;Men;159 CANTABRIA;Group 1903 Radius and ulna fracture 813;Women;249 CANTABRIA;Group 1904 Femur fracture 820-821;Both sexes;850 CANTABRIA;Group 1904 Femur fracture 820-821;Men;240 CANTABRIA;Group 1904 Femur fracture 820-821;Women;610 CANTABRIA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;519 CANTABRIA;Group 1905 Leg fracture, including the ankle 823-824;Men;270 CANTABRIA;Group 1905 Leg fracture, including the ankle 823-824;Women;249 CANTABRIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.949 CANTABRIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.255 CANTABRIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;694 CANTABRIA;Group 1907 Burns 940-949;Both sexes;30 CANTABRIA;Group 1907 Burns 940-949;Men;16 CANTABRIA;Group 1907 Burns 940-949;Women;14 CANTABRIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;110 CANTABRIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;54 CANTABRIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;56 CANTABRIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.150 CANTABRIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.267 CANTABRIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;883 CANTABRIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;33 CANTABRIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;21 CANTABRIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;12 CANTABRIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;383 CANTABRIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;174 CANTABRIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;209 CANTABRIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.015 CANTABRIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;616 CANTABRIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;399 CANTABRIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;64 CANTABRIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;41 CANTABRIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;23 CANTABRIA;Group 2102 Contraceptive management V25;Both sexes;4 CANTABRIA;Group 2102 Contraceptive management V25;Men;.. CANTABRIA;Group 2102 Contraceptive management V25;Women;4 CANTABRIA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CANTABRIA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CANTABRIA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CANTABRIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;464 CANTABRIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;296 CANTABRIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;168 CANTABRIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;483 CANTABRIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;279 CANTABRIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;204 CASTILLA Y LEËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;269.748 CASTILLA Y LEËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;134.989 CASTILLA Y LEËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;134.759 CASTILLA Y LEËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;5.783 CASTILLA Y LEËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;3.210 CASTILLA Y LEËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;2.573 CASTILLA Y LEËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;1.040 CASTILLA Y LEËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;544 CASTILLA Y LEËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;496 CASTILLA Y LEËN;Group 0102 Imprecise intestinal infections 009;Both sexes;368 CASTILLA Y LEËN;Group 0102 Imprecise intestinal infections 009;Men;163 CASTILLA Y LEËN;Group 0102 Imprecise intestinal infections 009;Women;205 CASTILLA Y LEËN;Group 0103 Tuberculosis 010-018, 137;Both sexes;202 CASTILLA Y LEËN;Group 0103 Tuberculosis 010-018, 137;Men;123 CASTILLA Y LEËN;Group 0103 Tuberculosis 010-018, 137;Women;79 CASTILLA Y LEËN;Group 0104 Septicaemia 038;Both sexes;2.555 CASTILLA Y LEËN;Group 0104 Septicaemia 038;Men;1.426 CASTILLA Y LEËN;Group 0104 Septicaemia 038;Women;1.129 CASTILLA Y LEËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;113 CASTILLA Y LEËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;88 CASTILLA Y LEËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;25 CASTILLA Y LEËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.505 CASTILLA Y LEËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;866 CASTILLA Y LEËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;639 CASTILLA Y LEËN;Group 0200 Neoplasms 140-239;Both sexes;28.102 CASTILLA Y LEËN;Group 0200 Neoplasms 140-239;Men;15.293 CASTILLA Y LEËN;Group 0200 Neoplasms 140-239;Women;12.809 CASTILLA Y LEËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;3.360 CASTILLA Y LEËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;2.053 CASTILLA Y LEËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;1.307 CASTILLA Y LEËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;2.122 CASTILLA Y LEËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1.674 CASTILLA Y LEËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;448 CASTILLA Y LEËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;622 CASTILLA Y LEËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;345 CASTILLA Y LEËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;277 CASTILLA Y LEËN;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.838 CASTILLA Y LEËN;Group 0204 Malignant neoplasm of breast 174-175;Men;20 CASTILLA Y LEËN;Group 0204 Malignant neoplasm of breast 174-175;Women;1.818 CASTILLA Y LEËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;441 CASTILLA Y LEËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CASTILLA Y LEËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;441 CASTILLA Y LEËN;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;318 CASTILLA Y LEËN;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CASTILLA Y LEËN;Group 0206 Malignant neoplasm of ovary 1830;Women;318 CASTILLA Y LEËN;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1.149 CASTILLA Y LEËN;Group 0207 Malignant neoplasm of prostate 185;Men;1.149 CASTILLA Y LEËN;Group 0207 Malignant neoplasm of prostate 185;Women;.. CASTILLA Y LEËN;Group 0208 Malignant neoplasm of bladder 188;Both sexes;2.468 CASTILLA Y LEËN;Group 0208 Malignant neoplasm of bladder 188;Men;2.077 CASTILLA Y LEËN;Group 0208 Malignant neoplasm of bladder 188;Women;391 CASTILLA Y LEËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;10.138 CASTILLA Y LEËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;6.012 CASTILLA Y LEËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;4.126 CASTILLA Y LEËN;Group 0210 Carcinoma in situ 230-234;Both sexes;527 CASTILLA Y LEËN;Group 0210 Carcinoma in situ 230-234;Men;203 CASTILLA Y LEËN;Group 0210 Carcinoma in situ 230-234;Women;324 CASTILLA Y LEËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;257 CASTILLA Y LEËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;157 CASTILLA Y LEËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;100 CASTILLA Y LEËN;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1.063 CASTILLA Y LEËN;Grupo 0212 Leiomyoma of uterus 218;Men;.. CASTILLA Y LEËN;Grupo 0212 Leiomyoma of uterus 218;Women;1.063 CASTILLA Y LEËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;3.799 CASTILLA Y LEËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.603 CASTILLA Y LEËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;2.196 CASTILLA Y LEËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;2.685 CASTILLA Y LEËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;1.299 CASTILLA Y LEËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;1.386 CASTILLA Y LEËN;Group 0301 Anaemias 280-285;Both sexes;1.755 CASTILLA Y LEËN;Group 0301 Anaemias 280-285;Men;825 CASTILLA Y LEËN;Group 0301 Anaemias 280-285;Women;930 CASTILLA Y LEËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;930 CASTILLA Y LEËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;474 CASTILLA Y LEËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;456 CASTILLA Y LEËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;4.932 CASTILLA Y LEËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;2.021 CASTILLA Y LEËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2.911 CASTILLA Y LEËN;Group 0401 Diabetes mellitus 249-250;Both sexes;1.805 CASTILLA Y LEËN;Group 0401 Diabetes mellitus 249-250;Men;962 CASTILLA Y LEËN;Group 0401 Diabetes mellitus 249-250;Women;843 CASTILLA Y LEËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;3.127 CASTILLA Y LEËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;1.059 CASTILLA Y LEËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;2.068 CASTILLA Y LEËN;Group 0500 Mental disorders 290-319;Both sexes;6.392 CASTILLA Y LEËN;Group 0500 Mental disorders 290-319;Men;3.186 CASTILLA Y LEËN;Group 0500 Mental disorders 290-319;Women;3.206 CASTILLA Y LEËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;158 CASTILLA Y LEËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;76 CASTILLA Y LEËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;82 CASTILLA Y LEËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;485 CASTILLA Y LEËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;365 CASTILLA Y LEËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;120 CASTILLA Y LEËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;445 CASTILLA Y LEËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;351 CASTILLA Y LEËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;94 CASTILLA Y LEËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.652 CASTILLA Y LEËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;984 CASTILLA Y LEËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;668 CASTILLA Y LEËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1.580 CASTILLA Y LEËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;499 CASTILLA Y LEËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;1.081 CASTILLA Y LEËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;2.072 CASTILLA Y LEËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;911 CASTILLA Y LEËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;1.161 CASTILLA Y LEËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;5.464 CASTILLA Y LEËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.648 CASTILLA Y LEËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2.816 CASTILLA Y LEËN;Group 0601 Alzheimer's disease 3310;Both sexes;164 CASTILLA Y LEËN;Group 0601 Alzheimer's disease 3310;Men;59 CASTILLA Y LEËN;Group 0601 Alzheimer's disease 3310;Women;105 CASTILLA Y LEËN;Group 0602 Multiple sclerosis 340;Both sexes;191 CASTILLA Y LEËN;Group 0602 Multiple sclerosis 340;Men;77 CASTILLA Y LEËN;Group 0602 Multiple sclerosis 340;Women;114 CASTILLA Y LEËN;Group 0603 Epilepsy 345;Both sexes;831 CASTILLA Y LEËN;Group 0603 Epilepsy 345;Men;449 CASTILLA Y LEËN;Group 0603 Epilepsy 345;Women;382 CASTILLA Y LEËN;Group 0604 Transient cerebral ischemia 435;Both sexes;1.008 CASTILLA Y LEËN;Group 0604 Transient cerebral ischemia 435;Men;468 CASTILLA Y LEËN;Group 0604 Transient cerebral ischemia 435;Women;540 CASTILLA Y LEËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.270 CASTILLA Y LEËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.595 CASTILLA Y LEËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.675 CASTILLA Y LEËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1.940 CASTILLA Y LEËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;964 CASTILLA Y LEËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;976 CASTILLA Y LEËN;Grupo 0701 Cataract 366;Both sexes;422 CASTILLA Y LEËN;Grupo 0701 Cataract 366;Men;204 CASTILLA Y LEËN;Grupo 0701 Cataract 366;Women;218 CASTILLA Y LEËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;1.518 CASTILLA Y LEËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;760 CASTILLA Y LEËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;758 CASTILLA Y LEËN;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;1.706 CASTILLA Y LEËN;Group 0800 Diseases of the ear and the mastoid 380-389;Men;843 CASTILLA Y LEËN;Group 0800 Diseases of the ear and the mastoid 380-389;Women;863 CASTILLA Y LEËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;37.863 CASTILLA Y LEËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;21.028 CASTILLA Y LEËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;16.835 CASTILLA Y LEËN;Group 0901 Hypertensive disease 401-405;Both sexes;2.288 CASTILLA Y LEËN;Group 0901 Hypertensive disease 401-405;Men;898 CASTILLA Y LEËN;Group 0901 Hypertensive disease 401-405;Women;1.390 CASTILLA Y LEËN;Group 0902 Angina pectoris 4111, 413;Both sexes;1.309 CASTILLA Y LEËN;Group 0902 Angina pectoris 4111, 413;Men;872 CASTILLA Y LEËN;Group 0902 Angina pectoris 4111, 413;Women;437 CASTILLA Y LEËN;Group 0903 Acute myocardial infarction 410;Both sexes;3.283 CASTILLA Y LEËN;Group 0903 Acute myocardial infarction 410;Men;2.361 CASTILLA Y LEËN;Group 0903 Acute myocardial infarction 410;Women;922 CASTILLA Y LEËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.785 CASTILLA Y LEËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.436 CASTILLA Y LEËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;349 CASTILLA Y LEËN;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;1.601 CASTILLA Y LEËN;Group 0905 Diseases of the lungs circulation 415-417;Men;741 CASTILLA Y LEËN;Group 0905 Diseases of the lungs circulation 415-417;Women;860 CASTILLA Y LEËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;4.768 CASTILLA Y LEËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;2.567 CASTILLA Y LEËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;2.201 CASTILLA Y LEËN;Grupo 0907 Heart failure 428;Both sexes;8.161 CASTILLA Y LEËN;Grupo 0907 Heart failure 428;Men;3.903 CASTILLA Y LEËN;Grupo 0907 Heart failure 428;Women;4.258 CASTILLA Y LEËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;6.149 CASTILLA Y LEËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;3.249 CASTILLA Y LEËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;2.900 CASTILLA Y LEËN;Grupo 0909 Atherosclerosis 440;Both sexes;1.228 CASTILLA Y LEËN;Grupo 0909 Atherosclerosis 440;Men;957 CASTILLA Y LEËN;Grupo 0909 Atherosclerosis 440;Women;271 CASTILLA Y LEËN;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.134 CASTILLA Y LEËN;Group 0910 Varicose veins of lower extremities 454;Men;460 CASTILLA Y LEËN;Group 0910 Varicose veins of lower extremities 454;Women;674 CASTILLA Y LEËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;6.157 CASTILLA Y LEËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;3.584 CASTILLA Y LEËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;2.573 CASTILLA Y LEËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;33.340 CASTILLA Y LEËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;19.626 CASTILLA Y LEËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;13.714 CASTILLA Y LEËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1.459 CASTILLA Y LEËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;787 CASTILLA Y LEËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;672 CASTILLA Y LEËN;Group 1002 Pneumonia 480-486;Both sexes;6.953 CASTILLA Y LEËN;Group 1002 Pneumonia 480-486;Men;4.260 CASTILLA Y LEËN;Group 1002 Pneumonia 480-486;Women;2.693 CASTILLA Y LEËN;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2.369 CASTILLA Y LEËN;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1.145 CASTILLA Y LEËN;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.224 CASTILLA Y LEËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1.874 CASTILLA Y LEËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1.005 CASTILLA Y LEËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;869 CASTILLA Y LEËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;3.526 CASTILLA Y LEËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;2.319 CASTILLA Y LEËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;1.207 CASTILLA Y LEËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;5.583 CASTILLA Y LEËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;4.426 CASTILLA Y LEËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1.157 CASTILLA Y LEËN;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1.240 CASTILLA Y LEËN;Group 1007 Asthma 4930-4931,4938-4939;Men;387 CASTILLA Y LEËN;Group 1007 Asthma 4930-4931,4938-4939;Women;853 CASTILLA Y LEËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;10.336 CASTILLA Y LEËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;5.297 CASTILLA Y LEËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;5.039 CASTILLA Y LEËN;Group 1100 Diseases of the digestive system 520-579;Both sexes;36.280 CASTILLA Y LEËN;Group 1100 Diseases of the digestive system 520-579;Men;21.436 CASTILLA Y LEËN;Group 1100 Diseases of the digestive system 520-579;Women;14.844 CASTILLA Y LEËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;436 CASTILLA Y LEËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;214 CASTILLA Y LEËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;222 CASTILLA Y LEËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;478 CASTILLA Y LEËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;267 CASTILLA Y LEËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;211 CASTILLA Y LEËN;Group 1103 Diseases of the esophagus 530;Both sexes;606 CASTILLA Y LEËN;Group 1103 Diseases of the esophagus 530;Men;383 CASTILLA Y LEËN;Group 1103 Diseases of the esophagus 530;Women;223 CASTILLA Y LEËN;Group 1104 Peptic ulcer 531-534;Both sexes;776 CASTILLA Y LEËN;Group 1104 Peptic ulcer 531-534;Men;541 CASTILLA Y LEËN;Group 1104 Peptic ulcer 531-534;Women;235 CASTILLA Y LEËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;916 CASTILLA Y LEËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;464 CASTILLA Y LEËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;452 CASTILLA Y LEËN;Group 1106 Appendicitis 540-543;Both sexes;2.803 CASTILLA Y LEËN;Group 1106 Appendicitis 540-543;Men;1.603 CASTILLA Y LEËN;Group 1106 Appendicitis 540-543;Women;1.200 CASTILLA Y LEËN;Group 1107 Inguinal hernia 550;Both sexes;5.184 CASTILLA Y LEËN;Group 1107 Inguinal hernia 550;Men;4.704 CASTILLA Y LEËN;Group 1107 Inguinal hernia 550;Women;480 CASTILLA Y LEËN;Group 1108 Other abdominal hernia 551-553;Both sexes;2.898 CASTILLA Y LEËN;Group 1108 Other abdominal hernia 551-553;Men;1.450 CASTILLA Y LEËN;Group 1108 Other abdominal hernia 551-553;Women;1.448 CASTILLA Y LEËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;553 CASTILLA Y LEËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;305 CASTILLA Y LEËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;248 CASTILLA Y LEËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;2.198 CASTILLA Y LEËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;1.023 CASTILLA Y LEËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;1.175 CASTILLA Y LEËN;Group 1111 Intestinal obstruction without hernia 560;Both sexes;2.177 CASTILLA Y LEËN;Group 1111 Intestinal obstruction without hernia 560;Men;1.144 CASTILLA Y LEËN;Group 1111 Intestinal obstruction without hernia 560;Women;1.033 CASTILLA Y LEËN;Group 1112 Intestinal diverticulosis 562;Both sexes;1.528 CASTILLA Y LEËN;Group 1112 Intestinal diverticulosis 562;Men;746 CASTILLA Y LEËN;Group 1112 Intestinal diverticulosis 562;Women;782 CASTILLA Y LEËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.881 CASTILLA Y LEËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;1.212 CASTILLA Y LEËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;669 CASTILLA Y LEËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;1.418 CASTILLA Y LEËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;690 CASTILLA Y LEËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;728 CASTILLA Y LEËN;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;518 CASTILLA Y LEËN;Group 1115 Alcoholic hepatitis 5710-5713;Men;457 CASTILLA Y LEËN;Group 1115 Alcoholic hepatitis 5710-5713;Women;61 CASTILLA Y LEËN;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;1.108 CASTILLA Y LEËN;Group 1116 Other diseases of the liver 570,5714-573;Men;667 CASTILLA Y LEËN;Group 1116 Other diseases of the liver 570,5714-573;Women;441 CASTILLA Y LEËN;Group 1117 Cholelithiasis 574;Both sexes;6.135 CASTILLA Y LEËN;Group 1117 Cholelithiasis 574;Men;2.925 CASTILLA Y LEËN;Group 1117 Cholelithiasis 574;Women;3.210 CASTILLA Y LEËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1.552 CASTILLA Y LEËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;911 CASTILLA Y LEËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;641 CASTILLA Y LEËN;Group 1119 Pancreatic diseases 577;Both sexes;1.573 CASTILLA Y LEËN;Group 1119 Pancreatic diseases 577;Men;904 CASTILLA Y LEËN;Group 1119 Pancreatic diseases 577;Women;669 CASTILLA Y LEËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1.542 CASTILLA Y LEËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;826 CASTILLA Y LEËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;716 CASTILLA Y LEËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;2.825 CASTILLA Y LEËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1.563 CASTILLA Y LEËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1.262 CASTILLA Y LEËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.623 CASTILLA Y LEËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;982 CASTILLA Y LEËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;641 CASTILLA Y LEËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;132 CASTILLA Y LEËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;65 CASTILLA Y LEËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;67 CASTILLA Y LEËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;1.070 CASTILLA Y LEËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;516 CASTILLA Y LEËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;554 CASTILLA Y LEËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;16.992 CASTILLA Y LEËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;8.174 CASTILLA Y LEËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;8.818 CASTILLA Y LEËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CASTILLA Y LEËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CASTILLA Y LEËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CASTILLA Y LEËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CASTILLA Y LEËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CASTILLA Y LEËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CASTILLA Y LEËN;Group 1303 Internal derangement of knee 717;Both sexes;2.082 CASTILLA Y LEËN;Group 1303 Internal derangement of knee 717;Men;1.438 CASTILLA Y LEËN;Group 1303 Internal derangement of knee 717;Women;644 CASTILLA Y LEËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;6.560 CASTILLA Y LEËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;2.970 CASTILLA Y LEËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;3.590 CASTILLA Y LEËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;433 CASTILLA Y LEËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;148 CASTILLA Y LEËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;285 CASTILLA Y LEËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;856 CASTILLA Y LEËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;420 CASTILLA Y LEËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;436 CASTILLA Y LEËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.355 CASTILLA Y LEËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;732 CASTILLA Y LEËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;623 CASTILLA Y LEËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;569 CASTILLA Y LEËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;261 CASTILLA Y LEËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;308 CASTILLA Y LEËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;2.354 CASTILLA Y LEËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1.274 CASTILLA Y LEËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;1.080 CASTILLA Y LEËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;2.783 CASTILLA Y LEËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;931 CASTILLA Y LEËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.852 CASTILLA Y LEËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;17.438 CASTILLA Y LEËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;8.599 CASTILLA Y LEËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;8.839 CASTILLA Y LEËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.242 CASTILLA Y LEËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;519 CASTILLA Y LEËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;723 CASTILLA Y LEËN;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1.515 CASTILLA Y LEËN;Group 1402 Renal failure 5836-5837, 584-586;Men;888 CASTILLA Y LEËN;Group 1402 Renal failure 5836-5837, 584-586;Women;627 CASTILLA Y LEËN;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;2.335 CASTILLA Y LEËN;Group 1403 Urolithiasis 592, 594, 7880;Men;1.417 CASTILLA Y LEËN;Group 1403 Urolithiasis 592, 594, 7880;Women;918 CASTILLA Y LEËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;5.301 CASTILLA Y LEËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;2.585 CASTILLA Y LEËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;2.716 CASTILLA Y LEËN;Group 1405 Prostatic hyperplasia 600;Both sexes;1.595 CASTILLA Y LEËN;Group 1405 Prostatic hyperplasia 600;Men;1.595 CASTILLA Y LEËN;Group 1405 Prostatic hyperplasia 600;Women;.. CASTILLA Y LEËN;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;1.463 CASTILLA Y LEËN;Group 1406 Other diseases of the male genital organs 601-608;Men;1.463 CASTILLA Y LEËN;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CASTILLA Y LEËN;Group 1407 Disorders of breast 610-612;Both sexes;706 CASTILLA Y LEËN;Group 1407 Disorders of breast 610-612;Men;99 CASTILLA Y LEËN;Group 1407 Disorders of breast 610-612;Women;607 CASTILLA Y LEËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;451 CASTILLA Y LEËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CASTILLA Y LEËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;451 CASTILLA Y LEËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;315 CASTILLA Y LEËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CASTILLA Y LEËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;315 CASTILLA Y LEËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;2.515 CASTILLA Y LEËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;33 CASTILLA Y LEËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;2.482 CASTILLA Y LEËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;20.426 CASTILLA Y LEËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CASTILLA Y LEËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;20.426 CASTILLA Y LEËN;Group 1501 Legally induced abortion 635;Both sexes;10 CASTILLA Y LEËN;Group 1501 Legally induced abortion 635;Men;.. CASTILLA Y LEËN;Group 1501 Legally induced abortion 635;Women;10 CASTILLA Y LEËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.457 CASTILLA Y LEËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CASTILLA Y LEËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.457 CASTILLA Y LEËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;11.805 CASTILLA Y LEËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CASTILLA Y LEËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;11.805 CASTILLA Y LEËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3.365 CASTILLA Y LEËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CASTILLA Y LEËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3.365 CASTILLA Y LEËN;Group 1505 Single spontaneous delivery 650;Both sexes;1.610 CASTILLA Y LEËN;Group 1505 Single spontaneous delivery 650;Men;.. CASTILLA Y LEËN;Group 1505 Single spontaneous delivery 650;Women;1.610 CASTILLA Y LEËN;Group 1506 Other deliveries 6695-6697;Both sexes;781 CASTILLA Y LEËN;Group 1506 Other deliveries 6695-6697;Men;.. CASTILLA Y LEËN;Group 1506 Other deliveries 6695-6697;Women;781 CASTILLA Y LEËN;Group 1507 Complications related to the puerperium 670-676;Both sexes;166 CASTILLA Y LEËN;Group 1507 Complications related to the puerperium 670-676;Men;.. CASTILLA Y LEËN;Group 1507 Complications related to the puerperium 670-676;Women;166 CASTILLA Y LEËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.232 CASTILLA Y LEËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CASTILLA Y LEËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.232 CASTILLA Y LEËN;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.891 CASTILLA Y LEËN;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.614 CASTILLA Y LEËN;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1.277 CASTILLA Y LEËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;703 CASTILLA Y LEËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;400 CASTILLA Y LEËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;303 CASTILLA Y LEËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;2.188 CASTILLA Y LEËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1.214 CASTILLA Y LEËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;974 CASTILLA Y LEËN;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.499 CASTILLA Y LEËN;Grupo 1700 Congenital abnormalities 740-759;Men;905 CASTILLA Y LEËN;Grupo 1700 Congenital abnormalities 740-759;Women;594 CASTILLA Y LEËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;13.111 CASTILLA Y LEËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;7.301 CASTILLA Y LEËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;5.810 CASTILLA Y LEËN;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.346 CASTILLA Y LEËN;Group 1801 Pain in throat and chest 7841, 7865;Men;822 CASTILLA Y LEËN;Group 1801 Pain in throat and chest 7841, 7865;Women;524 CASTILLA Y LEËN;Group 1802 Abdominal pain 7890;Both sexes;1.540 CASTILLA Y LEËN;Group 1802 Abdominal pain 7890;Men;649 CASTILLA Y LEËN;Group 1802 Abdominal pain 7890;Women;891 CASTILLA Y LEËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.798 CASTILLA Y LEËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1.021 CASTILLA Y LEËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;777 CASTILLA Y LEËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;8.427 CASTILLA Y LEËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;4.809 CASTILLA Y LEËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3.618 CASTILLA Y LEËN;Group 1900 Injuries and poisoning 800-999;Both sexes;24.545 CASTILLA Y LEËN;Group 1900 Injuries and poisoning 800-999;Men;12.345 CASTILLA Y LEËN;Group 1900 Injuries and poisoning 800-999;Women;12.200 CASTILLA Y LEËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1.401 CASTILLA Y LEËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;806 CASTILLA Y LEËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;595 CASTILLA Y LEËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;735 CASTILLA Y LEËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;517 CASTILLA Y LEËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;218 CASTILLA Y LEËN;Group 1903 Radius and ulna fracture 813;Both sexes;1.131 CASTILLA Y LEËN;Group 1903 Radius and ulna fracture 813;Men;538 CASTILLA Y LEËN;Group 1903 Radius and ulna fracture 813;Women;593 CASTILLA Y LEËN;Group 1904 Femur fracture 820-821;Both sexes;4.469 CASTILLA Y LEËN;Group 1904 Femur fracture 820-821;Men;1.144 CASTILLA Y LEËN;Group 1904 Femur fracture 820-821;Women;3.325 CASTILLA Y LEËN;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.544 CASTILLA Y LEËN;Group 1905 Leg fracture, including the ankle 823-824;Men;777 CASTILLA Y LEËN;Group 1905 Leg fracture, including the ankle 823-824;Women;767 CASTILLA Y LEËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;6.708 CASTILLA Y LEËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;3.977 CASTILLA Y LEËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2.731 CASTILLA Y LEËN;Group 1907 Burns 940-949;Both sexes;184 CASTILLA Y LEËN;Group 1907 Burns 940-949;Men;117 CASTILLA Y LEËN;Group 1907 Burns 940-949;Women;67 CASTILLA Y LEËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;726 CASTILLA Y LEËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;322 CASTILLA Y LEËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;404 CASTILLA Y LEËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;6.775 CASTILLA Y LEËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;3.693 CASTILLA Y LEËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;3.082 CASTILLA Y LEËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;30 CASTILLA Y LEËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;23 CASTILLA Y LEËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;7 CASTILLA Y LEËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;842 CASTILLA Y LEËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;431 CASTILLA Y LEËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;411 CASTILLA Y LEËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;5.534 CASTILLA Y LEËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;2.934 CASTILLA Y LEËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2.600 CASTILLA Y LEËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;297 CASTILLA Y LEËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;194 CASTILLA Y LEËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;103 CASTILLA Y LEËN;Group 2102 Contraceptive management V25;Both sexes;111 CASTILLA Y LEËN;Group 2102 Contraceptive management V25;Men;5 CASTILLA Y LEËN;Group 2102 Contraceptive management V25;Women;106 CASTILLA Y LEËN;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CASTILLA Y LEËN;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CASTILLA Y LEËN;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CASTILLA Y LEËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;2.420 CASTILLA Y LEËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;1.376 CASTILLA Y LEËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1.044 CASTILLA Y LEËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2.706 CASTILLA Y LEËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1.359 CASTILLA Y LEËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.347 ┴vila;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;14.353 ┴vila;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;7.237 ┴vila;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;7.116 ┴vila;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;328 ┴vila;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;181 ┴vila;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;147 ┴vila;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;54 ┴vila;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;25 ┴vila;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;29 ┴vila;Group 0102 Imprecise intestinal infections 009;Both sexes;6 ┴vila;Group 0102 Imprecise intestinal infections 009;Men;1 ┴vila;Group 0102 Imprecise intestinal infections 009;Women;5 ┴vila;Group 0103 Tuberculosis 010-018, 137;Both sexes;16 ┴vila;Group 0103 Tuberculosis 010-018, 137;Men;12 ┴vila;Group 0103 Tuberculosis 010-018, 137;Women;4 ┴vila;Group 0104 Septicaemia 038;Both sexes;124 ┴vila;Group 0104 Septicaemia 038;Men;76 ┴vila;Group 0104 Septicaemia 038;Women;48 ┴vila;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;10 ┴vila;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;8 ┴vila;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;2 ┴vila;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;118 ┴vila;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;59 ┴vila;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;59 ┴vila;Group 0200 Neoplasms 140-239;Both sexes;1.401 ┴vila;Group 0200 Neoplasms 140-239;Men;800 ┴vila;Group 0200 Neoplasms 140-239;Women;601 ┴vila;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;182 ┴vila;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;106 ┴vila;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;76 ┴vila;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;122 ┴vila;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;101 ┴vila;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;21 ┴vila;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;38 ┴vila;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;23 ┴vila;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;15 ┴vila;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;88 ┴vila;Group 0204 Malignant neoplasm of breast 174-175;Men;1 ┴vila;Group 0204 Malignant neoplasm of breast 174-175;Women;87 ┴vila;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;18 ┴vila;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. ┴vila;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;18 ┴vila;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;29 ┴vila;Group 0206 Malignant neoplasm of ovary 1830;Men;.. ┴vila;Group 0206 Malignant neoplasm of ovary 1830;Women;29 ┴vila;Group 0207 Malignant neoplasm of prostate 185;Both sexes;72 ┴vila;Group 0207 Malignant neoplasm of prostate 185;Men;72 ┴vila;Group 0207 Malignant neoplasm of prostate 185;Women;.. ┴vila;Group 0208 Malignant neoplasm of bladder 188;Both sexes;119 ┴vila;Group 0208 Malignant neoplasm of bladder 188;Men;101 ┴vila;Group 0208 Malignant neoplasm of bladder 188;Women;18 ┴vila;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;481 ┴vila;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;313 ┴vila;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;168 ┴vila;Group 0210 Carcinoma in situ 230-234;Both sexes;27 ┴vila;Group 0210 Carcinoma in situ 230-234;Men;13 ┴vila;Group 0210 Carcinoma in situ 230-234;Women;14 ┴vila;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;12 ┴vila;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;8 ┴vila;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;4 ┴vila;Grupo 0212 Leiomyoma of uterus 218;Both sexes;68 ┴vila;Grupo 0212 Leiomyoma of uterus 218;Men;.. ┴vila;Grupo 0212 Leiomyoma of uterus 218;Women;68 ┴vila;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;145 ┴vila;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;62 ┴vila;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;83 ┴vila;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;155 ┴vila;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;79 ┴vila;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;76 ┴vila;Group 0301 Anaemias 280-285;Both sexes;98 ┴vila;Group 0301 Anaemias 280-285;Men;43 ┴vila;Group 0301 Anaemias 280-285;Women;55 ┴vila;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;57 ┴vila;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;36 ┴vila;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;21 ┴vila;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;307 ┴vila;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;127 ┴vila;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;180 ┴vila;Group 0401 Diabetes mellitus 249-250;Both sexes;104 ┴vila;Group 0401 Diabetes mellitus 249-250;Men;55 ┴vila;Group 0401 Diabetes mellitus 249-250;Women;49 ┴vila;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;203 ┴vila;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;72 ┴vila;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;131 ┴vila;Group 0500 Mental disorders 290-319;Both sexes;357 ┴vila;Group 0500 Mental disorders 290-319;Men;186 ┴vila;Group 0500 Mental disorders 290-319;Women;171 ┴vila;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;6 ┴vila;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;5 ┴vila;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;1 ┴vila;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;20 ┴vila;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;15 ┴vila;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;5 ┴vila;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;8 ┴vila;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;5 ┴vila;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;3 ┴vila;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;98 ┴vila;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;60 ┴vila;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;38 ┴vila;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;81 ┴vila;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;32 ┴vila;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;49 ┴vila;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;144 ┴vila;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;69 ┴vila;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;75 ┴vila;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;275 ┴vila;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;135 ┴vila;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;140 ┴vila;Group 0601 Alzheimer's disease 3310;Both sexes;2 ┴vila;Group 0601 Alzheimer's disease 3310;Men;.. ┴vila;Group 0601 Alzheimer's disease 3310;Women;2 ┴vila;Group 0602 Multiple sclerosis 340;Both sexes;6 ┴vila;Group 0602 Multiple sclerosis 340;Men;1 ┴vila;Group 0602 Multiple sclerosis 340;Women;5 ┴vila;Group 0603 Epilepsy 345;Both sexes;58 ┴vila;Group 0603 Epilepsy 345;Men;41 ┴vila;Group 0603 Epilepsy 345;Women;17 ┴vila;Group 0604 Transient cerebral ischemia 435;Both sexes;45 ┴vila;Group 0604 Transient cerebral ischemia 435;Men;18 ┴vila;Group 0604 Transient cerebral ischemia 435;Women;27 ┴vila;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;164 ┴vila;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;75 ┴vila;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;89 ┴vila;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;105 ┴vila;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;58 ┴vila;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;47 ┴vila;Grupo 0701 Cataract 366;Both sexes;12 ┴vila;Grupo 0701 Cataract 366;Men;5 ┴vila;Grupo 0701 Cataract 366;Women;7 ┴vila;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;93 ┴vila;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;53 ┴vila;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;40 ┴vila;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;76 ┴vila;Group 0800 Diseases of the ear and the mastoid 380-389;Men;45 ┴vila;Group 0800 Diseases of the ear and the mastoid 380-389;Women;31 ┴vila;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;1.971 ┴vila;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;985 ┴vila;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;986 ┴vila;Group 0901 Hypertensive disease 401-405;Both sexes;113 ┴vila;Group 0901 Hypertensive disease 401-405;Men;40 ┴vila;Group 0901 Hypertensive disease 401-405;Women;73 ┴vila;Group 0902 Angina pectoris 4111, 413;Both sexes;104 ┴vila;Group 0902 Angina pectoris 4111, 413;Men;69 ┴vila;Group 0902 Angina pectoris 4111, 413;Women;35 ┴vila;Group 0903 Acute myocardial infarction 410;Both sexes;140 ┴vila;Group 0903 Acute myocardial infarction 410;Men;88 ┴vila;Group 0903 Acute myocardial infarction 410;Women;52 ┴vila;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;2 ┴vila;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;2 ┴vila;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;.. ┴vila;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;105 ┴vila;Group 0905 Diseases of the lungs circulation 415-417;Men;51 ┴vila;Group 0905 Diseases of the lungs circulation 415-417;Women;54 ┴vila;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;296 ┴vila;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;151 ┴vila;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;145 ┴vila;Grupo 0907 Heart failure 428;Both sexes;600 ┴vila;Grupo 0907 Heart failure 428;Men;263 ┴vila;Grupo 0907 Heart failure 428;Women;337 ┴vila;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;339 ┴vila;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;171 ┴vila;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;168 ┴vila;Grupo 0909 Atherosclerosis 440;Both sexes;2 ┴vila;Grupo 0909 Atherosclerosis 440;Men;1 ┴vila;Grupo 0909 Atherosclerosis 440;Women;1 ┴vila;Group 0910 Varicose veins of lower extremities 454;Both sexes;44 ┴vila;Group 0910 Varicose veins of lower extremities 454;Men;23 ┴vila;Group 0910 Varicose veins of lower extremities 454;Women;21 ┴vila;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;226 ┴vila;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;126 ┴vila;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;100 ┴vila;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;1.929 ┴vila;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.188 ┴vila;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;741 ┴vila;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;55 ┴vila;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;35 ┴vila;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;20 ┴vila;Group 1002 Pneumonia 480-486;Both sexes;307 ┴vila;Group 1002 Pneumonia 480-486;Men;201 ┴vila;Group 1002 Pneumonia 480-486;Women;106 ┴vila;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;62 ┴vila;Group 1003 Acute bronchitis and bronchiolitis 466;Men;34 ┴vila;Group 1003 Acute bronchitis and bronchiolitis 466;Women;28 ┴vila;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;118 ┴vila;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;65 ┴vila;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;53 ┴vila;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;258 ┴vila;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;171 ┴vila;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;87 ┴vila;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;306 ┴vila;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;265 ┴vila;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;41 ┴vila;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;63 ┴vila;Group 1007 Asthma 4930-4931,4938-4939;Men;15 ┴vila;Group 1007 Asthma 4930-4931,4938-4939;Women;48 ┴vila;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;760 ┴vila;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;402 ┴vila;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;358 ┴vila;Group 1100 Diseases of the digestive system 520-579;Both sexes;2.091 ┴vila;Group 1100 Diseases of the digestive system 520-579;Men;1.272 ┴vila;Group 1100 Diseases of the digestive system 520-579;Women;819 ┴vila;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;24 ┴vila;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;13 ┴vila;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;11 ┴vila;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;29 ┴vila;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;19 ┴vila;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;10 ┴vila;Group 1103 Diseases of the esophagus 530;Both sexes;35 ┴vila;Group 1103 Diseases of the esophagus 530;Men;22 ┴vila;Group 1103 Diseases of the esophagus 530;Women;13 ┴vila;Group 1104 Peptic ulcer 531-534;Both sexes;42 ┴vila;Group 1104 Peptic ulcer 531-534;Men;26 ┴vila;Group 1104 Peptic ulcer 531-534;Women;16 ┴vila;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;54 ┴vila;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;25 ┴vila;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;29 ┴vila;Group 1106 Appendicitis 540-543;Both sexes;134 ┴vila;Group 1106 Appendicitis 540-543;Men;81 ┴vila;Group 1106 Appendicitis 540-543;Women;53 ┴vila;Group 1107 Inguinal hernia 550;Both sexes;369 ┴vila;Group 1107 Inguinal hernia 550;Men;344 ┴vila;Group 1107 Inguinal hernia 550;Women;25 ┴vila;Group 1108 Other abdominal hernia 551-553;Both sexes;204 ┴vila;Group 1108 Other abdominal hernia 551-553;Men;104 ┴vila;Group 1108 Other abdominal hernia 551-553;Women;100 ┴vila;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;17 ┴vila;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;8 ┴vila;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;9 ┴vila;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;141 ┴vila;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;72 ┴vila;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;69 ┴vila;Group 1111 Intestinal obstruction without hernia 560;Both sexes;124 ┴vila;Group 1111 Intestinal obstruction without hernia 560;Men;58 ┴vila;Group 1111 Intestinal obstruction without hernia 560;Women;66 ┴vila;Group 1112 Intestinal diverticulosis 562;Both sexes;67 ┴vila;Group 1112 Intestinal diverticulosis 562;Men;27 ┴vila;Group 1112 Intestinal diverticulosis 562;Women;40 ┴vila;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;124 ┴vila;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;84 ┴vila;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;40 ┴vila;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;61 ┴vila;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;32 ┴vila;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;29 ┴vila;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;23 ┴vila;Group 1115 Alcoholic hepatitis 5710-5713;Men;18 ┴vila;Group 1115 Alcoholic hepatitis 5710-5713;Women;5 ┴vila;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;33 ┴vila;Group 1116 Other diseases of the liver 570,5714-573;Men;22 ┴vila;Group 1116 Other diseases of the liver 570,5714-573;Women;11 ┴vila;Group 1117 Cholelithiasis 574;Both sexes;314 ┴vila;Group 1117 Cholelithiasis 574;Men;139 ┴vila;Group 1117 Cholelithiasis 574;Women;175 ┴vila;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;87 ┴vila;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;60 ┴vila;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;27 ┴vila;Group 1119 Pancreatic diseases 577;Both sexes;94 ┴vila;Group 1119 Pancreatic diseases 577;Men;52 ┴vila;Group 1119 Pancreatic diseases 577;Women;42 ┴vila;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;115 ┴vila;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;66 ┴vila;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;49 ┴vila;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;146 ┴vila;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;79 ┴vila;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;67 ┴vila;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;84 ┴vila;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;49 ┴vila;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;35 ┴vila;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;7 ┴vila;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;5 ┴vila;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;2 ┴vila;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;55 ┴vila;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;25 ┴vila;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;30 ┴vila;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;528 ┴vila;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;268 ┴vila;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;260 ┴vila;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. ┴vila;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. ┴vila;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. ┴vila;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. ┴vila;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. ┴vila;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. ┴vila;Group 1303 Internal derangement of knee 717;Both sexes;76 ┴vila;Group 1303 Internal derangement of knee 717;Men;54 ┴vila;Group 1303 Internal derangement of knee 717;Women;22 ┴vila;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;234 ┴vila;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;108 ┴vila;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;126 ┴vila;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;10 ┴vila;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;4 ┴vila;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;6 ┴vila;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;5 ┴vila;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;3 ┴vila;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;2 ┴vila;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;28 ┴vila;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;21 ┴vila;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;7 ┴vila;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;7 ┴vila;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;6 ┴vila;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;1 ┴vila;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;75 ┴vila;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;44 ┴vila;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;31 ┴vila;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;93 ┴vila;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;28 ┴vila;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;65 ┴vila;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;964 ┴vila;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;521 ┴vila;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;443 ┴vila;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;47 ┴vila;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;27 ┴vila;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;20 ┴vila;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;91 ┴vila;Group 1402 Renal failure 5836-5837, 584-586;Men;52 ┴vila;Group 1402 Renal failure 5836-5837, 584-586;Women;39 ┴vila;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;107 ┴vila;Group 1403 Urolithiasis 592, 594, 7880;Men;58 ┴vila;Group 1403 Urolithiasis 592, 594, 7880;Women;49 ┴vila;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;320 ┴vila;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;165 ┴vila;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;155 ┴vila;Group 1405 Prostatic hyperplasia 600;Both sexes;100 ┴vila;Group 1405 Prostatic hyperplasia 600;Men;100 ┴vila;Group 1405 Prostatic hyperplasia 600;Women;.. ┴vila;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;114 ┴vila;Group 1406 Other diseases of the male genital organs 601-608;Men;114 ┴vila;Group 1406 Other diseases of the male genital organs 601-608;Women;.. ┴vila;Group 1407 Disorders of breast 610-612;Both sexes;12 ┴vila;Group 1407 Disorders of breast 610-612;Men;5 ┴vila;Group 1407 Disorders of breast 610-612;Women;7 ┴vila;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;28 ┴vila;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. ┴vila;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;28 ┴vila;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;13 ┴vila;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. ┴vila;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;13 ┴vila;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;132 ┴vila;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. ┴vila;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;132 ┴vila;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.191 ┴vila;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. ┴vila;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.191 ┴vila;Group 1501 Legally induced abortion 635;Both sexes;.. ┴vila;Group 1501 Legally induced abortion 635;Men;.. ┴vila;Group 1501 Legally induced abortion 635;Women;.. ┴vila;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;68 ┴vila;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. ┴vila;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;68 ┴vila;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;594 ┴vila;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. ┴vila;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;594 ┴vila;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;347 ┴vila;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. ┴vila;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;347 ┴vila;Group 1505 Single spontaneous delivery 650;Both sexes;61 ┴vila;Group 1505 Single spontaneous delivery 650;Men;.. ┴vila;Group 1505 Single spontaneous delivery 650;Women;61 ┴vila;Group 1506 Other deliveries 6695-6697;Both sexes;38 ┴vila;Group 1506 Other deliveries 6695-6697;Men;.. ┴vila;Group 1506 Other deliveries 6695-6697;Women;38 ┴vila;Group 1507 Complications related to the puerperium 670-676;Both sexes;13 ┴vila;Group 1507 Complications related to the puerperium 670-676;Men;.. ┴vila;Group 1507 Complications related to the puerperium 670-676;Women;13 ┴vila;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;70 ┴vila;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. ┴vila;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;70 ┴vila;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;231 ┴vila;Group 1600 Some disorders originating in the perinatal period 760-779;Men;143 ┴vila;Group 1600 Some disorders originating in the perinatal period 760-779;Women;88 ┴vila;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;31 ┴vila;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;18 ┴vila;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;13 ┴vila;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;200 ┴vila;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;125 ┴vila;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;75 ┴vila;Grupo 1700 Congenital abnormalities 740-759;Both sexes;70 ┴vila;Grupo 1700 Congenital abnormalities 740-759;Men;43 ┴vila;Grupo 1700 Congenital abnormalities 740-759;Women;27 ┴vila;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;906 ┴vila;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;485 ┴vila;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;421 ┴vila;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;145 ┴vila;Group 1801 Pain in throat and chest 7841, 7865;Men;82 ┴vila;Group 1801 Pain in throat and chest 7841, 7865;Women;63 ┴vila;Group 1802 Abdominal pain 7890;Both sexes;137 ┴vila;Group 1802 Abdominal pain 7890;Men;57 ┴vila;Group 1802 Abdominal pain 7890;Women;80 ┴vila;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;.. ┴vila;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;.. ┴vila;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;.. ┴vila;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;624 ┴vila;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;346 ┴vila;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;278 ┴vila;Group 1900 Injuries and poisoning 800-999;Both sexes;1.191 ┴vila;Group 1900 Injuries and poisoning 800-999;Men;565 ┴vila;Group 1900 Injuries and poisoning 800-999;Women;626 ┴vila;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;67 ┴vila;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;31 ┴vila;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;36 ┴vila;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;13 ┴vila;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;6 ┴vila;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;7 ┴vila;Group 1903 Radius and ulna fracture 813;Both sexes;45 ┴vila;Group 1903 Radius and ulna fracture 813;Men;26 ┴vila;Group 1903 Radius and ulna fracture 813;Women;19 ┴vila;Group 1904 Femur fracture 820-821;Both sexes;265 ┴vila;Group 1904 Femur fracture 820-821;Men;64 ┴vila;Group 1904 Femur fracture 820-821;Women;201 ┴vila;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;87 ┴vila;Group 1905 Leg fracture, including the ankle 823-824;Men;48 ┴vila;Group 1905 Leg fracture, including the ankle 823-824;Women;39 ┴vila;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;255 ┴vila;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;151 ┴vila;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;104 ┴vila;Group 1907 Burns 940-949;Both sexes;3 ┴vila;Group 1907 Burns 940-949;Men;3 ┴vila;Group 1907 Burns 940-949;Women;.. ┴vila;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;25 ┴vila;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;14 ┴vila;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;11 ┴vila;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;381 ┴vila;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;195 ┴vila;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;186 ┴vila;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. ┴vila;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. ┴vila;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. ┴vila;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;50 ┴vila;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;27 ┴vila;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;23 ┴vila;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;131 ┴vila;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;77 ┴vila;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;54 ┴vila;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;6 ┴vila;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;4 ┴vila;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;2 ┴vila;Group 2102 Contraceptive management V25;Both sexes;4 ┴vila;Group 2102 Contraceptive management V25;Men;.. ┴vila;Group 2102 Contraceptive management V25;Women;4 ┴vila;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. ┴vila;Group 2103 Living newborns by type of delivery V30-V39;Men;.. ┴vila;Group 2103 Living newborns by type of delivery V30-V39;Women;.. ┴vila;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;66 ┴vila;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;46 ┴vila;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;20 ┴vila;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;55 ┴vila;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;27 ┴vila;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;28 Burgos;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;42.901 Burgos;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;21.565 Burgos;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;21.336 Burgos;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;970 Burgos;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;552 Burgos;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;418 Burgos;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;161 Burgos;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;83 Burgos;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;78 Burgos;Group 0102 Imprecise intestinal infections 009;Both sexes;67 Burgos;Group 0102 Imprecise intestinal infections 009;Men;23 Burgos;Group 0102 Imprecise intestinal infections 009;Women;44 Burgos;Group 0103 Tuberculosis 010-018, 137;Both sexes;34 Burgos;Group 0103 Tuberculosis 010-018, 137;Men;21 Burgos;Group 0103 Tuberculosis 010-018, 137;Women;13 Burgos;Group 0104 Septicaemia 038;Both sexes;452 Burgos;Group 0104 Septicaemia 038;Men;266 Burgos;Group 0104 Septicaemia 038;Women;186 Burgos;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;41 Burgos;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;33 Burgos;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;8 Burgos;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;215 Burgos;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;126 Burgos;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;89 Burgos;Group 0200 Neoplasms 140-239;Both sexes;4.488 Burgos;Group 0200 Neoplasms 140-239;Men;2.487 Burgos;Group 0200 Neoplasms 140-239;Women;2.001 Burgos;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;505 Burgos;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;314 Burgos;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;191 Burgos;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;260 Burgos;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;192 Burgos;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;68 Burgos;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;76 Burgos;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;38 Burgos;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;38 Burgos;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;366 Burgos;Group 0204 Malignant neoplasm of breast 174-175;Men;4 Burgos;Group 0204 Malignant neoplasm of breast 174-175;Women;362 Burgos;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;56 Burgos;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Burgos;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;56 Burgos;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;22 Burgos;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Burgos;Group 0206 Malignant neoplasm of ovary 1830;Women;22 Burgos;Group 0207 Malignant neoplasm of prostate 185;Both sexes;185 Burgos;Group 0207 Malignant neoplasm of prostate 185;Men;185 Burgos;Group 0207 Malignant neoplasm of prostate 185;Women;.. Burgos;Group 0208 Malignant neoplasm of bladder 188;Both sexes;351 Burgos;Group 0208 Malignant neoplasm of bladder 188;Men;288 Burgos;Group 0208 Malignant neoplasm of bladder 188;Women;63 Burgos;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.752 Burgos;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.111 Burgos;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;641 Burgos;Group 0210 Carcinoma in situ 230-234;Both sexes;94 Burgos;Group 0210 Carcinoma in situ 230-234;Men;35 Burgos;Group 0210 Carcinoma in situ 230-234;Women;59 Burgos;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;87 Burgos;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;56 Burgos;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;31 Burgos;Grupo 0212 Leiomyoma of uterus 218;Both sexes;115 Burgos;Grupo 0212 Leiomyoma of uterus 218;Men;.. Burgos;Grupo 0212 Leiomyoma of uterus 218;Women;115 Burgos;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;619 Burgos;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;264 Burgos;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;355 Burgos;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;432 Burgos;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;196 Burgos;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;236 Burgos;Group 0301 Anaemias 280-285;Both sexes;296 Burgos;Group 0301 Anaemias 280-285;Men;136 Burgos;Group 0301 Anaemias 280-285;Women;160 Burgos;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;136 Burgos;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;60 Burgos;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;76 Burgos;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;735 Burgos;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;322 Burgos;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;413 Burgos;Group 0401 Diabetes mellitus 249-250;Both sexes;258 Burgos;Group 0401 Diabetes mellitus 249-250;Men;137 Burgos;Group 0401 Diabetes mellitus 249-250;Women;121 Burgos;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;477 Burgos;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;185 Burgos;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;292 Burgos;Group 0500 Mental disorders 290-319;Both sexes;1.009 Burgos;Group 0500 Mental disorders 290-319;Men;403 Burgos;Group 0500 Mental disorders 290-319;Women;606 Burgos;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;11 Burgos;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;6 Burgos;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;5 Burgos;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;58 Burgos;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;43 Burgos;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;15 Burgos;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;22 Burgos;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;13 Burgos;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;9 Burgos;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;239 Burgos;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;133 Burgos;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;106 Burgos;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;433 Burgos;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;102 Burgos;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;331 Burgos;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;246 Burgos;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;106 Burgos;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;140 Burgos;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;775 Burgos;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;385 Burgos;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;390 Burgos;Group 0601 Alzheimer's disease 3310;Both sexes;15 Burgos;Group 0601 Alzheimer's disease 3310;Men;3 Burgos;Group 0601 Alzheimer's disease 3310;Women;12 Burgos;Group 0602 Multiple sclerosis 340;Both sexes;13 Burgos;Group 0602 Multiple sclerosis 340;Men;3 Burgos;Group 0602 Multiple sclerosis 340;Women;10 Burgos;Group 0603 Epilepsy 345;Both sexes;141 Burgos;Group 0603 Epilepsy 345;Men;67 Burgos;Group 0603 Epilepsy 345;Women;74 Burgos;Group 0604 Transient cerebral ischemia 435;Both sexes;111 Burgos;Group 0604 Transient cerebral ischemia 435;Men;48 Burgos;Group 0604 Transient cerebral ischemia 435;Women;63 Burgos;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;495 Burgos;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;264 Burgos;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;231 Burgos;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;424 Burgos;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;210 Burgos;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;214 Burgos;Grupo 0701 Cataract 366;Both sexes;148 Burgos;Grupo 0701 Cataract 366;Men;77 Burgos;Grupo 0701 Cataract 366;Women;71 Burgos;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;276 Burgos;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;133 Burgos;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;143 Burgos;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;268 Burgos;Group 0800 Diseases of the ear and the mastoid 380-389;Men;140 Burgos;Group 0800 Diseases of the ear and the mastoid 380-389;Women;128 Burgos;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5.210 Burgos;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.905 Burgos;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.305 Burgos;Group 0901 Hypertensive disease 401-405;Both sexes;220 Burgos;Group 0901 Hypertensive disease 401-405;Men;93 Burgos;Group 0901 Hypertensive disease 401-405;Women;127 Burgos;Group 0902 Angina pectoris 4111, 413;Both sexes;146 Burgos;Group 0902 Angina pectoris 4111, 413;Men;102 Burgos;Group 0902 Angina pectoris 4111, 413;Women;44 Burgos;Group 0903 Acute myocardial infarction 410;Both sexes;343 Burgos;Group 0903 Acute myocardial infarction 410;Men;239 Burgos;Group 0903 Acute myocardial infarction 410;Women;104 Burgos;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;173 Burgos;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;141 Burgos;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;32 Burgos;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;192 Burgos;Group 0905 Diseases of the lungs circulation 415-417;Men;95 Burgos;Group 0905 Diseases of the lungs circulation 415-417;Women;97 Burgos;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;746 Burgos;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;405 Burgos;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;341 Burgos;Grupo 0907 Heart failure 428;Both sexes;1.579 Burgos;Grupo 0907 Heart failure 428;Men;754 Burgos;Grupo 0907 Heart failure 428;Women;825 Burgos;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;902 Burgos;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;491 Burgos;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;411 Burgos;Grupo 0909 Atherosclerosis 440;Both sexes;211 Burgos;Grupo 0909 Atherosclerosis 440;Men;167 Burgos;Grupo 0909 Atherosclerosis 440;Women;44 Burgos;Group 0910 Varicose veins of lower extremities 454;Both sexes;27 Burgos;Group 0910 Varicose veins of lower extremities 454;Men;12 Burgos;Group 0910 Varicose veins of lower extremities 454;Women;15 Burgos;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;671 Burgos;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;406 Burgos;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;265 Burgos;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5.684 Burgos;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3.301 Burgos;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.383 Burgos;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;360 Burgos;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;192 Burgos;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;168 Burgos;Group 1002 Pneumonia 480-486;Both sexes;1.261 Burgos;Group 1002 Pneumonia 480-486;Men;765 Burgos;Group 1002 Pneumonia 480-486;Women;496 Burgos;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;357 Burgos;Group 1003 Acute bronchitis and bronchiolitis 466;Men;177 Burgos;Group 1003 Acute bronchitis and bronchiolitis 466;Women;180 Burgos;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;317 Burgos;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;170 Burgos;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;147 Burgos;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;471 Burgos;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;314 Burgos;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;157 Burgos;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.064 Burgos;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;791 Burgos;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;273 Burgos;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;296 Burgos;Group 1007 Asthma 4930-4931,4938-4939;Men;116 Burgos;Group 1007 Asthma 4930-4931,4938-4939;Women;180 Burgos;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.558 Burgos;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;776 Burgos;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;782 Burgos;Group 1100 Diseases of the digestive system 520-579;Both sexes;5.724 Burgos;Group 1100 Diseases of the digestive system 520-579;Men;3.357 Burgos;Group 1100 Diseases of the digestive system 520-579;Women;2.367 Burgos;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;75 Burgos;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;43 Burgos;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;32 Burgos;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;68 Burgos;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;38 Burgos;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;30 Burgos;Group 1103 Diseases of the esophagus 530;Both sexes;64 Burgos;Group 1103 Diseases of the esophagus 530;Men;40 Burgos;Group 1103 Diseases of the esophagus 530;Women;24 Burgos;Group 1104 Peptic ulcer 531-534;Both sexes;127 Burgos;Group 1104 Peptic ulcer 531-534;Men;93 Burgos;Group 1104 Peptic ulcer 531-534;Women;34 Burgos;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;132 Burgos;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;66 Burgos;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;66 Burgos;Group 1106 Appendicitis 540-543;Both sexes;498 Burgos;Group 1106 Appendicitis 540-543;Men;282 Burgos;Group 1106 Appendicitis 540-543;Women;216 Burgos;Group 1107 Inguinal hernia 550;Both sexes;816 Burgos;Group 1107 Inguinal hernia 550;Men;725 Burgos;Group 1107 Inguinal hernia 550;Women;91 Burgos;Group 1108 Other abdominal hernia 551-553;Both sexes;413 Burgos;Group 1108 Other abdominal hernia 551-553;Men;224 Burgos;Group 1108 Other abdominal hernia 551-553;Women;189 Burgos;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;85 Burgos;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;41 Burgos;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;44 Burgos;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;393 Burgos;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;183 Burgos;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;210 Burgos;Group 1111 Intestinal obstruction without hernia 560;Both sexes;419 Burgos;Group 1111 Intestinal obstruction without hernia 560;Men;220 Burgos;Group 1111 Intestinal obstruction without hernia 560;Women;199 Burgos;Group 1112 Intestinal diverticulosis 562;Both sexes;195 Burgos;Group 1112 Intestinal diverticulosis 562;Men;110 Burgos;Group 1112 Intestinal diverticulosis 562;Women;85 Burgos;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;286 Burgos;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;179 Burgos;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;107 Burgos;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;187 Burgos;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;99 Burgos;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;88 Burgos;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;89 Burgos;Group 1115 Alcoholic hepatitis 5710-5713;Men;77 Burgos;Group 1115 Alcoholic hepatitis 5710-5713;Women;12 Burgos;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;209 Burgos;Group 1116 Other diseases of the liver 570,5714-573;Men;115 Burgos;Group 1116 Other diseases of the liver 570,5714-573;Women;94 Burgos;Group 1117 Cholelithiasis 574;Both sexes;895 Burgos;Group 1117 Cholelithiasis 574;Men;394 Burgos;Group 1117 Cholelithiasis 574;Women;501 Burgos;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;270 Burgos;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;156 Burgos;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;114 Burgos;Group 1119 Pancreatic diseases 577;Both sexes;271 Burgos;Group 1119 Pancreatic diseases 577;Men;139 Burgos;Group 1119 Pancreatic diseases 577;Women;132 Burgos;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;232 Burgos;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;133 Burgos;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;99 Burgos;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;527 Burgos;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;284 Burgos;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;243 Burgos;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;296 Burgos;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;182 Burgos;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;114 Burgos;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;22 Burgos;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;9 Burgos;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;13 Burgos;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;209 Burgos;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;93 Burgos;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;116 Burgos;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.826 Burgos;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.476 Burgos;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.350 Burgos;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Burgos;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Burgos;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Burgos;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Burgos;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Burgos;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Burgos;Group 1303 Internal derangement of knee 717;Both sexes;472 Burgos;Group 1303 Internal derangement of knee 717;Men;347 Burgos;Group 1303 Internal derangement of knee 717;Women;125 Burgos;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.030 Burgos;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;500 Burgos;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;530 Burgos;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;50 Burgos;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;21 Burgos;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;29 Burgos;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;100 Burgos;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;60 Burgos;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;40 Burgos;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;156 Burgos;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;88 Burgos;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;68 Burgos;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;130 Burgos;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;54 Burgos;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;76 Burgos;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;418 Burgos;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;243 Burgos;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;175 Burgos;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;470 Burgos;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;163 Burgos;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;307 Burgos;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.799 Burgos;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.345 Burgos;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.454 Burgos;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;236 Burgos;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;96 Burgos;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;140 Burgos;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;209 Burgos;Group 1402 Renal failure 5836-5837, 584-586;Men;131 Burgos;Group 1402 Renal failure 5836-5837, 584-586;Women;78 Burgos;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;412 Burgos;Group 1403 Urolithiasis 592, 594, 7880;Men;254 Burgos;Group 1403 Urolithiasis 592, 594, 7880;Women;158 Burgos;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.034 Burgos;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;467 Burgos;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;567 Burgos;Group 1405 Prostatic hyperplasia 600;Both sexes;217 Burgos;Group 1405 Prostatic hyperplasia 600;Men;217 Burgos;Group 1405 Prostatic hyperplasia 600;Women;.. Burgos;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;159 Burgos;Group 1406 Other diseases of the male genital organs 601-608;Men;159 Burgos;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Burgos;Group 1407 Disorders of breast 610-612;Both sexes;149 Burgos;Group 1407 Disorders of breast 610-612;Men;14 Burgos;Group 1407 Disorders of breast 610-612;Women;135 Burgos;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;68 Burgos;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Burgos;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;68 Burgos;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;22 Burgos;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Burgos;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;22 Burgos;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;293 Burgos;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;7 Burgos;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;286 Burgos;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3.269 Burgos;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Burgos;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3.269 Burgos;Group 1501 Legally induced abortion 635;Both sexes;8 Burgos;Group 1501 Legally induced abortion 635;Men;.. Burgos;Group 1501 Legally induced abortion 635;Women;8 Burgos;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;231 Burgos;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Burgos;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;231 Burgos;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;2.002 Burgos;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Burgos;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;2.002 Burgos;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;569 Burgos;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Burgos;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;569 Burgos;Group 1505 Single spontaneous delivery 650;Both sexes;158 Burgos;Group 1505 Single spontaneous delivery 650;Men;.. Burgos;Group 1505 Single spontaneous delivery 650;Women;158 Burgos;Group 1506 Other deliveries 6695-6697;Both sexes;29 Burgos;Group 1506 Other deliveries 6695-6697;Men;.. Burgos;Group 1506 Other deliveries 6695-6697;Women;29 Burgos;Group 1507 Complications related to the puerperium 670-676;Both sexes;29 Burgos;Group 1507 Complications related to the puerperium 670-676;Men;.. Burgos;Group 1507 Complications related to the puerperium 670-676;Women;29 Burgos;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;243 Burgos;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Burgos;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;243 Burgos;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;559 Burgos;Group 1600 Some disorders originating in the perinatal period 760-779;Men;309 Burgos;Group 1600 Some disorders originating in the perinatal period 760-779;Women;250 Burgos;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;120 Burgos;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;74 Burgos;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;46 Burgos;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;439 Burgos;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;235 Burgos;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;204 Burgos;Grupo 1700 Congenital abnormalities 740-759;Both sexes;341 Burgos;Grupo 1700 Congenital abnormalities 740-759;Men;208 Burgos;Grupo 1700 Congenital abnormalities 740-759;Women;133 Burgos;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.939 Burgos;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.088 Burgos;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;851 Burgos;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;164 Burgos;Group 1801 Pain in throat and chest 7841, 7865;Men;104 Burgos;Group 1801 Pain in throat and chest 7841, 7865;Women;60 Burgos;Group 1802 Abdominal pain 7890;Both sexes;294 Burgos;Group 1802 Abdominal pain 7890;Men;121 Burgos;Group 1802 Abdominal pain 7890;Women;173 Burgos;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1 Burgos;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1 Burgos;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;.. Burgos;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.480 Burgos;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;862 Burgos;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;618 Burgos;Group 1900 Injuries and poisoning 800-999;Both sexes;4.181 Burgos;Group 1900 Injuries and poisoning 800-999;Men;2.216 Burgos;Group 1900 Injuries and poisoning 800-999;Women;1.965 Burgos;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;278 Burgos;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;177 Burgos;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;101 Burgos;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;191 Burgos;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;145 Burgos;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;46 Burgos;Group 1903 Radius and ulna fracture 813;Both sexes;246 Burgos;Group 1903 Radius and ulna fracture 813;Men;109 Burgos;Group 1903 Radius and ulna fracture 813;Women;137 Burgos;Group 1904 Femur fracture 820-821;Both sexes;569 Burgos;Group 1904 Femur fracture 820-821;Men;149 Burgos;Group 1904 Femur fracture 820-821;Women;420 Burgos;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;240 Burgos;Group 1905 Leg fracture, including the ankle 823-824;Men;126 Burgos;Group 1905 Leg fracture, including the ankle 823-824;Women;114 Burgos;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.347 Burgos;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;825 Burgos;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;522 Burgos;Group 1907 Burns 940-949;Both sexes;69 Burgos;Group 1907 Burns 940-949;Men;40 Burgos;Group 1907 Burns 940-949;Women;29 Burgos;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;87 Burgos;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;37 Burgos;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;50 Burgos;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.015 Burgos;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;541 Burgos;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;474 Burgos;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;7 Burgos;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;4 Burgos;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;3 Burgos;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;132 Burgos;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;63 Burgos;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;69 Burgos;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;741 Burgos;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;381 Burgos;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;360 Burgos;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;26 Burgos;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;19 Burgos;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;7 Burgos;Group 2102 Contraceptive management V25;Both sexes;10 Burgos;Group 2102 Contraceptive management V25;Men;.. Burgos;Group 2102 Contraceptive management V25;Women;10 Burgos;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Burgos;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Burgos;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Burgos;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;145 Burgos;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;88 Burgos;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;57 Burgos;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;560 Burgos;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;274 Burgos;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;286 Le¾n;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;59.348 Le¾n;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;29.561 Le¾n;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;29.787 Le¾n;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.005 Le¾n;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;529 Le¾n;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;476 Le¾n;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;201 Le¾n;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;110 Le¾n;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;91 Le¾n;Group 0102 Imprecise intestinal infections 009;Both sexes;155 Le¾n;Group 0102 Imprecise intestinal infections 009;Men;66 Le¾n;Group 0102 Imprecise intestinal infections 009;Women;89 Le¾n;Group 0103 Tuberculosis 010-018, 137;Both sexes;54 Le¾n;Group 0103 Tuberculosis 010-018, 137;Men;39 Le¾n;Group 0103 Tuberculosis 010-018, 137;Women;15 Le¾n;Group 0104 Septicaemia 038;Both sexes;298 Le¾n;Group 0104 Septicaemia 038;Men;158 Le¾n;Group 0104 Septicaemia 038;Women;140 Le¾n;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;12 Le¾n;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;7 Le¾n;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;5 Le¾n;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;285 Le¾n;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;149 Le¾n;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;136 Le¾n;Group 0200 Neoplasms 140-239;Both sexes;5.924 Le¾n;Group 0200 Neoplasms 140-239;Men;3.132 Le¾n;Group 0200 Neoplasms 140-239;Women;2.792 Le¾n;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;785 Le¾n;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;437 Le¾n;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;348 Le¾n;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;397 Le¾n;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;312 Le¾n;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;85 Le¾n;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;253 Le¾n;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;137 Le¾n;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;116 Le¾n;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;378 Le¾n;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Le¾n;Group 0204 Malignant neoplasm of breast 174-175;Women;375 Le¾n;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;88 Le¾n;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Le¾n;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;88 Le¾n;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;86 Le¾n;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Le¾n;Group 0206 Malignant neoplasm of ovary 1830;Women;86 Le¾n;Group 0207 Malignant neoplasm of prostate 185;Both sexes;213 Le¾n;Group 0207 Malignant neoplasm of prostate 185;Men;213 Le¾n;Group 0207 Malignant neoplasm of prostate 185;Women;.. Le¾n;Group 0208 Malignant neoplasm of bladder 188;Both sexes;521 Le¾n;Group 0208 Malignant neoplasm of bladder 188;Men;446 Le¾n;Group 0208 Malignant neoplasm of bladder 188;Women;75 Le¾n;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.062 Le¾n;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.219 Le¾n;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;843 Le¾n;Group 0210 Carcinoma in situ 230-234;Both sexes;152 Le¾n;Group 0210 Carcinoma in situ 230-234;Men;50 Le¾n;Group 0210 Carcinoma in situ 230-234;Women;102 Le¾n;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;41 Le¾n;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;23 Le¾n;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;18 Le¾n;Grupo 0212 Leiomyoma of uterus 218;Both sexes;208 Le¾n;Grupo 0212 Leiomyoma of uterus 218;Men;.. Le¾n;Grupo 0212 Leiomyoma of uterus 218;Women;208 Le¾n;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;740 Le¾n;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;292 Le¾n;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;448 Le¾n;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;529 Le¾n;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;237 Le¾n;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;292 Le¾n;Group 0301 Anaemias 280-285;Both sexes;377 Le¾n;Group 0301 Anaemias 280-285;Men;160 Le¾n;Group 0301 Anaemias 280-285;Women;217 Le¾n;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;152 Le¾n;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;77 Le¾n;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;75 Le¾n;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;925 Le¾n;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;354 Le¾n;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;571 Le¾n;Group 0401 Diabetes mellitus 249-250;Both sexes;321 Le¾n;Group 0401 Diabetes mellitus 249-250;Men;167 Le¾n;Group 0401 Diabetes mellitus 249-250;Women;154 Le¾n;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;604 Le¾n;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;187 Le¾n;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;417 Le¾n;Group 0500 Mental disorders 290-319;Both sexes;1.203 Le¾n;Group 0500 Mental disorders 290-319;Men;596 Le¾n;Group 0500 Mental disorders 290-319;Women;607 Le¾n;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;56 Le¾n;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;34 Le¾n;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;22 Le¾n;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;67 Le¾n;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;52 Le¾n;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;15 Le¾n;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;26 Le¾n;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;23 Le¾n;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;3 Le¾n;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;343 Le¾n;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;206 Le¾n;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;137 Le¾n;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;246 Le¾n;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;75 Le¾n;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;171 Le¾n;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;465 Le¾n;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;206 Le¾n;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;259 Le¾n;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.157 Le¾n;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;599 Le¾n;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;558 Le¾n;Group 0601 Alzheimer's disease 3310;Both sexes;29 Le¾n;Group 0601 Alzheimer's disease 3310;Men;11 Le¾n;Group 0601 Alzheimer's disease 3310;Women;18 Le¾n;Group 0602 Multiple sclerosis 340;Both sexes;63 Le¾n;Group 0602 Multiple sclerosis 340;Men;31 Le¾n;Group 0602 Multiple sclerosis 340;Women;32 Le¾n;Group 0603 Epilepsy 345;Both sexes;147 Le¾n;Group 0603 Epilepsy 345;Men;74 Le¾n;Group 0603 Epilepsy 345;Women;73 Le¾n;Group 0604 Transient cerebral ischemia 435;Both sexes;303 Le¾n;Group 0604 Transient cerebral ischemia 435;Men;144 Le¾n;Group 0604 Transient cerebral ischemia 435;Women;159 Le¾n;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;615 Le¾n;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;339 Le¾n;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;276 Le¾n;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;701 Le¾n;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;349 Le¾n;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;352 Le¾n;Grupo 0701 Cataract 366;Both sexes;170 Le¾n;Grupo 0701 Cataract 366;Men;79 Le¾n;Grupo 0701 Cataract 366;Women;91 Le¾n;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;531 Le¾n;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;270 Le¾n;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;261 Le¾n;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;250 Le¾n;Group 0800 Diseases of the ear and the mastoid 380-389;Men;105 Le¾n;Group 0800 Diseases of the ear and the mastoid 380-389;Women;145 Le¾n;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;9.038 Le¾n;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;4.907 Le¾n;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4.131 Le¾n;Group 0901 Hypertensive disease 401-405;Both sexes;749 Le¾n;Group 0901 Hypertensive disease 401-405;Men;308 Le¾n;Group 0901 Hypertensive disease 401-405;Women;441 Le¾n;Group 0902 Angina pectoris 4111, 413;Both sexes;206 Le¾n;Group 0902 Angina pectoris 4111, 413;Men;139 Le¾n;Group 0902 Angina pectoris 4111, 413;Women;67 Le¾n;Group 0903 Acute myocardial infarction 410;Both sexes;688 Le¾n;Group 0903 Acute myocardial infarction 410;Men;504 Le¾n;Group 0903 Acute myocardial infarction 410;Women;184 Le¾n;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;485 Le¾n;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;401 Le¾n;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;84 Le¾n;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;382 Le¾n;Group 0905 Diseases of the lungs circulation 415-417;Men;176 Le¾n;Group 0905 Diseases of the lungs circulation 415-417;Women;206 Le¾n;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.043 Le¾n;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;552 Le¾n;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;491 Le¾n;Grupo 0907 Heart failure 428;Both sexes;1.716 Le¾n;Grupo 0907 Heart failure 428;Men;812 Le¾n;Grupo 0907 Heart failure 428;Women;904 Le¾n;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.441 Le¾n;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;756 Le¾n;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;685 Le¾n;Grupo 0909 Atherosclerosis 440;Both sexes;241 Le¾n;Grupo 0909 Atherosclerosis 440;Men;166 Le¾n;Grupo 0909 Atherosclerosis 440;Women;75 Le¾n;Group 0910 Varicose veins of lower extremities 454;Both sexes;478 Le¾n;Group 0910 Varicose veins of lower extremities 454;Men;181 Le¾n;Group 0910 Varicose veins of lower extremities 454;Women;297 Le¾n;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.609 Le¾n;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;912 Le¾n;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;697 Le¾n;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7.179 Le¾n;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.291 Le¾n;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.888 Le¾n;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;189 Le¾n;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;113 Le¾n;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;76 Le¾n;Group 1002 Pneumonia 480-486;Both sexes;1.609 Le¾n;Group 1002 Pneumonia 480-486;Men;1.007 Le¾n;Group 1002 Pneumonia 480-486;Women;602 Le¾n;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;431 Le¾n;Group 1003 Acute bronchitis and bronchiolitis 466;Men;221 Le¾n;Group 1003 Acute bronchitis and bronchiolitis 466;Women;210 Le¾n;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;272 Le¾n;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;130 Le¾n;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;142 Le¾n;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;656 Le¾n;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;422 Le¾n;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;234 Le¾n;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.293 Le¾n;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.023 Le¾n;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;270 Le¾n;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;241 Le¾n;Group 1007 Asthma 4930-4931,4938-4939;Men;74 Le¾n;Group 1007 Asthma 4930-4931,4938-4939;Women;167 Le¾n;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.488 Le¾n;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.301 Le¾n;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.187 Le¾n;Group 1100 Diseases of the digestive system 520-579;Both sexes;7.665 Le¾n;Group 1100 Diseases of the digestive system 520-579;Men;4.609 Le¾n;Group 1100 Diseases of the digestive system 520-579;Women;3.056 Le¾n;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;99 Le¾n;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;44 Le¾n;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;55 Le¾n;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;86 Le¾n;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;45 Le¾n;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;41 Le¾n;Group 1103 Diseases of the esophagus 530;Both sexes;98 Le¾n;Group 1103 Diseases of the esophagus 530;Men;58 Le¾n;Group 1103 Diseases of the esophagus 530;Women;40 Le¾n;Group 1104 Peptic ulcer 531-534;Both sexes;121 Le¾n;Group 1104 Peptic ulcer 531-534;Men;83 Le¾n;Group 1104 Peptic ulcer 531-534;Women;38 Le¾n;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;222 Le¾n;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;117 Le¾n;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;105 Le¾n;Group 1106 Appendicitis 540-543;Both sexes;545 Le¾n;Group 1106 Appendicitis 540-543;Men;324 Le¾n;Group 1106 Appendicitis 540-543;Women;221 Le¾n;Group 1107 Inguinal hernia 550;Both sexes;1.271 Le¾n;Group 1107 Inguinal hernia 550;Men;1.162 Le¾n;Group 1107 Inguinal hernia 550;Women;109 Le¾n;Group 1108 Other abdominal hernia 551-553;Both sexes;666 Le¾n;Group 1108 Other abdominal hernia 551-553;Men;342 Le¾n;Group 1108 Other abdominal hernia 551-553;Women;324 Le¾n;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;124 Le¾n;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;72 Le¾n;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;52 Le¾n;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;465 Le¾n;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;233 Le¾n;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;232 Le¾n;Group 1111 Intestinal obstruction without hernia 560;Both sexes;382 Le¾n;Group 1111 Intestinal obstruction without hernia 560;Men;198 Le¾n;Group 1111 Intestinal obstruction without hernia 560;Women;184 Le¾n;Group 1112 Intestinal diverticulosis 562;Both sexes;355 Le¾n;Group 1112 Intestinal diverticulosis 562;Men;176 Le¾n;Group 1112 Intestinal diverticulosis 562;Women;179 Le¾n;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;411 Le¾n;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;257 Le¾n;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;154 Le¾n;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;388 Le¾n;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;184 Le¾n;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;204 Le¾n;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;110 Le¾n;Group 1115 Alcoholic hepatitis 5710-5713;Men;92 Le¾n;Group 1115 Alcoholic hepatitis 5710-5713;Women;18 Le¾n;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;194 Le¾n;Group 1116 Other diseases of the liver 570,5714-573;Men;126 Le¾n;Group 1116 Other diseases of the liver 570,5714-573;Women;68 Le¾n;Group 1117 Cholelithiasis 574;Both sexes;1.288 Le¾n;Group 1117 Cholelithiasis 574;Men;607 Le¾n;Group 1117 Cholelithiasis 574;Women;681 Le¾n;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;313 Le¾n;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;189 Le¾n;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;124 Le¾n;Group 1119 Pancreatic diseases 577;Both sexes;312 Le¾n;Group 1119 Pancreatic diseases 577;Men;182 Le¾n;Group 1119 Pancreatic diseases 577;Women;130 Le¾n;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;215 Le¾n;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;118 Le¾n;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;97 Le¾n;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;799 Le¾n;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;444 Le¾n;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;355 Le¾n;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;405 Le¾n;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;259 Le¾n;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;146 Le¾n;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;40 Le¾n;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;17 Le¾n;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;23 Le¾n;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;354 Le¾n;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;168 Le¾n;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;186 Le¾n;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;4.885 Le¾n;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.299 Le¾n;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2.586 Le¾n;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Le¾n;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Le¾n;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Le¾n;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Le¾n;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Le¾n;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Le¾n;Group 1303 Internal derangement of knee 717;Both sexes;651 Le¾n;Group 1303 Internal derangement of knee 717;Men;416 Le¾n;Group 1303 Internal derangement of knee 717;Women;235 Le¾n;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.710 Le¾n;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;776 Le¾n;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;934 Le¾n;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;95 Le¾n;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;34 Le¾n;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;61 Le¾n;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;338 Le¾n;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;162 Le¾n;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;176 Le¾n;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;439 Le¾n;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;236 Le¾n;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;203 Le¾n;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;259 Le¾n;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;123 Le¾n;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;136 Le¾n;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;680 Le¾n;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;310 Le¾n;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;370 Le¾n;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;713 Le¾n;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;242 Le¾n;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;471 Le¾n;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.759 Le¾n;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.603 Le¾n;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2.156 Le¾n;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;196 Le¾n;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;87 Le¾n;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;109 Le¾n;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;329 Le¾n;Group 1402 Renal failure 5836-5837, 584-586;Men;194 Le¾n;Group 1402 Renal failure 5836-5837, 584-586;Women;135 Le¾n;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;329 Le¾n;Group 1403 Urolithiasis 592, 594, 7880;Men;184 Le¾n;Group 1403 Urolithiasis 592, 594, 7880;Women;145 Le¾n;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.186 Le¾n;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;478 Le¾n;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;708 Le¾n;Group 1405 Prostatic hyperplasia 600;Both sexes;329 Le¾n;Group 1405 Prostatic hyperplasia 600;Men;329 Le¾n;Group 1405 Prostatic hyperplasia 600;Women;.. Le¾n;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;307 Le¾n;Group 1406 Other diseases of the male genital organs 601-608;Men;307 Le¾n;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Le¾n;Group 1407 Disorders of breast 610-612;Both sexes;147 Le¾n;Group 1407 Disorders of breast 610-612;Men;20 Le¾n;Group 1407 Disorders of breast 610-612;Women;127 Le¾n;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;97 Le¾n;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Le¾n;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;97 Le¾n;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;184 Le¾n;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Le¾n;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;184 Le¾n;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;655 Le¾n;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;4 Le¾n;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;651 Le¾n;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3.669 Le¾n;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Le¾n;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3.669 Le¾n;Group 1501 Legally induced abortion 635;Both sexes;.. Le¾n;Group 1501 Legally induced abortion 635;Men;.. Le¾n;Group 1501 Legally induced abortion 635;Women;.. Le¾n;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;250 Le¾n;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Le¾n;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;250 Le¾n;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.996 Le¾n;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Le¾n;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.996 Le¾n;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;526 Le¾n;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Le¾n;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;526 Le¾n;Group 1505 Single spontaneous delivery 650;Both sexes;556 Le¾n;Group 1505 Single spontaneous delivery 650;Men;.. Le¾n;Group 1505 Single spontaneous delivery 650;Women;556 Le¾n;Group 1506 Other deliveries 6695-6697;Both sexes;141 Le¾n;Group 1506 Other deliveries 6695-6697;Men;.. Le¾n;Group 1506 Other deliveries 6695-6697;Women;141 Le¾n;Group 1507 Complications related to the puerperium 670-676;Both sexes;18 Le¾n;Group 1507 Complications related to the puerperium 670-676;Men;.. Le¾n;Group 1507 Complications related to the puerperium 670-676;Women;18 Le¾n;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;182 Le¾n;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Le¾n;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;182 Le¾n;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;545 Le¾n;Group 1600 Some disorders originating in the perinatal period 760-779;Men;303 Le¾n;Group 1600 Some disorders originating in the perinatal period 760-779;Women;242 Le¾n;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;172 Le¾n;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;93 Le¾n;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;79 Le¾n;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;373 Le¾n;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;210 Le¾n;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;163 Le¾n;Grupo 1700 Congenital abnormalities 740-759;Both sexes;244 Le¾n;Grupo 1700 Congenital abnormalities 740-759;Men;143 Le¾n;Grupo 1700 Congenital abnormalities 740-759;Women;101 Le¾n;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.716 Le¾n;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.463 Le¾n;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.253 Le¾n;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;220 Le¾n;Group 1801 Pain in throat and chest 7841, 7865;Men;123 Le¾n;Group 1801 Pain in throat and chest 7841, 7865;Women;97 Le¾n;Group 1802 Abdominal pain 7890;Both sexes;265 Le¾n;Group 1802 Abdominal pain 7890;Men;125 Le¾n;Group 1802 Abdominal pain 7890;Women;140 Le¾n;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;364 Le¾n;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;192 Le¾n;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;172 Le¾n;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.867 Le¾n;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.023 Le¾n;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;844 Le¾n;Group 1900 Injuries and poisoning 800-999;Both sexes;5.528 Le¾n;Group 1900 Injuries and poisoning 800-999;Men;2.746 Le¾n;Group 1900 Injuries and poisoning 800-999;Women;2.782 Le¾n;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;352 Le¾n;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;181 Le¾n;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;171 Le¾n;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;157 Le¾n;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;109 Le¾n;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;48 Le¾n;Group 1903 Radius and ulna fracture 813;Both sexes;193 Le¾n;Group 1903 Radius and ulna fracture 813;Men;86 Le¾n;Group 1903 Radius and ulna fracture 813;Women;107 Le¾n;Group 1904 Femur fracture 820-821;Both sexes;1.118 Le¾n;Group 1904 Femur fracture 820-821;Men;314 Le¾n;Group 1904 Femur fracture 820-821;Women;804 Le¾n;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;296 Le¾n;Group 1905 Leg fracture, including the ankle 823-824;Men;151 Le¾n;Group 1905 Leg fracture, including the ankle 823-824;Women;145 Le¾n;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.669 Le¾n;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;954 Le¾n;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;715 Le¾n;Group 1907 Burns 940-949;Both sexes;44 Le¾n;Group 1907 Burns 940-949;Men;31 Le¾n;Group 1907 Burns 940-949;Women;13 Le¾n;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;161 Le¾n;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;65 Le¾n;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;96 Le¾n;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.276 Le¾n;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;709 Le¾n;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;567 Le¾n;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;7 Le¾n;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;7 Le¾n;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Le¾n;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;255 Le¾n;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;139 Le¾n;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;116 Le¾n;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.627 Le¾n;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;852 Le¾n;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;775 Le¾n;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;56 Le¾n;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;38 Le¾n;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;18 Le¾n;Group 2102 Contraceptive management V25;Both sexes;36 Le¾n;Group 2102 Contraceptive management V25;Men;.. Le¾n;Group 2102 Contraceptive management V25;Women;36 Le¾n;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Le¾n;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Le¾n;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Le¾n;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;328 Le¾n;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;205 Le¾n;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;123 Le¾n;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.207 Le¾n;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;609 Le¾n;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;598 Palencia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;18.680 Palencia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;9.567 Palencia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;9.113 Palencia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;332 Palencia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;204 Palencia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;128 Palencia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;91 Palencia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;49 Palencia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;42 Palencia;Group 0102 Imprecise intestinal infections 009;Both sexes;12 Palencia;Group 0102 Imprecise intestinal infections 009;Men;7 Palencia;Group 0102 Imprecise intestinal infections 009;Women;5 Palencia;Group 0103 Tuberculosis 010-018, 137;Both sexes;13 Palencia;Group 0103 Tuberculosis 010-018, 137;Men;6 Palencia;Group 0103 Tuberculosis 010-018, 137;Women;7 Palencia;Group 0104 Septicaemia 038;Both sexes;66 Palencia;Group 0104 Septicaemia 038;Men;39 Palencia;Group 0104 Septicaemia 038;Women;27 Palencia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;10 Palencia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;7 Palencia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 Palencia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;140 Palencia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;96 Palencia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;44 Palencia;Group 0200 Neoplasms 140-239;Both sexes;1.640 Palencia;Group 0200 Neoplasms 140-239;Men;894 Palencia;Group 0200 Neoplasms 140-239;Women;746 Palencia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;221 Palencia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;133 Palencia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;88 Palencia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;124 Palencia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;102 Palencia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;22 Palencia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;3 Palencia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;1 Palencia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;2 Palencia;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;112 Palencia;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Palencia;Group 0204 Malignant neoplasm of breast 174-175;Women;111 Palencia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;39 Palencia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Palencia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;39 Palencia;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;16 Palencia;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Palencia;Group 0206 Malignant neoplasm of ovary 1830;Women;16 Palencia;Group 0207 Malignant neoplasm of prostate 185;Both sexes;63 Palencia;Group 0207 Malignant neoplasm of prostate 185;Men;63 Palencia;Group 0207 Malignant neoplasm of prostate 185;Women;.. Palencia;Group 0208 Malignant neoplasm of bladder 188;Both sexes;185 Palencia;Group 0208 Malignant neoplasm of bladder 188;Men;157 Palencia;Group 0208 Malignant neoplasm of bladder 188;Women;28 Palencia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;574 Palencia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;340 Palencia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;234 Palencia;Group 0210 Carcinoma in situ 230-234;Both sexes;29 Palencia;Group 0210 Carcinoma in situ 230-234;Men;8 Palencia;Group 0210 Carcinoma in situ 230-234;Women;21 Palencia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;13 Palencia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;10 Palencia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;3 Palencia;Grupo 0212 Leiomyoma of uterus 218;Both sexes;78 Palencia;Grupo 0212 Leiomyoma of uterus 218;Men;.. Palencia;Grupo 0212 Leiomyoma of uterus 218;Women;78 Palencia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;183 Palencia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;79 Palencia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;104 Palencia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;161 Palencia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;80 Palencia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;81 Palencia;Group 0301 Anaemias 280-285;Both sexes;115 Palencia;Group 0301 Anaemias 280-285;Men;57 Palencia;Group 0301 Anaemias 280-285;Women;58 Palencia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;46 Palencia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;23 Palencia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;23 Palencia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;277 Palencia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;120 Palencia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;157 Palencia;Group 0401 Diabetes mellitus 249-250;Both sexes;101 Palencia;Group 0401 Diabetes mellitus 249-250;Men;51 Palencia;Group 0401 Diabetes mellitus 249-250;Women;50 Palencia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;176 Palencia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;69 Palencia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;107 Palencia;Group 0500 Mental disorders 290-319;Both sexes;820 Palencia;Group 0500 Mental disorders 290-319;Men;463 Palencia;Group 0500 Mental disorders 290-319;Women;357 Palencia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;29 Palencia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;13 Palencia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;16 Palencia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;75 Palencia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;63 Palencia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;12 Palencia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;117 Palencia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;100 Palencia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;17 Palencia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;217 Palencia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;120 Palencia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;97 Palencia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;167 Palencia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;61 Palencia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;106 Palencia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;215 Palencia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;106 Palencia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;109 Palencia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;409 Palencia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;206 Palencia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;203 Palencia;Group 0601 Alzheimer's disease 3310;Both sexes;22 Palencia;Group 0601 Alzheimer's disease 3310;Men;8 Palencia;Group 0601 Alzheimer's disease 3310;Women;14 Palencia;Group 0602 Multiple sclerosis 340;Both sexes;26 Palencia;Group 0602 Multiple sclerosis 340;Men;11 Palencia;Group 0602 Multiple sclerosis 340;Women;15 Palencia;Group 0603 Epilepsy 345;Both sexes;73 Palencia;Group 0603 Epilepsy 345;Men;43 Palencia;Group 0603 Epilepsy 345;Women;30 Palencia;Group 0604 Transient cerebral ischemia 435;Both sexes;91 Palencia;Group 0604 Transient cerebral ischemia 435;Men;40 Palencia;Group 0604 Transient cerebral ischemia 435;Women;51 Palencia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;197 Palencia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;104 Palencia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;93 Palencia;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;78 Palencia;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;25 Palencia;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;53 Palencia;Grupo 0701 Cataract 366;Both sexes;11 Palencia;Grupo 0701 Cataract 366;Men;.. Palencia;Grupo 0701 Cataract 366;Women;11 Palencia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;67 Palencia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;25 Palencia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;42 Palencia;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;92 Palencia;Group 0800 Diseases of the ear and the mastoid 380-389;Men;45 Palencia;Group 0800 Diseases of the ear and the mastoid 380-389;Women;47 Palencia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;2.493 Palencia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1.248 Palencia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1.245 Palencia;Group 0901 Hypertensive disease 401-405;Both sexes;241 Palencia;Group 0901 Hypertensive disease 401-405;Men;69 Palencia;Group 0901 Hypertensive disease 401-405;Women;172 Palencia;Group 0902 Angina pectoris 4111, 413;Both sexes;87 Palencia;Group 0902 Angina pectoris 4111, 413;Men;50 Palencia;Group 0902 Angina pectoris 4111, 413;Women;37 Palencia;Group 0903 Acute myocardial infarction 410;Both sexes;243 Palencia;Group 0903 Acute myocardial infarction 410;Men;162 Palencia;Group 0903 Acute myocardial infarction 410;Women;81 Palencia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;115 Palencia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;91 Palencia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;24 Palencia;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;85 Palencia;Group 0905 Diseases of the lungs circulation 415-417;Men;33 Palencia;Group 0905 Diseases of the lungs circulation 415-417;Women;52 Palencia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;470 Palencia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;221 Palencia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;249 Palencia;Grupo 0907 Heart failure 428;Both sexes;553 Palencia;Grupo 0907 Heart failure 428;Men;269 Palencia;Grupo 0907 Heart failure 428;Women;284 Palencia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;380 Palencia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;177 Palencia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;203 Palencia;Grupo 0909 Atherosclerosis 440;Both sexes;29 Palencia;Grupo 0909 Atherosclerosis 440;Men;17 Palencia;Grupo 0909 Atherosclerosis 440;Women;12 Palencia;Group 0910 Varicose veins of lower extremities 454;Both sexes;2 Palencia;Group 0910 Varicose veins of lower extremities 454;Men;1 Palencia;Group 0910 Varicose veins of lower extremities 454;Women;1 Palencia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;288 Palencia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;158 Palencia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;130 Palencia;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2.765 Palencia;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.596 Palencia;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.169 Palencia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;144 Palencia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;85 Palencia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;59 Palencia;Group 1002 Pneumonia 480-486;Both sexes;484 Palencia;Group 1002 Pneumonia 480-486;Men;300 Palencia;Group 1002 Pneumonia 480-486;Women;184 Palencia;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;162 Palencia;Group 1003 Acute bronchitis and bronchiolitis 466;Men;74 Palencia;Group 1003 Acute bronchitis and bronchiolitis 466;Women;88 Palencia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;183 Palencia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;106 Palencia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;77 Palencia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;306 Palencia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;203 Palencia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;103 Palencia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;531 Palencia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;397 Palencia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;134 Palencia;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;123 Palencia;Group 1007 Asthma 4930-4931,4938-4939;Men;27 Palencia;Group 1007 Asthma 4930-4931,4938-4939;Women;96 Palencia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;832 Palencia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;404 Palencia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;428 Palencia;Group 1100 Diseases of the digestive system 520-579;Both sexes;2.694 Palencia;Group 1100 Diseases of the digestive system 520-579;Men;1.650 Palencia;Group 1100 Diseases of the digestive system 520-579;Women;1.044 Palencia;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;13 Palencia;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;7 Palencia;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;6 Palencia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;10 Palencia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;7 Palencia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;3 Palencia;Group 1103 Diseases of the esophagus 530;Both sexes;42 Palencia;Group 1103 Diseases of the esophagus 530;Men;33 Palencia;Group 1103 Diseases of the esophagus 530;Women;9 Palencia;Group 1104 Peptic ulcer 531-534;Both sexes;66 Palencia;Group 1104 Peptic ulcer 531-534;Men;47 Palencia;Group 1104 Peptic ulcer 531-534;Women;19 Palencia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;95 Palencia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;56 Palencia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;39 Palencia;Group 1106 Appendicitis 540-543;Both sexes;191 Palencia;Group 1106 Appendicitis 540-543;Men;106 Palencia;Group 1106 Appendicitis 540-543;Women;85 Palencia;Group 1107 Inguinal hernia 550;Both sexes;415 Palencia;Group 1107 Inguinal hernia 550;Men;386 Palencia;Group 1107 Inguinal hernia 550;Women;29 Palencia;Group 1108 Other abdominal hernia 551-553;Both sexes;190 Palencia;Group 1108 Other abdominal hernia 551-553;Men;86 Palencia;Group 1108 Other abdominal hernia 551-553;Women;104 Palencia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;26 Palencia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;11 Palencia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;15 Palencia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;193 Palencia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;99 Palencia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;94 Palencia;Group 1111 Intestinal obstruction without hernia 560;Both sexes;118 Palencia;Group 1111 Intestinal obstruction without hernia 560;Men;75 Palencia;Group 1111 Intestinal obstruction without hernia 560;Women;43 Palencia;Group 1112 Intestinal diverticulosis 562;Both sexes;95 Palencia;Group 1112 Intestinal diverticulosis 562;Men;46 Palencia;Group 1112 Intestinal diverticulosis 562;Women;49 Palencia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;150 Palencia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;100 Palencia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;50 Palencia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;112 Palencia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;53 Palencia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;59 Palencia;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;56 Palencia;Group 1115 Alcoholic hepatitis 5710-5713;Men;46 Palencia;Group 1115 Alcoholic hepatitis 5710-5713;Women;10 Palencia;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;89 Palencia;Group 1116 Other diseases of the liver 570,5714-573;Men;57 Palencia;Group 1116 Other diseases of the liver 570,5714-573;Women;32 Palencia;Group 1117 Cholelithiasis 574;Both sexes;443 Palencia;Group 1117 Cholelithiasis 574;Men;215 Palencia;Group 1117 Cholelithiasis 574;Women;228 Palencia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;146 Palencia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;80 Palencia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;66 Palencia;Group 1119 Pancreatic diseases 577;Both sexes;139 Palencia;Group 1119 Pancreatic diseases 577;Men;82 Palencia;Group 1119 Pancreatic diseases 577;Women;57 Palencia;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;105 Palencia;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;58 Palencia;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;47 Palencia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;198 Palencia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;114 Palencia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;84 Palencia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;140 Palencia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;93 Palencia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;47 Palencia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;6 Palencia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;3 Palencia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;3 Palencia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;52 Palencia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;18 Palencia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;34 Palencia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;1.036 Palencia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;533 Palencia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;503 Palencia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Palencia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Palencia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Palencia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Palencia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Palencia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Palencia;Group 1303 Internal derangement of knee 717;Both sexes;172 Palencia;Group 1303 Internal derangement of knee 717;Men;119 Palencia;Group 1303 Internal derangement of knee 717;Women;53 Palencia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;382 Palencia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;189 Palencia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;193 Palencia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;13 Palencia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;4 Palencia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;9 Palencia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;16 Palencia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;10 Palencia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;6 Palencia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;44 Palencia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;29 Palencia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;15 Palencia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;38 Palencia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;13 Palencia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;25 Palencia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;200 Palencia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;112 Palencia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;88 Palencia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;171 Palencia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;57 Palencia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;114 Palencia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1.331 Palencia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;704 Palencia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;627 Palencia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;90 Palencia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;31 Palencia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;59 Palencia;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;130 Palencia;Group 1402 Renal failure 5836-5837, 584-586;Men;75 Palencia;Group 1402 Renal failure 5836-5837, 584-586;Women;55 Palencia;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;228 Palencia;Group 1403 Urolithiasis 592, 594, 7880;Men;140 Palencia;Group 1403 Urolithiasis 592, 594, 7880;Women;88 Palencia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;423 Palencia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;233 Palencia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;190 Palencia;Group 1405 Prostatic hyperplasia 600;Both sexes;117 Palencia;Group 1405 Prostatic hyperplasia 600;Men;117 Palencia;Group 1405 Prostatic hyperplasia 600;Women;.. Palencia;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;104 Palencia;Group 1406 Other diseases of the male genital organs 601-608;Men;104 Palencia;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Palencia;Group 1407 Disorders of breast 610-612;Both sexes;26 Palencia;Group 1407 Disorders of breast 610-612;Men;4 Palencia;Group 1407 Disorders of breast 610-612;Women;22 Palencia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;28 Palencia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Palencia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;28 Palencia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;14 Palencia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Palencia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;14 Palencia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;171 Palencia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Palencia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;171 Palencia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.320 Palencia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Palencia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.320 Palencia;Group 1501 Legally induced abortion 635;Both sexes;.. Palencia;Group 1501 Legally induced abortion 635;Men;.. Palencia;Group 1501 Legally induced abortion 635;Women;.. Palencia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;188 Palencia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Palencia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;188 Palencia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;664 Palencia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Palencia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;664 Palencia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;273 Palencia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Palencia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;273 Palencia;Group 1505 Single spontaneous delivery 650;Both sexes;42 Palencia;Group 1505 Single spontaneous delivery 650;Men;.. Palencia;Group 1505 Single spontaneous delivery 650;Women;42 Palencia;Group 1506 Other deliveries 6695-6697;Both sexes;82 Palencia;Group 1506 Other deliveries 6695-6697;Men;.. Palencia;Group 1506 Other deliveries 6695-6697;Women;82 Palencia;Group 1507 Complications related to the puerperium 670-676;Both sexes;10 Palencia;Group 1507 Complications related to the puerperium 670-676;Men;.. Palencia;Group 1507 Complications related to the puerperium 670-676;Women;10 Palencia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;61 Palencia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Palencia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;61 Palencia;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;205 Palencia;Group 1600 Some disorders originating in the perinatal period 760-779;Men;102 Palencia;Group 1600 Some disorders originating in the perinatal period 760-779;Women;103 Palencia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;43 Palencia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;17 Palencia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;26 Palencia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;162 Palencia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;85 Palencia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;77 Palencia;Grupo 1700 Congenital abnormalities 740-759;Both sexes;53 Palencia;Grupo 1700 Congenital abnormalities 740-759;Men;26 Palencia;Grupo 1700 Congenital abnormalities 740-759;Women;27 Palencia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;903 Palencia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;543 Palencia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;360 Palencia;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;192 Palencia;Group 1801 Pain in throat and chest 7841, 7865;Men;130 Palencia;Group 1801 Pain in throat and chest 7841, 7865;Women;62 Palencia;Group 1802 Abdominal pain 7890;Both sexes;85 Palencia;Group 1802 Abdominal pain 7890;Men;35 Palencia;Group 1802 Abdominal pain 7890;Women;50 Palencia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;10 Palencia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;8 Palencia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;2 Palencia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;616 Palencia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;370 Palencia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;246 Palencia;Group 1900 Injuries and poisoning 800-999;Both sexes;1.617 Palencia;Group 1900 Injuries and poisoning 800-999;Men;821 Palencia;Group 1900 Injuries and poisoning 800-999;Women;796 Palencia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;109 Palencia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;63 Palencia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;46 Palencia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;22 Palencia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;11 Palencia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;11 Palencia;Group 1903 Radius and ulna fracture 813;Both sexes;85 Palencia;Group 1903 Radius and ulna fracture 813;Men;43 Palencia;Group 1903 Radius and ulna fracture 813;Women;42 Palencia;Group 1904 Femur fracture 820-821;Both sexes;330 Palencia;Group 1904 Femur fracture 820-821;Men;83 Palencia;Group 1904 Femur fracture 820-821;Women;247 Palencia;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;121 Palencia;Group 1905 Leg fracture, including the ankle 823-824;Men;63 Palencia;Group 1905 Leg fracture, including the ankle 823-824;Women;58 Palencia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;414 Palencia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;247 Palencia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;167 Palencia;Group 1907 Burns 940-949;Both sexes;2 Palencia;Group 1907 Burns 940-949;Men;1 Palencia;Group 1907 Burns 940-949;Women;1 Palencia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;76 Palencia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;39 Palencia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;37 Palencia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;393 Palencia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;240 Palencia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;153 Palencia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;4 Palencia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;3 Palencia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Palencia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;61 Palencia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;28 Palencia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;33 Palencia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;256 Palencia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;193 Palencia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;63 Palencia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;1 Palencia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;1 Palencia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;.. Palencia;Group 2102 Contraceptive management V25;Both sexes;1 Palencia;Group 2102 Contraceptive management V25;Men;1 Palencia;Group 2102 Contraceptive management V25;Women;.. Palencia;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Palencia;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Palencia;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Palencia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;177 Palencia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;140 Palencia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;37 Palencia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;77 Palencia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;51 Palencia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;26 Salamanca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;34.379 Salamanca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;16.939 Salamanca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;17.440 Salamanca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;952 Salamanca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;546 Salamanca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;406 Salamanca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;83 Salamanca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;39 Salamanca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;44 Salamanca;Group 0102 Imprecise intestinal infections 009;Both sexes;39 Salamanca;Group 0102 Imprecise intestinal infections 009;Men;21 Salamanca;Group 0102 Imprecise intestinal infections 009;Women;18 Salamanca;Group 0103 Tuberculosis 010-018, 137;Both sexes;20 Salamanca;Group 0103 Tuberculosis 010-018, 137;Men;14 Salamanca;Group 0103 Tuberculosis 010-018, 137;Women;6 Salamanca;Group 0104 Septicaemia 038;Both sexes;630 Salamanca;Group 0104 Septicaemia 038;Men;358 Salamanca;Group 0104 Septicaemia 038;Women;272 Salamanca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;16 Salamanca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;12 Salamanca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;4 Salamanca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;164 Salamanca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;102 Salamanca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;62 Salamanca;Group 0200 Neoplasms 140-239;Both sexes;3.774 Salamanca;Group 0200 Neoplasms 140-239;Men;2.019 Salamanca;Group 0200 Neoplasms 140-239;Women;1.755 Salamanca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;410 Salamanca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;236 Salamanca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;174 Salamanca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;297 Salamanca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;235 Salamanca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;62 Salamanca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;131 Salamanca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;73 Salamanca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;58 Salamanca;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;159 Salamanca;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Salamanca;Group 0204 Malignant neoplasm of breast 174-175;Women;156 Salamanca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;53 Salamanca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Salamanca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;53 Salamanca;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;51 Salamanca;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Salamanca;Group 0206 Malignant neoplasm of ovary 1830;Women;51 Salamanca;Group 0207 Malignant neoplasm of prostate 185;Both sexes;123 Salamanca;Group 0207 Malignant neoplasm of prostate 185;Men;123 Salamanca;Group 0207 Malignant neoplasm of prostate 185;Women;.. Salamanca;Group 0208 Malignant neoplasm of bladder 188;Both sexes;338 Salamanca;Group 0208 Malignant neoplasm of bladder 188;Men;282 Salamanca;Group 0208 Malignant neoplasm of bladder 188;Women;56 Salamanca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.470 Salamanca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;788 Salamanca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;682 Salamanca;Group 0210 Carcinoma in situ 230-234;Both sexes;33 Salamanca;Group 0210 Carcinoma in situ 230-234;Men;10 Salamanca;Group 0210 Carcinoma in situ 230-234;Women;23 Salamanca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;25 Salamanca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;14 Salamanca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;11 Salamanca;Grupo 0212 Leiomyoma of uterus 218;Both sexes;146 Salamanca;Grupo 0212 Leiomyoma of uterus 218;Men;.. Salamanca;Grupo 0212 Leiomyoma of uterus 218;Women;146 Salamanca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;538 Salamanca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;255 Salamanca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;283 Salamanca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;368 Salamanca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;180 Salamanca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;188 Salamanca;Group 0301 Anaemias 280-285;Both sexes;247 Salamanca;Group 0301 Anaemias 280-285;Men;112 Salamanca;Group 0301 Anaemias 280-285;Women;135 Salamanca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;121 Salamanca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;68 Salamanca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;53 Salamanca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;749 Salamanca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;325 Salamanca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;424 Salamanca;Group 0401 Diabetes mellitus 249-250;Both sexes;365 Salamanca;Group 0401 Diabetes mellitus 249-250;Men;191 Salamanca;Group 0401 Diabetes mellitus 249-250;Women;174 Salamanca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;384 Salamanca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;134 Salamanca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;250 Salamanca;Group 0500 Mental disorders 290-319;Both sexes;748 Salamanca;Group 0500 Mental disorders 290-319;Men;438 Salamanca;Group 0500 Mental disorders 290-319;Women;310 Salamanca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;8 Salamanca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;2 Salamanca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;6 Salamanca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;70 Salamanca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;58 Salamanca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;12 Salamanca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;187 Salamanca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;144 Salamanca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;43 Salamanca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;162 Salamanca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;106 Salamanca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;56 Salamanca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;132 Salamanca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;46 Salamanca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;86 Salamanca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;189 Salamanca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;82 Salamanca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;107 Salamanca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;905 Salamanca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;372 Salamanca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;533 Salamanca;Group 0601 Alzheimer's disease 3310;Both sexes;6 Salamanca;Group 0601 Alzheimer's disease 3310;Men;2 Salamanca;Group 0601 Alzheimer's disease 3310;Women;4 Salamanca;Group 0602 Multiple sclerosis 340;Both sexes;4 Salamanca;Group 0602 Multiple sclerosis 340;Men;1 Salamanca;Group 0602 Multiple sclerosis 340;Women;3 Salamanca;Group 0603 Epilepsy 345;Both sexes;91 Salamanca;Group 0603 Epilepsy 345;Men;45 Salamanca;Group 0603 Epilepsy 345;Women;46 Salamanca;Group 0604 Transient cerebral ischemia 435;Both sexes;84 Salamanca;Group 0604 Transient cerebral ischemia 435;Men;34 Salamanca;Group 0604 Transient cerebral ischemia 435;Women;50 Salamanca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;720 Salamanca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;290 Salamanca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;430 Salamanca;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;118 Salamanca;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;68 Salamanca;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;50 Salamanca;Grupo 0701 Cataract 366;Both sexes;10 Salamanca;Grupo 0701 Cataract 366;Men;3 Salamanca;Grupo 0701 Cataract 366;Women;7 Salamanca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;108 Salamanca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;65 Salamanca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;43 Salamanca;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;241 Salamanca;Group 0800 Diseases of the ear and the mastoid 380-389;Men;130 Salamanca;Group 0800 Diseases of the ear and the mastoid 380-389;Women;111 Salamanca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4.891 Salamanca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.779 Salamanca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.112 Salamanca;Group 0901 Hypertensive disease 401-405;Both sexes;338 Salamanca;Group 0901 Hypertensive disease 401-405;Men;130 Salamanca;Group 0901 Hypertensive disease 401-405;Women;208 Salamanca;Group 0902 Angina pectoris 4111, 413;Both sexes;120 Salamanca;Group 0902 Angina pectoris 4111, 413;Men;89 Salamanca;Group 0902 Angina pectoris 4111, 413;Women;31 Salamanca;Group 0903 Acute myocardial infarction 410;Both sexes;575 Salamanca;Group 0903 Acute myocardial infarction 410;Men;419 Salamanca;Group 0903 Acute myocardial infarction 410;Women;156 Salamanca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;210 Salamanca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;163 Salamanca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;47 Salamanca;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;215 Salamanca;Group 0905 Diseases of the lungs circulation 415-417;Men;105 Salamanca;Group 0905 Diseases of the lungs circulation 415-417;Women;110 Salamanca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;475 Salamanca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;268 Salamanca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;207 Salamanca;Grupo 0907 Heart failure 428;Both sexes;963 Salamanca;Grupo 0907 Heart failure 428;Men;439 Salamanca;Grupo 0907 Heart failure 428;Women;524 Salamanca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;778 Salamanca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;438 Salamanca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;340 Salamanca;Grupo 0909 Atherosclerosis 440;Both sexes;124 Salamanca;Grupo 0909 Atherosclerosis 440;Men;105 Salamanca;Grupo 0909 Atherosclerosis 440;Women;19 Salamanca;Group 0910 Varicose veins of lower extremities 454;Both sexes;190 Salamanca;Group 0910 Varicose veins of lower extremities 454;Men;74 Salamanca;Group 0910 Varicose veins of lower extremities 454;Women;116 Salamanca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;903 Salamanca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;549 Salamanca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;354 Salamanca;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;3.632 Salamanca;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2.168 Salamanca;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.464 Salamanca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;104 Salamanca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;51 Salamanca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;53 Salamanca;Group 1002 Pneumonia 480-486;Both sexes;728 Salamanca;Group 1002 Pneumonia 480-486;Men;440 Salamanca;Group 1002 Pneumonia 480-486;Women;288 Salamanca;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;494 Salamanca;Group 1003 Acute bronchitis and bronchiolitis 466;Men;228 Salamanca;Group 1003 Acute bronchitis and bronchiolitis 466;Women;266 Salamanca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;101 Salamanca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;52 Salamanca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;49 Salamanca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;409 Salamanca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;262 Salamanca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;147 Salamanca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;569 Salamanca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;488 Salamanca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;81 Salamanca;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;109 Salamanca;Group 1007 Asthma 4930-4931,4938-4939;Men;34 Salamanca;Group 1007 Asthma 4930-4931,4938-4939;Women;75 Salamanca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.118 Salamanca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;613 Salamanca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;505 Salamanca;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.018 Salamanca;Group 1100 Diseases of the digestive system 520-579;Men;2.226 Salamanca;Group 1100 Diseases of the digestive system 520-579;Women;1.792 Salamanca;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;49 Salamanca;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;22 Salamanca;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;27 Salamanca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;63 Salamanca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;37 Salamanca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;26 Salamanca;Group 1103 Diseases of the esophagus 530;Both sexes;92 Salamanca;Group 1103 Diseases of the esophagus 530;Men;46 Salamanca;Group 1103 Diseases of the esophagus 530;Women;46 Salamanca;Group 1104 Peptic ulcer 531-534;Both sexes;102 Salamanca;Group 1104 Peptic ulcer 531-534;Men;63 Salamanca;Group 1104 Peptic ulcer 531-534;Women;39 Salamanca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;100 Salamanca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;59 Salamanca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;41 Salamanca;Group 1106 Appendicitis 540-543;Both sexes;303 Salamanca;Group 1106 Appendicitis 540-543;Men;173 Salamanca;Group 1106 Appendicitis 540-543;Women;130 Salamanca;Group 1107 Inguinal hernia 550;Both sexes;372 Salamanca;Group 1107 Inguinal hernia 550;Men;320 Salamanca;Group 1107 Inguinal hernia 550;Women;52 Salamanca;Group 1108 Other abdominal hernia 551-553;Both sexes;323 Salamanca;Group 1108 Other abdominal hernia 551-553;Men;156 Salamanca;Group 1108 Other abdominal hernia 551-553;Women;167 Salamanca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;39 Salamanca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;24 Salamanca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;15 Salamanca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;167 Salamanca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;65 Salamanca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;102 Salamanca;Group 1111 Intestinal obstruction without hernia 560;Both sexes;302 Salamanca;Group 1111 Intestinal obstruction without hernia 560;Men;146 Salamanca;Group 1111 Intestinal obstruction without hernia 560;Women;156 Salamanca;Group 1112 Intestinal diverticulosis 562;Both sexes;198 Salamanca;Group 1112 Intestinal diverticulosis 562;Men;96 Salamanca;Group 1112 Intestinal diverticulosis 562;Women;102 Salamanca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;184 Salamanca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;120 Salamanca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;64 Salamanca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;171 Salamanca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;87 Salamanca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;84 Salamanca;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;49 Salamanca;Group 1115 Alcoholic hepatitis 5710-5713;Men;41 Salamanca;Group 1115 Alcoholic hepatitis 5710-5713;Women;8 Salamanca;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;134 Salamanca;Group 1116 Other diseases of the liver 570,5714-573;Men;89 Salamanca;Group 1116 Other diseases of the liver 570,5714-573;Women;45 Salamanca;Group 1117 Cholelithiasis 574;Both sexes;782 Salamanca;Group 1117 Cholelithiasis 574;Men;355 Salamanca;Group 1117 Cholelithiasis 574;Women;427 Salamanca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;178 Salamanca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;99 Salamanca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;79 Salamanca;Group 1119 Pancreatic diseases 577;Both sexes;178 Salamanca;Group 1119 Pancreatic diseases 577;Men;104 Salamanca;Group 1119 Pancreatic diseases 577;Women;74 Salamanca;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;232 Salamanca;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;124 Salamanca;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;108 Salamanca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;250 Salamanca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;144 Salamanca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;106 Salamanca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;131 Salamanca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;75 Salamanca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;56 Salamanca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;12 Salamanca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;8 Salamanca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;4 Salamanca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;107 Salamanca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;61 Salamanca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;46 Salamanca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;1.697 Salamanca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;738 Salamanca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;959 Salamanca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Salamanca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Salamanca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Salamanca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Salamanca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Salamanca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Salamanca;Group 1303 Internal derangement of knee 717;Both sexes;47 Salamanca;Group 1303 Internal derangement of knee 717;Men;35 Salamanca;Group 1303 Internal derangement of knee 717;Women;12 Salamanca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;719 Salamanca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;283 Salamanca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;436 Salamanca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;48 Salamanca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;24 Salamanca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;24 Salamanca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;160 Salamanca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;71 Salamanca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;89 Salamanca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;244 Salamanca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;120 Salamanca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;124 Salamanca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;27 Salamanca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;12 Salamanca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;15 Salamanca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;183 Salamanca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;90 Salamanca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;93 Salamanca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;269 Salamanca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;103 Salamanca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;166 Salamanca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1.992 Salamanca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;978 Salamanca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.014 Salamanca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;167 Salamanca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;72 Salamanca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;95 Salamanca;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;223 Salamanca;Group 1402 Renal failure 5836-5837, 584-586;Men;132 Salamanca;Group 1402 Renal failure 5836-5837, 584-586;Women;91 Salamanca;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;255 Salamanca;Group 1403 Urolithiasis 592, 594, 7880;Men;160 Salamanca;Group 1403 Urolithiasis 592, 594, 7880;Women;95 Salamanca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;442 Salamanca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;226 Salamanca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;216 Salamanca;Group 1405 Prostatic hyperplasia 600;Both sexes;216 Salamanca;Group 1405 Prostatic hyperplasia 600;Men;216 Salamanca;Group 1405 Prostatic hyperplasia 600;Women;.. Salamanca;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;154 Salamanca;Group 1406 Other diseases of the male genital organs 601-608;Men;154 Salamanca;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Salamanca;Group 1407 Disorders of breast 610-612;Both sexes;97 Salamanca;Group 1407 Disorders of breast 610-612;Men;6 Salamanca;Group 1407 Disorders of breast 610-612;Women;91 Salamanca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;69 Salamanca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Salamanca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;69 Salamanca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;23 Salamanca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Salamanca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;23 Salamanca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;346 Salamanca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;12 Salamanca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;334 Salamanca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;2.895 Salamanca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Salamanca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;2.895 Salamanca;Group 1501 Legally induced abortion 635;Both sexes;1 Salamanca;Group 1501 Legally induced abortion 635;Men;.. Salamanca;Group 1501 Legally induced abortion 635;Women;1 Salamanca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;236 Salamanca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Salamanca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;236 Salamanca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.646 Salamanca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Salamanca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.646 Salamanca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;574 Salamanca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Salamanca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;574 Salamanca;Group 1505 Single spontaneous delivery 650;Both sexes;179 Salamanca;Group 1505 Single spontaneous delivery 650;Men;.. Salamanca;Group 1505 Single spontaneous delivery 650;Women;179 Salamanca;Group 1506 Other deliveries 6695-6697;Both sexes;63 Salamanca;Group 1506 Other deliveries 6695-6697;Men;.. Salamanca;Group 1506 Other deliveries 6695-6697;Women;63 Salamanca;Group 1507 Complications related to the puerperium 670-676;Both sexes;20 Salamanca;Group 1507 Complications related to the puerperium 670-676;Men;.. Salamanca;Group 1507 Complications related to the puerperium 670-676;Women;20 Salamanca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;176 Salamanca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Salamanca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;176 Salamanca;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;371 Salamanca;Group 1600 Some disorders originating in the perinatal period 760-779;Men;204 Salamanca;Group 1600 Some disorders originating in the perinatal period 760-779;Women;167 Salamanca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;131 Salamanca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;86 Salamanca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;45 Salamanca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;240 Salamanca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;118 Salamanca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;122 Salamanca;Grupo 1700 Congenital abnormalities 740-759;Both sexes;224 Salamanca;Grupo 1700 Congenital abnormalities 740-759;Men;156 Salamanca;Grupo 1700 Congenital abnormalities 740-759;Women;68 Salamanca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.368 Salamanca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.322 Salamanca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.046 Salamanca;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;104 Salamanca;Group 1801 Pain in throat and chest 7841, 7865;Men;64 Salamanca;Group 1801 Pain in throat and chest 7841, 7865;Women;40 Salamanca;Group 1802 Abdominal pain 7890;Both sexes;170 Salamanca;Group 1802 Abdominal pain 7890;Men;75 Salamanca;Group 1802 Abdominal pain 7890;Women;95 Salamanca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.220 Salamanca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;701 Salamanca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;519 Salamanca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;874 Salamanca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;482 Salamanca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;392 Salamanca;Group 1900 Injuries and poisoning 800-999;Both sexes;3.365 Salamanca;Group 1900 Injuries and poisoning 800-999;Men;1.679 Salamanca;Group 1900 Injuries and poisoning 800-999;Women;1.686 Salamanca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;214 Salamanca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;132 Salamanca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;82 Salamanca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;76 Salamanca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;55 Salamanca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;21 Salamanca;Group 1903 Radius and ulna fracture 813;Both sexes;183 Salamanca;Group 1903 Radius and ulna fracture 813;Men;80 Salamanca;Group 1903 Radius and ulna fracture 813;Women;103 Salamanca;Group 1904 Femur fracture 820-821;Both sexes;603 Salamanca;Group 1904 Femur fracture 820-821;Men;145 Salamanca;Group 1904 Femur fracture 820-821;Women;458 Salamanca;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;224 Salamanca;Group 1905 Leg fracture, including the ankle 823-824;Men;103 Salamanca;Group 1905 Leg fracture, including the ankle 823-824;Women;121 Salamanca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;874 Salamanca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;540 Salamanca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;334 Salamanca;Group 1907 Burns 940-949;Both sexes;28 Salamanca;Group 1907 Burns 940-949;Men;16 Salamanca;Group 1907 Burns 940-949;Women;12 Salamanca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;93 Salamanca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;41 Salamanca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;52 Salamanca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;970 Salamanca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;511 Salamanca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;459 Salamanca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Salamanca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Salamanca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Salamanca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;100 Salamanca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;56 Salamanca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;44 Salamanca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;821 Salamanca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;467 Salamanca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;354 Salamanca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;20 Salamanca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;14 Salamanca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;6 Salamanca;Group 2102 Contraceptive management V25;Both sexes;11 Salamanca;Group 2102 Contraceptive management V25;Men;1 Salamanca;Group 2102 Contraceptive management V25;Women;10 Salamanca;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Salamanca;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Salamanca;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Salamanca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;624 Salamanca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;373 Salamanca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;251 Salamanca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;166 Salamanca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;79 Salamanca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;87 Segovia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;12.781 Segovia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;6.382 Segovia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;6.399 Segovia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;238 Segovia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;133 Segovia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;105 Segovia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;67 Segovia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;33 Segovia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;34 Segovia;Group 0102 Imprecise intestinal infections 009;Both sexes;6 Segovia;Group 0102 Imprecise intestinal infections 009;Men;1 Segovia;Group 0102 Imprecise intestinal infections 009;Women;5 Segovia;Group 0103 Tuberculosis 010-018, 137;Both sexes;1 Segovia;Group 0103 Tuberculosis 010-018, 137;Men;.. Segovia;Group 0103 Tuberculosis 010-018, 137;Women;1 Segovia;Group 0104 Septicaemia 038;Both sexes;95 Segovia;Group 0104 Septicaemia 038;Men;57 Segovia;Group 0104 Septicaemia 038;Women;38 Segovia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;2 Segovia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;2 Segovia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;.. Segovia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;67 Segovia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;40 Segovia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;27 Segovia;Group 0200 Neoplasms 140-239;Both sexes;1.208 Segovia;Group 0200 Neoplasms 140-239;Men;684 Segovia;Group 0200 Neoplasms 140-239;Women;524 Segovia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;196 Segovia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;131 Segovia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;65 Segovia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;82 Segovia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;64 Segovia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;18 Segovia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;21 Segovia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;12 Segovia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;9 Segovia;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;92 Segovia;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Segovia;Group 0204 Malignant neoplasm of breast 174-175;Women;92 Segovia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;24 Segovia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Segovia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;24 Segovia;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;13 Segovia;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Segovia;Group 0206 Malignant neoplasm of ovary 1830;Women;13 Segovia;Group 0207 Malignant neoplasm of prostate 185;Both sexes;51 Segovia;Group 0207 Malignant neoplasm of prostate 185;Men;51 Segovia;Group 0207 Malignant neoplasm of prostate 185;Women;.. Segovia;Group 0208 Malignant neoplasm of bladder 188;Both sexes;121 Segovia;Group 0208 Malignant neoplasm of bladder 188;Men;99 Segovia;Group 0208 Malignant neoplasm of bladder 188;Women;22 Segovia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;403 Segovia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;243 Segovia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;160 Segovia;Group 0210 Carcinoma in situ 230-234;Both sexes;52 Segovia;Group 0210 Carcinoma in situ 230-234;Men;31 Segovia;Group 0210 Carcinoma in situ 230-234;Women;21 Segovia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;5 Segovia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;4 Segovia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;1 Segovia;Grupo 0212 Leiomyoma of uterus 218;Both sexes;40 Segovia;Grupo 0212 Leiomyoma of uterus 218;Men;.. Segovia;Grupo 0212 Leiomyoma of uterus 218;Women;40 Segovia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;108 Segovia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;49 Segovia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;59 Segovia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;113 Segovia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;67 Segovia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;46 Segovia;Group 0301 Anaemias 280-285;Both sexes;68 Segovia;Group 0301 Anaemias 280-285;Men;45 Segovia;Group 0301 Anaemias 280-285;Women;23 Segovia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;45 Segovia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;22 Segovia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;23 Segovia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;191 Segovia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;68 Segovia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;123 Segovia;Group 0401 Diabetes mellitus 249-250;Both sexes;52 Segovia;Group 0401 Diabetes mellitus 249-250;Men;32 Segovia;Group 0401 Diabetes mellitus 249-250;Women;20 Segovia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;139 Segovia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;36 Segovia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;103 Segovia;Group 0500 Mental disorders 290-319;Both sexes;347 Segovia;Group 0500 Mental disorders 290-319;Men;170 Segovia;Group 0500 Mental disorders 290-319;Women;177 Segovia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;8 Segovia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;3 Segovia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;5 Segovia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;37 Segovia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;25 Segovia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;12 Segovia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;9 Segovia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;6 Segovia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;3 Segovia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;83 Segovia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;48 Segovia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;35 Segovia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;122 Segovia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;44 Segovia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;78 Segovia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;88 Segovia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;44 Segovia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;44 Segovia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;251 Segovia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;135 Segovia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;116 Segovia;Group 0601 Alzheimer's disease 3310;Both sexes;11 Segovia;Group 0601 Alzheimer's disease 3310;Men;5 Segovia;Group 0601 Alzheimer's disease 3310;Women;6 Segovia;Group 0602 Multiple sclerosis 340;Both sexes;16 Segovia;Group 0602 Multiple sclerosis 340;Men;8 Segovia;Group 0602 Multiple sclerosis 340;Women;8 Segovia;Group 0603 Epilepsy 345;Both sexes;36 Segovia;Group 0603 Epilepsy 345;Men;16 Segovia;Group 0603 Epilepsy 345;Women;20 Segovia;Group 0604 Transient cerebral ischemia 435;Both sexes;48 Segovia;Group 0604 Transient cerebral ischemia 435;Men;27 Segovia;Group 0604 Transient cerebral ischemia 435;Women;21 Segovia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;140 Segovia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;79 Segovia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;61 Segovia;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;187 Segovia;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;94 Segovia;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;93 Segovia;Grupo 0701 Cataract 366;Both sexes;35 Segovia;Grupo 0701 Cataract 366;Men;19 Segovia;Grupo 0701 Cataract 366;Women;16 Segovia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;152 Segovia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;75 Segovia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;77 Segovia;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;64 Segovia;Group 0800 Diseases of the ear and the mastoid 380-389;Men;28 Segovia;Group 0800 Diseases of the ear and the mastoid 380-389;Women;36 Segovia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;1.643 Segovia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;890 Segovia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;753 Segovia;Group 0901 Hypertensive disease 401-405;Both sexes;59 Segovia;Group 0901 Hypertensive disease 401-405;Men;28 Segovia;Group 0901 Hypertensive disease 401-405;Women;31 Segovia;Group 0902 Angina pectoris 4111, 413;Both sexes;38 Segovia;Group 0902 Angina pectoris 4111, 413;Men;29 Segovia;Group 0902 Angina pectoris 4111, 413;Women;9 Segovia;Group 0903 Acute myocardial infarction 410;Both sexes;195 Segovia;Group 0903 Acute myocardial infarction 410;Men;149 Segovia;Group 0903 Acute myocardial infarction 410;Women;46 Segovia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;55 Segovia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;40 Segovia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;15 Segovia;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;61 Segovia;Group 0905 Diseases of the lungs circulation 415-417;Men;31 Segovia;Group 0905 Diseases of the lungs circulation 415-417;Women;30 Segovia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;203 Segovia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;104 Segovia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;99 Segovia;Grupo 0907 Heart failure 428;Both sexes;438 Segovia;Grupo 0907 Heart failure 428;Men;203 Segovia;Grupo 0907 Heart failure 428;Women;235 Segovia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;310 Segovia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;149 Segovia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;161 Segovia;Grupo 0909 Atherosclerosis 440;Both sexes;35 Segovia;Grupo 0909 Atherosclerosis 440;Men;25 Segovia;Grupo 0909 Atherosclerosis 440;Women;10 Segovia;Group 0910 Varicose veins of lower extremities 454;Both sexes;12 Segovia;Group 0910 Varicose veins of lower extremities 454;Men;5 Segovia;Group 0910 Varicose veins of lower extremities 454;Women;7 Segovia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;237 Segovia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;127 Segovia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;110 Segovia;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;1.559 Segovia;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;940 Segovia;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;619 Segovia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;126 Segovia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;62 Segovia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;64 Segovia;Group 1002 Pneumonia 480-486;Both sexes;338 Segovia;Group 1002 Pneumonia 480-486;Men;198 Segovia;Group 1002 Pneumonia 480-486;Women;140 Segovia;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;90 Segovia;Group 1003 Acute bronchitis and bronchiolitis 466;Men;55 Segovia;Group 1003 Acute bronchitis and bronchiolitis 466;Women;35 Segovia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;82 Segovia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;47 Segovia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;35 Segovia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;165 Segovia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;111 Segovia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;54 Segovia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;252 Segovia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;209 Segovia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;43 Segovia;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;62 Segovia;Group 1007 Asthma 4930-4931,4938-4939;Men;29 Segovia;Group 1007 Asthma 4930-4931,4938-4939;Women;33 Segovia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;444 Segovia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;229 Segovia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;215 Segovia;Group 1100 Diseases of the digestive system 520-579;Both sexes;1.834 Segovia;Group 1100 Diseases of the digestive system 520-579;Men;1.097 Segovia;Group 1100 Diseases of the digestive system 520-579;Women;737 Segovia;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;19 Segovia;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;10 Segovia;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;9 Segovia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;27 Segovia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;17 Segovia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;10 Segovia;Group 1103 Diseases of the esophagus 530;Both sexes;30 Segovia;Group 1103 Diseases of the esophagus 530;Men;18 Segovia;Group 1103 Diseases of the esophagus 530;Women;12 Segovia;Group 1104 Peptic ulcer 531-534;Both sexes;35 Segovia;Group 1104 Peptic ulcer 531-534;Men;26 Segovia;Group 1104 Peptic ulcer 531-534;Women;9 Segovia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;32 Segovia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;21 Segovia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;11 Segovia;Group 1106 Appendicitis 540-543;Both sexes;178 Segovia;Group 1106 Appendicitis 540-543;Men;102 Segovia;Group 1106 Appendicitis 540-543;Women;76 Segovia;Group 1107 Inguinal hernia 550;Both sexes;257 Segovia;Group 1107 Inguinal hernia 550;Men;235 Segovia;Group 1107 Inguinal hernia 550;Women;22 Segovia;Group 1108 Other abdominal hernia 551-553;Both sexes;131 Segovia;Group 1108 Other abdominal hernia 551-553;Men;64 Segovia;Group 1108 Other abdominal hernia 551-553;Women;67 Segovia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;16 Segovia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;8 Segovia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;8 Segovia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;139 Segovia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;75 Segovia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;64 Segovia;Group 1111 Intestinal obstruction without hernia 560;Both sexes;118 Segovia;Group 1111 Intestinal obstruction without hernia 560;Men;62 Segovia;Group 1111 Intestinal obstruction without hernia 560;Women;56 Segovia;Group 1112 Intestinal diverticulosis 562;Both sexes;73 Segovia;Group 1112 Intestinal diverticulosis 562;Men;38 Segovia;Group 1112 Intestinal diverticulosis 562;Women;35 Segovia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;117 Segovia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;77 Segovia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;40 Segovia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;42 Segovia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;22 Segovia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;20 Segovia;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;11 Segovia;Group 1115 Alcoholic hepatitis 5710-5713;Men;9 Segovia;Group 1115 Alcoholic hepatitis 5710-5713;Women;2 Segovia;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;54 Segovia;Group 1116 Other diseases of the liver 570,5714-573;Men;30 Segovia;Group 1116 Other diseases of the liver 570,5714-573;Women;24 Segovia;Group 1117 Cholelithiasis 574;Both sexes;321 Segovia;Group 1117 Cholelithiasis 574;Men;149 Segovia;Group 1117 Cholelithiasis 574;Women;172 Segovia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;75 Segovia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;45 Segovia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;30 Segovia;Group 1119 Pancreatic diseases 577;Both sexes;99 Segovia;Group 1119 Pancreatic diseases 577;Men;55 Segovia;Group 1119 Pancreatic diseases 577;Women;44 Segovia;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;60 Segovia;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;34 Segovia;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;26 Segovia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;149 Segovia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;70 Segovia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;79 Segovia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;94 Segovia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;42 Segovia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;52 Segovia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;6 Segovia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;4 Segovia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;2 Segovia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;49 Segovia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;24 Segovia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;25 Segovia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;736 Segovia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;380 Segovia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;356 Segovia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Segovia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Segovia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Segovia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Segovia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Segovia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Segovia;Group 1303 Internal derangement of knee 717;Both sexes;124 Segovia;Group 1303 Internal derangement of knee 717;Men;87 Segovia;Group 1303 Internal derangement of knee 717;Women;37 Segovia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;391 Segovia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;176 Segovia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;215 Segovia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;12 Segovia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;4 Segovia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;8 Segovia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;1 Segovia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;.. Segovia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1 Segovia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;12 Segovia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;3 Segovia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;9 Segovia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;4 Segovia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;2 Segovia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;2 Segovia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;115 Segovia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;69 Segovia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;46 Segovia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;77 Segovia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;39 Segovia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;38 Segovia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;893 Segovia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;485 Segovia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;408 Segovia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;66 Segovia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;13 Segovia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;53 Segovia;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;61 Segovia;Group 1402 Renal failure 5836-5837, 584-586;Men;34 Segovia;Group 1402 Renal failure 5836-5837, 584-586;Women;27 Segovia;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;179 Segovia;Group 1403 Urolithiasis 592, 594, 7880;Men;116 Segovia;Group 1403 Urolithiasis 592, 594, 7880;Women;63 Segovia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;214 Segovia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;131 Segovia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;83 Segovia;Group 1405 Prostatic hyperplasia 600;Both sexes;111 Segovia;Group 1405 Prostatic hyperplasia 600;Men;111 Segovia;Group 1405 Prostatic hyperplasia 600;Women;.. Segovia;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;79 Segovia;Group 1406 Other diseases of the male genital organs 601-608;Men;79 Segovia;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Segovia;Group 1407 Disorders of breast 610-612;Both sexes;10 Segovia;Group 1407 Disorders of breast 610-612;Men;.. Segovia;Group 1407 Disorders of breast 610-612;Women;10 Segovia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;15 Segovia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Segovia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;15 Segovia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;11 Segovia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Segovia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;11 Segovia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;147 Segovia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Segovia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;146 Segovia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.132 Segovia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Segovia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.132 Segovia;Group 1501 Legally induced abortion 635;Both sexes;1 Segovia;Group 1501 Legally induced abortion 635;Men;.. Segovia;Group 1501 Legally induced abortion 635;Women;1 Segovia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;45 Segovia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Segovia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;45 Segovia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;578 Segovia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Segovia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;578 Segovia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;260 Segovia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Segovia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;260 Segovia;Group 1505 Single spontaneous delivery 650;Both sexes;100 Segovia;Group 1505 Single spontaneous delivery 650;Men;.. Segovia;Group 1505 Single spontaneous delivery 650;Women;100 Segovia;Group 1506 Other deliveries 6695-6697;Both sexes;2 Segovia;Group 1506 Other deliveries 6695-6697;Men;.. Segovia;Group 1506 Other deliveries 6695-6697;Women;2 Segovia;Group 1507 Complications related to the puerperium 670-676;Both sexes;4 Segovia;Group 1507 Complications related to the puerperium 670-676;Men;.. Segovia;Group 1507 Complications related to the puerperium 670-676;Women;4 Segovia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;142 Segovia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Segovia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;142 Segovia;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;149 Segovia;Group 1600 Some disorders originating in the perinatal period 760-779;Men;87 Segovia;Group 1600 Some disorders originating in the perinatal period 760-779;Women;62 Segovia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;45 Segovia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;25 Segovia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;20 Segovia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;104 Segovia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;62 Segovia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;42 Segovia;Grupo 1700 Congenital abnormalities 740-759;Both sexes;42 Segovia;Grupo 1700 Congenital abnormalities 740-759;Men;21 Segovia;Grupo 1700 Congenital abnormalities 740-759;Women;21 Segovia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;581 Segovia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;326 Segovia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;255 Segovia;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;39 Segovia;Group 1801 Pain in throat and chest 7841, 7865;Men;27 Segovia;Group 1801 Pain in throat and chest 7841, 7865;Women;12 Segovia;Group 1802 Abdominal pain 7890;Both sexes;98 Segovia;Group 1802 Abdominal pain 7890;Men;38 Segovia;Group 1802 Abdominal pain 7890;Women;60 Segovia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1 Segovia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;.. Segovia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;1 Segovia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;443 Segovia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;261 Segovia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;182 Segovia;Group 1900 Injuries and poisoning 800-999;Both sexes;1.212 Segovia;Group 1900 Injuries and poisoning 800-999;Men;563 Segovia;Group 1900 Injuries and poisoning 800-999;Women;649 Segovia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;67 Segovia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;39 Segovia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;28 Segovia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;24 Segovia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;15 Segovia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;9 Segovia;Group 1903 Radius and ulna fracture 813;Both sexes;64 Segovia;Group 1903 Radius and ulna fracture 813;Men;31 Segovia;Group 1903 Radius and ulna fracture 813;Women;33 Segovia;Group 1904 Femur fracture 820-821;Both sexes;242 Segovia;Group 1904 Femur fracture 820-821;Men;64 Segovia;Group 1904 Femur fracture 820-821;Women;178 Segovia;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;84 Segovia;Group 1905 Leg fracture, including the ankle 823-824;Men;36 Segovia;Group 1905 Leg fracture, including the ankle 823-824;Women;48 Segovia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;309 Segovia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;162 Segovia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;147 Segovia;Group 1907 Burns 940-949;Both sexes;3 Segovia;Group 1907 Burns 940-949;Men;2 Segovia;Group 1907 Burns 940-949;Women;1 Segovia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;22 Segovia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;13 Segovia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;9 Segovia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;344 Segovia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;171 Segovia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;173 Segovia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Segovia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Segovia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Segovia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;53 Segovia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;30 Segovia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;23 Segovia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;252 Segovia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;144 Segovia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;108 Segovia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;7 Segovia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;5 Segovia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;2 Segovia;Group 2102 Contraceptive management V25;Both sexes;6 Segovia;Group 2102 Contraceptive management V25;Men;.. Segovia;Group 2102 Contraceptive management V25;Women;6 Segovia;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Segovia;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Segovia;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Segovia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;189 Segovia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;109 Segovia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;80 Segovia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;50 Segovia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;30 Segovia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;20 Soria;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;8.609 Soria;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;4.458 Soria;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;4.151 Soria;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;221 Soria;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;116 Soria;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;105 Soria;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;33 Soria;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;17 Soria;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;16 Soria;Group 0102 Imprecise intestinal infections 009;Both sexes;1 Soria;Group 0102 Imprecise intestinal infections 009;Men;1 Soria;Group 0102 Imprecise intestinal infections 009;Women;.. Soria;Group 0103 Tuberculosis 010-018, 137;Both sexes;4 Soria;Group 0103 Tuberculosis 010-018, 137;Men;3 Soria;Group 0103 Tuberculosis 010-018, 137;Women;1 Soria;Group 0104 Septicaemia 038;Both sexes;151 Soria;Group 0104 Septicaemia 038;Men;79 Soria;Group 0104 Septicaemia 038;Women;72 Soria;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;2 Soria;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;2 Soria;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;.. Soria;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;30 Soria;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;14 Soria;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;16 Soria;Group 0200 Neoplasms 140-239;Both sexes;861 Soria;Group 0200 Neoplasms 140-239;Men;496 Soria;Group 0200 Neoplasms 140-239;Women;365 Soria;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;123 Soria;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;81 Soria;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;42 Soria;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;48 Soria;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;40 Soria;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;8 Soria;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;9 Soria;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;4 Soria;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;5 Soria;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;59 Soria;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Soria;Group 0204 Malignant neoplasm of breast 174-175;Women;59 Soria;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;20 Soria;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Soria;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;20 Soria;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;9 Soria;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Soria;Group 0206 Malignant neoplasm of ovary 1830;Women;9 Soria;Group 0207 Malignant neoplasm of prostate 185;Both sexes;63 Soria;Group 0207 Malignant neoplasm of prostate 185;Men;63 Soria;Group 0207 Malignant neoplasm of prostate 185;Women;.. Soria;Group 0208 Malignant neoplasm of bladder 188;Both sexes;92 Soria;Group 0208 Malignant neoplasm of bladder 188;Men;78 Soria;Group 0208 Malignant neoplasm of bladder 188;Women;14 Soria;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;324 Soria;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;186 Soria;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;138 Soria;Group 0210 Carcinoma in situ 230-234;Both sexes;14 Soria;Group 0210 Carcinoma in situ 230-234;Men;7 Soria;Group 0210 Carcinoma in situ 230-234;Women;7 Soria;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;5 Soria;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;2 Soria;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;3 Soria;Grupo 0212 Leiomyoma of uterus 218;Both sexes;16 Soria;Grupo 0212 Leiomyoma of uterus 218;Men;.. Soria;Grupo 0212 Leiomyoma of uterus 218;Women;16 Soria;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;79 Soria;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;35 Soria;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;44 Soria;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;81 Soria;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;45 Soria;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;36 Soria;Group 0301 Anaemias 280-285;Both sexes;53 Soria;Group 0301 Anaemias 280-285;Men;27 Soria;Group 0301 Anaemias 280-285;Women;26 Soria;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;28 Soria;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;18 Soria;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;10 Soria;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;142 Soria;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;65 Soria;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;77 Soria;Group 0401 Diabetes mellitus 249-250;Both sexes;59 Soria;Group 0401 Diabetes mellitus 249-250;Men;34 Soria;Group 0401 Diabetes mellitus 249-250;Women;25 Soria;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;83 Soria;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;31 Soria;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;52 Soria;Group 0500 Mental disorders 290-319;Both sexes;312 Soria;Group 0500 Mental disorders 290-319;Men;166 Soria;Group 0500 Mental disorders 290-319;Women;146 Soria;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;6 Soria;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;1 Soria;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;5 Soria;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;19 Soria;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;16 Soria;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;3 Soria;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;3 Soria;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;2 Soria;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;1 Soria;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;131 Soria;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;86 Soria;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;45 Soria;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;27 Soria;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;10 Soria;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;17 Soria;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;126 Soria;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;51 Soria;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;75 Soria;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;182 Soria;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;100 Soria;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;82 Soria;Group 0601 Alzheimer's disease 3310;Both sexes;6 Soria;Group 0601 Alzheimer's disease 3310;Men;4 Soria;Group 0601 Alzheimer's disease 3310;Women;2 Soria;Group 0602 Multiple sclerosis 340;Both sexes;3 Soria;Group 0602 Multiple sclerosis 340;Men;2 Soria;Group 0602 Multiple sclerosis 340;Women;1 Soria;Group 0603 Epilepsy 345;Both sexes;35 Soria;Group 0603 Epilepsy 345;Men;12 Soria;Group 0603 Epilepsy 345;Women;23 Soria;Group 0604 Transient cerebral ischemia 435;Both sexes;54 Soria;Group 0604 Transient cerebral ischemia 435;Men;32 Soria;Group 0604 Transient cerebral ischemia 435;Women;22 Soria;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;84 Soria;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;50 Soria;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;34 Soria;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;21 Soria;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;7 Soria;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;14 Soria;Grupo 0701 Cataract 366;Both sexes;.. Soria;Grupo 0701 Cataract 366;Men;.. Soria;Grupo 0701 Cataract 366;Women;.. Soria;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;21 Soria;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;7 Soria;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;14 Soria;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;28 Soria;Group 0800 Diseases of the ear and the mastoid 380-389;Men;12 Soria;Group 0800 Diseases of the ear and the mastoid 380-389;Women;16 Soria;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;1.403 Soria;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;759 Soria;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;644 Soria;Group 0901 Hypertensive disease 401-405;Both sexes;59 Soria;Group 0901 Hypertensive disease 401-405;Men;27 Soria;Group 0901 Hypertensive disease 401-405;Women;32 Soria;Group 0902 Angina pectoris 4111, 413;Both sexes;91 Soria;Group 0902 Angina pectoris 4111, 413;Men;55 Soria;Group 0902 Angina pectoris 4111, 413;Women;36 Soria;Group 0903 Acute myocardial infarction 410;Both sexes;154 Soria;Group 0903 Acute myocardial infarction 410;Men;96 Soria;Group 0903 Acute myocardial infarction 410;Women;58 Soria;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;32 Soria;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;26 Soria;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;6 Soria;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;58 Soria;Group 0905 Diseases of the lungs circulation 415-417;Men;25 Soria;Group 0905 Diseases of the lungs circulation 415-417;Women;33 Soria;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;170 Soria;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;91 Soria;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;79 Soria;Grupo 0907 Heart failure 428;Both sexes;390 Soria;Grupo 0907 Heart failure 428;Men;209 Soria;Grupo 0907 Heart failure 428;Women;181 Soria;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;203 Soria;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;103 Soria;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;100 Soria;Grupo 0909 Atherosclerosis 440;Both sexes;15 Soria;Grupo 0909 Atherosclerosis 440;Men;9 Soria;Grupo 0909 Atherosclerosis 440;Women;6 Soria;Group 0910 Varicose veins of lower extremities 454;Both sexes;97 Soria;Group 0910 Varicose veins of lower extremities 454;Men;44 Soria;Group 0910 Varicose veins of lower extremities 454;Women;53 Soria;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;134 Soria;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;74 Soria;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;60 Soria;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;1.138 Soria;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;645 Soria;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;493 Soria;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;18 Soria;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;13 Soria;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;5 Soria;Group 1002 Pneumonia 480-486;Both sexes;245 Soria;Group 1002 Pneumonia 480-486;Men;145 Soria;Group 1002 Pneumonia 480-486;Women;100 Soria;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;23 Soria;Group 1003 Acute bronchitis and bronchiolitis 466;Men;14 Soria;Group 1003 Acute bronchitis and bronchiolitis 466;Women;9 Soria;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;83 Soria;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;38 Soria;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;45 Soria;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;102 Soria;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;72 Soria;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;30 Soria;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;136 Soria;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;108 Soria;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;28 Soria;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;24 Soria;Group 1007 Asthma 4930-4931,4938-4939;Men;5 Soria;Group 1007 Asthma 4930-4931,4938-4939;Women;19 Soria;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;507 Soria;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;250 Soria;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;257 Soria;Group 1100 Diseases of the digestive system 520-579;Both sexes;1.242 Soria;Group 1100 Diseases of the digestive system 520-579;Men;787 Soria;Group 1100 Diseases of the digestive system 520-579;Women;455 Soria;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;2 Soria;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;1 Soria;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;1 Soria;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;18 Soria;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;12 Soria;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;6 Soria;Group 1103 Diseases of the esophagus 530;Both sexes;32 Soria;Group 1103 Diseases of the esophagus 530;Men;17 Soria;Group 1103 Diseases of the esophagus 530;Women;15 Soria;Group 1104 Peptic ulcer 531-534;Both sexes;34 Soria;Group 1104 Peptic ulcer 531-534;Men;27 Soria;Group 1104 Peptic ulcer 531-534;Women;7 Soria;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;20 Soria;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;11 Soria;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;9 Soria;Group 1106 Appendicitis 540-543;Both sexes;108 Soria;Group 1106 Appendicitis 540-543;Men;67 Soria;Group 1106 Appendicitis 540-543;Women;41 Soria;Group 1107 Inguinal hernia 550;Both sexes;163 Soria;Group 1107 Inguinal hernia 550;Men;157 Soria;Group 1107 Inguinal hernia 550;Women;6 Soria;Group 1108 Other abdominal hernia 551-553;Both sexes;108 Soria;Group 1108 Other abdominal hernia 551-553;Men;48 Soria;Group 1108 Other abdominal hernia 551-553;Women;60 Soria;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;18 Soria;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;15 Soria;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;3 Soria;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;47 Soria;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;25 Soria;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;22 Soria;Group 1111 Intestinal obstruction without hernia 560;Both sexes;102 Soria;Group 1111 Intestinal obstruction without hernia 560;Men;60 Soria;Group 1111 Intestinal obstruction without hernia 560;Women;42 Soria;Group 1112 Intestinal diverticulosis 562;Both sexes;54 Soria;Group 1112 Intestinal diverticulosis 562;Men;32 Soria;Group 1112 Intestinal diverticulosis 562;Women;22 Soria;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;34 Soria;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;26 Soria;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;8 Soria;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;26 Soria;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;16 Soria;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;10 Soria;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;9 Soria;Group 1115 Alcoholic hepatitis 5710-5713;Men;9 Soria;Group 1115 Alcoholic hepatitis 5710-5713;Women;.. Soria;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;31 Soria;Group 1116 Other diseases of the liver 570,5714-573;Men;26 Soria;Group 1116 Other diseases of the liver 570,5714-573;Women;5 Soria;Group 1117 Cholelithiasis 574;Both sexes;200 Soria;Group 1117 Cholelithiasis 574;Men;105 Soria;Group 1117 Cholelithiasis 574;Women;95 Soria;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;53 Soria;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;31 Soria;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;22 Soria;Group 1119 Pancreatic diseases 577;Both sexes;65 Soria;Group 1119 Pancreatic diseases 577;Men;42 Soria;Group 1119 Pancreatic diseases 577;Women;23 Soria;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;118 Soria;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;60 Soria;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;58 Soria;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;71 Soria;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;45 Soria;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;26 Soria;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;53 Soria;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;34 Soria;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;19 Soria;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;2 Soria;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;1 Soria;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;1 Soria;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;16 Soria;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;10 Soria;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;6 Soria;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;505 Soria;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;269 Soria;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;236 Soria;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Soria;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Soria;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Soria;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Soria;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Soria;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Soria;Group 1303 Internal derangement of knee 717;Both sexes;122 Soria;Group 1303 Internal derangement of knee 717;Men;85 Soria;Group 1303 Internal derangement of knee 717;Women;37 Soria;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;198 Soria;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;89 Soria;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;109 Soria;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;13 Soria;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;5 Soria;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;8 Soria;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;6 Soria;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1 Soria;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;5 Soria;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;13 Soria;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;10 Soria;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;3 Soria;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;17 Soria;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;9 Soria;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;8 Soria;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;68 Soria;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;45 Soria;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;23 Soria;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;68 Soria;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;25 Soria;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;43 Soria;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;457 Soria;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;264 Soria;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;193 Soria;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;36 Soria;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;20 Soria;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;16 Soria;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;42 Soria;Group 1402 Renal failure 5836-5837, 584-586;Men;22 Soria;Group 1402 Renal failure 5836-5837, 584-586;Women;20 Soria;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;43 Soria;Group 1403 Urolithiasis 592, 594, 7880;Men;33 Soria;Group 1403 Urolithiasis 592, 594, 7880;Women;10 Soria;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;178 Soria;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;80 Soria;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;98 Soria;Group 1405 Prostatic hyperplasia 600;Both sexes;41 Soria;Group 1405 Prostatic hyperplasia 600;Men;41 Soria;Group 1405 Prostatic hyperplasia 600;Women;.. Soria;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;68 Soria;Group 1406 Other diseases of the male genital organs 601-608;Men;68 Soria;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Soria;Group 1407 Disorders of breast 610-612;Both sexes;17 Soria;Group 1407 Disorders of breast 610-612;Men;.. Soria;Group 1407 Disorders of breast 610-612;Women;17 Soria;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;6 Soria;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Soria;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;6 Soria;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;2 Soria;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Soria;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;2 Soria;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;24 Soria;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Soria;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;24 Soria;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;652 Soria;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Soria;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;652 Soria;Group 1501 Legally induced abortion 635;Both sexes;.. Soria;Group 1501 Legally induced abortion 635;Men;.. Soria;Group 1501 Legally induced abortion 635;Women;.. Soria;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;24 Soria;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Soria;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;24 Soria;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;460 Soria;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Soria;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;460 Soria;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;127 Soria;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Soria;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;127 Soria;Group 1505 Single spontaneous delivery 650;Both sexes;12 Soria;Group 1505 Single spontaneous delivery 650;Men;.. Soria;Group 1505 Single spontaneous delivery 650;Women;12 Soria;Group 1506 Other deliveries 6695-6697;Both sexes;8 Soria;Group 1506 Other deliveries 6695-6697;Men;.. Soria;Group 1506 Other deliveries 6695-6697;Women;8 Soria;Group 1507 Complications related to the puerperium 670-676;Both sexes;.. Soria;Group 1507 Complications related to the puerperium 670-676;Men;.. Soria;Group 1507 Complications related to the puerperium 670-676;Women;.. Soria;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;21 Soria;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Soria;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;21 Soria;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;83 Soria;Group 1600 Some disorders originating in the perinatal period 760-779;Men;46 Soria;Group 1600 Some disorders originating in the perinatal period 760-779;Women;37 Soria;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;13 Soria;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;6 Soria;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;7 Soria;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;70 Soria;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;40 Soria;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;30 Soria;Grupo 1700 Congenital abnormalities 740-759;Both sexes;28 Soria;Grupo 1700 Congenital abnormalities 740-759;Men;21 Soria;Grupo 1700 Congenital abnormalities 740-759;Women;7 Soria;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;348 Soria;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;203 Soria;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;145 Soria;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;48 Soria;Group 1801 Pain in throat and chest 7841, 7865;Men;28 Soria;Group 1801 Pain in throat and chest 7841, 7865;Women;20 Soria;Group 1802 Abdominal pain 7890;Both sexes;62 Soria;Group 1802 Abdominal pain 7890;Men;22 Soria;Group 1802 Abdominal pain 7890;Women;40 Soria;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;2 Soria;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1 Soria;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;1 Soria;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;236 Soria;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;152 Soria;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;84 Soria;Group 1900 Injuries and poisoning 800-999;Both sexes;735 Soria;Group 1900 Injuries and poisoning 800-999;Men;369 Soria;Group 1900 Injuries and poisoning 800-999;Women;366 Soria;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;55 Soria;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;29 Soria;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;26 Soria;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;13 Soria;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;10 Soria;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;3 Soria;Group 1903 Radius and ulna fracture 813;Both sexes;28 Soria;Group 1903 Radius and ulna fracture 813;Men;16 Soria;Group 1903 Radius and ulna fracture 813;Women;12 Soria;Group 1904 Femur fracture 820-821;Both sexes;173 Soria;Group 1904 Femur fracture 820-821;Men;51 Soria;Group 1904 Femur fracture 820-821;Women;122 Soria;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;55 Soria;Group 1905 Leg fracture, including the ankle 823-824;Men;23 Soria;Group 1905 Leg fracture, including the ankle 823-824;Women;32 Soria;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;192 Soria;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;110 Soria;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;82 Soria;Group 1907 Burns 940-949;Both sexes;2 Soria;Group 1907 Burns 940-949;Men;2 Soria;Group 1907 Burns 940-949;Women;.. Soria;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;25 Soria;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;14 Soria;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;11 Soria;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;173 Soria;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;106 Soria;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;67 Soria;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;3 Soria;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;3 Soria;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Soria;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;16 Soria;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;5 Soria;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;11 Soria;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;99 Soria;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;43 Soria;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;56 Soria;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;2 Soria;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;2 Soria;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;.. Soria;Group 2102 Contraceptive management V25;Both sexes;3 Soria;Group 2102 Contraceptive management V25;Men;3 Soria;Group 2102 Contraceptive management V25;Women;.. Soria;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Soria;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Soria;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Soria;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;68 Soria;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;23 Soria;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;45 Soria;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;26 Soria;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;15 Soria;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;11 Valladolid;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;60.404 Valladolid;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;30.252 Valladolid;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;30.152 Valladolid;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.108 Valladolid;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;604 Valladolid;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;504 Valladolid;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;219 Valladolid;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;115 Valladolid;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;104 Valladolid;Group 0102 Imprecise intestinal infections 009;Both sexes;40 Valladolid;Group 0102 Imprecise intestinal infections 009;Men;19 Valladolid;Group 0102 Imprecise intestinal infections 009;Women;21 Valladolid;Group 0103 Tuberculosis 010-018, 137;Both sexes;29 Valladolid;Group 0103 Tuberculosis 010-018, 137;Men;17 Valladolid;Group 0103 Tuberculosis 010-018, 137;Women;12 Valladolid;Group 0104 Septicaemia 038;Both sexes;504 Valladolid;Group 0104 Septicaemia 038;Men;271 Valladolid;Group 0104 Septicaemia 038;Women;233 Valladolid;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;6 Valladolid;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;4 Valladolid;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;2 Valladolid;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;310 Valladolid;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;178 Valladolid;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;132 Valladolid;Group 0200 Neoplasms 140-239;Both sexes;6.758 Valladolid;Group 0200 Neoplasms 140-239;Men;3.651 Valladolid;Group 0200 Neoplasms 140-239;Women;3.107 Valladolid;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;630 Valladolid;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;419 Valladolid;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;211 Valladolid;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;642 Valladolid;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;504 Valladolid;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;138 Valladolid;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;78 Valladolid;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;48 Valladolid;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;30 Valladolid;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;426 Valladolid;Group 0204 Malignant neoplasm of breast 174-175;Men;5 Valladolid;Group 0204 Malignant neoplasm of breast 174-175;Women;421 Valladolid;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;93 Valladolid;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Valladolid;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;93 Valladolid;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;58 Valladolid;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Valladolid;Group 0206 Malignant neoplasm of ovary 1830;Women;58 Valladolid;Group 0207 Malignant neoplasm of prostate 185;Both sexes;297 Valladolid;Group 0207 Malignant neoplasm of prostate 185;Men;297 Valladolid;Group 0207 Malignant neoplasm of prostate 185;Women;.. Valladolid;Group 0208 Malignant neoplasm of bladder 188;Both sexes;522 Valladolid;Group 0208 Malignant neoplasm of bladder 188;Men;440 Valladolid;Group 0208 Malignant neoplasm of bladder 188;Women;82 Valladolid;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.351 Valladolid;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.382 Valladolid;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;969 Valladolid;Group 0210 Carcinoma in situ 230-234;Both sexes;99 Valladolid;Group 0210 Carcinoma in situ 230-234;Men;39 Valladolid;Group 0210 Carcinoma in situ 230-234;Women;60 Valladolid;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;49 Valladolid;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;27 Valladolid;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;22 Valladolid;Grupo 0212 Leiomyoma of uterus 218;Both sexes;335 Valladolid;Grupo 0212 Leiomyoma of uterus 218;Men;.. Valladolid;Grupo 0212 Leiomyoma of uterus 218;Women;335 Valladolid;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.178 Valladolid;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;490 Valladolid;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;688 Valladolid;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;712 Valladolid;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;345 Valladolid;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;367 Valladolid;Group 0301 Anaemias 280-285;Both sexes;435 Valladolid;Group 0301 Anaemias 280-285;Men;213 Valladolid;Group 0301 Anaemias 280-285;Women;222 Valladolid;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;277 Valladolid;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;132 Valladolid;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;145 Valladolid;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.261 Valladolid;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;501 Valladolid;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;760 Valladolid;Group 0401 Diabetes mellitus 249-250;Both sexes;398 Valladolid;Group 0401 Diabetes mellitus 249-250;Men;222 Valladolid;Group 0401 Diabetes mellitus 249-250;Women;176 Valladolid;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;863 Valladolid;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;279 Valladolid;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;584 Valladolid;Group 0500 Mental disorders 290-319;Both sexes;1.256 Valladolid;Group 0500 Mental disorders 290-319;Men;582 Valladolid;Group 0500 Mental disorders 290-319;Women;674 Valladolid;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;25 Valladolid;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;8 Valladolid;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;17 Valladolid;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;117 Valladolid;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;75 Valladolid;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;42 Valladolid;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;59 Valladolid;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;47 Valladolid;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;12 Valladolid;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;274 Valladolid;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;161 Valladolid;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;113 Valladolid;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;304 Valladolid;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;97 Valladolid;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;207 Valladolid;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;477 Valladolid;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;194 Valladolid;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;283 Valladolid;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.204 Valladolid;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;557 Valladolid;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;647 Valladolid;Group 0601 Alzheimer's disease 3310;Both sexes;67 Valladolid;Group 0601 Alzheimer's disease 3310;Men;25 Valladolid;Group 0601 Alzheimer's disease 3310;Women;42 Valladolid;Group 0602 Multiple sclerosis 340;Both sexes;53 Valladolid;Group 0602 Multiple sclerosis 340;Men;17 Valladolid;Group 0602 Multiple sclerosis 340;Women;36 Valladolid;Group 0603 Epilepsy 345;Both sexes;200 Valladolid;Group 0603 Epilepsy 345;Men;119 Valladolid;Group 0603 Epilepsy 345;Women;81 Valladolid;Group 0604 Transient cerebral ischemia 435;Both sexes;182 Valladolid;Group 0604 Transient cerebral ischemia 435;Men;77 Valladolid;Group 0604 Transient cerebral ischemia 435;Women;105 Valladolid;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;702 Valladolid;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;319 Valladolid;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;383 Valladolid;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;286 Valladolid;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;140 Valladolid;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;146 Valladolid;Grupo 0701 Cataract 366;Both sexes;35 Valladolid;Grupo 0701 Cataract 366;Men;21 Valladolid;Grupo 0701 Cataract 366;Women;14 Valladolid;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;251 Valladolid;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;119 Valladolid;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;132 Valladolid;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;494 Valladolid;Group 0800 Diseases of the ear and the mastoid 380-389;Men;248 Valladolid;Group 0800 Diseases of the ear and the mastoid 380-389;Women;246 Valladolid;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;8.905 Valladolid;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5.308 Valladolid;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3.597 Valladolid;Group 0901 Hypertensive disease 401-405;Both sexes;423 Valladolid;Group 0901 Hypertensive disease 401-405;Men;170 Valladolid;Group 0901 Hypertensive disease 401-405;Women;253 Valladolid;Group 0902 Angina pectoris 4111, 413;Both sexes;465 Valladolid;Group 0902 Angina pectoris 4111, 413;Men;300 Valladolid;Group 0902 Angina pectoris 4111, 413;Women;165 Valladolid;Group 0903 Acute myocardial infarction 410;Both sexes;788 Valladolid;Group 0903 Acute myocardial infarction 410;Men;588 Valladolid;Group 0903 Acute myocardial infarction 410;Women;200 Valladolid;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;616 Valladolid;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;491 Valladolid;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;125 Valladolid;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;385 Valladolid;Group 0905 Diseases of the lungs circulation 415-417;Men;165 Valladolid;Group 0905 Diseases of the lungs circulation 415-417;Women;220 Valladolid;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.067 Valladolid;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;611 Valladolid;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;456 Valladolid;Grupo 0907 Heart failure 428;Both sexes;1.312 Valladolid;Grupo 0907 Heart failure 428;Men;661 Valladolid;Grupo 0907 Heart failure 428;Women;651 Valladolid;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.369 Valladolid;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;743 Valladolid;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;626 Valladolid;Grupo 0909 Atherosclerosis 440;Both sexes;553 Valladolid;Grupo 0909 Atherosclerosis 440;Men;457 Valladolid;Grupo 0909 Atherosclerosis 440;Women;96 Valladolid;Group 0910 Varicose veins of lower extremities 454;Both sexes;204 Valladolid;Group 0910 Varicose veins of lower extremities 454;Men;88 Valladolid;Group 0910 Varicose veins of lower extremities 454;Women;116 Valladolid;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.723 Valladolid;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.034 Valladolid;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;689 Valladolid;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;6.806 Valladolid;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3.989 Valladolid;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.817 Valladolid;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;317 Valladolid;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;167 Valladolid;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;150 Valladolid;Group 1002 Pneumonia 480-486;Both sexes;1.436 Valladolid;Group 1002 Pneumonia 480-486;Men;879 Valladolid;Group 1002 Pneumonia 480-486;Women;557 Valladolid;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;523 Valladolid;Group 1003 Acute bronchitis and bronchiolitis 466;Men;235 Valladolid;Group 1003 Acute bronchitis and bronchiolitis 466;Women;288 Valladolid;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;512 Valladolid;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;294 Valladolid;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;218 Valladolid;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;858 Valladolid;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;587 Valladolid;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;271 Valladolid;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;979 Valladolid;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;764 Valladolid;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;215 Valladolid;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;195 Valladolid;Group 1007 Asthma 4930-4931,4938-4939;Men;49 Valladolid;Group 1007 Asthma 4930-4931,4938-4939;Women;146 Valladolid;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.986 Valladolid;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.014 Valladolid;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;972 Valladolid;Group 1100 Diseases of the digestive system 520-579;Both sexes;8.246 Valladolid;Group 1100 Diseases of the digestive system 520-579;Men;4.812 Valladolid;Group 1100 Diseases of the digestive system 520-579;Women;3.434 Valladolid;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;138 Valladolid;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;67 Valladolid;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;71 Valladolid;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;136 Valladolid;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;74 Valladolid;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;62 Valladolid;Group 1103 Diseases of the esophagus 530;Both sexes;159 Valladolid;Group 1103 Diseases of the esophagus 530;Men;105 Valladolid;Group 1103 Diseases of the esophagus 530;Women;54 Valladolid;Group 1104 Peptic ulcer 531-534;Both sexes;191 Valladolid;Group 1104 Peptic ulcer 531-534;Men;133 Valladolid;Group 1104 Peptic ulcer 531-534;Women;58 Valladolid;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;182 Valladolid;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;75 Valladolid;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;107 Valladolid;Group 1106 Appendicitis 540-543;Both sexes;642 Valladolid;Group 1106 Appendicitis 540-543;Men;351 Valladolid;Group 1106 Appendicitis 540-543;Women;291 Valladolid;Group 1107 Inguinal hernia 550;Both sexes;1.187 Valladolid;Group 1107 Inguinal hernia 550;Men;1.068 Valladolid;Group 1107 Inguinal hernia 550;Women;119 Valladolid;Group 1108 Other abdominal hernia 551-553;Both sexes;716 Valladolid;Group 1108 Other abdominal hernia 551-553;Men;360 Valladolid;Group 1108 Other abdominal hernia 551-553;Women;356 Valladolid;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;181 Valladolid;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;101 Valladolid;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;80 Valladolid;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;439 Valladolid;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;183 Valladolid;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;256 Valladolid;Group 1111 Intestinal obstruction without hernia 560;Both sexes;430 Valladolid;Group 1111 Intestinal obstruction without hernia 560;Men;224 Valladolid;Group 1111 Intestinal obstruction without hernia 560;Women;206 Valladolid;Group 1112 Intestinal diverticulosis 562;Both sexes;339 Valladolid;Group 1112 Intestinal diverticulosis 562;Men;145 Valladolid;Group 1112 Intestinal diverticulosis 562;Women;194 Valladolid;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;460 Valladolid;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;282 Valladolid;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;178 Valladolid;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;313 Valladolid;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;139 Valladolid;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;174 Valladolid;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;128 Valladolid;Group 1115 Alcoholic hepatitis 5710-5713;Men;125 Valladolid;Group 1115 Alcoholic hepatitis 5710-5713;Women;3 Valladolid;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;290 Valladolid;Group 1116 Other diseases of the liver 570,5714-573;Men;162 Valladolid;Group 1116 Other diseases of the liver 570,5714-573;Women;128 Valladolid;Group 1117 Cholelithiasis 574;Both sexes;1.351 Valladolid;Group 1117 Cholelithiasis 574;Men;667 Valladolid;Group 1117 Cholelithiasis 574;Women;684 Valladolid;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;351 Valladolid;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;204 Valladolid;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;147 Valladolid;Group 1119 Pancreatic diseases 577;Both sexes;303 Valladolid;Group 1119 Pancreatic diseases 577;Men;187 Valladolid;Group 1119 Pancreatic diseases 577;Women;116 Valladolid;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;310 Valladolid;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;160 Valladolid;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;150 Valladolid;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;533 Valladolid;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;303 Valladolid;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;230 Valladolid;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;323 Valladolid;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;199 Valladolid;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;124 Valladolid;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;28 Valladolid;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;13 Valladolid;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;15 Valladolid;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;182 Valladolid;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;91 Valladolid;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;91 Valladolid;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;3.781 Valladolid;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.765 Valladolid;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2.016 Valladolid;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Valladolid;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Valladolid;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Valladolid;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Valladolid;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Valladolid;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Valladolid;Group 1303 Internal derangement of knee 717;Both sexes;342 Valladolid;Group 1303 Internal derangement of knee 717;Men;244 Valladolid;Group 1303 Internal derangement of knee 717;Women;98 Valladolid;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.360 Valladolid;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;606 Valladolid;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;754 Valladolid;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;171 Valladolid;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;43 Valladolid;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;128 Valladolid;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;222 Valladolid;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;108 Valladolid;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;114 Valladolid;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;394 Valladolid;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;215 Valladolid;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;179 Valladolid;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;79 Valladolid;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;36 Valladolid;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;43 Valladolid;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;505 Valladolid;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;290 Valladolid;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;215 Valladolid;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;708 Valladolid;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;223 Valladolid;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;485 Valladolid;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;4.083 Valladolid;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.103 Valladolid;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.980 Valladolid;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;316 Valladolid;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;137 Valladolid;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;179 Valladolid;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;324 Valladolid;Group 1402 Renal failure 5836-5837, 584-586;Men;202 Valladolid;Group 1402 Renal failure 5836-5837, 584-586;Women;122 Valladolid;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;666 Valladolid;Group 1403 Urolithiasis 592, 594, 7880;Men;405 Valladolid;Group 1403 Urolithiasis 592, 594, 7880;Women;261 Valladolid;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.082 Valladolid;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;575 Valladolid;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;507 Valladolid;Group 1405 Prostatic hyperplasia 600;Both sexes;321 Valladolid;Group 1405 Prostatic hyperplasia 600;Men;321 Valladolid;Group 1405 Prostatic hyperplasia 600;Women;.. Valladolid;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;410 Valladolid;Group 1406 Other diseases of the male genital organs 601-608;Men;410 Valladolid;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Valladolid;Group 1407 Disorders of breast 610-612;Both sexes;218 Valladolid;Group 1407 Disorders of breast 610-612;Men;44 Valladolid;Group 1407 Disorders of breast 610-612;Women;174 Valladolid;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;112 Valladolid;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Valladolid;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;112 Valladolid;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;35 Valladolid;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Valladolid;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;35 Valladolid;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;599 Valladolid;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;9 Valladolid;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;590 Valladolid;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5.026 Valladolid;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Valladolid;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5.026 Valladolid;Group 1501 Legally induced abortion 635;Both sexes;.. Valladolid;Group 1501 Legally induced abortion 635;Men;.. Valladolid;Group 1501 Legally induced abortion 635;Women;.. Valladolid;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;309 Valladolid;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Valladolid;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;309 Valladolid;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.005 Valladolid;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Valladolid;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.005 Valladolid;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;523 Valladolid;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Valladolid;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;523 Valladolid;Group 1505 Single spontaneous delivery 650;Both sexes;460 Valladolid;Group 1505 Single spontaneous delivery 650;Men;.. Valladolid;Group 1505 Single spontaneous delivery 650;Women;460 Valladolid;Group 1506 Other deliveries 6695-6697;Both sexes;405 Valladolid;Group 1506 Other deliveries 6695-6697;Men;.. Valladolid;Group 1506 Other deliveries 6695-6697;Women;405 Valladolid;Group 1507 Complications related to the puerperium 670-676;Both sexes;44 Valladolid;Group 1507 Complications related to the puerperium 670-676;Men;.. Valladolid;Group 1507 Complications related to the puerperium 670-676;Women;44 Valladolid;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;280 Valladolid;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Valladolid;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;280 Valladolid;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;620 Valladolid;Group 1600 Some disorders originating in the perinatal period 760-779;Men;349 Valladolid;Group 1600 Some disorders originating in the perinatal period 760-779;Women;271 Valladolid;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;112 Valladolid;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;65 Valladolid;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;47 Valladolid;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;508 Valladolid;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;284 Valladolid;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;224 Valladolid;Grupo 1700 Congenital abnormalities 740-759;Both sexes;447 Valladolid;Grupo 1700 Congenital abnormalities 740-759;Men;266 Valladolid;Grupo 1700 Congenital abnormalities 740-759;Women;181 Valladolid;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.631 Valladolid;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.470 Valladolid;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.161 Valladolid;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;341 Valladolid;Group 1801 Pain in throat and chest 7841, 7865;Men;200 Valladolid;Group 1801 Pain in throat and chest 7841, 7865;Women;141 Valladolid;Group 1802 Abdominal pain 7890;Both sexes;319 Valladolid;Group 1802 Abdominal pain 7890;Men;131 Valladolid;Group 1802 Abdominal pain 7890;Women;188 Valladolid;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;143 Valladolid;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;84 Valladolid;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;59 Valladolid;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.828 Valladolid;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.055 Valladolid;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;773 Valladolid;Group 1900 Injuries and poisoning 800-999;Both sexes;5.147 Valladolid;Group 1900 Injuries and poisoning 800-999;Men;2.675 Valladolid;Group 1900 Injuries and poisoning 800-999;Women;2.472 Valladolid;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;170 Valladolid;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;106 Valladolid;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;64 Valladolid;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;177 Valladolid;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;127 Valladolid;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;50 Valladolid;Group 1903 Radius and ulna fracture 813;Both sexes;207 Valladolid;Group 1903 Radius and ulna fracture 813;Men;117 Valladolid;Group 1903 Radius and ulna fracture 813;Women;90 Valladolid;Group 1904 Femur fracture 820-821;Both sexes;831 Valladolid;Group 1904 Femur fracture 820-821;Men;202 Valladolid;Group 1904 Femur fracture 820-821;Women;629 Valladolid;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;341 Valladolid;Group 1905 Leg fracture, including the ankle 823-824;Men;186 Valladolid;Group 1905 Leg fracture, including the ankle 823-824;Women;155 Valladolid;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.369 Valladolid;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;814 Valladolid;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;555 Valladolid;Group 1907 Burns 940-949;Both sexes;32 Valladolid;Group 1907 Burns 940-949;Men;21 Valladolid;Group 1907 Burns 940-949;Women;11 Valladolid;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;178 Valladolid;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;77 Valladolid;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;101 Valladolid;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.730 Valladolid;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;966 Valladolid;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;764 Valladolid;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;9 Valladolid;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;6 Valladolid;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;3 Valladolid;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;103 Valladolid;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;53 Valladolid;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;50 Valladolid;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.100 Valladolid;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;584 Valladolid;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;516 Valladolid;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;171 Valladolid;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;107 Valladolid;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;64 Valladolid;Group 2102 Contraceptive management V25;Both sexes;33 Valladolid;Group 2102 Contraceptive management V25;Men;.. Valladolid;Group 2102 Contraceptive management V25;Women;33 Valladolid;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Valladolid;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Valladolid;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Valladolid;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;506 Valladolid;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;296 Valladolid;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;210 Valladolid;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;390 Valladolid;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;181 Valladolid;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;209 Zamora;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;18.293 Zamora;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;9.028 Zamora;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;9.265 Zamora;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;629 Zamora;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;345 Zamora;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;284 Zamora;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;131 Zamora;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;73 Zamora;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;58 Zamora;Group 0102 Imprecise intestinal infections 009;Both sexes;42 Zamora;Group 0102 Imprecise intestinal infections 009;Men;24 Zamora;Group 0102 Imprecise intestinal infections 009;Women;18 Zamora;Group 0103 Tuberculosis 010-018, 137;Both sexes;31 Zamora;Group 0103 Tuberculosis 010-018, 137;Men;11 Zamora;Group 0103 Tuberculosis 010-018, 137;Women;20 Zamora;Group 0104 Septicaemia 038;Both sexes;235 Zamora;Group 0104 Septicaemia 038;Men;122 Zamora;Group 0104 Septicaemia 038;Women;113 Zamora;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;14 Zamora;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;13 Zamora;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Zamora;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;176 Zamora;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;102 Zamora;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;74 Zamora;Group 0200 Neoplasms 140-239;Both sexes;2.048 Zamora;Group 0200 Neoplasms 140-239;Men;1.130 Zamora;Group 0200 Neoplasms 140-239;Women;918 Zamora;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;308 Zamora;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;196 Zamora;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;112 Zamora;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;150 Zamora;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;124 Zamora;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;26 Zamora;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;13 Zamora;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;9 Zamora;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;4 Zamora;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;158 Zamora;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Zamora;Group 0204 Malignant neoplasm of breast 174-175;Women;155 Zamora;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;50 Zamora;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Zamora;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;50 Zamora;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;34 Zamora;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Zamora;Group 0206 Malignant neoplasm of ovary 1830;Women;34 Zamora;Group 0207 Malignant neoplasm of prostate 185;Both sexes;82 Zamora;Group 0207 Malignant neoplasm of prostate 185;Men;82 Zamora;Group 0207 Malignant neoplasm of prostate 185;Women;.. Zamora;Group 0208 Malignant neoplasm of bladder 188;Both sexes;219 Zamora;Group 0208 Malignant neoplasm of bladder 188;Men;186 Zamora;Group 0208 Malignant neoplasm of bladder 188;Women;33 Zamora;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;721 Zamora;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;430 Zamora;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;291 Zamora;Group 0210 Carcinoma in situ 230-234;Both sexes;27 Zamora;Group 0210 Carcinoma in situ 230-234;Men;10 Zamora;Group 0210 Carcinoma in situ 230-234;Women;17 Zamora;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;20 Zamora;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;13 Zamora;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;7 Zamora;Grupo 0212 Leiomyoma of uterus 218;Both sexes;57 Zamora;Grupo 0212 Leiomyoma of uterus 218;Men;.. Zamora;Grupo 0212 Leiomyoma of uterus 218;Women;57 Zamora;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;209 Zamora;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;77 Zamora;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;132 Zamora;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;134 Zamora;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;70 Zamora;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;64 Zamora;Group 0301 Anaemias 280-285;Both sexes;66 Zamora;Group 0301 Anaemias 280-285;Men;32 Zamora;Group 0301 Anaemias 280-285;Women;34 Zamora;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;68 Zamora;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;38 Zamora;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;30 Zamora;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;345 Zamora;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;139 Zamora;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;206 Zamora;Group 0401 Diabetes mellitus 249-250;Both sexes;147 Zamora;Group 0401 Diabetes mellitus 249-250;Men;73 Zamora;Group 0401 Diabetes mellitus 249-250;Women;74 Zamora;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;198 Zamora;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;66 Zamora;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;132 Zamora;Group 0500 Mental disorders 290-319;Both sexes;340 Zamora;Group 0500 Mental disorders 290-319;Men;182 Zamora;Group 0500 Mental disorders 290-319;Women;158 Zamora;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;9 Zamora;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;4 Zamora;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;5 Zamora;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;22 Zamora;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;18 Zamora;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;4 Zamora;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;14 Zamora;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;11 Zamora;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;3 Zamora;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;105 Zamora;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;64 Zamora;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;41 Zamora;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;68 Zamora;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;32 Zamora;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;36 Zamora;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;122 Zamora;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;53 Zamora;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;69 Zamora;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;306 Zamora;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;159 Zamora;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;147 Zamora;Group 0601 Alzheimer's disease 3310;Both sexes;6 Zamora;Group 0601 Alzheimer's disease 3310;Men;1 Zamora;Group 0601 Alzheimer's disease 3310;Women;5 Zamora;Group 0602 Multiple sclerosis 340;Both sexes;7 Zamora;Group 0602 Multiple sclerosis 340;Men;3 Zamora;Group 0602 Multiple sclerosis 340;Women;4 Zamora;Group 0603 Epilepsy 345;Both sexes;50 Zamora;Group 0603 Epilepsy 345;Men;32 Zamora;Group 0603 Epilepsy 345;Women;18 Zamora;Group 0604 Transient cerebral ischemia 435;Both sexes;90 Zamora;Group 0604 Transient cerebral ischemia 435;Men;48 Zamora;Group 0604 Transient cerebral ischemia 435;Women;42 Zamora;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;153 Zamora;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;75 Zamora;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;78 Zamora;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;20 Zamora;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;13 Zamora;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;7 Zamora;Grupo 0701 Cataract 366;Both sexes;1 Zamora;Grupo 0701 Cataract 366;Men;.. Zamora;Grupo 0701 Cataract 366;Women;1 Zamora;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;19 Zamora;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;13 Zamora;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;6 Zamora;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;193 Zamora;Group 0800 Diseases of the ear and the mastoid 380-389;Men;90 Zamora;Group 0800 Diseases of the ear and the mastoid 380-389;Women;103 Zamora;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;2.309 Zamora;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1.247 Zamora;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1.062 Zamora;Group 0901 Hypertensive disease 401-405;Both sexes;86 Zamora;Group 0901 Hypertensive disease 401-405;Men;33 Zamora;Group 0901 Hypertensive disease 401-405;Women;53 Zamora;Group 0902 Angina pectoris 4111, 413;Both sexes;52 Zamora;Group 0902 Angina pectoris 4111, 413;Men;39 Zamora;Group 0902 Angina pectoris 4111, 413;Women;13 Zamora;Group 0903 Acute myocardial infarction 410;Both sexes;157 Zamora;Group 0903 Acute myocardial infarction 410;Men;116 Zamora;Group 0903 Acute myocardial infarction 410;Women;41 Zamora;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;97 Zamora;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;81 Zamora;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;16 Zamora;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;118 Zamora;Group 0905 Diseases of the lungs circulation 415-417;Men;60 Zamora;Group 0905 Diseases of the lungs circulation 415-417;Women;58 Zamora;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;298 Zamora;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;164 Zamora;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;134 Zamora;Grupo 0907 Heart failure 428;Both sexes;610 Zamora;Grupo 0907 Heart failure 428;Men;293 Zamora;Grupo 0907 Heart failure 428;Women;317 Zamora;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;427 Zamora;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;221 Zamora;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;206 Zamora;Grupo 0909 Atherosclerosis 440;Both sexes;18 Zamora;Grupo 0909 Atherosclerosis 440;Men;10 Zamora;Grupo 0909 Atherosclerosis 440;Women;8 Zamora;Group 0910 Varicose veins of lower extremities 454;Both sexes;80 Zamora;Group 0910 Varicose veins of lower extremities 454;Men;32 Zamora;Group 0910 Varicose veins of lower extremities 454;Women;48 Zamora;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;366 Zamora;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;198 Zamora;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;168 Zamora;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2.648 Zamora;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.508 Zamora;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.140 Zamora;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;146 Zamora;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;69 Zamora;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;77 Zamora;Group 1002 Pneumonia 480-486;Both sexes;545 Zamora;Group 1002 Pneumonia 480-486;Men;325 Zamora;Group 1002 Pneumonia 480-486;Women;220 Zamora;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;227 Zamora;Group 1003 Acute bronchitis and bronchiolitis 466;Men;107 Zamora;Group 1003 Acute bronchitis and bronchiolitis 466;Women;120 Zamora;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;206 Zamora;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;103 Zamora;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;103 Zamora;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;301 Zamora;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;177 Zamora;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;124 Zamora;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;453 Zamora;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;381 Zamora;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;72 Zamora;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;127 Zamora;Group 1007 Asthma 4930-4931,4938-4939;Men;38 Zamora;Group 1007 Asthma 4930-4931,4938-4939;Women;89 Zamora;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;643 Zamora;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;308 Zamora;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;335 Zamora;Group 1100 Diseases of the digestive system 520-579;Both sexes;2.766 Zamora;Group 1100 Diseases of the digestive system 520-579;Men;1.626 Zamora;Group 1100 Diseases of the digestive system 520-579;Women;1.140 Zamora;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;17 Zamora;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;7 Zamora;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;10 Zamora;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;41 Zamora;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;18 Zamora;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;23 Zamora;Group 1103 Diseases of the esophagus 530;Both sexes;54 Zamora;Group 1103 Diseases of the esophagus 530;Men;44 Zamora;Group 1103 Diseases of the esophagus 530;Women;10 Zamora;Group 1104 Peptic ulcer 531-534;Both sexes;58 Zamora;Group 1104 Peptic ulcer 531-534;Men;43 Zamora;Group 1104 Peptic ulcer 531-534;Women;15 Zamora;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;79 Zamora;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;34 Zamora;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;45 Zamora;Group 1106 Appendicitis 540-543;Both sexes;204 Zamora;Group 1106 Appendicitis 540-543;Men;117 Zamora;Group 1106 Appendicitis 540-543;Women;87 Zamora;Group 1107 Inguinal hernia 550;Both sexes;334 Zamora;Group 1107 Inguinal hernia 550;Men;307 Zamora;Group 1107 Inguinal hernia 550;Women;27 Zamora;Group 1108 Other abdominal hernia 551-553;Both sexes;147 Zamora;Group 1108 Other abdominal hernia 551-553;Men;66 Zamora;Group 1108 Other abdominal hernia 551-553;Women;81 Zamora;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;47 Zamora;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;25 Zamora;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;22 Zamora;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;214 Zamora;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;88 Zamora;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;126 Zamora;Group 1111 Intestinal obstruction without hernia 560;Both sexes;182 Zamora;Group 1111 Intestinal obstruction without hernia 560;Men;101 Zamora;Group 1111 Intestinal obstruction without hernia 560;Women;81 Zamora;Group 1112 Intestinal diverticulosis 562;Both sexes;152 Zamora;Group 1112 Intestinal diverticulosis 562;Men;76 Zamora;Group 1112 Intestinal diverticulosis 562;Women;76 Zamora;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;115 Zamora;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;87 Zamora;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;28 Zamora;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;118 Zamora;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;58 Zamora;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;60 Zamora;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;43 Zamora;Group 1115 Alcoholic hepatitis 5710-5713;Men;40 Zamora;Group 1115 Alcoholic hepatitis 5710-5713;Women;3 Zamora;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;74 Zamora;Group 1116 Other diseases of the liver 570,5714-573;Men;40 Zamora;Group 1116 Other diseases of the liver 570,5714-573;Women;34 Zamora;Group 1117 Cholelithiasis 574;Both sexes;541 Zamora;Group 1117 Cholelithiasis 574;Men;294 Zamora;Group 1117 Cholelithiasis 574;Women;247 Zamora;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;79 Zamora;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;47 Zamora;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;32 Zamora;Group 1119 Pancreatic diseases 577;Both sexes;112 Zamora;Group 1119 Pancreatic diseases 577;Men;61 Zamora;Group 1119 Pancreatic diseases 577;Women;51 Zamora;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;155 Zamora;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;73 Zamora;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;82 Zamora;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;152 Zamora;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;80 Zamora;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;72 Zamora;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;97 Zamora;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;49 Zamora;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;48 Zamora;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;9 Zamora;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;5 Zamora;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;4 Zamora;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;46 Zamora;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;26 Zamora;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;20 Zamora;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;998 Zamora;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;446 Zamora;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;552 Zamora;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Zamora;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Zamora;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Zamora;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Zamora;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Zamora;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Zamora;Group 1303 Internal derangement of knee 717;Both sexes;76 Zamora;Group 1303 Internal derangement of knee 717;Men;51 Zamora;Group 1303 Internal derangement of knee 717;Women;25 Zamora;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;536 Zamora;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;243 Zamora;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;293 Zamora;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;21 Zamora;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;9 Zamora;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;12 Zamora;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;8 Zamora;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;5 Zamora;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;3 Zamora;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;25 Zamora;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;10 Zamora;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;15 Zamora;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;8 Zamora;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;6 Zamora;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;2 Zamora;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;110 Zamora;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;71 Zamora;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;39 Zamora;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;214 Zamora;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;51 Zamora;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;163 Zamora;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1.160 Zamora;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;596 Zamora;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;564 Zamora;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;88 Zamora;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;36 Zamora;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;52 Zamora;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;106 Zamora;Group 1402 Renal failure 5836-5837, 584-586;Men;46 Zamora;Group 1402 Renal failure 5836-5837, 584-586;Women;60 Zamora;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;116 Zamora;Group 1403 Urolithiasis 592, 594, 7880;Men;67 Zamora;Group 1403 Urolithiasis 592, 594, 7880;Women;49 Zamora;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;422 Zamora;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;230 Zamora;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;192 Zamora;Group 1405 Prostatic hyperplasia 600;Both sexes;143 Zamora;Group 1405 Prostatic hyperplasia 600;Men;143 Zamora;Group 1405 Prostatic hyperplasia 600;Women;.. Zamora;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;68 Zamora;Group 1406 Other diseases of the male genital organs 601-608;Men;68 Zamora;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Zamora;Group 1407 Disorders of breast 610-612;Both sexes;30 Zamora;Group 1407 Disorders of breast 610-612;Men;6 Zamora;Group 1407 Disorders of breast 610-612;Women;24 Zamora;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;28 Zamora;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Zamora;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;28 Zamora;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;11 Zamora;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Zamora;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;11 Zamora;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;148 Zamora;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Zamora;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;148 Zamora;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.272 Zamora;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Zamora;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.272 Zamora;Group 1501 Legally induced abortion 635;Both sexes;.. Zamora;Group 1501 Legally induced abortion 635;Men;.. Zamora;Group 1501 Legally induced abortion 635;Women;.. Zamora;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;106 Zamora;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Zamora;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;106 Zamora;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;860 Zamora;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Zamora;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;860 Zamora;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;166 Zamora;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Zamora;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;166 Zamora;Group 1505 Single spontaneous delivery 650;Both sexes;42 Zamora;Group 1505 Single spontaneous delivery 650;Men;.. Zamora;Group 1505 Single spontaneous delivery 650;Women;42 Zamora;Group 1506 Other deliveries 6695-6697;Both sexes;13 Zamora;Group 1506 Other deliveries 6695-6697;Men;.. Zamora;Group 1506 Other deliveries 6695-6697;Women;13 Zamora;Group 1507 Complications related to the puerperium 670-676;Both sexes;28 Zamora;Group 1507 Complications related to the puerperium 670-676;Men;.. Zamora;Group 1507 Complications related to the puerperium 670-676;Women;28 Zamora;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;57 Zamora;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Zamora;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;57 Zamora;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;128 Zamora;Group 1600 Some disorders originating in the perinatal period 760-779;Men;71 Zamora;Group 1600 Some disorders originating in the perinatal period 760-779;Women;57 Zamora;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;36 Zamora;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;16 Zamora;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;20 Zamora;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;92 Zamora;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;55 Zamora;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;37 Zamora;Grupo 1700 Congenital abnormalities 740-759;Both sexes;50 Zamora;Grupo 1700 Congenital abnormalities 740-759;Men;21 Zamora;Grupo 1700 Congenital abnormalities 740-759;Women;29 Zamora;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;719 Zamora;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;401 Zamora;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;318 Zamora;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;93 Zamora;Group 1801 Pain in throat and chest 7841, 7865;Men;64 Zamora;Group 1801 Pain in throat and chest 7841, 7865;Women;29 Zamora;Group 1802 Abdominal pain 7890;Both sexes;110 Zamora;Group 1802 Abdominal pain 7890;Men;45 Zamora;Group 1802 Abdominal pain 7890;Women;65 Zamora;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;57 Zamora;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;34 Zamora;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;23 Zamora;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;459 Zamora;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;258 Zamora;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;201 Zamora;Group 1900 Injuries and poisoning 800-999;Both sexes;1.569 Zamora;Group 1900 Injuries and poisoning 800-999;Men;711 Zamora;Group 1900 Injuries and poisoning 800-999;Women;858 Zamora;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;89 Zamora;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;48 Zamora;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;41 Zamora;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;62 Zamora;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;39 Zamora;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;23 Zamora;Group 1903 Radius and ulna fracture 813;Both sexes;80 Zamora;Group 1903 Radius and ulna fracture 813;Men;30 Zamora;Group 1903 Radius and ulna fracture 813;Women;50 Zamora;Group 1904 Femur fracture 820-821;Both sexes;338 Zamora;Group 1904 Femur fracture 820-821;Men;72 Zamora;Group 1904 Femur fracture 820-821;Women;266 Zamora;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;96 Zamora;Group 1905 Leg fracture, including the ankle 823-824;Men;41 Zamora;Group 1905 Leg fracture, including the ankle 823-824;Women;55 Zamora;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;279 Zamora;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;174 Zamora;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;105 Zamora;Group 1907 Burns 940-949;Both sexes;1 Zamora;Group 1907 Burns 940-949;Men;1 Zamora;Group 1907 Burns 940-949;Women;.. Zamora;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;59 Zamora;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;22 Zamora;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;37 Zamora;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;493 Zamora;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;254 Zamora;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;239 Zamora;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Zamora;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Zamora;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Zamora;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;72 Zamora;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;30 Zamora;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;42 Zamora;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;507 Zamora;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;193 Zamora;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;314 Zamora;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;8 Zamora;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;4 Zamora;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;4 Zamora;Group 2102 Contraceptive management V25;Both sexes;7 Zamora;Group 2102 Contraceptive management V25;Men;.. Zamora;Group 2102 Contraceptive management V25;Women;7 Zamora;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Zamora;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Zamora;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Zamora;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;317 Zamora;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;96 Zamora;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;221 Zamora;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;175 Zamora;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;93 Zamora;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;82 CASTILLA - LA MANCHA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;173.204 CASTILLA - LA MANCHA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;82.897 CASTILLA - LA MANCHA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;90.307 CASTILLA - LA MANCHA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;4.289 CASTILLA - LA MANCHA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2.445 CASTILLA - LA MANCHA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.844 CASTILLA - LA MANCHA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;643 CASTILLA - LA MANCHA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;344 CASTILLA - LA MANCHA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;299 CASTILLA - LA MANCHA;Group 0102 Imprecise intestinal infections 009;Both sexes;185 CASTILLA - LA MANCHA;Group 0102 Imprecise intestinal infections 009;Men;92 CASTILLA - LA MANCHA;Group 0102 Imprecise intestinal infections 009;Women;93 CASTILLA - LA MANCHA;Group 0103 Tuberculosis 010-018, 137;Both sexes;111 CASTILLA - LA MANCHA;Group 0103 Tuberculosis 010-018, 137;Men;73 CASTILLA - LA MANCHA;Group 0103 Tuberculosis 010-018, 137;Women;38 CASTILLA - LA MANCHA;Group 0104 Septicaemia 038;Both sexes;2.055 CASTILLA - LA MANCHA;Group 0104 Septicaemia 038;Men;1.135 CASTILLA - LA MANCHA;Group 0104 Septicaemia 038;Women;920 CASTILLA - LA MANCHA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;63 CASTILLA - LA MANCHA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;49 CASTILLA - LA MANCHA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;14 CASTILLA - LA MANCHA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.232 CASTILLA - LA MANCHA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;752 CASTILLA - LA MANCHA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;480 CASTILLA - LA MANCHA;Group 0200 Neoplasms 140-239;Both sexes;16.097 CASTILLA - LA MANCHA;Group 0200 Neoplasms 140-239;Men;8.911 CASTILLA - LA MANCHA;Group 0200 Neoplasms 140-239;Women;7.186 CASTILLA - LA MANCHA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.781 CASTILLA - LA MANCHA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;1.108 CASTILLA - LA MANCHA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;673 CASTILLA - LA MANCHA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.309 CASTILLA - LA MANCHA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1.119 CASTILLA - LA MANCHA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;190 CASTILLA - LA MANCHA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;341 CASTILLA - LA MANCHA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;217 CASTILLA - LA MANCHA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;124 CASTILLA - LA MANCHA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.115 CASTILLA - LA MANCHA;Group 0204 Malignant neoplasm of breast 174-175;Men;11 CASTILLA - LA MANCHA;Group 0204 Malignant neoplasm of breast 174-175;Women;1.104 CASTILLA - LA MANCHA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;366 CASTILLA - LA MANCHA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CASTILLA - LA MANCHA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;366 CASTILLA - LA MANCHA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;145 CASTILLA - LA MANCHA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CASTILLA - LA MANCHA;Group 0206 Malignant neoplasm of ovary 1830;Women;145 CASTILLA - LA MANCHA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;428 CASTILLA - LA MANCHA;Group 0207 Malignant neoplasm of prostate 185;Men;428 CASTILLA - LA MANCHA;Group 0207 Malignant neoplasm of prostate 185;Women;.. CASTILLA - LA MANCHA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.351 CASTILLA - LA MANCHA;Group 0208 Malignant neoplasm of bladder 188;Men;1.158 CASTILLA - LA MANCHA;Group 0208 Malignant neoplasm of bladder 188;Women;193 CASTILLA - LA MANCHA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5.526 CASTILLA - LA MANCHA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3.331 CASTILLA - LA MANCHA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2.195 CASTILLA - LA MANCHA;Group 0210 Carcinoma in situ 230-234;Both sexes;227 CASTILLA - LA MANCHA;Group 0210 Carcinoma in situ 230-234;Men;99 CASTILLA - LA MANCHA;Group 0210 Carcinoma in situ 230-234;Women;128 CASTILLA - LA MANCHA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;184 CASTILLA - LA MANCHA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;118 CASTILLA - LA MANCHA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;66 CASTILLA - LA MANCHA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;707 CASTILLA - LA MANCHA;Grupo 0212 Leiomyoma of uterus 218;Men;.. CASTILLA - LA MANCHA;Grupo 0212 Leiomyoma of uterus 218;Women;707 CASTILLA - LA MANCHA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2.617 CASTILLA - LA MANCHA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.322 CASTILLA - LA MANCHA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.295 CASTILLA - LA MANCHA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.545 CASTILLA - LA MANCHA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;800 CASTILLA - LA MANCHA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;745 CASTILLA - LA MANCHA;Group 0301 Anaemias 280-285;Both sexes;853 CASTILLA - LA MANCHA;Group 0301 Anaemias 280-285;Men;424 CASTILLA - LA MANCHA;Group 0301 Anaemias 280-285;Women;429 CASTILLA - LA MANCHA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;692 CASTILLA - LA MANCHA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;376 CASTILLA - LA MANCHA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;316 CASTILLA - LA MANCHA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2.916 CASTILLA - LA MANCHA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.161 CASTILLA - LA MANCHA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.755 CASTILLA - LA MANCHA;Group 0401 Diabetes mellitus 249-250;Both sexes;994 CASTILLA - LA MANCHA;Group 0401 Diabetes mellitus 249-250;Men;532 CASTILLA - LA MANCHA;Group 0401 Diabetes mellitus 249-250;Women;462 CASTILLA - LA MANCHA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.922 CASTILLA - LA MANCHA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;629 CASTILLA - LA MANCHA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.293 CASTILLA - LA MANCHA;Group 0500 Mental disorders 290-319;Both sexes;4.112 CASTILLA - LA MANCHA;Group 0500 Mental disorders 290-319;Men;2.107 CASTILLA - LA MANCHA;Group 0500 Mental disorders 290-319;Women;2.005 CASTILLA - LA MANCHA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;79 CASTILLA - LA MANCHA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;47 CASTILLA - LA MANCHA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;32 CASTILLA - LA MANCHA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;222 CASTILLA - LA MANCHA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;166 CASTILLA - LA MANCHA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;56 CASTILLA - LA MANCHA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;155 CASTILLA - LA MANCHA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;121 CASTILLA - LA MANCHA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;34 CASTILLA - LA MANCHA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.278 CASTILLA - LA MANCHA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;843 CASTILLA - LA MANCHA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;435 CASTILLA - LA MANCHA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;956 CASTILLA - LA MANCHA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;373 CASTILLA - LA MANCHA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;583 CASTILLA - LA MANCHA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.422 CASTILLA - LA MANCHA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;557 CASTILLA - LA MANCHA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;865 CASTILLA - LA MANCHA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;4.610 CASTILLA - LA MANCHA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.438 CASTILLA - LA MANCHA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2.172 CASTILLA - LA MANCHA;Group 0601 Alzheimer's disease 3310;Both sexes;51 CASTILLA - LA MANCHA;Group 0601 Alzheimer's disease 3310;Men;18 CASTILLA - LA MANCHA;Group 0601 Alzheimer's disease 3310;Women;33 CASTILLA - LA MANCHA;Group 0602 Multiple sclerosis 340;Both sexes;155 CASTILLA - LA MANCHA;Group 0602 Multiple sclerosis 340;Men;50 CASTILLA - LA MANCHA;Group 0602 Multiple sclerosis 340;Women;105 CASTILLA - LA MANCHA;Group 0603 Epilepsy 345;Both sexes;553 CASTILLA - LA MANCHA;Group 0603 Epilepsy 345;Men;309 CASTILLA - LA MANCHA;Group 0603 Epilepsy 345;Women;244 CASTILLA - LA MANCHA;Group 0604 Transient cerebral ischemia 435;Both sexes;734 CASTILLA - LA MANCHA;Group 0604 Transient cerebral ischemia 435;Men;365 CASTILLA - LA MANCHA;Group 0604 Transient cerebral ischemia 435;Women;369 CASTILLA - LA MANCHA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.117 CASTILLA - LA MANCHA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.696 CASTILLA - LA MANCHA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.421 CASTILLA - LA MANCHA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1.029 CASTILLA - LA MANCHA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;558 CASTILLA - LA MANCHA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;471 CASTILLA - LA MANCHA;Grupo 0701 Cataract 366;Both sexes;153 CASTILLA - LA MANCHA;Grupo 0701 Cataract 366;Men;74 CASTILLA - LA MANCHA;Grupo 0701 Cataract 366;Women;79 CASTILLA - LA MANCHA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;876 CASTILLA - LA MANCHA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;484 CASTILLA - LA MANCHA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;392 CASTILLA - LA MANCHA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;771 CASTILLA - LA MANCHA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;383 CASTILLA - LA MANCHA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;388 CASTILLA - LA MANCHA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;22.768 CASTILLA - LA MANCHA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;12.693 CASTILLA - LA MANCHA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;10.075 CASTILLA - LA MANCHA;Group 0901 Hypertensive disease 401-405;Both sexes;1.134 CASTILLA - LA MANCHA;Group 0901 Hypertensive disease 401-405;Men;469 CASTILLA - LA MANCHA;Group 0901 Hypertensive disease 401-405;Women;665 CASTILLA - LA MANCHA;Group 0902 Angina pectoris 4111, 413;Both sexes;1.215 CASTILLA - LA MANCHA;Group 0902 Angina pectoris 4111, 413;Men;781 CASTILLA - LA MANCHA;Group 0902 Angina pectoris 4111, 413;Women;434 CASTILLA - LA MANCHA;Group 0903 Acute myocardial infarction 410;Both sexes;2.190 CASTILLA - LA MANCHA;Group 0903 Acute myocardial infarction 410;Men;1.545 CASTILLA - LA MANCHA;Group 0903 Acute myocardial infarction 410;Women;645 CASTILLA - LA MANCHA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.367 CASTILLA - LA MANCHA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.039 CASTILLA - LA MANCHA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;328 CASTILLA - LA MANCHA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;776 CASTILLA - LA MANCHA;Group 0905 Diseases of the lungs circulation 415-417;Men;361 CASTILLA - LA MANCHA;Group 0905 Diseases of the lungs circulation 415-417;Women;415 CASTILLA - LA MANCHA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;3.041 CASTILLA - LA MANCHA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.656 CASTILLA - LA MANCHA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.385 CASTILLA - LA MANCHA;Grupo 0907 Heart failure 428;Both sexes;4.703 CASTILLA - LA MANCHA;Grupo 0907 Heart failure 428;Men;2.037 CASTILLA - LA MANCHA;Grupo 0907 Heart failure 428;Women;2.666 CASTILLA - LA MANCHA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3.983 CASTILLA - LA MANCHA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;2.165 CASTILLA - LA MANCHA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.818 CASTILLA - LA MANCHA;Grupo 0909 Atherosclerosis 440;Both sexes;841 CASTILLA - LA MANCHA;Grupo 0909 Atherosclerosis 440;Men;620 CASTILLA - LA MANCHA;Grupo 0909 Atherosclerosis 440;Women;221 CASTILLA - LA MANCHA;Group 0910 Varicose veins of lower extremities 454;Both sexes;212 CASTILLA - LA MANCHA;Group 0910 Varicose veins of lower extremities 454;Men;79 CASTILLA - LA MANCHA;Group 0910 Varicose veins of lower extremities 454;Women;133 CASTILLA - LA MANCHA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;3.306 CASTILLA - LA MANCHA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.941 CASTILLA - LA MANCHA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.365 CASTILLA - LA MANCHA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;21.455 CASTILLA - LA MANCHA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;12.639 CASTILLA - LA MANCHA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;8.816 CASTILLA - LA MANCHA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1.031 CASTILLA - LA MANCHA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;526 CASTILLA - LA MANCHA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;505 CASTILLA - LA MANCHA;Group 1002 Pneumonia 480-486;Both sexes;5.159 CASTILLA - LA MANCHA;Group 1002 Pneumonia 480-486;Men;3.217 CASTILLA - LA MANCHA;Group 1002 Pneumonia 480-486;Women;1.942 CASTILLA - LA MANCHA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.696 CASTILLA - LA MANCHA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;814 CASTILLA - LA MANCHA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;882 CASTILLA - LA MANCHA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;883 CASTILLA - LA MANCHA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;486 CASTILLA - LA MANCHA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;397 CASTILLA - LA MANCHA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.327 CASTILLA - LA MANCHA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;898 CASTILLA - LA MANCHA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;429 CASTILLA - LA MANCHA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;3.088 CASTILLA - LA MANCHA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2.570 CASTILLA - LA MANCHA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;518 CASTILLA - LA MANCHA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;725 CASTILLA - LA MANCHA;Group 1007 Asthma 4930-4931,4938-4939;Men;252 CASTILLA - LA MANCHA;Group 1007 Asthma 4930-4931,4938-4939;Women;473 CASTILLA - LA MANCHA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;7.546 CASTILLA - LA MANCHA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;3.876 CASTILLA - LA MANCHA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;3.670 CASTILLA - LA MANCHA;Group 1100 Diseases of the digestive system 520-579;Both sexes;22.666 CASTILLA - LA MANCHA;Group 1100 Diseases of the digestive system 520-579;Men;12.711 CASTILLA - LA MANCHA;Group 1100 Diseases of the digestive system 520-579;Women;9.955 CASTILLA - LA MANCHA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;265 CASTILLA - LA MANCHA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;135 CASTILLA - LA MANCHA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;130 CASTILLA - LA MANCHA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;278 CASTILLA - LA MANCHA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;158 CASTILLA - LA MANCHA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;120 CASTILLA - LA MANCHA;Group 1103 Diseases of the esophagus 530;Both sexes;435 CASTILLA - LA MANCHA;Group 1103 Diseases of the esophagus 530;Men;273 CASTILLA - LA MANCHA;Group 1103 Diseases of the esophagus 530;Women;162 CASTILLA - LA MANCHA;Group 1104 Peptic ulcer 531-534;Both sexes;546 CASTILLA - LA MANCHA;Group 1104 Peptic ulcer 531-534;Men;369 CASTILLA - LA MANCHA;Group 1104 Peptic ulcer 531-534;Women;177 CASTILLA - LA MANCHA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;598 CASTILLA - LA MANCHA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;304 CASTILLA - LA MANCHA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;294 CASTILLA - LA MANCHA;Group 1106 Appendicitis 540-543;Both sexes;1.868 CASTILLA - LA MANCHA;Group 1106 Appendicitis 540-543;Men;1.098 CASTILLA - LA MANCHA;Group 1106 Appendicitis 540-543;Women;770 CASTILLA - LA MANCHA;Group 1107 Inguinal hernia 550;Both sexes;1.644 CASTILLA - LA MANCHA;Group 1107 Inguinal hernia 550;Men;1.468 CASTILLA - LA MANCHA;Group 1107 Inguinal hernia 550;Women;176 CASTILLA - LA MANCHA;Group 1108 Other abdominal hernia 551-553;Both sexes;1.747 CASTILLA - LA MANCHA;Group 1108 Other abdominal hernia 551-553;Men;761 CASTILLA - LA MANCHA;Group 1108 Other abdominal hernia 551-553;Women;986 CASTILLA - LA MANCHA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;405 CASTILLA - LA MANCHA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;217 CASTILLA - LA MANCHA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;188 CASTILLA - LA MANCHA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.326 CASTILLA - LA MANCHA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;668 CASTILLA - LA MANCHA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;658 CASTILLA - LA MANCHA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1.367 CASTILLA - LA MANCHA;Group 1111 Intestinal obstruction without hernia 560;Men;710 CASTILLA - LA MANCHA;Group 1111 Intestinal obstruction without hernia 560;Women;657 CASTILLA - LA MANCHA;Group 1112 Intestinal diverticulosis 562;Both sexes;810 CASTILLA - LA MANCHA;Group 1112 Intestinal diverticulosis 562;Men;418 CASTILLA - LA MANCHA;Group 1112 Intestinal diverticulosis 562;Women;392 CASTILLA - LA MANCHA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.296 CASTILLA - LA MANCHA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;870 CASTILLA - LA MANCHA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;426 CASTILLA - LA MANCHA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;870 CASTILLA - LA MANCHA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;399 CASTILLA - LA MANCHA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;471 CASTILLA - LA MANCHA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;292 CASTILLA - LA MANCHA;Group 1115 Alcoholic hepatitis 5710-5713;Men;256 CASTILLA - LA MANCHA;Group 1115 Alcoholic hepatitis 5710-5713;Women;36 CASTILLA - LA MANCHA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;747 CASTILLA - LA MANCHA;Group 1116 Other diseases of the liver 570,5714-573;Men;499 CASTILLA - LA MANCHA;Group 1116 Other diseases of the liver 570,5714-573;Women;248 CASTILLA - LA MANCHA;Group 1117 Cholelithiasis 574;Both sexes;4.293 CASTILLA - LA MANCHA;Group 1117 Cholelithiasis 574;Men;1.984 CASTILLA - LA MANCHA;Group 1117 Cholelithiasis 574;Women;2.309 CASTILLA - LA MANCHA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1.288 CASTILLA - LA MANCHA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;695 CASTILLA - LA MANCHA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;593 CASTILLA - LA MANCHA;Group 1119 Pancreatic diseases 577;Both sexes;1.593 CASTILLA - LA MANCHA;Group 1119 Pancreatic diseases 577;Men;865 CASTILLA - LA MANCHA;Group 1119 Pancreatic diseases 577;Women;728 CASTILLA - LA MANCHA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;998 CASTILLA - LA MANCHA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;564 CASTILLA - LA MANCHA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;434 CASTILLA - LA MANCHA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.330 CASTILLA - LA MANCHA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;686 CASTILLA - LA MANCHA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;644 CASTILLA - LA MANCHA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;807 CASTILLA - LA MANCHA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;440 CASTILLA - LA MANCHA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;367 CASTILLA - LA MANCHA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;63 CASTILLA - LA MANCHA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;27 CASTILLA - LA MANCHA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;36 CASTILLA - LA MANCHA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;460 CASTILLA - LA MANCHA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;219 CASTILLA - LA MANCHA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;241 CASTILLA - LA MANCHA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;9.720 CASTILLA - LA MANCHA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.665 CASTILLA - LA MANCHA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5.055 CASTILLA - LA MANCHA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CASTILLA - LA MANCHA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CASTILLA - LA MANCHA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CASTILLA - LA MANCHA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CASTILLA - LA MANCHA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CASTILLA - LA MANCHA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CASTILLA - LA MANCHA;Group 1303 Internal derangement of knee 717;Both sexes;949 CASTILLA - LA MANCHA;Group 1303 Internal derangement of knee 717;Men;671 CASTILLA - LA MANCHA;Group 1303 Internal derangement of knee 717;Women;278 CASTILLA - LA MANCHA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3.852 CASTILLA - LA MANCHA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.583 CASTILLA - LA MANCHA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.269 CASTILLA - LA MANCHA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;165 CASTILLA - LA MANCHA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;70 CASTILLA - LA MANCHA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;95 CASTILLA - LA MANCHA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;647 CASTILLA - LA MANCHA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;335 CASTILLA - LA MANCHA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;312 CASTILLA - LA MANCHA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;889 CASTILLA - LA MANCHA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;466 CASTILLA - LA MANCHA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;423 CASTILLA - LA MANCHA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;169 CASTILLA - LA MANCHA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;84 CASTILLA - LA MANCHA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;85 CASTILLA - LA MANCHA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.399 CASTILLA - LA MANCHA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;769 CASTILLA - LA MANCHA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;630 CASTILLA - LA MANCHA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.650 CASTILLA - LA MANCHA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;687 CASTILLA - LA MANCHA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;963 CASTILLA - LA MANCHA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;11.284 CASTILLA - LA MANCHA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;5.218 CASTILLA - LA MANCHA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;6.066 CASTILLA - LA MANCHA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.143 CASTILLA - LA MANCHA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;414 CASTILLA - LA MANCHA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;729 CASTILLA - LA MANCHA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1.184 CASTILLA - LA MANCHA;Group 1402 Renal failure 5836-5837, 584-586;Men;678 CASTILLA - LA MANCHA;Group 1402 Renal failure 5836-5837, 584-586;Women;506 CASTILLA - LA MANCHA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.415 CASTILLA - LA MANCHA;Group 1403 Urolithiasis 592, 594, 7880;Men;866 CASTILLA - LA MANCHA;Group 1403 Urolithiasis 592, 594, 7880;Women;549 CASTILLA - LA MANCHA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;3.304 CASTILLA - LA MANCHA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.634 CASTILLA - LA MANCHA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.670 CASTILLA - LA MANCHA;Group 1405 Prostatic hyperplasia 600;Both sexes;672 CASTILLA - LA MANCHA;Group 1405 Prostatic hyperplasia 600;Men;672 CASTILLA - LA MANCHA;Group 1405 Prostatic hyperplasia 600;Women;.. CASTILLA - LA MANCHA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;884 CASTILLA - LA MANCHA;Group 1406 Other diseases of the male genital organs 601-608;Men;884 CASTILLA - LA MANCHA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CASTILLA - LA MANCHA;Group 1407 Disorders of breast 610-612;Both sexes;471 CASTILLA - LA MANCHA;Group 1407 Disorders of breast 610-612;Men;63 CASTILLA - LA MANCHA;Group 1407 Disorders of breast 610-612;Women;408 CASTILLA - LA MANCHA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;319 CASTILLA - LA MANCHA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CASTILLA - LA MANCHA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;319 CASTILLA - LA MANCHA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;169 CASTILLA - LA MANCHA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CASTILLA - LA MANCHA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;169 CASTILLA - LA MANCHA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.723 CASTILLA - LA MANCHA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;7 CASTILLA - LA MANCHA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.716 CASTILLA - LA MANCHA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;19.117 CASTILLA - LA MANCHA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CASTILLA - LA MANCHA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;19.117 CASTILLA - LA MANCHA;Group 1501 Legally induced abortion 635;Both sexes;20 CASTILLA - LA MANCHA;Group 1501 Legally induced abortion 635;Men;.. CASTILLA - LA MANCHA;Group 1501 Legally induced abortion 635;Women;20 CASTILLA - LA MANCHA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.605 CASTILLA - LA MANCHA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CASTILLA - LA MANCHA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.605 CASTILLA - LA MANCHA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;11.860 CASTILLA - LA MANCHA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CASTILLA - LA MANCHA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;11.860 CASTILLA - LA MANCHA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2.430 CASTILLA - LA MANCHA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CASTILLA - LA MANCHA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2.430 CASTILLA - LA MANCHA;Group 1505 Single spontaneous delivery 650;Both sexes;1.114 CASTILLA - LA MANCHA;Group 1505 Single spontaneous delivery 650;Men;.. CASTILLA - LA MANCHA;Group 1505 Single spontaneous delivery 650;Women;1.114 CASTILLA - LA MANCHA;Group 1506 Other deliveries 6695-6697;Both sexes;675 CASTILLA - LA MANCHA;Group 1506 Other deliveries 6695-6697;Men;.. CASTILLA - LA MANCHA;Group 1506 Other deliveries 6695-6697;Women;675 CASTILLA - LA MANCHA;Group 1507 Complications related to the puerperium 670-676;Both sexes;115 CASTILLA - LA MANCHA;Group 1507 Complications related to the puerperium 670-676;Men;.. CASTILLA - LA MANCHA;Group 1507 Complications related to the puerperium 670-676;Women;115 CASTILLA - LA MANCHA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.298 CASTILLA - LA MANCHA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CASTILLA - LA MANCHA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.298 CASTILLA - LA MANCHA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.958 CASTILLA - LA MANCHA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.642 CASTILLA - LA MANCHA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1.316 CASTILLA - LA MANCHA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;847 CASTILLA - LA MANCHA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;455 CASTILLA - LA MANCHA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;392 CASTILLA - LA MANCHA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;2.111 CASTILLA - LA MANCHA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1.187 CASTILLA - LA MANCHA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;924 CASTILLA - LA MANCHA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.015 CASTILLA - LA MANCHA;Grupo 1700 Congenital abnormalities 740-759;Men;649 CASTILLA - LA MANCHA;Grupo 1700 Congenital abnormalities 740-759;Women;366 CASTILLA - LA MANCHA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;7.976 CASTILLA - LA MANCHA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4.242 CASTILLA - LA MANCHA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3.734 CASTILLA - LA MANCHA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;874 CASTILLA - LA MANCHA;Group 1801 Pain in throat and chest 7841, 7865;Men;479 CASTILLA - LA MANCHA;Group 1801 Pain in throat and chest 7841, 7865;Women;395 CASTILLA - LA MANCHA;Group 1802 Abdominal pain 7890;Both sexes;1.025 CASTILLA - LA MANCHA;Group 1802 Abdominal pain 7890;Men;439 CASTILLA - LA MANCHA;Group 1802 Abdominal pain 7890;Women;586 CASTILLA - LA MANCHA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;897 CASTILLA - LA MANCHA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;419 CASTILLA - LA MANCHA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;478 CASTILLA - LA MANCHA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5.180 CASTILLA - LA MANCHA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.905 CASTILLA - LA MANCHA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.275 CASTILLA - LA MANCHA;Group 1900 Injuries and poisoning 800-999;Both sexes;14.831 CASTILLA - LA MANCHA;Group 1900 Injuries and poisoning 800-999;Men;7.382 CASTILLA - LA MANCHA;Group 1900 Injuries and poisoning 800-999;Women;7.449 CASTILLA - LA MANCHA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;790 CASTILLA - LA MANCHA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;483 CASTILLA - LA MANCHA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;307 CASTILLA - LA MANCHA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;361 CASTILLA - LA MANCHA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;256 CASTILLA - LA MANCHA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;105 CASTILLA - LA MANCHA;Group 1903 Radius and ulna fracture 813;Both sexes;811 CASTILLA - LA MANCHA;Group 1903 Radius and ulna fracture 813;Men;402 CASTILLA - LA MANCHA;Group 1903 Radius and ulna fracture 813;Women;409 CASTILLA - LA MANCHA;Group 1904 Femur fracture 820-821;Both sexes;3.099 CASTILLA - LA MANCHA;Group 1904 Femur fracture 820-821;Men;848 CASTILLA - LA MANCHA;Group 1904 Femur fracture 820-821;Women;2.251 CASTILLA - LA MANCHA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.086 CASTILLA - LA MANCHA;Group 1905 Leg fracture, including the ankle 823-824;Men;549 CASTILLA - LA MANCHA;Group 1905 Leg fracture, including the ankle 823-824;Women;537 CASTILLA - LA MANCHA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3.986 CASTILLA - LA MANCHA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.463 CASTILLA - LA MANCHA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.523 CASTILLA - LA MANCHA;Group 1907 Burns 940-949;Both sexes;39 CASTILLA - LA MANCHA;Group 1907 Burns 940-949;Men;28 CASTILLA - LA MANCHA;Group 1907 Burns 940-949;Women;11 CASTILLA - LA MANCHA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;478 CASTILLA - LA MANCHA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;200 CASTILLA - LA MANCHA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;278 CASTILLA - LA MANCHA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3.664 CASTILLA - LA MANCHA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.866 CASTILLA - LA MANCHA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.798 CASTILLA - LA MANCHA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;36 CASTILLA - LA MANCHA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;25 CASTILLA - LA MANCHA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;11 CASTILLA - LA MANCHA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;481 CASTILLA - LA MANCHA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;262 CASTILLA - LA MANCHA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;219 CASTILLA - LA MANCHA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.715 CASTILLA - LA MANCHA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.567 CASTILLA - LA MANCHA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.148 CASTILLA - LA MANCHA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;165 CASTILLA - LA MANCHA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;113 CASTILLA - LA MANCHA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;52 CASTILLA - LA MANCHA;Group 2102 Contraceptive management V25;Both sexes;58 CASTILLA - LA MANCHA;Group 2102 Contraceptive management V25;Men;6 CASTILLA - LA MANCHA;Group 2102 Contraceptive management V25;Women;52 CASTILLA - LA MANCHA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CASTILLA - LA MANCHA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CASTILLA - LA MANCHA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CASTILLA - LA MANCHA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1.242 CASTILLA - LA MANCHA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;765 CASTILLA - LA MANCHA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;477 CASTILLA - LA MANCHA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.250 CASTILLA - LA MANCHA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;683 CASTILLA - LA MANCHA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;567 Albacete;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;40.021 Albacete;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;18.782 Albacete;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;21.239 Albacete;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;989 Albacete;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;582 Albacete;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;407 Albacete;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;158 Albacete;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;91 Albacete;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;67 Albacete;Group 0102 Imprecise intestinal infections 009;Both sexes;59 Albacete;Group 0102 Imprecise intestinal infections 009;Men;31 Albacete;Group 0102 Imprecise intestinal infections 009;Women;28 Albacete;Group 0103 Tuberculosis 010-018, 137;Both sexes;41 Albacete;Group 0103 Tuberculosis 010-018, 137;Men;30 Albacete;Group 0103 Tuberculosis 010-018, 137;Women;11 Albacete;Group 0104 Septicaemia 038;Both sexes;434 Albacete;Group 0104 Septicaemia 038;Men;244 Albacete;Group 0104 Septicaemia 038;Women;190 Albacete;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;15 Albacete;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;10 Albacete;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;5 Albacete;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;282 Albacete;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;176 Albacete;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;106 Albacete;Group 0200 Neoplasms 140-239;Both sexes;3.609 Albacete;Group 0200 Neoplasms 140-239;Men;2.003 Albacete;Group 0200 Neoplasms 140-239;Women;1.606 Albacete;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;384 Albacete;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;234 Albacete;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;150 Albacete;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;284 Albacete;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;244 Albacete;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;40 Albacete;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;77 Albacete;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;44 Albacete;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;33 Albacete;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;208 Albacete;Group 0204 Malignant neoplasm of breast 174-175;Men;2 Albacete;Group 0204 Malignant neoplasm of breast 174-175;Women;206 Albacete;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;62 Albacete;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Albacete;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;62 Albacete;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;16 Albacete;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Albacete;Group 0206 Malignant neoplasm of ovary 1830;Women;16 Albacete;Group 0207 Malignant neoplasm of prostate 185;Both sexes;74 Albacete;Group 0207 Malignant neoplasm of prostate 185;Men;74 Albacete;Group 0207 Malignant neoplasm of prostate 185;Women;.. Albacete;Group 0208 Malignant neoplasm of bladder 188;Both sexes;300 Albacete;Group 0208 Malignant neoplasm of bladder 188;Men;261 Albacete;Group 0208 Malignant neoplasm of bladder 188;Women;39 Albacete;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.337 Albacete;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;814 Albacete;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;523 Albacete;Group 0210 Carcinoma in situ 230-234;Both sexes;45 Albacete;Group 0210 Carcinoma in situ 230-234;Men;18 Albacete;Group 0210 Carcinoma in situ 230-234;Women;27 Albacete;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;25 Albacete;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;15 Albacete;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;10 Albacete;Grupo 0212 Leiomyoma of uterus 218;Both sexes;207 Albacete;Grupo 0212 Leiomyoma of uterus 218;Men;.. Albacete;Grupo 0212 Leiomyoma of uterus 218;Women;207 Albacete;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;590 Albacete;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;297 Albacete;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;293 Albacete;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;275 Albacete;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;133 Albacete;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;142 Albacete;Group 0301 Anaemias 280-285;Both sexes;144 Albacete;Group 0301 Anaemias 280-285;Men;74 Albacete;Group 0301 Anaemias 280-285;Women;70 Albacete;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;131 Albacete;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;59 Albacete;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;72 Albacete;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;634 Albacete;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;261 Albacete;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;373 Albacete;Group 0401 Diabetes mellitus 249-250;Both sexes;233 Albacete;Group 0401 Diabetes mellitus 249-250;Men;147 Albacete;Group 0401 Diabetes mellitus 249-250;Women;86 Albacete;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;401 Albacete;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;114 Albacete;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;287 Albacete;Group 0500 Mental disorders 290-319;Both sexes;895 Albacete;Group 0500 Mental disorders 290-319;Men;393 Albacete;Group 0500 Mental disorders 290-319;Women;502 Albacete;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;17 Albacete;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;11 Albacete;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;6 Albacete;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;28 Albacete;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;23 Albacete;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;5 Albacete;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;39 Albacete;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;30 Albacete;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;9 Albacete;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;225 Albacete;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;144 Albacete;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;81 Albacete;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;246 Albacete;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;92 Albacete;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;154 Albacete;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;340 Albacete;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;93 Albacete;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;247 Albacete;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;537 Albacete;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;303 Albacete;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;234 Albacete;Group 0601 Alzheimer's disease 3310;Both sexes;5 Albacete;Group 0601 Alzheimer's disease 3310;Men;1 Albacete;Group 0601 Alzheimer's disease 3310;Women;4 Albacete;Group 0602 Multiple sclerosis 340;Both sexes;11 Albacete;Group 0602 Multiple sclerosis 340;Men;4 Albacete;Group 0602 Multiple sclerosis 340;Women;7 Albacete;Group 0603 Epilepsy 345;Both sexes;85 Albacete;Group 0603 Epilepsy 345;Men;58 Albacete;Group 0603 Epilepsy 345;Women;27 Albacete;Group 0604 Transient cerebral ischemia 435;Both sexes;125 Albacete;Group 0604 Transient cerebral ischemia 435;Men;65 Albacete;Group 0604 Transient cerebral ischemia 435;Women;60 Albacete;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;311 Albacete;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;175 Albacete;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;136 Albacete;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;183 Albacete;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;88 Albacete;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;95 Albacete;Grupo 0701 Cataract 366;Both sexes;59 Albacete;Grupo 0701 Cataract 366;Men;27 Albacete;Grupo 0701 Cataract 366;Women;32 Albacete;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;124 Albacete;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;61 Albacete;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;63 Albacete;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;142 Albacete;Group 0800 Diseases of the ear and the mastoid 380-389;Men;70 Albacete;Group 0800 Diseases of the ear and the mastoid 380-389;Women;72 Albacete;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5.085 Albacete;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.843 Albacete;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.242 Albacete;Group 0901 Hypertensive disease 401-405;Both sexes;226 Albacete;Group 0901 Hypertensive disease 401-405;Men;95 Albacete;Group 0901 Hypertensive disease 401-405;Women;131 Albacete;Group 0902 Angina pectoris 4111, 413;Both sexes;242 Albacete;Group 0902 Angina pectoris 4111, 413;Men;139 Albacete;Group 0902 Angina pectoris 4111, 413;Women;103 Albacete;Group 0903 Acute myocardial infarction 410;Both sexes;450 Albacete;Group 0903 Acute myocardial infarction 410;Men;326 Albacete;Group 0903 Acute myocardial infarction 410;Women;124 Albacete;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;329 Albacete;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;254 Albacete;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;75 Albacete;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;201 Albacete;Group 0905 Diseases of the lungs circulation 415-417;Men;92 Albacete;Group 0905 Diseases of the lungs circulation 415-417;Women;109 Albacete;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;579 Albacete;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;317 Albacete;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;262 Albacete;Grupo 0907 Heart failure 428;Both sexes;1.038 Albacete;Grupo 0907 Heart failure 428;Men;477 Albacete;Grupo 0907 Heart failure 428;Women;561 Albacete;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;979 Albacete;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;525 Albacete;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;454 Albacete;Grupo 0909 Atherosclerosis 440;Both sexes;151 Albacete;Grupo 0909 Atherosclerosis 440;Men;110 Albacete;Grupo 0909 Atherosclerosis 440;Women;41 Albacete;Group 0910 Varicose veins of lower extremities 454;Both sexes;37 Albacete;Group 0910 Varicose veins of lower extremities 454;Men;14 Albacete;Group 0910 Varicose veins of lower extremities 454;Women;23 Albacete;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;853 Albacete;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;494 Albacete;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;359 Albacete;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;4.582 Albacete;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2.680 Albacete;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.902 Albacete;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;214 Albacete;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;124 Albacete;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;90 Albacete;Group 1002 Pneumonia 480-486;Both sexes;1.010 Albacete;Group 1002 Pneumonia 480-486;Men;626 Albacete;Group 1002 Pneumonia 480-486;Women;384 Albacete;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;378 Albacete;Group 1003 Acute bronchitis and bronchiolitis 466;Men;195 Albacete;Group 1003 Acute bronchitis and bronchiolitis 466;Women;183 Albacete;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;239 Albacete;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;129 Albacete;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;110 Albacete;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;211 Albacete;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;132 Albacete;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;79 Albacete;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;518 Albacete;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;424 Albacete;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;94 Albacete;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;142 Albacete;Group 1007 Asthma 4930-4931,4938-4939;Men;64 Albacete;Group 1007 Asthma 4930-4931,4938-4939;Women;78 Albacete;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.870 Albacete;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;986 Albacete;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;884 Albacete;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.658 Albacete;Group 1100 Diseases of the digestive system 520-579;Men;2.627 Albacete;Group 1100 Diseases of the digestive system 520-579;Women;2.031 Albacete;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;56 Albacete;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;35 Albacete;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;21 Albacete;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;49 Albacete;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;25 Albacete;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;24 Albacete;Group 1103 Diseases of the esophagus 530;Both sexes;88 Albacete;Group 1103 Diseases of the esophagus 530;Men;51 Albacete;Group 1103 Diseases of the esophagus 530;Women;37 Albacete;Group 1104 Peptic ulcer 531-534;Both sexes;165 Albacete;Group 1104 Peptic ulcer 531-534;Men;97 Albacete;Group 1104 Peptic ulcer 531-534;Women;68 Albacete;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;151 Albacete;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;86 Albacete;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;65 Albacete;Group 1106 Appendicitis 540-543;Both sexes;438 Albacete;Group 1106 Appendicitis 540-543;Men;260 Albacete;Group 1106 Appendicitis 540-543;Women;178 Albacete;Group 1107 Inguinal hernia 550;Both sexes;264 Albacete;Group 1107 Inguinal hernia 550;Men;232 Albacete;Group 1107 Inguinal hernia 550;Women;32 Albacete;Group 1108 Other abdominal hernia 551-553;Both sexes;276 Albacete;Group 1108 Other abdominal hernia 551-553;Men;126 Albacete;Group 1108 Other abdominal hernia 551-553;Women;150 Albacete;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;63 Albacete;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;35 Albacete;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;28 Albacete;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;254 Albacete;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;129 Albacete;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;125 Albacete;Group 1111 Intestinal obstruction without hernia 560;Both sexes;303 Albacete;Group 1111 Intestinal obstruction without hernia 560;Men;176 Albacete;Group 1111 Intestinal obstruction without hernia 560;Women;127 Albacete;Group 1112 Intestinal diverticulosis 562;Both sexes;173 Albacete;Group 1112 Intestinal diverticulosis 562;Men;89 Albacete;Group 1112 Intestinal diverticulosis 562;Women;84 Albacete;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;373 Albacete;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;257 Albacete;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;116 Albacete;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;140 Albacete;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;72 Albacete;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;68 Albacete;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;62 Albacete;Group 1115 Alcoholic hepatitis 5710-5713;Men;51 Albacete;Group 1115 Alcoholic hepatitis 5710-5713;Women;11 Albacete;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;161 Albacete;Group 1116 Other diseases of the liver 570,5714-573;Men;101 Albacete;Group 1116 Other diseases of the liver 570,5714-573;Women;60 Albacete;Group 1117 Cholelithiasis 574;Both sexes;747 Albacete;Group 1117 Cholelithiasis 574;Men;322 Albacete;Group 1117 Cholelithiasis 574;Women;425 Albacete;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;334 Albacete;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;181 Albacete;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;153 Albacete;Group 1119 Pancreatic diseases 577;Both sexes;333 Albacete;Group 1119 Pancreatic diseases 577;Men;180 Albacete;Group 1119 Pancreatic diseases 577;Women;153 Albacete;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;228 Albacete;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;122 Albacete;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;106 Albacete;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;295 Albacete;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;144 Albacete;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;151 Albacete;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;178 Albacete;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;84 Albacete;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;94 Albacete;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;12 Albacete;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;5 Albacete;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;7 Albacete;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;105 Albacete;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;55 Albacete;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;50 Albacete;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.132 Albacete;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.024 Albacete;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.108 Albacete;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Albacete;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Albacete;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Albacete;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Albacete;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Albacete;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Albacete;Group 1303 Internal derangement of knee 717;Both sexes;95 Albacete;Group 1303 Internal derangement of knee 717;Men;72 Albacete;Group 1303 Internal derangement of knee 717;Women;23 Albacete;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;958 Albacete;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;410 Albacete;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;548 Albacete;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;28 Albacete;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;12 Albacete;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;16 Albacete;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;137 Albacete;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;71 Albacete;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;66 Albacete;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;273 Albacete;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;132 Albacete;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;141 Albacete;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;36 Albacete;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;15 Albacete;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;21 Albacete;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;333 Albacete;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;187 Albacete;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;146 Albacete;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;272 Albacete;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;125 Albacete;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;147 Albacete;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.986 Albacete;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.318 Albacete;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.668 Albacete;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;229 Albacete;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;87 Albacete;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;142 Albacete;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;318 Albacete;Group 1402 Renal failure 5836-5837, 584-586;Men;185 Albacete;Group 1402 Renal failure 5836-5837, 584-586;Women;133 Albacete;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;513 Albacete;Group 1403 Urolithiasis 592, 594, 7880;Men;312 Albacete;Group 1403 Urolithiasis 592, 594, 7880;Women;201 Albacete;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;722 Albacete;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;354 Albacete;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;368 Albacete;Group 1405 Prostatic hyperplasia 600;Both sexes;171 Albacete;Group 1405 Prostatic hyperplasia 600;Men;171 Albacete;Group 1405 Prostatic hyperplasia 600;Women;.. Albacete;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;185 Albacete;Group 1406 Other diseases of the male genital organs 601-608;Men;185 Albacete;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Albacete;Group 1407 Disorders of breast 610-612;Both sexes;194 Albacete;Group 1407 Disorders of breast 610-612;Men;21 Albacete;Group 1407 Disorders of breast 610-612;Women;173 Albacete;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;74 Albacete;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Albacete;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;74 Albacete;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;25 Albacete;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Albacete;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;25 Albacete;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;555 Albacete;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;3 Albacete;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;552 Albacete;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5.003 Albacete;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Albacete;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5.003 Albacete;Group 1501 Legally induced abortion 635;Both sexes;16 Albacete;Group 1501 Legally induced abortion 635;Men;.. Albacete;Group 1501 Legally induced abortion 635;Women;16 Albacete;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;401 Albacete;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Albacete;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;401 Albacete;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;2.639 Albacete;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Albacete;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;2.639 Albacete;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;920 Albacete;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Albacete;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;920 Albacete;Group 1505 Single spontaneous delivery 650;Both sexes;507 Albacete;Group 1505 Single spontaneous delivery 650;Men;.. Albacete;Group 1505 Single spontaneous delivery 650;Women;507 Albacete;Group 1506 Other deliveries 6695-6697;Both sexes;259 Albacete;Group 1506 Other deliveries 6695-6697;Men;.. Albacete;Group 1506 Other deliveries 6695-6697;Women;259 Albacete;Group 1507 Complications related to the puerperium 670-676;Both sexes;31 Albacete;Group 1507 Complications related to the puerperium 670-676;Men;.. Albacete;Group 1507 Complications related to the puerperium 670-676;Women;31 Albacete;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;230 Albacete;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Albacete;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;230 Albacete;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;694 Albacete;Group 1600 Some disorders originating in the perinatal period 760-779;Men;397 Albacete;Group 1600 Some disorders originating in the perinatal period 760-779;Women;297 Albacete;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;219 Albacete;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;117 Albacete;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;102 Albacete;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;475 Albacete;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;280 Albacete;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;195 Albacete;Grupo 1700 Congenital abnormalities 740-759;Both sexes;323 Albacete;Grupo 1700 Congenital abnormalities 740-759;Men;216 Albacete;Grupo 1700 Congenital abnormalities 740-759;Women;107 Albacete;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.541 Albacete;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.310 Albacete;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.231 Albacete;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;171 Albacete;Group 1801 Pain in throat and chest 7841, 7865;Men;97 Albacete;Group 1801 Pain in throat and chest 7841, 7865;Women;74 Albacete;Group 1802 Abdominal pain 7890;Both sexes;287 Albacete;Group 1802 Abdominal pain 7890;Men;121 Albacete;Group 1802 Abdominal pain 7890;Women;166 Albacete;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;880 Albacete;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;413 Albacete;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;467 Albacete;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.203 Albacete;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;679 Albacete;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;524 Albacete;Group 1900 Injuries and poisoning 800-999;Both sexes;3.657 Albacete;Group 1900 Injuries and poisoning 800-999;Men;1.921 Albacete;Group 1900 Injuries and poisoning 800-999;Women;1.736 Albacete;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;203 Albacete;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;136 Albacete;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;67 Albacete;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;86 Albacete;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;64 Albacete;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;22 Albacete;Group 1903 Radius and ulna fracture 813;Both sexes;185 Albacete;Group 1903 Radius and ulna fracture 813;Men;96 Albacete;Group 1903 Radius and ulna fracture 813;Women;89 Albacete;Group 1904 Femur fracture 820-821;Both sexes;687 Albacete;Group 1904 Femur fracture 820-821;Men;200 Albacete;Group 1904 Femur fracture 820-821;Women;487 Albacete;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;256 Albacete;Group 1905 Leg fracture, including the ankle 823-824;Men;126 Albacete;Group 1905 Leg fracture, including the ankle 823-824;Women;130 Albacete;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.031 Albacete;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;681 Albacete;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;350 Albacete;Group 1907 Burns 940-949;Both sexes;16 Albacete;Group 1907 Burns 940-949;Men;12 Albacete;Group 1907 Burns 940-949;Women;4 Albacete;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;103 Albacete;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;37 Albacete;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;66 Albacete;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;943 Albacete;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;486 Albacete;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;457 Albacete;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;15 Albacete;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;11 Albacete;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;4 Albacete;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;132 Albacete;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;72 Albacete;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;60 Albacete;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;801 Albacete;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;469 Albacete;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;332 Albacete;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;71 Albacete;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;49 Albacete;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;22 Albacete;Group 2102 Contraceptive management V25;Both sexes;8 Albacete;Group 2102 Contraceptive management V25;Men;1 Albacete;Group 2102 Contraceptive management V25;Women;7 Albacete;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Albacete;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Albacete;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Albacete;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;435 Albacete;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;280 Albacete;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;155 Albacete;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;287 Albacete;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;139 Albacete;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;148 Ciudad Real;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;52.778 Ciudad Real;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;24.934 Ciudad Real;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;27.844 Ciudad Real;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.145 Ciudad Real;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;650 Ciudad Real;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;495 Ciudad Real;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;189 Ciudad Real;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;99 Ciudad Real;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;90 Ciudad Real;Group 0102 Imprecise intestinal infections 009;Both sexes;31 Ciudad Real;Group 0102 Imprecise intestinal infections 009;Men;19 Ciudad Real;Group 0102 Imprecise intestinal infections 009;Women;12 Ciudad Real;Group 0103 Tuberculosis 010-018, 137;Both sexes;27 Ciudad Real;Group 0103 Tuberculosis 010-018, 137;Men;18 Ciudad Real;Group 0103 Tuberculosis 010-018, 137;Women;9 Ciudad Real;Group 0104 Septicaemia 038;Both sexes;525 Ciudad Real;Group 0104 Septicaemia 038;Men;275 Ciudad Real;Group 0104 Septicaemia 038;Women;250 Ciudad Real;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;15 Ciudad Real;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;12 Ciudad Real;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 Ciudad Real;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;358 Ciudad Real;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;227 Ciudad Real;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;131 Ciudad Real;Group 0200 Neoplasms 140-239;Both sexes;5.334 Ciudad Real;Group 0200 Neoplasms 140-239;Men;2.950 Ciudad Real;Group 0200 Neoplasms 140-239;Women;2.384 Ciudad Real;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;595 Ciudad Real;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;364 Ciudad Real;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;231 Ciudad Real;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;484 Ciudad Real;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;422 Ciudad Real;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;62 Ciudad Real;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;62 Ciudad Real;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;41 Ciudad Real;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;21 Ciudad Real;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;425 Ciudad Real;Group 0204 Malignant neoplasm of breast 174-175;Men;4 Ciudad Real;Group 0204 Malignant neoplasm of breast 174-175;Women;421 Ciudad Real;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;136 Ciudad Real;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Ciudad Real;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;136 Ciudad Real;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;48 Ciudad Real;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Ciudad Real;Group 0206 Malignant neoplasm of ovary 1830;Women;48 Ciudad Real;Group 0207 Malignant neoplasm of prostate 185;Both sexes;141 Ciudad Real;Group 0207 Malignant neoplasm of prostate 185;Men;141 Ciudad Real;Group 0207 Malignant neoplasm of prostate 185;Women;.. Ciudad Real;Group 0208 Malignant neoplasm of bladder 188;Both sexes;557 Ciudad Real;Group 0208 Malignant neoplasm of bladder 188;Men;483 Ciudad Real;Group 0208 Malignant neoplasm of bladder 188;Women;74 Ciudad Real;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.891 Ciudad Real;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.126 Ciudad Real;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;765 Ciudad Real;Group 0210 Carcinoma in situ 230-234;Both sexes;56 Ciudad Real;Group 0210 Carcinoma in situ 230-234;Men;26 Ciudad Real;Group 0210 Carcinoma in situ 230-234;Women;30 Ciudad Real;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;79 Ciudad Real;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;51 Ciudad Real;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;28 Ciudad Real;Grupo 0212 Leiomyoma of uterus 218;Both sexes;215 Ciudad Real;Grupo 0212 Leiomyoma of uterus 218;Men;.. Ciudad Real;Grupo 0212 Leiomyoma of uterus 218;Women;215 Ciudad Real;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;645 Ciudad Real;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;292 Ciudad Real;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;353 Ciudad Real;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;504 Ciudad Real;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;255 Ciudad Real;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;249 Ciudad Real;Group 0301 Anaemias 280-285;Both sexes;290 Ciudad Real;Group 0301 Anaemias 280-285;Men;132 Ciudad Real;Group 0301 Anaemias 280-285;Women;158 Ciudad Real;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;214 Ciudad Real;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;123 Ciudad Real;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;91 Ciudad Real;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;860 Ciudad Real;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;323 Ciudad Real;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;537 Ciudad Real;Group 0401 Diabetes mellitus 249-250;Both sexes;270 Ciudad Real;Group 0401 Diabetes mellitus 249-250;Men;115 Ciudad Real;Group 0401 Diabetes mellitus 249-250;Women;155 Ciudad Real;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;590 Ciudad Real;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;208 Ciudad Real;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;382 Ciudad Real;Group 0500 Mental disorders 290-319;Both sexes;977 Ciudad Real;Group 0500 Mental disorders 290-319;Men;472 Ciudad Real;Group 0500 Mental disorders 290-319;Women;505 Ciudad Real;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;26 Ciudad Real;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;12 Ciudad Real;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;14 Ciudad Real;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;46 Ciudad Real;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;37 Ciudad Real;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;9 Ciudad Real;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;27 Ciudad Real;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;20 Ciudad Real;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;7 Ciudad Real;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;204 Ciudad Real;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;130 Ciudad Real;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;74 Ciudad Real;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;216 Ciudad Real;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;93 Ciudad Real;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;123 Ciudad Real;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;458 Ciudad Real;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;180 Ciudad Real;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;278 Ciudad Real;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.452 Ciudad Real;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;695 Ciudad Real;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;757 Ciudad Real;Group 0601 Alzheimer's disease 3310;Both sexes;21 Ciudad Real;Group 0601 Alzheimer's disease 3310;Men;6 Ciudad Real;Group 0601 Alzheimer's disease 3310;Women;15 Ciudad Real;Group 0602 Multiple sclerosis 340;Both sexes;47 Ciudad Real;Group 0602 Multiple sclerosis 340;Men;18 Ciudad Real;Group 0602 Multiple sclerosis 340;Women;29 Ciudad Real;Group 0603 Epilepsy 345;Both sexes;135 Ciudad Real;Group 0603 Epilepsy 345;Men;71 Ciudad Real;Group 0603 Epilepsy 345;Women;64 Ciudad Real;Group 0604 Transient cerebral ischemia 435;Both sexes;244 Ciudad Real;Group 0604 Transient cerebral ischemia 435;Men;131 Ciudad Real;Group 0604 Transient cerebral ischemia 435;Women;113 Ciudad Real;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.005 Ciudad Real;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;469 Ciudad Real;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;536 Ciudad Real;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;336 Ciudad Real;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;198 Ciudad Real;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;138 Ciudad Real;Grupo 0701 Cataract 366;Both sexes;27 Ciudad Real;Grupo 0701 Cataract 366;Men;15 Ciudad Real;Grupo 0701 Cataract 366;Women;12 Ciudad Real;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;309 Ciudad Real;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;183 Ciudad Real;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;126 Ciudad Real;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;289 Ciudad Real;Group 0800 Diseases of the ear and the mastoid 380-389;Men;145 Ciudad Real;Group 0800 Diseases of the ear and the mastoid 380-389;Women;144 Ciudad Real;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;6.886 Ciudad Real;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3.746 Ciudad Real;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3.140 Ciudad Real;Group 0901 Hypertensive disease 401-405;Both sexes;303 Ciudad Real;Group 0901 Hypertensive disease 401-405;Men;135 Ciudad Real;Group 0901 Hypertensive disease 401-405;Women;168 Ciudad Real;Group 0902 Angina pectoris 4111, 413;Both sexes;460 Ciudad Real;Group 0902 Angina pectoris 4111, 413;Men;288 Ciudad Real;Group 0902 Angina pectoris 4111, 413;Women;172 Ciudad Real;Group 0903 Acute myocardial infarction 410;Both sexes;698 Ciudad Real;Group 0903 Acute myocardial infarction 410;Men;482 Ciudad Real;Group 0903 Acute myocardial infarction 410;Women;216 Ciudad Real;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;422 Ciudad Real;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;315 Ciudad Real;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;107 Ciudad Real;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;245 Ciudad Real;Group 0905 Diseases of the lungs circulation 415-417;Men;111 Ciudad Real;Group 0905 Diseases of the lungs circulation 415-417;Women;134 Ciudad Real;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;931 Ciudad Real;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;497 Ciudad Real;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;434 Ciudad Real;Grupo 0907 Heart failure 428;Both sexes;1.457 Ciudad Real;Grupo 0907 Heart failure 428;Men;571 Ciudad Real;Grupo 0907 Heart failure 428;Women;886 Ciudad Real;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.127 Ciudad Real;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;603 Ciudad Real;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;524 Ciudad Real;Grupo 0909 Atherosclerosis 440;Both sexes;311 Ciudad Real;Grupo 0909 Atherosclerosis 440;Men;221 Ciudad Real;Grupo 0909 Atherosclerosis 440;Women;90 Ciudad Real;Group 0910 Varicose veins of lower extremities 454;Both sexes;45 Ciudad Real;Group 0910 Varicose veins of lower extremities 454;Men;24 Ciudad Real;Group 0910 Varicose veins of lower extremities 454;Women;21 Ciudad Real;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;887 Ciudad Real;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;499 Ciudad Real;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;388 Ciudad Real;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7.247 Ciudad Real;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.260 Ciudad Real;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.987 Ciudad Real;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;346 Ciudad Real;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;175 Ciudad Real;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;171 Ciudad Real;Group 1002 Pneumonia 480-486;Both sexes;1.555 Ciudad Real;Group 1002 Pneumonia 480-486;Men;978 Ciudad Real;Group 1002 Pneumonia 480-486;Women;577 Ciudad Real;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;676 Ciudad Real;Group 1003 Acute bronchitis and bronchiolitis 466;Men;298 Ciudad Real;Group 1003 Acute bronchitis and bronchiolitis 466;Women;378 Ciudad Real;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;332 Ciudad Real;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;179 Ciudad Real;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;153 Ciudad Real;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;475 Ciudad Real;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;312 Ciudad Real;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;163 Ciudad Real;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.150 Ciudad Real;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;971 Ciudad Real;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;179 Ciudad Real;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;229 Ciudad Real;Group 1007 Asthma 4930-4931,4938-4939;Men;62 Ciudad Real;Group 1007 Asthma 4930-4931,4938-4939;Women;167 Ciudad Real;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.484 Ciudad Real;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.285 Ciudad Real;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.199 Ciudad Real;Group 1100 Diseases of the digestive system 520-579;Both sexes;7.422 Ciudad Real;Group 1100 Diseases of the digestive system 520-579;Men;4.146 Ciudad Real;Group 1100 Diseases of the digestive system 520-579;Women;3.276 Ciudad Real;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;75 Ciudad Real;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;38 Ciudad Real;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;37 Ciudad Real;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;97 Ciudad Real;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;56 Ciudad Real;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;41 Ciudad Real;Group 1103 Diseases of the esophagus 530;Both sexes;164 Ciudad Real;Group 1103 Diseases of the esophagus 530;Men;111 Ciudad Real;Group 1103 Diseases of the esophagus 530;Women;53 Ciudad Real;Group 1104 Peptic ulcer 531-534;Both sexes;176 Ciudad Real;Group 1104 Peptic ulcer 531-534;Men;127 Ciudad Real;Group 1104 Peptic ulcer 531-534;Women;49 Ciudad Real;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;206 Ciudad Real;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;106 Ciudad Real;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;100 Ciudad Real;Group 1106 Appendicitis 540-543;Both sexes;541 Ciudad Real;Group 1106 Appendicitis 540-543;Men;322 Ciudad Real;Group 1106 Appendicitis 540-543;Women;219 Ciudad Real;Group 1107 Inguinal hernia 550;Both sexes;533 Ciudad Real;Group 1107 Inguinal hernia 550;Men;476 Ciudad Real;Group 1107 Inguinal hernia 550;Women;57 Ciudad Real;Group 1108 Other abdominal hernia 551-553;Both sexes;645 Ciudad Real;Group 1108 Other abdominal hernia 551-553;Men;288 Ciudad Real;Group 1108 Other abdominal hernia 551-553;Women;357 Ciudad Real;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;142 Ciudad Real;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;66 Ciudad Real;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;76 Ciudad Real;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;346 Ciudad Real;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;173 Ciudad Real;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;173 Ciudad Real;Group 1111 Intestinal obstruction without hernia 560;Both sexes;425 Ciudad Real;Group 1111 Intestinal obstruction without hernia 560;Men;217 Ciudad Real;Group 1111 Intestinal obstruction without hernia 560;Women;208 Ciudad Real;Group 1112 Intestinal diverticulosis 562;Both sexes;229 Ciudad Real;Group 1112 Intestinal diverticulosis 562;Men;119 Ciudad Real;Group 1112 Intestinal diverticulosis 562;Women;110 Ciudad Real;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;286 Ciudad Real;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;191 Ciudad Real;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;95 Ciudad Real;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;284 Ciudad Real;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;138 Ciudad Real;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;146 Ciudad Real;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;122 Ciudad Real;Group 1115 Alcoholic hepatitis 5710-5713;Men;114 Ciudad Real;Group 1115 Alcoholic hepatitis 5710-5713;Women;8 Ciudad Real;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;201 Ciudad Real;Group 1116 Other diseases of the liver 570,5714-573;Men;123 Ciudad Real;Group 1116 Other diseases of the liver 570,5714-573;Women;78 Ciudad Real;Group 1117 Cholelithiasis 574;Both sexes;1.709 Ciudad Real;Group 1117 Cholelithiasis 574;Men;803 Ciudad Real;Group 1117 Cholelithiasis 574;Women;906 Ciudad Real;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;368 Ciudad Real;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;206 Ciudad Real;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;162 Ciudad Real;Group 1119 Pancreatic diseases 577;Both sexes;559 Ciudad Real;Group 1119 Pancreatic diseases 577;Men;296 Ciudad Real;Group 1119 Pancreatic diseases 577;Women;263 Ciudad Real;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;314 Ciudad Real;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;176 Ciudad Real;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;138 Ciudad Real;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;359 Ciudad Real;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;178 Ciudad Real;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;181 Ciudad Real;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;217 Ciudad Real;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;109 Ciudad Real;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;108 Ciudad Real;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;15 Ciudad Real;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;7 Ciudad Real;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;8 Ciudad Real;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;127 Ciudad Real;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;62 Ciudad Real;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;65 Ciudad Real;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;3.257 Ciudad Real;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.498 Ciudad Real;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.759 Ciudad Real;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Ciudad Real;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Ciudad Real;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Ciudad Real;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Ciudad Real;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Ciudad Real;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Ciudad Real;Group 1303 Internal derangement of knee 717;Both sexes;315 Ciudad Real;Group 1303 Internal derangement of knee 717;Men;228 Ciudad Real;Group 1303 Internal derangement of knee 717;Women;87 Ciudad Real;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.235 Ciudad Real;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;458 Ciudad Real;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;777 Ciudad Real;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;59 Ciudad Real;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;23 Ciudad Real;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;36 Ciudad Real;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;313 Ciudad Real;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;167 Ciudad Real;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;146 Ciudad Real;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;292 Ciudad Real;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;156 Ciudad Real;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;136 Ciudad Real;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;34 Ciudad Real;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;17 Ciudad Real;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;17 Ciudad Real;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;444 Ciudad Real;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;226 Ciudad Real;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;218 Ciudad Real;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;565 Ciudad Real;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;223 Ciudad Real;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;342 Ciudad Real;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.269 Ciudad Real;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.494 Ciudad Real;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.775 Ciudad Real;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;284 Ciudad Real;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;111 Ciudad Real;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;173 Ciudad Real;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;351 Ciudad Real;Group 1402 Renal failure 5836-5837, 584-586;Men;203 Ciudad Real;Group 1402 Renal failure 5836-5837, 584-586;Women;148 Ciudad Real;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;294 Ciudad Real;Group 1403 Urolithiasis 592, 594, 7880;Men;198 Ciudad Real;Group 1403 Urolithiasis 592, 594, 7880;Women;96 Ciudad Real;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.119 Ciudad Real;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;534 Ciudad Real;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;585 Ciudad Real;Group 1405 Prostatic hyperplasia 600;Both sexes;210 Ciudad Real;Group 1405 Prostatic hyperplasia 600;Men;210 Ciudad Real;Group 1405 Prostatic hyperplasia 600;Women;.. Ciudad Real;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;223 Ciudad Real;Group 1406 Other diseases of the male genital organs 601-608;Men;223 Ciudad Real;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Ciudad Real;Group 1407 Disorders of breast 610-612;Both sexes;104 Ciudad Real;Group 1407 Disorders of breast 610-612;Men;15 Ciudad Real;Group 1407 Disorders of breast 610-612;Women;89 Ciudad Real;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;100 Ciudad Real;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Ciudad Real;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;100 Ciudad Real;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;82 Ciudad Real;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Ciudad Real;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;82 Ciudad Real;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;502 Ciudad Real;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Ciudad Real;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;502 Ciudad Real;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5.736 Ciudad Real;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Ciudad Real;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5.736 Ciudad Real;Group 1501 Legally induced abortion 635;Both sexes;1 Ciudad Real;Group 1501 Legally induced abortion 635;Men;.. Ciudad Real;Group 1501 Legally induced abortion 635;Women;1 Ciudad Real;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;550 Ciudad Real;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Ciudad Real;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;550 Ciudad Real;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.806 Ciudad Real;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Ciudad Real;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.806 Ciudad Real;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;814 Ciudad Real;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Ciudad Real;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;814 Ciudad Real;Group 1505 Single spontaneous delivery 650;Both sexes;192 Ciudad Real;Group 1505 Single spontaneous delivery 650;Men;.. Ciudad Real;Group 1505 Single spontaneous delivery 650;Women;192 Ciudad Real;Group 1506 Other deliveries 6695-6697;Both sexes;23 Ciudad Real;Group 1506 Other deliveries 6695-6697;Men;.. Ciudad Real;Group 1506 Other deliveries 6695-6697;Women;23 Ciudad Real;Group 1507 Complications related to the puerperium 670-676;Both sexes;24 Ciudad Real;Group 1507 Complications related to the puerperium 670-676;Men;.. Ciudad Real;Group 1507 Complications related to the puerperium 670-676;Women;24 Ciudad Real;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;326 Ciudad Real;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Ciudad Real;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;326 Ciudad Real;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.108 Ciudad Real;Group 1600 Some disorders originating in the perinatal period 760-779;Men;616 Ciudad Real;Group 1600 Some disorders originating in the perinatal period 760-779;Women;492 Ciudad Real;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;243 Ciudad Real;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;133 Ciudad Real;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;110 Ciudad Real;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;865 Ciudad Real;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;483 Ciudad Real;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;382 Ciudad Real;Grupo 1700 Congenital abnormalities 740-759;Both sexes;241 Ciudad Real;Grupo 1700 Congenital abnormalities 740-759;Men;160 Ciudad Real;Grupo 1700 Congenital abnormalities 740-759;Women;81 Ciudad Real;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.936 Ciudad Real;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.021 Ciudad Real;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;915 Ciudad Real;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;280 Ciudad Real;Group 1801 Pain in throat and chest 7841, 7865;Men;145 Ciudad Real;Group 1801 Pain in throat and chest 7841, 7865;Women;135 Ciudad Real;Group 1802 Abdominal pain 7890;Both sexes;168 Ciudad Real;Group 1802 Abdominal pain 7890;Men;77 Ciudad Real;Group 1802 Abdominal pain 7890;Women;91 Ciudad Real;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;2 Ciudad Real;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;.. Ciudad Real;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;2 Ciudad Real;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.486 Ciudad Real;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;799 Ciudad Real;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;687 Ciudad Real;Group 1900 Injuries and poisoning 800-999;Both sexes;3.795 Ciudad Real;Group 1900 Injuries and poisoning 800-999;Men;1.804 Ciudad Real;Group 1900 Injuries and poisoning 800-999;Women;1.991 Ciudad Real;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;168 Ciudad Real;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;92 Ciudad Real;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;76 Ciudad Real;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;94 Ciudad Real;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;56 Ciudad Real;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;38 Ciudad Real;Group 1903 Radius and ulna fracture 813;Both sexes;244 Ciudad Real;Group 1903 Radius and ulna fracture 813;Men;114 Ciudad Real;Group 1903 Radius and ulna fracture 813;Women;130 Ciudad Real;Group 1904 Femur fracture 820-821;Both sexes;935 Ciudad Real;Group 1904 Femur fracture 820-821;Men;274 Ciudad Real;Group 1904 Femur fracture 820-821;Women;661 Ciudad Real;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;273 Ciudad Real;Group 1905 Leg fracture, including the ankle 823-824;Men;134 Ciudad Real;Group 1905 Leg fracture, including the ankle 823-824;Women;139 Ciudad Real;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;790 Ciudad Real;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;472 Ciudad Real;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;318 Ciudad Real;Group 1907 Burns 940-949;Both sexes;7 Ciudad Real;Group 1907 Burns 940-949;Men;4 Ciudad Real;Group 1907 Burns 940-949;Women;3 Ciudad Real;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;130 Ciudad Real;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;60 Ciudad Real;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;70 Ciudad Real;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.027 Ciudad Real;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;522 Ciudad Real;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;505 Ciudad Real;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;13 Ciudad Real;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;11 Ciudad Real;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 Ciudad Real;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;114 Ciudad Real;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;65 Ciudad Real;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;49 Ciudad Real;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;625 Ciudad Real;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;323 Ciudad Real;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;302 Ciudad Real;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;21 Ciudad Real;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;14 Ciudad Real;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;7 Ciudad Real;Group 2102 Contraceptive management V25;Both sexes;32 Ciudad Real;Group 2102 Contraceptive management V25;Men;.. Ciudad Real;Group 2102 Contraceptive management V25;Women;32 Ciudad Real;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Ciudad Real;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Ciudad Real;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Ciudad Real;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;253 Ciudad Real;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;144 Ciudad Real;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;109 Ciudad Real;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;319 Ciudad Real;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;165 Ciudad Real;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;154 Cuenca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;14.000 Cuenca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;6.880 Cuenca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;7.120 Cuenca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;399 Cuenca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;221 Cuenca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;178 Cuenca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;56 Cuenca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;28 Cuenca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;28 Cuenca;Group 0102 Imprecise intestinal infections 009;Both sexes;11 Cuenca;Group 0102 Imprecise intestinal infections 009;Men;5 Cuenca;Group 0102 Imprecise intestinal infections 009;Women;6 Cuenca;Group 0103 Tuberculosis 010-018, 137;Both sexes;7 Cuenca;Group 0103 Tuberculosis 010-018, 137;Men;3 Cuenca;Group 0103 Tuberculosis 010-018, 137;Women;4 Cuenca;Group 0104 Septicaemia 038;Both sexes;208 Cuenca;Group 0104 Septicaemia 038;Men;123 Cuenca;Group 0104 Septicaemia 038;Women;85 Cuenca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;7 Cuenca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;7 Cuenca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;.. Cuenca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;110 Cuenca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;55 Cuenca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;55 Cuenca;Group 0200 Neoplasms 140-239;Both sexes;976 Cuenca;Group 0200 Neoplasms 140-239;Men;540 Cuenca;Group 0200 Neoplasms 140-239;Women;436 Cuenca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;131 Cuenca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;81 Cuenca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;50 Cuenca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;55 Cuenca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;48 Cuenca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;7 Cuenca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;21 Cuenca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;12 Cuenca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;9 Cuenca;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;68 Cuenca;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Cuenca;Group 0204 Malignant neoplasm of breast 174-175;Women;67 Cuenca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;17 Cuenca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Cuenca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;17 Cuenca;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;13 Cuenca;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Cuenca;Group 0206 Malignant neoplasm of ovary 1830;Women;13 Cuenca;Group 0207 Malignant neoplasm of prostate 185;Both sexes;25 Cuenca;Group 0207 Malignant neoplasm of prostate 185;Men;25 Cuenca;Group 0207 Malignant neoplasm of prostate 185;Women;.. Cuenca;Group 0208 Malignant neoplasm of bladder 188;Both sexes;52 Cuenca;Group 0208 Malignant neoplasm of bladder 188;Men;36 Cuenca;Group 0208 Malignant neoplasm of bladder 188;Women;16 Cuenca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;302 Cuenca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;194 Cuenca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;108 Cuenca;Group 0210 Carcinoma in situ 230-234;Both sexes;23 Cuenca;Group 0210 Carcinoma in situ 230-234;Men;7 Cuenca;Group 0210 Carcinoma in situ 230-234;Women;16 Cuenca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;21 Cuenca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;17 Cuenca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;4 Cuenca;Grupo 0212 Leiomyoma of uterus 218;Both sexes;34 Cuenca;Grupo 0212 Leiomyoma of uterus 218;Men;.. Cuenca;Grupo 0212 Leiomyoma of uterus 218;Women;34 Cuenca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;214 Cuenca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;119 Cuenca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;95 Cuenca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;132 Cuenca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;62 Cuenca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;70 Cuenca;Group 0301 Anaemias 280-285;Both sexes;98 Cuenca;Group 0301 Anaemias 280-285;Men;41 Cuenca;Group 0301 Anaemias 280-285;Women;57 Cuenca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;34 Cuenca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;21 Cuenca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;13 Cuenca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;255 Cuenca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;96 Cuenca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;159 Cuenca;Group 0401 Diabetes mellitus 249-250;Both sexes;99 Cuenca;Group 0401 Diabetes mellitus 249-250;Men;46 Cuenca;Group 0401 Diabetes mellitus 249-250;Women;53 Cuenca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;156 Cuenca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;50 Cuenca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;106 Cuenca;Group 0500 Mental disorders 290-319;Both sexes;460 Cuenca;Group 0500 Mental disorders 290-319;Men;256 Cuenca;Group 0500 Mental disorders 290-319;Women;204 Cuenca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;12 Cuenca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;10 Cuenca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;2 Cuenca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;52 Cuenca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;43 Cuenca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;9 Cuenca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;25 Cuenca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;22 Cuenca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;3 Cuenca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;150 Cuenca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;100 Cuenca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;50 Cuenca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;99 Cuenca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;27 Cuenca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;72 Cuenca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;122 Cuenca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;54 Cuenca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;68 Cuenca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;443 Cuenca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;214 Cuenca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;229 Cuenca;Group 0601 Alzheimer's disease 3310;Both sexes;7 Cuenca;Group 0601 Alzheimer's disease 3310;Men;1 Cuenca;Group 0601 Alzheimer's disease 3310;Women;6 Cuenca;Group 0602 Multiple sclerosis 340;Both sexes;41 Cuenca;Group 0602 Multiple sclerosis 340;Men;10 Cuenca;Group 0602 Multiple sclerosis 340;Women;31 Cuenca;Group 0603 Epilepsy 345;Both sexes;91 Cuenca;Group 0603 Epilepsy 345;Men;57 Cuenca;Group 0603 Epilepsy 345;Women;34 Cuenca;Group 0604 Transient cerebral ischemia 435;Both sexes;91 Cuenca;Group 0604 Transient cerebral ischemia 435;Men;35 Cuenca;Group 0604 Transient cerebral ischemia 435;Women;56 Cuenca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;213 Cuenca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;111 Cuenca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;102 Cuenca;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;111 Cuenca;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;66 Cuenca;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;45 Cuenca;Grupo 0701 Cataract 366;Both sexes;9 Cuenca;Grupo 0701 Cataract 366;Men;5 Cuenca;Grupo 0701 Cataract 366;Women;4 Cuenca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;102 Cuenca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;61 Cuenca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;41 Cuenca;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;59 Cuenca;Group 0800 Diseases of the ear and the mastoid 380-389;Men;27 Cuenca;Group 0800 Diseases of the ear and the mastoid 380-389;Women;32 Cuenca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;1.995 Cuenca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1.086 Cuenca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;909 Cuenca;Group 0901 Hypertensive disease 401-405;Both sexes;136 Cuenca;Group 0901 Hypertensive disease 401-405;Men;54 Cuenca;Group 0901 Hypertensive disease 401-405;Women;82 Cuenca;Group 0902 Angina pectoris 4111, 413;Both sexes;126 Cuenca;Group 0902 Angina pectoris 4111, 413;Men;94 Cuenca;Group 0902 Angina pectoris 4111, 413;Women;32 Cuenca;Group 0903 Acute myocardial infarction 410;Both sexes;104 Cuenca;Group 0903 Acute myocardial infarction 410;Men;59 Cuenca;Group 0903 Acute myocardial infarction 410;Women;45 Cuenca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;48 Cuenca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;41 Cuenca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;7 Cuenca;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;42 Cuenca;Group 0905 Diseases of the lungs circulation 415-417;Men;18 Cuenca;Group 0905 Diseases of the lungs circulation 415-417;Women;24 Cuenca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;284 Cuenca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;136 Cuenca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;148 Cuenca;Grupo 0907 Heart failure 428;Both sexes;451 Cuenca;Grupo 0907 Heart failure 428;Men;213 Cuenca;Grupo 0907 Heart failure 428;Women;238 Cuenca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;415 Cuenca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;228 Cuenca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;187 Cuenca;Grupo 0909 Atherosclerosis 440;Both sexes;90 Cuenca;Grupo 0909 Atherosclerosis 440;Men;75 Cuenca;Grupo 0909 Atherosclerosis 440;Women;15 Cuenca;Group 0910 Varicose veins of lower extremities 454;Both sexes;45 Cuenca;Group 0910 Varicose veins of lower extremities 454;Men;20 Cuenca;Group 0910 Varicose veins of lower extremities 454;Women;25 Cuenca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;254 Cuenca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;148 Cuenca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;106 Cuenca;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;1.839 Cuenca;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.089 Cuenca;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;750 Cuenca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;64 Cuenca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;32 Cuenca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;32 Cuenca;Group 1002 Pneumonia 480-486;Both sexes;424 Cuenca;Group 1002 Pneumonia 480-486;Men;250 Cuenca;Group 1002 Pneumonia 480-486;Women;174 Cuenca;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;75 Cuenca;Group 1003 Acute bronchitis and bronchiolitis 466;Men;36 Cuenca;Group 1003 Acute bronchitis and bronchiolitis 466;Women;39 Cuenca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;57 Cuenca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;32 Cuenca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;25 Cuenca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;95 Cuenca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;70 Cuenca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;25 Cuenca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;278 Cuenca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;226 Cuenca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;52 Cuenca;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;51 Cuenca;Group 1007 Asthma 4930-4931,4938-4939;Men;21 Cuenca;Group 1007 Asthma 4930-4931,4938-4939;Women;30 Cuenca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;795 Cuenca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;422 Cuenca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;373 Cuenca;Group 1100 Diseases of the digestive system 520-579;Both sexes;2.164 Cuenca;Group 1100 Diseases of the digestive system 520-579;Men;1.211 Cuenca;Group 1100 Diseases of the digestive system 520-579;Women;953 Cuenca;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;49 Cuenca;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;22 Cuenca;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;27 Cuenca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;21 Cuenca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;11 Cuenca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;10 Cuenca;Group 1103 Diseases of the esophagus 530;Both sexes;37 Cuenca;Group 1103 Diseases of the esophagus 530;Men;26 Cuenca;Group 1103 Diseases of the esophagus 530;Women;11 Cuenca;Group 1104 Peptic ulcer 531-534;Both sexes;47 Cuenca;Group 1104 Peptic ulcer 531-534;Men;29 Cuenca;Group 1104 Peptic ulcer 531-534;Women;18 Cuenca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;67 Cuenca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;38 Cuenca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;29 Cuenca;Group 1106 Appendicitis 540-543;Both sexes;142 Cuenca;Group 1106 Appendicitis 540-543;Men;74 Cuenca;Group 1106 Appendicitis 540-543;Women;68 Cuenca;Group 1107 Inguinal hernia 550;Both sexes;185 Cuenca;Group 1107 Inguinal hernia 550;Men;171 Cuenca;Group 1107 Inguinal hernia 550;Women;14 Cuenca;Group 1108 Other abdominal hernia 551-553;Both sexes;121 Cuenca;Group 1108 Other abdominal hernia 551-553;Men;43 Cuenca;Group 1108 Other abdominal hernia 551-553;Women;78 Cuenca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;51 Cuenca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;36 Cuenca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;15 Cuenca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;184 Cuenca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;90 Cuenca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;94 Cuenca;Group 1111 Intestinal obstruction without hernia 560;Both sexes;113 Cuenca;Group 1111 Intestinal obstruction without hernia 560;Men;47 Cuenca;Group 1111 Intestinal obstruction without hernia 560;Women;66 Cuenca;Group 1112 Intestinal diverticulosis 562;Both sexes;75 Cuenca;Group 1112 Intestinal diverticulosis 562;Men;44 Cuenca;Group 1112 Intestinal diverticulosis 562;Women;31 Cuenca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;145 Cuenca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;94 Cuenca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;51 Cuenca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;110 Cuenca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;44 Cuenca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;66 Cuenca;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;10 Cuenca;Group 1115 Alcoholic hepatitis 5710-5713;Men;10 Cuenca;Group 1115 Alcoholic hepatitis 5710-5713;Women;.. Cuenca;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;71 Cuenca;Group 1116 Other diseases of the liver 570,5714-573;Men;64 Cuenca;Group 1116 Other diseases of the liver 570,5714-573;Women;7 Cuenca;Group 1117 Cholelithiasis 574;Both sexes;364 Cuenca;Group 1117 Cholelithiasis 574;Men;163 Cuenca;Group 1117 Cholelithiasis 574;Women;201 Cuenca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;110 Cuenca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;56 Cuenca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;54 Cuenca;Group 1119 Pancreatic diseases 577;Both sexes;132 Cuenca;Group 1119 Pancreatic diseases 577;Men;76 Cuenca;Group 1119 Pancreatic diseases 577;Women;56 Cuenca;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;130 Cuenca;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;73 Cuenca;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;57 Cuenca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;134 Cuenca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;64 Cuenca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;70 Cuenca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;76 Cuenca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;40 Cuenca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;36 Cuenca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;4 Cuenca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;2 Cuenca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;2 Cuenca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;54 Cuenca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;22 Cuenca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;32 Cuenca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;611 Cuenca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;282 Cuenca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;329 Cuenca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Cuenca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Cuenca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Cuenca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Cuenca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Cuenca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Cuenca;Group 1303 Internal derangement of knee 717;Both sexes;98 Cuenca;Group 1303 Internal derangement of knee 717;Men;64 Cuenca;Group 1303 Internal derangement of knee 717;Women;34 Cuenca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;259 Cuenca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;103 Cuenca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;156 Cuenca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;15 Cuenca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;5 Cuenca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;10 Cuenca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;19 Cuenca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;11 Cuenca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;8 Cuenca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;31 Cuenca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;16 Cuenca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;15 Cuenca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;25 Cuenca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;13 Cuenca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;12 Cuenca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;64 Cuenca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;36 Cuenca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;28 Cuenca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;100 Cuenca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;34 Cuenca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;66 Cuenca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;829 Cuenca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;383 Cuenca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;446 Cuenca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;73 Cuenca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;17 Cuenca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;56 Cuenca;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;82 Cuenca;Group 1402 Renal failure 5836-5837, 584-586;Men;46 Cuenca;Group 1402 Renal failure 5836-5837, 584-586;Women;36 Cuenca;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;107 Cuenca;Group 1403 Urolithiasis 592, 594, 7880;Men;65 Cuenca;Group 1403 Urolithiasis 592, 594, 7880;Women;42 Cuenca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;257 Cuenca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;119 Cuenca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;138 Cuenca;Group 1405 Prostatic hyperplasia 600;Both sexes;66 Cuenca;Group 1405 Prostatic hyperplasia 600;Men;66 Cuenca;Group 1405 Prostatic hyperplasia 600;Women;.. Cuenca;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;68 Cuenca;Group 1406 Other diseases of the male genital organs 601-608;Men;68 Cuenca;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Cuenca;Group 1407 Disorders of breast 610-612;Both sexes;12 Cuenca;Group 1407 Disorders of breast 610-612;Men;.. Cuenca;Group 1407 Disorders of breast 610-612;Women;12 Cuenca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;22 Cuenca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Cuenca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;22 Cuenca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;6 Cuenca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Cuenca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;6 Cuenca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;136 Cuenca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;2 Cuenca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;134 Cuenca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.141 Cuenca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Cuenca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.141 Cuenca;Group 1501 Legally induced abortion 635;Both sexes;.. Cuenca;Group 1501 Legally induced abortion 635;Men;.. Cuenca;Group 1501 Legally induced abortion 635;Women;.. Cuenca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;146 Cuenca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Cuenca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;146 Cuenca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;589 Cuenca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Cuenca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;589 Cuenca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;184 Cuenca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Cuenca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;184 Cuenca;Group 1505 Single spontaneous delivery 650;Both sexes;58 Cuenca;Group 1505 Single spontaneous delivery 650;Men;.. Cuenca;Group 1505 Single spontaneous delivery 650;Women;58 Cuenca;Group 1506 Other deliveries 6695-6697;Both sexes;108 Cuenca;Group 1506 Other deliveries 6695-6697;Men;.. Cuenca;Group 1506 Other deliveries 6695-6697;Women;108 Cuenca;Group 1507 Complications related to the puerperium 670-676;Both sexes;3 Cuenca;Group 1507 Complications related to the puerperium 670-676;Men;.. Cuenca;Group 1507 Complications related to the puerperium 670-676;Women;3 Cuenca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;53 Cuenca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Cuenca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;53 Cuenca;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;106 Cuenca;Group 1600 Some disorders originating in the perinatal period 760-779;Men;62 Cuenca;Group 1600 Some disorders originating in the perinatal period 760-779;Women;44 Cuenca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;34 Cuenca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;16 Cuenca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;18 Cuenca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;72 Cuenca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;46 Cuenca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;26 Cuenca;Grupo 1700 Congenital abnormalities 740-759;Both sexes;39 Cuenca;Grupo 1700 Congenital abnormalities 740-759;Men;18 Cuenca;Grupo 1700 Congenital abnormalities 740-759;Women;21 Cuenca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;916 Cuenca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;489 Cuenca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;427 Cuenca;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;133 Cuenca;Group 1801 Pain in throat and chest 7841, 7865;Men;76 Cuenca;Group 1801 Pain in throat and chest 7841, 7865;Women;57 Cuenca;Group 1802 Abdominal pain 7890;Both sexes;128 Cuenca;Group 1802 Abdominal pain 7890;Men;61 Cuenca;Group 1802 Abdominal pain 7890;Women;67 Cuenca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;11 Cuenca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;6 Cuenca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;5 Cuenca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;644 Cuenca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;346 Cuenca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;298 Cuenca;Group 1900 Injuries and poisoning 800-999;Both sexes;1.185 Cuenca;Group 1900 Injuries and poisoning 800-999;Men;595 Cuenca;Group 1900 Injuries and poisoning 800-999;Women;590 Cuenca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;83 Cuenca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;43 Cuenca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;40 Cuenca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;30 Cuenca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;26 Cuenca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;4 Cuenca;Group 1903 Radius and ulna fracture 813;Both sexes;48 Cuenca;Group 1903 Radius and ulna fracture 813;Men;32 Cuenca;Group 1903 Radius and ulna fracture 813;Women;16 Cuenca;Group 1904 Femur fracture 820-821;Both sexes;288 Cuenca;Group 1904 Femur fracture 820-821;Men;73 Cuenca;Group 1904 Femur fracture 820-821;Women;215 Cuenca;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;87 Cuenca;Group 1905 Leg fracture, including the ankle 823-824;Men;43 Cuenca;Group 1905 Leg fracture, including the ankle 823-824;Women;44 Cuenca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;398 Cuenca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;237 Cuenca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;161 Cuenca;Group 1907 Burns 940-949;Both sexes;4 Cuenca;Group 1907 Burns 940-949;Men;3 Cuenca;Group 1907 Burns 940-949;Women;1 Cuenca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;50 Cuenca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;25 Cuenca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;25 Cuenca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;169 Cuenca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;93 Cuenca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;76 Cuenca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;2 Cuenca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;1 Cuenca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Cuenca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;26 Cuenca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;19 Cuenca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;7 Cuenca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;206 Cuenca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;119 Cuenca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;87 Cuenca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;9 Cuenca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;7 Cuenca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;2 Cuenca;Group 2102 Contraceptive management V25;Both sexes;1 Cuenca;Group 2102 Contraceptive management V25;Men;1 Cuenca;Group 2102 Contraceptive management V25;Women;.. Cuenca;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Cuenca;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Cuenca;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Cuenca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;85 Cuenca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;44 Cuenca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;41 Cuenca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;111 Cuenca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;67 Cuenca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;44 Guadalajara;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;18.288 Guadalajara;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;8.911 Guadalajara;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;9.377 Guadalajara;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;578 Guadalajara;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;326 Guadalajara;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;252 Guadalajara;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;114 Guadalajara;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;61 Guadalajara;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;53 Guadalajara;Group 0102 Imprecise intestinal infections 009;Both sexes;14 Guadalajara;Group 0102 Imprecise intestinal infections 009;Men;7 Guadalajara;Group 0102 Imprecise intestinal infections 009;Women;7 Guadalajara;Group 0103 Tuberculosis 010-018, 137;Both sexes;5 Guadalajara;Group 0103 Tuberculosis 010-018, 137;Men;2 Guadalajara;Group 0103 Tuberculosis 010-018, 137;Women;3 Guadalajara;Group 0104 Septicaemia 038;Both sexes;226 Guadalajara;Group 0104 Septicaemia 038;Men;119 Guadalajara;Group 0104 Septicaemia 038;Women;107 Guadalajara;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;15 Guadalajara;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;13 Guadalajara;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;2 Guadalajara;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;204 Guadalajara;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;124 Guadalajara;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;80 Guadalajara;Group 0200 Neoplasms 140-239;Both sexes;1.491 Guadalajara;Group 0200 Neoplasms 140-239;Men;832 Guadalajara;Group 0200 Neoplasms 140-239;Women;659 Guadalajara;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;180 Guadalajara;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;119 Guadalajara;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;61 Guadalajara;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;92 Guadalajara;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;70 Guadalajara;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;22 Guadalajara;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;57 Guadalajara;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;41 Guadalajara;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;16 Guadalajara;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;74 Guadalajara;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Guadalajara;Group 0204 Malignant neoplasm of breast 174-175;Women;74 Guadalajara;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;33 Guadalajara;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Guadalajara;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;33 Guadalajara;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;17 Guadalajara;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Guadalajara;Group 0206 Malignant neoplasm of ovary 1830;Women;17 Guadalajara;Group 0207 Malignant neoplasm of prostate 185;Both sexes;56 Guadalajara;Group 0207 Malignant neoplasm of prostate 185;Men;56 Guadalajara;Group 0207 Malignant neoplasm of prostate 185;Women;.. Guadalajara;Group 0208 Malignant neoplasm of bladder 188;Both sexes;179 Guadalajara;Group 0208 Malignant neoplasm of bladder 188;Men;154 Guadalajara;Group 0208 Malignant neoplasm of bladder 188;Women;25 Guadalajara;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;525 Guadalajara;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;309 Guadalajara;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;216 Guadalajara;Group 0210 Carcinoma in situ 230-234;Both sexes;24 Guadalajara;Group 0210 Carcinoma in situ 230-234;Men;14 Guadalajara;Group 0210 Carcinoma in situ 230-234;Women;10 Guadalajara;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;8 Guadalajara;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;7 Guadalajara;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;1 Guadalajara;Grupo 0212 Leiomyoma of uterus 218;Both sexes;64 Guadalajara;Grupo 0212 Leiomyoma of uterus 218;Men;.. Guadalajara;Grupo 0212 Leiomyoma of uterus 218;Women;64 Guadalajara;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;182 Guadalajara;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;62 Guadalajara;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;120 Guadalajara;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;223 Guadalajara;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;126 Guadalajara;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;97 Guadalajara;Group 0301 Anaemias 280-285;Both sexes;120 Guadalajara;Group 0301 Anaemias 280-285;Men;61 Guadalajara;Group 0301 Anaemias 280-285;Women;59 Guadalajara;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;103 Guadalajara;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;65 Guadalajara;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;38 Guadalajara;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;358 Guadalajara;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;169 Guadalajara;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;189 Guadalajara;Group 0401 Diabetes mellitus 249-250;Both sexes;151 Guadalajara;Group 0401 Diabetes mellitus 249-250;Men;86 Guadalajara;Group 0401 Diabetes mellitus 249-250;Women;65 Guadalajara;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;207 Guadalajara;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;83 Guadalajara;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;124 Guadalajara;Group 0500 Mental disorders 290-319;Both sexes;380 Guadalajara;Group 0500 Mental disorders 290-319;Men;210 Guadalajara;Group 0500 Mental disorders 290-319;Women;170 Guadalajara;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;6 Guadalajara;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;3 Guadalajara;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;3 Guadalajara;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;24 Guadalajara;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;13 Guadalajara;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;11 Guadalajara;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;16 Guadalajara;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;11 Guadalajara;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;5 Guadalajara;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;166 Guadalajara;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;110 Guadalajara;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;56 Guadalajara;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;78 Guadalajara;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;37 Guadalajara;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;41 Guadalajara;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;90 Guadalajara;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;36 Guadalajara;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;54 Guadalajara;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;408 Guadalajara;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;191 Guadalajara;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;217 Guadalajara;Group 0601 Alzheimer's disease 3310;Both sexes;2 Guadalajara;Group 0601 Alzheimer's disease 3310;Men;.. Guadalajara;Group 0601 Alzheimer's disease 3310;Women;2 Guadalajara;Group 0602 Multiple sclerosis 340;Both sexes;16 Guadalajara;Group 0602 Multiple sclerosis 340;Men;4 Guadalajara;Group 0602 Multiple sclerosis 340;Women;12 Guadalajara;Group 0603 Epilepsy 345;Both sexes;88 Guadalajara;Group 0603 Epilepsy 345;Men;42 Guadalajara;Group 0603 Epilepsy 345;Women;46 Guadalajara;Group 0604 Transient cerebral ischemia 435;Both sexes;92 Guadalajara;Group 0604 Transient cerebral ischemia 435;Men;46 Guadalajara;Group 0604 Transient cerebral ischemia 435;Women;46 Guadalajara;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;210 Guadalajara;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;99 Guadalajara;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;111 Guadalajara;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;95 Guadalajara;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;45 Guadalajara;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;50 Guadalajara;Grupo 0701 Cataract 366;Both sexes;43 Guadalajara;Grupo 0701 Cataract 366;Men;21 Guadalajara;Grupo 0701 Cataract 366;Women;22 Guadalajara;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;52 Guadalajara;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;24 Guadalajara;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;28 Guadalajara;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;86 Guadalajara;Group 0800 Diseases of the ear and the mastoid 380-389;Men;43 Guadalajara;Group 0800 Diseases of the ear and the mastoid 380-389;Women;43 Guadalajara;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;2.573 Guadalajara;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1.470 Guadalajara;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1.103 Guadalajara;Group 0901 Hypertensive disease 401-405;Both sexes;241 Guadalajara;Group 0901 Hypertensive disease 401-405;Men;95 Guadalajara;Group 0901 Hypertensive disease 401-405;Women;146 Guadalajara;Group 0902 Angina pectoris 4111, 413;Both sexes;64 Guadalajara;Group 0902 Angina pectoris 4111, 413;Men;35 Guadalajara;Group 0902 Angina pectoris 4111, 413;Women;29 Guadalajara;Group 0903 Acute myocardial infarction 410;Both sexes;189 Guadalajara;Group 0903 Acute myocardial infarction 410;Men;137 Guadalajara;Group 0903 Acute myocardial infarction 410;Women;52 Guadalajara;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;239 Guadalajara;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;175 Guadalajara;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;64 Guadalajara;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;85 Guadalajara;Group 0905 Diseases of the lungs circulation 415-417;Men;43 Guadalajara;Group 0905 Diseases of the lungs circulation 415-417;Women;42 Guadalajara;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;448 Guadalajara;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;274 Guadalajara;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;174 Guadalajara;Grupo 0907 Heart failure 428;Both sexes;547 Guadalajara;Grupo 0907 Heart failure 428;Men;260 Guadalajara;Grupo 0907 Heart failure 428;Women;287 Guadalajara;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;314 Guadalajara;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;166 Guadalajara;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;148 Guadalajara;Grupo 0909 Atherosclerosis 440;Both sexes;103 Guadalajara;Grupo 0909 Atherosclerosis 440;Men;83 Guadalajara;Grupo 0909 Atherosclerosis 440;Women;20 Guadalajara;Group 0910 Varicose veins of lower extremities 454;Both sexes;36 Guadalajara;Group 0910 Varicose veins of lower extremities 454;Men;9 Guadalajara;Group 0910 Varicose veins of lower extremities 454;Women;27 Guadalajara;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;307 Guadalajara;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;193 Guadalajara;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;114 Guadalajara;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2.352 Guadalajara;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.417 Guadalajara;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;935 Guadalajara;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;155 Guadalajara;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;74 Guadalajara;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;81 Guadalajara;Group 1002 Pneumonia 480-486;Both sexes;761 Guadalajara;Group 1002 Pneumonia 480-486;Men;494 Guadalajara;Group 1002 Pneumonia 480-486;Women;267 Guadalajara;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;209 Guadalajara;Group 1003 Acute bronchitis and bronchiolitis 466;Men;88 Guadalajara;Group 1003 Acute bronchitis and bronchiolitis 466;Women;121 Guadalajara;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;98 Guadalajara;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;54 Guadalajara;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;44 Guadalajara;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;114 Guadalajara;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;79 Guadalajara;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;35 Guadalajara;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;305 Guadalajara;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;262 Guadalajara;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;43 Guadalajara;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;77 Guadalajara;Group 1007 Asthma 4930-4931,4938-4939;Men;21 Guadalajara;Group 1007 Asthma 4930-4931,4938-4939;Women;56 Guadalajara;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;633 Guadalajara;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;345 Guadalajara;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;288 Guadalajara;Group 1100 Diseases of the digestive system 520-579;Both sexes;2.672 Guadalajara;Group 1100 Diseases of the digestive system 520-579;Men;1.467 Guadalajara;Group 1100 Diseases of the digestive system 520-579;Women;1.205 Guadalajara;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;32 Guadalajara;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;10 Guadalajara;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;22 Guadalajara;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;29 Guadalajara;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;14 Guadalajara;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;15 Guadalajara;Group 1103 Diseases of the esophagus 530;Both sexes;61 Guadalajara;Group 1103 Diseases of the esophagus 530;Men;36 Guadalajara;Group 1103 Diseases of the esophagus 530;Women;25 Guadalajara;Group 1104 Peptic ulcer 531-534;Both sexes;57 Guadalajara;Group 1104 Peptic ulcer 531-534;Men;37 Guadalajara;Group 1104 Peptic ulcer 531-534;Women;20 Guadalajara;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;56 Guadalajara;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;21 Guadalajara;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;35 Guadalajara;Group 1106 Appendicitis 540-543;Both sexes;220 Guadalajara;Group 1106 Appendicitis 540-543;Men;145 Guadalajara;Group 1106 Appendicitis 540-543;Women;75 Guadalajara;Group 1107 Inguinal hernia 550;Both sexes;237 Guadalajara;Group 1107 Inguinal hernia 550;Men;211 Guadalajara;Group 1107 Inguinal hernia 550;Women;26 Guadalajara;Group 1108 Other abdominal hernia 551-553;Both sexes;216 Guadalajara;Group 1108 Other abdominal hernia 551-553;Men;96 Guadalajara;Group 1108 Other abdominal hernia 551-553;Women;120 Guadalajara;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;40 Guadalajara;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;22 Guadalajara;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;18 Guadalajara;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;229 Guadalajara;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;115 Guadalajara;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;114 Guadalajara;Group 1111 Intestinal obstruction without hernia 560;Both sexes;144 Guadalajara;Group 1111 Intestinal obstruction without hernia 560;Men;70 Guadalajara;Group 1111 Intestinal obstruction without hernia 560;Women;74 Guadalajara;Group 1112 Intestinal diverticulosis 562;Both sexes;103 Guadalajara;Group 1112 Intestinal diverticulosis 562;Men;45 Guadalajara;Group 1112 Intestinal diverticulosis 562;Women;58 Guadalajara;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;100 Guadalajara;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;74 Guadalajara;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;26 Guadalajara;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;110 Guadalajara;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;42 Guadalajara;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;68 Guadalajara;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;25 Guadalajara;Group 1115 Alcoholic hepatitis 5710-5713;Men;20 Guadalajara;Group 1115 Alcoholic hepatitis 5710-5713;Women;5 Guadalajara;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;82 Guadalajara;Group 1116 Other diseases of the liver 570,5714-573;Men;57 Guadalajara;Group 1116 Other diseases of the liver 570,5714-573;Women;25 Guadalajara;Group 1117 Cholelithiasis 574;Both sexes;519 Guadalajara;Group 1117 Cholelithiasis 574;Men;229 Guadalajara;Group 1117 Cholelithiasis 574;Women;290 Guadalajara;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;156 Guadalajara;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;85 Guadalajara;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;71 Guadalajara;Group 1119 Pancreatic diseases 577;Both sexes;152 Guadalajara;Group 1119 Pancreatic diseases 577;Men;75 Guadalajara;Group 1119 Pancreatic diseases 577;Women;77 Guadalajara;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;104 Guadalajara;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;63 Guadalajara;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;41 Guadalajara;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;143 Guadalajara;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;81 Guadalajara;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;62 Guadalajara;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;87 Guadalajara;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;56 Guadalajara;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;31 Guadalajara;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;11 Guadalajara;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;5 Guadalajara;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;6 Guadalajara;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;45 Guadalajara;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;20 Guadalajara;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;25 Guadalajara;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;1.082 Guadalajara;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;496 Guadalajara;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;586 Guadalajara;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Guadalajara;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Guadalajara;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Guadalajara;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Guadalajara;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Guadalajara;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Guadalajara;Group 1303 Internal derangement of knee 717;Both sexes;91 Guadalajara;Group 1303 Internal derangement of knee 717;Men;65 Guadalajara;Group 1303 Internal derangement of knee 717;Women;26 Guadalajara;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;367 Guadalajara;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;156 Guadalajara;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;211 Guadalajara;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;15 Guadalajara;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;6 Guadalajara;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;9 Guadalajara;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;69 Guadalajara;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;31 Guadalajara;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;38 Guadalajara;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;71 Guadalajara;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;33 Guadalajara;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;38 Guadalajara;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;22 Guadalajara;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;14 Guadalajara;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;8 Guadalajara;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;158 Guadalajara;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;79 Guadalajara;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;79 Guadalajara;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;289 Guadalajara;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;112 Guadalajara;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;177 Guadalajara;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1.127 Guadalajara;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;519 Guadalajara;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;608 Guadalajara;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;177 Guadalajara;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;54 Guadalajara;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;123 Guadalajara;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;107 Guadalajara;Group 1402 Renal failure 5836-5837, 584-586;Men;58 Guadalajara;Group 1402 Renal failure 5836-5837, 584-586;Women;49 Guadalajara;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;98 Guadalajara;Group 1403 Urolithiasis 592, 594, 7880;Men;56 Guadalajara;Group 1403 Urolithiasis 592, 594, 7880;Women;42 Guadalajara;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;395 Guadalajara;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;202 Guadalajara;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;193 Guadalajara;Group 1405 Prostatic hyperplasia 600;Both sexes;63 Guadalajara;Group 1405 Prostatic hyperplasia 600;Men;63 Guadalajara;Group 1405 Prostatic hyperplasia 600;Women;.. Guadalajara;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;77 Guadalajara;Group 1406 Other diseases of the male genital organs 601-608;Men;77 Guadalajara;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Guadalajara;Group 1407 Disorders of breast 610-612;Both sexes;36 Guadalajara;Group 1407 Disorders of breast 610-612;Men;8 Guadalajara;Group 1407 Disorders of breast 610-612;Women;28 Guadalajara;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;28 Guadalajara;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Guadalajara;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;28 Guadalajara;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;4 Guadalajara;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Guadalajara;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;4 Guadalajara;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;142 Guadalajara;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Guadalajara;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;141 Guadalajara;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.830 Guadalajara;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Guadalajara;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.830 Guadalajara;Group 1501 Legally induced abortion 635;Both sexes;1 Guadalajara;Group 1501 Legally induced abortion 635;Men;.. Guadalajara;Group 1501 Legally induced abortion 635;Women;1 Guadalajara;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;111 Guadalajara;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Guadalajara;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;111 Guadalajara;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.270 Guadalajara;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Guadalajara;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.270 Guadalajara;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;166 Guadalajara;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Guadalajara;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;166 Guadalajara;Group 1505 Single spontaneous delivery 650;Both sexes;12 Guadalajara;Group 1505 Single spontaneous delivery 650;Men;.. Guadalajara;Group 1505 Single spontaneous delivery 650;Women;12 Guadalajara;Group 1506 Other deliveries 6695-6697;Both sexes;71 Guadalajara;Group 1506 Other deliveries 6695-6697;Men;.. Guadalajara;Group 1506 Other deliveries 6695-6697;Women;71 Guadalajara;Group 1507 Complications related to the puerperium 670-676;Both sexes;22 Guadalajara;Group 1507 Complications related to the puerperium 670-676;Men;.. Guadalajara;Group 1507 Complications related to the puerperium 670-676;Women;22 Guadalajara;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;177 Guadalajara;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Guadalajara;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;177 Guadalajara;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;177 Guadalajara;Group 1600 Some disorders originating in the perinatal period 760-779;Men;93 Guadalajara;Group 1600 Some disorders originating in the perinatal period 760-779;Women;84 Guadalajara;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;74 Guadalajara;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;37 Guadalajara;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;37 Guadalajara;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;103 Guadalajara;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;56 Guadalajara;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;47 Guadalajara;Grupo 1700 Congenital abnormalities 740-759;Both sexes;69 Guadalajara;Grupo 1700 Congenital abnormalities 740-759;Men;41 Guadalajara;Grupo 1700 Congenital abnormalities 740-759;Women;28 Guadalajara;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;863 Guadalajara;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;471 Guadalajara;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;392 Guadalajara;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;135 Guadalajara;Group 1801 Pain in throat and chest 7841, 7865;Men;64 Guadalajara;Group 1801 Pain in throat and chest 7841, 7865;Women;71 Guadalajara;Group 1802 Abdominal pain 7890;Both sexes;138 Guadalajara;Group 1802 Abdominal pain 7890;Men;60 Guadalajara;Group 1802 Abdominal pain 7890;Women;78 Guadalajara;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1 Guadalajara;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;.. Guadalajara;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;1 Guadalajara;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;589 Guadalajara;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;347 Guadalajara;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;242 Guadalajara;Group 1900 Injuries and poisoning 800-999;Both sexes;1.448 Guadalajara;Group 1900 Injuries and poisoning 800-999;Men;698 Guadalajara;Group 1900 Injuries and poisoning 800-999;Women;750 Guadalajara;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;79 Guadalajara;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;46 Guadalajara;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;33 Guadalajara;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;36 Guadalajara;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;24 Guadalajara;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;12 Guadalajara;Group 1903 Radius and ulna fracture 813;Both sexes;53 Guadalajara;Group 1903 Radius and ulna fracture 813;Men;27 Guadalajara;Group 1903 Radius and ulna fracture 813;Women;26 Guadalajara;Group 1904 Femur fracture 820-821;Both sexes;318 Guadalajara;Group 1904 Femur fracture 820-821;Men;61 Guadalajara;Group 1904 Femur fracture 820-821;Women;257 Guadalajara;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;84 Guadalajara;Group 1905 Leg fracture, including the ankle 823-824;Men;52 Guadalajara;Group 1905 Leg fracture, including the ankle 823-824;Women;32 Guadalajara;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;292 Guadalajara;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;185 Guadalajara;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;107 Guadalajara;Group 1907 Burns 940-949;Both sexes;5 Guadalajara;Group 1907 Burns 940-949;Men;3 Guadalajara;Group 1907 Burns 940-949;Women;2 Guadalajara;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;60 Guadalajara;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;30 Guadalajara;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;30 Guadalajara;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;419 Guadalajara;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;227 Guadalajara;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;192 Guadalajara;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Guadalajara;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Guadalajara;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Guadalajara;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;102 Guadalajara;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;43 Guadalajara;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;59 Guadalajara;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;333 Guadalajara;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;216 Guadalajara;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;117 Guadalajara;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;44 Guadalajara;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;30 Guadalajara;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;14 Guadalajara;Group 2102 Contraceptive management V25;Both sexes;6 Guadalajara;Group 2102 Contraceptive management V25;Men;.. Guadalajara;Group 2102 Contraceptive management V25;Women;6 Guadalajara;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Guadalajara;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Guadalajara;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Guadalajara;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;122 Guadalajara;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;85 Guadalajara;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;37 Guadalajara;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;161 Guadalajara;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;101 Guadalajara;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;60 Toledo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;48.117 Toledo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;23.390 Toledo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;24.727 Toledo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.178 Toledo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;666 Toledo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;512 Toledo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;126 Toledo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;65 Toledo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;61 Toledo;Group 0102 Imprecise intestinal infections 009;Both sexes;70 Toledo;Group 0102 Imprecise intestinal infections 009;Men;30 Toledo;Group 0102 Imprecise intestinal infections 009;Women;40 Toledo;Group 0103 Tuberculosis 010-018, 137;Both sexes;31 Toledo;Group 0103 Tuberculosis 010-018, 137;Men;20 Toledo;Group 0103 Tuberculosis 010-018, 137;Women;11 Toledo;Group 0104 Septicaemia 038;Both sexes;662 Toledo;Group 0104 Septicaemia 038;Men;374 Toledo;Group 0104 Septicaemia 038;Women;288 Toledo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;11 Toledo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;7 Toledo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;4 Toledo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;278 Toledo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;170 Toledo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;108 Toledo;Group 0200 Neoplasms 140-239;Both sexes;4.687 Toledo;Group 0200 Neoplasms 140-239;Men;2.586 Toledo;Group 0200 Neoplasms 140-239;Women;2.101 Toledo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;491 Toledo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;310 Toledo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;181 Toledo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;394 Toledo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;335 Toledo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;59 Toledo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;124 Toledo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;79 Toledo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;45 Toledo;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;340 Toledo;Group 0204 Malignant neoplasm of breast 174-175;Men;4 Toledo;Group 0204 Malignant neoplasm of breast 174-175;Women;336 Toledo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;118 Toledo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Toledo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;118 Toledo;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;51 Toledo;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Toledo;Group 0206 Malignant neoplasm of ovary 1830;Women;51 Toledo;Group 0207 Malignant neoplasm of prostate 185;Both sexes;132 Toledo;Group 0207 Malignant neoplasm of prostate 185;Men;132 Toledo;Group 0207 Malignant neoplasm of prostate 185;Women;.. Toledo;Group 0208 Malignant neoplasm of bladder 188;Both sexes;263 Toledo;Group 0208 Malignant neoplasm of bladder 188;Men;224 Toledo;Group 0208 Malignant neoplasm of bladder 188;Women;39 Toledo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.471 Toledo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;888 Toledo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;583 Toledo;Group 0210 Carcinoma in situ 230-234;Both sexes;79 Toledo;Group 0210 Carcinoma in situ 230-234;Men;34 Toledo;Group 0210 Carcinoma in situ 230-234;Women;45 Toledo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;51 Toledo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;28 Toledo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;23 Toledo;Grupo 0212 Leiomyoma of uterus 218;Both sexes;187 Toledo;Grupo 0212 Leiomyoma of uterus 218;Men;.. Toledo;Grupo 0212 Leiomyoma of uterus 218;Women;187 Toledo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;986 Toledo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;552 Toledo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;434 Toledo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;411 Toledo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;224 Toledo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;187 Toledo;Group 0301 Anaemias 280-285;Both sexes;201 Toledo;Group 0301 Anaemias 280-285;Men;116 Toledo;Group 0301 Anaemias 280-285;Women;85 Toledo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;210 Toledo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;108 Toledo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;102 Toledo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;809 Toledo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;312 Toledo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;497 Toledo;Group 0401 Diabetes mellitus 249-250;Both sexes;241 Toledo;Group 0401 Diabetes mellitus 249-250;Men;138 Toledo;Group 0401 Diabetes mellitus 249-250;Women;103 Toledo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;568 Toledo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;174 Toledo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;394 Toledo;Group 0500 Mental disorders 290-319;Both sexes;1.400 Toledo;Group 0500 Mental disorders 290-319;Men;776 Toledo;Group 0500 Mental disorders 290-319;Women;624 Toledo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;18 Toledo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;11 Toledo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;7 Toledo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;72 Toledo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;50 Toledo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;22 Toledo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;48 Toledo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;38 Toledo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;10 Toledo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;533 Toledo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;359 Toledo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;174 Toledo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;317 Toledo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;124 Toledo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;193 Toledo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;412 Toledo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;194 Toledo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;218 Toledo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.770 Toledo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.035 Toledo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;735 Toledo;Group 0601 Alzheimer's disease 3310;Both sexes;16 Toledo;Group 0601 Alzheimer's disease 3310;Men;10 Toledo;Group 0601 Alzheimer's disease 3310;Women;6 Toledo;Group 0602 Multiple sclerosis 340;Both sexes;40 Toledo;Group 0602 Multiple sclerosis 340;Men;14 Toledo;Group 0602 Multiple sclerosis 340;Women;26 Toledo;Group 0603 Epilepsy 345;Both sexes;154 Toledo;Group 0603 Epilepsy 345;Men;81 Toledo;Group 0603 Epilepsy 345;Women;73 Toledo;Group 0604 Transient cerebral ischemia 435;Both sexes;182 Toledo;Group 0604 Transient cerebral ischemia 435;Men;88 Toledo;Group 0604 Transient cerebral ischemia 435;Women;94 Toledo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.378 Toledo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;842 Toledo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;536 Toledo;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;304 Toledo;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;161 Toledo;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;143 Toledo;Grupo 0701 Cataract 366;Both sexes;15 Toledo;Grupo 0701 Cataract 366;Men;6 Toledo;Grupo 0701 Cataract 366;Women;9 Toledo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;289 Toledo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;155 Toledo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;134 Toledo;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;195 Toledo;Group 0800 Diseases of the ear and the mastoid 380-389;Men;98 Toledo;Group 0800 Diseases of the ear and the mastoid 380-389;Women;97 Toledo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;6.229 Toledo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3.548 Toledo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.681 Toledo;Group 0901 Hypertensive disease 401-405;Both sexes;228 Toledo;Group 0901 Hypertensive disease 401-405;Men;90 Toledo;Group 0901 Hypertensive disease 401-405;Women;138 Toledo;Group 0902 Angina pectoris 4111, 413;Both sexes;323 Toledo;Group 0902 Angina pectoris 4111, 413;Men;225 Toledo;Group 0902 Angina pectoris 4111, 413;Women;98 Toledo;Group 0903 Acute myocardial infarction 410;Both sexes;749 Toledo;Group 0903 Acute myocardial infarction 410;Men;541 Toledo;Group 0903 Acute myocardial infarction 410;Women;208 Toledo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;329 Toledo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;254 Toledo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;75 Toledo;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;203 Toledo;Group 0905 Diseases of the lungs circulation 415-417;Men;97 Toledo;Group 0905 Diseases of the lungs circulation 415-417;Women;106 Toledo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;799 Toledo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;432 Toledo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;367 Toledo;Grupo 0907 Heart failure 428;Both sexes;1.210 Toledo;Grupo 0907 Heart failure 428;Men;516 Toledo;Grupo 0907 Heart failure 428;Women;694 Toledo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.148 Toledo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;643 Toledo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;505 Toledo;Grupo 0909 Atherosclerosis 440;Both sexes;186 Toledo;Grupo 0909 Atherosclerosis 440;Men;131 Toledo;Grupo 0909 Atherosclerosis 440;Women;55 Toledo;Group 0910 Varicose veins of lower extremities 454;Both sexes;49 Toledo;Group 0910 Varicose veins of lower extremities 454;Men;12 Toledo;Group 0910 Varicose veins of lower extremities 454;Women;37 Toledo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.005 Toledo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;607 Toledo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;398 Toledo;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5.435 Toledo;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3.193 Toledo;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.242 Toledo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;252 Toledo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;121 Toledo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;131 Toledo;Group 1002 Pneumonia 480-486;Both sexes;1.409 Toledo;Group 1002 Pneumonia 480-486;Men;869 Toledo;Group 1002 Pneumonia 480-486;Women;540 Toledo;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;358 Toledo;Group 1003 Acute bronchitis and bronchiolitis 466;Men;197 Toledo;Group 1003 Acute bronchitis and bronchiolitis 466;Women;161 Toledo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;157 Toledo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;92 Toledo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;65 Toledo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;432 Toledo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;305 Toledo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;127 Toledo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;837 Toledo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;687 Toledo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;150 Toledo;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;226 Toledo;Group 1007 Asthma 4930-4931,4938-4939;Men;84 Toledo;Group 1007 Asthma 4930-4931,4938-4939;Women;142 Toledo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.764 Toledo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;838 Toledo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;926 Toledo;Group 1100 Diseases of the digestive system 520-579;Both sexes;5.750 Toledo;Group 1100 Diseases of the digestive system 520-579;Men;3.260 Toledo;Group 1100 Diseases of the digestive system 520-579;Women;2.490 Toledo;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;53 Toledo;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;30 Toledo;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;23 Toledo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;82 Toledo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;52 Toledo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;30 Toledo;Group 1103 Diseases of the esophagus 530;Both sexes;85 Toledo;Group 1103 Diseases of the esophagus 530;Men;49 Toledo;Group 1103 Diseases of the esophagus 530;Women;36 Toledo;Group 1104 Peptic ulcer 531-534;Both sexes;101 Toledo;Group 1104 Peptic ulcer 531-534;Men;79 Toledo;Group 1104 Peptic ulcer 531-534;Women;22 Toledo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;118 Toledo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;53 Toledo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;65 Toledo;Group 1106 Appendicitis 540-543;Both sexes;527 Toledo;Group 1106 Appendicitis 540-543;Men;297 Toledo;Group 1106 Appendicitis 540-543;Women;230 Toledo;Group 1107 Inguinal hernia 550;Both sexes;425 Toledo;Group 1107 Inguinal hernia 550;Men;378 Toledo;Group 1107 Inguinal hernia 550;Women;47 Toledo;Group 1108 Other abdominal hernia 551-553;Both sexes;489 Toledo;Group 1108 Other abdominal hernia 551-553;Men;208 Toledo;Group 1108 Other abdominal hernia 551-553;Women;281 Toledo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;109 Toledo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;58 Toledo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;51 Toledo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;313 Toledo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;161 Toledo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;152 Toledo;Group 1111 Intestinal obstruction without hernia 560;Both sexes;382 Toledo;Group 1111 Intestinal obstruction without hernia 560;Men;200 Toledo;Group 1111 Intestinal obstruction without hernia 560;Women;182 Toledo;Group 1112 Intestinal diverticulosis 562;Both sexes;230 Toledo;Group 1112 Intestinal diverticulosis 562;Men;121 Toledo;Group 1112 Intestinal diverticulosis 562;Women;109 Toledo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;392 Toledo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;254 Toledo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;138 Toledo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;226 Toledo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;103 Toledo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;123 Toledo;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;73 Toledo;Group 1115 Alcoholic hepatitis 5710-5713;Men;61 Toledo;Group 1115 Alcoholic hepatitis 5710-5713;Women;12 Toledo;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;232 Toledo;Group 1116 Other diseases of the liver 570,5714-573;Men;154 Toledo;Group 1116 Other diseases of the liver 570,5714-573;Women;78 Toledo;Group 1117 Cholelithiasis 574;Both sexes;954 Toledo;Group 1117 Cholelithiasis 574;Men;467 Toledo;Group 1117 Cholelithiasis 574;Women;487 Toledo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;320 Toledo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;167 Toledo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;153 Toledo;Group 1119 Pancreatic diseases 577;Both sexes;417 Toledo;Group 1119 Pancreatic diseases 577;Men;238 Toledo;Group 1119 Pancreatic diseases 577;Women;179 Toledo;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;222 Toledo;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;130 Toledo;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;92 Toledo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;399 Toledo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;219 Toledo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;180 Toledo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;249 Toledo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;151 Toledo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;98 Toledo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;21 Toledo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;8 Toledo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;13 Toledo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;129 Toledo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;60 Toledo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;69 Toledo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.638 Toledo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.365 Toledo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.273 Toledo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Toledo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Toledo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Toledo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Toledo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Toledo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Toledo;Group 1303 Internal derangement of knee 717;Both sexes;350 Toledo;Group 1303 Internal derangement of knee 717;Men;242 Toledo;Group 1303 Internal derangement of knee 717;Women;108 Toledo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.033 Toledo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;456 Toledo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;577 Toledo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;48 Toledo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;24 Toledo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;24 Toledo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;109 Toledo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;55 Toledo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;54 Toledo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;222 Toledo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;129 Toledo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;93 Toledo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;52 Toledo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;25 Toledo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;27 Toledo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;400 Toledo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;241 Toledo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;159 Toledo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;424 Toledo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;193 Toledo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;231 Toledo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.073 Toledo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.504 Toledo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.569 Toledo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;380 Toledo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;145 Toledo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;235 Toledo;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;326 Toledo;Group 1402 Renal failure 5836-5837, 584-586;Men;186 Toledo;Group 1402 Renal failure 5836-5837, 584-586;Women;140 Toledo;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;403 Toledo;Group 1403 Urolithiasis 592, 594, 7880;Men;235 Toledo;Group 1403 Urolithiasis 592, 594, 7880;Women;168 Toledo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;811 Toledo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;425 Toledo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;386 Toledo;Group 1405 Prostatic hyperplasia 600;Both sexes;162 Toledo;Group 1405 Prostatic hyperplasia 600;Men;162 Toledo;Group 1405 Prostatic hyperplasia 600;Women;.. Toledo;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;331 Toledo;Group 1406 Other diseases of the male genital organs 601-608;Men;331 Toledo;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Toledo;Group 1407 Disorders of breast 610-612;Both sexes;125 Toledo;Group 1407 Disorders of breast 610-612;Men;19 Toledo;Group 1407 Disorders of breast 610-612;Women;106 Toledo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;95 Toledo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Toledo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;95 Toledo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;52 Toledo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Toledo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;52 Toledo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;388 Toledo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Toledo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;387 Toledo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5.407 Toledo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Toledo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5.407 Toledo;Group 1501 Legally induced abortion 635;Both sexes;2 Toledo;Group 1501 Legally induced abortion 635;Men;.. Toledo;Group 1501 Legally induced abortion 635;Women;2 Toledo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;397 Toledo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Toledo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;397 Toledo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.556 Toledo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Toledo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.556 Toledo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;346 Toledo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Toledo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;346 Toledo;Group 1505 Single spontaneous delivery 650;Both sexes;345 Toledo;Group 1505 Single spontaneous delivery 650;Men;.. Toledo;Group 1505 Single spontaneous delivery 650;Women;345 Toledo;Group 1506 Other deliveries 6695-6697;Both sexes;214 Toledo;Group 1506 Other deliveries 6695-6697;Men;.. Toledo;Group 1506 Other deliveries 6695-6697;Women;214 Toledo;Group 1507 Complications related to the puerperium 670-676;Both sexes;35 Toledo;Group 1507 Complications related to the puerperium 670-676;Men;.. Toledo;Group 1507 Complications related to the puerperium 670-676;Women;35 Toledo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;512 Toledo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Toledo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;512 Toledo;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;873 Toledo;Group 1600 Some disorders originating in the perinatal period 760-779;Men;474 Toledo;Group 1600 Some disorders originating in the perinatal period 760-779;Women;399 Toledo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;277 Toledo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;152 Toledo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;125 Toledo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;596 Toledo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;322 Toledo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;274 Toledo;Grupo 1700 Congenital abnormalities 740-759;Both sexes;343 Toledo;Grupo 1700 Congenital abnormalities 740-759;Men;214 Toledo;Grupo 1700 Congenital abnormalities 740-759;Women;129 Toledo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.720 Toledo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;951 Toledo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;769 Toledo;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;155 Toledo;Group 1801 Pain in throat and chest 7841, 7865;Men;97 Toledo;Group 1801 Pain in throat and chest 7841, 7865;Women;58 Toledo;Group 1802 Abdominal pain 7890;Both sexes;304 Toledo;Group 1802 Abdominal pain 7890;Men;120 Toledo;Group 1802 Abdominal pain 7890;Women;184 Toledo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;3 Toledo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;.. Toledo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;3 Toledo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.258 Toledo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;734 Toledo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;524 Toledo;Group 1900 Injuries and poisoning 800-999;Both sexes;4.746 Toledo;Group 1900 Injuries and poisoning 800-999;Men;2.364 Toledo;Group 1900 Injuries and poisoning 800-999;Women;2.382 Toledo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;257 Toledo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;166 Toledo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;91 Toledo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;115 Toledo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;86 Toledo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;29 Toledo;Group 1903 Radius and ulna fracture 813;Both sexes;281 Toledo;Group 1903 Radius and ulna fracture 813;Men;133 Toledo;Group 1903 Radius and ulna fracture 813;Women;148 Toledo;Group 1904 Femur fracture 820-821;Both sexes;871 Toledo;Group 1904 Femur fracture 820-821;Men;240 Toledo;Group 1904 Femur fracture 820-821;Women;631 Toledo;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;386 Toledo;Group 1905 Leg fracture, including the ankle 823-824;Men;194 Toledo;Group 1905 Leg fracture, including the ankle 823-824;Women;192 Toledo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.475 Toledo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;888 Toledo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;587 Toledo;Group 1907 Burns 940-949;Both sexes;7 Toledo;Group 1907 Burns 940-949;Men;6 Toledo;Group 1907 Burns 940-949;Women;1 Toledo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;135 Toledo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;48 Toledo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;87 Toledo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.106 Toledo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;538 Toledo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;568 Toledo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;6 Toledo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;2 Toledo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;4 Toledo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;107 Toledo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;63 Toledo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;44 Toledo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;750 Toledo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;440 Toledo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;310 Toledo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;20 Toledo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;13 Toledo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;7 Toledo;Group 2102 Contraceptive management V25;Both sexes;11 Toledo;Group 2102 Contraceptive management V25;Men;4 Toledo;Group 2102 Contraceptive management V25;Women;7 Toledo;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Toledo;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Toledo;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Toledo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;347 Toledo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;212 Toledo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;135 Toledo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;372 Toledo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;211 Toledo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;161 CATALUÐA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;829.556 CATALUÐA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;390.473 CATALUÐA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;439.083 CATALUÐA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;14.922 CATALUÐA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;8.279 CATALUÐA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;6.643 CATALUÐA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;2.591 CATALUÐA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;1.348 CATALUÐA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;1.242 CATALUÐA;Group 0102 Imprecise intestinal infections 009;Both sexes;1.941 CATALUÐA;Group 0102 Imprecise intestinal infections 009;Men;968 CATALUÐA;Group 0102 Imprecise intestinal infections 009;Women;973 CATALUÐA;Group 0103 Tuberculosis 010-018, 137;Both sexes;720 CATALUÐA;Group 0103 Tuberculosis 010-018, 137;Men;459 CATALUÐA;Group 0103 Tuberculosis 010-018, 137;Women;260 CATALUÐA;Group 0104 Septicaemia 038;Both sexes;4.125 CATALUÐA;Group 0104 Septicaemia 038;Men;2.259 CATALUÐA;Group 0104 Septicaemia 038;Women;1.865 CATALUÐA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;639 CATALUÐA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;452 CATALUÐA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;187 CATALUÐA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;4.908 CATALUÐA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;2.793 CATALUÐA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;2.115 CATALUÐA;Group 0200 Neoplasms 140-239;Both sexes;79.048 CATALUÐA;Group 0200 Neoplasms 140-239;Men;42.962 CATALUÐA;Group 0200 Neoplasms 140-239;Women;36.086 CATALUÐA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;8.699 CATALUÐA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;5.275 CATALUÐA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;3.424 CATALUÐA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;6.621 CATALUÐA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;5.206 CATALUÐA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;1.415 CATALUÐA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;1.059 CATALUÐA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;619 CATALUÐA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;440 CATALUÐA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;5.604 CATALUÐA;Group 0204 Malignant neoplasm of breast 174-175;Men;43 CATALUÐA;Group 0204 Malignant neoplasm of breast 174-175;Women;5.562 CATALUÐA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1.602 CATALUÐA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CATALUÐA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1.602 CATALUÐA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;916 CATALUÐA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CATALUÐA;Group 0206 Malignant neoplasm of ovary 1830;Women;916 CATALUÐA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;3.013 CATALUÐA;Group 0207 Malignant neoplasm of prostate 185;Men;3.013 CATALUÐA;Group 0207 Malignant neoplasm of prostate 185;Women;.. CATALUÐA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;8.552 CATALUÐA;Group 0208 Malignant neoplasm of bladder 188;Men;7.199 CATALUÐA;Group 0208 Malignant neoplasm of bladder 188;Women;1.354 CATALUÐA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;28.839 CATALUÐA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;17.028 CATALUÐA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;11.811 CATALUÐA;Group 0210 Carcinoma in situ 230-234;Both sexes;820 CATALUÐA;Group 0210 Carcinoma in situ 230-234;Men;324 CATALUÐA;Group 0210 Carcinoma in situ 230-234;Women;496 CATALUÐA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;832 CATALUÐA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;521 CATALUÐA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;312 CATALUÐA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;3.745 CATALUÐA;Grupo 0212 Leiomyoma of uterus 218;Men;.. CATALUÐA;Grupo 0212 Leiomyoma of uterus 218;Women;3.745 CATALUÐA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;8.745 CATALUÐA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;3.735 CATALUÐA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;5.010 CATALUÐA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;6.818 CATALUÐA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;3.401 CATALUÐA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;3.417 CATALUÐA;Group 0301 Anaemias 280-285;Both sexes;3.744 CATALUÐA;Group 0301 Anaemias 280-285;Men;1.777 CATALUÐA;Group 0301 Anaemias 280-285;Women;1.967 CATALUÐA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;3.074 CATALUÐA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;1.624 CATALUÐA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;1.450 CATALUÐA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;13.877 CATALUÐA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;5.379 CATALUÐA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;8.499 CATALUÐA;Group 0401 Diabetes mellitus 249-250;Both sexes;4.348 CATALUÐA;Group 0401 Diabetes mellitus 249-250;Men;2.481 CATALUÐA;Group 0401 Diabetes mellitus 249-250;Women;1.868 CATALUÐA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;9.529 CATALUÐA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;2.898 CATALUÐA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;6.631 CATALUÐA;Group 0500 Mental disorders 290-319;Both sexes;29.031 CATALUÐA;Group 0500 Mental disorders 290-319;Men;14.904 CATALUÐA;Group 0500 Mental disorders 290-319;Women;14.127 CATALUÐA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;2.143 CATALUÐA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;897 CATALUÐA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;1.246 CATALUÐA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;1.774 CATALUÐA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;1.301 CATALUÐA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;472 CATALUÐA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;1.661 CATALUÐA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;1.204 CATALUÐA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;457 CATALUÐA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;8.741 CATALUÐA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;5.473 CATALUÐA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;3.267 CATALUÐA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;6.678 CATALUÐA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;2.619 CATALUÐA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;4.060 CATALUÐA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;8.033 CATALUÐA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;3.409 CATALUÐA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;4.624 CATALUÐA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;16.774 CATALUÐA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;8.001 CATALUÐA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;8.772 CATALUÐA;Group 0601 Alzheimer's disease 3310;Both sexes;1.685 CATALUÐA;Group 0601 Alzheimer's disease 3310;Men;544 CATALUÐA;Group 0601 Alzheimer's disease 3310;Women;1.141 CATALUÐA;Group 0602 Multiple sclerosis 340;Both sexes;207 CATALUÐA;Group 0602 Multiple sclerosis 340;Men;78 CATALUÐA;Group 0602 Multiple sclerosis 340;Women;129 CATALUÐA;Group 0603 Epilepsy 345;Both sexes;2.763 CATALUÐA;Group 0603 Epilepsy 345;Men;1.497 CATALUÐA;Group 0603 Epilepsy 345;Women;1.265 CATALUÐA;Group 0604 Transient cerebral ischemia 435;Both sexes;2.192 CATALUÐA;Group 0604 Transient cerebral ischemia 435;Men;1.123 CATALUÐA;Group 0604 Transient cerebral ischemia 435;Women;1.069 CATALUÐA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;9.926 CATALUÐA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;4.758 CATALUÐA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;5.168 CATALUÐA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;5.426 CATALUÐA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;2.709 CATALUÐA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;2.717 CATALUÐA;Grupo 0701 Cataract 366;Both sexes;1.757 CATALUÐA;Grupo 0701 Cataract 366;Men;768 CATALUÐA;Grupo 0701 Cataract 366;Women;989 CATALUÐA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;3.669 CATALUÐA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;1.941 CATALUÐA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;1.728 CATALUÐA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;4.027 CATALUÐA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1.952 CATALUÐA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;2.075 CATALUÐA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;106.085 CATALUÐA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;58.596 CATALUÐA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;47.490 CATALUÐA;Group 0901 Hypertensive disease 401-405;Both sexes;4.157 CATALUÐA;Group 0901 Hypertensive disease 401-405;Men;1.689 CATALUÐA;Group 0901 Hypertensive disease 401-405;Women;2.468 CATALUÐA;Group 0902 Angina pectoris 4111, 413;Both sexes;3.404 CATALUÐA;Group 0902 Angina pectoris 4111, 413;Men;2.134 CATALUÐA;Group 0902 Angina pectoris 4111, 413;Women;1.270 CATALUÐA;Group 0903 Acute myocardial infarction 410;Both sexes;9.427 CATALUÐA;Group 0903 Acute myocardial infarction 410;Men;6.688 CATALUÐA;Group 0903 Acute myocardial infarction 410;Women;2.738 CATALUÐA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;7.380 CATALUÐA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;5.664 CATALUÐA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1.716 CATALUÐA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;2.954 CATALUÐA;Group 0905 Diseases of the lungs circulation 415-417;Men;1.385 CATALUÐA;Group 0905 Diseases of the lungs circulation 415-417;Women;1.569 CATALUÐA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;13.276 CATALUÐA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;6.994 CATALUÐA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;6.282 CATALUÐA;Grupo 0907 Heart failure 428;Both sexes;25.042 CATALUÐA;Grupo 0907 Heart failure 428;Men;11.285 CATALUÐA;Grupo 0907 Heart failure 428;Women;13.757 CATALUÐA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;19.040 CATALUÐA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;10.082 CATALUÐA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;8.958 CATALUÐA;Grupo 0909 Atherosclerosis 440;Both sexes;4.675 CATALUÐA;Grupo 0909 Atherosclerosis 440;Men;3.308 CATALUÐA;Grupo 0909 Atherosclerosis 440;Women;1.368 CATALUÐA;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.902 CATALUÐA;Group 0910 Varicose veins of lower extremities 454;Men;641 CATALUÐA;Group 0910 Varicose veins of lower extremities 454;Women;1.261 CATALUÐA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;14.828 CATALUÐA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;8.725 CATALUÐA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;6.103 CATALUÐA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;97.779 CATALUÐA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;55.452 CATALUÐA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;42.327 CATALUÐA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;3.455 CATALUÐA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;1.832 CATALUÐA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;1.623 CATALUÐA;Group 1002 Pneumonia 480-486;Both sexes;20.138 CATALUÐA;Group 1002 Pneumonia 480-486;Men;11.821 CATALUÐA;Group 1002 Pneumonia 480-486;Women;8.317 CATALUÐA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;13.509 CATALUÐA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;6.316 CATALUÐA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;7.193 CATALUÐA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;3.880 CATALUÐA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;2.038 CATALUÐA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1.842 CATALUÐA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;6.561 CATALUÐA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;3.904 CATALUÐA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;2.657 CATALUÐA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;18.800 CATALUÐA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;14.062 CATALUÐA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;4.738 CATALUÐA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;3.815 CATALUÐA;Group 1007 Asthma 4930-4931,4938-4939;Men;1.039 CATALUÐA;Group 1007 Asthma 4930-4931,4938-4939;Women;2.776 CATALUÐA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;27.621 CATALUÐA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;14.439 CATALUÐA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;13.183 CATALUÐA;Group 1100 Diseases of the digestive system 520-579;Both sexes;95.164 CATALUÐA;Group 1100 Diseases of the digestive system 520-579;Men;52.260 CATALUÐA;Group 1100 Diseases of the digestive system 520-579;Women;42.904 CATALUÐA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;1.392 CATALUÐA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;668 CATALUÐA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;724 CATALUÐA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;1.225 CATALUÐA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;726 CATALUÐA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;498 CATALUÐA;Group 1103 Diseases of the esophagus 530;Both sexes;1.514 CATALUÐA;Group 1103 Diseases of the esophagus 530;Men;881 CATALUÐA;Group 1103 Diseases of the esophagus 530;Women;633 CATALUÐA;Group 1104 Peptic ulcer 531-534;Both sexes;1.764 CATALUÐA;Group 1104 Peptic ulcer 531-534;Men;1.246 CATALUÐA;Group 1104 Peptic ulcer 531-534;Women;518 CATALUÐA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;2.130 CATALUÐA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;1.021 CATALUÐA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;1.110 CATALUÐA;Group 1106 Appendicitis 540-543;Both sexes;8.101 CATALUÐA;Group 1106 Appendicitis 540-543;Men;4.605 CATALUÐA;Group 1106 Appendicitis 540-543;Women;3.496 CATALUÐA;Group 1107 Inguinal hernia 550;Both sexes;10.123 CATALUÐA;Group 1107 Inguinal hernia 550;Men;8.918 CATALUÐA;Group 1107 Inguinal hernia 550;Women;1.205 CATALUÐA;Group 1108 Other abdominal hernia 551-553;Both sexes;7.969 CATALUÐA;Group 1108 Other abdominal hernia 551-553;Men;3.442 CATALUÐA;Group 1108 Other abdominal hernia 551-553;Women;4.528 CATALUÐA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;1.573 CATALUÐA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;795 CATALUÐA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;778 CATALUÐA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;4.369 CATALUÐA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;2.047 CATALUÐA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;2.322 CATALUÐA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;4.631 CATALUÐA;Group 1111 Intestinal obstruction without hernia 560;Men;2.354 CATALUÐA;Group 1111 Intestinal obstruction without hernia 560;Women;2.277 CATALUÐA;Group 1112 Intestinal diverticulosis 562;Both sexes;4.319 CATALUÐA;Group 1112 Intestinal diverticulosis 562;Men;2.156 CATALUÐA;Group 1112 Intestinal diverticulosis 562;Women;2.163 CATALUÐA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;5.283 CATALUÐA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;3.277 CATALUÐA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;2.006 CATALUÐA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;3.192 CATALUÐA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;1.447 CATALUÐA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1.745 CATALUÐA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1.739 CATALUÐA;Group 1115 Alcoholic hepatitis 5710-5713;Men;1.458 CATALUÐA;Group 1115 Alcoholic hepatitis 5710-5713;Women;281 CATALUÐA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;3.680 CATALUÐA;Group 1116 Other diseases of the liver 570,5714-573;Men;2.111 CATALUÐA;Group 1116 Other diseases of the liver 570,5714-573;Women;1.569 CATALUÐA;Group 1117 Cholelithiasis 574;Both sexes;18.709 CATALUÐA;Group 1117 Cholelithiasis 574;Men;7.685 CATALUÐA;Group 1117 Cholelithiasis 574;Women;11.025 CATALUÐA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;4.750 CATALUÐA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;2.580 CATALUÐA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;2.170 CATALUÐA;Group 1119 Pancreatic diseases 577;Both sexes;5.125 CATALUÐA;Group 1119 Pancreatic diseases 577;Men;2.863 CATALUÐA;Group 1119 Pancreatic diseases 577;Women;2.262 CATALUÐA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;3.576 CATALUÐA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1.980 CATALUÐA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1.595 CATALUÐA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;8.850 CATALUÐA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;4.723 CATALUÐA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;4.126 CATALUÐA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;5.705 CATALUÐA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;3.247 CATALUÐA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;2.458 CATALUÐA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;326 CATALUÐA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;182 CATALUÐA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;144 CATALUÐA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;2.819 CATALUÐA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;1.294 CATALUÐA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;1.525 CATALUÐA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;68.180 CATALUÐA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;31.291 CATALUÐA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;36.889 CATALUÐA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CATALUÐA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CATALUÐA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CATALUÐA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CATALUÐA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CATALUÐA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CATALUÐA;Group 1303 Internal derangement of knee 717;Both sexes;9.322 CATALUÐA;Group 1303 Internal derangement of knee 717;Men;5.961 CATALUÐA;Group 1303 Internal derangement of knee 717;Women;3.361 CATALUÐA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;26.055 CATALUÐA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;10.520 CATALUÐA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;15.535 CATALUÐA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;975 CATALUÐA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;374 CATALUÐA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;602 CATALUÐA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;3.373 CATALUÐA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1.488 CATALUÐA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1.886 CATALUÐA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;5.512 CATALUÐA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;2.975 CATALUÐA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;2.537 CATALUÐA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;1.840 CATALUÐA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;818 CATALUÐA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;1.022 CATALUÐA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;10.657 CATALUÐA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;5.106 CATALUÐA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;5.551 CATALUÐA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;10.445 CATALUÐA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;4.050 CATALUÐA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;6.395 CATALUÐA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;61.901 CATALUÐA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;28.420 CATALUÐA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;33.480 CATALUÐA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;7.411 CATALUÐA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;2.226 CATALUÐA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;5.186 CATALUÐA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;5.827 CATALUÐA;Group 1402 Renal failure 5836-5837, 584-586;Men;3.333 CATALUÐA;Group 1402 Renal failure 5836-5837, 584-586;Women;2.494 CATALUÐA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;7.620 CATALUÐA;Group 1403 Urolithiasis 592, 594, 7880;Men;4.572 CATALUÐA;Group 1403 Urolithiasis 592, 594, 7880;Women;3.048 CATALUÐA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;15.121 CATALUÐA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;7.302 CATALUÐA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;7.819 CATALUÐA;Group 1405 Prostatic hyperplasia 600;Both sexes;5.471 CATALUÐA;Group 1405 Prostatic hyperplasia 600;Men;5.471 CATALUÐA;Group 1405 Prostatic hyperplasia 600;Women;.. CATALUÐA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;5.071 CATALUÐA;Group 1406 Other diseases of the male genital organs 601-608;Men;5.071 CATALUÐA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CATALUÐA;Group 1407 Disorders of breast 610-612;Both sexes;5.012 CATALUÐA;Group 1407 Disorders of breast 610-612;Men;255 CATALUÐA;Group 1407 Disorders of breast 610-612;Women;4.757 CATALUÐA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;1.244 CATALUÐA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CATALUÐA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;1.244 CATALUÐA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;473 CATALUÐA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CATALUÐA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;473 CATALUÐA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;8.652 CATALUÐA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;191 CATALUÐA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;8.460 CATALUÐA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;78.938 CATALUÐA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CATALUÐA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;78.938 CATALUÐA;Group 1501 Legally induced abortion 635;Both sexes;605 CATALUÐA;Group 1501 Legally induced abortion 635;Men;.. CATALUÐA;Group 1501 Legally induced abortion 635;Women;605 CATALUÐA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;2.779 CATALUÐA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CATALUÐA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;2.779 CATALUÐA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;39.858 CATALUÐA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CATALUÐA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;39.858 CATALUÐA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;19.242 CATALUÐA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CATALUÐA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;19.242 CATALUÐA;Group 1505 Single spontaneous delivery 650;Both sexes;6.512 CATALUÐA;Group 1505 Single spontaneous delivery 650;Men;.. CATALUÐA;Group 1505 Single spontaneous delivery 650;Women;6.512 CATALUÐA;Group 1506 Other deliveries 6695-6697;Both sexes;2.196 CATALUÐA;Group 1506 Other deliveries 6695-6697;Men;.. CATALUÐA;Group 1506 Other deliveries 6695-6697;Women;2.196 CATALUÐA;Group 1507 Complications related to the puerperium 670-676;Both sexes;890 CATALUÐA;Group 1507 Complications related to the puerperium 670-676;Men;.. CATALUÐA;Group 1507 Complications related to the puerperium 670-676;Women;890 CATALUÐA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;6.855 CATALUÐA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CATALUÐA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;6.855 CATALUÐA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;11.368 CATALUÐA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;6.138 CATALUÐA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;5.229 CATALUÐA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;3.633 CATALUÐA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;1.909 CATALUÐA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;1.724 CATALUÐA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;7.735 CATALUÐA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;4.229 CATALUÐA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;3.506 CATALUÐA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;6.911 CATALUÐA;Grupo 1700 Congenital abnormalities 740-759;Men;3.761 CATALUÐA;Grupo 1700 Congenital abnormalities 740-759;Women;3.149 CATALUÐA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;29.722 CATALUÐA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;16.341 CATALUÐA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;13.380 CATALUÐA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;3.024 CATALUÐA;Group 1801 Pain in throat and chest 7841, 7865;Men;1.737 CATALUÐA;Group 1801 Pain in throat and chest 7841, 7865;Women;1.287 CATALUÐA;Group 1802 Abdominal pain 7890;Both sexes;3.622 CATALUÐA;Group 1802 Abdominal pain 7890;Men;1.428 CATALUÐA;Group 1802 Abdominal pain 7890;Women;2.194 CATALUÐA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;830 CATALUÐA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;415 CATALUÐA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;415 CATALUÐA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;22.246 CATALUÐA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;12.761 CATALUÐA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;9.485 CATALUÐA;Group 1900 Injuries and poisoning 800-999;Both sexes;78.458 CATALUÐA;Group 1900 Injuries and poisoning 800-999;Men;37.545 CATALUÐA;Group 1900 Injuries and poisoning 800-999;Women;40.913 CATALUÐA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;4.892 CATALUÐA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;2.662 CATALUÐA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;2.230 CATALUÐA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1.645 CATALUÐA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;1.082 CATALUÐA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;563 CATALUÐA;Group 1903 Radius and ulna fracture 813;Both sexes;4.254 CATALUÐA;Group 1903 Radius and ulna fracture 813;Men;2.004 CATALUÐA;Group 1903 Radius and ulna fracture 813;Women;2.251 CATALUÐA;Group 1904 Femur fracture 820-821;Both sexes;15.795 CATALUÐA;Group 1904 Femur fracture 820-821;Men;4.420 CATALUÐA;Group 1904 Femur fracture 820-821;Women;11.376 CATALUÐA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;5.213 CATALUÐA;Group 1905 Leg fracture, including the ankle 823-824;Men;2.543 CATALUÐA;Group 1905 Leg fracture, including the ankle 823-824;Women;2.669 CATALUÐA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;22.391 CATALUÐA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;12.379 CATALUÐA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;10.012 CATALUÐA;Group 1907 Burns 940-949;Both sexes;611 CATALUÐA;Group 1907 Burns 940-949;Men;378 CATALUÐA;Group 1907 Burns 940-949;Women;232 CATALUÐA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;2.229 CATALUÐA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;968 CATALUÐA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;1.261 CATALUÐA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;19.384 CATALUÐA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;9.976 CATALUÐA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;9.408 CATALUÐA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;220 CATALUÐA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;136 CATALUÐA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;84 CATALUÐA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;1.824 CATALUÐA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;998 CATALUÐA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;825 CATALUÐA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;16.277 CATALUÐA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;8.356 CATALUÐA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;7.921 CATALUÐA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;346 CATALUÐA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;217 CATALUÐA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;129 CATALUÐA;Group 2102 Contraceptive management V25;Both sexes;298 CATALUÐA;Group 2102 Contraceptive management V25;Men;21 CATALUÐA;Group 2102 Contraceptive management V25;Women;277 CATALUÐA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CATALUÐA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CATALUÐA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CATALUÐA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;4.168 CATALUÐA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;2.575 CATALUÐA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1.593 CATALUÐA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;11.465 CATALUÐA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;5.543 CATALUÐA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;5.922 Barcelona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;643.805 Barcelona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;302.523 Barcelona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;341.281 Barcelona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;11.931 Barcelona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;6.565 Barcelona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;5.366 Barcelona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;2.127 Barcelona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;1.099 Barcelona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;1.027 Barcelona;Group 0102 Imprecise intestinal infections 009;Both sexes;1.425 Barcelona;Group 0102 Imprecise intestinal infections 009;Men;695 Barcelona;Group 0102 Imprecise intestinal infections 009;Women;730 Barcelona;Group 0103 Tuberculosis 010-018, 137;Both sexes;536 Barcelona;Group 0103 Tuberculosis 010-018, 137;Men;338 Barcelona;Group 0103 Tuberculosis 010-018, 137;Women;198 Barcelona;Group 0104 Septicaemia 038;Both sexes;3.415 Barcelona;Group 0104 Septicaemia 038;Men;1.850 Barcelona;Group 0104 Septicaemia 038;Women;1.565 Barcelona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;502 Barcelona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;350 Barcelona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;153 Barcelona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;3.926 Barcelona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;2.233 Barcelona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;1.693 Barcelona;Group 0200 Neoplasms 140-239;Both sexes;62.358 Barcelona;Group 0200 Neoplasms 140-239;Men;33.678 Barcelona;Group 0200 Neoplasms 140-239;Women;28.680 Barcelona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;6.579 Barcelona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;3.964 Barcelona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;2.615 Barcelona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;5.099 Barcelona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;4.024 Barcelona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;1.074 Barcelona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;831 Barcelona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;473 Barcelona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;358 Barcelona;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;4.376 Barcelona;Group 0204 Malignant neoplasm of breast 174-175;Men;32 Barcelona;Group 0204 Malignant neoplasm of breast 174-175;Women;4.344 Barcelona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1.265 Barcelona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Barcelona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1.265 Barcelona;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;752 Barcelona;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Barcelona;Group 0206 Malignant neoplasm of ovary 1830;Women;752 Barcelona;Group 0207 Malignant neoplasm of prostate 185;Both sexes;2.455 Barcelona;Group 0207 Malignant neoplasm of prostate 185;Men;2.455 Barcelona;Group 0207 Malignant neoplasm of prostate 185;Women;.. Barcelona;Group 0208 Malignant neoplasm of bladder 188;Both sexes;6.467 Barcelona;Group 0208 Malignant neoplasm of bladder 188;Men;5.439 Barcelona;Group 0208 Malignant neoplasm of bladder 188;Women;1.028 Barcelona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;23.297 Barcelona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;13.689 Barcelona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;9.607 Barcelona;Group 0210 Carcinoma in situ 230-234;Both sexes;675 Barcelona;Group 0210 Carcinoma in situ 230-234;Men;272 Barcelona;Group 0210 Carcinoma in situ 230-234;Women;404 Barcelona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;625 Barcelona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;385 Barcelona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;240 Barcelona;Grupo 0212 Leiomyoma of uterus 218;Both sexes;2.973 Barcelona;Grupo 0212 Leiomyoma of uterus 218;Men;.. Barcelona;Grupo 0212 Leiomyoma of uterus 218;Women;2.973 Barcelona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;6.964 Barcelona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;2.945 Barcelona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;4.019 Barcelona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;5.334 Barcelona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;2.650 Barcelona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;2.684 Barcelona;Group 0301 Anaemias 280-285;Both sexes;2.777 Barcelona;Group 0301 Anaemias 280-285;Men;1.299 Barcelona;Group 0301 Anaemias 280-285;Women;1.478 Barcelona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;2.557 Barcelona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;1.351 Barcelona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;1.206 Barcelona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;11.349 Barcelona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;4.325 Barcelona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;7.024 Barcelona;Group 0401 Diabetes mellitus 249-250;Both sexes;3.459 Barcelona;Group 0401 Diabetes mellitus 249-250;Men;1.976 Barcelona;Group 0401 Diabetes mellitus 249-250;Women;1.483 Barcelona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;7.890 Barcelona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;2.349 Barcelona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;5.541 Barcelona;Group 0500 Mental disorders 290-319;Both sexes;22.676 Barcelona;Group 0500 Mental disorders 290-319;Men;11.475 Barcelona;Group 0500 Mental disorders 290-319;Women;11.200 Barcelona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;1.751 Barcelona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;734 Barcelona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;1.017 Barcelona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;1.462 Barcelona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;1.068 Barcelona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;394 Barcelona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;1.344 Barcelona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;970 Barcelona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;373 Barcelona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;6.678 Barcelona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;4.118 Barcelona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;2.560 Barcelona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;5.351 Barcelona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;2.068 Barcelona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;3.283 Barcelona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;6.090 Barcelona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;2.517 Barcelona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;3.573 Barcelona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;13.677 Barcelona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;6.515 Barcelona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;7.162 Barcelona;Group 0601 Alzheimer's disease 3310;Both sexes;1.405 Barcelona;Group 0601 Alzheimer's disease 3310;Men;447 Barcelona;Group 0601 Alzheimer's disease 3310;Women;958 Barcelona;Group 0602 Multiple sclerosis 340;Both sexes;156 Barcelona;Group 0602 Multiple sclerosis 340;Men;60 Barcelona;Group 0602 Multiple sclerosis 340;Women;96 Barcelona;Group 0603 Epilepsy 345;Both sexes;2.310 Barcelona;Group 0603 Epilepsy 345;Men;1.233 Barcelona;Group 0603 Epilepsy 345;Women;1.077 Barcelona;Group 0604 Transient cerebral ischemia 435;Both sexes;1.740 Barcelona;Group 0604 Transient cerebral ischemia 435;Men;883 Barcelona;Group 0604 Transient cerebral ischemia 435;Women;857 Barcelona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;8.065 Barcelona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;3.892 Barcelona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;4.173 Barcelona;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;4.259 Barcelona;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;2.162 Barcelona;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;2.097 Barcelona;Grupo 0701 Cataract 366;Both sexes;1.087 Barcelona;Grupo 0701 Cataract 366;Men;470 Barcelona;Grupo 0701 Cataract 366;Women;617 Barcelona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;3.172 Barcelona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;1.692 Barcelona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;1.480 Barcelona;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;3.204 Barcelona;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1.562 Barcelona;Group 0800 Diseases of the ear and the mastoid 380-389;Women;1.642 Barcelona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;83.082 Barcelona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;45.721 Barcelona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;37.360 Barcelona;Group 0901 Hypertensive disease 401-405;Both sexes;3.720 Barcelona;Group 0901 Hypertensive disease 401-405;Men;1.481 Barcelona;Group 0901 Hypertensive disease 401-405;Women;2.239 Barcelona;Group 0902 Angina pectoris 4111, 413;Both sexes;2.400 Barcelona;Group 0902 Angina pectoris 4111, 413;Men;1.475 Barcelona;Group 0902 Angina pectoris 4111, 413;Women;925 Barcelona;Group 0903 Acute myocardial infarction 410;Both sexes;7.109 Barcelona;Group 0903 Acute myocardial infarction 410;Men;5.004 Barcelona;Group 0903 Acute myocardial infarction 410;Women;2.105 Barcelona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;6.266 Barcelona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;4.845 Barcelona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1.421 Barcelona;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;2.231 Barcelona;Group 0905 Diseases of the lungs circulation 415-417;Men;1.046 Barcelona;Group 0905 Diseases of the lungs circulation 415-417;Women;1.185 Barcelona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;10.401 Barcelona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;5.481 Barcelona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;4.921 Barcelona;Grupo 0907 Heart failure 428;Both sexes;19.443 Barcelona;Grupo 0907 Heart failure 428;Men;8.568 Barcelona;Grupo 0907 Heart failure 428;Women;10.875 Barcelona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;14.568 Barcelona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;7.668 Barcelona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;6.900 Barcelona;Grupo 0909 Atherosclerosis 440;Both sexes;3.748 Barcelona;Grupo 0909 Atherosclerosis 440;Men;2.663 Barcelona;Grupo 0909 Atherosclerosis 440;Women;1.085 Barcelona;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.282 Barcelona;Group 0910 Varicose veins of lower extremities 454;Men;407 Barcelona;Group 0910 Varicose veins of lower extremities 454;Women;875 Barcelona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;11.914 Barcelona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;7.084 Barcelona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;4.831 Barcelona;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;74.739 Barcelona;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;42.179 Barcelona;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;32.560 Barcelona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;2.656 Barcelona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;1.386 Barcelona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;1.271 Barcelona;Group 1002 Pneumonia 480-486;Both sexes;15.188 Barcelona;Group 1002 Pneumonia 480-486;Men;8.871 Barcelona;Group 1002 Pneumonia 480-486;Women;6.316 Barcelona;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;9.234 Barcelona;Group 1003 Acute bronchitis and bronchiolitis 466;Men;4.293 Barcelona;Group 1003 Acute bronchitis and bronchiolitis 466;Women;4.941 Barcelona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;2.638 Barcelona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1.382 Barcelona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1.257 Barcelona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;5.034 Barcelona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;2.961 Barcelona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;2.073 Barcelona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;14.406 Barcelona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;10.867 Barcelona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;3.539 Barcelona;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;2.892 Barcelona;Group 1007 Asthma 4930-4931,4938-4939;Men;753 Barcelona;Group 1007 Asthma 4930-4931,4938-4939;Women;2.139 Barcelona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;22.691 Barcelona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;11.666 Barcelona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;11.024 Barcelona;Group 1100 Diseases of the digestive system 520-579;Both sexes;72.081 Barcelona;Group 1100 Diseases of the digestive system 520-579;Men;39.348 Barcelona;Group 1100 Diseases of the digestive system 520-579;Women;32.733 Barcelona;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;964 Barcelona;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;450 Barcelona;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;514 Barcelona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;996 Barcelona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;585 Barcelona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;411 Barcelona;Group 1103 Diseases of the esophagus 530;Both sexes;1.221 Barcelona;Group 1103 Diseases of the esophagus 530;Men;693 Barcelona;Group 1103 Diseases of the esophagus 530;Women;527 Barcelona;Group 1104 Peptic ulcer 531-534;Both sexes;1.366 Barcelona;Group 1104 Peptic ulcer 531-534;Men;938 Barcelona;Group 1104 Peptic ulcer 531-534;Women;427 Barcelona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;1.673 Barcelona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;794 Barcelona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;879 Barcelona;Group 1106 Appendicitis 540-543;Both sexes;6.255 Barcelona;Group 1106 Appendicitis 540-543;Men;3.535 Barcelona;Group 1106 Appendicitis 540-543;Women;2.720 Barcelona;Group 1107 Inguinal hernia 550;Both sexes;7.497 Barcelona;Group 1107 Inguinal hernia 550;Men;6.606 Barcelona;Group 1107 Inguinal hernia 550;Women;891 Barcelona;Group 1108 Other abdominal hernia 551-553;Both sexes;5.975 Barcelona;Group 1108 Other abdominal hernia 551-553;Men;2.567 Barcelona;Group 1108 Other abdominal hernia 551-553;Women;3.407 Barcelona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;1.267 Barcelona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;644 Barcelona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;622 Barcelona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;3.263 Barcelona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;1.517 Barcelona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;1.746 Barcelona;Group 1111 Intestinal obstruction without hernia 560;Both sexes;3.477 Barcelona;Group 1111 Intestinal obstruction without hernia 560;Men;1.777 Barcelona;Group 1111 Intestinal obstruction without hernia 560;Women;1.700 Barcelona;Group 1112 Intestinal diverticulosis 562;Both sexes;3.451 Barcelona;Group 1112 Intestinal diverticulosis 562;Men;1.724 Barcelona;Group 1112 Intestinal diverticulosis 562;Women;1.726 Barcelona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;3.792 Barcelona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;2.364 Barcelona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;1.428 Barcelona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;2.529 Barcelona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;1.123 Barcelona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1.406 Barcelona;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1.293 Barcelona;Group 1115 Alcoholic hepatitis 5710-5713;Men;1.078 Barcelona;Group 1115 Alcoholic hepatitis 5710-5713;Women;215 Barcelona;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;2.956 Barcelona;Group 1116 Other diseases of the liver 570,5714-573;Men;1.685 Barcelona;Group 1116 Other diseases of the liver 570,5714-573;Women;1.271 Barcelona;Group 1117 Cholelithiasis 574;Both sexes;14.066 Barcelona;Group 1117 Cholelithiasis 574;Men;5.730 Barcelona;Group 1117 Cholelithiasis 574;Women;8.336 Barcelona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;3.508 Barcelona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;1.909 Barcelona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;1.599 Barcelona;Group 1119 Pancreatic diseases 577;Both sexes;3.878 Barcelona;Group 1119 Pancreatic diseases 577;Men;2.151 Barcelona;Group 1119 Pancreatic diseases 577;Women;1.727 Barcelona;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;2.656 Barcelona;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1.476 Barcelona;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1.180 Barcelona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;6.859 Barcelona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;3.627 Barcelona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;3.232 Barcelona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;4.310 Barcelona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;2.440 Barcelona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;1.870 Barcelona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;269 Barcelona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;146 Barcelona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;123 Barcelona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;2.279 Barcelona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;1.041 Barcelona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;1.238 Barcelona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;53.912 Barcelona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;24.807 Barcelona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;29.105 Barcelona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Barcelona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Barcelona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Barcelona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Barcelona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Barcelona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Barcelona;Group 1303 Internal derangement of knee 717;Both sexes;7.794 Barcelona;Group 1303 Internal derangement of knee 717;Men;5.028 Barcelona;Group 1303 Internal derangement of knee 717;Women;2.765 Barcelona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;19.632 Barcelona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;7.775 Barcelona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;11.857 Barcelona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;792 Barcelona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;296 Barcelona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;496 Barcelona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;2.905 Barcelona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1.249 Barcelona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1.657 Barcelona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;4.676 Barcelona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;2.554 Barcelona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;2.121 Barcelona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;1.311 Barcelona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;595 Barcelona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;716 Barcelona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;8.373 Barcelona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;4.009 Barcelona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;4.364 Barcelona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;8.429 Barcelona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;3.301 Barcelona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;5.129 Barcelona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;48.715 Barcelona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;22.237 Barcelona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;26.478 Barcelona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;5.727 Barcelona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;1.701 Barcelona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;4.026 Barcelona;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;4.668 Barcelona;Group 1402 Renal failure 5836-5837, 584-586;Men;2.644 Barcelona;Group 1402 Renal failure 5836-5837, 584-586;Women;2.024 Barcelona;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;5.891 Barcelona;Group 1403 Urolithiasis 592, 594, 7880;Men;3.510 Barcelona;Group 1403 Urolithiasis 592, 594, 7880;Women;2.381 Barcelona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;11.840 Barcelona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;5.619 Barcelona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;6.221 Barcelona;Group 1405 Prostatic hyperplasia 600;Both sexes;4.309 Barcelona;Group 1405 Prostatic hyperplasia 600;Men;4.309 Barcelona;Group 1405 Prostatic hyperplasia 600;Women;.. Barcelona;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;4.090 Barcelona;Group 1406 Other diseases of the male genital organs 601-608;Men;4.090 Barcelona;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Barcelona;Group 1407 Disorders of breast 610-612;Both sexes;4.449 Barcelona;Group 1407 Disorders of breast 610-612;Men;213 Barcelona;Group 1407 Disorders of breast 610-612;Women;4.236 Barcelona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;931 Barcelona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Barcelona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;931 Barcelona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;299 Barcelona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Barcelona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;299 Barcelona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;6.512 Barcelona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;151 Barcelona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;6.361 Barcelona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;59.225 Barcelona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Barcelona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;59.225 Barcelona;Group 1501 Legally induced abortion 635;Both sexes;488 Barcelona;Group 1501 Legally induced abortion 635;Men;.. Barcelona;Group 1501 Legally induced abortion 635;Women;488 Barcelona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.883 Barcelona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Barcelona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.883 Barcelona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;30.488 Barcelona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Barcelona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;30.488 Barcelona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;14.834 Barcelona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Barcelona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;14.834 Barcelona;Group 1505 Single spontaneous delivery 650;Both sexes;3.937 Barcelona;Group 1505 Single spontaneous delivery 650;Men;.. Barcelona;Group 1505 Single spontaneous delivery 650;Women;3.937 Barcelona;Group 1506 Other deliveries 6695-6697;Both sexes;1.828 Barcelona;Group 1506 Other deliveries 6695-6697;Men;.. Barcelona;Group 1506 Other deliveries 6695-6697;Women;1.828 Barcelona;Group 1507 Complications related to the puerperium 670-676;Both sexes;614 Barcelona;Group 1507 Complications related to the puerperium 670-676;Men;.. Barcelona;Group 1507 Complications related to the puerperium 670-676;Women;614 Barcelona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;5.152 Barcelona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Barcelona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;5.152 Barcelona;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;8.949 Barcelona;Group 1600 Some disorders originating in the perinatal period 760-779;Men;4.793 Barcelona;Group 1600 Some disorders originating in the perinatal period 760-779;Women;4.156 Barcelona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;2.876 Barcelona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;1.486 Barcelona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;1.390 Barcelona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;6.073 Barcelona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;3.306 Barcelona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;2.766 Barcelona;Grupo 1700 Congenital abnormalities 740-759;Both sexes;6.032 Barcelona;Grupo 1700 Congenital abnormalities 740-759;Men;3.242 Barcelona;Grupo 1700 Congenital abnormalities 740-759;Women;2.791 Barcelona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;21.931 Barcelona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;11.948 Barcelona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;9.983 Barcelona;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;2.227 Barcelona;Group 1801 Pain in throat and chest 7841, 7865;Men;1.283 Barcelona;Group 1801 Pain in throat and chest 7841, 7865;Women;943 Barcelona;Group 1802 Abdominal pain 7890;Both sexes;2.520 Barcelona;Group 1802 Abdominal pain 7890;Men;978 Barcelona;Group 1802 Abdominal pain 7890;Women;1.543 Barcelona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;759 Barcelona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;383 Barcelona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;376 Barcelona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;16.425 Barcelona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;9.304 Barcelona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;7.121 Barcelona;Group 1900 Injuries and poisoning 800-999;Both sexes;60.036 Barcelona;Group 1900 Injuries and poisoning 800-999;Men;28.805 Barcelona;Group 1900 Injuries and poisoning 800-999;Women;31.230 Barcelona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;3.588 Barcelona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;1.915 Barcelona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;1.673 Barcelona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1.239 Barcelona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;809 Barcelona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;429 Barcelona;Group 1903 Radius and ulna fracture 813;Both sexes;3.111 Barcelona;Group 1903 Radius and ulna fracture 813;Men;1.433 Barcelona;Group 1903 Radius and ulna fracture 813;Women;1.677 Barcelona;Group 1904 Femur fracture 820-821;Both sexes;11.515 Barcelona;Group 1904 Femur fracture 820-821;Men;3.222 Barcelona;Group 1904 Femur fracture 820-821;Women;8.294 Barcelona;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;3.939 Barcelona;Group 1905 Leg fracture, including the ankle 823-824;Men;1.879 Barcelona;Group 1905 Leg fracture, including the ankle 823-824;Women;2.060 Barcelona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;16.847 Barcelona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;9.333 Barcelona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;7.514 Barcelona;Group 1907 Burns 940-949;Both sexes;560 Barcelona;Group 1907 Burns 940-949;Men;353 Barcelona;Group 1907 Burns 940-949;Women;207 Barcelona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;1.719 Barcelona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;744 Barcelona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;974 Barcelona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;15.981 Barcelona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;8.259 Barcelona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;7.722 Barcelona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;169 Barcelona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;107 Barcelona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;62 Barcelona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;1.368 Barcelona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;751 Barcelona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;618 Barcelona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;13.457 Barcelona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;6.884 Barcelona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;6.573 Barcelona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;315 Barcelona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;195 Barcelona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;120 Barcelona;Group 2102 Contraceptive management V25;Both sexes;166 Barcelona;Group 2102 Contraceptive management V25;Men;14 Barcelona;Group 2102 Contraceptive management V25;Women;152 Barcelona;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Barcelona;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Barcelona;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Barcelona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;3.444 Barcelona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;2.106 Barcelona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1.338 Barcelona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;9.532 Barcelona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;4.568 Barcelona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;4.964 Girona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;68.245 Girona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;32.219 Girona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;36.026 Girona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.176 Girona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;667 Girona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;509 Girona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;139 Girona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;82 Girona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;57 Girona;Group 0102 Imprecise intestinal infections 009;Both sexes;247 Girona;Group 0102 Imprecise intestinal infections 009;Men;126 Girona;Group 0102 Imprecise intestinal infections 009;Women;121 Girona;Group 0103 Tuberculosis 010-018, 137;Both sexes;73 Girona;Group 0103 Tuberculosis 010-018, 137;Men;49 Girona;Group 0103 Tuberculosis 010-018, 137;Women;24 Girona;Group 0104 Septicaemia 038;Both sexes;342 Girona;Group 0104 Septicaemia 038;Men;196 Girona;Group 0104 Septicaemia 038;Women;146 Girona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;21 Girona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;17 Girona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;4 Girona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;355 Girona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;198 Girona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;156 Girona;Group 0200 Neoplasms 140-239;Both sexes;5.914 Girona;Group 0200 Neoplasms 140-239;Men;3.177 Girona;Group 0200 Neoplasms 140-239;Women;2.737 Girona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;724 Girona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;438 Girona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;286 Girona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;489 Girona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;372 Girona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;118 Girona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;113 Girona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;69 Girona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;43 Girona;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;500 Girona;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Girona;Group 0204 Malignant neoplasm of breast 174-175;Women;497 Girona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;106 Girona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Girona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;106 Girona;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;51 Girona;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Girona;Group 0206 Malignant neoplasm of ovary 1830;Women;51 Girona;Group 0207 Malignant neoplasm of prostate 185;Both sexes;184 Girona;Group 0207 Malignant neoplasm of prostate 185;Men;184 Girona;Group 0207 Malignant neoplasm of prostate 185;Women;.. Girona;Group 0208 Malignant neoplasm of bladder 188;Both sexes;626 Girona;Group 0208 Malignant neoplasm of bladder 188;Men;519 Girona;Group 0208 Malignant neoplasm of bladder 188;Women;108 Girona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.089 Girona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.271 Girona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;818 Girona;Group 0210 Carcinoma in situ 230-234;Both sexes;49 Girona;Group 0210 Carcinoma in situ 230-234;Men;9 Girona;Group 0210 Carcinoma in situ 230-234;Women;39 Girona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;40 Girona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;25 Girona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;16 Girona;Grupo 0212 Leiomyoma of uterus 218;Both sexes;266 Girona;Grupo 0212 Leiomyoma of uterus 218;Men;.. Girona;Grupo 0212 Leiomyoma of uterus 218;Women;266 Girona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;675 Girona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;286 Girona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;389 Girona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;517 Girona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;251 Girona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;265 Girona;Group 0301 Anaemias 280-285;Both sexes;307 Girona;Group 0301 Anaemias 280-285;Men;143 Girona;Group 0301 Anaemias 280-285;Women;164 Girona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;210 Girona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;109 Girona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;101 Girona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;895 Girona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;365 Girona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;530 Girona;Group 0401 Diabetes mellitus 249-250;Both sexes;311 Girona;Group 0401 Diabetes mellitus 249-250;Men;175 Girona;Group 0401 Diabetes mellitus 249-250;Women;136 Girona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;584 Girona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;189 Girona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;395 Girona;Group 0500 Mental disorders 290-319;Both sexes;1.839 Girona;Group 0500 Mental disorders 290-319;Men;1.031 Girona;Group 0500 Mental disorders 290-319;Women;808 Girona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;107 Girona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;49 Girona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;57 Girona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;96 Girona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;77 Girona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;19 Girona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;80 Girona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;62 Girona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;18 Girona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;764 Girona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;505 Girona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;259 Girona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;378 Girona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;161 Girona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;216 Girona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;415 Girona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;177 Girona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;238 Girona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.260 Girona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;629 Girona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;631 Girona;Group 0601 Alzheimer's disease 3310;Both sexes;115 Girona;Group 0601 Alzheimer's disease 3310;Men;47 Girona;Group 0601 Alzheimer's disease 3310;Women;67 Girona;Group 0602 Multiple sclerosis 340;Both sexes;11 Girona;Group 0602 Multiple sclerosis 340;Men;6 Girona;Group 0602 Multiple sclerosis 340;Women;5 Girona;Group 0603 Epilepsy 345;Both sexes;214 Girona;Group 0603 Epilepsy 345;Men;131 Girona;Group 0603 Epilepsy 345;Women;84 Girona;Group 0604 Transient cerebral ischemia 435;Both sexes;133 Girona;Group 0604 Transient cerebral ischemia 435;Men;76 Girona;Group 0604 Transient cerebral ischemia 435;Women;57 Girona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;787 Girona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;369 Girona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;418 Girona;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;717 Girona;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;339 Girona;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;379 Girona;Grupo 0701 Cataract 366;Both sexes;450 Girona;Grupo 0701 Cataract 366;Men;201 Girona;Grupo 0701 Cataract 366;Women;248 Girona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;268 Girona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;137 Girona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;131 Girona;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;271 Girona;Group 0800 Diseases of the ear and the mastoid 380-389;Men;133 Girona;Group 0800 Diseases of the ear and the mastoid 380-389;Women;138 Girona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;8.565 Girona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;4.761 Girona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3.804 Girona;Group 0901 Hypertensive disease 401-405;Both sexes;130 Girona;Group 0901 Hypertensive disease 401-405;Men;55 Girona;Group 0901 Hypertensive disease 401-405;Women;75 Girona;Group 0902 Angina pectoris 4111, 413;Both sexes;353 Girona;Group 0902 Angina pectoris 4111, 413;Men;223 Girona;Group 0902 Angina pectoris 4111, 413;Women;130 Girona;Group 0903 Acute myocardial infarction 410;Both sexes;909 Girona;Group 0903 Acute myocardial infarction 410;Men;660 Girona;Group 0903 Acute myocardial infarction 410;Women;249 Girona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;422 Girona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;300 Girona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;122 Girona;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;277 Girona;Group 0905 Diseases of the lungs circulation 415-417;Men;133 Girona;Group 0905 Diseases of the lungs circulation 415-417;Women;143 Girona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.043 Girona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;548 Girona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;495 Girona;Grupo 0907 Heart failure 428;Both sexes;1.858 Girona;Grupo 0907 Heart failure 428;Men;923 Girona;Grupo 0907 Heart failure 428;Women;935 Girona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.609 Girona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;866 Girona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;743 Girona;Grupo 0909 Atherosclerosis 440;Both sexes;367 Girona;Grupo 0909 Atherosclerosis 440;Men;231 Girona;Grupo 0909 Atherosclerosis 440;Women;136 Girona;Group 0910 Varicose veins of lower extremities 454;Both sexes;345 Girona;Group 0910 Varicose veins of lower extremities 454;Men;126 Girona;Group 0910 Varicose veins of lower extremities 454;Women;219 Girona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.251 Girona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;695 Girona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;556 Girona;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7.858 Girona;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.576 Girona;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3.282 Girona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;201 Girona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;119 Girona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;82 Girona;Group 1002 Pneumonia 480-486;Both sexes;1.622 Girona;Group 1002 Pneumonia 480-486;Men;964 Girona;Group 1002 Pneumonia 480-486;Women;658 Girona;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.253 Girona;Group 1003 Acute bronchitis and bronchiolitis 466;Men;609 Girona;Group 1003 Acute bronchitis and bronchiolitis 466;Women;644 Girona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;572 Girona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;312 Girona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;261 Girona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;606 Girona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;382 Girona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;224 Girona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.319 Girona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;982 Girona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;337 Girona;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;331 Girona;Group 1007 Asthma 4930-4931,4938-4939;Men;126 Girona;Group 1007 Asthma 4930-4931,4938-4939;Women;205 Girona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.954 Girona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.083 Girona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;871 Girona;Group 1100 Diseases of the digestive system 520-579;Both sexes;7.924 Girona;Group 1100 Diseases of the digestive system 520-579;Men;4.559 Girona;Group 1100 Diseases of the digestive system 520-579;Women;3.365 Girona;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;34 Girona;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;23 Girona;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;11 Girona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;74 Girona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;43 Girona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;31 Girona;Group 1103 Diseases of the esophagus 530;Both sexes;97 Girona;Group 1103 Diseases of the esophagus 530;Men;65 Girona;Group 1103 Diseases of the esophagus 530;Women;32 Girona;Group 1104 Peptic ulcer 531-534;Both sexes;131 Girona;Group 1104 Peptic ulcer 531-534;Men;105 Girona;Group 1104 Peptic ulcer 531-534;Women;26 Girona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;144 Girona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;78 Girona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;66 Girona;Group 1106 Appendicitis 540-543;Both sexes;706 Girona;Group 1106 Appendicitis 540-543;Men;431 Girona;Group 1106 Appendicitis 540-543;Women;275 Girona;Group 1107 Inguinal hernia 550;Both sexes;1.008 Girona;Group 1107 Inguinal hernia 550;Men;874 Girona;Group 1107 Inguinal hernia 550;Women;134 Girona;Group 1108 Other abdominal hernia 551-553;Both sexes;751 Girona;Group 1108 Other abdominal hernia 551-553;Men;357 Girona;Group 1108 Other abdominal hernia 551-553;Women;393 Girona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;97 Girona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;45 Girona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;53 Girona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;361 Girona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;171 Girona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;190 Girona;Group 1111 Intestinal obstruction without hernia 560;Both sexes;372 Girona;Group 1111 Intestinal obstruction without hernia 560;Men;189 Girona;Group 1111 Intestinal obstruction without hernia 560;Women;183 Girona;Group 1112 Intestinal diverticulosis 562;Both sexes;290 Girona;Group 1112 Intestinal diverticulosis 562;Men;152 Girona;Group 1112 Intestinal diverticulosis 562;Women;138 Girona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;500 Girona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;306 Girona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;194 Girona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;215 Girona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;98 Girona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;117 Girona;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;116 Girona;Group 1115 Alcoholic hepatitis 5710-5713;Men;93 Girona;Group 1115 Alcoholic hepatitis 5710-5713;Women;23 Girona;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;233 Girona;Group 1116 Other diseases of the liver 570,5714-573;Men;153 Girona;Group 1116 Other diseases of the liver 570,5714-573;Women;80 Girona;Group 1117 Cholelithiasis 574;Both sexes;1.583 Girona;Group 1117 Cholelithiasis 574;Men;702 Girona;Group 1117 Cholelithiasis 574;Women;881 Girona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;462 Girona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;246 Girona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;217 Girona;Group 1119 Pancreatic diseases 577;Both sexes;429 Girona;Group 1119 Pancreatic diseases 577;Men;256 Girona;Group 1119 Pancreatic diseases 577;Women;172 Girona;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;320 Girona;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;172 Girona;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;148 Girona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;821 Girona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;455 Girona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;367 Girona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;585 Girona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;347 Girona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;237 Girona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;9 Girona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;6 Girona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;3 Girona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;227 Girona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;101 Girona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;126 Girona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;5.977 Girona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.728 Girona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.250 Girona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Girona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Girona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Girona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Girona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Girona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Girona;Group 1303 Internal derangement of knee 717;Both sexes;532 Girona;Group 1303 Internal derangement of knee 717;Men;313 Girona;Group 1303 Internal derangement of knee 717;Women;219 Girona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.512 Girona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.101 Girona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.411 Girona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;61 Girona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;25 Girona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;36 Girona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;180 Girona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;83 Girona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;97 Girona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;346 Girona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;175 Girona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;170 Girona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;250 Girona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;105 Girona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;145 Girona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.171 Girona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;570 Girona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;601 Girona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;926 Girona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;356 Girona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;570 Girona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;4.736 Girona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.233 Girona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2.503 Girona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;673 Girona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;234 Girona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;439 Girona;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;472 Girona;Group 1402 Renal failure 5836-5837, 584-586;Men;276 Girona;Group 1402 Renal failure 5836-5837, 584-586;Women;196 Girona;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;528 Girona;Group 1403 Urolithiasis 592, 594, 7880;Men;335 Girona;Group 1403 Urolithiasis 592, 594, 7880;Women;193 Girona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.045 Girona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;577 Girona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;468 Girona;Group 1405 Prostatic hyperplasia 600;Both sexes;378 Girona;Group 1405 Prostatic hyperplasia 600;Men;378 Girona;Group 1405 Prostatic hyperplasia 600;Women;.. Girona;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;394 Girona;Group 1406 Other diseases of the male genital organs 601-608;Men;394 Girona;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Girona;Group 1407 Disorders of breast 610-612;Both sexes;279 Girona;Group 1407 Disorders of breast 610-612;Men;25 Girona;Group 1407 Disorders of breast 610-612;Women;254 Girona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;108 Girona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Girona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;108 Girona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;49 Girona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Girona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;49 Girona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;809 Girona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;13 Girona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;795 Girona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;7.389 Girona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Girona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;7.389 Girona;Group 1501 Legally induced abortion 635;Both sexes;57 Girona;Group 1501 Legally induced abortion 635;Men;.. Girona;Group 1501 Legally induced abortion 635;Women;57 Girona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;288 Girona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Girona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;288 Girona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.617 Girona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Girona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.617 Girona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.596 Girona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Girona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.596 Girona;Group 1505 Single spontaneous delivery 650;Both sexes;939 Girona;Group 1505 Single spontaneous delivery 650;Men;.. Girona;Group 1505 Single spontaneous delivery 650;Women;939 Girona;Group 1506 Other deliveries 6695-6697;Both sexes;186 Girona;Group 1506 Other deliveries 6695-6697;Men;.. Girona;Group 1506 Other deliveries 6695-6697;Women;186 Girona;Group 1507 Complications related to the puerperium 670-676;Both sexes;75 Girona;Group 1507 Complications related to the puerperium 670-676;Men;.. Girona;Group 1507 Complications related to the puerperium 670-676;Women;75 Girona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;632 Girona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Girona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;632 Girona;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;893 Girona;Group 1600 Some disorders originating in the perinatal period 760-779;Men;520 Girona;Group 1600 Some disorders originating in the perinatal period 760-779;Women;373 Girona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;291 Girona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;163 Girona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;128 Girona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;602 Girona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;357 Girona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;245 Girona;Grupo 1700 Congenital abnormalities 740-759;Both sexes;317 Girona;Grupo 1700 Congenital abnormalities 740-759;Men;193 Girona;Grupo 1700 Congenital abnormalities 740-759;Women;123 Girona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.542 Girona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.437 Girona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.105 Girona;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;239 Girona;Group 1801 Pain in throat and chest 7841, 7865;Men;138 Girona;Group 1801 Pain in throat and chest 7841, 7865;Women;101 Girona;Group 1802 Abdominal pain 7890;Both sexes;373 Girona;Group 1802 Abdominal pain 7890;Men;167 Girona;Group 1802 Abdominal pain 7890;Women;206 Girona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;58 Girona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;27 Girona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;31 Girona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.873 Girona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.105 Girona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;768 Girona;Group 1900 Injuries and poisoning 800-999;Both sexes;7.492 Girona;Group 1900 Injuries and poisoning 800-999;Men;3.548 Girona;Group 1900 Injuries and poisoning 800-999;Women;3.944 Girona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;438 Girona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;257 Girona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;181 Girona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;127 Girona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;83 Girona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;44 Girona;Group 1903 Radius and ulna fracture 813;Both sexes;518 Girona;Group 1903 Radius and ulna fracture 813;Men;244 Girona;Group 1903 Radius and ulna fracture 813;Women;274 Girona;Group 1904 Femur fracture 820-821;Both sexes;1.755 Girona;Group 1904 Femur fracture 820-821;Men;498 Girona;Group 1904 Femur fracture 820-821;Women;1.257 Girona;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;581 Girona;Group 1905 Leg fracture, including the ankle 823-824;Men;307 Girona;Group 1905 Leg fracture, including the ankle 823-824;Women;274 Girona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2.350 Girona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.312 Girona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.038 Girona;Group 1907 Burns 940-949;Both sexes;18 Girona;Group 1907 Burns 940-949;Men;10 Girona;Group 1907 Burns 940-949;Women;7 Girona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;197 Girona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;73 Girona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;123 Girona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.359 Girona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;678 Girona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;681 Girona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;22 Girona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;9 Girona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;12 Girona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;128 Girona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;76 Girona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;53 Girona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.142 Girona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;618 Girona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;524 Girona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;8 Girona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;3 Girona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;5 Girona;Group 2102 Contraceptive management V25;Both sexes;21 Girona;Group 2102 Contraceptive management V25;Men;2 Girona;Group 2102 Contraceptive management V25;Women;19 Girona;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Girona;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Girona;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Girona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;236 Girona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;155 Girona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;81 Girona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;877 Girona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;458 Girona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;419 Lleida;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;38.298 Lleida;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;18.210 Lleida;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;20.088 Lleida;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;626 Lleida;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;372 Lleida;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;254 Lleida;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;122 Lleida;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;62 Lleida;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;60 Lleida;Group 0102 Imprecise intestinal infections 009;Both sexes;98 Lleida;Group 0102 Imprecise intestinal infections 009;Men;57 Lleida;Group 0102 Imprecise intestinal infections 009;Women;41 Lleida;Group 0103 Tuberculosis 010-018, 137;Both sexes;51 Lleida;Group 0103 Tuberculosis 010-018, 137;Men;35 Lleida;Group 0103 Tuberculosis 010-018, 137;Women;16 Lleida;Group 0104 Septicaemia 038;Both sexes;128 Lleida;Group 0104 Septicaemia 038;Men;79 Lleida;Group 0104 Septicaemia 038;Women;49 Lleida;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;33 Lleida;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;24 Lleida;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;9 Lleida;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;194 Lleida;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;115 Lleida;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;79 Lleida;Group 0200 Neoplasms 140-239;Both sexes;3.551 Lleida;Group 0200 Neoplasms 140-239;Men;1.972 Lleida;Group 0200 Neoplasms 140-239;Women;1.579 Lleida;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;473 Lleida;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;268 Lleida;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;205 Lleida;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;278 Lleida;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;209 Lleida;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;69 Lleida;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;23 Lleida;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;11 Lleida;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;12 Lleida;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;215 Lleida;Group 0204 Malignant neoplasm of breast 174-175;Men;4 Lleida;Group 0204 Malignant neoplasm of breast 174-175;Women;211 Lleida;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;73 Lleida;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Lleida;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;73 Lleida;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;28 Lleida;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Lleida;Group 0206 Malignant neoplasm of ovary 1830;Women;28 Lleida;Group 0207 Malignant neoplasm of prostate 185;Both sexes;143 Lleida;Group 0207 Malignant neoplasm of prostate 185;Men;143 Lleida;Group 0207 Malignant neoplasm of prostate 185;Women;.. Lleida;Group 0208 Malignant neoplasm of bladder 188;Both sexes;467 Lleida;Group 0208 Malignant neoplasm of bladder 188;Men;398 Lleida;Group 0208 Malignant neoplasm of bladder 188;Women;69 Lleida;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.222 Lleida;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;710 Lleida;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;512 Lleida;Group 0210 Carcinoma in situ 230-234;Both sexes;30 Lleida;Group 0210 Carcinoma in situ 230-234;Men;16 Lleida;Group 0210 Carcinoma in situ 230-234;Women;14 Lleida;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;76 Lleida;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;47 Lleida;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;29 Lleida;Grupo 0212 Leiomyoma of uterus 218;Both sexes;146 Lleida;Grupo 0212 Leiomyoma of uterus 218;Men;.. Lleida;Grupo 0212 Leiomyoma of uterus 218;Women;146 Lleida;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;377 Lleida;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;166 Lleida;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;211 Lleida;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;268 Lleida;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;152 Lleida;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;116 Lleida;Group 0301 Anaemias 280-285;Both sexes;156 Lleida;Group 0301 Anaemias 280-285;Men;83 Lleida;Group 0301 Anaemias 280-285;Women;73 Lleida;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;112 Lleida;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;69 Lleida;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;43 Lleida;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;458 Lleida;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;209 Lleida;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;249 Lleida;Group 0401 Diabetes mellitus 249-250;Both sexes;177 Lleida;Group 0401 Diabetes mellitus 249-250;Men;103 Lleida;Group 0401 Diabetes mellitus 249-250;Women;74 Lleida;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;281 Lleida;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;106 Lleida;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;175 Lleida;Group 0500 Mental disorders 290-319;Both sexes;1.997 Lleida;Group 0500 Mental disorders 290-319;Men;1.035 Lleida;Group 0500 Mental disorders 290-319;Women;962 Lleida;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;95 Lleida;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;44 Lleida;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;51 Lleida;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;84 Lleida;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;59 Lleida;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;25 Lleida;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;140 Lleida;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;98 Lleida;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;42 Lleida;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;635 Lleida;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;405 Lleida;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;230 Lleida;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;470 Lleida;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;174 Lleida;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;296 Lleida;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;573 Lleida;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;255 Lleida;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;318 Lleida;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;646 Lleida;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;289 Lleida;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;357 Lleida;Group 0601 Alzheimer's disease 3310;Both sexes;78 Lleida;Group 0601 Alzheimer's disease 3310;Men;24 Lleida;Group 0601 Alzheimer's disease 3310;Women;54 Lleida;Group 0602 Multiple sclerosis 340;Both sexes;9 Lleida;Group 0602 Multiple sclerosis 340;Men;4 Lleida;Group 0602 Multiple sclerosis 340;Women;5 Lleida;Group 0603 Epilepsy 345;Both sexes;61 Lleida;Group 0603 Epilepsy 345;Men;35 Lleida;Group 0603 Epilepsy 345;Women;26 Lleida;Group 0604 Transient cerebral ischemia 435;Both sexes;115 Lleida;Group 0604 Transient cerebral ischemia 435;Men;56 Lleida;Group 0604 Transient cerebral ischemia 435;Women;59 Lleida;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;383 Lleida;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;170 Lleida;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;213 Lleida;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;127 Lleida;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;63 Lleida;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;64 Lleida;Grupo 0701 Cataract 366;Both sexes;32 Lleida;Grupo 0701 Cataract 366;Men;19 Lleida;Grupo 0701 Cataract 366;Women;13 Lleida;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;95 Lleida;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;44 Lleida;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;51 Lleida;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;109 Lleida;Group 0800 Diseases of the ear and the mastoid 380-389;Men;47 Lleida;Group 0800 Diseases of the ear and the mastoid 380-389;Women;62 Lleida;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4.763 Lleida;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.639 Lleida;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.124 Lleida;Group 0901 Hypertensive disease 401-405;Both sexes;103 Lleida;Group 0901 Hypertensive disease 401-405;Men;51 Lleida;Group 0901 Hypertensive disease 401-405;Women;52 Lleida;Group 0902 Angina pectoris 4111, 413;Both sexes;209 Lleida;Group 0902 Angina pectoris 4111, 413;Men;144 Lleida;Group 0902 Angina pectoris 4111, 413;Women;65 Lleida;Group 0903 Acute myocardial infarction 410;Both sexes;336 Lleida;Group 0903 Acute myocardial infarction 410;Men;256 Lleida;Group 0903 Acute myocardial infarction 410;Women;80 Lleida;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;226 Lleida;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;171 Lleida;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;55 Lleida;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;154 Lleida;Group 0905 Diseases of the lungs circulation 415-417;Men;60 Lleida;Group 0905 Diseases of the lungs circulation 415-417;Women;94 Lleida;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;600 Lleida;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;293 Lleida;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;307 Lleida;Grupo 0907 Heart failure 428;Both sexes;1.346 Lleida;Grupo 0907 Heart failure 428;Men;646 Lleida;Grupo 0907 Heart failure 428;Women;700 Lleida;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.023 Lleida;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;573 Lleida;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;450 Lleida;Grupo 0909 Atherosclerosis 440;Both sexes;217 Lleida;Grupo 0909 Atherosclerosis 440;Men;148 Lleida;Grupo 0909 Atherosclerosis 440;Women;69 Lleida;Group 0910 Varicose veins of lower extremities 454;Both sexes;35 Lleida;Group 0910 Varicose veins of lower extremities 454;Men;10 Lleida;Group 0910 Varicose veins of lower extremities 454;Women;25 Lleida;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;514 Lleida;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;287 Lleida;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;227 Lleida;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;4.922 Lleida;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2.861 Lleida;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.061 Lleida;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;109 Lleida;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;63 Lleida;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;46 Lleida;Group 1002 Pneumonia 480-486;Both sexes;953 Lleida;Group 1002 Pneumonia 480-486;Men;567 Lleida;Group 1002 Pneumonia 480-486;Women;386 Lleida;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;905 Lleida;Group 1003 Acute bronchitis and bronchiolitis 466;Men;418 Lleida;Group 1003 Acute bronchitis and bronchiolitis 466;Women;487 Lleida;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;210 Lleida;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;111 Lleida;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;99 Lleida;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;249 Lleida;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;152 Lleida;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;97 Lleida;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.124 Lleida;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;796 Lleida;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;328 Lleida;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;127 Lleida;Group 1007 Asthma 4930-4931,4938-4939;Men;41 Lleida;Group 1007 Asthma 4930-4931,4938-4939;Women;86 Lleida;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.245 Lleida;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;713 Lleida;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;532 Lleida;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.724 Lleida;Group 1100 Diseases of the digestive system 520-579;Men;2.621 Lleida;Group 1100 Diseases of the digestive system 520-579;Women;2.103 Lleida;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;66 Lleida;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;34 Lleida;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;32 Lleida;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;54 Lleida;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;40 Lleida;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;14 Lleida;Group 1103 Diseases of the esophagus 530;Both sexes;61 Lleida;Group 1103 Diseases of the esophagus 530;Men;38 Lleida;Group 1103 Diseases of the esophagus 530;Women;23 Lleida;Group 1104 Peptic ulcer 531-534;Both sexes;91 Lleida;Group 1104 Peptic ulcer 531-534;Men;74 Lleida;Group 1104 Peptic ulcer 531-534;Women;17 Lleida;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;96 Lleida;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;47 Lleida;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;49 Lleida;Group 1106 Appendicitis 540-543;Both sexes;385 Lleida;Group 1106 Appendicitis 540-543;Men;208 Lleida;Group 1106 Appendicitis 540-543;Women;177 Lleida;Group 1107 Inguinal hernia 550;Both sexes;364 Lleida;Group 1107 Inguinal hernia 550;Men;330 Lleida;Group 1107 Inguinal hernia 550;Women;34 Lleida;Group 1108 Other abdominal hernia 551-553;Both sexes;328 Lleida;Group 1108 Other abdominal hernia 551-553;Men;135 Lleida;Group 1108 Other abdominal hernia 551-553;Women;193 Lleida;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;61 Lleida;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;32 Lleida;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;29 Lleida;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;246 Lleida;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;117 Lleida;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;129 Lleida;Group 1111 Intestinal obstruction without hernia 560;Both sexes;247 Lleida;Group 1111 Intestinal obstruction without hernia 560;Men;128 Lleida;Group 1111 Intestinal obstruction without hernia 560;Women;119 Lleida;Group 1112 Intestinal diverticulosis 562;Both sexes;186 Lleida;Group 1112 Intestinal diverticulosis 562;Men;85 Lleida;Group 1112 Intestinal diverticulosis 562;Women;101 Lleida;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;215 Lleida;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;140 Lleida;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;75 Lleida;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;161 Lleida;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;84 Lleida;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;77 Lleida;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;141 Lleida;Group 1115 Alcoholic hepatitis 5710-5713;Men;121 Lleida;Group 1115 Alcoholic hepatitis 5710-5713;Women;20 Lleida;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;171 Lleida;Group 1116 Other diseases of the liver 570,5714-573;Men;101 Lleida;Group 1116 Other diseases of the liver 570,5714-573;Women;70 Lleida;Group 1117 Cholelithiasis 574;Both sexes;1.103 Lleida;Group 1117 Cholelithiasis 574;Men;479 Lleida;Group 1117 Cholelithiasis 574;Women;624 Lleida;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;318 Lleida;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;170 Lleida;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;148 Lleida;Group 1119 Pancreatic diseases 577;Both sexes;235 Lleida;Group 1119 Pancreatic diseases 577;Men;134 Lleida;Group 1119 Pancreatic diseases 577;Women;101 Lleida;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;195 Lleida;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;124 Lleida;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;71 Lleida;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;302 Lleida;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;174 Lleida;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;128 Lleida;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;187 Lleida;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;126 Lleida;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;61 Lleida;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;9 Lleida;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;5 Lleida;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;4 Lleida;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;106 Lleida;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;43 Lleida;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;63 Lleida;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.351 Lleida;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.061 Lleida;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.290 Lleida;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Lleida;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Lleida;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Lleida;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Lleida;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Lleida;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Lleida;Group 1303 Internal derangement of knee 717;Both sexes;165 Lleida;Group 1303 Internal derangement of knee 717;Men;97 Lleida;Group 1303 Internal derangement of knee 717;Women;68 Lleida;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.108 Lleida;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;464 Lleida;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;644 Lleida;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;51 Lleida;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;24 Lleida;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;27 Lleida;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;101 Lleida;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;55 Lleida;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;46 Lleida;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;209 Lleida;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;102 Lleida;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;107 Lleida;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;86 Lleida;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;36 Lleida;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;50 Lleida;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;341 Lleida;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;166 Lleida;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;175 Lleida;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;290 Lleida;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;117 Lleida;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;173 Lleida;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.800 Lleida;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.425 Lleida;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.375 Lleida;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;360 Lleida;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;99 Lleida;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;261 Lleida;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;205 Lleida;Group 1402 Renal failure 5836-5837, 584-586;Men;124 Lleida;Group 1402 Renal failure 5836-5837, 584-586;Women;81 Lleida;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;471 Lleida;Group 1403 Urolithiasis 592, 594, 7880;Men;270 Lleida;Group 1403 Urolithiasis 592, 594, 7880;Women;201 Lleida;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;743 Lleida;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;416 Lleida;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;327 Lleida;Group 1405 Prostatic hyperplasia 600;Both sexes;341 Lleida;Group 1405 Prostatic hyperplasia 600;Men;341 Lleida;Group 1405 Prostatic hyperplasia 600;Women;.. Lleida;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;146 Lleida;Group 1406 Other diseases of the male genital organs 601-608;Men;146 Lleida;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Lleida;Group 1407 Disorders of breast 610-612;Both sexes;101 Lleida;Group 1407 Disorders of breast 610-612;Men;8 Lleida;Group 1407 Disorders of breast 610-612;Women;93 Lleida;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;60 Lleida;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Lleida;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;60 Lleida;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;35 Lleida;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Lleida;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;35 Lleida;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;338 Lleida;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;21 Lleida;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;317 Lleida;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;4.185 Lleida;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Lleida;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;4.185 Lleida;Group 1501 Legally induced abortion 635;Both sexes;33 Lleida;Group 1501 Legally induced abortion 635;Men;.. Lleida;Group 1501 Legally induced abortion 635;Women;33 Lleida;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;182 Lleida;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Lleida;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;182 Lleida;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;2.247 Lleida;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Lleida;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;2.247 Lleida;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;862 Lleida;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Lleida;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;862 Lleida;Group 1505 Single spontaneous delivery 650;Both sexes;373 Lleida;Group 1505 Single spontaneous delivery 650;Men;.. Lleida;Group 1505 Single spontaneous delivery 650;Women;373 Lleida;Group 1506 Other deliveries 6695-6697;Both sexes;68 Lleida;Group 1506 Other deliveries 6695-6697;Men;.. Lleida;Group 1506 Other deliveries 6695-6697;Women;68 Lleida;Group 1507 Complications related to the puerperium 670-676;Both sexes;60 Lleida;Group 1507 Complications related to the puerperium 670-676;Men;.. Lleida;Group 1507 Complications related to the puerperium 670-676;Women;60 Lleida;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;360 Lleida;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Lleida;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;360 Lleida;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;355 Lleida;Group 1600 Some disorders originating in the perinatal period 760-779;Men;208 Lleida;Group 1600 Some disorders originating in the perinatal period 760-779;Women;147 Lleida;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;86 Lleida;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;44 Lleida;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;42 Lleida;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;269 Lleida;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;164 Lleida;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;105 Lleida;Grupo 1700 Congenital abnormalities 740-759;Both sexes;71 Lleida;Grupo 1700 Congenital abnormalities 740-759;Men;33 Lleida;Grupo 1700 Congenital abnormalities 740-759;Women;38 Lleida;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.768 Lleida;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;977 Lleida;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;791 Lleida;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;149 Lleida;Group 1801 Pain in throat and chest 7841, 7865;Men;84 Lleida;Group 1801 Pain in throat and chest 7841, 7865;Women;65 Lleida;Group 1802 Abdominal pain 7890;Both sexes;254 Lleida;Group 1802 Abdominal pain 7890;Men;97 Lleida;Group 1802 Abdominal pain 7890;Women;157 Lleida;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;10 Lleida;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;3 Lleida;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;7 Lleida;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.355 Lleida;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;793 Lleida;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;562 Lleida;Group 1900 Injuries and poisoning 800-999;Both sexes;3.842 Lleida;Group 1900 Injuries and poisoning 800-999;Men;1.839 Lleida;Group 1900 Injuries and poisoning 800-999;Women;2.003 Lleida;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;358 Lleida;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;204 Lleida;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;154 Lleida;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;92 Lleida;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;66 Lleida;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;26 Lleida;Group 1903 Radius and ulna fracture 813;Both sexes;173 Lleida;Group 1903 Radius and ulna fracture 813;Men;95 Lleida;Group 1903 Radius and ulna fracture 813;Women;78 Lleida;Group 1904 Femur fracture 820-821;Both sexes;987 Lleida;Group 1904 Femur fracture 820-821;Men;281 Lleida;Group 1904 Femur fracture 820-821;Women;706 Lleida;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;224 Lleida;Group 1905 Leg fracture, including the ankle 823-824;Men;108 Lleida;Group 1905 Leg fracture, including the ankle 823-824;Women;116 Lleida;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.140 Lleida;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;656 Lleida;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;484 Lleida;Group 1907 Burns 940-949;Both sexes;13 Lleida;Group 1907 Burns 940-949;Men;6 Lleida;Group 1907 Burns 940-949;Women;7 Lleida;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;110 Lleida;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;50 Lleida;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;60 Lleida;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;656 Lleida;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;328 Lleida;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;328 Lleida;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;2 Lleida;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;2 Lleida;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Lleida;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;87 Lleida;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;43 Lleida;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;44 Lleida;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;433 Lleida;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;233 Lleida;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;200 Lleida;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;11 Lleida;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;8 Lleida;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;3 Lleida;Group 2102 Contraceptive management V25;Both sexes;13 Lleida;Group 2102 Contraceptive management V25;Men;1 Lleida;Group 2102 Contraceptive management V25;Women;12 Lleida;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Lleida;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Lleida;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Lleida;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;174 Lleida;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;115 Lleida;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;59 Lleida;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;235 Lleida;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;109 Lleida;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;126 Tarragona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;79.208 Tarragona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;37.521 Tarragona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;41.687 Tarragona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.190 Tarragona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;675 Tarragona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;515 Tarragona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;203 Tarragona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;105 Tarragona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;98 Tarragona;Group 0102 Imprecise intestinal infections 009;Both sexes;170 Tarragona;Group 0102 Imprecise intestinal infections 009;Men;90 Tarragona;Group 0102 Imprecise intestinal infections 009;Women;81 Tarragona;Group 0103 Tuberculosis 010-018, 137;Both sexes;60 Tarragona;Group 0103 Tuberculosis 010-018, 137;Men;38 Tarragona;Group 0103 Tuberculosis 010-018, 137;Women;22 Tarragona;Group 0104 Septicaemia 038;Both sexes;240 Tarragona;Group 0104 Septicaemia 038;Men;134 Tarragona;Group 0104 Septicaemia 038;Women;106 Tarragona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;83 Tarragona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;61 Tarragona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;21 Tarragona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;434 Tarragona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;248 Tarragona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;186 Tarragona;Group 0200 Neoplasms 140-239;Both sexes;7.225 Tarragona;Group 0200 Neoplasms 140-239;Men;4.135 Tarragona;Group 0200 Neoplasms 140-239;Women;3.091 Tarragona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;922 Tarragona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;604 Tarragona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;318 Tarragona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;755 Tarragona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;601 Tarragona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;153 Tarragona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;92 Tarragona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;66 Tarragona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;27 Tarragona;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;514 Tarragona;Group 0204 Malignant neoplasm of breast 174-175;Men;4 Tarragona;Group 0204 Malignant neoplasm of breast 174-175;Women;509 Tarragona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;159 Tarragona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Tarragona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;159 Tarragona;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;85 Tarragona;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Tarragona;Group 0206 Malignant neoplasm of ovary 1830;Women;85 Tarragona;Group 0207 Malignant neoplasm of prostate 185;Both sexes;230 Tarragona;Group 0207 Malignant neoplasm of prostate 185;Men;230 Tarragona;Group 0207 Malignant neoplasm of prostate 185;Women;.. Tarragona;Group 0208 Malignant neoplasm of bladder 188;Both sexes;992 Tarragona;Group 0208 Malignant neoplasm of bladder 188;Men;843 Tarragona;Group 0208 Malignant neoplasm of bladder 188;Women;149 Tarragona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.232 Tarragona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.358 Tarragona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;874 Tarragona;Group 0210 Carcinoma in situ 230-234;Both sexes;65 Tarragona;Group 0210 Carcinoma in situ 230-234;Men;27 Tarragona;Group 0210 Carcinoma in situ 230-234;Women;39 Tarragona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;91 Tarragona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;64 Tarragona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;27 Tarragona;Grupo 0212 Leiomyoma of uterus 218;Both sexes;360 Tarragona;Grupo 0212 Leiomyoma of uterus 218;Men;.. Tarragona;Grupo 0212 Leiomyoma of uterus 218;Women;360 Tarragona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;729 Tarragona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;338 Tarragona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;391 Tarragona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;700 Tarragona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;348 Tarragona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;352 Tarragona;Group 0301 Anaemias 280-285;Both sexes;504 Tarragona;Group 0301 Anaemias 280-285;Men;252 Tarragona;Group 0301 Anaemias 280-285;Women;252 Tarragona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;196 Tarragona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;96 Tarragona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;100 Tarragona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.175 Tarragona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;480 Tarragona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;695 Tarragona;Group 0401 Diabetes mellitus 249-250;Both sexes;402 Tarragona;Group 0401 Diabetes mellitus 249-250;Men;227 Tarragona;Group 0401 Diabetes mellitus 249-250;Women;175 Tarragona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;774 Tarragona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;254 Tarragona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;520 Tarragona;Group 0500 Mental disorders 290-319;Both sexes;2.518 Tarragona;Group 0500 Mental disorders 290-319;Men;1.362 Tarragona;Group 0500 Mental disorders 290-319;Women;1.156 Tarragona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;190 Tarragona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;70 Tarragona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;120 Tarragona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;132 Tarragona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;97 Tarragona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;34 Tarragona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;97 Tarragona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;73 Tarragona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;24 Tarragona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;664 Tarragona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;445 Tarragona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;218 Tarragona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;480 Tarragona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;215 Tarragona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;265 Tarragona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;955 Tarragona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;461 Tarragona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;494 Tarragona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.191 Tarragona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;568 Tarragona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;622 Tarragona;Group 0601 Alzheimer's disease 3310;Both sexes;87 Tarragona;Group 0601 Alzheimer's disease 3310;Men;26 Tarragona;Group 0601 Alzheimer's disease 3310;Women;61 Tarragona;Group 0602 Multiple sclerosis 340;Both sexes;31 Tarragona;Group 0602 Multiple sclerosis 340;Men;8 Tarragona;Group 0602 Multiple sclerosis 340;Women;23 Tarragona;Group 0603 Epilepsy 345;Both sexes;177 Tarragona;Group 0603 Epilepsy 345;Men;99 Tarragona;Group 0603 Epilepsy 345;Women;79 Tarragona;Group 0604 Transient cerebral ischemia 435;Both sexes;204 Tarragona;Group 0604 Transient cerebral ischemia 435;Men;108 Tarragona;Group 0604 Transient cerebral ischemia 435;Women;96 Tarragona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;691 Tarragona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;327 Tarragona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;364 Tarragona;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;323 Tarragona;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;146 Tarragona;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;177 Tarragona;Grupo 0701 Cataract 366;Both sexes;188 Tarragona;Grupo 0701 Cataract 366;Men;78 Tarragona;Grupo 0701 Cataract 366;Women;110 Tarragona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;135 Tarragona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;68 Tarragona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;67 Tarragona;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;443 Tarragona;Group 0800 Diseases of the ear and the mastoid 380-389;Men;210 Tarragona;Group 0800 Diseases of the ear and the mastoid 380-389;Women;233 Tarragona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;9.676 Tarragona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5.474 Tarragona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4.201 Tarragona;Group 0901 Hypertensive disease 401-405;Both sexes;203 Tarragona;Group 0901 Hypertensive disease 401-405;Men;102 Tarragona;Group 0901 Hypertensive disease 401-405;Women;101 Tarragona;Group 0902 Angina pectoris 4111, 413;Both sexes;442 Tarragona;Group 0902 Angina pectoris 4111, 413;Men;291 Tarragona;Group 0902 Angina pectoris 4111, 413;Women;151 Tarragona;Group 0903 Acute myocardial infarction 410;Both sexes;1.073 Tarragona;Group 0903 Acute myocardial infarction 410;Men;769 Tarragona;Group 0903 Acute myocardial infarction 410;Women;305 Tarragona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;466 Tarragona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;349 Tarragona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;117 Tarragona;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;293 Tarragona;Group 0905 Diseases of the lungs circulation 415-417;Men;146 Tarragona;Group 0905 Diseases of the lungs circulation 415-417;Women;147 Tarragona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.231 Tarragona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;672 Tarragona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;559 Tarragona;Grupo 0907 Heart failure 428;Both sexes;2.396 Tarragona;Grupo 0907 Heart failure 428;Men;1.148 Tarragona;Grupo 0907 Heart failure 428;Women;1.248 Tarragona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.840 Tarragona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;975 Tarragona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;864 Tarragona;Grupo 0909 Atherosclerosis 440;Both sexes;343 Tarragona;Grupo 0909 Atherosclerosis 440;Men;265 Tarragona;Grupo 0909 Atherosclerosis 440;Women;78 Tarragona;Group 0910 Varicose veins of lower extremities 454;Both sexes;240 Tarragona;Group 0910 Varicose veins of lower extremities 454;Men;98 Tarragona;Group 0910 Varicose veins of lower extremities 454;Women;142 Tarragona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.148 Tarragona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;660 Tarragona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;489 Tarragona;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;10.259 Tarragona;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;5.835 Tarragona;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;4.424 Tarragona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;489 Tarragona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;264 Tarragona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;224 Tarragona;Group 1002 Pneumonia 480-486;Both sexes;2.376 Tarragona;Group 1002 Pneumonia 480-486;Men;1.419 Tarragona;Group 1002 Pneumonia 480-486;Women;957 Tarragona;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2.117 Tarragona;Group 1003 Acute bronchitis and bronchiolitis 466;Men;997 Tarragona;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.120 Tarragona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;459 Tarragona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;234 Tarragona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;225 Tarragona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;671 Tarragona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;408 Tarragona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;263 Tarragona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.950 Tarragona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.417 Tarragona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;533 Tarragona;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;466 Tarragona;Group 1007 Asthma 4930-4931,4938-4939;Men;120 Tarragona;Group 1007 Asthma 4930-4931,4938-4939;Women;346 Tarragona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.732 Tarragona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;976 Tarragona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;756 Tarragona;Group 1100 Diseases of the digestive system 520-579;Both sexes;10.435 Tarragona;Group 1100 Diseases of the digestive system 520-579;Men;5.732 Tarragona;Group 1100 Diseases of the digestive system 520-579;Women;4.703 Tarragona;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;328 Tarragona;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;162 Tarragona;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;167 Tarragona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;101 Tarragona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;58 Tarragona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;42 Tarragona;Group 1103 Diseases of the esophagus 530;Both sexes;135 Tarragona;Group 1103 Diseases of the esophagus 530;Men;85 Tarragona;Group 1103 Diseases of the esophagus 530;Women;50 Tarragona;Group 1104 Peptic ulcer 531-534;Both sexes;176 Tarragona;Group 1104 Peptic ulcer 531-534;Men;128 Tarragona;Group 1104 Peptic ulcer 531-534;Women;48 Tarragona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;217 Tarragona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;102 Tarragona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;115 Tarragona;Group 1106 Appendicitis 540-543;Both sexes;755 Tarragona;Group 1106 Appendicitis 540-543;Men;430 Tarragona;Group 1106 Appendicitis 540-543;Women;324 Tarragona;Group 1107 Inguinal hernia 550;Both sexes;1.254 Tarragona;Group 1107 Inguinal hernia 550;Men;1.108 Tarragona;Group 1107 Inguinal hernia 550;Women;146 Tarragona;Group 1108 Other abdominal hernia 551-553;Both sexes;916 Tarragona;Group 1108 Other abdominal hernia 551-553;Men;382 Tarragona;Group 1108 Other abdominal hernia 551-553;Women;534 Tarragona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;148 Tarragona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;74 Tarragona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;74 Tarragona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;499 Tarragona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;242 Tarragona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;257 Tarragona;Group 1111 Intestinal obstruction without hernia 560;Both sexes;535 Tarragona;Group 1111 Intestinal obstruction without hernia 560;Men;260 Tarragona;Group 1111 Intestinal obstruction without hernia 560;Women;276 Tarragona;Group 1112 Intestinal diverticulosis 562;Both sexes;392 Tarragona;Group 1112 Intestinal diverticulosis 562;Men;195 Tarragona;Group 1112 Intestinal diverticulosis 562;Women;198 Tarragona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;776 Tarragona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;467 Tarragona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;308 Tarragona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;287 Tarragona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;142 Tarragona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;145 Tarragona;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;189 Tarragona;Group 1115 Alcoholic hepatitis 5710-5713;Men;165 Tarragona;Group 1115 Alcoholic hepatitis 5710-5713;Women;24 Tarragona;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;320 Tarragona;Group 1116 Other diseases of the liver 570,5714-573;Men;172 Tarragona;Group 1116 Other diseases of the liver 570,5714-573;Women;148 Tarragona;Group 1117 Cholelithiasis 574;Both sexes;1.957 Tarragona;Group 1117 Cholelithiasis 574;Men;774 Tarragona;Group 1117 Cholelithiasis 574;Women;1.183 Tarragona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;461 Tarragona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;255 Tarragona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;206 Tarragona;Group 1119 Pancreatic diseases 577;Both sexes;584 Tarragona;Group 1119 Pancreatic diseases 577;Men;322 Tarragona;Group 1119 Pancreatic diseases 577;Women;262 Tarragona;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;405 Tarragona;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;209 Tarragona;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;196 Tarragona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;868 Tarragona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;468 Tarragona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;399 Tarragona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;624 Tarragona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;334 Tarragona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;289 Tarragona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;38 Tarragona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;24 Tarragona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;13 Tarragona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;206 Tarragona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;109 Tarragona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;97 Tarragona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;5.940 Tarragona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.695 Tarragona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.245 Tarragona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Tarragona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Tarragona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Tarragona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Tarragona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Tarragona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Tarragona;Group 1303 Internal derangement of knee 717;Both sexes;832 Tarragona;Group 1303 Internal derangement of knee 717;Men;523 Tarragona;Group 1303 Internal derangement of knee 717;Women;309 Tarragona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.803 Tarragona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.180 Tarragona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.623 Tarragona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;72 Tarragona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;29 Tarragona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;43 Tarragona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;187 Tarragona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;101 Tarragona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;86 Tarragona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;281 Tarragona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;143 Tarragona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;138 Tarragona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;193 Tarragona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;82 Tarragona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;112 Tarragona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;773 Tarragona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;361 Tarragona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;412 Tarragona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;800 Tarragona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;277 Tarragona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;523 Tarragona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;5.650 Tarragona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.526 Tarragona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3.124 Tarragona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;651 Tarragona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;191 Tarragona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;460 Tarragona;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;482 Tarragona;Group 1402 Renal failure 5836-5837, 584-586;Men;289 Tarragona;Group 1402 Renal failure 5836-5837, 584-586;Women;193 Tarragona;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;730 Tarragona;Group 1403 Urolithiasis 592, 594, 7880;Men;457 Tarragona;Group 1403 Urolithiasis 592, 594, 7880;Women;273 Tarragona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.493 Tarragona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;690 Tarragona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;803 Tarragona;Group 1405 Prostatic hyperplasia 600;Both sexes;443 Tarragona;Group 1405 Prostatic hyperplasia 600;Men;443 Tarragona;Group 1405 Prostatic hyperplasia 600;Women;.. Tarragona;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;441 Tarragona;Group 1406 Other diseases of the male genital organs 601-608;Men;441 Tarragona;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Tarragona;Group 1407 Disorders of breast 610-612;Both sexes;183 Tarragona;Group 1407 Disorders of breast 610-612;Men;9 Tarragona;Group 1407 Disorders of breast 610-612;Women;173 Tarragona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;145 Tarragona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Tarragona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;145 Tarragona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;90 Tarragona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Tarragona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;90 Tarragona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;993 Tarragona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;6 Tarragona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;986 Tarragona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;8.139 Tarragona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Tarragona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;8.139 Tarragona;Group 1501 Legally induced abortion 635;Both sexes;26 Tarragona;Group 1501 Legally induced abortion 635;Men;.. Tarragona;Group 1501 Legally induced abortion 635;Women;26 Tarragona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;427 Tarragona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Tarragona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;427 Tarragona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.506 Tarragona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Tarragona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.506 Tarragona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.951 Tarragona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Tarragona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.951 Tarragona;Group 1505 Single spontaneous delivery 650;Both sexes;1.264 Tarragona;Group 1505 Single spontaneous delivery 650;Men;.. Tarragona;Group 1505 Single spontaneous delivery 650;Women;1.264 Tarragona;Group 1506 Other deliveries 6695-6697;Both sexes;114 Tarragona;Group 1506 Other deliveries 6695-6697;Men;.. Tarragona;Group 1506 Other deliveries 6695-6697;Women;114 Tarragona;Group 1507 Complications related to the puerperium 670-676;Both sexes;142 Tarragona;Group 1507 Complications related to the puerperium 670-676;Men;.. Tarragona;Group 1507 Complications related to the puerperium 670-676;Women;142 Tarragona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;710 Tarragona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Tarragona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;710 Tarragona;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.171 Tarragona;Group 1600 Some disorders originating in the perinatal period 760-779;Men;618 Tarragona;Group 1600 Some disorders originating in the perinatal period 760-779;Women;553 Tarragona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;380 Tarragona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;216 Tarragona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;164 Tarragona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;791 Tarragona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;402 Tarragona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;389 Tarragona;Grupo 1700 Congenital abnormalities 740-759;Both sexes;491 Tarragona;Grupo 1700 Congenital abnormalities 740-759;Men;294 Tarragona;Grupo 1700 Congenital abnormalities 740-759;Women;197 Tarragona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;3.481 Tarragona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.980 Tarragona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.502 Tarragona;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;410 Tarragona;Group 1801 Pain in throat and chest 7841, 7865;Men;232 Tarragona;Group 1801 Pain in throat and chest 7841, 7865;Women;178 Tarragona;Group 1802 Abdominal pain 7890;Both sexes;475 Tarragona;Group 1802 Abdominal pain 7890;Men;186 Tarragona;Group 1802 Abdominal pain 7890;Women;289 Tarragona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;3 Tarragona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;2 Tarragona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;1 Tarragona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;2.594 Tarragona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.560 Tarragona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.034 Tarragona;Group 1900 Injuries and poisoning 800-999;Both sexes;7.088 Tarragona;Group 1900 Injuries and poisoning 800-999;Men;3.353 Tarragona;Group 1900 Injuries and poisoning 800-999;Women;3.735 Tarragona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;509 Tarragona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;286 Tarragona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;222 Tarragona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;188 Tarragona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;123 Tarragona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;64 Tarragona;Group 1903 Radius and ulna fracture 813;Both sexes;452 Tarragona;Group 1903 Radius and ulna fracture 813;Men;231 Tarragona;Group 1903 Radius and ulna fracture 813;Women;221 Tarragona;Group 1904 Femur fracture 820-821;Both sexes;1.538 Tarragona;Group 1904 Femur fracture 820-821;Men;419 Tarragona;Group 1904 Femur fracture 820-821;Women;1.119 Tarragona;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;469 Tarragona;Group 1905 Leg fracture, including the ankle 823-824;Men;249 Tarragona;Group 1905 Leg fracture, including the ankle 823-824;Women;220 Tarragona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2.055 Tarragona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.078 Tarragona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;977 Tarragona;Group 1907 Burns 940-949;Both sexes;20 Tarragona;Group 1907 Burns 940-949;Men;9 Tarragona;Group 1907 Burns 940-949;Women;11 Tarragona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;204 Tarragona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;100 Tarragona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;104 Tarragona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.388 Tarragona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;711 Tarragona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;677 Tarragona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;27 Tarragona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;17 Tarragona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;9 Tarragona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;240 Tarragona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;129 Tarragona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;111 Tarragona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.245 Tarragona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;622 Tarragona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;623 Tarragona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;11 Tarragona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;10 Tarragona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;1 Tarragona;Group 2102 Contraceptive management V25;Both sexes;99 Tarragona;Group 2102 Contraceptive management V25;Men;4 Tarragona;Group 2102 Contraceptive management V25;Women;95 Tarragona;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Tarragona;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Tarragona;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Tarragona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;314 Tarragona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;200 Tarragona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;114 Tarragona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;821 Tarragona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;408 Tarragona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;414 COMUNITAT VALENCIANA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;508.486 COMUNITAT VALENCIANA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;241.981 COMUNITAT VALENCIANA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;266.505 COMUNITAT VALENCIANA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;11.551 COMUNITAT VALENCIANA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;6.317 COMUNITAT VALENCIANA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;5.234 COMUNITAT VALENCIANA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;1.813 COMUNITAT VALENCIANA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;963 COMUNITAT VALENCIANA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;850 COMUNITAT VALENCIANA;Group 0102 Imprecise intestinal infections 009;Both sexes;1.158 COMUNITAT VALENCIANA;Group 0102 Imprecise intestinal infections 009;Men;588 COMUNITAT VALENCIANA;Group 0102 Imprecise intestinal infections 009;Women;570 COMUNITAT VALENCIANA;Group 0103 Tuberculosis 010-018, 137;Both sexes;360 COMUNITAT VALENCIANA;Group 0103 Tuberculosis 010-018, 137;Men;238 COMUNITAT VALENCIANA;Group 0103 Tuberculosis 010-018, 137;Women;122 COMUNITAT VALENCIANA;Group 0104 Septicaemia 038;Both sexes;4.261 COMUNITAT VALENCIANA;Group 0104 Septicaemia 038;Men;2.256 COMUNITAT VALENCIANA;Group 0104 Septicaemia 038;Women;2.005 COMUNITAT VALENCIANA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;404 COMUNITAT VALENCIANA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;267 COMUNITAT VALENCIANA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;137 COMUNITAT VALENCIANA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;3.555 COMUNITAT VALENCIANA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;2.005 COMUNITAT VALENCIANA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;1.550 COMUNITAT VALENCIANA;Group 0200 Neoplasms 140-239;Both sexes;51.274 COMUNITAT VALENCIANA;Group 0200 Neoplasms 140-239;Men;27.059 COMUNITAT VALENCIANA;Group 0200 Neoplasms 140-239;Women;24.215 COMUNITAT VALENCIANA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;5.396 COMUNITAT VALENCIANA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;3.170 COMUNITAT VALENCIANA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;2.226 COMUNITAT VALENCIANA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;4.268 COMUNITAT VALENCIANA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;3.347 COMUNITAT VALENCIANA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;921 COMUNITAT VALENCIANA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;738 COMUNITAT VALENCIANA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;437 COMUNITAT VALENCIANA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;301 COMUNITAT VALENCIANA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;4.294 COMUNITAT VALENCIANA;Group 0204 Malignant neoplasm of breast 174-175;Men;35 COMUNITAT VALENCIANA;Group 0204 Malignant neoplasm of breast 174-175;Women;4.259 COMUNITAT VALENCIANA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1.115 COMUNITAT VALENCIANA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. COMUNITAT VALENCIANA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1.115 COMUNITAT VALENCIANA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;668 COMUNITAT VALENCIANA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. COMUNITAT VALENCIANA;Group 0206 Malignant neoplasm of ovary 1830;Women;668 COMUNITAT VALENCIANA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1.884 COMUNITAT VALENCIANA;Group 0207 Malignant neoplasm of prostate 185;Men;1.884 COMUNITAT VALENCIANA;Group 0207 Malignant neoplasm of prostate 185;Women;.. COMUNITAT VALENCIANA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;5.531 COMUNITAT VALENCIANA;Group 0208 Malignant neoplasm of bladder 188;Men;4.686 COMUNITAT VALENCIANA;Group 0208 Malignant neoplasm of bladder 188;Women;845 COMUNITAT VALENCIANA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;16.364 COMUNITAT VALENCIANA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;9.801 COMUNITAT VALENCIANA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;6.563 COMUNITAT VALENCIANA;Group 0210 Carcinoma in situ 230-234;Both sexes;745 COMUNITAT VALENCIANA;Group 0210 Carcinoma in situ 230-234;Men;203 COMUNITAT VALENCIANA;Group 0210 Carcinoma in situ 230-234;Women;542 COMUNITAT VALENCIANA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;685 COMUNITAT VALENCIANA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;413 COMUNITAT VALENCIANA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;272 COMUNITAT VALENCIANA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;2.791 COMUNITAT VALENCIANA;Grupo 0212 Leiomyoma of uterus 218;Men;.. COMUNITAT VALENCIANA;Grupo 0212 Leiomyoma of uterus 218;Women;2.791 COMUNITAT VALENCIANA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;6.795 COMUNITAT VALENCIANA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;3.083 COMUNITAT VALENCIANA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;3.712 COMUNITAT VALENCIANA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;4.406 COMUNITAT VALENCIANA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;2.158 COMUNITAT VALENCIANA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;2.248 COMUNITAT VALENCIANA;Group 0301 Anaemias 280-285;Both sexes;2.306 COMUNITAT VALENCIANA;Group 0301 Anaemias 280-285;Men;1.070 COMUNITAT VALENCIANA;Group 0301 Anaemias 280-285;Women;1.236 COMUNITAT VALENCIANA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;2.100 COMUNITAT VALENCIANA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;1.088 COMUNITAT VALENCIANA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;1.012 COMUNITAT VALENCIANA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;10.054 COMUNITAT VALENCIANA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;4.031 COMUNITAT VALENCIANA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;6.023 COMUNITAT VALENCIANA;Group 0401 Diabetes mellitus 249-250;Both sexes;3.363 COMUNITAT VALENCIANA;Group 0401 Diabetes mellitus 249-250;Men;1.977 COMUNITAT VALENCIANA;Group 0401 Diabetes mellitus 249-250;Women;1.386 COMUNITAT VALENCIANA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;6.691 COMUNITAT VALENCIANA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;2.054 COMUNITAT VALENCIANA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;4.637 COMUNITAT VALENCIANA;Group 0500 Mental disorders 290-319;Both sexes;10.780 COMUNITAT VALENCIANA;Group 0500 Mental disorders 290-319;Men;5.648 COMUNITAT VALENCIANA;Group 0500 Mental disorders 290-319;Women;5.132 COMUNITAT VALENCIANA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;305 COMUNITAT VALENCIANA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;147 COMUNITAT VALENCIANA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;158 COMUNITAT VALENCIANA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;768 COMUNITAT VALENCIANA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;593 COMUNITAT VALENCIANA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;175 COMUNITAT VALENCIANA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;636 COMUNITAT VALENCIANA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;456 COMUNITAT VALENCIANA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;180 COMUNITAT VALENCIANA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;3.172 COMUNITAT VALENCIANA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;1.937 COMUNITAT VALENCIANA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;1.235 COMUNITAT VALENCIANA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;2.343 COMUNITAT VALENCIANA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;988 COMUNITAT VALENCIANA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;1.355 COMUNITAT VALENCIANA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;3.556 COMUNITAT VALENCIANA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;1.527 COMUNITAT VALENCIANA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;2.029 COMUNITAT VALENCIANA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;12.219 COMUNITAT VALENCIANA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;6.231 COMUNITAT VALENCIANA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;5.988 COMUNITAT VALENCIANA;Group 0601 Alzheimer's disease 3310;Both sexes;190 COMUNITAT VALENCIANA;Group 0601 Alzheimer's disease 3310;Men;69 COMUNITAT VALENCIANA;Group 0601 Alzheimer's disease 3310;Women;121 COMUNITAT VALENCIANA;Group 0602 Multiple sclerosis 340;Both sexes;267 COMUNITAT VALENCIANA;Group 0602 Multiple sclerosis 340;Men;74 COMUNITAT VALENCIANA;Group 0602 Multiple sclerosis 340;Women;193 COMUNITAT VALENCIANA;Group 0603 Epilepsy 345;Both sexes;2.692 COMUNITAT VALENCIANA;Group 0603 Epilepsy 345;Men;1.488 COMUNITAT VALENCIANA;Group 0603 Epilepsy 345;Women;1.204 COMUNITAT VALENCIANA;Group 0604 Transient cerebral ischemia 435;Both sexes;1.922 COMUNITAT VALENCIANA;Group 0604 Transient cerebral ischemia 435;Men;991 COMUNITAT VALENCIANA;Group 0604 Transient cerebral ischemia 435;Women;931 COMUNITAT VALENCIANA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;7.148 COMUNITAT VALENCIANA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;3.609 COMUNITAT VALENCIANA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;3.539 COMUNITAT VALENCIANA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;2.628 COMUNITAT VALENCIANA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;1.434 COMUNITAT VALENCIANA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;1.194 COMUNITAT VALENCIANA;Grupo 0701 Cataract 366;Both sexes;307 COMUNITAT VALENCIANA;Grupo 0701 Cataract 366;Men;153 COMUNITAT VALENCIANA;Grupo 0701 Cataract 366;Women;154 COMUNITAT VALENCIANA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;2.321 COMUNITAT VALENCIANA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;1.281 COMUNITAT VALENCIANA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;1.040 COMUNITAT VALENCIANA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;2.435 COMUNITAT VALENCIANA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1.164 COMUNITAT VALENCIANA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;1.271 COMUNITAT VALENCIANA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;65.521 COMUNITAT VALENCIANA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;37.092 COMUNITAT VALENCIANA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;28.429 COMUNITAT VALENCIANA;Group 0901 Hypertensive disease 401-405;Both sexes;2.141 COMUNITAT VALENCIANA;Group 0901 Hypertensive disease 401-405;Men;1.048 COMUNITAT VALENCIANA;Group 0901 Hypertensive disease 401-405;Women;1.093 COMUNITAT VALENCIANA;Group 0902 Angina pectoris 4111, 413;Both sexes;3.439 COMUNITAT VALENCIANA;Group 0902 Angina pectoris 4111, 413;Men;2.174 COMUNITAT VALENCIANA;Group 0902 Angina pectoris 4111, 413;Women;1.265 COMUNITAT VALENCIANA;Group 0903 Acute myocardial infarction 410;Both sexes;5.857 COMUNITAT VALENCIANA;Group 0903 Acute myocardial infarction 410;Men;4.211 COMUNITAT VALENCIANA;Group 0903 Acute myocardial infarction 410;Women;1.646 COMUNITAT VALENCIANA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;4.372 COMUNITAT VALENCIANA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;3.258 COMUNITAT VALENCIANA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1.114 COMUNITAT VALENCIANA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;2.057 COMUNITAT VALENCIANA;Group 0905 Diseases of the lungs circulation 415-417;Men;944 COMUNITAT VALENCIANA;Group 0905 Diseases of the lungs circulation 415-417;Women;1.113 COMUNITAT VALENCIANA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;8.815 COMUNITAT VALENCIANA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;4.704 COMUNITAT VALENCIANA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;4.111 COMUNITAT VALENCIANA;Grupo 0907 Heart failure 428;Both sexes;13.062 COMUNITAT VALENCIANA;Grupo 0907 Heart failure 428;Men;6.078 COMUNITAT VALENCIANA;Grupo 0907 Heart failure 428;Women;6.984 COMUNITAT VALENCIANA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;11.930 COMUNITAT VALENCIANA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;6.602 COMUNITAT VALENCIANA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;5.328 COMUNITAT VALENCIANA;Grupo 0909 Atherosclerosis 440;Both sexes;1.595 COMUNITAT VALENCIANA;Grupo 0909 Atherosclerosis 440;Men;1.213 COMUNITAT VALENCIANA;Grupo 0909 Atherosclerosis 440;Women;382 COMUNITAT VALENCIANA;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.399 COMUNITAT VALENCIANA;Group 0910 Varicose veins of lower extremities 454;Men;504 COMUNITAT VALENCIANA;Group 0910 Varicose veins of lower extremities 454;Women;895 COMUNITAT VALENCIANA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;10.854 COMUNITAT VALENCIANA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;6.356 COMUNITAT VALENCIANA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;4.498 COMUNITAT VALENCIANA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;55.370 COMUNITAT VALENCIANA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;31.711 COMUNITAT VALENCIANA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;23.659 COMUNITAT VALENCIANA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;3.433 COMUNITAT VALENCIANA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;1.822 COMUNITAT VALENCIANA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;1.611 COMUNITAT VALENCIANA;Group 1002 Pneumonia 480-486;Both sexes;13.107 COMUNITAT VALENCIANA;Group 1002 Pneumonia 480-486;Men;7.634 COMUNITAT VALENCIANA;Group 1002 Pneumonia 480-486;Women;5.473 COMUNITAT VALENCIANA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;5.348 COMUNITAT VALENCIANA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;2.683 COMUNITAT VALENCIANA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;2.665 COMUNITAT VALENCIANA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;3.877 COMUNITAT VALENCIANA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;2.116 COMUNITAT VALENCIANA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1.761 COMUNITAT VALENCIANA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;3.722 COMUNITAT VALENCIANA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;2.300 COMUNITAT VALENCIANA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;1.422 COMUNITAT VALENCIANA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;8.060 COMUNITAT VALENCIANA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;6.154 COMUNITAT VALENCIANA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1.906 COMUNITAT VALENCIANA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1.779 COMUNITAT VALENCIANA;Group 1007 Asthma 4930-4931,4938-4939;Men;481 COMUNITAT VALENCIANA;Group 1007 Asthma 4930-4931,4938-4939;Women;1.298 COMUNITAT VALENCIANA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;16.044 COMUNITAT VALENCIANA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;8.521 COMUNITAT VALENCIANA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;7.523 COMUNITAT VALENCIANA;Group 1100 Diseases of the digestive system 520-579;Both sexes;64.148 COMUNITAT VALENCIANA;Group 1100 Diseases of the digestive system 520-579;Men;35.546 COMUNITAT VALENCIANA;Group 1100 Diseases of the digestive system 520-579;Women;28.602 COMUNITAT VALENCIANA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;1.202 COMUNITAT VALENCIANA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;551 COMUNITAT VALENCIANA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;651 COMUNITAT VALENCIANA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;908 COMUNITAT VALENCIANA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;499 COMUNITAT VALENCIANA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;409 COMUNITAT VALENCIANA;Group 1103 Diseases of the esophagus 530;Both sexes;1.240 COMUNITAT VALENCIANA;Group 1103 Diseases of the esophagus 530;Men;759 COMUNITAT VALENCIANA;Group 1103 Diseases of the esophagus 530;Women;481 COMUNITAT VALENCIANA;Group 1104 Peptic ulcer 531-534;Both sexes;1.485 COMUNITAT VALENCIANA;Group 1104 Peptic ulcer 531-534;Men;1.041 COMUNITAT VALENCIANA;Group 1104 Peptic ulcer 531-534;Women;444 COMUNITAT VALENCIANA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;1.884 COMUNITAT VALENCIANA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;907 COMUNITAT VALENCIANA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;977 COMUNITAT VALENCIANA;Group 1106 Appendicitis 540-543;Both sexes;5.480 COMUNITAT VALENCIANA;Group 1106 Appendicitis 540-543;Men;3.093 COMUNITAT VALENCIANA;Group 1106 Appendicitis 540-543;Women;2.387 COMUNITAT VALENCIANA;Group 1107 Inguinal hernia 550;Both sexes;5.962 COMUNITAT VALENCIANA;Group 1107 Inguinal hernia 550;Men;5.252 COMUNITAT VALENCIANA;Group 1107 Inguinal hernia 550;Women;710 COMUNITAT VALENCIANA;Group 1108 Other abdominal hernia 551-553;Both sexes;5.144 COMUNITAT VALENCIANA;Group 1108 Other abdominal hernia 551-553;Men;2.469 COMUNITAT VALENCIANA;Group 1108 Other abdominal hernia 551-553;Women;2.675 COMUNITAT VALENCIANA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;1.473 COMUNITAT VALENCIANA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;729 COMUNITAT VALENCIANA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;744 COMUNITAT VALENCIANA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;3.786 COMUNITAT VALENCIANA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;1.741 COMUNITAT VALENCIANA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;2.045 COMUNITAT VALENCIANA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;2.810 COMUNITAT VALENCIANA;Group 1111 Intestinal obstruction without hernia 560;Men;1.446 COMUNITAT VALENCIANA;Group 1111 Intestinal obstruction without hernia 560;Women;1.364 COMUNITAT VALENCIANA;Group 1112 Intestinal diverticulosis 562;Both sexes;2.515 COMUNITAT VALENCIANA;Group 1112 Intestinal diverticulosis 562;Men;1.236 COMUNITAT VALENCIANA;Group 1112 Intestinal diverticulosis 562;Women;1.279 COMUNITAT VALENCIANA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;3.892 COMUNITAT VALENCIANA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;2.467 COMUNITAT VALENCIANA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;1.425 COMUNITAT VALENCIANA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;2.030 COMUNITAT VALENCIANA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;897 COMUNITAT VALENCIANA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1.133 COMUNITAT VALENCIANA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1.042 COMUNITAT VALENCIANA;Group 1115 Alcoholic hepatitis 5710-5713;Men;890 COMUNITAT VALENCIANA;Group 1115 Alcoholic hepatitis 5710-5713;Women;152 COMUNITAT VALENCIANA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;2.523 COMUNITAT VALENCIANA;Group 1116 Other diseases of the liver 570,5714-573;Men;1.513 COMUNITAT VALENCIANA;Group 1116 Other diseases of the liver 570,5714-573;Women;1.010 COMUNITAT VALENCIANA;Group 1117 Cholelithiasis 574;Both sexes;10.550 COMUNITAT VALENCIANA;Group 1117 Cholelithiasis 574;Men;4.332 COMUNITAT VALENCIANA;Group 1117 Cholelithiasis 574;Women;6.218 COMUNITAT VALENCIANA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;3.408 COMUNITAT VALENCIANA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;1.844 COMUNITAT VALENCIANA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;1.564 COMUNITAT VALENCIANA;Group 1119 Pancreatic diseases 577;Both sexes;3.516 COMUNITAT VALENCIANA;Group 1119 Pancreatic diseases 577;Men;2.029 COMUNITAT VALENCIANA;Group 1119 Pancreatic diseases 577;Women;1.487 COMUNITAT VALENCIANA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;3.298 COMUNITAT VALENCIANA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1.851 COMUNITAT VALENCIANA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1.447 COMUNITAT VALENCIANA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;4.936 COMUNITAT VALENCIANA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;2.799 COMUNITAT VALENCIANA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;2.137 COMUNITAT VALENCIANA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;3.249 COMUNITAT VALENCIANA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;1.986 COMUNITAT VALENCIANA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;1.263 COMUNITAT VALENCIANA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;190 COMUNITAT VALENCIANA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;97 COMUNITAT VALENCIANA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;93 COMUNITAT VALENCIANA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;1.497 COMUNITAT VALENCIANA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;716 COMUNITAT VALENCIANA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;781 COMUNITAT VALENCIANA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;35.732 COMUNITAT VALENCIANA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;17.960 COMUNITAT VALENCIANA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;17.772 COMUNITAT VALENCIANA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. COMUNITAT VALENCIANA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. COMUNITAT VALENCIANA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. COMUNITAT VALENCIANA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. COMUNITAT VALENCIANA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. COMUNITAT VALENCIANA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. COMUNITAT VALENCIANA;Group 1303 Internal derangement of knee 717;Both sexes;5.773 COMUNITAT VALENCIANA;Group 1303 Internal derangement of knee 717;Men;4.098 COMUNITAT VALENCIANA;Group 1303 Internal derangement of knee 717;Women;1.675 COMUNITAT VALENCIANA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;11.977 COMUNITAT VALENCIANA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;5.252 COMUNITAT VALENCIANA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;6.725 COMUNITAT VALENCIANA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;623 COMUNITAT VALENCIANA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;241 COMUNITAT VALENCIANA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;382 COMUNITAT VALENCIANA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;2.064 COMUNITAT VALENCIANA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1.053 COMUNITAT VALENCIANA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1.011 COMUNITAT VALENCIANA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;3.174 COMUNITAT VALENCIANA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;1.721 COMUNITAT VALENCIANA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;1.453 COMUNITAT VALENCIANA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;817 COMUNITAT VALENCIANA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;389 COMUNITAT VALENCIANA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;428 COMUNITAT VALENCIANA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;5.531 COMUNITAT VALENCIANA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;2.943 COMUNITAT VALENCIANA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;2.588 COMUNITAT VALENCIANA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;5.773 COMUNITAT VALENCIANA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;2.263 COMUNITAT VALENCIANA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;3.510 COMUNITAT VALENCIANA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;35.032 COMUNITAT VALENCIANA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;15.784 COMUNITAT VALENCIANA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;19.248 COMUNITAT VALENCIANA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;3.625 COMUNITAT VALENCIANA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;1.258 COMUNITAT VALENCIANA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;2.367 COMUNITAT VALENCIANA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;2.960 COMUNITAT VALENCIANA;Group 1402 Renal failure 5836-5837, 584-586;Men;1.776 COMUNITAT VALENCIANA;Group 1402 Renal failure 5836-5837, 584-586;Women;1.184 COMUNITAT VALENCIANA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;4.480 COMUNITAT VALENCIANA;Group 1403 Urolithiasis 592, 594, 7880;Men;2.656 COMUNITAT VALENCIANA;Group 1403 Urolithiasis 592, 594, 7880;Women;1.824 COMUNITAT VALENCIANA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;9.563 COMUNITAT VALENCIANA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;4.849 COMUNITAT VALENCIANA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;4.714 COMUNITAT VALENCIANA;Group 1405 Prostatic hyperplasia 600;Both sexes;2.862 COMUNITAT VALENCIANA;Group 1405 Prostatic hyperplasia 600;Men;2.862 COMUNITAT VALENCIANA;Group 1405 Prostatic hyperplasia 600;Women;.. COMUNITAT VALENCIANA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;2.133 COMUNITAT VALENCIANA;Group 1406 Other diseases of the male genital organs 601-608;Men;2.133 COMUNITAT VALENCIANA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. COMUNITAT VALENCIANA;Group 1407 Disorders of breast 610-612;Both sexes;2.657 COMUNITAT VALENCIANA;Group 1407 Disorders of breast 610-612;Men;211 COMUNITAT VALENCIANA;Group 1407 Disorders of breast 610-612;Women;2.446 COMUNITAT VALENCIANA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;923 COMUNITAT VALENCIANA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. COMUNITAT VALENCIANA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;923 COMUNITAT VALENCIANA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;501 COMUNITAT VALENCIANA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. COMUNITAT VALENCIANA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;501 COMUNITAT VALENCIANA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;5.328 COMUNITAT VALENCIANA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;39 COMUNITAT VALENCIANA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;5.289 COMUNITAT VALENCIANA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;52.499 COMUNITAT VALENCIANA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. COMUNITAT VALENCIANA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;52.499 COMUNITAT VALENCIANA;Group 1501 Legally induced abortion 635;Both sexes;229 COMUNITAT VALENCIANA;Group 1501 Legally induced abortion 635;Men;.. COMUNITAT VALENCIANA;Group 1501 Legally induced abortion 635;Women;229 COMUNITAT VALENCIANA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;3.392 COMUNITAT VALENCIANA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. COMUNITAT VALENCIANA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;3.392 COMUNITAT VALENCIANA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;31.190 COMUNITAT VALENCIANA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. COMUNITAT VALENCIANA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;31.190 COMUNITAT VALENCIANA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;7.893 COMUNITAT VALENCIANA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. COMUNITAT VALENCIANA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;7.893 COMUNITAT VALENCIANA;Group 1505 Single spontaneous delivery 650;Both sexes;3.649 COMUNITAT VALENCIANA;Group 1505 Single spontaneous delivery 650;Men;.. COMUNITAT VALENCIANA;Group 1505 Single spontaneous delivery 650;Women;3.649 COMUNITAT VALENCIANA;Group 1506 Other deliveries 6695-6697;Both sexes;1.714 COMUNITAT VALENCIANA;Group 1506 Other deliveries 6695-6697;Men;.. COMUNITAT VALENCIANA;Group 1506 Other deliveries 6695-6697;Women;1.714 COMUNITAT VALENCIANA;Group 1507 Complications related to the puerperium 670-676;Both sexes;432 COMUNITAT VALENCIANA;Group 1507 Complications related to the puerperium 670-676;Men;.. COMUNITAT VALENCIANA;Group 1507 Complications related to the puerperium 670-676;Women;432 COMUNITAT VALENCIANA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;4.000 COMUNITAT VALENCIANA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. COMUNITAT VALENCIANA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;4.000 COMUNITAT VALENCIANA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;7.160 COMUNITAT VALENCIANA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;3.974 COMUNITAT VALENCIANA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;3.186 COMUNITAT VALENCIANA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;2.091 COMUNITAT VALENCIANA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;1.133 COMUNITAT VALENCIANA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;958 COMUNITAT VALENCIANA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;5.069 COMUNITAT VALENCIANA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;2.841 COMUNITAT VALENCIANA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;2.228 COMUNITAT VALENCIANA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;3.787 COMUNITAT VALENCIANA;Grupo 1700 Congenital abnormalities 740-759;Men;2.219 COMUNITAT VALENCIANA;Grupo 1700 Congenital abnormalities 740-759;Women;1.568 COMUNITAT VALENCIANA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;23.620 COMUNITAT VALENCIANA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;12.799 COMUNITAT VALENCIANA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;10.821 COMUNITAT VALENCIANA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;3.550 COMUNITAT VALENCIANA;Group 1801 Pain in throat and chest 7841, 7865;Men;2.055 COMUNITAT VALENCIANA;Group 1801 Pain in throat and chest 7841, 7865;Women;1.495 COMUNITAT VALENCIANA;Group 1802 Abdominal pain 7890;Both sexes;2.560 COMUNITAT VALENCIANA;Group 1802 Abdominal pain 7890;Men;930 COMUNITAT VALENCIANA;Group 1802 Abdominal pain 7890;Women;1.630 COMUNITAT VALENCIANA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;293 COMUNITAT VALENCIANA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;155 COMUNITAT VALENCIANA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;138 COMUNITAT VALENCIANA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;17.217 COMUNITAT VALENCIANA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;9.659 COMUNITAT VALENCIANA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;7.558 COMUNITAT VALENCIANA;Group 1900 Injuries and poisoning 800-999;Both sexes;44.878 COMUNITAT VALENCIANA;Group 1900 Injuries and poisoning 800-999;Men;23.139 COMUNITAT VALENCIANA;Group 1900 Injuries and poisoning 800-999;Women;21.739 COMUNITAT VALENCIANA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;2.405 COMUNITAT VALENCIANA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;1.383 COMUNITAT VALENCIANA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;1.022 COMUNITAT VALENCIANA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1.088 COMUNITAT VALENCIANA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;761 COMUNITAT VALENCIANA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;327 COMUNITAT VALENCIANA;Group 1903 Radius and ulna fracture 813;Both sexes;3.346 COMUNITAT VALENCIANA;Group 1903 Radius and ulna fracture 813;Men;1.567 COMUNITAT VALENCIANA;Group 1903 Radius and ulna fracture 813;Women;1.779 COMUNITAT VALENCIANA;Group 1904 Femur fracture 820-821;Both sexes;6.875 COMUNITAT VALENCIANA;Group 1904 Femur fracture 820-821;Men;2.038 COMUNITAT VALENCIANA;Group 1904 Femur fracture 820-821;Women;4.837 COMUNITAT VALENCIANA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;3.377 COMUNITAT VALENCIANA;Group 1905 Leg fracture, including the ankle 823-824;Men;1.772 COMUNITAT VALENCIANA;Group 1905 Leg fracture, including the ankle 823-824;Women;1.605 COMUNITAT VALENCIANA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;13.874 COMUNITAT VALENCIANA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;8.325 COMUNITAT VALENCIANA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;5.549 COMUNITAT VALENCIANA;Group 1907 Burns 940-949;Both sexes;301 COMUNITAT VALENCIANA;Group 1907 Burns 940-949;Men;185 COMUNITAT VALENCIANA;Group 1907 Burns 940-949;Women;116 COMUNITAT VALENCIANA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;1.331 COMUNITAT VALENCIANA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;593 COMUNITAT VALENCIANA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;738 COMUNITAT VALENCIANA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;10.429 COMUNITAT VALENCIANA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;5.527 COMUNITAT VALENCIANA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;4.902 COMUNITAT VALENCIANA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;245 COMUNITAT VALENCIANA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;158 COMUNITAT VALENCIANA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;87 COMUNITAT VALENCIANA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;1.607 COMUNITAT VALENCIANA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;830 COMUNITAT VALENCIANA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;777 COMUNITAT VALENCIANA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;10.456 COMUNITAT VALENCIANA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;4.916 COMUNITAT VALENCIANA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;5.540 COMUNITAT VALENCIANA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;444 COMUNITAT VALENCIANA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;231 COMUNITAT VALENCIANA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;213 COMUNITAT VALENCIANA;Group 2102 Contraceptive management V25;Both sexes;149 COMUNITAT VALENCIANA;Group 2102 Contraceptive management V25;Men;11 COMUNITAT VALENCIANA;Group 2102 Contraceptive management V25;Women;138 COMUNITAT VALENCIANA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. COMUNITAT VALENCIANA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. COMUNITAT VALENCIANA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. COMUNITAT VALENCIANA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;2.990 COMUNITAT VALENCIANA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;1.830 COMUNITAT VALENCIANA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1.160 COMUNITAT VALENCIANA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;6.873 COMUNITAT VALENCIANA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;2.844 COMUNITAT VALENCIANA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;4.029 Alicante/Alacant;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;197.815 Alicante/Alacant;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;94.052 Alicante/Alacant;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;103.763 Alicante/Alacant;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;5.064 Alicante/Alacant;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2.705 Alicante/Alacant;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;2.359 Alicante/Alacant;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;682 Alicante/Alacant;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;359 Alicante/Alacant;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;323 Alicante/Alacant;Group 0102 Imprecise intestinal infections 009;Both sexes;625 Alicante/Alacant;Group 0102 Imprecise intestinal infections 009;Men;317 Alicante/Alacant;Group 0102 Imprecise intestinal infections 009;Women;308 Alicante/Alacant;Group 0103 Tuberculosis 010-018, 137;Both sexes;112 Alicante/Alacant;Group 0103 Tuberculosis 010-018, 137;Men;74 Alicante/Alacant;Group 0103 Tuberculosis 010-018, 137;Women;38 Alicante/Alacant;Group 0104 Septicaemia 038;Both sexes;2.274 Alicante/Alacant;Group 0104 Septicaemia 038;Men;1.186 Alicante/Alacant;Group 0104 Septicaemia 038;Women;1.088 Alicante/Alacant;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;133 Alicante/Alacant;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;84 Alicante/Alacant;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;49 Alicante/Alacant;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.238 Alicante/Alacant;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;685 Alicante/Alacant;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;553 Alicante/Alacant;Group 0200 Neoplasms 140-239;Both sexes;17.129 Alicante/Alacant;Group 0200 Neoplasms 140-239;Men;8.924 Alicante/Alacant;Group 0200 Neoplasms 140-239;Women;8.205 Alicante/Alacant;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;2.008 Alicante/Alacant;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;1.154 Alicante/Alacant;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;854 Alicante/Alacant;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.430 Alicante/Alacant;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1.065 Alicante/Alacant;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;365 Alicante/Alacant;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;196 Alicante/Alacant;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;122 Alicante/Alacant;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;74 Alicante/Alacant;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.239 Alicante/Alacant;Group 0204 Malignant neoplasm of breast 174-175;Men;13 Alicante/Alacant;Group 0204 Malignant neoplasm of breast 174-175;Women;1.226 Alicante/Alacant;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;352 Alicante/Alacant;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Alicante/Alacant;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;352 Alicante/Alacant;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;174 Alicante/Alacant;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Alicante/Alacant;Group 0206 Malignant neoplasm of ovary 1830;Women;174 Alicante/Alacant;Group 0207 Malignant neoplasm of prostate 185;Both sexes;454 Alicante/Alacant;Group 0207 Malignant neoplasm of prostate 185;Men;454 Alicante/Alacant;Group 0207 Malignant neoplasm of prostate 185;Women;.. Alicante/Alacant;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.635 Alicante/Alacant;Group 0208 Malignant neoplasm of bladder 188;Men;1.366 Alicante/Alacant;Group 0208 Malignant neoplasm of bladder 188;Women;269 Alicante/Alacant;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5.455 Alicante/Alacant;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3.263 Alicante/Alacant;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2.192 Alicante/Alacant;Group 0210 Carcinoma in situ 230-234;Both sexes;226 Alicante/Alacant;Group 0210 Carcinoma in situ 230-234;Men;43 Alicante/Alacant;Group 0210 Carcinoma in situ 230-234;Women;183 Alicante/Alacant;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;320 Alicante/Alacant;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;197 Alicante/Alacant;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;123 Alicante/Alacant;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1.042 Alicante/Alacant;Grupo 0212 Leiomyoma of uterus 218;Men;.. Alicante/Alacant;Grupo 0212 Leiomyoma of uterus 218;Women;1.042 Alicante/Alacant;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2.598 Alicante/Alacant;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.247 Alicante/Alacant;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.351 Alicante/Alacant;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.790 Alicante/Alacant;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;859 Alicante/Alacant;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;931 Alicante/Alacant;Group 0301 Anaemias 280-285;Both sexes;1.020 Alicante/Alacant;Group 0301 Anaemias 280-285;Men;460 Alicante/Alacant;Group 0301 Anaemias 280-285;Women;560 Alicante/Alacant;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;770 Alicante/Alacant;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;399 Alicante/Alacant;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;371 Alicante/Alacant;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;3.889 Alicante/Alacant;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.669 Alicante/Alacant;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2.220 Alicante/Alacant;Group 0401 Diabetes mellitus 249-250;Both sexes;1.403 Alicante/Alacant;Group 0401 Diabetes mellitus 249-250;Men;837 Alicante/Alacant;Group 0401 Diabetes mellitus 249-250;Women;566 Alicante/Alacant;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2.486 Alicante/Alacant;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;832 Alicante/Alacant;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.654 Alicante/Alacant;Group 0500 Mental disorders 290-319;Both sexes;4.179 Alicante/Alacant;Group 0500 Mental disorders 290-319;Men;2.238 Alicante/Alacant;Group 0500 Mental disorders 290-319;Women;1.941 Alicante/Alacant;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;136 Alicante/Alacant;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;70 Alicante/Alacant;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;66 Alicante/Alacant;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;310 Alicante/Alacant;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;229 Alicante/Alacant;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;81 Alicante/Alacant;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;242 Alicante/Alacant;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;181 Alicante/Alacant;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;61 Alicante/Alacant;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.188 Alicante/Alacant;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;756 Alicante/Alacant;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;432 Alicante/Alacant;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;843 Alicante/Alacant;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;322 Alicante/Alacant;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;521 Alicante/Alacant;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.460 Alicante/Alacant;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;680 Alicante/Alacant;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;780 Alicante/Alacant;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;5.843 Alicante/Alacant;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;3.030 Alicante/Alacant;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2.813 Alicante/Alacant;Group 0601 Alzheimer's disease 3310;Both sexes;81 Alicante/Alacant;Group 0601 Alzheimer's disease 3310;Men;33 Alicante/Alacant;Group 0601 Alzheimer's disease 3310;Women;48 Alicante/Alacant;Group 0602 Multiple sclerosis 340;Both sexes;104 Alicante/Alacant;Group 0602 Multiple sclerosis 340;Men;26 Alicante/Alacant;Group 0602 Multiple sclerosis 340;Women;78 Alicante/Alacant;Group 0603 Epilepsy 345;Both sexes;1.207 Alicante/Alacant;Group 0603 Epilepsy 345;Men;650 Alicante/Alacant;Group 0603 Epilepsy 345;Women;557 Alicante/Alacant;Group 0604 Transient cerebral ischemia 435;Both sexes;995 Alicante/Alacant;Group 0604 Transient cerebral ischemia 435;Men;491 Alicante/Alacant;Group 0604 Transient cerebral ischemia 435;Women;504 Alicante/Alacant;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.456 Alicante/Alacant;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.830 Alicante/Alacant;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.626 Alicante/Alacant;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1.027 Alicante/Alacant;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;558 Alicante/Alacant;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;469 Alicante/Alacant;Grupo 0701 Cataract 366;Both sexes;125 Alicante/Alacant;Grupo 0701 Cataract 366;Men;59 Alicante/Alacant;Grupo 0701 Cataract 366;Women;66 Alicante/Alacant;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;902 Alicante/Alacant;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;499 Alicante/Alacant;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;403 Alicante/Alacant;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;865 Alicante/Alacant;Group 0800 Diseases of the ear and the mastoid 380-389;Men;418 Alicante/Alacant;Group 0800 Diseases of the ear and the mastoid 380-389;Women;447 Alicante/Alacant;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;28.722 Alicante/Alacant;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;16.293 Alicante/Alacant;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;12.429 Alicante/Alacant;Group 0901 Hypertensive disease 401-405;Both sexes;1.089 Alicante/Alacant;Group 0901 Hypertensive disease 401-405;Men;526 Alicante/Alacant;Group 0901 Hypertensive disease 401-405;Women;563 Alicante/Alacant;Group 0902 Angina pectoris 4111, 413;Both sexes;1.576 Alicante/Alacant;Group 0902 Angina pectoris 4111, 413;Men;952 Alicante/Alacant;Group 0902 Angina pectoris 4111, 413;Women;624 Alicante/Alacant;Group 0903 Acute myocardial infarction 410;Both sexes;2.672 Alicante/Alacant;Group 0903 Acute myocardial infarction 410;Men;1.951 Alicante/Alacant;Group 0903 Acute myocardial infarction 410;Women;721 Alicante/Alacant;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.922 Alicante/Alacant;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.427 Alicante/Alacant;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;495 Alicante/Alacant;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;928 Alicante/Alacant;Group 0905 Diseases of the lungs circulation 415-417;Men;452 Alicante/Alacant;Group 0905 Diseases of the lungs circulation 415-417;Women;476 Alicante/Alacant;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;4.326 Alicante/Alacant;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;2.300 Alicante/Alacant;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;2.026 Alicante/Alacant;Grupo 0907 Heart failure 428;Both sexes;5.906 Alicante/Alacant;Grupo 0907 Heart failure 428;Men;2.733 Alicante/Alacant;Grupo 0907 Heart failure 428;Women;3.173 Alicante/Alacant;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;4.920 Alicante/Alacant;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;2.772 Alicante/Alacant;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;2.148 Alicante/Alacant;Grupo 0909 Atherosclerosis 440;Both sexes;561 Alicante/Alacant;Grupo 0909 Atherosclerosis 440;Men;407 Alicante/Alacant;Grupo 0909 Atherosclerosis 440;Women;154 Alicante/Alacant;Group 0910 Varicose veins of lower extremities 454;Both sexes;531 Alicante/Alacant;Group 0910 Varicose veins of lower extremities 454;Men;217 Alicante/Alacant;Group 0910 Varicose veins of lower extremities 454;Women;314 Alicante/Alacant;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;4.291 Alicante/Alacant;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;2.556 Alicante/Alacant;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.735 Alicante/Alacant;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;20.786 Alicante/Alacant;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;11.791 Alicante/Alacant;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;8.995 Alicante/Alacant;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1.306 Alicante/Alacant;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;672 Alicante/Alacant;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;634 Alicante/Alacant;Group 1002 Pneumonia 480-486;Both sexes;4.610 Alicante/Alacant;Group 1002 Pneumonia 480-486;Men;2.706 Alicante/Alacant;Group 1002 Pneumonia 480-486;Women;1.904 Alicante/Alacant;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2.133 Alicante/Alacant;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1.057 Alicante/Alacant;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.076 Alicante/Alacant;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1.140 Alicante/Alacant;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;605 Alicante/Alacant;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;535 Alicante/Alacant;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.231 Alicante/Alacant;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;785 Alicante/Alacant;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;446 Alicante/Alacant;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;3.309 Alicante/Alacant;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2.468 Alicante/Alacant;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;841 Alicante/Alacant;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;747 Alicante/Alacant;Group 1007 Asthma 4930-4931,4938-4939;Men;174 Alicante/Alacant;Group 1007 Asthma 4930-4931,4938-4939;Women;573 Alicante/Alacant;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;6.310 Alicante/Alacant;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;3.324 Alicante/Alacant;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2.986 Alicante/Alacant;Group 1100 Diseases of the digestive system 520-579;Both sexes;25.821 Alicante/Alacant;Group 1100 Diseases of the digestive system 520-579;Men;14.222 Alicante/Alacant;Group 1100 Diseases of the digestive system 520-579;Women;11.599 Alicante/Alacant;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;325 Alicante/Alacant;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;142 Alicante/Alacant;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;183 Alicante/Alacant;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;270 Alicante/Alacant;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;159 Alicante/Alacant;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;111 Alicante/Alacant;Group 1103 Diseases of the esophagus 530;Both sexes;593 Alicante/Alacant;Group 1103 Diseases of the esophagus 530;Men;367 Alicante/Alacant;Group 1103 Diseases of the esophagus 530;Women;226 Alicante/Alacant;Group 1104 Peptic ulcer 531-534;Both sexes;661 Alicante/Alacant;Group 1104 Peptic ulcer 531-534;Men;443 Alicante/Alacant;Group 1104 Peptic ulcer 531-534;Women;218 Alicante/Alacant;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;814 Alicante/Alacant;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;374 Alicante/Alacant;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;440 Alicante/Alacant;Group 1106 Appendicitis 540-543;Both sexes;2.175 Alicante/Alacant;Group 1106 Appendicitis 540-543;Men;1.203 Alicante/Alacant;Group 1106 Appendicitis 540-543;Women;972 Alicante/Alacant;Group 1107 Inguinal hernia 550;Both sexes;2.498 Alicante/Alacant;Group 1107 Inguinal hernia 550;Men;2.215 Alicante/Alacant;Group 1107 Inguinal hernia 550;Women;283 Alicante/Alacant;Group 1108 Other abdominal hernia 551-553;Both sexes;1.934 Alicante/Alacant;Group 1108 Other abdominal hernia 551-553;Men;938 Alicante/Alacant;Group 1108 Other abdominal hernia 551-553;Women;996 Alicante/Alacant;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;613 Alicante/Alacant;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;304 Alicante/Alacant;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;309 Alicante/Alacant;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.945 Alicante/Alacant;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;889 Alicante/Alacant;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;1.056 Alicante/Alacant;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1.102 Alicante/Alacant;Group 1111 Intestinal obstruction without hernia 560;Men;555 Alicante/Alacant;Group 1111 Intestinal obstruction without hernia 560;Women;547 Alicante/Alacant;Group 1112 Intestinal diverticulosis 562;Both sexes;1.180 Alicante/Alacant;Group 1112 Intestinal diverticulosis 562;Men;569 Alicante/Alacant;Group 1112 Intestinal diverticulosis 562;Women;611 Alicante/Alacant;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.423 Alicante/Alacant;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;886 Alicante/Alacant;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;537 Alicante/Alacant;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;904 Alicante/Alacant;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;409 Alicante/Alacant;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;495 Alicante/Alacant;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;493 Alicante/Alacant;Group 1115 Alcoholic hepatitis 5710-5713;Men;409 Alicante/Alacant;Group 1115 Alcoholic hepatitis 5710-5713;Women;84 Alicante/Alacant;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;1.041 Alicante/Alacant;Group 1116 Other diseases of the liver 570,5714-573;Men;609 Alicante/Alacant;Group 1116 Other diseases of the liver 570,5714-573;Women;432 Alicante/Alacant;Group 1117 Cholelithiasis 574;Both sexes;4.064 Alicante/Alacant;Group 1117 Cholelithiasis 574;Men;1.621 Alicante/Alacant;Group 1117 Cholelithiasis 574;Women;2.443 Alicante/Alacant;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1.144 Alicante/Alacant;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;638 Alicante/Alacant;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;506 Alicante/Alacant;Group 1119 Pancreatic diseases 577;Both sexes;1.525 Alicante/Alacant;Group 1119 Pancreatic diseases 577;Men;851 Alicante/Alacant;Group 1119 Pancreatic diseases 577;Women;674 Alicante/Alacant;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1.117 Alicante/Alacant;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;641 Alicante/Alacant;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;476 Alicante/Alacant;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;2.129 Alicante/Alacant;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1.239 Alicante/Alacant;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;890 Alicante/Alacant;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.449 Alicante/Alacant;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;912 Alicante/Alacant;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;537 Alicante/Alacant;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;89 Alicante/Alacant;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;46 Alicante/Alacant;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;43 Alicante/Alacant;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;591 Alicante/Alacant;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;281 Alicante/Alacant;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;310 Alicante/Alacant;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;12.368 Alicante/Alacant;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;5.922 Alicante/Alacant;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;6.446 Alicante/Alacant;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Alicante/Alacant;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Alicante/Alacant;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Alicante/Alacant;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Alicante/Alacant;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Alicante/Alacant;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Alicante/Alacant;Group 1303 Internal derangement of knee 717;Both sexes;1.540 Alicante/Alacant;Group 1303 Internal derangement of knee 717;Men;1.070 Alicante/Alacant;Group 1303 Internal derangement of knee 717;Women;470 Alicante/Alacant;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;4.362 Alicante/Alacant;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.858 Alicante/Alacant;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.504 Alicante/Alacant;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;232 Alicante/Alacant;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;108 Alicante/Alacant;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;124 Alicante/Alacant;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;926 Alicante/Alacant;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;489 Alicante/Alacant;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;437 Alicante/Alacant;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;970 Alicante/Alacant;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;499 Alicante/Alacant;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;471 Alicante/Alacant;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;321 Alicante/Alacant;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;130 Alicante/Alacant;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;191 Alicante/Alacant;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.920 Alicante/Alacant;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1.003 Alicante/Alacant;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;917 Alicante/Alacant;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;2.097 Alicante/Alacant;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;765 Alicante/Alacant;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.332 Alicante/Alacant;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;13.130 Alicante/Alacant;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;5.784 Alicante/Alacant;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;7.346 Alicante/Alacant;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.468 Alicante/Alacant;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;478 Alicante/Alacant;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;990 Alicante/Alacant;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1.156 Alicante/Alacant;Group 1402 Renal failure 5836-5837, 584-586;Men;692 Alicante/Alacant;Group 1402 Renal failure 5836-5837, 584-586;Women;464 Alicante/Alacant;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.809 Alicante/Alacant;Group 1403 Urolithiasis 592, 594, 7880;Men;1.110 Alicante/Alacant;Group 1403 Urolithiasis 592, 594, 7880;Women;699 Alicante/Alacant;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;3.250 Alicante/Alacant;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.636 Alicante/Alacant;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.614 Alicante/Alacant;Group 1405 Prostatic hyperplasia 600;Both sexes;919 Alicante/Alacant;Group 1405 Prostatic hyperplasia 600;Men;919 Alicante/Alacant;Group 1405 Prostatic hyperplasia 600;Women;.. Alicante/Alacant;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;830 Alicante/Alacant;Group 1406 Other diseases of the male genital organs 601-608;Men;830 Alicante/Alacant;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Alicante/Alacant;Group 1407 Disorders of breast 610-612;Both sexes;1.290 Alicante/Alacant;Group 1407 Disorders of breast 610-612;Men;108 Alicante/Alacant;Group 1407 Disorders of breast 610-612;Women;1.182 Alicante/Alacant;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;375 Alicante/Alacant;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Alicante/Alacant;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;375 Alicante/Alacant;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;186 Alicante/Alacant;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Alicante/Alacant;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;186 Alicante/Alacant;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.847 Alicante/Alacant;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;11 Alicante/Alacant;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.836 Alicante/Alacant;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;19.420 Alicante/Alacant;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Alicante/Alacant;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;19.420 Alicante/Alacant;Group 1501 Legally induced abortion 635;Both sexes;52 Alicante/Alacant;Group 1501 Legally induced abortion 635;Men;.. Alicante/Alacant;Group 1501 Legally induced abortion 635;Women;52 Alicante/Alacant;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.933 Alicante/Alacant;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Alicante/Alacant;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.933 Alicante/Alacant;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;11.226 Alicante/Alacant;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Alicante/Alacant;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;11.226 Alicante/Alacant;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2.794 Alicante/Alacant;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Alicante/Alacant;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2.794 Alicante/Alacant;Group 1505 Single spontaneous delivery 650;Both sexes;1.247 Alicante/Alacant;Group 1505 Single spontaneous delivery 650;Men;.. Alicante/Alacant;Group 1505 Single spontaneous delivery 650;Women;1.247 Alicante/Alacant;Group 1506 Other deliveries 6695-6697;Both sexes;836 Alicante/Alacant;Group 1506 Other deliveries 6695-6697;Men;.. Alicante/Alacant;Group 1506 Other deliveries 6695-6697;Women;836 Alicante/Alacant;Group 1507 Complications related to the puerperium 670-676;Both sexes;184 Alicante/Alacant;Group 1507 Complications related to the puerperium 670-676;Men;.. Alicante/Alacant;Group 1507 Complications related to the puerperium 670-676;Women;184 Alicante/Alacant;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.148 Alicante/Alacant;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Alicante/Alacant;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.148 Alicante/Alacant;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.552 Alicante/Alacant;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.387 Alicante/Alacant;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1.165 Alicante/Alacant;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;670 Alicante/Alacant;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;368 Alicante/Alacant;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;302 Alicante/Alacant;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.882 Alicante/Alacant;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1.019 Alicante/Alacant;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;863 Alicante/Alacant;Grupo 1700 Congenital abnormalities 740-759;Both sexes;988 Alicante/Alacant;Grupo 1700 Congenital abnormalities 740-759;Men;600 Alicante/Alacant;Grupo 1700 Congenital abnormalities 740-759;Women;388 Alicante/Alacant;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;10.820 Alicante/Alacant;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;5.791 Alicante/Alacant;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;5.029 Alicante/Alacant;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.817 Alicante/Alacant;Group 1801 Pain in throat and chest 7841, 7865;Men;1.055 Alicante/Alacant;Group 1801 Pain in throat and chest 7841, 7865;Women;762 Alicante/Alacant;Group 1802 Abdominal pain 7890;Both sexes;1.217 Alicante/Alacant;Group 1802 Abdominal pain 7890;Men;440 Alicante/Alacant;Group 1802 Abdominal pain 7890;Women;777 Alicante/Alacant;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;144 Alicante/Alacant;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;75 Alicante/Alacant;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;69 Alicante/Alacant;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;7.642 Alicante/Alacant;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;4.221 Alicante/Alacant;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3.421 Alicante/Alacant;Group 1900 Injuries and poisoning 800-999;Both sexes;16.974 Alicante/Alacant;Group 1900 Injuries and poisoning 800-999;Men;8.634 Alicante/Alacant;Group 1900 Injuries and poisoning 800-999;Women;8.340 Alicante/Alacant;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;974 Alicante/Alacant;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;549 Alicante/Alacant;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;425 Alicante/Alacant;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;410 Alicante/Alacant;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;285 Alicante/Alacant;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;125 Alicante/Alacant;Group 1903 Radius and ulna fracture 813;Both sexes;1.322 Alicante/Alacant;Group 1903 Radius and ulna fracture 813;Men;573 Alicante/Alacant;Group 1903 Radius and ulna fracture 813;Women;749 Alicante/Alacant;Group 1904 Femur fracture 820-821;Both sexes;2.544 Alicante/Alacant;Group 1904 Femur fracture 820-821;Men;772 Alicante/Alacant;Group 1904 Femur fracture 820-821;Women;1.772 Alicante/Alacant;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.256 Alicante/Alacant;Group 1905 Leg fracture, including the ankle 823-824;Men;611 Alicante/Alacant;Group 1905 Leg fracture, including the ankle 823-824;Women;645 Alicante/Alacant;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;5.245 Alicante/Alacant;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;3.078 Alicante/Alacant;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2.167 Alicante/Alacant;Group 1907 Burns 940-949;Both sexes;131 Alicante/Alacant;Group 1907 Burns 940-949;Men;78 Alicante/Alacant;Group 1907 Burns 940-949;Women;53 Alicante/Alacant;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;583 Alicante/Alacant;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;274 Alicante/Alacant;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;309 Alicante/Alacant;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3.831 Alicante/Alacant;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;2.045 Alicante/Alacant;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.786 Alicante/Alacant;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;69 Alicante/Alacant;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;42 Alicante/Alacant;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;27 Alicante/Alacant;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;609 Alicante/Alacant;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;327 Alicante/Alacant;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;282 Alicante/Alacant;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;4.319 Alicante/Alacant;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.988 Alicante/Alacant;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2.331 Alicante/Alacant;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;242 Alicante/Alacant;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;113 Alicante/Alacant;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;129 Alicante/Alacant;Group 2102 Contraceptive management V25;Both sexes;25 Alicante/Alacant;Group 2102 Contraceptive management V25;Men;3 Alicante/Alacant;Group 2102 Contraceptive management V25;Women;22 Alicante/Alacant;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Alicante/Alacant;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Alicante/Alacant;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Alicante/Alacant;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;952 Alicante/Alacant;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;615 Alicante/Alacant;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;337 Alicante/Alacant;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;3.100 Alicante/Alacant;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1.257 Alicante/Alacant;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.843 Castell¾n/Castell¾;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;49.559 Castell¾n/Castell¾;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;23.800 Castell¾n/Castell¾;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;25.759 Castell¾n/Castell¾;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.267 Castell¾n/Castell¾;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;710 Castell¾n/Castell¾;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;557 Castell¾n/Castell¾;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;229 Castell¾n/Castell¾;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;130 Castell¾n/Castell¾;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;99 Castell¾n/Castell¾;Group 0102 Imprecise intestinal infections 009;Both sexes;181 Castell¾n/Castell¾;Group 0102 Imprecise intestinal infections 009;Men;90 Castell¾n/Castell¾;Group 0102 Imprecise intestinal infections 009;Women;91 Castell¾n/Castell¾;Group 0103 Tuberculosis 010-018, 137;Both sexes;41 Castell¾n/Castell¾;Group 0103 Tuberculosis 010-018, 137;Men;23 Castell¾n/Castell¾;Group 0103 Tuberculosis 010-018, 137;Women;18 Castell¾n/Castell¾;Group 0104 Septicaemia 038;Both sexes;374 Castell¾n/Castell¾;Group 0104 Septicaemia 038;Men;196 Castell¾n/Castell¾;Group 0104 Septicaemia 038;Women;178 Castell¾n/Castell¾;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;27 Castell¾n/Castell¾;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;19 Castell¾n/Castell¾;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;8 Castell¾n/Castell¾;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;415 Castell¾n/Castell¾;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;252 Castell¾n/Castell¾;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;163 Castell¾n/Castell¾;Group 0200 Neoplasms 140-239;Both sexes;4.941 Castell¾n/Castell¾;Group 0200 Neoplasms 140-239;Men;2.650 Castell¾n/Castell¾;Group 0200 Neoplasms 140-239;Women;2.291 Castell¾n/Castell¾;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;604 Castell¾n/Castell¾;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;363 Castell¾n/Castell¾;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;241 Castell¾n/Castell¾;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;399 Castell¾n/Castell¾;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;335 Castell¾n/Castell¾;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;64 Castell¾n/Castell¾;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;59 Castell¾n/Castell¾;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;31 Castell¾n/Castell¾;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;28 Castell¾n/Castell¾;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;439 Castell¾n/Castell¾;Group 0204 Malignant neoplasm of breast 174-175;Men;9 Castell¾n/Castell¾;Group 0204 Malignant neoplasm of breast 174-175;Women;430 Castell¾n/Castell¾;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;141 Castell¾n/Castell¾;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Castell¾n/Castell¾;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;141 Castell¾n/Castell¾;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;78 Castell¾n/Castell¾;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Castell¾n/Castell¾;Group 0206 Malignant neoplasm of ovary 1830;Women;78 Castell¾n/Castell¾;Group 0207 Malignant neoplasm of prostate 185;Both sexes;220 Castell¾n/Castell¾;Group 0207 Malignant neoplasm of prostate 185;Men;220 Castell¾n/Castell¾;Group 0207 Malignant neoplasm of prostate 185;Women;.. Castell¾n/Castell¾;Group 0208 Malignant neoplasm of bladder 188;Both sexes;544 Castell¾n/Castell¾;Group 0208 Malignant neoplasm of bladder 188;Men;466 Castell¾n/Castell¾;Group 0208 Malignant neoplasm of bladder 188;Women;78 Castell¾n/Castell¾;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.533 Castell¾n/Castell¾;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;936 Castell¾n/Castell¾;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;597 Castell¾n/Castell¾;Group 0210 Carcinoma in situ 230-234;Both sexes;69 Castell¾n/Castell¾;Group 0210 Carcinoma in situ 230-234;Men;23 Castell¾n/Castell¾;Group 0210 Carcinoma in situ 230-234;Women;46 Castell¾n/Castell¾;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;87 Castell¾n/Castell¾;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;50 Castell¾n/Castell¾;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;37 Castell¾n/Castell¾;Grupo 0212 Leiomyoma of uterus 218;Both sexes;228 Castell¾n/Castell¾;Grupo 0212 Leiomyoma of uterus 218;Men;.. Castell¾n/Castell¾;Grupo 0212 Leiomyoma of uterus 218;Women;228 Castell¾n/Castell¾;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;540 Castell¾n/Castell¾;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;217 Castell¾n/Castell¾;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;323 Castell¾n/Castell¾;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;426 Castell¾n/Castell¾;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;218 Castell¾n/Castell¾;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;208 Castell¾n/Castell¾;Group 0301 Anaemias 280-285;Both sexes;245 Castell¾n/Castell¾;Group 0301 Anaemias 280-285;Men;132 Castell¾n/Castell¾;Group 0301 Anaemias 280-285;Women;113 Castell¾n/Castell¾;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;181 Castell¾n/Castell¾;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;86 Castell¾n/Castell¾;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;95 Castell¾n/Castell¾;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;916 Castell¾n/Castell¾;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;355 Castell¾n/Castell¾;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;561 Castell¾n/Castell¾;Group 0401 Diabetes mellitus 249-250;Both sexes;337 Castell¾n/Castell¾;Group 0401 Diabetes mellitus 249-250;Men;193 Castell¾n/Castell¾;Group 0401 Diabetes mellitus 249-250;Women;144 Castell¾n/Castell¾;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;579 Castell¾n/Castell¾;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;162 Castell¾n/Castell¾;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;417 Castell¾n/Castell¾;Group 0500 Mental disorders 290-319;Both sexes;774 Castell¾n/Castell¾;Group 0500 Mental disorders 290-319;Men;447 Castell¾n/Castell¾;Group 0500 Mental disorders 290-319;Women;327 Castell¾n/Castell¾;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;14 Castell¾n/Castell¾;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;10 Castell¾n/Castell¾;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;4 Castell¾n/Castell¾;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;68 Castell¾n/Castell¾;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;62 Castell¾n/Castell¾;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;6 Castell¾n/Castell¾;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;52 Castell¾n/Castell¾;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;40 Castell¾n/Castell¾;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;12 Castell¾n/Castell¾;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;268 Castell¾n/Castell¾;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;175 Castell¾n/Castell¾;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;93 Castell¾n/Castell¾;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;200 Castell¾n/Castell¾;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;78 Castell¾n/Castell¾;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;122 Castell¾n/Castell¾;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;172 Castell¾n/Castell¾;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;82 Castell¾n/Castell¾;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;90 Castell¾n/Castell¾;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;916 Castell¾n/Castell¾;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;479 Castell¾n/Castell¾;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;437 Castell¾n/Castell¾;Group 0601 Alzheimer's disease 3310;Both sexes;14 Castell¾n/Castell¾;Group 0601 Alzheimer's disease 3310;Men;5 Castell¾n/Castell¾;Group 0601 Alzheimer's disease 3310;Women;9 Castell¾n/Castell¾;Group 0602 Multiple sclerosis 340;Both sexes;24 Castell¾n/Castell¾;Group 0602 Multiple sclerosis 340;Men;9 Castell¾n/Castell¾;Group 0602 Multiple sclerosis 340;Women;15 Castell¾n/Castell¾;Group 0603 Epilepsy 345;Both sexes;221 Castell¾n/Castell¾;Group 0603 Epilepsy 345;Men;134 Castell¾n/Castell¾;Group 0603 Epilepsy 345;Women;87 Castell¾n/Castell¾;Group 0604 Transient cerebral ischemia 435;Both sexes;178 Castell¾n/Castell¾;Group 0604 Transient cerebral ischemia 435;Men;91 Castell¾n/Castell¾;Group 0604 Transient cerebral ischemia 435;Women;87 Castell¾n/Castell¾;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;479 Castell¾n/Castell¾;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;240 Castell¾n/Castell¾;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;239 Castell¾n/Castell¾;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;241 Castell¾n/Castell¾;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;125 Castell¾n/Castell¾;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;116 Castell¾n/Castell¾;Grupo 0701 Cataract 366;Both sexes;34 Castell¾n/Castell¾;Grupo 0701 Cataract 366;Men;19 Castell¾n/Castell¾;Grupo 0701 Cataract 366;Women;15 Castell¾n/Castell¾;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;207 Castell¾n/Castell¾;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;106 Castell¾n/Castell¾;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;101 Castell¾n/Castell¾;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;167 Castell¾n/Castell¾;Group 0800 Diseases of the ear and the mastoid 380-389;Men;83 Castell¾n/Castell¾;Group 0800 Diseases of the ear and the mastoid 380-389;Women;84 Castell¾n/Castell¾;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;6.271 Castell¾n/Castell¾;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3.546 Castell¾n/Castell¾;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.725 Castell¾n/Castell¾;Group 0901 Hypertensive disease 401-405;Both sexes;271 Castell¾n/Castell¾;Group 0901 Hypertensive disease 401-405;Men;148 Castell¾n/Castell¾;Group 0901 Hypertensive disease 401-405;Women;123 Castell¾n/Castell¾;Group 0902 Angina pectoris 4111, 413;Both sexes;316 Castell¾n/Castell¾;Group 0902 Angina pectoris 4111, 413;Men;203 Castell¾n/Castell¾;Group 0902 Angina pectoris 4111, 413;Women;113 Castell¾n/Castell¾;Group 0903 Acute myocardial infarction 410;Both sexes;504 Castell¾n/Castell¾;Group 0903 Acute myocardial infarction 410;Men;380 Castell¾n/Castell¾;Group 0903 Acute myocardial infarction 410;Women;124 Castell¾n/Castell¾;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;339 Castell¾n/Castell¾;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;248 Castell¾n/Castell¾;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;91 Castell¾n/Castell¾;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;122 Castell¾n/Castell¾;Group 0905 Diseases of the lungs circulation 415-417;Men;47 Castell¾n/Castell¾;Group 0905 Diseases of the lungs circulation 415-417;Women;75 Castell¾n/Castell¾;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;834 Castell¾n/Castell¾;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;444 Castell¾n/Castell¾;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;390 Castell¾n/Castell¾;Grupo 0907 Heart failure 428;Both sexes;1.407 Castell¾n/Castell¾;Grupo 0907 Heart failure 428;Men;659 Castell¾n/Castell¾;Grupo 0907 Heart failure 428;Women;748 Castell¾n/Castell¾;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.229 Castell¾n/Castell¾;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;698 Castell¾n/Castell¾;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;531 Castell¾n/Castell¾;Grupo 0909 Atherosclerosis 440;Both sexes;113 Castell¾n/Castell¾;Grupo 0909 Atherosclerosis 440;Men;85 Castell¾n/Castell¾;Grupo 0909 Atherosclerosis 440;Women;28 Castell¾n/Castell¾;Group 0910 Varicose veins of lower extremities 454;Both sexes;170 Castell¾n/Castell¾;Group 0910 Varicose veins of lower extremities 454;Men;64 Castell¾n/Castell¾;Group 0910 Varicose veins of lower extremities 454;Women;106 Castell¾n/Castell¾;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;966 Castell¾n/Castell¾;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;570 Castell¾n/Castell¾;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;396 Castell¾n/Castell¾;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5.935 Castell¾n/Castell¾;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3.421 Castell¾n/Castell¾;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.514 Castell¾n/Castell¾;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;409 Castell¾n/Castell¾;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;233 Castell¾n/Castell¾;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;176 Castell¾n/Castell¾;Group 1002 Pneumonia 480-486;Both sexes;1.441 Castell¾n/Castell¾;Group 1002 Pneumonia 480-486;Men;850 Castell¾n/Castell¾;Group 1002 Pneumonia 480-486;Women;591 Castell¾n/Castell¾;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;708 Castell¾n/Castell¾;Group 1003 Acute bronchitis and bronchiolitis 466;Men;325 Castell¾n/Castell¾;Group 1003 Acute bronchitis and bronchiolitis 466;Women;383 Castell¾n/Castell¾;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;548 Castell¾n/Castell¾;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;280 Castell¾n/Castell¾;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;268 Castell¾n/Castell¾;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;290 Castell¾n/Castell¾;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;183 Castell¾n/Castell¾;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;107 Castell¾n/Castell¾;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.177 Castell¾n/Castell¾;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;920 Castell¾n/Castell¾;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;257 Castell¾n/Castell¾;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;221 Castell¾n/Castell¾;Group 1007 Asthma 4930-4931,4938-4939;Men;62 Castell¾n/Castell¾;Group 1007 Asthma 4930-4931,4938-4939;Women;159 Castell¾n/Castell¾;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.141 Castell¾n/Castell¾;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;568 Castell¾n/Castell¾;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;573 Castell¾n/Castell¾;Group 1100 Diseases of the digestive system 520-579;Both sexes;6.372 Castell¾n/Castell¾;Group 1100 Diseases of the digestive system 520-579;Men;3.646 Castell¾n/Castell¾;Group 1100 Diseases of the digestive system 520-579;Women;2.726 Castell¾n/Castell¾;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;52 Castell¾n/Castell¾;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;18 Castell¾n/Castell¾;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;34 Castell¾n/Castell¾;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;68 Castell¾n/Castell¾;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;39 Castell¾n/Castell¾;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;29 Castell¾n/Castell¾;Group 1103 Diseases of the esophagus 530;Both sexes;88 Castell¾n/Castell¾;Group 1103 Diseases of the esophagus 530;Men;54 Castell¾n/Castell¾;Group 1103 Diseases of the esophagus 530;Women;34 Castell¾n/Castell¾;Group 1104 Peptic ulcer 531-534;Both sexes;173 Castell¾n/Castell¾;Group 1104 Peptic ulcer 531-534;Men;122 Castell¾n/Castell¾;Group 1104 Peptic ulcer 531-534;Women;51 Castell¾n/Castell¾;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;192 Castell¾n/Castell¾;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;96 Castell¾n/Castell¾;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;96 Castell¾n/Castell¾;Group 1106 Appendicitis 540-543;Both sexes;521 Castell¾n/Castell¾;Group 1106 Appendicitis 540-543;Men;284 Castell¾n/Castell¾;Group 1106 Appendicitis 540-543;Women;237 Castell¾n/Castell¾;Group 1107 Inguinal hernia 550;Both sexes;725 Castell¾n/Castell¾;Group 1107 Inguinal hernia 550;Men;639 Castell¾n/Castell¾;Group 1107 Inguinal hernia 550;Women;86 Castell¾n/Castell¾;Group 1108 Other abdominal hernia 551-553;Both sexes;577 Castell¾n/Castell¾;Group 1108 Other abdominal hernia 551-553;Men;280 Castell¾n/Castell¾;Group 1108 Other abdominal hernia 551-553;Women;297 Castell¾n/Castell¾;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;105 Castell¾n/Castell¾;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;51 Castell¾n/Castell¾;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;54 Castell¾n/Castell¾;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;281 Castell¾n/Castell¾;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;133 Castell¾n/Castell¾;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;148 Castell¾n/Castell¾;Group 1111 Intestinal obstruction without hernia 560;Both sexes;281 Castell¾n/Castell¾;Group 1111 Intestinal obstruction without hernia 560;Men;154 Castell¾n/Castell¾;Group 1111 Intestinal obstruction without hernia 560;Women;127 Castell¾n/Castell¾;Group 1112 Intestinal diverticulosis 562;Both sexes;199 Castell¾n/Castell¾;Group 1112 Intestinal diverticulosis 562;Men;96 Castell¾n/Castell¾;Group 1112 Intestinal diverticulosis 562;Women;103 Castell¾n/Castell¾;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;392 Castell¾n/Castell¾;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;251 Castell¾n/Castell¾;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;141 Castell¾n/Castell¾;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;130 Castell¾n/Castell¾;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;76 Castell¾n/Castell¾;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;54 Castell¾n/Castell¾;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;131 Castell¾n/Castell¾;Group 1115 Alcoholic hepatitis 5710-5713;Men;115 Castell¾n/Castell¾;Group 1115 Alcoholic hepatitis 5710-5713;Women;16 Castell¾n/Castell¾;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;195 Castell¾n/Castell¾;Group 1116 Other diseases of the liver 570,5714-573;Men;118 Castell¾n/Castell¾;Group 1116 Other diseases of the liver 570,5714-573;Women;77 Castell¾n/Castell¾;Group 1117 Cholelithiasis 574;Both sexes;1.242 Castell¾n/Castell¾;Group 1117 Cholelithiasis 574;Men;549 Castell¾n/Castell¾;Group 1117 Cholelithiasis 574;Women;693 Castell¾n/Castell¾;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;398 Castell¾n/Castell¾;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;206 Castell¾n/Castell¾;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;192 Castell¾n/Castell¾;Group 1119 Pancreatic diseases 577;Both sexes;335 Castell¾n/Castell¾;Group 1119 Pancreatic diseases 577;Men;206 Castell¾n/Castell¾;Group 1119 Pancreatic diseases 577;Women;129 Castell¾n/Castell¾;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;287 Castell¾n/Castell¾;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;159 Castell¾n/Castell¾;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;128 Castell¾n/Castell¾;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;389 Castell¾n/Castell¾;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;227 Castell¾n/Castell¾;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;162 Castell¾n/Castell¾;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;245 Castell¾n/Castell¾;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;154 Castell¾n/Castell¾;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;91 Castell¾n/Castell¾;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;21 Castell¾n/Castell¾;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;10 Castell¾n/Castell¾;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;11 Castell¾n/Castell¾;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;123 Castell¾n/Castell¾;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;63 Castell¾n/Castell¾;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;60 Castell¾n/Castell¾;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;3.008 Castell¾n/Castell¾;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.572 Castell¾n/Castell¾;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.436 Castell¾n/Castell¾;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Castell¾n/Castell¾;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Castell¾n/Castell¾;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Castell¾n/Castell¾;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Castell¾n/Castell¾;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Castell¾n/Castell¾;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Castell¾n/Castell¾;Group 1303 Internal derangement of knee 717;Both sexes;484 Castell¾n/Castell¾;Group 1303 Internal derangement of knee 717;Men;377 Castell¾n/Castell¾;Group 1303 Internal derangement of knee 717;Women;107 Castell¾n/Castell¾;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.061 Castell¾n/Castell¾;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;492 Castell¾n/Castell¾;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;569 Castell¾n/Castell¾;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;48 Castell¾n/Castell¾;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;19 Castell¾n/Castell¾;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;29 Castell¾n/Castell¾;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;131 Castell¾n/Castell¾;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;81 Castell¾n/Castell¾;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;50 Castell¾n/Castell¾;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;234 Castell¾n/Castell¾;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;135 Castell¾n/Castell¾;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;99 Castell¾n/Castell¾;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;76 Castell¾n/Castell¾;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;50 Castell¾n/Castell¾;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;26 Castell¾n/Castell¾;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;378 Castell¾n/Castell¾;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;196 Castell¾n/Castell¾;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;182 Castell¾n/Castell¾;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;596 Castell¾n/Castell¾;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;222 Castell¾n/Castell¾;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;374 Castell¾n/Castell¾;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.633 Castell¾n/Castell¾;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.688 Castell¾n/Castell¾;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.945 Castell¾n/Castell¾;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;453 Castell¾n/Castell¾;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;173 Castell¾n/Castell¾;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;280 Castell¾n/Castell¾;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;258 Castell¾n/Castell¾;Group 1402 Renal failure 5836-5837, 584-586;Men;158 Castell¾n/Castell¾;Group 1402 Renal failure 5836-5837, 584-586;Women;100 Castell¾n/Castell¾;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;473 Castell¾n/Castell¾;Group 1403 Urolithiasis 592, 594, 7880;Men;288 Castell¾n/Castell¾;Group 1403 Urolithiasis 592, 594, 7880;Women;185 Castell¾n/Castell¾;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;860 Castell¾n/Castell¾;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;434 Castell¾n/Castell¾;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;426 Castell¾n/Castell¾;Group 1405 Prostatic hyperplasia 600;Both sexes;330 Castell¾n/Castell¾;Group 1405 Prostatic hyperplasia 600;Men;330 Castell¾n/Castell¾;Group 1405 Prostatic hyperplasia 600;Women;.. Castell¾n/Castell¾;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;279 Castell¾n/Castell¾;Group 1406 Other diseases of the male genital organs 601-608;Men;279 Castell¾n/Castell¾;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Castell¾n/Castell¾;Group 1407 Disorders of breast 610-612;Both sexes;193 Castell¾n/Castell¾;Group 1407 Disorders of breast 610-612;Men;17 Castell¾n/Castell¾;Group 1407 Disorders of breast 610-612;Women;176 Castell¾n/Castell¾;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;95 Castell¾n/Castell¾;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Castell¾n/Castell¾;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;95 Castell¾n/Castell¾;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;60 Castell¾n/Castell¾;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Castell¾n/Castell¾;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;60 Castell¾n/Castell¾;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;632 Castell¾n/Castell¾;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;9 Castell¾n/Castell¾;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;623 Castell¾n/Castell¾;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5.793 Castell¾n/Castell¾;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Castell¾n/Castell¾;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5.793 Castell¾n/Castell¾;Group 1501 Legally induced abortion 635;Both sexes;27 Castell¾n/Castell¾;Group 1501 Legally induced abortion 635;Men;.. Castell¾n/Castell¾;Group 1501 Legally induced abortion 635;Women;27 Castell¾n/Castell¾;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;251 Castell¾n/Castell¾;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Castell¾n/Castell¾;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;251 Castell¾n/Castell¾;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.896 Castell¾n/Castell¾;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Castell¾n/Castell¾;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.896 Castell¾n/Castell¾;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;785 Castell¾n/Castell¾;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Castell¾n/Castell¾;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;785 Castell¾n/Castell¾;Group 1505 Single spontaneous delivery 650;Both sexes;188 Castell¾n/Castell¾;Group 1505 Single spontaneous delivery 650;Men;.. Castell¾n/Castell¾;Group 1505 Single spontaneous delivery 650;Women;188 Castell¾n/Castell¾;Group 1506 Other deliveries 6695-6697;Both sexes;42 Castell¾n/Castell¾;Group 1506 Other deliveries 6695-6697;Men;.. Castell¾n/Castell¾;Group 1506 Other deliveries 6695-6697;Women;42 Castell¾n/Castell¾;Group 1507 Complications related to the puerperium 670-676;Both sexes;39 Castell¾n/Castell¾;Group 1507 Complications related to the puerperium 670-676;Men;.. Castell¾n/Castell¾;Group 1507 Complications related to the puerperium 670-676;Women;39 Castell¾n/Castell¾;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;565 Castell¾n/Castell¾;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Castell¾n/Castell¾;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;565 Castell¾n/Castell¾;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;972 Castell¾n/Castell¾;Group 1600 Some disorders originating in the perinatal period 760-779;Men;525 Castell¾n/Castell¾;Group 1600 Some disorders originating in the perinatal period 760-779;Women;447 Castell¾n/Castell¾;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;305 Castell¾n/Castell¾;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;153 Castell¾n/Castell¾;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;152 Castell¾n/Castell¾;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;667 Castell¾n/Castell¾;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;372 Castell¾n/Castell¾;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;295 Castell¾n/Castell¾;Grupo 1700 Congenital abnormalities 740-759;Both sexes;281 Castell¾n/Castell¾;Grupo 1700 Congenital abnormalities 740-759;Men;178 Castell¾n/Castell¾;Grupo 1700 Congenital abnormalities 740-759;Women;103 Castell¾n/Castell¾;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.783 Castell¾n/Castell¾;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.000 Castell¾n/Castell¾;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;783 Castell¾n/Castell¾;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;267 Castell¾n/Castell¾;Group 1801 Pain in throat and chest 7841, 7865;Men;160 Castell¾n/Castell¾;Group 1801 Pain in throat and chest 7841, 7865;Women;107 Castell¾n/Castell¾;Group 1802 Abdominal pain 7890;Both sexes;223 Castell¾n/Castell¾;Group 1802 Abdominal pain 7890;Men;82 Castell¾n/Castell¾;Group 1802 Abdominal pain 7890;Women;141 Castell¾n/Castell¾;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;26 Castell¾n/Castell¾;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;13 Castell¾n/Castell¾;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;13 Castell¾n/Castell¾;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.267 Castell¾n/Castell¾;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;745 Castell¾n/Castell¾;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;522 Castell¾n/Castell¾;Group 1900 Injuries and poisoning 800-999;Both sexes;4.351 Castell¾n/Castell¾;Group 1900 Injuries and poisoning 800-999;Men;2.253 Castell¾n/Castell¾;Group 1900 Injuries and poisoning 800-999;Women;2.098 Castell¾n/Castell¾;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;311 Castell¾n/Castell¾;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;184 Castell¾n/Castell¾;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;127 Castell¾n/Castell¾;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;122 Castell¾n/Castell¾;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;72 Castell¾n/Castell¾;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;50 Castell¾n/Castell¾;Group 1903 Radius and ulna fracture 813;Both sexes;301 Castell¾n/Castell¾;Group 1903 Radius and ulna fracture 813;Men;147 Castell¾n/Castell¾;Group 1903 Radius and ulna fracture 813;Women;154 Castell¾n/Castell¾;Group 1904 Femur fracture 820-821;Both sexes;749 Castell¾n/Castell¾;Group 1904 Femur fracture 820-821;Men;220 Castell¾n/Castell¾;Group 1904 Femur fracture 820-821;Women;529 Castell¾n/Castell¾;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;317 Castell¾n/Castell¾;Group 1905 Leg fracture, including the ankle 823-824;Men;166 Castell¾n/Castell¾;Group 1905 Leg fracture, including the ankle 823-824;Women;151 Castell¾n/Castell¾;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.245 Castell¾n/Castell¾;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;773 Castell¾n/Castell¾;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;472 Castell¾n/Castell¾;Group 1907 Burns 940-949;Both sexes;6 Castell¾n/Castell¾;Group 1907 Burns 940-949;Men;3 Castell¾n/Castell¾;Group 1907 Burns 940-949;Women;3 Castell¾n/Castell¾;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;118 Castell¾n/Castell¾;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;55 Castell¾n/Castell¾;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;63 Castell¾n/Castell¾;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.009 Castell¾n/Castell¾;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;537 Castell¾n/Castell¾;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;472 Castell¾n/Castell¾;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;7 Castell¾n/Castell¾;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;3 Castell¾n/Castell¾;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;4 Castell¾n/Castell¾;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;166 Castell¾n/Castell¾;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;93 Castell¾n/Castell¾;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;73 Castell¾n/Castell¾;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.123 Castell¾n/Castell¾;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;677 Castell¾n/Castell¾;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;446 Castell¾n/Castell¾;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;50 Castell¾n/Castell¾;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;31 Castell¾n/Castell¾;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;19 Castell¾n/Castell¾;Group 2102 Contraceptive management V25;Both sexes;44 Castell¾n/Castell¾;Group 2102 Contraceptive management V25;Men;1 Castell¾n/Castell¾;Group 2102 Contraceptive management V25;Women;43 Castell¾n/Castell¾;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Castell¾n/Castell¾;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Castell¾n/Castell¾;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Castell¾n/Castell¾;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;467 Castell¾n/Castell¾;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;338 Castell¾n/Castell¾;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;129 Castell¾n/Castell¾;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;562 Castell¾n/Castell¾;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;307 Castell¾n/Castell¾;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;255 Valencia/ValÞncia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;261.112 Valencia/ValÞncia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;124.129 Valencia/ValÞncia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;136.983 Valencia/ValÞncia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;5.220 Valencia/ValÞncia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2.902 Valencia/ValÞncia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;2.318 Valencia/ValÞncia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;902 Valencia/ValÞncia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;474 Valencia/ValÞncia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;428 Valencia/ValÞncia;Group 0102 Imprecise intestinal infections 009;Both sexes;352 Valencia/ValÞncia;Group 0102 Imprecise intestinal infections 009;Men;181 Valencia/ValÞncia;Group 0102 Imprecise intestinal infections 009;Women;171 Valencia/ValÞncia;Group 0103 Tuberculosis 010-018, 137;Both sexes;207 Valencia/ValÞncia;Group 0103 Tuberculosis 010-018, 137;Men;141 Valencia/ValÞncia;Group 0103 Tuberculosis 010-018, 137;Women;66 Valencia/ValÞncia;Group 0104 Septicaemia 038;Both sexes;1.613 Valencia/ValÞncia;Group 0104 Septicaemia 038;Men;874 Valencia/ValÞncia;Group 0104 Septicaemia 038;Women;739 Valencia/ValÞncia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;244 Valencia/ValÞncia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;164 Valencia/ValÞncia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;80 Valencia/ValÞncia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.902 Valencia/ValÞncia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;1.068 Valencia/ValÞncia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;834 Valencia/ValÞncia;Group 0200 Neoplasms 140-239;Both sexes;29.204 Valencia/ValÞncia;Group 0200 Neoplasms 140-239;Men;15.485 Valencia/ValÞncia;Group 0200 Neoplasms 140-239;Women;13.719 Valencia/ValÞncia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;2.784 Valencia/ValÞncia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;1.653 Valencia/ValÞncia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;1.131 Valencia/ValÞncia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;2.439 Valencia/ValÞncia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1.947 Valencia/ValÞncia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;492 Valencia/ValÞncia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;483 Valencia/ValÞncia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;284 Valencia/ValÞncia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;199 Valencia/ValÞncia;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;2.616 Valencia/ValÞncia;Group 0204 Malignant neoplasm of breast 174-175;Men;13 Valencia/ValÞncia;Group 0204 Malignant neoplasm of breast 174-175;Women;2.603 Valencia/ValÞncia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;622 Valencia/ValÞncia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Valencia/ValÞncia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;622 Valencia/ValÞncia;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;416 Valencia/ValÞncia;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Valencia/ValÞncia;Group 0206 Malignant neoplasm of ovary 1830;Women;416 Valencia/ValÞncia;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1.210 Valencia/ValÞncia;Group 0207 Malignant neoplasm of prostate 185;Men;1.210 Valencia/ValÞncia;Group 0207 Malignant neoplasm of prostate 185;Women;.. Valencia/ValÞncia;Group 0208 Malignant neoplasm of bladder 188;Both sexes;3.352 Valencia/ValÞncia;Group 0208 Malignant neoplasm of bladder 188;Men;2.854 Valencia/ValÞncia;Group 0208 Malignant neoplasm of bladder 188;Women;498 Valencia/ValÞncia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;9.376 Valencia/ValÞncia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;5.602 Valencia/ValÞncia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;3.774 Valencia/ValÞncia;Group 0210 Carcinoma in situ 230-234;Both sexes;450 Valencia/ValÞncia;Group 0210 Carcinoma in situ 230-234;Men;137 Valencia/ValÞncia;Group 0210 Carcinoma in situ 230-234;Women;313 Valencia/ValÞncia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;278 Valencia/ValÞncia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;166 Valencia/ValÞncia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;112 Valencia/ValÞncia;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1.521 Valencia/ValÞncia;Grupo 0212 Leiomyoma of uterus 218;Men;.. Valencia/ValÞncia;Grupo 0212 Leiomyoma of uterus 218;Women;1.521 Valencia/ValÞncia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;3.657 Valencia/ValÞncia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.619 Valencia/ValÞncia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;2.038 Valencia/ValÞncia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;2.190 Valencia/ValÞncia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;1.081 Valencia/ValÞncia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;1.109 Valencia/ValÞncia;Group 0301 Anaemias 280-285;Both sexes;1.041 Valencia/ValÞncia;Group 0301 Anaemias 280-285;Men;478 Valencia/ValÞncia;Group 0301 Anaemias 280-285;Women;563 Valencia/ValÞncia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;1.149 Valencia/ValÞncia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;603 Valencia/ValÞncia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;546 Valencia/ValÞncia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;5.249 Valencia/ValÞncia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;2.007 Valencia/ValÞncia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;3.242 Valencia/ValÞncia;Group 0401 Diabetes mellitus 249-250;Both sexes;1.623 Valencia/ValÞncia;Group 0401 Diabetes mellitus 249-250;Men;947 Valencia/ValÞncia;Group 0401 Diabetes mellitus 249-250;Women;676 Valencia/ValÞncia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;3.626 Valencia/ValÞncia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;1.060 Valencia/ValÞncia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;2.566 Valencia/ValÞncia;Group 0500 Mental disorders 290-319;Both sexes;5.827 Valencia/ValÞncia;Group 0500 Mental disorders 290-319;Men;2.963 Valencia/ValÞncia;Group 0500 Mental disorders 290-319;Women;2.864 Valencia/ValÞncia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;155 Valencia/ValÞncia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;67 Valencia/ValÞncia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;88 Valencia/ValÞncia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;390 Valencia/ValÞncia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;302 Valencia/ValÞncia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;88 Valencia/ValÞncia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;342 Valencia/ValÞncia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;235 Valencia/ValÞncia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;107 Valencia/ValÞncia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.716 Valencia/ValÞncia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;1.006 Valencia/ValÞncia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;710 Valencia/ValÞncia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1.300 Valencia/ValÞncia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;588 Valencia/ValÞncia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;712 Valencia/ValÞncia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.924 Valencia/ValÞncia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;765 Valencia/ValÞncia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;1.159 Valencia/ValÞncia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;5.460 Valencia/ValÞncia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.722 Valencia/ValÞncia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2.738 Valencia/ValÞncia;Group 0601 Alzheimer's disease 3310;Both sexes;95 Valencia/ValÞncia;Group 0601 Alzheimer's disease 3310;Men;31 Valencia/ValÞncia;Group 0601 Alzheimer's disease 3310;Women;64 Valencia/ValÞncia;Group 0602 Multiple sclerosis 340;Both sexes;139 Valencia/ValÞncia;Group 0602 Multiple sclerosis 340;Men;39 Valencia/ValÞncia;Group 0602 Multiple sclerosis 340;Women;100 Valencia/ValÞncia;Group 0603 Epilepsy 345;Both sexes;1.264 Valencia/ValÞncia;Group 0603 Epilepsy 345;Men;704 Valencia/ValÞncia;Group 0603 Epilepsy 345;Women;560 Valencia/ValÞncia;Group 0604 Transient cerebral ischemia 435;Both sexes;749 Valencia/ValÞncia;Group 0604 Transient cerebral ischemia 435;Men;409 Valencia/ValÞncia;Group 0604 Transient cerebral ischemia 435;Women;340 Valencia/ValÞncia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.213 Valencia/ValÞncia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.539 Valencia/ValÞncia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.674 Valencia/ValÞncia;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1.360 Valencia/ValÞncia;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;751 Valencia/ValÞncia;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;609 Valencia/ValÞncia;Grupo 0701 Cataract 366;Both sexes;148 Valencia/ValÞncia;Grupo 0701 Cataract 366;Men;75 Valencia/ValÞncia;Grupo 0701 Cataract 366;Women;73 Valencia/ValÞncia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;1.212 Valencia/ValÞncia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;676 Valencia/ValÞncia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;536 Valencia/ValÞncia;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;1.403 Valencia/ValÞncia;Group 0800 Diseases of the ear and the mastoid 380-389;Men;663 Valencia/ValÞncia;Group 0800 Diseases of the ear and the mastoid 380-389;Women;740 Valencia/ValÞncia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;30.528 Valencia/ValÞncia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;17.253 Valencia/ValÞncia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;13.275 Valencia/ValÞncia;Group 0901 Hypertensive disease 401-405;Both sexes;781 Valencia/ValÞncia;Group 0901 Hypertensive disease 401-405;Men;374 Valencia/ValÞncia;Group 0901 Hypertensive disease 401-405;Women;407 Valencia/ValÞncia;Group 0902 Angina pectoris 4111, 413;Both sexes;1.547 Valencia/ValÞncia;Group 0902 Angina pectoris 4111, 413;Men;1.019 Valencia/ValÞncia;Group 0902 Angina pectoris 4111, 413;Women;528 Valencia/ValÞncia;Group 0903 Acute myocardial infarction 410;Both sexes;2.681 Valencia/ValÞncia;Group 0903 Acute myocardial infarction 410;Men;1.880 Valencia/ValÞncia;Group 0903 Acute myocardial infarction 410;Women;801 Valencia/ValÞncia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;2.111 Valencia/ValÞncia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.583 Valencia/ValÞncia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;528 Valencia/ValÞncia;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;1.007 Valencia/ValÞncia;Group 0905 Diseases of the lungs circulation 415-417;Men;445 Valencia/ValÞncia;Group 0905 Diseases of the lungs circulation 415-417;Women;562 Valencia/ValÞncia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;3.655 Valencia/ValÞncia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.960 Valencia/ValÞncia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.695 Valencia/ValÞncia;Grupo 0907 Heart failure 428;Both sexes;5.749 Valencia/ValÞncia;Grupo 0907 Heart failure 428;Men;2.686 Valencia/ValÞncia;Grupo 0907 Heart failure 428;Women;3.063 Valencia/ValÞncia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;5.781 Valencia/ValÞncia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;3.132 Valencia/ValÞncia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;2.649 Valencia/ValÞncia;Grupo 0909 Atherosclerosis 440;Both sexes;921 Valencia/ValÞncia;Grupo 0909 Atherosclerosis 440;Men;721 Valencia/ValÞncia;Grupo 0909 Atherosclerosis 440;Women;200 Valencia/ValÞncia;Group 0910 Varicose veins of lower extremities 454;Both sexes;698 Valencia/ValÞncia;Group 0910 Varicose veins of lower extremities 454;Men;223 Valencia/ValÞncia;Group 0910 Varicose veins of lower extremities 454;Women;475 Valencia/ValÞncia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;5.597 Valencia/ValÞncia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;3.230 Valencia/ValÞncia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;2.367 Valencia/ValÞncia;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;28.649 Valencia/ValÞncia;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;16.499 Valencia/ValÞncia;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;12.150 Valencia/ValÞncia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1.718 Valencia/ValÞncia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;917 Valencia/ValÞncia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;801 Valencia/ValÞncia;Group 1002 Pneumonia 480-486;Both sexes;7.056 Valencia/ValÞncia;Group 1002 Pneumonia 480-486;Men;4.078 Valencia/ValÞncia;Group 1002 Pneumonia 480-486;Women;2.978 Valencia/ValÞncia;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2.507 Valencia/ValÞncia;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1.301 Valencia/ValÞncia;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.206 Valencia/ValÞncia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;2.189 Valencia/ValÞncia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1.231 Valencia/ValÞncia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;958 Valencia/ValÞncia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;2.201 Valencia/ValÞncia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1.332 Valencia/ValÞncia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;869 Valencia/ValÞncia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;3.574 Valencia/ValÞncia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2.766 Valencia/ValÞncia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;808 Valencia/ValÞncia;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;811 Valencia/ValÞncia;Group 1007 Asthma 4930-4931,4938-4939;Men;245 Valencia/ValÞncia;Group 1007 Asthma 4930-4931,4938-4939;Women;566 Valencia/ValÞncia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;8.593 Valencia/ValÞncia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;4.629 Valencia/ValÞncia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;3.964 Valencia/ValÞncia;Group 1100 Diseases of the digestive system 520-579;Both sexes;31.955 Valencia/ValÞncia;Group 1100 Diseases of the digestive system 520-579;Men;17.678 Valencia/ValÞncia;Group 1100 Diseases of the digestive system 520-579;Women;14.277 Valencia/ValÞncia;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;825 Valencia/ValÞncia;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;391 Valencia/ValÞncia;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;434 Valencia/ValÞncia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;570 Valencia/ValÞncia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;301 Valencia/ValÞncia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;269 Valencia/ValÞncia;Group 1103 Diseases of the esophagus 530;Both sexes;559 Valencia/ValÞncia;Group 1103 Diseases of the esophagus 530;Men;338 Valencia/ValÞncia;Group 1103 Diseases of the esophagus 530;Women;221 Valencia/ValÞncia;Group 1104 Peptic ulcer 531-534;Both sexes;651 Valencia/ValÞncia;Group 1104 Peptic ulcer 531-534;Men;476 Valencia/ValÞncia;Group 1104 Peptic ulcer 531-534;Women;175 Valencia/ValÞncia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;878 Valencia/ValÞncia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;437 Valencia/ValÞncia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;441 Valencia/ValÞncia;Group 1106 Appendicitis 540-543;Both sexes;2.784 Valencia/ValÞncia;Group 1106 Appendicitis 540-543;Men;1.606 Valencia/ValÞncia;Group 1106 Appendicitis 540-543;Women;1.178 Valencia/ValÞncia;Group 1107 Inguinal hernia 550;Both sexes;2.739 Valencia/ValÞncia;Group 1107 Inguinal hernia 550;Men;2.398 Valencia/ValÞncia;Group 1107 Inguinal hernia 550;Women;341 Valencia/ValÞncia;Group 1108 Other abdominal hernia 551-553;Both sexes;2.633 Valencia/ValÞncia;Group 1108 Other abdominal hernia 551-553;Men;1.251 Valencia/ValÞncia;Group 1108 Other abdominal hernia 551-553;Women;1.382 Valencia/ValÞncia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;755 Valencia/ValÞncia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;374 Valencia/ValÞncia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;381 Valencia/ValÞncia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.560 Valencia/ValÞncia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;719 Valencia/ValÞncia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;841 Valencia/ValÞncia;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1.427 Valencia/ValÞncia;Group 1111 Intestinal obstruction without hernia 560;Men;737 Valencia/ValÞncia;Group 1111 Intestinal obstruction without hernia 560;Women;690 Valencia/ValÞncia;Group 1112 Intestinal diverticulosis 562;Both sexes;1.136 Valencia/ValÞncia;Group 1112 Intestinal diverticulosis 562;Men;571 Valencia/ValÞncia;Group 1112 Intestinal diverticulosis 562;Women;565 Valencia/ValÞncia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;2.077 Valencia/ValÞncia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;1.330 Valencia/ValÞncia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;747 Valencia/ValÞncia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;996 Valencia/ValÞncia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;412 Valencia/ValÞncia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;584 Valencia/ValÞncia;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;418 Valencia/ValÞncia;Group 1115 Alcoholic hepatitis 5710-5713;Men;366 Valencia/ValÞncia;Group 1115 Alcoholic hepatitis 5710-5713;Women;52 Valencia/ValÞncia;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;1.287 Valencia/ValÞncia;Group 1116 Other diseases of the liver 570,5714-573;Men;786 Valencia/ValÞncia;Group 1116 Other diseases of the liver 570,5714-573;Women;501 Valencia/ValÞncia;Group 1117 Cholelithiasis 574;Both sexes;5.244 Valencia/ValÞncia;Group 1117 Cholelithiasis 574;Men;2.162 Valencia/ValÞncia;Group 1117 Cholelithiasis 574;Women;3.082 Valencia/ValÞncia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1.866 Valencia/ValÞncia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;1.000 Valencia/ValÞncia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;866 Valencia/ValÞncia;Group 1119 Pancreatic diseases 577;Both sexes;1.656 Valencia/ValÞncia;Group 1119 Pancreatic diseases 577;Men;972 Valencia/ValÞncia;Group 1119 Pancreatic diseases 577;Women;684 Valencia/ValÞncia;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1.894 Valencia/ValÞncia;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1.051 Valencia/ValÞncia;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;843 Valencia/ValÞncia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;2.418 Valencia/ValÞncia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1.333 Valencia/ValÞncia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1.085 Valencia/ValÞncia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.555 Valencia/ValÞncia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;920 Valencia/ValÞncia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;635 Valencia/ValÞncia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;80 Valencia/ValÞncia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;41 Valencia/ValÞncia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;39 Valencia/ValÞncia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;783 Valencia/ValÞncia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;372 Valencia/ValÞncia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;411 Valencia/ValÞncia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;20.356 Valencia/ValÞncia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;10.466 Valencia/ValÞncia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;9.890 Valencia/ValÞncia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Valencia/ValÞncia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Valencia/ValÞncia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Valencia/ValÞncia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Valencia/ValÞncia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Valencia/ValÞncia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Valencia/ValÞncia;Group 1303 Internal derangement of knee 717;Both sexes;3.749 Valencia/ValÞncia;Group 1303 Internal derangement of knee 717;Men;2.651 Valencia/ValÞncia;Group 1303 Internal derangement of knee 717;Women;1.098 Valencia/ValÞncia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;6.554 Valencia/ValÞncia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;2.902 Valencia/ValÞncia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;3.652 Valencia/ValÞncia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;343 Valencia/ValÞncia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;114 Valencia/ValÞncia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;229 Valencia/ValÞncia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;1.007 Valencia/ValÞncia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;483 Valencia/ValÞncia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;524 Valencia/ValÞncia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.970 Valencia/ValÞncia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;1.087 Valencia/ValÞncia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;883 Valencia/ValÞncia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;420 Valencia/ValÞncia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;209 Valencia/ValÞncia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;211 Valencia/ValÞncia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;3.233 Valencia/ValÞncia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1.744 Valencia/ValÞncia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;1.489 Valencia/ValÞncia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;3.080 Valencia/ValÞncia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;1.276 Valencia/ValÞncia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.804 Valencia/ValÞncia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;18.269 Valencia/ValÞncia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;8.312 Valencia/ValÞncia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;9.957 Valencia/ValÞncia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.704 Valencia/ValÞncia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;607 Valencia/ValÞncia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;1.097 Valencia/ValÞncia;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1.546 Valencia/ValÞncia;Group 1402 Renal failure 5836-5837, 584-586;Men;926 Valencia/ValÞncia;Group 1402 Renal failure 5836-5837, 584-586;Women;620 Valencia/ValÞncia;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;2.198 Valencia/ValÞncia;Group 1403 Urolithiasis 592, 594, 7880;Men;1.258 Valencia/ValÞncia;Group 1403 Urolithiasis 592, 594, 7880;Women;940 Valencia/ValÞncia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;5.453 Valencia/ValÞncia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;2.779 Valencia/ValÞncia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;2.674 Valencia/ValÞncia;Group 1405 Prostatic hyperplasia 600;Both sexes;1.613 Valencia/ValÞncia;Group 1405 Prostatic hyperplasia 600;Men;1.613 Valencia/ValÞncia;Group 1405 Prostatic hyperplasia 600;Women;.. Valencia/ValÞncia;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;1.024 Valencia/ValÞncia;Group 1406 Other diseases of the male genital organs 601-608;Men;1.024 Valencia/ValÞncia;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Valencia/ValÞncia;Group 1407 Disorders of breast 610-612;Both sexes;1.174 Valencia/ValÞncia;Group 1407 Disorders of breast 610-612;Men;86 Valencia/ValÞncia;Group 1407 Disorders of breast 610-612;Women;1.088 Valencia/ValÞncia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;453 Valencia/ValÞncia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Valencia/ValÞncia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;453 Valencia/ValÞncia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;255 Valencia/ValÞncia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Valencia/ValÞncia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;255 Valencia/ValÞncia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;2.849 Valencia/ValÞncia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;19 Valencia/ValÞncia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;2.830 Valencia/ValÞncia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;27.286 Valencia/ValÞncia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Valencia/ValÞncia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;27.286 Valencia/ValÞncia;Group 1501 Legally induced abortion 635;Both sexes;150 Valencia/ValÞncia;Group 1501 Legally induced abortion 635;Men;.. Valencia/ValÞncia;Group 1501 Legally induced abortion 635;Women;150 Valencia/ValÞncia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.208 Valencia/ValÞncia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Valencia/ValÞncia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.208 Valencia/ValÞncia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;16.068 Valencia/ValÞncia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Valencia/ValÞncia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;16.068 Valencia/ValÞncia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;4.314 Valencia/ValÞncia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Valencia/ValÞncia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;4.314 Valencia/ValÞncia;Group 1505 Single spontaneous delivery 650;Both sexes;2.214 Valencia/ValÞncia;Group 1505 Single spontaneous delivery 650;Men;.. Valencia/ValÞncia;Group 1505 Single spontaneous delivery 650;Women;2.214 Valencia/ValÞncia;Group 1506 Other deliveries 6695-6697;Both sexes;836 Valencia/ValÞncia;Group 1506 Other deliveries 6695-6697;Men;.. Valencia/ValÞncia;Group 1506 Other deliveries 6695-6697;Women;836 Valencia/ValÞncia;Group 1507 Complications related to the puerperium 670-676;Both sexes;209 Valencia/ValÞncia;Group 1507 Complications related to the puerperium 670-676;Men;.. Valencia/ValÞncia;Group 1507 Complications related to the puerperium 670-676;Women;209 Valencia/ValÞncia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;2.287 Valencia/ValÞncia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Valencia/ValÞncia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;2.287 Valencia/ValÞncia;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;3.636 Valencia/ValÞncia;Group 1600 Some disorders originating in the perinatal period 760-779;Men;2.062 Valencia/ValÞncia;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1.574 Valencia/ValÞncia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;1.116 Valencia/ValÞncia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;612 Valencia/ValÞncia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;504 Valencia/ValÞncia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;2.520 Valencia/ValÞncia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1.450 Valencia/ValÞncia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;1.070 Valencia/ValÞncia;Grupo 1700 Congenital abnormalities 740-759;Both sexes;2.518 Valencia/ValÞncia;Grupo 1700 Congenital abnormalities 740-759;Men;1.441 Valencia/ValÞncia;Grupo 1700 Congenital abnormalities 740-759;Women;1.077 Valencia/ValÞncia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;11.017 Valencia/ValÞncia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;6.008 Valencia/ValÞncia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;5.009 Valencia/ValÞncia;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.466 Valencia/ValÞncia;Group 1801 Pain in throat and chest 7841, 7865;Men;840 Valencia/ValÞncia;Group 1801 Pain in throat and chest 7841, 7865;Women;626 Valencia/ValÞncia;Group 1802 Abdominal pain 7890;Both sexes;1.120 Valencia/ValÞncia;Group 1802 Abdominal pain 7890;Men;408 Valencia/ValÞncia;Group 1802 Abdominal pain 7890;Women;712 Valencia/ValÞncia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;123 Valencia/ValÞncia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;67 Valencia/ValÞncia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;56 Valencia/ValÞncia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;8.308 Valencia/ValÞncia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;4.693 Valencia/ValÞncia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3.615 Valencia/ValÞncia;Group 1900 Injuries and poisoning 800-999;Both sexes;23.553 Valencia/ValÞncia;Group 1900 Injuries and poisoning 800-999;Men;12.252 Valencia/ValÞncia;Group 1900 Injuries and poisoning 800-999;Women;11.301 Valencia/ValÞncia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1.120 Valencia/ValÞncia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;650 Valencia/ValÞncia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;470 Valencia/ValÞncia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;556 Valencia/ValÞncia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;404 Valencia/ValÞncia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;152 Valencia/ValÞncia;Group 1903 Radius and ulna fracture 813;Both sexes;1.723 Valencia/ValÞncia;Group 1903 Radius and ulna fracture 813;Men;847 Valencia/ValÞncia;Group 1903 Radius and ulna fracture 813;Women;876 Valencia/ValÞncia;Group 1904 Femur fracture 820-821;Both sexes;3.582 Valencia/ValÞncia;Group 1904 Femur fracture 820-821;Men;1.046 Valencia/ValÞncia;Group 1904 Femur fracture 820-821;Women;2.536 Valencia/ValÞncia;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.804 Valencia/ValÞncia;Group 1905 Leg fracture, including the ankle 823-824;Men;995 Valencia/ValÞncia;Group 1905 Leg fracture, including the ankle 823-824;Women;809 Valencia/ValÞncia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;7.384 Valencia/ValÞncia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;4.474 Valencia/ValÞncia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2.910 Valencia/ValÞncia;Group 1907 Burns 940-949;Both sexes;164 Valencia/ValÞncia;Group 1907 Burns 940-949;Men;104 Valencia/ValÞncia;Group 1907 Burns 940-949;Women;60 Valencia/ValÞncia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;630 Valencia/ValÞncia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;264 Valencia/ValÞncia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;366 Valencia/ValÞncia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;5.589 Valencia/ValÞncia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;2.945 Valencia/ValÞncia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;2.644 Valencia/ValÞncia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;169 Valencia/ValÞncia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;113 Valencia/ValÞncia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;56 Valencia/ValÞncia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;832 Valencia/ValÞncia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;410 Valencia/ValÞncia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;422 Valencia/ValÞncia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;5.014 Valencia/ValÞncia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;2.251 Valencia/ValÞncia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2.763 Valencia/ValÞncia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;152 Valencia/ValÞncia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;87 Valencia/ValÞncia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;65 Valencia/ValÞncia;Group 2102 Contraceptive management V25;Both sexes;80 Valencia/ValÞncia;Group 2102 Contraceptive management V25;Men;7 Valencia/ValÞncia;Group 2102 Contraceptive management V25;Women;73 Valencia/ValÞncia;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Valencia/ValÞncia;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Valencia/ValÞncia;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Valencia/ValÞncia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1.571 Valencia/ValÞncia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;877 Valencia/ValÞncia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;694 Valencia/ValÞncia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;3.211 Valencia/ValÞncia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1.280 Valencia/ValÞncia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.931 EXTREMADURA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;111.830 EXTREMADURA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;53.042 EXTREMADURA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;58.788 EXTREMADURA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.834 EXTREMADURA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;982 EXTREMADURA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;852 EXTREMADURA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;328 EXTREMADURA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;177 EXTREMADURA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;151 EXTREMADURA;Group 0102 Imprecise intestinal infections 009;Both sexes;268 EXTREMADURA;Group 0102 Imprecise intestinal infections 009;Men;126 EXTREMADURA;Group 0102 Imprecise intestinal infections 009;Women;143 EXTREMADURA;Group 0103 Tuberculosis 010-018, 137;Both sexes;65 EXTREMADURA;Group 0103 Tuberculosis 010-018, 137;Men;33 EXTREMADURA;Group 0103 Tuberculosis 010-018, 137;Women;32 EXTREMADURA;Group 0104 Septicaemia 038;Both sexes;417 EXTREMADURA;Group 0104 Septicaemia 038;Men;204 EXTREMADURA;Group 0104 Septicaemia 038;Women;213 EXTREMADURA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;43 EXTREMADURA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;29 EXTREMADURA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;14 EXTREMADURA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;712 EXTREMADURA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;413 EXTREMADURA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;299 EXTREMADURA;Group 0200 Neoplasms 140-239;Both sexes;10.248 EXTREMADURA;Group 0200 Neoplasms 140-239;Men;5.363 EXTREMADURA;Group 0200 Neoplasms 140-239;Women;4.885 EXTREMADURA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.013 EXTREMADURA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;627 EXTREMADURA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;386 EXTREMADURA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;733 EXTREMADURA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;634 EXTREMADURA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;98 EXTREMADURA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;459 EXTREMADURA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;260 EXTREMADURA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;198 EXTREMADURA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;817 EXTREMADURA;Group 0204 Malignant neoplasm of breast 174-175;Men;4 EXTREMADURA;Group 0204 Malignant neoplasm of breast 174-175;Women;813 EXTREMADURA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;219 EXTREMADURA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. EXTREMADURA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;219 EXTREMADURA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;101 EXTREMADURA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. EXTREMADURA;Group 0206 Malignant neoplasm of ovary 1830;Women;101 EXTREMADURA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;301 EXTREMADURA;Group 0207 Malignant neoplasm of prostate 185;Men;301 EXTREMADURA;Group 0207 Malignant neoplasm of prostate 185;Women;.. EXTREMADURA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;774 EXTREMADURA;Group 0208 Malignant neoplasm of bladder 188;Men;665 EXTREMADURA;Group 0208 Malignant neoplasm of bladder 188;Women;109 EXTREMADURA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.847 EXTREMADURA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.712 EXTREMADURA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.136 EXTREMADURA;Group 0210 Carcinoma in situ 230-234;Both sexes;242 EXTREMADURA;Group 0210 Carcinoma in situ 230-234;Men;63 EXTREMADURA;Group 0210 Carcinoma in situ 230-234;Women;179 EXTREMADURA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;122 EXTREMADURA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;82 EXTREMADURA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;39 EXTREMADURA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;552 EXTREMADURA;Grupo 0212 Leiomyoma of uterus 218;Men;.. EXTREMADURA;Grupo 0212 Leiomyoma of uterus 218;Women;552 EXTREMADURA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2.069 EXTREMADURA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.014 EXTREMADURA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.055 EXTREMADURA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.112 EXTREMADURA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;532 EXTREMADURA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;580 EXTREMADURA;Group 0301 Anaemias 280-285;Both sexes;719 EXTREMADURA;Group 0301 Anaemias 280-285;Men;327 EXTREMADURA;Group 0301 Anaemias 280-285;Women;392 EXTREMADURA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;393 EXTREMADURA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;205 EXTREMADURA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;188 EXTREMADURA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.642 EXTREMADURA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;680 EXTREMADURA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;961 EXTREMADURA;Group 0401 Diabetes mellitus 249-250;Both sexes;575 EXTREMADURA;Group 0401 Diabetes mellitus 249-250;Men;316 EXTREMADURA;Group 0401 Diabetes mellitus 249-250;Women;259 EXTREMADURA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.067 EXTREMADURA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;365 EXTREMADURA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;702 EXTREMADURA;Group 0500 Mental disorders 290-319;Both sexes;3.231 EXTREMADURA;Group 0500 Mental disorders 290-319;Men;1.824 EXTREMADURA;Group 0500 Mental disorders 290-319;Women;1.407 EXTREMADURA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;51 EXTREMADURA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;28 EXTREMADURA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;23 EXTREMADURA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;247 EXTREMADURA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;210 EXTREMADURA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;37 EXTREMADURA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;91 EXTREMADURA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;67 EXTREMADURA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;24 EXTREMADURA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;749 EXTREMADURA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;501 EXTREMADURA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;249 EXTREMADURA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;743 EXTREMADURA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;346 EXTREMADURA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;397 EXTREMADURA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.350 EXTREMADURA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;673 EXTREMADURA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;677 EXTREMADURA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.623 EXTREMADURA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.249 EXTREMADURA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.374 EXTREMADURA;Group 0601 Alzheimer's disease 3310;Both sexes;51 EXTREMADURA;Group 0601 Alzheimer's disease 3310;Men;23 EXTREMADURA;Group 0601 Alzheimer's disease 3310;Women;28 EXTREMADURA;Group 0602 Multiple sclerosis 340;Both sexes;104 EXTREMADURA;Group 0602 Multiple sclerosis 340;Men;36 EXTREMADURA;Group 0602 Multiple sclerosis 340;Women;67 EXTREMADURA;Group 0603 Epilepsy 345;Both sexes;508 EXTREMADURA;Group 0603 Epilepsy 345;Men;283 EXTREMADURA;Group 0603 Epilepsy 345;Women;225 EXTREMADURA;Group 0604 Transient cerebral ischemia 435;Both sexes;629 EXTREMADURA;Group 0604 Transient cerebral ischemia 435;Men;301 EXTREMADURA;Group 0604 Transient cerebral ischemia 435;Women;328 EXTREMADURA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.332 EXTREMADURA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;606 EXTREMADURA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;725 EXTREMADURA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1.698 EXTREMADURA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;914 EXTREMADURA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;785 EXTREMADURA;Grupo 0701 Cataract 366;Both sexes;598 EXTREMADURA;Grupo 0701 Cataract 366;Men;274 EXTREMADURA;Grupo 0701 Cataract 366;Women;324 EXTREMADURA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;1.100 EXTREMADURA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;639 EXTREMADURA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;461 EXTREMADURA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;530 EXTREMADURA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;241 EXTREMADURA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;288 EXTREMADURA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;14.848 EXTREMADURA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;8.293 EXTREMADURA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;6.555 EXTREMADURA;Group 0901 Hypertensive disease 401-405;Both sexes;519 EXTREMADURA;Group 0901 Hypertensive disease 401-405;Men;225 EXTREMADURA;Group 0901 Hypertensive disease 401-405;Women;294 EXTREMADURA;Group 0902 Angina pectoris 4111, 413;Both sexes;906 EXTREMADURA;Group 0902 Angina pectoris 4111, 413;Men;536 EXTREMADURA;Group 0902 Angina pectoris 4111, 413;Women;370 EXTREMADURA;Group 0903 Acute myocardial infarction 410;Both sexes;1.288 EXTREMADURA;Group 0903 Acute myocardial infarction 410;Men;899 EXTREMADURA;Group 0903 Acute myocardial infarction 410;Women;390 EXTREMADURA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.091 EXTREMADURA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;811 EXTREMADURA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;280 EXTREMADURA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;589 EXTREMADURA;Group 0905 Diseases of the lungs circulation 415-417;Men;312 EXTREMADURA;Group 0905 Diseases of the lungs circulation 415-417;Women;277 EXTREMADURA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.095 EXTREMADURA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.118 EXTREMADURA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;977 EXTREMADURA;Grupo 0907 Heart failure 428;Both sexes;2.905 EXTREMADURA;Grupo 0907 Heart failure 428;Men;1.311 EXTREMADURA;Grupo 0907 Heart failure 428;Women;1.595 EXTREMADURA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.594 EXTREMADURA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.373 EXTREMADURA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.222 EXTREMADURA;Grupo 0909 Atherosclerosis 440;Both sexes;299 EXTREMADURA;Grupo 0909 Atherosclerosis 440;Men;234 EXTREMADURA;Grupo 0909 Atherosclerosis 440;Women;65 EXTREMADURA;Group 0910 Varicose veins of lower extremities 454;Both sexes;340 EXTREMADURA;Group 0910 Varicose veins of lower extremities 454;Men;111 EXTREMADURA;Group 0910 Varicose veins of lower extremities 454;Women;229 EXTREMADURA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.221 EXTREMADURA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.365 EXTREMADURA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;856 EXTREMADURA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;13.626 EXTREMADURA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;8.127 EXTREMADURA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;5.499 EXTREMADURA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;610 EXTREMADURA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;332 EXTREMADURA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;278 EXTREMADURA;Group 1002 Pneumonia 480-486;Both sexes;2.690 EXTREMADURA;Group 1002 Pneumonia 480-486;Men;1.656 EXTREMADURA;Group 1002 Pneumonia 480-486;Women;1.034 EXTREMADURA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;826 EXTREMADURA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;475 EXTREMADURA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;351 EXTREMADURA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;884 EXTREMADURA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;459 EXTREMADURA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;424 EXTREMADURA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;967 EXTREMADURA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;638 EXTREMADURA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;329 EXTREMADURA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.538 EXTREMADURA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.358 EXTREMADURA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;180 EXTREMADURA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;301 EXTREMADURA;Group 1007 Asthma 4930-4931,4938-4939;Men;99 EXTREMADURA;Group 1007 Asthma 4930-4931,4938-4939;Women;202 EXTREMADURA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5.810 EXTREMADURA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;3.110 EXTREMADURA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2.700 EXTREMADURA;Group 1100 Diseases of the digestive system 520-579;Both sexes;13.885 EXTREMADURA;Group 1100 Diseases of the digestive system 520-579;Men;7.894 EXTREMADURA;Group 1100 Diseases of the digestive system 520-579;Women;5.991 EXTREMADURA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;162 EXTREMADURA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;64 EXTREMADURA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;98 EXTREMADURA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;168 EXTREMADURA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;86 EXTREMADURA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;81 EXTREMADURA;Group 1103 Diseases of the esophagus 530;Both sexes;282 EXTREMADURA;Group 1103 Diseases of the esophagus 530;Men;175 EXTREMADURA;Group 1103 Diseases of the esophagus 530;Women;107 EXTREMADURA;Group 1104 Peptic ulcer 531-534;Both sexes;231 EXTREMADURA;Group 1104 Peptic ulcer 531-534;Men;153 EXTREMADURA;Group 1104 Peptic ulcer 531-534;Women;78 EXTREMADURA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;411 EXTREMADURA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;203 EXTREMADURA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;208 EXTREMADURA;Group 1106 Appendicitis 540-543;Both sexes;1.049 EXTREMADURA;Group 1106 Appendicitis 540-543;Men;608 EXTREMADURA;Group 1106 Appendicitis 540-543;Women;441 EXTREMADURA;Group 1107 Inguinal hernia 550;Both sexes;1.283 EXTREMADURA;Group 1107 Inguinal hernia 550;Men;1.136 EXTREMADURA;Group 1107 Inguinal hernia 550;Women;148 EXTREMADURA;Group 1108 Other abdominal hernia 551-553;Both sexes;985 EXTREMADURA;Group 1108 Other abdominal hernia 551-553;Men;481 EXTREMADURA;Group 1108 Other abdominal hernia 551-553;Women;504 EXTREMADURA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;247 EXTREMADURA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;126 EXTREMADURA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;122 EXTREMADURA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;907 EXTREMADURA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;491 EXTREMADURA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;415 EXTREMADURA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;836 EXTREMADURA;Group 1111 Intestinal obstruction without hernia 560;Men;457 EXTREMADURA;Group 1111 Intestinal obstruction without hernia 560;Women;379 EXTREMADURA;Group 1112 Intestinal diverticulosis 562;Both sexes;443 EXTREMADURA;Group 1112 Intestinal diverticulosis 562;Men;242 EXTREMADURA;Group 1112 Intestinal diverticulosis 562;Women;201 EXTREMADURA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.025 EXTREMADURA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;691 EXTREMADURA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;333 EXTREMADURA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;450 EXTREMADURA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;219 EXTREMADURA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;230 EXTREMADURA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;215 EXTREMADURA;Group 1115 Alcoholic hepatitis 5710-5713;Men;196 EXTREMADURA;Group 1115 Alcoholic hepatitis 5710-5713;Women;19 EXTREMADURA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;405 EXTREMADURA;Group 1116 Other diseases of the liver 570,5714-573;Men;248 EXTREMADURA;Group 1116 Other diseases of the liver 570,5714-573;Women;157 EXTREMADURA;Group 1117 Cholelithiasis 574;Both sexes;2.261 EXTREMADURA;Group 1117 Cholelithiasis 574;Men;933 EXTREMADURA;Group 1117 Cholelithiasis 574;Women;1.328 EXTREMADURA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;864 EXTREMADURA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;461 EXTREMADURA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;403 EXTREMADURA;Group 1119 Pancreatic diseases 577;Both sexes;884 EXTREMADURA;Group 1119 Pancreatic diseases 577;Men;484 EXTREMADURA;Group 1119 Pancreatic diseases 577;Women;400 EXTREMADURA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;775 EXTREMADURA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;438 EXTREMADURA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;337 EXTREMADURA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.048 EXTREMADURA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;549 EXTREMADURA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;499 EXTREMADURA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;605 EXTREMADURA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;350 EXTREMADURA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;255 EXTREMADURA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;54 EXTREMADURA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;24 EXTREMADURA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;30 EXTREMADURA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;389 EXTREMADURA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;175 EXTREMADURA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;214 EXTREMADURA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;6.610 EXTREMADURA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.944 EXTREMADURA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.665 EXTREMADURA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. EXTREMADURA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. EXTREMADURA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. EXTREMADURA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. EXTREMADURA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. EXTREMADURA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. EXTREMADURA;Group 1303 Internal derangement of knee 717;Both sexes;721 EXTREMADURA;Group 1303 Internal derangement of knee 717;Men;504 EXTREMADURA;Group 1303 Internal derangement of knee 717;Women;217 EXTREMADURA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.531 EXTREMADURA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;960 EXTREMADURA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.572 EXTREMADURA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;108 EXTREMADURA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;46 EXTREMADURA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;61 EXTREMADURA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;397 EXTREMADURA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;205 EXTREMADURA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;192 EXTREMADURA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;625 EXTREMADURA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;345 EXTREMADURA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;280 EXTREMADURA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;176 EXTREMADURA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;80 EXTREMADURA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;95 EXTREMADURA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;799 EXTREMADURA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;440 EXTREMADURA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;359 EXTREMADURA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.253 EXTREMADURA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;364 EXTREMADURA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;889 EXTREMADURA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;7.511 EXTREMADURA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3.006 EXTREMADURA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4.505 EXTREMADURA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;642 EXTREMADURA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;270 EXTREMADURA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;372 EXTREMADURA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;812 EXTREMADURA;Group 1402 Renal failure 5836-5837, 584-586;Men;431 EXTREMADURA;Group 1402 Renal failure 5836-5837, 584-586;Women;381 EXTREMADURA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;725 EXTREMADURA;Group 1403 Urolithiasis 592, 594, 7880;Men;403 EXTREMADURA;Group 1403 Urolithiasis 592, 594, 7880;Women;322 EXTREMADURA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.602 EXTREMADURA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;719 EXTREMADURA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;883 EXTREMADURA;Group 1405 Prostatic hyperplasia 600;Both sexes;443 EXTREMADURA;Group 1405 Prostatic hyperplasia 600;Men;443 EXTREMADURA;Group 1405 Prostatic hyperplasia 600;Women;.. EXTREMADURA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;669 EXTREMADURA;Group 1406 Other diseases of the male genital organs 601-608;Men;669 EXTREMADURA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. EXTREMADURA;Group 1407 Disorders of breast 610-612;Both sexes;362 EXTREMADURA;Group 1407 Disorders of breast 610-612;Men;43 EXTREMADURA;Group 1407 Disorders of breast 610-612;Women;318 EXTREMADURA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;254 EXTREMADURA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. EXTREMADURA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;254 EXTREMADURA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;279 EXTREMADURA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. EXTREMADURA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;279 EXTREMADURA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.722 EXTREMADURA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;27 EXTREMADURA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.695 EXTREMADURA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;11.736 EXTREMADURA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. EXTREMADURA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;11.736 EXTREMADURA;Group 1501 Legally induced abortion 635;Both sexes;1 EXTREMADURA;Group 1501 Legally induced abortion 635;Men;.. EXTREMADURA;Group 1501 Legally induced abortion 635;Women;1 EXTREMADURA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.187 EXTREMADURA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. EXTREMADURA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.187 EXTREMADURA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6.035 EXTREMADURA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. EXTREMADURA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6.035 EXTREMADURA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2.765 EXTREMADURA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. EXTREMADURA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2.765 EXTREMADURA;Group 1505 Single spontaneous delivery 650;Both sexes;533 EXTREMADURA;Group 1505 Single spontaneous delivery 650;Men;.. EXTREMADURA;Group 1505 Single spontaneous delivery 650;Women;533 EXTREMADURA;Group 1506 Other deliveries 6695-6697;Both sexes;580 EXTREMADURA;Group 1506 Other deliveries 6695-6697;Men;.. EXTREMADURA;Group 1506 Other deliveries 6695-6697;Women;580 EXTREMADURA;Group 1507 Complications related to the puerperium 670-676;Both sexes;55 EXTREMADURA;Group 1507 Complications related to the puerperium 670-676;Men;.. EXTREMADURA;Group 1507 Complications related to the puerperium 670-676;Women;55 EXTREMADURA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;579 EXTREMADURA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. EXTREMADURA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;579 EXTREMADURA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.667 EXTREMADURA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;884 EXTREMADURA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;783 EXTREMADURA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;325 EXTREMADURA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;173 EXTREMADURA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;153 EXTREMADURA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.342 EXTREMADURA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;712 EXTREMADURA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;630 EXTREMADURA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;790 EXTREMADURA;Grupo 1700 Congenital abnormalities 740-759;Men;505 EXTREMADURA;Grupo 1700 Congenital abnormalities 740-759;Women;285 EXTREMADURA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;7.248 EXTREMADURA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4.012 EXTREMADURA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3.236 EXTREMADURA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;676 EXTREMADURA;Group 1801 Pain in throat and chest 7841, 7865;Men;385 EXTREMADURA;Group 1801 Pain in throat and chest 7841, 7865;Women;291 EXTREMADURA;Group 1802 Abdominal pain 7890;Both sexes;649 EXTREMADURA;Group 1802 Abdominal pain 7890;Men;275 EXTREMADURA;Group 1802 Abdominal pain 7890;Women;374 EXTREMADURA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;889 EXTREMADURA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;462 EXTREMADURA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;427 EXTREMADURA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5.033 EXTREMADURA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.890 EXTREMADURA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.143 EXTREMADURA;Group 1900 Injuries and poisoning 800-999;Both sexes;8.015 EXTREMADURA;Group 1900 Injuries and poisoning 800-999;Men;3.940 EXTREMADURA;Group 1900 Injuries and poisoning 800-999;Women;4.075 EXTREMADURA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;360 EXTREMADURA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;206 EXTREMADURA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;154 EXTREMADURA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;221 EXTREMADURA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;155 EXTREMADURA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;66 EXTREMADURA;Group 1903 Radius and ulna fracture 813;Both sexes;462 EXTREMADURA;Group 1903 Radius and ulna fracture 813;Men;209 EXTREMADURA;Group 1903 Radius and ulna fracture 813;Women;253 EXTREMADURA;Group 1904 Femur fracture 820-821;Both sexes;1.532 EXTREMADURA;Group 1904 Femur fracture 820-821;Men;423 EXTREMADURA;Group 1904 Femur fracture 820-821;Women;1.109 EXTREMADURA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;606 EXTREMADURA;Group 1905 Leg fracture, including the ankle 823-824;Men;305 EXTREMADURA;Group 1905 Leg fracture, including the ankle 823-824;Women;301 EXTREMADURA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2.104 EXTREMADURA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.272 EXTREMADURA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;833 EXTREMADURA;Group 1907 Burns 940-949;Both sexes;78 EXTREMADURA;Group 1907 Burns 940-949;Men;46 EXTREMADURA;Group 1907 Burns 940-949;Women;32 EXTREMADURA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;287 EXTREMADURA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;132 EXTREMADURA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;156 EXTREMADURA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.042 EXTREMADURA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.047 EXTREMADURA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;995 EXTREMADURA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;50 EXTREMADURA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;27 EXTREMADURA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;23 EXTREMADURA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;271 EXTREMADURA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;119 EXTREMADURA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;153 EXTREMADURA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.931 EXTREMADURA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.104 EXTREMADURA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;827 EXTREMADURA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;390 EXTREMADURA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;285 EXTREMADURA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;105 EXTREMADURA;Group 2102 Contraceptive management V25;Both sexes;72 EXTREMADURA;Group 2102 Contraceptive management V25;Men;1 EXTREMADURA;Group 2102 Contraceptive management V25;Women;71 EXTREMADURA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. EXTREMADURA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. EXTREMADURA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. EXTREMADURA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;634 EXTREMADURA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;375 EXTREMADURA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;259 EXTREMADURA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;836 EXTREMADURA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;443 EXTREMADURA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;392 Badajoz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;72.886 Badajoz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;34.361 Badajoz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;38.525 Badajoz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.194 Badajoz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;644 Badajoz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;550 Badajoz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;154 Badajoz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;92 Badajoz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;62 Badajoz;Group 0102 Imprecise intestinal infections 009;Both sexes;169 Badajoz;Group 0102 Imprecise intestinal infections 009;Men;82 Badajoz;Group 0102 Imprecise intestinal infections 009;Women;88 Badajoz;Group 0103 Tuberculosis 010-018, 137;Both sexes;45 Badajoz;Group 0103 Tuberculosis 010-018, 137;Men;24 Badajoz;Group 0103 Tuberculosis 010-018, 137;Women;21 Badajoz;Group 0104 Septicaemia 038;Both sexes;281 Badajoz;Group 0104 Septicaemia 038;Men;127 Badajoz;Group 0104 Septicaemia 038;Women;154 Badajoz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;38 Badajoz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;27 Badajoz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;11 Badajoz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;506 Badajoz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;292 Badajoz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;214 Badajoz;Group 0200 Neoplasms 140-239;Both sexes;6.267 Badajoz;Group 0200 Neoplasms 140-239;Men;3.299 Badajoz;Group 0200 Neoplasms 140-239;Women;2.968 Badajoz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;631 Badajoz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;394 Badajoz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;237 Badajoz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;468 Badajoz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;406 Badajoz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;61 Badajoz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;68 Badajoz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;33 Badajoz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;34 Badajoz;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;489 Badajoz;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Badajoz;Group 0204 Malignant neoplasm of breast 174-175;Women;486 Badajoz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;131 Badajoz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Badajoz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;131 Badajoz;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;61 Badajoz;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Badajoz;Group 0206 Malignant neoplasm of ovary 1830;Women;61 Badajoz;Group 0207 Malignant neoplasm of prostate 185;Both sexes;156 Badajoz;Group 0207 Malignant neoplasm of prostate 185;Men;156 Badajoz;Group 0207 Malignant neoplasm of prostate 185;Women;.. Badajoz;Group 0208 Malignant neoplasm of bladder 188;Both sexes;438 Badajoz;Group 0208 Malignant neoplasm of bladder 188;Men;381 Badajoz;Group 0208 Malignant neoplasm of bladder 188;Women;57 Badajoz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.888 Badajoz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.133 Badajoz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;756 Badajoz;Group 0210 Carcinoma in situ 230-234;Both sexes;162 Badajoz;Group 0210 Carcinoma in situ 230-234;Men;47 Badajoz;Group 0210 Carcinoma in situ 230-234;Women;115 Badajoz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;67 Badajoz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;43 Badajoz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;23 Badajoz;Grupo 0212 Leiomyoma of uterus 218;Both sexes;336 Badajoz;Grupo 0212 Leiomyoma of uterus 218;Men;.. Badajoz;Grupo 0212 Leiomyoma of uterus 218;Women;336 Badajoz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.373 Badajoz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;702 Badajoz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;671 Badajoz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;748 Badajoz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;359 Badajoz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;389 Badajoz;Group 0301 Anaemias 280-285;Both sexes;523 Badajoz;Group 0301 Anaemias 280-285;Men;240 Badajoz;Group 0301 Anaemias 280-285;Women;283 Badajoz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;225 Badajoz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;119 Badajoz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;106 Badajoz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.004 Badajoz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;425 Badajoz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;578 Badajoz;Group 0401 Diabetes mellitus 249-250;Both sexes;376 Badajoz;Group 0401 Diabetes mellitus 249-250;Men;204 Badajoz;Group 0401 Diabetes mellitus 249-250;Women;172 Badajoz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;628 Badajoz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;222 Badajoz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;406 Badajoz;Group 0500 Mental disorders 290-319;Both sexes;1.625 Badajoz;Group 0500 Mental disorders 290-319;Men;871 Badajoz;Group 0500 Mental disorders 290-319;Women;754 Badajoz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;43 Badajoz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;23 Badajoz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;20 Badajoz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;97 Badajoz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;81 Badajoz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;16 Badajoz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;60 Badajoz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;44 Badajoz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;16 Badajoz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;304 Badajoz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;201 Badajoz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;104 Badajoz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;380 Badajoz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;161 Badajoz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;219 Badajoz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;741 Badajoz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;362 Badajoz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;379 Badajoz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.016 Badajoz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;956 Badajoz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.060 Badajoz;Group 0601 Alzheimer's disease 3310;Both sexes;42 Badajoz;Group 0601 Alzheimer's disease 3310;Men;19 Badajoz;Group 0601 Alzheimer's disease 3310;Women;23 Badajoz;Group 0602 Multiple sclerosis 340;Both sexes;87 Badajoz;Group 0602 Multiple sclerosis 340;Men;27 Badajoz;Group 0602 Multiple sclerosis 340;Women;59 Badajoz;Group 0603 Epilepsy 345;Both sexes;369 Badajoz;Group 0603 Epilepsy 345;Men;204 Badajoz;Group 0603 Epilepsy 345;Women;165 Badajoz;Group 0604 Transient cerebral ischemia 435;Both sexes;510 Badajoz;Group 0604 Transient cerebral ischemia 435;Men;242 Badajoz;Group 0604 Transient cerebral ischemia 435;Women;268 Badajoz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.009 Badajoz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;464 Badajoz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;544 Badajoz;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;851 Badajoz;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;472 Badajoz;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;380 Badajoz;Grupo 0701 Cataract 366;Both sexes;134 Badajoz;Grupo 0701 Cataract 366;Men;60 Badajoz;Grupo 0701 Cataract 366;Women;74 Badajoz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;717 Badajoz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;411 Badajoz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;306 Badajoz;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;345 Badajoz;Group 0800 Diseases of the ear and the mastoid 380-389;Men;154 Badajoz;Group 0800 Diseases of the ear and the mastoid 380-389;Women;190 Badajoz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;9.809 Badajoz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5.433 Badajoz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4.376 Badajoz;Group 0901 Hypertensive disease 401-405;Both sexes;372 Badajoz;Group 0901 Hypertensive disease 401-405;Men;154 Badajoz;Group 0901 Hypertensive disease 401-405;Women;218 Badajoz;Group 0902 Angina pectoris 4111, 413;Both sexes;640 Badajoz;Group 0902 Angina pectoris 4111, 413;Men;376 Badajoz;Group 0902 Angina pectoris 4111, 413;Women;264 Badajoz;Group 0903 Acute myocardial infarction 410;Both sexes;730 Badajoz;Group 0903 Acute myocardial infarction 410;Men;493 Badajoz;Group 0903 Acute myocardial infarction 410;Women;238 Badajoz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;683 Badajoz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;507 Badajoz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;176 Badajoz;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;383 Badajoz;Group 0905 Diseases of the lungs circulation 415-417;Men;207 Badajoz;Group 0905 Diseases of the lungs circulation 415-417;Women;176 Badajoz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.519 Badajoz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;808 Badajoz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;711 Badajoz;Grupo 0907 Heart failure 428;Both sexes;2.056 Badajoz;Grupo 0907 Heart failure 428;Men;920 Badajoz;Grupo 0907 Heart failure 428;Women;1.137 Badajoz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.619 Badajoz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;877 Badajoz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;743 Badajoz;Grupo 0909 Atherosclerosis 440;Both sexes;120 Badajoz;Grupo 0909 Atherosclerosis 440;Men;95 Badajoz;Grupo 0909 Atherosclerosis 440;Women;25 Badajoz;Group 0910 Varicose veins of lower extremities 454;Both sexes;209 Badajoz;Group 0910 Varicose veins of lower extremities 454;Men;72 Badajoz;Group 0910 Varicose veins of lower extremities 454;Women;137 Badajoz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.477 Badajoz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;926 Badajoz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;551 Badajoz;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;9.114 Badajoz;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;5.383 Badajoz;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3.731 Badajoz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;394 Badajoz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;208 Badajoz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;186 Badajoz;Group 1002 Pneumonia 480-486;Both sexes;1.705 Badajoz;Group 1002 Pneumonia 480-486;Men;1.045 Badajoz;Group 1002 Pneumonia 480-486;Women;660 Badajoz;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;500 Badajoz;Group 1003 Acute bronchitis and bronchiolitis 466;Men;293 Badajoz;Group 1003 Acute bronchitis and bronchiolitis 466;Women;207 Badajoz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;634 Badajoz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;322 Badajoz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;311 Badajoz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;532 Badajoz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;344 Badajoz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;188 Badajoz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.001 Badajoz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;871 Badajoz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;130 Badajoz;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;191 Badajoz;Group 1007 Asthma 4930-4931,4938-4939;Men;60 Badajoz;Group 1007 Asthma 4930-4931,4938-4939;Women;131 Badajoz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;4.157 Badajoz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.240 Badajoz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.917 Badajoz;Group 1100 Diseases of the digestive system 520-579;Both sexes;8.960 Badajoz;Group 1100 Diseases of the digestive system 520-579;Men;5.019 Badajoz;Group 1100 Diseases of the digestive system 520-579;Women;3.941 Badajoz;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;146 Badajoz;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;58 Badajoz;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;88 Badajoz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;122 Badajoz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;63 Badajoz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;58 Badajoz;Group 1103 Diseases of the esophagus 530;Both sexes;172 Badajoz;Group 1103 Diseases of the esophagus 530;Men;109 Badajoz;Group 1103 Diseases of the esophagus 530;Women;63 Badajoz;Group 1104 Peptic ulcer 531-534;Both sexes;151 Badajoz;Group 1104 Peptic ulcer 531-534;Men;101 Badajoz;Group 1104 Peptic ulcer 531-534;Women;50 Badajoz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;308 Badajoz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;145 Badajoz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;163 Badajoz;Group 1106 Appendicitis 540-543;Both sexes;725 Badajoz;Group 1106 Appendicitis 540-543;Men;406 Badajoz;Group 1106 Appendicitis 540-543;Women;319 Badajoz;Group 1107 Inguinal hernia 550;Both sexes;700 Badajoz;Group 1107 Inguinal hernia 550;Men;616 Badajoz;Group 1107 Inguinal hernia 550;Women;85 Badajoz;Group 1108 Other abdominal hernia 551-553;Both sexes;661 Badajoz;Group 1108 Other abdominal hernia 551-553;Men;333 Badajoz;Group 1108 Other abdominal hernia 551-553;Women;328 Badajoz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;177 Badajoz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;92 Badajoz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;86 Badajoz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;614 Badajoz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;323 Badajoz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;290 Badajoz;Group 1111 Intestinal obstruction without hernia 560;Both sexes;556 Badajoz;Group 1111 Intestinal obstruction without hernia 560;Men;294 Badajoz;Group 1111 Intestinal obstruction without hernia 560;Women;262 Badajoz;Group 1112 Intestinal diverticulosis 562;Both sexes;292 Badajoz;Group 1112 Intestinal diverticulosis 562;Men;153 Badajoz;Group 1112 Intestinal diverticulosis 562;Women;139 Badajoz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;612 Badajoz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;434 Badajoz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;177 Badajoz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;343 Badajoz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;165 Badajoz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;177 Badajoz;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;169 Badajoz;Group 1115 Alcoholic hepatitis 5710-5713;Men;152 Badajoz;Group 1115 Alcoholic hepatitis 5710-5713;Women;17 Badajoz;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;279 Badajoz;Group 1116 Other diseases of the liver 570,5714-573;Men;162 Badajoz;Group 1116 Other diseases of the liver 570,5714-573;Women;117 Badajoz;Group 1117 Cholelithiasis 574;Both sexes;1.369 Badajoz;Group 1117 Cholelithiasis 574;Men;560 Badajoz;Group 1117 Cholelithiasis 574;Women;809 Badajoz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;509 Badajoz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;270 Badajoz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;239 Badajoz;Group 1119 Pancreatic diseases 577;Both sexes;536 Badajoz;Group 1119 Pancreatic diseases 577;Men;302 Badajoz;Group 1119 Pancreatic diseases 577;Women;234 Badajoz;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;517 Badajoz;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;279 Badajoz;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;238 Badajoz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;652 Badajoz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;349 Badajoz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;303 Badajoz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;373 Badajoz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;206 Badajoz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;167 Badajoz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;40 Badajoz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;19 Badajoz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;21 Badajoz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;239 Badajoz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;124 Badajoz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;115 Badajoz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;4.456 Badajoz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.017 Badajoz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2.438 Badajoz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Badajoz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Badajoz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Badajoz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Badajoz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Badajoz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Badajoz;Group 1303 Internal derangement of knee 717;Both sexes;525 Badajoz;Group 1303 Internal derangement of knee 717;Men;375 Badajoz;Group 1303 Internal derangement of knee 717;Women;150 Badajoz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.613 Badajoz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;616 Badajoz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;998 Badajoz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;77 Badajoz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;30 Badajoz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;46 Badajoz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;295 Badajoz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;159 Badajoz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;136 Badajoz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;484 Badajoz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;265 Badajoz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;219 Badajoz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;99 Badajoz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;41 Badajoz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;57 Badajoz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;552 Badajoz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;296 Badajoz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;256 Badajoz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;811 Badajoz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;235 Badajoz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;576 Badajoz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;4.842 Badajoz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.957 Badajoz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2.885 Badajoz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;473 Badajoz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;203 Badajoz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;270 Badajoz;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;569 Badajoz;Group 1402 Renal failure 5836-5837, 584-586;Men;291 Badajoz;Group 1402 Renal failure 5836-5837, 584-586;Women;278 Badajoz;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;506 Badajoz;Group 1403 Urolithiasis 592, 594, 7880;Men;278 Badajoz;Group 1403 Urolithiasis 592, 594, 7880;Women;228 Badajoz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;978 Badajoz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;440 Badajoz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;538 Badajoz;Group 1405 Prostatic hyperplasia 600;Both sexes;249 Badajoz;Group 1405 Prostatic hyperplasia 600;Men;249 Badajoz;Group 1405 Prostatic hyperplasia 600;Women;.. Badajoz;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;447 Badajoz;Group 1406 Other diseases of the male genital organs 601-608;Men;447 Badajoz;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Badajoz;Group 1407 Disorders of breast 610-612;Both sexes;214 Badajoz;Group 1407 Disorders of breast 610-612;Men;25 Badajoz;Group 1407 Disorders of breast 610-612;Women;188 Badajoz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;161 Badajoz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Badajoz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;161 Badajoz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;150 Badajoz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Badajoz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;150 Badajoz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.094 Badajoz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;23 Badajoz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.071 Badajoz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;8.098 Badajoz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Badajoz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;8.098 Badajoz;Group 1501 Legally induced abortion 635;Both sexes;.. Badajoz;Group 1501 Legally induced abortion 635;Men;.. Badajoz;Group 1501 Legally induced abortion 635;Women;.. Badajoz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;805 Badajoz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Badajoz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;805 Badajoz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4.155 Badajoz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Badajoz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4.155 Badajoz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.887 Badajoz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Badajoz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.887 Badajoz;Group 1505 Single spontaneous delivery 650;Both sexes;309 Badajoz;Group 1505 Single spontaneous delivery 650;Men;.. Badajoz;Group 1505 Single spontaneous delivery 650;Women;309 Badajoz;Group 1506 Other deliveries 6695-6697;Both sexes;518 Badajoz;Group 1506 Other deliveries 6695-6697;Men;.. Badajoz;Group 1506 Other deliveries 6695-6697;Women;518 Badajoz;Group 1507 Complications related to the puerperium 670-676;Both sexes;42 Badajoz;Group 1507 Complications related to the puerperium 670-676;Men;.. Badajoz;Group 1507 Complications related to the puerperium 670-676;Women;42 Badajoz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;381 Badajoz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Badajoz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;381 Badajoz;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;829 Badajoz;Group 1600 Some disorders originating in the perinatal period 760-779;Men;443 Badajoz;Group 1600 Some disorders originating in the perinatal period 760-779;Women;386 Badajoz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;180 Badajoz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;95 Badajoz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;86 Badajoz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;649 Badajoz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;349 Badajoz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;300 Badajoz;Grupo 1700 Congenital abnormalities 740-759;Both sexes;605 Badajoz;Grupo 1700 Congenital abnormalities 740-759;Men;401 Badajoz;Grupo 1700 Congenital abnormalities 740-759;Women;204 Badajoz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;5.293 Badajoz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;2.938 Badajoz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2.355 Badajoz;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;428 Badajoz;Group 1801 Pain in throat and chest 7841, 7865;Men;243 Badajoz;Group 1801 Pain in throat and chest 7841, 7865;Women;185 Badajoz;Group 1802 Abdominal pain 7890;Both sexes;435 Badajoz;Group 1802 Abdominal pain 7890;Men;181 Badajoz;Group 1802 Abdominal pain 7890;Women;254 Badajoz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;809 Badajoz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;411 Badajoz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;398 Badajoz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;3.620 Badajoz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.103 Badajoz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.517 Badajoz;Group 1900 Injuries and poisoning 800-999;Both sexes;5.043 Badajoz;Group 1900 Injuries and poisoning 800-999;Men;2.537 Badajoz;Group 1900 Injuries and poisoning 800-999;Women;2.506 Badajoz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;260 Badajoz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;154 Badajoz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;106 Badajoz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;154 Badajoz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;114 Badajoz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;40 Badajoz;Group 1903 Radius and ulna fracture 813;Both sexes;269 Badajoz;Group 1903 Radius and ulna fracture 813;Men;125 Badajoz;Group 1903 Radius and ulna fracture 813;Women;144 Badajoz;Group 1904 Femur fracture 820-821;Both sexes;928 Badajoz;Group 1904 Femur fracture 820-821;Men;258 Badajoz;Group 1904 Femur fracture 820-821;Women;670 Badajoz;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;383 Badajoz;Group 1905 Leg fracture, including the ankle 823-824;Men;206 Badajoz;Group 1905 Leg fracture, including the ankle 823-824;Women;177 Badajoz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.257 Badajoz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;784 Badajoz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;474 Badajoz;Group 1907 Burns 940-949;Both sexes;17 Badajoz;Group 1907 Burns 940-949;Men;10 Badajoz;Group 1907 Burns 940-949;Women;7 Badajoz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;184 Badajoz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;87 Badajoz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;98 Badajoz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.358 Badajoz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;694 Badajoz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;664 Badajoz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;49 Badajoz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;26 Badajoz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;23 Badajoz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;182 Badajoz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;80 Badajoz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;103 Badajoz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.138 Badajoz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;705 Badajoz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;433 Badajoz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;377 Badajoz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;277 Badajoz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;100 Badajoz;Group 2102 Contraceptive management V25;Both sexes;34 Badajoz;Group 2102 Contraceptive management V25;Men;1 Badajoz;Group 2102 Contraceptive management V25;Women;33 Badajoz;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Badajoz;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Badajoz;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Badajoz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;262 Badajoz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;156 Badajoz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;106 Badajoz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;466 Badajoz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;271 Badajoz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;194 Cßceres;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;38.944 Cßceres;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;18.681 Cßceres;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;20.263 Cßceres;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;640 Cßceres;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;338 Cßceres;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;302 Cßceres;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;174 Cßceres;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;85 Cßceres;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;89 Cßceres;Group 0102 Imprecise intestinal infections 009;Both sexes;99 Cßceres;Group 0102 Imprecise intestinal infections 009;Men;44 Cßceres;Group 0102 Imprecise intestinal infections 009;Women;55 Cßceres;Group 0103 Tuberculosis 010-018, 137;Both sexes;20 Cßceres;Group 0103 Tuberculosis 010-018, 137;Men;9 Cßceres;Group 0103 Tuberculosis 010-018, 137;Women;11 Cßceres;Group 0104 Septicaemia 038;Both sexes;136 Cßceres;Group 0104 Septicaemia 038;Men;77 Cßceres;Group 0104 Septicaemia 038;Women;59 Cßceres;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;5 Cßceres;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;2 Cßceres;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 Cßceres;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;206 Cßceres;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;121 Cßceres;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;85 Cßceres;Group 0200 Neoplasms 140-239;Both sexes;3.981 Cßceres;Group 0200 Neoplasms 140-239;Men;2.064 Cßceres;Group 0200 Neoplasms 140-239;Women;1.917 Cßceres;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;382 Cßceres;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;233 Cßceres;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;149 Cßceres;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;265 Cßceres;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;228 Cßceres;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;37 Cßceres;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;391 Cßceres;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;227 Cßceres;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;164 Cßceres;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;328 Cßceres;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Cßceres;Group 0204 Malignant neoplasm of breast 174-175;Women;327 Cßceres;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;88 Cßceres;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Cßceres;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;88 Cßceres;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;40 Cßceres;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Cßceres;Group 0206 Malignant neoplasm of ovary 1830;Women;40 Cßceres;Group 0207 Malignant neoplasm of prostate 185;Both sexes;145 Cßceres;Group 0207 Malignant neoplasm of prostate 185;Men;145 Cßceres;Group 0207 Malignant neoplasm of prostate 185;Women;.. Cßceres;Group 0208 Malignant neoplasm of bladder 188;Both sexes;336 Cßceres;Group 0208 Malignant neoplasm of bladder 188;Men;284 Cßceres;Group 0208 Malignant neoplasm of bladder 188;Women;52 Cßceres;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;959 Cßceres;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;579 Cßceres;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;380 Cßceres;Group 0210 Carcinoma in situ 230-234;Both sexes;80 Cßceres;Group 0210 Carcinoma in situ 230-234;Men;16 Cßceres;Group 0210 Carcinoma in situ 230-234;Women;64 Cßceres;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;55 Cßceres;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;39 Cßceres;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;16 Cßceres;Grupo 0212 Leiomyoma of uterus 218;Both sexes;216 Cßceres;Grupo 0212 Leiomyoma of uterus 218;Men;.. Cßceres;Grupo 0212 Leiomyoma of uterus 218;Women;216 Cßceres;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;696 Cßceres;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;312 Cßceres;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;384 Cßceres;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;364 Cßceres;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;173 Cßceres;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;191 Cßceres;Group 0301 Anaemias 280-285;Both sexes;196 Cßceres;Group 0301 Anaemias 280-285;Men;87 Cßceres;Group 0301 Anaemias 280-285;Women;109 Cßceres;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;168 Cßceres;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;86 Cßceres;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;82 Cßceres;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;638 Cßceres;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;255 Cßceres;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;383 Cßceres;Group 0401 Diabetes mellitus 249-250;Both sexes;199 Cßceres;Group 0401 Diabetes mellitus 249-250;Men;112 Cßceres;Group 0401 Diabetes mellitus 249-250;Women;87 Cßceres;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;439 Cßceres;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;143 Cßceres;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;296 Cßceres;Group 0500 Mental disorders 290-319;Both sexes;1.606 Cßceres;Group 0500 Mental disorders 290-319;Men;953 Cßceres;Group 0500 Mental disorders 290-319;Women;653 Cßceres;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;8 Cßceres;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;5 Cßceres;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;3 Cßceres;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;150 Cßceres;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;129 Cßceres;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;21 Cßceres;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;31 Cßceres;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;23 Cßceres;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;8 Cßceres;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;445 Cßceres;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;300 Cßceres;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;145 Cßceres;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;363 Cßceres;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;185 Cßceres;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;178 Cßceres;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;609 Cßceres;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;311 Cßceres;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;298 Cßceres;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;607 Cßceres;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;293 Cßceres;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;314 Cßceres;Group 0601 Alzheimer's disease 3310;Both sexes;9 Cßceres;Group 0601 Alzheimer's disease 3310;Men;4 Cßceres;Group 0601 Alzheimer's disease 3310;Women;5 Cßceres;Group 0602 Multiple sclerosis 340;Both sexes;17 Cßceres;Group 0602 Multiple sclerosis 340;Men;9 Cßceres;Group 0602 Multiple sclerosis 340;Women;8 Cßceres;Group 0603 Epilepsy 345;Both sexes;139 Cßceres;Group 0603 Epilepsy 345;Men;79 Cßceres;Group 0603 Epilepsy 345;Women;60 Cßceres;Group 0604 Transient cerebral ischemia 435;Both sexes;119 Cßceres;Group 0604 Transient cerebral ischemia 435;Men;59 Cßceres;Group 0604 Transient cerebral ischemia 435;Women;60 Cßceres;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;323 Cßceres;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;142 Cßceres;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;181 Cßceres;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;847 Cßceres;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;442 Cßceres;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;405 Cßceres;Grupo 0701 Cataract 366;Both sexes;464 Cßceres;Grupo 0701 Cataract 366;Men;214 Cßceres;Grupo 0701 Cataract 366;Women;250 Cßceres;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;383 Cßceres;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;228 Cßceres;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;155 Cßceres;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;185 Cßceres;Group 0800 Diseases of the ear and the mastoid 380-389;Men;87 Cßceres;Group 0800 Diseases of the ear and the mastoid 380-389;Women;98 Cßceres;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5.039 Cßceres;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.860 Cßceres;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.179 Cßceres;Group 0901 Hypertensive disease 401-405;Both sexes;147 Cßceres;Group 0901 Hypertensive disease 401-405;Men;71 Cßceres;Group 0901 Hypertensive disease 401-405;Women;76 Cßceres;Group 0902 Angina pectoris 4111, 413;Both sexes;266 Cßceres;Group 0902 Angina pectoris 4111, 413;Men;160 Cßceres;Group 0902 Angina pectoris 4111, 413;Women;106 Cßceres;Group 0903 Acute myocardial infarction 410;Both sexes;558 Cßceres;Group 0903 Acute myocardial infarction 410;Men;406 Cßceres;Group 0903 Acute myocardial infarction 410;Women;152 Cßceres;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;408 Cßceres;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;304 Cßceres;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;104 Cßceres;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;206 Cßceres;Group 0905 Diseases of the lungs circulation 415-417;Men;105 Cßceres;Group 0905 Diseases of the lungs circulation 415-417;Women;101 Cßceres;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;576 Cßceres;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;310 Cßceres;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;266 Cßceres;Grupo 0907 Heart failure 428;Both sexes;849 Cßceres;Grupo 0907 Heart failure 428;Men;391 Cßceres;Grupo 0907 Heart failure 428;Women;458 Cßceres;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;975 Cßceres;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;496 Cßceres;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;479 Cßceres;Grupo 0909 Atherosclerosis 440;Both sexes;179 Cßceres;Grupo 0909 Atherosclerosis 440;Men;139 Cßceres;Grupo 0909 Atherosclerosis 440;Women;40 Cßceres;Group 0910 Varicose veins of lower extremities 454;Both sexes;131 Cßceres;Group 0910 Varicose veins of lower extremities 454;Men;39 Cßceres;Group 0910 Varicose veins of lower extremities 454;Women;92 Cßceres;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;744 Cßceres;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;439 Cßceres;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;305 Cßceres;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;4.512 Cßceres;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2.744 Cßceres;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.768 Cßceres;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;216 Cßceres;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;124 Cßceres;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;92 Cßceres;Group 1002 Pneumonia 480-486;Both sexes;985 Cßceres;Group 1002 Pneumonia 480-486;Men;611 Cßceres;Group 1002 Pneumonia 480-486;Women;374 Cßceres;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;326 Cßceres;Group 1003 Acute bronchitis and bronchiolitis 466;Men;182 Cßceres;Group 1003 Acute bronchitis and bronchiolitis 466;Women;144 Cßceres;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;250 Cßceres;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;137 Cßceres;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;113 Cßceres;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;435 Cßceres;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;294 Cßceres;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;141 Cßceres;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;537 Cßceres;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;487 Cßceres;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;50 Cßceres;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;110 Cßceres;Group 1007 Asthma 4930-4931,4938-4939;Men;39 Cßceres;Group 1007 Asthma 4930-4931,4938-4939;Women;71 Cßceres;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.653 Cßceres;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;870 Cßceres;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;783 Cßceres;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.925 Cßceres;Group 1100 Diseases of the digestive system 520-579;Men;2.875 Cßceres;Group 1100 Diseases of the digestive system 520-579;Women;2.050 Cßceres;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;16 Cßceres;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;6 Cßceres;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;10 Cßceres;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;46 Cßceres;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;23 Cßceres;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;23 Cßceres;Group 1103 Diseases of the esophagus 530;Both sexes;110 Cßceres;Group 1103 Diseases of the esophagus 530;Men;66 Cßceres;Group 1103 Diseases of the esophagus 530;Women;44 Cßceres;Group 1104 Peptic ulcer 531-534;Both sexes;80 Cßceres;Group 1104 Peptic ulcer 531-534;Men;52 Cßceres;Group 1104 Peptic ulcer 531-534;Women;28 Cßceres;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;103 Cßceres;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;58 Cßceres;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;45 Cßceres;Group 1106 Appendicitis 540-543;Both sexes;324 Cßceres;Group 1106 Appendicitis 540-543;Men;202 Cßceres;Group 1106 Appendicitis 540-543;Women;122 Cßceres;Group 1107 Inguinal hernia 550;Both sexes;583 Cßceres;Group 1107 Inguinal hernia 550;Men;520 Cßceres;Group 1107 Inguinal hernia 550;Women;63 Cßceres;Group 1108 Other abdominal hernia 551-553;Both sexes;324 Cßceres;Group 1108 Other abdominal hernia 551-553;Men;148 Cßceres;Group 1108 Other abdominal hernia 551-553;Women;176 Cßceres;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;70 Cßceres;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;34 Cßceres;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;36 Cßceres;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;293 Cßceres;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;168 Cßceres;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;125 Cßceres;Group 1111 Intestinal obstruction without hernia 560;Both sexes;280 Cßceres;Group 1111 Intestinal obstruction without hernia 560;Men;163 Cßceres;Group 1111 Intestinal obstruction without hernia 560;Women;117 Cßceres;Group 1112 Intestinal diverticulosis 562;Both sexes;151 Cßceres;Group 1112 Intestinal diverticulosis 562;Men;89 Cßceres;Group 1112 Intestinal diverticulosis 562;Women;62 Cßceres;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;413 Cßceres;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;257 Cßceres;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;156 Cßceres;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;107 Cßceres;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;54 Cßceres;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;53 Cßceres;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;46 Cßceres;Group 1115 Alcoholic hepatitis 5710-5713;Men;44 Cßceres;Group 1115 Alcoholic hepatitis 5710-5713;Women;2 Cßceres;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;126 Cßceres;Group 1116 Other diseases of the liver 570,5714-573;Men;86 Cßceres;Group 1116 Other diseases of the liver 570,5714-573;Women;40 Cßceres;Group 1117 Cholelithiasis 574;Both sexes;892 Cßceres;Group 1117 Cholelithiasis 574;Men;373 Cßceres;Group 1117 Cholelithiasis 574;Women;519 Cßceres;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;355 Cßceres;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;191 Cßceres;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;164 Cßceres;Group 1119 Pancreatic diseases 577;Both sexes;348 Cßceres;Group 1119 Pancreatic diseases 577;Men;182 Cßceres;Group 1119 Pancreatic diseases 577;Women;166 Cßceres;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;258 Cßceres;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;159 Cßceres;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;99 Cßceres;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;396 Cßceres;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;200 Cßceres;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;196 Cßceres;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;232 Cßceres;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;144 Cßceres;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;88 Cßceres;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;14 Cßceres;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;5 Cßceres;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;9 Cßceres;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;150 Cßceres;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;51 Cßceres;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;99 Cßceres;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.154 Cßceres;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;927 Cßceres;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.227 Cßceres;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Cßceres;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Cßceres;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Cßceres;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Cßceres;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Cßceres;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Cßceres;Group 1303 Internal derangement of knee 717;Both sexes;196 Cßceres;Group 1303 Internal derangement of knee 717;Men;129 Cßceres;Group 1303 Internal derangement of knee 717;Women;67 Cßceres;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;918 Cßceres;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;344 Cßceres;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;574 Cßceres;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;31 Cßceres;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;16 Cßceres;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;15 Cßceres;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;102 Cßceres;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;46 Cßceres;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;56 Cßceres;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;141 Cßceres;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;80 Cßceres;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;61 Cßceres;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;77 Cßceres;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;39 Cßceres;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;38 Cßceres;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;247 Cßceres;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;144 Cßceres;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;103 Cßceres;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;442 Cßceres;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;129 Cßceres;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;313 Cßceres;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.669 Cßceres;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.049 Cßceres;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.620 Cßceres;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;169 Cßceres;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;67 Cßceres;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;102 Cßceres;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;243 Cßceres;Group 1402 Renal failure 5836-5837, 584-586;Men;140 Cßceres;Group 1402 Renal failure 5836-5837, 584-586;Women;103 Cßceres;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;219 Cßceres;Group 1403 Urolithiasis 592, 594, 7880;Men;125 Cßceres;Group 1403 Urolithiasis 592, 594, 7880;Women;94 Cßceres;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;624 Cßceres;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;279 Cßceres;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;345 Cßceres;Group 1405 Prostatic hyperplasia 600;Both sexes;194 Cßceres;Group 1405 Prostatic hyperplasia 600;Men;194 Cßceres;Group 1405 Prostatic hyperplasia 600;Women;.. Cßceres;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;222 Cßceres;Group 1406 Other diseases of the male genital organs 601-608;Men;222 Cßceres;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Cßceres;Group 1407 Disorders of breast 610-612;Both sexes;148 Cßceres;Group 1407 Disorders of breast 610-612;Men;18 Cßceres;Group 1407 Disorders of breast 610-612;Women;130 Cßceres;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;93 Cßceres;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Cßceres;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;93 Cßceres;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;129 Cßceres;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Cßceres;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;129 Cßceres;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;628 Cßceres;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;4 Cßceres;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;624 Cßceres;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3.638 Cßceres;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Cßceres;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3.638 Cßceres;Group 1501 Legally induced abortion 635;Both sexes;1 Cßceres;Group 1501 Legally induced abortion 635;Men;.. Cßceres;Group 1501 Legally induced abortion 635;Women;1 Cßceres;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;382 Cßceres;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Cßceres;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;382 Cßceres;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.880 Cßceres;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Cßceres;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.880 Cßceres;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;878 Cßceres;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Cßceres;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;878 Cßceres;Group 1505 Single spontaneous delivery 650;Both sexes;224 Cßceres;Group 1505 Single spontaneous delivery 650;Men;.. Cßceres;Group 1505 Single spontaneous delivery 650;Women;224 Cßceres;Group 1506 Other deliveries 6695-6697;Both sexes;62 Cßceres;Group 1506 Other deliveries 6695-6697;Men;.. Cßceres;Group 1506 Other deliveries 6695-6697;Women;62 Cßceres;Group 1507 Complications related to the puerperium 670-676;Both sexes;13 Cßceres;Group 1507 Complications related to the puerperium 670-676;Men;.. Cßceres;Group 1507 Complications related to the puerperium 670-676;Women;13 Cßceres;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;198 Cßceres;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Cßceres;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;198 Cßceres;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;838 Cßceres;Group 1600 Some disorders originating in the perinatal period 760-779;Men;441 Cßceres;Group 1600 Some disorders originating in the perinatal period 760-779;Women;397 Cßceres;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;145 Cßceres;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;78 Cßceres;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;67 Cßceres;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;693 Cßceres;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;363 Cßceres;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;330 Cßceres;Grupo 1700 Congenital abnormalities 740-759;Both sexes;185 Cßceres;Grupo 1700 Congenital abnormalities 740-759;Men;104 Cßceres;Grupo 1700 Congenital abnormalities 740-759;Women;81 Cßceres;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.955 Cßceres;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.074 Cßceres;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;881 Cßceres;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;248 Cßceres;Group 1801 Pain in throat and chest 7841, 7865;Men;142 Cßceres;Group 1801 Pain in throat and chest 7841, 7865;Women;106 Cßceres;Group 1802 Abdominal pain 7890;Both sexes;214 Cßceres;Group 1802 Abdominal pain 7890;Men;94 Cßceres;Group 1802 Abdominal pain 7890;Women;120 Cßceres;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;80 Cßceres;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;51 Cßceres;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;29 Cßceres;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.413 Cßceres;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;787 Cßceres;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;626 Cßceres;Group 1900 Injuries and poisoning 800-999;Both sexes;2.972 Cßceres;Group 1900 Injuries and poisoning 800-999;Men;1.403 Cßceres;Group 1900 Injuries and poisoning 800-999;Women;1.569 Cßceres;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;100 Cßceres;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;52 Cßceres;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;48 Cßceres;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;67 Cßceres;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;41 Cßceres;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;26 Cßceres;Group 1903 Radius and ulna fracture 813;Both sexes;193 Cßceres;Group 1903 Radius and ulna fracture 813;Men;84 Cßceres;Group 1903 Radius and ulna fracture 813;Women;109 Cßceres;Group 1904 Femur fracture 820-821;Both sexes;604 Cßceres;Group 1904 Femur fracture 820-821;Men;165 Cßceres;Group 1904 Femur fracture 820-821;Women;439 Cßceres;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;223 Cßceres;Group 1905 Leg fracture, including the ankle 823-824;Men;99 Cßceres;Group 1905 Leg fracture, including the ankle 823-824;Women;124 Cßceres;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;847 Cßceres;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;488 Cßceres;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;359 Cßceres;Group 1907 Burns 940-949;Both sexes;61 Cßceres;Group 1907 Burns 940-949;Men;36 Cßceres;Group 1907 Burns 940-949;Women;25 Cßceres;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;103 Cßceres;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;45 Cßceres;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;58 Cßceres;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;684 Cßceres;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;353 Cßceres;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;331 Cßceres;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;1 Cßceres;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;1 Cßceres;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Cßceres;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;89 Cßceres;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;39 Cßceres;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;50 Cßceres;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;793 Cßceres;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;399 Cßceres;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;394 Cßceres;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;13 Cßceres;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;8 Cßceres;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;5 Cßceres;Group 2102 Contraceptive management V25;Both sexes;38 Cßceres;Group 2102 Contraceptive management V25;Men;.. Cßceres;Group 2102 Contraceptive management V25;Women;38 Cßceres;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Cßceres;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Cßceres;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Cßceres;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;372 Cßceres;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;219 Cßceres;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;153 Cßceres;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;370 Cßceres;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;172 Cßceres;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;198 GALICIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;293.533 GALICIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;142.872 GALICIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;150.661 GALICIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;5.635 GALICIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;3.108 GALICIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;2.527 GALICIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;1.045 GALICIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;550 GALICIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;495 GALICIA;Group 0102 Imprecise intestinal infections 009;Both sexes;206 GALICIA;Group 0102 Imprecise intestinal infections 009;Men;88 GALICIA;Group 0102 Imprecise intestinal infections 009;Women;118 GALICIA;Group 0103 Tuberculosis 010-018, 137;Both sexes;246 GALICIA;Group 0103 Tuberculosis 010-018, 137;Men;176 GALICIA;Group 0103 Tuberculosis 010-018, 137;Women;70 GALICIA;Group 0104 Septicaemia 038;Both sexes;1.854 GALICIA;Group 0104 Septicaemia 038;Men;940 GALICIA;Group 0104 Septicaemia 038;Women;914 GALICIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;248 GALICIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;182 GALICIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;66 GALICIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;2.036 GALICIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;1.172 GALICIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;864 GALICIA;Group 0200 Neoplasms 140-239;Both sexes;30.411 GALICIA;Group 0200 Neoplasms 140-239;Men;16.190 GALICIA;Group 0200 Neoplasms 140-239;Women;14.221 GALICIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;3.114 GALICIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;1.860 GALICIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;1.254 GALICIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;2.131 GALICIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1.704 GALICIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;427 GALICIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;497 GALICIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;236 GALICIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;261 GALICIA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;2.152 GALICIA;Group 0204 Malignant neoplasm of breast 174-175;Men;16 GALICIA;Group 0204 Malignant neoplasm of breast 174-175;Women;2.136 GALICIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;693 GALICIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. GALICIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;693 GALICIA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;330 GALICIA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. GALICIA;Group 0206 Malignant neoplasm of ovary 1830;Women;330 GALICIA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1.710 GALICIA;Group 0207 Malignant neoplasm of prostate 185;Men;1.710 GALICIA;Group 0207 Malignant neoplasm of prostate 185;Women;.. GALICIA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;2.334 GALICIA;Group 0208 Malignant neoplasm of bladder 188;Men;1.960 GALICIA;Group 0208 Malignant neoplasm of bladder 188;Women;374 GALICIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;11.353 GALICIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;6.678 GALICIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;4.675 GALICIA;Group 0210 Carcinoma in situ 230-234;Both sexes;640 GALICIA;Group 0210 Carcinoma in situ 230-234;Men;277 GALICIA;Group 0210 Carcinoma in situ 230-234;Women;363 GALICIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;330 GALICIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;210 GALICIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;120 GALICIA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1.244 GALICIA;Grupo 0212 Leiomyoma of uterus 218;Men;.. GALICIA;Grupo 0212 Leiomyoma of uterus 218;Women;1.244 GALICIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;3.883 GALICIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.539 GALICIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;2.344 GALICIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;2.640 GALICIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;1.345 GALICIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;1.295 GALICIA;Group 0301 Anaemias 280-285;Both sexes;1.637 GALICIA;Group 0301 Anaemias 280-285;Men;804 GALICIA;Group 0301 Anaemias 280-285;Women;833 GALICIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;1.003 GALICIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;541 GALICIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;462 GALICIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;4.720 GALICIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.930 GALICIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2.790 GALICIA;Group 0401 Diabetes mellitus 249-250;Both sexes;1.646 GALICIA;Group 0401 Diabetes mellitus 249-250;Men;918 GALICIA;Group 0401 Diabetes mellitus 249-250;Women;728 GALICIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;3.074 GALICIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;1.012 GALICIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;2.062 GALICIA;Group 0500 Mental disorders 290-319;Both sexes;5.533 GALICIA;Group 0500 Mental disorders 290-319;Men;2.699 GALICIA;Group 0500 Mental disorders 290-319;Women;2.834 GALICIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;183 GALICIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;74 GALICIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;109 GALICIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;401 GALICIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;304 GALICIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;97 GALICIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;256 GALICIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;179 GALICIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;77 GALICIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.576 GALICIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;880 GALICIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;696 GALICIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1.318 GALICIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;469 GALICIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;849 GALICIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.799 GALICIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;793 GALICIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;1.006 GALICIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;5.755 GALICIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.771 GALICIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2.984 GALICIA;Group 0601 Alzheimer's disease 3310;Both sexes;86 GALICIA;Group 0601 Alzheimer's disease 3310;Men;24 GALICIA;Group 0601 Alzheimer's disease 3310;Women;62 GALICIA;Group 0602 Multiple sclerosis 340;Both sexes;334 GALICIA;Group 0602 Multiple sclerosis 340;Men;86 GALICIA;Group 0602 Multiple sclerosis 340;Women;248 GALICIA;Group 0603 Epilepsy 345;Both sexes;927 GALICIA;Group 0603 Epilepsy 345;Men;493 GALICIA;Group 0603 Epilepsy 345;Women;434 GALICIA;Group 0604 Transient cerebral ischemia 435;Both sexes;1.010 GALICIA;Group 0604 Transient cerebral ischemia 435;Men;463 GALICIA;Group 0604 Transient cerebral ischemia 435;Women;547 GALICIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.398 GALICIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.705 GALICIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.693 GALICIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1.352 GALICIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;709 GALICIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;643 GALICIA;Grupo 0701 Cataract 366;Both sexes;137 GALICIA;Grupo 0701 Cataract 366;Men;70 GALICIA;Grupo 0701 Cataract 366;Women;67 GALICIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;1.215 GALICIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;639 GALICIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;576 GALICIA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;1.304 GALICIA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;641 GALICIA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;663 GALICIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;39.988 GALICIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;22.521 GALICIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;17.467 GALICIA;Group 0901 Hypertensive disease 401-405;Both sexes;2.468 GALICIA;Group 0901 Hypertensive disease 401-405;Men;1.117 GALICIA;Group 0901 Hypertensive disease 401-405;Women;1.351 GALICIA;Group 0902 Angina pectoris 4111, 413;Both sexes;1.456 GALICIA;Group 0902 Angina pectoris 4111, 413;Men;897 GALICIA;Group 0902 Angina pectoris 4111, 413;Women;559 GALICIA;Group 0903 Acute myocardial infarction 410;Both sexes;3.203 GALICIA;Group 0903 Acute myocardial infarction 410;Men;2.297 GALICIA;Group 0903 Acute myocardial infarction 410;Women;906 GALICIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;2.896 GALICIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;2.260 GALICIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;636 GALICIA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;1.512 GALICIA;Group 0905 Diseases of the lungs circulation 415-417;Men;636 GALICIA;Group 0905 Diseases of the lungs circulation 415-417;Women;876 GALICIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;4.725 GALICIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;2.708 GALICIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;2.017 GALICIA;Grupo 0907 Heart failure 428;Both sexes;7.938 GALICIA;Grupo 0907 Heart failure 428;Men;3.970 GALICIA;Grupo 0907 Heart failure 428;Women;3.968 GALICIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;6.371 GALICIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;3.211 GALICIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;3.160 GALICIA;Grupo 0909 Atherosclerosis 440;Both sexes;1.474 GALICIA;Grupo 0909 Atherosclerosis 440;Men;1.079 GALICIA;Grupo 0909 Atherosclerosis 440;Women;395 GALICIA;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.375 GALICIA;Group 0910 Varicose veins of lower extremities 454;Men;458 GALICIA;Group 0910 Varicose veins of lower extremities 454;Women;917 GALICIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;6.570 GALICIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;3.888 GALICIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;2.682 GALICIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;38.335 GALICIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;21.614 GALICIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;16.721 GALICIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1.413 GALICIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;754 GALICIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;659 GALICIA;Group 1002 Pneumonia 480-486;Both sexes;8.096 GALICIA;Group 1002 Pneumonia 480-486;Men;4.760 GALICIA;Group 1002 Pneumonia 480-486;Women;3.336 GALICIA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.533 GALICIA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;839 GALICIA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;694 GALICIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;2.028 GALICIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1.034 GALICIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;994 GALICIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;2.836 GALICIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1.745 GALICIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;1.091 GALICIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;6.385 GALICIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;4.700 GALICIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1.685 GALICIA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1.414 GALICIA;Group 1007 Asthma 4930-4931,4938-4939;Men;428 GALICIA;Group 1007 Asthma 4930-4931,4938-4939;Women;986 GALICIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;14.630 GALICIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;7.354 GALICIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;7.276 GALICIA;Group 1100 Diseases of the digestive system 520-579;Both sexes;35.589 GALICIA;Group 1100 Diseases of the digestive system 520-579;Men;20.117 GALICIA;Group 1100 Diseases of the digestive system 520-579;Women;15.472 GALICIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;486 GALICIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;231 GALICIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;255 GALICIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;448 GALICIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;247 GALICIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;201 GALICIA;Group 1103 Diseases of the esophagus 530;Both sexes;602 GALICIA;Group 1103 Diseases of the esophagus 530;Men;373 GALICIA;Group 1103 Diseases of the esophagus 530;Women;229 GALICIA;Group 1104 Peptic ulcer 531-534;Both sexes;542 GALICIA;Group 1104 Peptic ulcer 531-534;Men;357 GALICIA;Group 1104 Peptic ulcer 531-534;Women;185 GALICIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;787 GALICIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;412 GALICIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;375 GALICIA;Group 1106 Appendicitis 540-543;Both sexes;3.034 GALICIA;Group 1106 Appendicitis 540-543;Men;1.705 GALICIA;Group 1106 Appendicitis 540-543;Women;1.329 GALICIA;Group 1107 Inguinal hernia 550;Both sexes;3.951 GALICIA;Group 1107 Inguinal hernia 550;Men;3.547 GALICIA;Group 1107 Inguinal hernia 550;Women;404 GALICIA;Group 1108 Other abdominal hernia 551-553;Both sexes;2.664 GALICIA;Group 1108 Other abdominal hernia 551-553;Men;1.365 GALICIA;Group 1108 Other abdominal hernia 551-553;Women;1.299 GALICIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;712 GALICIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;382 GALICIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;330 GALICIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.735 GALICIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;819 GALICIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;916 GALICIA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1.810 GALICIA;Group 1111 Intestinal obstruction without hernia 560;Men;937 GALICIA;Group 1111 Intestinal obstruction without hernia 560;Women;873 GALICIA;Group 1112 Intestinal diverticulosis 562;Both sexes;1.471 GALICIA;Group 1112 Intestinal diverticulosis 562;Men;689 GALICIA;Group 1112 Intestinal diverticulosis 562;Women;782 GALICIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;2.098 GALICIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;1.333 GALICIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;765 GALICIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;1.176 GALICIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;529 GALICIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;647 GALICIA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;847 GALICIA;Group 1115 Alcoholic hepatitis 5710-5713;Men;703 GALICIA;Group 1115 Alcoholic hepatitis 5710-5713;Women;144 GALICIA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;1.405 GALICIA;Group 1116 Other diseases of the liver 570,5714-573;Men;883 GALICIA;Group 1116 Other diseases of the liver 570,5714-573;Women;522 GALICIA;Group 1117 Cholelithiasis 574;Both sexes;6.860 GALICIA;Group 1117 Cholelithiasis 574;Men;2.909 GALICIA;Group 1117 Cholelithiasis 574;Women;3.951 GALICIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1.544 GALICIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;851 GALICIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;693 GALICIA;Group 1119 Pancreatic diseases 577;Both sexes;2.074 GALICIA;Group 1119 Pancreatic diseases 577;Men;1.133 GALICIA;Group 1119 Pancreatic diseases 577;Women;941 GALICIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1.343 GALICIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;712 GALICIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;631 GALICIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;3.695 GALICIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;2.007 GALICIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1.688 GALICIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;2.435 GALICIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;1.422 GALICIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;1.013 GALICIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;222 GALICIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;112 GALICIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;110 GALICIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;1.038 GALICIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;473 GALICIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;565 GALICIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;21.829 GALICIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;10.129 GALICIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;11.700 GALICIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. GALICIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. GALICIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. GALICIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. GALICIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. GALICIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. GALICIA;Group 1303 Internal derangement of knee 717;Both sexes;3.092 GALICIA;Group 1303 Internal derangement of knee 717;Men;2.050 GALICIA;Group 1303 Internal derangement of knee 717;Women;1.042 GALICIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;8.356 GALICIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;3.411 GALICIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;4.945 GALICIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;464 GALICIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;158 GALICIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;306 GALICIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;788 GALICIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;386 GALICIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;402 GALICIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.735 GALICIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;942 GALICIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;793 GALICIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;313 GALICIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;144 GALICIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;169 GALICIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;3.395 GALICIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1.846 GALICIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;1.549 GALICIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;3.686 GALICIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;1.192 GALICIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;2.494 GALICIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;17.746 GALICIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;8.421 GALICIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;9.325 GALICIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.595 GALICIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;621 GALICIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;974 GALICIA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1.484 GALICIA;Group 1402 Renal failure 5836-5837, 584-586;Men;834 GALICIA;Group 1402 Renal failure 5836-5837, 584-586;Women;650 GALICIA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.807 GALICIA;Group 1403 Urolithiasis 592, 594, 7880;Men;1.057 GALICIA;Group 1403 Urolithiasis 592, 594, 7880;Women;750 GALICIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;5.541 GALICIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;2.592 GALICIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;2.949 GALICIA;Group 1405 Prostatic hyperplasia 600;Both sexes;1.782 GALICIA;Group 1405 Prostatic hyperplasia 600;Men;1.782 GALICIA;Group 1405 Prostatic hyperplasia 600;Women;.. GALICIA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;1.416 GALICIA;Group 1406 Other diseases of the male genital organs 601-608;Men;1.416 GALICIA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. GALICIA;Group 1407 Disorders of breast 610-612;Both sexes;744 GALICIA;Group 1407 Disorders of breast 610-612;Men;87 GALICIA;Group 1407 Disorders of breast 610-612;Women;657 GALICIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;469 GALICIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. GALICIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;469 GALICIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;290 GALICIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. GALICIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;290 GALICIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;2.618 GALICIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;32 GALICIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;2.586 GALICIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;25.153 GALICIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. GALICIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;25.153 GALICIA;Group 1501 Legally induced abortion 635;Both sexes;278 GALICIA;Group 1501 Legally induced abortion 635;Men;.. GALICIA;Group 1501 Legally induced abortion 635;Women;278 GALICIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;2.641 GALICIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. GALICIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;2.641 GALICIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;14.868 GALICIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. GALICIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;14.868 GALICIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3.976 GALICIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. GALICIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3.976 GALICIA;Group 1505 Single spontaneous delivery 650;Both sexes;1.218 GALICIA;Group 1505 Single spontaneous delivery 650;Men;.. GALICIA;Group 1505 Single spontaneous delivery 650;Women;1.218 GALICIA;Group 1506 Other deliveries 6695-6697;Both sexes;624 GALICIA;Group 1506 Other deliveries 6695-6697;Men;.. GALICIA;Group 1506 Other deliveries 6695-6697;Women;624 GALICIA;Group 1507 Complications related to the puerperium 670-676;Both sexes;206 GALICIA;Group 1507 Complications related to the puerperium 670-676;Men;.. GALICIA;Group 1507 Complications related to the puerperium 670-676;Women;206 GALICIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.342 GALICIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. GALICIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.342 GALICIA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;3.596 GALICIA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;2.031 GALICIA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1.565 GALICIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;903 GALICIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;493 GALICIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;410 GALICIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;2.693 GALICIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1.538 GALICIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;1.155 GALICIA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;2.313 GALICIA;Grupo 1700 Congenital abnormalities 740-759;Men;1.422 GALICIA;Grupo 1700 Congenital abnormalities 740-759;Women;891 GALICIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;12.966 GALICIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;6.870 GALICIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;6.096 GALICIA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.235 GALICIA;Group 1801 Pain in throat and chest 7841, 7865;Men;731 GALICIA;Group 1801 Pain in throat and chest 7841, 7865;Women;504 GALICIA;Group 1802 Abdominal pain 7890;Both sexes;1.185 GALICIA;Group 1802 Abdominal pain 7890;Men;442 GALICIA;Group 1802 Abdominal pain 7890;Women;743 GALICIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;2.654 GALICIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1.314 GALICIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;1.340 GALICIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;7.892 GALICIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;4.383 GALICIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3.509 GALICIA;Group 1900 Injuries and poisoning 800-999;Both sexes;29.171 GALICIA;Group 1900 Injuries and poisoning 800-999;Men;15.134 GALICIA;Group 1900 Injuries and poisoning 800-999;Women;14.037 GALICIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1.895 GALICIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;1.078 GALICIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;817 GALICIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;947 GALICIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;666 GALICIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;281 GALICIA;Group 1903 Radius and ulna fracture 813;Both sexes;1.644 GALICIA;Group 1903 Radius and ulna fracture 813;Men;695 GALICIA;Group 1903 Radius and ulna fracture 813;Women;949 GALICIA;Group 1904 Femur fracture 820-821;Both sexes;4.061 GALICIA;Group 1904 Femur fracture 820-821;Men;1.005 GALICIA;Group 1904 Femur fracture 820-821;Women;3.056 GALICIA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;2.153 GALICIA;Group 1905 Leg fracture, including the ankle 823-824;Men;1.056 GALICIA;Group 1905 Leg fracture, including the ankle 823-824;Women;1.097 GALICIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;9.106 GALICIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;5.493 GALICIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;3.613 GALICIA;Group 1907 Burns 940-949;Both sexes;324 GALICIA;Group 1907 Burns 940-949;Men;192 GALICIA;Group 1907 Burns 940-949;Women;132 GALICIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;677 GALICIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;344 GALICIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;333 GALICIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;7.742 GALICIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;4.269 GALICIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;3.473 GALICIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;57 GALICIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;34 GALICIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;23 GALICIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;565 GALICIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;302 GALICIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;263 GALICIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;5.802 GALICIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;3.213 GALICIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2.589 GALICIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;306 GALICIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;160 GALICIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;146 GALICIA;Group 2102 Contraceptive management V25;Both sexes;126 GALICIA;Group 2102 Contraceptive management V25;Men;3 GALICIA;Group 2102 Contraceptive management V25;Women;123 GALICIA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. GALICIA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. GALICIA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. GALICIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;2.576 GALICIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;1.721 GALICIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;855 GALICIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2.794 GALICIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1.329 GALICIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.465 Coru±a, A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;124.590 Coru±a, A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;60.744 Coru±a, A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;63.846 Coru±a, A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2.311 Coru±a, A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.290 Coru±a, A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.021 Coru±a, A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;406 Coru±a, A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;213 Coru±a, A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;193 Coru±a, A;Group 0102 Imprecise intestinal infections 009;Both sexes;116 Coru±a, A;Group 0102 Imprecise intestinal infections 009;Men;56 Coru±a, A;Group 0102 Imprecise intestinal infections 009;Women;60 Coru±a, A;Group 0103 Tuberculosis 010-018, 137;Both sexes;108 Coru±a, A;Group 0103 Tuberculosis 010-018, 137;Men;72 Coru±a, A;Group 0103 Tuberculosis 010-018, 137;Women;36 Coru±a, A;Group 0104 Septicaemia 038;Both sexes;710 Coru±a, A;Group 0104 Septicaemia 038;Men;383 Coru±a, A;Group 0104 Septicaemia 038;Women;327 Coru±a, A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;106 Coru±a, A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;81 Coru±a, A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;25 Coru±a, A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;865 Coru±a, A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;485 Coru±a, A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;380 Coru±a, A;Group 0200 Neoplasms 140-239;Both sexes;14.430 Coru±a, A;Group 0200 Neoplasms 140-239;Men;7.742 Coru±a, A;Group 0200 Neoplasms 140-239;Women;6.688 Coru±a, A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.368 Coru±a, A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;839 Coru±a, A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;529 Coru±a, A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.132 Coru±a, A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;890 Coru±a, A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;242 Coru±a, A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;268 Coru±a, A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;130 Coru±a, A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;138 Coru±a, A;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.014 Coru±a, A;Group 0204 Malignant neoplasm of breast 174-175;Men;7 Coru±a, A;Group 0204 Malignant neoplasm of breast 174-175;Women;1.007 Coru±a, A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;346 Coru±a, A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Coru±a, A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;346 Coru±a, A;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;197 Coru±a, A;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Coru±a, A;Group 0206 Malignant neoplasm of ovary 1830;Women;197 Coru±a, A;Group 0207 Malignant neoplasm of prostate 185;Both sexes;747 Coru±a, A;Group 0207 Malignant neoplasm of prostate 185;Men;747 Coru±a, A;Group 0207 Malignant neoplasm of prostate 185;Women;.. Coru±a, A;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.004 Coru±a, A;Group 0208 Malignant neoplasm of bladder 188;Men;855 Coru±a, A;Group 0208 Malignant neoplasm of bladder 188;Women;149 Coru±a, A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5.375 Coru±a, A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3.211 Coru±a, A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2.164 Coru±a, A;Group 0210 Carcinoma in situ 230-234;Both sexes;329 Coru±a, A;Group 0210 Carcinoma in situ 230-234;Men;172 Coru±a, A;Group 0210 Carcinoma in situ 230-234;Women;157 Coru±a, A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;177 Coru±a, A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;115 Coru±a, A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;62 Coru±a, A;Grupo 0212 Leiomyoma of uterus 218;Both sexes;572 Coru±a, A;Grupo 0212 Leiomyoma of uterus 218;Men;.. Coru±a, A;Grupo 0212 Leiomyoma of uterus 218;Women;572 Coru±a, A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.901 Coru±a, A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;776 Coru±a, A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.125 Coru±a, A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.026 Coru±a, A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;498 Coru±a, A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;528 Coru±a, A;Group 0301 Anaemias 280-285;Both sexes;587 Coru±a, A;Group 0301 Anaemias 280-285;Men;288 Coru±a, A;Group 0301 Anaemias 280-285;Women;299 Coru±a, A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;439 Coru±a, A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;210 Coru±a, A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;229 Coru±a, A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.808 Coru±a, A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;737 Coru±a, A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.071 Coru±a, A;Group 0401 Diabetes mellitus 249-250;Both sexes;630 Coru±a, A;Group 0401 Diabetes mellitus 249-250;Men;377 Coru±a, A;Group 0401 Diabetes mellitus 249-250;Women;253 Coru±a, A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.178 Coru±a, A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;360 Coru±a, A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;818 Coru±a, A;Group 0500 Mental disorders 290-319;Both sexes;2.263 Coru±a, A;Group 0500 Mental disorders 290-319;Men;1.116 Coru±a, A;Group 0500 Mental disorders 290-319;Women;1.147 Coru±a, A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;74 Coru±a, A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;32 Coru±a, A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;42 Coru±a, A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;194 Coru±a, A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;148 Coru±a, A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;46 Coru±a, A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;125 Coru±a, A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;89 Coru±a, A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;36 Coru±a, A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;638 Coru±a, A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;340 Coru±a, A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;298 Coru±a, A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;587 Coru±a, A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;220 Coru±a, A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;367 Coru±a, A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;645 Coru±a, A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;287 Coru±a, A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;358 Coru±a, A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.362 Coru±a, A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.169 Coru±a, A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.193 Coru±a, A;Group 0601 Alzheimer's disease 3310;Both sexes;31 Coru±a, A;Group 0601 Alzheimer's disease 3310;Men;10 Coru±a, A;Group 0601 Alzheimer's disease 3310;Women;21 Coru±a, A;Group 0602 Multiple sclerosis 340;Both sexes;78 Coru±a, A;Group 0602 Multiple sclerosis 340;Men;22 Coru±a, A;Group 0602 Multiple sclerosis 340;Women;56 Coru±a, A;Group 0603 Epilepsy 345;Both sexes;394 Coru±a, A;Group 0603 Epilepsy 345;Men;220 Coru±a, A;Group 0603 Epilepsy 345;Women;174 Coru±a, A;Group 0604 Transient cerebral ischemia 435;Both sexes;368 Coru±a, A;Group 0604 Transient cerebral ischemia 435;Men;168 Coru±a, A;Group 0604 Transient cerebral ischemia 435;Women;200 Coru±a, A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.491 Coru±a, A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;749 Coru±a, A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;742 Coru±a, A;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;495 Coru±a, A;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;249 Coru±a, A;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;246 Coru±a, A;Grupo 0701 Cataract 366;Both sexes;32 Coru±a, A;Grupo 0701 Cataract 366;Men;13 Coru±a, A;Grupo 0701 Cataract 366;Women;19 Coru±a, A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;463 Coru±a, A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;236 Coru±a, A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;227 Coru±a, A;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;497 Coru±a, A;Group 0800 Diseases of the ear and the mastoid 380-389;Men;230 Coru±a, A;Group 0800 Diseases of the ear and the mastoid 380-389;Women;267 Coru±a, A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;17.602 Coru±a, A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;10.106 Coru±a, A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;7.496 Coru±a, A;Group 0901 Hypertensive disease 401-405;Both sexes;1.032 Coru±a, A;Group 0901 Hypertensive disease 401-405;Men;504 Coru±a, A;Group 0901 Hypertensive disease 401-405;Women;528 Coru±a, A;Group 0902 Angina pectoris 4111, 413;Both sexes;599 Coru±a, A;Group 0902 Angina pectoris 4111, 413;Men;344 Coru±a, A;Group 0902 Angina pectoris 4111, 413;Women;255 Coru±a, A;Group 0903 Acute myocardial infarction 410;Both sexes;1.566 Coru±a, A;Group 0903 Acute myocardial infarction 410;Men;1.113 Coru±a, A;Group 0903 Acute myocardial infarction 410;Women;453 Coru±a, A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.578 Coru±a, A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.244 Coru±a, A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;334 Coru±a, A;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;579 Coru±a, A;Group 0905 Diseases of the lungs circulation 415-417;Men;239 Coru±a, A;Group 0905 Diseases of the lungs circulation 415-417;Women;340 Coru±a, A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.077 Coru±a, A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.216 Coru±a, A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;861 Coru±a, A;Grupo 0907 Heart failure 428;Both sexes;2.998 Coru±a, A;Grupo 0907 Heart failure 428;Men;1.521 Coru±a, A;Grupo 0907 Heart failure 428;Women;1.477 Coru±a, A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.572 Coru±a, A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.305 Coru±a, A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.267 Coru±a, A;Grupo 0909 Atherosclerosis 440;Both sexes;615 Coru±a, A;Grupo 0909 Atherosclerosis 440;Men;471 Coru±a, A;Grupo 0909 Atherosclerosis 440;Women;144 Coru±a, A;Group 0910 Varicose veins of lower extremities 454;Both sexes;776 Coru±a, A;Group 0910 Varicose veins of lower extremities 454;Men;254 Coru±a, A;Group 0910 Varicose veins of lower extremities 454;Women;522 Coru±a, A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;3.210 Coru±a, A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.895 Coru±a, A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.315 Coru±a, A;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;15.122 Coru±a, A;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;8.627 Coru±a, A;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6.495 Coru±a, A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;606 Coru±a, A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;323 Coru±a, A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;283 Coru±a, A;Group 1002 Pneumonia 480-486;Both sexes;3.033 Coru±a, A;Group 1002 Pneumonia 480-486;Men;1.765 Coru±a, A;Group 1002 Pneumonia 480-486;Women;1.268 Coru±a, A;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;526 Coru±a, A;Group 1003 Acute bronchitis and bronchiolitis 466;Men;277 Coru±a, A;Group 1003 Acute bronchitis and bronchiolitis 466;Women;249 Coru±a, A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;744 Coru±a, A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;363 Coru±a, A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;381 Coru±a, A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.146 Coru±a, A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;696 Coru±a, A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;450 Coru±a, A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.808 Coru±a, A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2.182 Coru±a, A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;626 Coru±a, A;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;649 Coru±a, A;Group 1007 Asthma 4930-4931,4938-4939;Men;150 Coru±a, A;Group 1007 Asthma 4930-4931,4938-4939;Women;499 Coru±a, A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5.610 Coru±a, A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.871 Coru±a, A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2.739 Coru±a, A;Group 1100 Diseases of the digestive system 520-579;Both sexes;14.861 Coru±a, A;Group 1100 Diseases of the digestive system 520-579;Men;8.295 Coru±a, A;Group 1100 Diseases of the digestive system 520-579;Women;6.566 Coru±a, A;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;212 Coru±a, A;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;100 Coru±a, A;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;112 Coru±a, A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;173 Coru±a, A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;96 Coru±a, A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;77 Coru±a, A;Group 1103 Diseases of the esophagus 530;Both sexes;295 Coru±a, A;Group 1103 Diseases of the esophagus 530;Men;181 Coru±a, A;Group 1103 Diseases of the esophagus 530;Women;114 Coru±a, A;Group 1104 Peptic ulcer 531-534;Both sexes;253 Coru±a, A;Group 1104 Peptic ulcer 531-534;Men;166 Coru±a, A;Group 1104 Peptic ulcer 531-534;Women;87 Coru±a, A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;316 Coru±a, A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;167 Coru±a, A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;149 Coru±a, A;Group 1106 Appendicitis 540-543;Both sexes;1.192 Coru±a, A;Group 1106 Appendicitis 540-543;Men;642 Coru±a, A;Group 1106 Appendicitis 540-543;Women;550 Coru±a, A;Group 1107 Inguinal hernia 550;Both sexes;1.578 Coru±a, A;Group 1107 Inguinal hernia 550;Men;1.413 Coru±a, A;Group 1107 Inguinal hernia 550;Women;165 Coru±a, A;Group 1108 Other abdominal hernia 551-553;Both sexes;1.074 Coru±a, A;Group 1108 Other abdominal hernia 551-553;Men;554 Coru±a, A;Group 1108 Other abdominal hernia 551-553;Women;520 Coru±a, A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;330 Coru±a, A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;160 Coru±a, A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;170 Coru±a, A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;651 Coru±a, A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;299 Coru±a, A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;352 Coru±a, A;Group 1111 Intestinal obstruction without hernia 560;Both sexes;763 Coru±a, A;Group 1111 Intestinal obstruction without hernia 560;Men;413 Coru±a, A;Group 1111 Intestinal obstruction without hernia 560;Women;350 Coru±a, A;Group 1112 Intestinal diverticulosis 562;Both sexes;545 Coru±a, A;Group 1112 Intestinal diverticulosis 562;Men;256 Coru±a, A;Group 1112 Intestinal diverticulosis 562;Women;289 Coru±a, A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;858 Coru±a, A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;552 Coru±a, A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;306 Coru±a, A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;451 Coru±a, A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;214 Coru±a, A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;237 Coru±a, A;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;347 Coru±a, A;Group 1115 Alcoholic hepatitis 5710-5713;Men;298 Coru±a, A;Group 1115 Alcoholic hepatitis 5710-5713;Women;49 Coru±a, A;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;536 Coru±a, A;Group 1116 Other diseases of the liver 570,5714-573;Men;316 Coru±a, A;Group 1116 Other diseases of the liver 570,5714-573;Women;220 Coru±a, A;Group 1117 Cholelithiasis 574;Both sexes;3.218 Coru±a, A;Group 1117 Cholelithiasis 574;Men;1.330 Coru±a, A;Group 1117 Cholelithiasis 574;Women;1.888 Coru±a, A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;604 Coru±a, A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;347 Coru±a, A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;257 Coru±a, A;Group 1119 Pancreatic diseases 577;Both sexes;874 Coru±a, A;Group 1119 Pancreatic diseases 577;Men;466 Coru±a, A;Group 1119 Pancreatic diseases 577;Women;408 Coru±a, A;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;591 Coru±a, A;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;325 Coru±a, A;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;266 Coru±a, A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.428 Coru±a, A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;814 Coru±a, A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;614 Coru±a, A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;918 Coru±a, A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;548 Coru±a, A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;370 Coru±a, A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;89 Coru±a, A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;50 Coru±a, A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;39 Coru±a, A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;421 Coru±a, A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;216 Coru±a, A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;205 Coru±a, A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;9.176 Coru±a, A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.106 Coru±a, A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5.070 Coru±a, A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Coru±a, A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Coru±a, A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Coru±a, A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Coru±a, A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Coru±a, A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Coru±a, A;Group 1303 Internal derangement of knee 717;Both sexes;929 Coru±a, A;Group 1303 Internal derangement of knee 717;Men;642 Coru±a, A;Group 1303 Internal derangement of knee 717;Women;287 Coru±a, A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3.527 Coru±a, A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.428 Coru±a, A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.099 Coru±a, A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;235 Coru±a, A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;75 Coru±a, A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;160 Coru±a, A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;304 Coru±a, A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;142 Coru±a, A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;162 Coru±a, A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;749 Coru±a, A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;411 Coru±a, A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;338 Coru±a, A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;110 Coru±a, A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;57 Coru±a, A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;53 Coru±a, A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.489 Coru±a, A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;785 Coru±a, A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;704 Coru±a, A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.833 Coru±a, A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;566 Coru±a, A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.267 Coru±a, A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;6.998 Coru±a, A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3.306 Coru±a, A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3.692 Coru±a, A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;634 Coru±a, A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;253 Coru±a, A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;381 Coru±a, A;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;587 Coru±a, A;Group 1402 Renal failure 5836-5837, 584-586;Men;324 Coru±a, A;Group 1402 Renal failure 5836-5837, 584-586;Women;263 Coru±a, A;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;699 Coru±a, A;Group 1403 Urolithiasis 592, 594, 7880;Men;409 Coru±a, A;Group 1403 Urolithiasis 592, 594, 7880;Women;290 Coru±a, A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2.051 Coru±a, A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.016 Coru±a, A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.035 Coru±a, A;Group 1405 Prostatic hyperplasia 600;Both sexes;719 Coru±a, A;Group 1405 Prostatic hyperplasia 600;Men;719 Coru±a, A;Group 1405 Prostatic hyperplasia 600;Women;.. Coru±a, A;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;536 Coru±a, A;Group 1406 Other diseases of the male genital organs 601-608;Men;536 Coru±a, A;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Coru±a, A;Group 1407 Disorders of breast 610-612;Both sexes;393 Coru±a, A;Group 1407 Disorders of breast 610-612;Men;42 Coru±a, A;Group 1407 Disorders of breast 610-612;Women;351 Coru±a, A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;162 Coru±a, A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Coru±a, A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;162 Coru±a, A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;135 Coru±a, A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Coru±a, A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;135 Coru±a, A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.082 Coru±a, A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;7 Coru±a, A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.075 Coru±a, A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;11.265 Coru±a, A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Coru±a, A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;11.265 Coru±a, A;Group 1501 Legally induced abortion 635;Both sexes;79 Coru±a, A;Group 1501 Legally induced abortion 635;Men;.. Coru±a, A;Group 1501 Legally induced abortion 635;Women;79 Coru±a, A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.250 Coru±a, A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Coru±a, A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.250 Coru±a, A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6.994 Coru±a, A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Coru±a, A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6.994 Coru±a, A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.290 Coru±a, A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Coru±a, A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.290 Coru±a, A;Group 1505 Single spontaneous delivery 650;Both sexes;622 Coru±a, A;Group 1505 Single spontaneous delivery 650;Men;.. Coru±a, A;Group 1505 Single spontaneous delivery 650;Women;622 Coru±a, A;Group 1506 Other deliveries 6695-6697;Both sexes;305 Coru±a, A;Group 1506 Other deliveries 6695-6697;Men;.. Coru±a, A;Group 1506 Other deliveries 6695-6697;Women;305 Coru±a, A;Group 1507 Complications related to the puerperium 670-676;Both sexes;78 Coru±a, A;Group 1507 Complications related to the puerperium 670-676;Men;.. Coru±a, A;Group 1507 Complications related to the puerperium 670-676;Women;78 Coru±a, A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;647 Coru±a, A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Coru±a, A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;647 Coru±a, A;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.945 Coru±a, A;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.088 Coru±a, A;Group 1600 Some disorders originating in the perinatal period 760-779;Women;857 Coru±a, A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;432 Coru±a, A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;230 Coru±a, A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;202 Coru±a, A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.513 Coru±a, A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;858 Coru±a, A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;655 Coru±a, A;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.327 Coru±a, A;Grupo 1700 Congenital abnormalities 740-759;Men;784 Coru±a, A;Grupo 1700 Congenital abnormalities 740-759;Women;543 Coru±a, A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;4.892 Coru±a, A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;2.633 Coru±a, A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2.259 Coru±a, A;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;589 Coru±a, A;Group 1801 Pain in throat and chest 7841, 7865;Men;351 Coru±a, A;Group 1801 Pain in throat and chest 7841, 7865;Women;238 Coru±a, A;Group 1802 Abdominal pain 7890;Both sexes;411 Coru±a, A;Group 1802 Abdominal pain 7890;Men;151 Coru±a, A;Group 1802 Abdominal pain 7890;Women;260 Coru±a, A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;878 Coru±a, A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;456 Coru±a, A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;422 Coru±a, A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;3.014 Coru±a, A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.675 Coru±a, A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.339 Coru±a, A;Group 1900 Injuries and poisoning 800-999;Both sexes;11.853 Coru±a, A;Group 1900 Injuries and poisoning 800-999;Men;6.321 Coru±a, A;Group 1900 Injuries and poisoning 800-999;Women;5.532 Coru±a, A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;590 Coru±a, A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;336 Coru±a, A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;254 Coru±a, A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;421 Coru±a, A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;300 Coru±a, A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;121 Coru±a, A;Group 1903 Radius and ulna fracture 813;Both sexes;734 Coru±a, A;Group 1903 Radius and ulna fracture 813;Men;309 Coru±a, A;Group 1903 Radius and ulna fracture 813;Women;425 Coru±a, A;Group 1904 Femur fracture 820-821;Both sexes;1.629 Coru±a, A;Group 1904 Femur fracture 820-821;Men;399 Coru±a, A;Group 1904 Femur fracture 820-821;Women;1.230 Coru±a, A;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;860 Coru±a, A;Group 1905 Leg fracture, including the ankle 823-824;Men;411 Coru±a, A;Group 1905 Leg fracture, including the ankle 823-824;Women;449 Coru±a, A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3.256 Coru±a, A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.068 Coru±a, A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.188 Coru±a, A;Group 1907 Burns 940-949;Both sexes;172 Coru±a, A;Group 1907 Burns 940-949;Men;109 Coru±a, A;Group 1907 Burns 940-949;Women;63 Coru±a, A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;270 Coru±a, A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;141 Coru±a, A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;129 Coru±a, A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3.631 Coru±a, A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;2.092 Coru±a, A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.539 Coru±a, A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;49 Coru±a, A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;27 Coru±a, A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;22 Coru±a, A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;241 Coru±a, A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;129 Coru±a, A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;112 Coru±a, A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.929 Coru±a, A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.633 Coru±a, A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.296 Coru±a, A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;157 Coru±a, A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;77 Coru±a, A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;80 Coru±a, A;Group 2102 Contraceptive management V25;Both sexes;12 Coru±a, A;Group 2102 Contraceptive management V25;Men;.. Coru±a, A;Group 2102 Contraceptive management V25;Women;12 Coru±a, A;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Coru±a, A;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Coru±a, A;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Coru±a, A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1.218 Coru±a, A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;806 Coru±a, A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;412 Coru±a, A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.542 Coru±a, A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;750 Coru±a, A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;792 Lugo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;34.847 Lugo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;17.147 Lugo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;17.700 Lugo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;654 Lugo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;373 Lugo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;281 Lugo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;161 Lugo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;85 Lugo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;76 Lugo;Group 0102 Imprecise intestinal infections 009;Both sexes;28 Lugo;Group 0102 Imprecise intestinal infections 009;Men;12 Lugo;Group 0102 Imprecise intestinal infections 009;Women;16 Lugo;Group 0103 Tuberculosis 010-018, 137;Both sexes;27 Lugo;Group 0103 Tuberculosis 010-018, 137;Men;23 Lugo;Group 0103 Tuberculosis 010-018, 137;Women;4 Lugo;Group 0104 Septicaemia 038;Both sexes;139 Lugo;Group 0104 Septicaemia 038;Men;70 Lugo;Group 0104 Septicaemia 038;Women;69 Lugo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;28 Lugo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;20 Lugo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;8 Lugo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;271 Lugo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;163 Lugo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;108 Lugo;Group 0200 Neoplasms 140-239;Both sexes;2.991 Lugo;Group 0200 Neoplasms 140-239;Men;1.480 Lugo;Group 0200 Neoplasms 140-239;Women;1.511 Lugo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;403 Lugo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;246 Lugo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;157 Lugo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;142 Lugo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;110 Lugo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;32 Lugo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;45 Lugo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;21 Lugo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;24 Lugo;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;256 Lugo;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Lugo;Group 0204 Malignant neoplasm of breast 174-175;Women;255 Lugo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;100 Lugo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Lugo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;100 Lugo;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;37 Lugo;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Lugo;Group 0206 Malignant neoplasm of ovary 1830;Women;37 Lugo;Group 0207 Malignant neoplasm of prostate 185;Both sexes;133 Lugo;Group 0207 Malignant neoplasm of prostate 185;Men;133 Lugo;Group 0207 Malignant neoplasm of prostate 185;Women;.. Lugo;Group 0208 Malignant neoplasm of bladder 188;Both sexes;267 Lugo;Group 0208 Malignant neoplasm of bladder 188;Men;222 Lugo;Group 0208 Malignant neoplasm of bladder 188;Women;45 Lugo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;953 Lugo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;573 Lugo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;380 Lugo;Group 0210 Carcinoma in situ 230-234;Both sexes;55 Lugo;Group 0210 Carcinoma in situ 230-234;Men;21 Lugo;Group 0210 Carcinoma in situ 230-234;Women;34 Lugo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;24 Lugo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;14 Lugo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;10 Lugo;Grupo 0212 Leiomyoma of uterus 218;Both sexes;177 Lugo;Grupo 0212 Leiomyoma of uterus 218;Men;.. Lugo;Grupo 0212 Leiomyoma of uterus 218;Women;177 Lugo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;399 Lugo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;139 Lugo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;260 Lugo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;412 Lugo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;228 Lugo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;184 Lugo;Group 0301 Anaemias 280-285;Both sexes;241 Lugo;Group 0301 Anaemias 280-285;Men;121 Lugo;Group 0301 Anaemias 280-285;Women;120 Lugo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;171 Lugo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;107 Lugo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;64 Lugo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;640 Lugo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;297 Lugo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;343 Lugo;Group 0401 Diabetes mellitus 249-250;Both sexes;248 Lugo;Group 0401 Diabetes mellitus 249-250;Men;145 Lugo;Group 0401 Diabetes mellitus 249-250;Women;103 Lugo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;392 Lugo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;152 Lugo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;240 Lugo;Group 0500 Mental disorders 290-319;Both sexes;652 Lugo;Group 0500 Mental disorders 290-319;Men;332 Lugo;Group 0500 Mental disorders 290-319;Women;320 Lugo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;44 Lugo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;19 Lugo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;25 Lugo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;49 Lugo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;39 Lugo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;10 Lugo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;29 Lugo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;18 Lugo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;11 Lugo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;206 Lugo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;110 Lugo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;96 Lugo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;124 Lugo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;50 Lugo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;74 Lugo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;200 Lugo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;96 Lugo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;104 Lugo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;731 Lugo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;335 Lugo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;396 Lugo;Group 0601 Alzheimer's disease 3310;Both sexes;17 Lugo;Group 0601 Alzheimer's disease 3310;Men;5 Lugo;Group 0601 Alzheimer's disease 3310;Women;12 Lugo;Group 0602 Multiple sclerosis 340;Both sexes;75 Lugo;Group 0602 Multiple sclerosis 340;Men;15 Lugo;Group 0602 Multiple sclerosis 340;Women;60 Lugo;Group 0603 Epilepsy 345;Both sexes;155 Lugo;Group 0603 Epilepsy 345;Men;86 Lugo;Group 0603 Epilepsy 345;Women;69 Lugo;Group 0604 Transient cerebral ischemia 435;Both sexes;91 Lugo;Group 0604 Transient cerebral ischemia 435;Men;44 Lugo;Group 0604 Transient cerebral ischemia 435;Women;47 Lugo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;393 Lugo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;185 Lugo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;208 Lugo;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;272 Lugo;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;161 Lugo;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;111 Lugo;Grupo 0701 Cataract 366;Both sexes;55 Lugo;Grupo 0701 Cataract 366;Men;33 Lugo;Grupo 0701 Cataract 366;Women;22 Lugo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;217 Lugo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;128 Lugo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;89 Lugo;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;151 Lugo;Group 0800 Diseases of the ear and the mastoid 380-389;Men;89 Lugo;Group 0800 Diseases of the ear and the mastoid 380-389;Women;62 Lugo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4.612 Lugo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.614 Lugo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1.998 Lugo;Group 0901 Hypertensive disease 401-405;Both sexes;327 Lugo;Group 0901 Hypertensive disease 401-405;Men;138 Lugo;Group 0901 Hypertensive disease 401-405;Women;189 Lugo;Group 0902 Angina pectoris 4111, 413;Both sexes;250 Lugo;Group 0902 Angina pectoris 4111, 413;Men;171 Lugo;Group 0902 Angina pectoris 4111, 413;Women;79 Lugo;Group 0903 Acute myocardial infarction 410;Both sexes;336 Lugo;Group 0903 Acute myocardial infarction 410;Men;239 Lugo;Group 0903 Acute myocardial infarction 410;Women;97 Lugo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;276 Lugo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;206 Lugo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;70 Lugo;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;257 Lugo;Group 0905 Diseases of the lungs circulation 415-417;Men;105 Lugo;Group 0905 Diseases of the lungs circulation 415-417;Women;152 Lugo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;479 Lugo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;260 Lugo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;219 Lugo;Grupo 0907 Heart failure 428;Both sexes;751 Lugo;Grupo 0907 Heart failure 428;Men;387 Lugo;Grupo 0907 Heart failure 428;Women;364 Lugo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;918 Lugo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;470 Lugo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;448 Lugo;Grupo 0909 Atherosclerosis 440;Both sexes;205 Lugo;Grupo 0909 Atherosclerosis 440;Men;143 Lugo;Grupo 0909 Atherosclerosis 440;Women;62 Lugo;Group 0910 Varicose veins of lower extremities 454;Both sexes;28 Lugo;Group 0910 Varicose veins of lower extremities 454;Men;10 Lugo;Group 0910 Varicose veins of lower extremities 454;Women;18 Lugo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;785 Lugo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;485 Lugo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;300 Lugo;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;4.004 Lugo;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2.317 Lugo;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.687 Lugo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;219 Lugo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;118 Lugo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;101 Lugo;Group 1002 Pneumonia 480-486;Both sexes;1.004 Lugo;Group 1002 Pneumonia 480-486;Men;638 Lugo;Group 1002 Pneumonia 480-486;Women;366 Lugo;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;145 Lugo;Group 1003 Acute bronchitis and bronchiolitis 466;Men;75 Lugo;Group 1003 Acute bronchitis and bronchiolitis 466;Women;70 Lugo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;107 Lugo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;55 Lugo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;52 Lugo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;267 Lugo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;162 Lugo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;105 Lugo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;498 Lugo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;379 Lugo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;119 Lugo;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;143 Lugo;Group 1007 Asthma 4930-4931,4938-4939;Men;61 Lugo;Group 1007 Asthma 4930-4931,4938-4939;Women;82 Lugo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.621 Lugo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;829 Lugo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;792 Lugo;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.850 Lugo;Group 1100 Diseases of the digestive system 520-579;Men;2.773 Lugo;Group 1100 Diseases of the digestive system 520-579;Women;2.077 Lugo;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;61 Lugo;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;28 Lugo;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;33 Lugo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;43 Lugo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;23 Lugo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;20 Lugo;Group 1103 Diseases of the esophagus 530;Both sexes;73 Lugo;Group 1103 Diseases of the esophagus 530;Men;53 Lugo;Group 1103 Diseases of the esophagus 530;Women;20 Lugo;Group 1104 Peptic ulcer 531-534;Both sexes;66 Lugo;Group 1104 Peptic ulcer 531-534;Men;42 Lugo;Group 1104 Peptic ulcer 531-534;Women;24 Lugo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;104 Lugo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;60 Lugo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;44 Lugo;Group 1106 Appendicitis 540-543;Both sexes;416 Lugo;Group 1106 Appendicitis 540-543;Men;240 Lugo;Group 1106 Appendicitis 540-543;Women;176 Lugo;Group 1107 Inguinal hernia 550;Both sexes;518 Lugo;Group 1107 Inguinal hernia 550;Men;468 Lugo;Group 1107 Inguinal hernia 550;Women;50 Lugo;Group 1108 Other abdominal hernia 551-553;Both sexes;339 Lugo;Group 1108 Other abdominal hernia 551-553;Men;171 Lugo;Group 1108 Other abdominal hernia 551-553;Women;168 Lugo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;67 Lugo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;36 Lugo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;31 Lugo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;270 Lugo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;127 Lugo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;143 Lugo;Group 1111 Intestinal obstruction without hernia 560;Both sexes;286 Lugo;Group 1111 Intestinal obstruction without hernia 560;Men;132 Lugo;Group 1111 Intestinal obstruction without hernia 560;Women;154 Lugo;Group 1112 Intestinal diverticulosis 562;Both sexes;224 Lugo;Group 1112 Intestinal diverticulosis 562;Men;106 Lugo;Group 1112 Intestinal diverticulosis 562;Women;118 Lugo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;236 Lugo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;168 Lugo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;68 Lugo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;180 Lugo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;76 Lugo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;104 Lugo;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;113 Lugo;Group 1115 Alcoholic hepatitis 5710-5713;Men;95 Lugo;Group 1115 Alcoholic hepatitis 5710-5713;Women;18 Lugo;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;124 Lugo;Group 1116 Other diseases of the liver 570,5714-573;Men;74 Lugo;Group 1116 Other diseases of the liver 570,5714-573;Women;50 Lugo;Group 1117 Cholelithiasis 574;Both sexes;958 Lugo;Group 1117 Cholelithiasis 574;Men;452 Lugo;Group 1117 Cholelithiasis 574;Women;506 Lugo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;285 Lugo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;153 Lugo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;132 Lugo;Group 1119 Pancreatic diseases 577;Both sexes;300 Lugo;Group 1119 Pancreatic diseases 577;Men;176 Lugo;Group 1119 Pancreatic diseases 577;Women;124 Lugo;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;187 Lugo;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;93 Lugo;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;94 Lugo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;499 Lugo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;259 Lugo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;240 Lugo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;355 Lugo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;199 Lugo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;156 Lugo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;27 Lugo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;13 Lugo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;14 Lugo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;117 Lugo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;47 Lugo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;70 Lugo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.497 Lugo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.112 Lugo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.385 Lugo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Lugo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Lugo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Lugo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Lugo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Lugo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Lugo;Group 1303 Internal derangement of knee 717;Both sexes;283 Lugo;Group 1303 Internal derangement of knee 717;Men;189 Lugo;Group 1303 Internal derangement of knee 717;Women;94 Lugo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.057 Lugo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;413 Lugo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;644 Lugo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;60 Lugo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;25 Lugo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;35 Lugo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;112 Lugo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;50 Lugo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;62 Lugo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;129 Lugo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;74 Lugo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;55 Lugo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;56 Lugo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;23 Lugo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;33 Lugo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;432 Lugo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;220 Lugo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;212 Lugo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;368 Lugo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;118 Lugo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;250 Lugo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.126 Lugo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.074 Lugo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.052 Lugo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;186 Lugo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;92 Lugo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;94 Lugo;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;213 Lugo;Group 1402 Renal failure 5836-5837, 584-586;Men;129 Lugo;Group 1402 Renal failure 5836-5837, 584-586;Women;84 Lugo;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;187 Lugo;Group 1403 Urolithiasis 592, 594, 7880;Men;118 Lugo;Group 1403 Urolithiasis 592, 594, 7880;Women;69 Lugo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;626 Lugo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;282 Lugo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;344 Lugo;Group 1405 Prostatic hyperplasia 600;Both sexes;239 Lugo;Group 1405 Prostatic hyperplasia 600;Men;239 Lugo;Group 1405 Prostatic hyperplasia 600;Women;.. Lugo;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;196 Lugo;Group 1406 Other diseases of the male genital organs 601-608;Men;196 Lugo;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Lugo;Group 1407 Disorders of breast 610-612;Both sexes;59 Lugo;Group 1407 Disorders of breast 610-612;Men;17 Lugo;Group 1407 Disorders of breast 610-612;Women;42 Lugo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;59 Lugo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Lugo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;59 Lugo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;42 Lugo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Lugo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;42 Lugo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;319 Lugo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Lugo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;318 Lugo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;2.724 Lugo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Lugo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;2.724 Lugo;Group 1501 Legally induced abortion 635;Both sexes;14 Lugo;Group 1501 Legally induced abortion 635;Men;.. Lugo;Group 1501 Legally induced abortion 635;Women;14 Lugo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;315 Lugo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Lugo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;315 Lugo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.456 Lugo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Lugo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.456 Lugo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;648 Lugo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Lugo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;648 Lugo;Group 1505 Single spontaneous delivery 650;Both sexes;90 Lugo;Group 1505 Single spontaneous delivery 650;Men;.. Lugo;Group 1505 Single spontaneous delivery 650;Women;90 Lugo;Group 1506 Other deliveries 6695-6697;Both sexes;63 Lugo;Group 1506 Other deliveries 6695-6697;Men;.. Lugo;Group 1506 Other deliveries 6695-6697;Women;63 Lugo;Group 1507 Complications related to the puerperium 670-676;Both sexes;14 Lugo;Group 1507 Complications related to the puerperium 670-676;Men;.. Lugo;Group 1507 Complications related to the puerperium 670-676;Women;14 Lugo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;124 Lugo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Lugo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;124 Lugo;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;371 Lugo;Group 1600 Some disorders originating in the perinatal period 760-779;Men;218 Lugo;Group 1600 Some disorders originating in the perinatal period 760-779;Women;153 Lugo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;97 Lugo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;50 Lugo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;47 Lugo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;274 Lugo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;168 Lugo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;106 Lugo;Grupo 1700 Congenital abnormalities 740-759;Both sexes;104 Lugo;Grupo 1700 Congenital abnormalities 740-759;Men;55 Lugo;Grupo 1700 Congenital abnormalities 740-759;Women;49 Lugo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.164 Lugo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.147 Lugo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.017 Lugo;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;157 Lugo;Group 1801 Pain in throat and chest 7841, 7865;Men;106 Lugo;Group 1801 Pain in throat and chest 7841, 7865;Women;51 Lugo;Group 1802 Abdominal pain 7890;Both sexes;185 Lugo;Group 1802 Abdominal pain 7890;Men;75 Lugo;Group 1802 Abdominal pain 7890;Women;110 Lugo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;689 Lugo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;342 Lugo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;347 Lugo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.133 Lugo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;624 Lugo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;509 Lugo;Group 1900 Injuries and poisoning 800-999;Both sexes;3.800 Lugo;Group 1900 Injuries and poisoning 800-999;Men;1.945 Lugo;Group 1900 Injuries and poisoning 800-999;Women;1.855 Lugo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;253 Lugo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;145 Lugo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;108 Lugo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;121 Lugo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;90 Lugo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;31 Lugo;Group 1903 Radius and ulna fracture 813;Both sexes;154 Lugo;Group 1903 Radius and ulna fracture 813;Men;57 Lugo;Group 1903 Radius and ulna fracture 813;Women;97 Lugo;Group 1904 Femur fracture 820-821;Both sexes;640 Lugo;Group 1904 Femur fracture 820-821;Men;171 Lugo;Group 1904 Femur fracture 820-821;Women;469 Lugo;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;257 Lugo;Group 1905 Leg fracture, including the ankle 823-824;Men;132 Lugo;Group 1905 Leg fracture, including the ankle 823-824;Women;125 Lugo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.138 Lugo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;704 Lugo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;434 Lugo;Group 1907 Burns 940-949;Both sexes;45 Lugo;Group 1907 Burns 940-949;Men;23 Lugo;Group 1907 Burns 940-949;Women;22 Lugo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;78 Lugo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;37 Lugo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;41 Lugo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.013 Lugo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;535 Lugo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;478 Lugo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;3 Lugo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;3 Lugo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Lugo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;98 Lugo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;48 Lugo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;50 Lugo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;593 Lugo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;338 Lugo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;255 Lugo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;41 Lugo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;23 Lugo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;18 Lugo;Group 2102 Contraceptive management V25;Both sexes;15 Lugo;Group 2102 Contraceptive management V25;Men;.. Lugo;Group 2102 Contraceptive management V25;Women;15 Lugo;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Lugo;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Lugo;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Lugo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;222 Lugo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;143 Lugo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;79 Lugo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;315 Lugo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;172 Lugo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;143 Ourense;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;38.373 Ourense;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;19.253 Ourense;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;19.120 Ourense;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;764 Ourense;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;431 Ourense;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;333 Ourense;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;165 Ourense;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;85 Ourense;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;80 Ourense;Group 0102 Imprecise intestinal infections 009;Both sexes;14 Ourense;Group 0102 Imprecise intestinal infections 009;Men;2 Ourense;Group 0102 Imprecise intestinal infections 009;Women;12 Ourense;Group 0103 Tuberculosis 010-018, 137;Both sexes;35 Ourense;Group 0103 Tuberculosis 010-018, 137;Men;28 Ourense;Group 0103 Tuberculosis 010-018, 137;Women;7 Ourense;Group 0104 Septicaemia 038;Both sexes;348 Ourense;Group 0104 Septicaemia 038;Men;182 Ourense;Group 0104 Septicaemia 038;Women;166 Ourense;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;13 Ourense;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;11 Ourense;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;2 Ourense;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;189 Ourense;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;123 Ourense;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;66 Ourense;Group 0200 Neoplasms 140-239;Both sexes;3.364 Ourense;Group 0200 Neoplasms 140-239;Men;1.891 Ourense;Group 0200 Neoplasms 140-239;Women;1.473 Ourense;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;457 Ourense;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;276 Ourense;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;181 Ourense;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;195 Ourense;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;166 Ourense;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;29 Ourense;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;31 Ourense;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;11 Ourense;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;20 Ourense;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;225 Ourense;Group 0204 Malignant neoplasm of breast 174-175;Men;2 Ourense;Group 0204 Malignant neoplasm of breast 174-175;Women;223 Ourense;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;79 Ourense;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Ourense;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;79 Ourense;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;22 Ourense;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Ourense;Group 0206 Malignant neoplasm of ovary 1830;Women;22 Ourense;Group 0207 Malignant neoplasm of prostate 185;Both sexes;130 Ourense;Group 0207 Malignant neoplasm of prostate 185;Men;130 Ourense;Group 0207 Malignant neoplasm of prostate 185;Women;.. Ourense;Group 0208 Malignant neoplasm of bladder 188;Both sexes;399 Ourense;Group 0208 Malignant neoplasm of bladder 188;Men;332 Ourense;Group 0208 Malignant neoplasm of bladder 188;Women;67 Ourense;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.212 Ourense;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;733 Ourense;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;479 Ourense;Group 0210 Carcinoma in situ 230-234;Both sexes;52 Ourense;Group 0210 Carcinoma in situ 230-234;Men;18 Ourense;Group 0210 Carcinoma in situ 230-234;Women;34 Ourense;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;61 Ourense;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;37 Ourense;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;24 Ourense;Grupo 0212 Leiomyoma of uterus 218;Both sexes;71 Ourense;Grupo 0212 Leiomyoma of uterus 218;Men;.. Ourense;Grupo 0212 Leiomyoma of uterus 218;Women;71 Ourense;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;430 Ourense;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;186 Ourense;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;244 Ourense;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;298 Ourense;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;151 Ourense;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;147 Ourense;Group 0301 Anaemias 280-285;Both sexes;225 Ourense;Group 0301 Anaemias 280-285;Men;105 Ourense;Group 0301 Anaemias 280-285;Women;120 Ourense;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;73 Ourense;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;46 Ourense;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;27 Ourense;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;507 Ourense;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;240 Ourense;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;267 Ourense;Group 0401 Diabetes mellitus 249-250;Both sexes;207 Ourense;Group 0401 Diabetes mellitus 249-250;Men;115 Ourense;Group 0401 Diabetes mellitus 249-250;Women;92 Ourense;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;300 Ourense;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;125 Ourense;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;175 Ourense;Group 0500 Mental disorders 290-319;Both sexes;567 Ourense;Group 0500 Mental disorders 290-319;Men;261 Ourense;Group 0500 Mental disorders 290-319;Women;306 Ourense;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;9 Ourense;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;6 Ourense;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;3 Ourense;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;37 Ourense;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;29 Ourense;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;8 Ourense;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;19 Ourense;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;14 Ourense;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;5 Ourense;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;168 Ourense;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;93 Ourense;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;75 Ourense;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;129 Ourense;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;41 Ourense;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;88 Ourense;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;205 Ourense;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;78 Ourense;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;127 Ourense;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;831 Ourense;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;395 Ourense;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;436 Ourense;Group 0601 Alzheimer's disease 3310;Both sexes;10 Ourense;Group 0601 Alzheimer's disease 3310;Men;.. Ourense;Group 0601 Alzheimer's disease 3310;Women;10 Ourense;Group 0602 Multiple sclerosis 340;Both sexes;89 Ourense;Group 0602 Multiple sclerosis 340;Men;24 Ourense;Group 0602 Multiple sclerosis 340;Women;65 Ourense;Group 0603 Epilepsy 345;Both sexes;103 Ourense;Group 0603 Epilepsy 345;Men;51 Ourense;Group 0603 Epilepsy 345;Women;52 Ourense;Group 0604 Transient cerebral ischemia 435;Both sexes;248 Ourense;Group 0604 Transient cerebral ischemia 435;Men;119 Ourense;Group 0604 Transient cerebral ischemia 435;Women;129 Ourense;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;381 Ourense;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;201 Ourense;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;180 Ourense;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;116 Ourense;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;68 Ourense;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;48 Ourense;Grupo 0701 Cataract 366;Both sexes;4 Ourense;Grupo 0701 Cataract 366;Men;3 Ourense;Grupo 0701 Cataract 366;Women;1 Ourense;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;112 Ourense;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;65 Ourense;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;47 Ourense;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;137 Ourense;Group 0800 Diseases of the ear and the mastoid 380-389;Men;73 Ourense;Group 0800 Diseases of the ear and the mastoid 380-389;Women;64 Ourense;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5.127 Ourense;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.837 Ourense;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.290 Ourense;Group 0901 Hypertensive disease 401-405;Both sexes;234 Ourense;Group 0901 Hypertensive disease 401-405;Men;112 Ourense;Group 0901 Hypertensive disease 401-405;Women;122 Ourense;Group 0902 Angina pectoris 4111, 413;Both sexes;364 Ourense;Group 0902 Angina pectoris 4111, 413;Men;228 Ourense;Group 0902 Angina pectoris 4111, 413;Women;136 Ourense;Group 0903 Acute myocardial infarction 410;Both sexes;300 Ourense;Group 0903 Acute myocardial infarction 410;Men;197 Ourense;Group 0903 Acute myocardial infarction 410;Women;103 Ourense;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;206 Ourense;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;158 Ourense;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;48 Ourense;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;204 Ourense;Group 0905 Diseases of the lungs circulation 415-417;Men;86 Ourense;Group 0905 Diseases of the lungs circulation 415-417;Women;118 Ourense;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;658 Ourense;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;366 Ourense;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;292 Ourense;Grupo 0907 Heart failure 428;Both sexes;1.272 Ourense;Grupo 0907 Heart failure 428;Men;638 Ourense;Grupo 0907 Heart failure 428;Women;634 Ourense;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;948 Ourense;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;481 Ourense;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;467 Ourense;Grupo 0909 Atherosclerosis 440;Both sexes;171 Ourense;Grupo 0909 Atherosclerosis 440;Men;122 Ourense;Grupo 0909 Atherosclerosis 440;Women;49 Ourense;Group 0910 Varicose veins of lower extremities 454;Both sexes;63 Ourense;Group 0910 Varicose veins of lower extremities 454;Men;25 Ourense;Group 0910 Varicose veins of lower extremities 454;Women;38 Ourense;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;707 Ourense;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;424 Ourense;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;283 Ourense;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5.747 Ourense;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3.260 Ourense;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.487 Ourense;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;174 Ourense;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;91 Ourense;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;83 Ourense;Group 1002 Pneumonia 480-486;Both sexes;1.402 Ourense;Group 1002 Pneumonia 480-486;Men;869 Ourense;Group 1002 Pneumonia 480-486;Women;533 Ourense;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;209 Ourense;Group 1003 Acute bronchitis and bronchiolitis 466;Men;131 Ourense;Group 1003 Acute bronchitis and bronchiolitis 466;Women;78 Ourense;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;185 Ourense;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;94 Ourense;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;91 Ourense;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;312 Ourense;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;199 Ourense;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;113 Ourense;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;950 Ourense;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;672 Ourense;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;278 Ourense;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;211 Ourense;Group 1007 Asthma 4930-4931,4938-4939;Men;50 Ourense;Group 1007 Asthma 4930-4931,4938-4939;Women;161 Ourense;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.304 Ourense;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.154 Ourense;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.150 Ourense;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.836 Ourense;Group 1100 Diseases of the digestive system 520-579;Men;2.795 Ourense;Group 1100 Diseases of the digestive system 520-579;Women;2.041 Ourense;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;15 Ourense;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;8 Ourense;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;7 Ourense;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;56 Ourense;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;27 Ourense;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;29 Ourense;Group 1103 Diseases of the esophagus 530;Both sexes;68 Ourense;Group 1103 Diseases of the esophagus 530;Men;42 Ourense;Group 1103 Diseases of the esophagus 530;Women;26 Ourense;Group 1104 Peptic ulcer 531-534;Both sexes;61 Ourense;Group 1104 Peptic ulcer 531-534;Men;39 Ourense;Group 1104 Peptic ulcer 531-534;Women;22 Ourense;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;124 Ourense;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;60 Ourense;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;64 Ourense;Group 1106 Appendicitis 540-543;Both sexes;347 Ourense;Group 1106 Appendicitis 540-543;Men;201 Ourense;Group 1106 Appendicitis 540-543;Women;146 Ourense;Group 1107 Inguinal hernia 550;Both sexes;588 Ourense;Group 1107 Inguinal hernia 550;Men;544 Ourense;Group 1107 Inguinal hernia 550;Women;44 Ourense;Group 1108 Other abdominal hernia 551-553;Both sexes;345 Ourense;Group 1108 Other abdominal hernia 551-553;Men;161 Ourense;Group 1108 Other abdominal hernia 551-553;Women;184 Ourense;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;54 Ourense;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;29 Ourense;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;25 Ourense;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;265 Ourense;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;141 Ourense;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;124 Ourense;Group 1111 Intestinal obstruction without hernia 560;Both sexes;276 Ourense;Group 1111 Intestinal obstruction without hernia 560;Men;143 Ourense;Group 1111 Intestinal obstruction without hernia 560;Women;133 Ourense;Group 1112 Intestinal diverticulosis 562;Both sexes;218 Ourense;Group 1112 Intestinal diverticulosis 562;Men;91 Ourense;Group 1112 Intestinal diverticulosis 562;Women;127 Ourense;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;285 Ourense;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;167 Ourense;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;118 Ourense;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;167 Ourense;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;69 Ourense;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;98 Ourense;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;115 Ourense;Group 1115 Alcoholic hepatitis 5710-5713;Men;95 Ourense;Group 1115 Alcoholic hepatitis 5710-5713;Women;20 Ourense;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;213 Ourense;Group 1116 Other diseases of the liver 570,5714-573;Men;157 Ourense;Group 1116 Other diseases of the liver 570,5714-573;Women;56 Ourense;Group 1117 Cholelithiasis 574;Both sexes;876 Ourense;Group 1117 Cholelithiasis 574;Men;404 Ourense;Group 1117 Cholelithiasis 574;Women;472 Ourense;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;276 Ourense;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;145 Ourense;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;131 Ourense;Group 1119 Pancreatic diseases 577;Both sexes;295 Ourense;Group 1119 Pancreatic diseases 577;Men;167 Ourense;Group 1119 Pancreatic diseases 577;Women;128 Ourense;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;192 Ourense;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;105 Ourense;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;87 Ourense;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;504 Ourense;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;272 Ourense;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;232 Ourense;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;345 Ourense;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;204 Ourense;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;141 Ourense;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;16 Ourense;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;10 Ourense;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;6 Ourense;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;143 Ourense;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;58 Ourense;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;85 Ourense;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.783 Ourense;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.263 Ourense;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.520 Ourense;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Ourense;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Ourense;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Ourense;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Ourense;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Ourense;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Ourense;Group 1303 Internal derangement of knee 717;Both sexes;425 Ourense;Group 1303 Internal derangement of knee 717;Men;262 Ourense;Group 1303 Internal derangement of knee 717;Women;163 Ourense;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.194 Ourense;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;497 Ourense;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;697 Ourense;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;46 Ourense;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;19 Ourense;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;27 Ourense;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;89 Ourense;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;46 Ourense;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;43 Ourense;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;158 Ourense;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;79 Ourense;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;79 Ourense;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;33 Ourense;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;17 Ourense;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;16 Ourense;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;407 Ourense;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;217 Ourense;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;190 Ourense;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;431 Ourense;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;126 Ourense;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;305 Ourense;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.472 Ourense;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.179 Ourense;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.293 Ourense;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;187 Ourense;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;80 Ourense;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;107 Ourense;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;259 Ourense;Group 1402 Renal failure 5836-5837, 584-586;Men;164 Ourense;Group 1402 Renal failure 5836-5837, 584-586;Women;95 Ourense;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;259 Ourense;Group 1403 Urolithiasis 592, 594, 7880;Men;155 Ourense;Group 1403 Urolithiasis 592, 594, 7880;Women;104 Ourense;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;971 Ourense;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;428 Ourense;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;543 Ourense;Group 1405 Prostatic hyperplasia 600;Both sexes;167 Ourense;Group 1405 Prostatic hyperplasia 600;Men;167 Ourense;Group 1405 Prostatic hyperplasia 600;Women;.. Ourense;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;174 Ourense;Group 1406 Other diseases of the male genital organs 601-608;Men;174 Ourense;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Ourense;Group 1407 Disorders of breast 610-612;Both sexes;55 Ourense;Group 1407 Disorders of breast 610-612;Men;10 Ourense;Group 1407 Disorders of breast 610-612;Women;45 Ourense;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;44 Ourense;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Ourense;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;44 Ourense;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;43 Ourense;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Ourense;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;43 Ourense;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;313 Ourense;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Ourense;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;312 Ourense;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;2.154 Ourense;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Ourense;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;2.154 Ourense;Group 1501 Legally induced abortion 635;Both sexes;2 Ourense;Group 1501 Legally induced abortion 635;Men;.. Ourense;Group 1501 Legally induced abortion 635;Women;2 Ourense;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;105 Ourense;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Ourense;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;105 Ourense;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.284 Ourense;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Ourense;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.284 Ourense;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;516 Ourense;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Ourense;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;516 Ourense;Group 1505 Single spontaneous delivery 650;Both sexes;81 Ourense;Group 1505 Single spontaneous delivery 650;Men;.. Ourense;Group 1505 Single spontaneous delivery 650;Women;81 Ourense;Group 1506 Other deliveries 6695-6697;Both sexes;15 Ourense;Group 1506 Other deliveries 6695-6697;Men;.. Ourense;Group 1506 Other deliveries 6695-6697;Women;15 Ourense;Group 1507 Complications related to the puerperium 670-676;Both sexes;9 Ourense;Group 1507 Complications related to the puerperium 670-676;Men;.. Ourense;Group 1507 Complications related to the puerperium 670-676;Women;9 Ourense;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;142 Ourense;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Ourense;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;142 Ourense;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;299 Ourense;Group 1600 Some disorders originating in the perinatal period 760-779;Men;162 Ourense;Group 1600 Some disorders originating in the perinatal period 760-779;Women;137 Ourense;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;79 Ourense;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;43 Ourense;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;36 Ourense;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;220 Ourense;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;119 Ourense;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;101 Ourense;Grupo 1700 Congenital abnormalities 740-759;Both sexes;145 Ourense;Grupo 1700 Congenital abnormalities 740-759;Men;83 Ourense;Grupo 1700 Congenital abnormalities 740-759;Women;62 Ourense;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;3.299 Ourense;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.728 Ourense;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.571 Ourense;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;257 Ourense;Group 1801 Pain in throat and chest 7841, 7865;Men;143 Ourense;Group 1801 Pain in throat and chest 7841, 7865;Women;114 Ourense;Group 1802 Abdominal pain 7890;Both sexes;269 Ourense;Group 1802 Abdominal pain 7890;Men;110 Ourense;Group 1802 Abdominal pain 7890;Women;159 Ourense;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.077 Ourense;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;516 Ourense;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;561 Ourense;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.696 Ourense;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;959 Ourense;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;737 Ourense;Group 1900 Injuries and poisoning 800-999;Both sexes;3.827 Ourense;Group 1900 Injuries and poisoning 800-999;Men;1.778 Ourense;Group 1900 Injuries and poisoning 800-999;Women;2.049 Ourense;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;295 Ourense;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;168 Ourense;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;127 Ourense;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;72 Ourense;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;46 Ourense;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;26 Ourense;Group 1903 Radius and ulna fracture 813;Both sexes;238 Ourense;Group 1903 Radius and ulna fracture 813;Men;100 Ourense;Group 1903 Radius and ulna fracture 813;Women;138 Ourense;Group 1904 Femur fracture 820-821;Both sexes;684 Ourense;Group 1904 Femur fracture 820-821;Men;166 Ourense;Group 1904 Femur fracture 820-821;Women;518 Ourense;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;266 Ourense;Group 1905 Leg fracture, including the ankle 823-824;Men;116 Ourense;Group 1905 Leg fracture, including the ankle 823-824;Women;150 Ourense;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.410 Ourense;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;780 Ourense;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;630 Ourense;Group 1907 Burns 940-949;Both sexes;11 Ourense;Group 1907 Burns 940-949;Men;5 Ourense;Group 1907 Burns 940-949;Women;6 Ourense;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;92 Ourense;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;43 Ourense;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;49 Ourense;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;684 Ourense;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;310 Ourense;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;374 Ourense;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;3 Ourense;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;2 Ourense;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Ourense;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;72 Ourense;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;42 Ourense;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;30 Ourense;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;596 Ourense;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;386 Ourense;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;210 Ourense;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;38 Ourense;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;20 Ourense;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;18 Ourense;Group 2102 Contraceptive management V25;Both sexes;20 Ourense;Group 2102 Contraceptive management V25;Men;1 Ourense;Group 2102 Contraceptive management V25;Women;19 Ourense;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Ourense;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Ourense;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Ourense;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;312 Ourense;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;224 Ourense;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;88 Ourense;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;226 Ourense;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;141 Ourense;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;85 Pontevedra;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;95.723 Pontevedra;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;45.728 Pontevedra;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;49.995 Pontevedra;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.906 Pontevedra;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.014 Pontevedra;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;892 Pontevedra;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;313 Pontevedra;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;167 Pontevedra;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;146 Pontevedra;Group 0102 Imprecise intestinal infections 009;Both sexes;48 Pontevedra;Group 0102 Imprecise intestinal infections 009;Men;18 Pontevedra;Group 0102 Imprecise intestinal infections 009;Women;30 Pontevedra;Group 0103 Tuberculosis 010-018, 137;Both sexes;76 Pontevedra;Group 0103 Tuberculosis 010-018, 137;Men;53 Pontevedra;Group 0103 Tuberculosis 010-018, 137;Women;23 Pontevedra;Group 0104 Septicaemia 038;Both sexes;657 Pontevedra;Group 0104 Septicaemia 038;Men;305 Pontevedra;Group 0104 Septicaemia 038;Women;352 Pontevedra;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;101 Pontevedra;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;70 Pontevedra;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;31 Pontevedra;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;711 Pontevedra;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;401 Pontevedra;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;310 Pontevedra;Group 0200 Neoplasms 140-239;Both sexes;9.626 Pontevedra;Group 0200 Neoplasms 140-239;Men;5.077 Pontevedra;Group 0200 Neoplasms 140-239;Women;4.549 Pontevedra;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;886 Pontevedra;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;499 Pontevedra;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;387 Pontevedra;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;662 Pontevedra;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;538 Pontevedra;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;124 Pontevedra;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;153 Pontevedra;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;74 Pontevedra;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;79 Pontevedra;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;657 Pontevedra;Group 0204 Malignant neoplasm of breast 174-175;Men;6 Pontevedra;Group 0204 Malignant neoplasm of breast 174-175;Women;651 Pontevedra;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;168 Pontevedra;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Pontevedra;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;168 Pontevedra;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;74 Pontevedra;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Pontevedra;Group 0206 Malignant neoplasm of ovary 1830;Women;74 Pontevedra;Group 0207 Malignant neoplasm of prostate 185;Both sexes;700 Pontevedra;Group 0207 Malignant neoplasm of prostate 185;Men;700 Pontevedra;Group 0207 Malignant neoplasm of prostate 185;Women;.. Pontevedra;Group 0208 Malignant neoplasm of bladder 188;Both sexes;664 Pontevedra;Group 0208 Malignant neoplasm of bladder 188;Men;551 Pontevedra;Group 0208 Malignant neoplasm of bladder 188;Women;113 Pontevedra;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;3.813 Pontevedra;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2.161 Pontevedra;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.652 Pontevedra;Group 0210 Carcinoma in situ 230-234;Both sexes;204 Pontevedra;Group 0210 Carcinoma in situ 230-234;Men;66 Pontevedra;Group 0210 Carcinoma in situ 230-234;Women;138 Pontevedra;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;68 Pontevedra;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;44 Pontevedra;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;24 Pontevedra;Grupo 0212 Leiomyoma of uterus 218;Both sexes;424 Pontevedra;Grupo 0212 Leiomyoma of uterus 218;Men;.. Pontevedra;Grupo 0212 Leiomyoma of uterus 218;Women;424 Pontevedra;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.153 Pontevedra;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;438 Pontevedra;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;715 Pontevedra;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;904 Pontevedra;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;468 Pontevedra;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;436 Pontevedra;Group 0301 Anaemias 280-285;Both sexes;584 Pontevedra;Group 0301 Anaemias 280-285;Men;290 Pontevedra;Group 0301 Anaemias 280-285;Women;294 Pontevedra;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;320 Pontevedra;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;178 Pontevedra;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;142 Pontevedra;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.765 Pontevedra;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;656 Pontevedra;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.109 Pontevedra;Group 0401 Diabetes mellitus 249-250;Both sexes;561 Pontevedra;Group 0401 Diabetes mellitus 249-250;Men;281 Pontevedra;Group 0401 Diabetes mellitus 249-250;Women;280 Pontevedra;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.204 Pontevedra;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;375 Pontevedra;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;829 Pontevedra;Group 0500 Mental disorders 290-319;Both sexes;2.051 Pontevedra;Group 0500 Mental disorders 290-319;Men;990 Pontevedra;Group 0500 Mental disorders 290-319;Women;1.061 Pontevedra;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;56 Pontevedra;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;17 Pontevedra;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;39 Pontevedra;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;121 Pontevedra;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;88 Pontevedra;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;33 Pontevedra;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;83 Pontevedra;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;58 Pontevedra;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;25 Pontevedra;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;564 Pontevedra;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;337 Pontevedra;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;227 Pontevedra;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;478 Pontevedra;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;158 Pontevedra;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;320 Pontevedra;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;749 Pontevedra;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;332 Pontevedra;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;417 Pontevedra;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.831 Pontevedra;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;872 Pontevedra;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;959 Pontevedra;Group 0601 Alzheimer's disease 3310;Both sexes;28 Pontevedra;Group 0601 Alzheimer's disease 3310;Men;9 Pontevedra;Group 0601 Alzheimer's disease 3310;Women;19 Pontevedra;Group 0602 Multiple sclerosis 340;Both sexes;92 Pontevedra;Group 0602 Multiple sclerosis 340;Men;25 Pontevedra;Group 0602 Multiple sclerosis 340;Women;67 Pontevedra;Group 0603 Epilepsy 345;Both sexes;275 Pontevedra;Group 0603 Epilepsy 345;Men;136 Pontevedra;Group 0603 Epilepsy 345;Women;139 Pontevedra;Group 0604 Transient cerebral ischemia 435;Both sexes;303 Pontevedra;Group 0604 Transient cerebral ischemia 435;Men;132 Pontevedra;Group 0604 Transient cerebral ischemia 435;Women;171 Pontevedra;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.133 Pontevedra;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;570 Pontevedra;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;563 Pontevedra;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;469 Pontevedra;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;231 Pontevedra;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;238 Pontevedra;Grupo 0701 Cataract 366;Both sexes;46 Pontevedra;Grupo 0701 Cataract 366;Men;21 Pontevedra;Grupo 0701 Cataract 366;Women;25 Pontevedra;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;423 Pontevedra;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;210 Pontevedra;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;213 Pontevedra;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;519 Pontevedra;Group 0800 Diseases of the ear and the mastoid 380-389;Men;249 Pontevedra;Group 0800 Diseases of the ear and the mastoid 380-389;Women;270 Pontevedra;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;12.647 Pontevedra;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;6.964 Pontevedra;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;5.683 Pontevedra;Group 0901 Hypertensive disease 401-405;Both sexes;875 Pontevedra;Group 0901 Hypertensive disease 401-405;Men;363 Pontevedra;Group 0901 Hypertensive disease 401-405;Women;512 Pontevedra;Group 0902 Angina pectoris 4111, 413;Both sexes;243 Pontevedra;Group 0902 Angina pectoris 4111, 413;Men;154 Pontevedra;Group 0902 Angina pectoris 4111, 413;Women;89 Pontevedra;Group 0903 Acute myocardial infarction 410;Both sexes;1.001 Pontevedra;Group 0903 Acute myocardial infarction 410;Men;748 Pontevedra;Group 0903 Acute myocardial infarction 410;Women;253 Pontevedra;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;836 Pontevedra;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;652 Pontevedra;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;184 Pontevedra;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;472 Pontevedra;Group 0905 Diseases of the lungs circulation 415-417;Men;206 Pontevedra;Group 0905 Diseases of the lungs circulation 415-417;Women;266 Pontevedra;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.511 Pontevedra;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;866 Pontevedra;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;645 Pontevedra;Grupo 0907 Heart failure 428;Both sexes;2.917 Pontevedra;Grupo 0907 Heart failure 428;Men;1.424 Pontevedra;Grupo 0907 Heart failure 428;Women;1.493 Pontevedra;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.933 Pontevedra;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;955 Pontevedra;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;978 Pontevedra;Grupo 0909 Atherosclerosis 440;Both sexes;483 Pontevedra;Grupo 0909 Atherosclerosis 440;Men;343 Pontevedra;Grupo 0909 Atherosclerosis 440;Women;140 Pontevedra;Group 0910 Varicose veins of lower extremities 454;Both sexes;508 Pontevedra;Group 0910 Varicose veins of lower extremities 454;Men;169 Pontevedra;Group 0910 Varicose veins of lower extremities 454;Women;339 Pontevedra;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.868 Pontevedra;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.084 Pontevedra;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;784 Pontevedra;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;13.462 Pontevedra;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;7.410 Pontevedra;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6.052 Pontevedra;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;414 Pontevedra;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;222 Pontevedra;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;192 Pontevedra;Group 1002 Pneumonia 480-486;Both sexes;2.657 Pontevedra;Group 1002 Pneumonia 480-486;Men;1.488 Pontevedra;Group 1002 Pneumonia 480-486;Women;1.169 Pontevedra;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;653 Pontevedra;Group 1003 Acute bronchitis and bronchiolitis 466;Men;356 Pontevedra;Group 1003 Acute bronchitis and bronchiolitis 466;Women;297 Pontevedra;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;992 Pontevedra;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;522 Pontevedra;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;470 Pontevedra;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.111 Pontevedra;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;688 Pontevedra;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;423 Pontevedra;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.129 Pontevedra;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.467 Pontevedra;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;662 Pontevedra;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;411 Pontevedra;Group 1007 Asthma 4930-4931,4938-4939;Men;167 Pontevedra;Group 1007 Asthma 4930-4931,4938-4939;Women;244 Pontevedra;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5.095 Pontevedra;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.500 Pontevedra;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2.595 Pontevedra;Group 1100 Diseases of the digestive system 520-579;Both sexes;11.042 Pontevedra;Group 1100 Diseases of the digestive system 520-579;Men;6.254 Pontevedra;Group 1100 Diseases of the digestive system 520-579;Women;4.788 Pontevedra;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;198 Pontevedra;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;95 Pontevedra;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;103 Pontevedra;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;176 Pontevedra;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;101 Pontevedra;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;75 Pontevedra;Group 1103 Diseases of the esophagus 530;Both sexes;166 Pontevedra;Group 1103 Diseases of the esophagus 530;Men;97 Pontevedra;Group 1103 Diseases of the esophagus 530;Women;69 Pontevedra;Group 1104 Peptic ulcer 531-534;Both sexes;162 Pontevedra;Group 1104 Peptic ulcer 531-534;Men;110 Pontevedra;Group 1104 Peptic ulcer 531-534;Women;52 Pontevedra;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;243 Pontevedra;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;125 Pontevedra;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;118 Pontevedra;Group 1106 Appendicitis 540-543;Both sexes;1.079 Pontevedra;Group 1106 Appendicitis 540-543;Men;622 Pontevedra;Group 1106 Appendicitis 540-543;Women;457 Pontevedra;Group 1107 Inguinal hernia 550;Both sexes;1.267 Pontevedra;Group 1107 Inguinal hernia 550;Men;1.122 Pontevedra;Group 1107 Inguinal hernia 550;Women;145 Pontevedra;Group 1108 Other abdominal hernia 551-553;Both sexes;906 Pontevedra;Group 1108 Other abdominal hernia 551-553;Men;479 Pontevedra;Group 1108 Other abdominal hernia 551-553;Women;427 Pontevedra;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;261 Pontevedra;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;157 Pontevedra;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;104 Pontevedra;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;549 Pontevedra;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;252 Pontevedra;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;297 Pontevedra;Group 1111 Intestinal obstruction without hernia 560;Both sexes;485 Pontevedra;Group 1111 Intestinal obstruction without hernia 560;Men;249 Pontevedra;Group 1111 Intestinal obstruction without hernia 560;Women;236 Pontevedra;Group 1112 Intestinal diverticulosis 562;Both sexes;484 Pontevedra;Group 1112 Intestinal diverticulosis 562;Men;236 Pontevedra;Group 1112 Intestinal diverticulosis 562;Women;248 Pontevedra;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;719 Pontevedra;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;446 Pontevedra;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;273 Pontevedra;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;378 Pontevedra;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;170 Pontevedra;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;208 Pontevedra;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;272 Pontevedra;Group 1115 Alcoholic hepatitis 5710-5713;Men;215 Pontevedra;Group 1115 Alcoholic hepatitis 5710-5713;Women;57 Pontevedra;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;532 Pontevedra;Group 1116 Other diseases of the liver 570,5714-573;Men;336 Pontevedra;Group 1116 Other diseases of the liver 570,5714-573;Women;196 Pontevedra;Group 1117 Cholelithiasis 574;Both sexes;1.808 Pontevedra;Group 1117 Cholelithiasis 574;Men;723 Pontevedra;Group 1117 Cholelithiasis 574;Women;1.085 Pontevedra;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;379 Pontevedra;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;206 Pontevedra;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;173 Pontevedra;Group 1119 Pancreatic diseases 577;Both sexes;605 Pontevedra;Group 1119 Pancreatic diseases 577;Men;324 Pontevedra;Group 1119 Pancreatic diseases 577;Women;281 Pontevedra;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;373 Pontevedra;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;189 Pontevedra;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;184 Pontevedra;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.264 Pontevedra;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;662 Pontevedra;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;602 Pontevedra;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;817 Pontevedra;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;471 Pontevedra;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;346 Pontevedra;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;90 Pontevedra;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;39 Pontevedra;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;51 Pontevedra;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;357 Pontevedra;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;152 Pontevedra;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;205 Pontevedra;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;7.373 Pontevedra;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3.648 Pontevedra;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.725 Pontevedra;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Pontevedra;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Pontevedra;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Pontevedra;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Pontevedra;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Pontevedra;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Pontevedra;Group 1303 Internal derangement of knee 717;Both sexes;1.455 Pontevedra;Group 1303 Internal derangement of knee 717;Men;957 Pontevedra;Group 1303 Internal derangement of knee 717;Women;498 Pontevedra;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.578 Pontevedra;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.073 Pontevedra;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.505 Pontevedra;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;123 Pontevedra;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;39 Pontevedra;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;84 Pontevedra;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;283 Pontevedra;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;148 Pontevedra;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;135 Pontevedra;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;699 Pontevedra;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;378 Pontevedra;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;321 Pontevedra;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;114 Pontevedra;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;47 Pontevedra;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;67 Pontevedra;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.067 Pontevedra;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;624 Pontevedra;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;443 Pontevedra;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.054 Pontevedra;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;382 Pontevedra;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;672 Pontevedra;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;6.150 Pontevedra;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.862 Pontevedra;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3.288 Pontevedra;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;588 Pontevedra;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;196 Pontevedra;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;392 Pontevedra;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;425 Pontevedra;Group 1402 Renal failure 5836-5837, 584-586;Men;217 Pontevedra;Group 1402 Renal failure 5836-5837, 584-586;Women;208 Pontevedra;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;662 Pontevedra;Group 1403 Urolithiasis 592, 594, 7880;Men;375 Pontevedra;Group 1403 Urolithiasis 592, 594, 7880;Women;287 Pontevedra;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.893 Pontevedra;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;866 Pontevedra;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.027 Pontevedra;Group 1405 Prostatic hyperplasia 600;Both sexes;657 Pontevedra;Group 1405 Prostatic hyperplasia 600;Men;657 Pontevedra;Group 1405 Prostatic hyperplasia 600;Women;.. Pontevedra;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;510 Pontevedra;Group 1406 Other diseases of the male genital organs 601-608;Men;510 Pontevedra;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Pontevedra;Group 1407 Disorders of breast 610-612;Both sexes;237 Pontevedra;Group 1407 Disorders of breast 610-612;Men;18 Pontevedra;Group 1407 Disorders of breast 610-612;Women;219 Pontevedra;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;204 Pontevedra;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Pontevedra;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;204 Pontevedra;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;70 Pontevedra;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Pontevedra;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;70 Pontevedra;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;904 Pontevedra;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;23 Pontevedra;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;881 Pontevedra;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;9.010 Pontevedra;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Pontevedra;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;9.010 Pontevedra;Group 1501 Legally induced abortion 635;Both sexes;183 Pontevedra;Group 1501 Legally induced abortion 635;Men;.. Pontevedra;Group 1501 Legally induced abortion 635;Women;183 Pontevedra;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;971 Pontevedra;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Pontevedra;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;971 Pontevedra;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;5.134 Pontevedra;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Pontevedra;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;5.134 Pontevedra;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.522 Pontevedra;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Pontevedra;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.522 Pontevedra;Group 1505 Single spontaneous delivery 650;Both sexes;425 Pontevedra;Group 1505 Single spontaneous delivery 650;Men;.. Pontevedra;Group 1505 Single spontaneous delivery 650;Women;425 Pontevedra;Group 1506 Other deliveries 6695-6697;Both sexes;241 Pontevedra;Group 1506 Other deliveries 6695-6697;Men;.. Pontevedra;Group 1506 Other deliveries 6695-6697;Women;241 Pontevedra;Group 1507 Complications related to the puerperium 670-676;Both sexes;105 Pontevedra;Group 1507 Complications related to the puerperium 670-676;Men;.. Pontevedra;Group 1507 Complications related to the puerperium 670-676;Women;105 Pontevedra;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;429 Pontevedra;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Pontevedra;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;429 Pontevedra;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;981 Pontevedra;Group 1600 Some disorders originating in the perinatal period 760-779;Men;563 Pontevedra;Group 1600 Some disorders originating in the perinatal period 760-779;Women;418 Pontevedra;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;295 Pontevedra;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;170 Pontevedra;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;125 Pontevedra;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;686 Pontevedra;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;393 Pontevedra;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;293 Pontevedra;Grupo 1700 Congenital abnormalities 740-759;Both sexes;737 Pontevedra;Grupo 1700 Congenital abnormalities 740-759;Men;500 Pontevedra;Grupo 1700 Congenital abnormalities 740-759;Women;237 Pontevedra;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.611 Pontevedra;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.362 Pontevedra;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.249 Pontevedra;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;232 Pontevedra;Group 1801 Pain in throat and chest 7841, 7865;Men;131 Pontevedra;Group 1801 Pain in throat and chest 7841, 7865;Women;101 Pontevedra;Group 1802 Abdominal pain 7890;Both sexes;320 Pontevedra;Group 1802 Abdominal pain 7890;Men;106 Pontevedra;Group 1802 Abdominal pain 7890;Women;214 Pontevedra;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;10 Pontevedra;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;.. Pontevedra;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;10 Pontevedra;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;2.049 Pontevedra;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.125 Pontevedra;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;924 Pontevedra;Group 1900 Injuries and poisoning 800-999;Both sexes;9.691 Pontevedra;Group 1900 Injuries and poisoning 800-999;Men;5.090 Pontevedra;Group 1900 Injuries and poisoning 800-999;Women;4.601 Pontevedra;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;757 Pontevedra;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;429 Pontevedra;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;328 Pontevedra;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;333 Pontevedra;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;230 Pontevedra;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;103 Pontevedra;Group 1903 Radius and ulna fracture 813;Both sexes;518 Pontevedra;Group 1903 Radius and ulna fracture 813;Men;229 Pontevedra;Group 1903 Radius and ulna fracture 813;Women;289 Pontevedra;Group 1904 Femur fracture 820-821;Both sexes;1.108 Pontevedra;Group 1904 Femur fracture 820-821;Men;269 Pontevedra;Group 1904 Femur fracture 820-821;Women;839 Pontevedra;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;770 Pontevedra;Group 1905 Leg fracture, including the ankle 823-824;Men;397 Pontevedra;Group 1905 Leg fracture, including the ankle 823-824;Women;373 Pontevedra;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3.302 Pontevedra;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.941 Pontevedra;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.361 Pontevedra;Group 1907 Burns 940-949;Both sexes;96 Pontevedra;Group 1907 Burns 940-949;Men;55 Pontevedra;Group 1907 Burns 940-949;Women;41 Pontevedra;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;237 Pontevedra;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;123 Pontevedra;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;114 Pontevedra;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.414 Pontevedra;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.332 Pontevedra;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.082 Pontevedra;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;2 Pontevedra;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;2 Pontevedra;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Pontevedra;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;154 Pontevedra;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;83 Pontevedra;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;71 Pontevedra;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.684 Pontevedra;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;856 Pontevedra;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;828 Pontevedra;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;70 Pontevedra;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;40 Pontevedra;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;30 Pontevedra;Group 2102 Contraceptive management V25;Both sexes;79 Pontevedra;Group 2102 Contraceptive management V25;Men;2 Pontevedra;Group 2102 Contraceptive management V25;Women;77 Pontevedra;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Pontevedra;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Pontevedra;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Pontevedra;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;824 Pontevedra;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;548 Pontevedra;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;276 Pontevedra;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;711 Pontevedra;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;266 Pontevedra;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;445 MADRID, COMUNIDAD DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;692.090 MADRID, COMUNIDAD DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;317.375 MADRID, COMUNIDAD DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;374.715 MADRID, COMUNIDAD DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;15.651 MADRID, COMUNIDAD DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;8.423 MADRID, COMUNIDAD DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;7.229 MADRID, COMUNIDAD DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;2.374 MADRID, COMUNIDAD DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;1.177 MADRID, COMUNIDAD DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;1.197 MADRID, COMUNIDAD DE;Group 0102 Imprecise intestinal infections 009;Both sexes;856 MADRID, COMUNIDAD DE;Group 0102 Imprecise intestinal infections 009;Men;403 MADRID, COMUNIDAD DE;Group 0102 Imprecise intestinal infections 009;Women;453 MADRID, COMUNIDAD DE;Group 0103 Tuberculosis 010-018, 137;Both sexes;481 MADRID, COMUNIDAD DE;Group 0103 Tuberculosis 010-018, 137;Men;276 MADRID, COMUNIDAD DE;Group 0103 Tuberculosis 010-018, 137;Women;205 MADRID, COMUNIDAD DE;Group 0104 Septicaemia 038;Both sexes;6.858 MADRID, COMUNIDAD DE;Group 0104 Septicaemia 038;Men;3.594 MADRID, COMUNIDAD DE;Group 0104 Septicaemia 038;Women;3.264 MADRID, COMUNIDAD DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;156 MADRID, COMUNIDAD DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;112 MADRID, COMUNIDAD DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;44 MADRID, COMUNIDAD DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;4.926 MADRID, COMUNIDAD DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;2.860 MADRID, COMUNIDAD DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;2.065 MADRID, COMUNIDAD DE;Group 0200 Neoplasms 140-239;Both sexes;69.724 MADRID, COMUNIDAD DE;Group 0200 Neoplasms 140-239;Men;34.676 MADRID, COMUNIDAD DE;Group 0200 Neoplasms 140-239;Women;35.048 MADRID, COMUNIDAD DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;5.914 MADRID, COMUNIDAD DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;3.391 MADRID, COMUNIDAD DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;2.524 MADRID, COMUNIDAD DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;4.639 MADRID, COMUNIDAD DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;3.510 MADRID, COMUNIDAD DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;1.129 MADRID, COMUNIDAD DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;1.141 MADRID, COMUNIDAD DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;677 MADRID, COMUNIDAD DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;464 MADRID, COMUNIDAD DE;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;5.689 MADRID, COMUNIDAD DE;Group 0204 Malignant neoplasm of breast 174-175;Men;40 MADRID, COMUNIDAD DE;Group 0204 Malignant neoplasm of breast 174-175;Women;5.649 MADRID, COMUNIDAD DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1.210 MADRID, COMUNIDAD DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. MADRID, COMUNIDAD DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1.210 MADRID, COMUNIDAD DE;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;740 MADRID, COMUNIDAD DE;Group 0206 Malignant neoplasm of ovary 1830;Men;.. MADRID, COMUNIDAD DE;Group 0206 Malignant neoplasm of ovary 1830;Women;740 MADRID, COMUNIDAD DE;Group 0207 Malignant neoplasm of prostate 185;Both sexes;2.714 MADRID, COMUNIDAD DE;Group 0207 Malignant neoplasm of prostate 185;Men;2.714 MADRID, COMUNIDAD DE;Group 0207 Malignant neoplasm of prostate 185;Women;.. MADRID, COMUNIDAD DE;Group 0208 Malignant neoplasm of bladder 188;Both sexes;6.094 MADRID, COMUNIDAD DE;Group 0208 Malignant neoplasm of bladder 188;Men;4.996 MADRID, COMUNIDAD DE;Group 0208 Malignant neoplasm of bladder 188;Women;1.098 MADRID, COMUNIDAD DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;25.877 MADRID, COMUNIDAD DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;14.361 MADRID, COMUNIDAD DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;11.516 MADRID, COMUNIDAD DE;Group 0210 Carcinoma in situ 230-234;Both sexes;1.068 MADRID, COMUNIDAD DE;Group 0210 Carcinoma in situ 230-234;Men;315 MADRID, COMUNIDAD DE;Group 0210 Carcinoma in situ 230-234;Women;753 MADRID, COMUNIDAD DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;954 MADRID, COMUNIDAD DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;580 MADRID, COMUNIDAD DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;374 MADRID, COMUNIDAD DE;Grupo 0212 Leiomyoma of uterus 218;Both sexes;3.663 MADRID, COMUNIDAD DE;Grupo 0212 Leiomyoma of uterus 218;Men;.. MADRID, COMUNIDAD DE;Grupo 0212 Leiomyoma of uterus 218;Women;3.663 MADRID, COMUNIDAD DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;10.019 MADRID, COMUNIDAD DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;4.092 MADRID, COMUNIDAD DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;5.927 MADRID, COMUNIDAD DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;6.266 MADRID, COMUNIDAD DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;2.988 MADRID, COMUNIDAD DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;3.278 MADRID, COMUNIDAD DE;Group 0301 Anaemias 280-285;Both sexes;3.553 MADRID, COMUNIDAD DE;Group 0301 Anaemias 280-285;Men;1.650 MADRID, COMUNIDAD DE;Group 0301 Anaemias 280-285;Women;1.903 MADRID, COMUNIDAD DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;2.713 MADRID, COMUNIDAD DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;1.338 MADRID, COMUNIDAD DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;1.375 MADRID, COMUNIDAD DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;13.231 MADRID, COMUNIDAD DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;4.756 MADRID, COMUNIDAD DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;8.474 MADRID, COMUNIDAD DE;Group 0401 Diabetes mellitus 249-250;Both sexes;2.864 MADRID, COMUNIDAD DE;Group 0401 Diabetes mellitus 249-250;Men;1.699 MADRID, COMUNIDAD DE;Group 0401 Diabetes mellitus 249-250;Women;1.165 MADRID, COMUNIDAD DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;10.366 MADRID, COMUNIDAD DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;3.057 MADRID, COMUNIDAD DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;7.309 MADRID, COMUNIDAD DE;Group 0500 Mental disorders 290-319;Both sexes;17.371 MADRID, COMUNIDAD DE;Group 0500 Mental disorders 290-319;Men;8.530 MADRID, COMUNIDAD DE;Group 0500 Mental disorders 290-319;Women;8.841 MADRID, COMUNIDAD DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;318 MADRID, COMUNIDAD DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;139 MADRID, COMUNIDAD DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;179 MADRID, COMUNIDAD DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;1.738 MADRID, COMUNIDAD DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;1.195 MADRID, COMUNIDAD DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;543 MADRID, COMUNIDAD DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;1.308 MADRID, COMUNIDAD DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;940 MADRID, COMUNIDAD DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;368 MADRID, COMUNIDAD DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;4.390 MADRID, COMUNIDAD DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;2.545 MADRID, COMUNIDAD DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;1.845 MADRID, COMUNIDAD DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;4.129 MADRID, COMUNIDAD DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;1.486 MADRID, COMUNIDAD DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;2.643 MADRID, COMUNIDAD DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;5.488 MADRID, COMUNIDAD DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;2.225 MADRID, COMUNIDAD DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;3.263 MADRID, COMUNIDAD DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;18.510 MADRID, COMUNIDAD DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;9.881 MADRID, COMUNIDAD DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;8.629 MADRID, COMUNIDAD DE;Group 0601 Alzheimer's disease 3310;Both sexes;240 MADRID, COMUNIDAD DE;Group 0601 Alzheimer's disease 3310;Men;83 MADRID, COMUNIDAD DE;Group 0601 Alzheimer's disease 3310;Women;157 MADRID, COMUNIDAD DE;Group 0602 Multiple sclerosis 340;Both sexes;252 MADRID, COMUNIDAD DE;Group 0602 Multiple sclerosis 340;Men;94 MADRID, COMUNIDAD DE;Group 0602 Multiple sclerosis 340;Women;158 MADRID, COMUNIDAD DE;Group 0603 Epilepsy 345;Both sexes;3.242 MADRID, COMUNIDAD DE;Group 0603 Epilepsy 345;Men;1.692 MADRID, COMUNIDAD DE;Group 0603 Epilepsy 345;Women;1.550 MADRID, COMUNIDAD DE;Group 0604 Transient cerebral ischemia 435;Both sexes;2.202 MADRID, COMUNIDAD DE;Group 0604 Transient cerebral ischemia 435;Men;1.099 MADRID, COMUNIDAD DE;Group 0604 Transient cerebral ischemia 435;Women;1.103 MADRID, COMUNIDAD DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;12.574 MADRID, COMUNIDAD DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;6.913 MADRID, COMUNIDAD DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;5.660 MADRID, COMUNIDAD DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;4.233 MADRID, COMUNIDAD DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;2.181 MADRID, COMUNIDAD DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;2.052 MADRID, COMUNIDAD DE;Grupo 0701 Cataract 366;Both sexes;493 MADRID, COMUNIDAD DE;Grupo 0701 Cataract 366;Men;247 MADRID, COMUNIDAD DE;Grupo 0701 Cataract 366;Women;246 MADRID, COMUNIDAD DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;3.739 MADRID, COMUNIDAD DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;1.934 MADRID, COMUNIDAD DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;1.806 MADRID, COMUNIDAD DE;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;3.406 MADRID, COMUNIDAD DE;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1.634 MADRID, COMUNIDAD DE;Group 0800 Diseases of the ear and the mastoid 380-389;Women;1.771 MADRID, COMUNIDAD DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;79.850 MADRID, COMUNIDAD DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;42.964 MADRID, COMUNIDAD DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;36.886 MADRID, COMUNIDAD DE;Group 0901 Hypertensive disease 401-405;Both sexes;4.345 MADRID, COMUNIDAD DE;Group 0901 Hypertensive disease 401-405;Men;1.758 MADRID, COMUNIDAD DE;Group 0901 Hypertensive disease 401-405;Women;2.587 MADRID, COMUNIDAD DE;Group 0902 Angina pectoris 4111, 413;Both sexes;2.053 MADRID, COMUNIDAD DE;Group 0902 Angina pectoris 4111, 413;Men;1.261 MADRID, COMUNIDAD DE;Group 0902 Angina pectoris 4111, 413;Women;792 MADRID, COMUNIDAD DE;Group 0903 Acute myocardial infarction 410;Both sexes;5.780 MADRID, COMUNIDAD DE;Group 0903 Acute myocardial infarction 410;Men;4.128 MADRID, COMUNIDAD DE;Group 0903 Acute myocardial infarction 410;Women;1.652 MADRID, COMUNIDAD DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;6.419 MADRID, COMUNIDAD DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;4.980 MADRID, COMUNIDAD DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1.439 MADRID, COMUNIDAD DE;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;3.026 MADRID, COMUNIDAD DE;Group 0905 Diseases of the lungs circulation 415-417;Men;1.316 MADRID, COMUNIDAD DE;Group 0905 Diseases of the lungs circulation 415-417;Women;1.710 MADRID, COMUNIDAD DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;10.348 MADRID, COMUNIDAD DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;5.573 MADRID, COMUNIDAD DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;4.775 MADRID, COMUNIDAD DE;Grupo 0907 Heart failure 428;Both sexes;16.789 MADRID, COMUNIDAD DE;Grupo 0907 Heart failure 428;Men;7.210 MADRID, COMUNIDAD DE;Grupo 0907 Heart failure 428;Women;9.579 MADRID, COMUNIDAD DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;11.937 MADRID, COMUNIDAD DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;6.083 MADRID, COMUNIDAD DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;5.855 MADRID, COMUNIDAD DE;Grupo 0909 Atherosclerosis 440;Both sexes;2.296 MADRID, COMUNIDAD DE;Grupo 0909 Atherosclerosis 440;Men;1.706 MADRID, COMUNIDAD DE;Grupo 0909 Atherosclerosis 440;Women;590 MADRID, COMUNIDAD DE;Group 0910 Varicose veins of lower extremities 454;Both sexes;2.291 MADRID, COMUNIDAD DE;Group 0910 Varicose veins of lower extremities 454;Men;846 MADRID, COMUNIDAD DE;Group 0910 Varicose veins of lower extremities 454;Women;1.445 MADRID, COMUNIDAD DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;14.565 MADRID, COMUNIDAD DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;8.103 MADRID, COMUNIDAD DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;6.462 MADRID, COMUNIDAD DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;78.445 MADRID, COMUNIDAD DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;43.300 MADRID, COMUNIDAD DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;35.145 MADRID, COMUNIDAD DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;3.279 MADRID, COMUNIDAD DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;1.742 MADRID, COMUNIDAD DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;1.537 MADRID, COMUNIDAD DE;Group 1002 Pneumonia 480-486;Both sexes;17.860 MADRID, COMUNIDAD DE;Group 1002 Pneumonia 480-486;Men;10.201 MADRID, COMUNIDAD DE;Group 1002 Pneumonia 480-486;Women;7.659 MADRID, COMUNIDAD DE;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;6.056 MADRID, COMUNIDAD DE;Group 1003 Acute bronchitis and bronchiolitis 466;Men;3.052 MADRID, COMUNIDAD DE;Group 1003 Acute bronchitis and bronchiolitis 466;Women;3.003 MADRID, COMUNIDAD DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;3.866 MADRID, COMUNIDAD DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;2.030 MADRID, COMUNIDAD DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1.837 MADRID, COMUNIDAD DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;6.479 MADRID, COMUNIDAD DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;3.906 MADRID, COMUNIDAD DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;2.573 MADRID, COMUNIDAD DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;12.831 MADRID, COMUNIDAD DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;9.252 MADRID, COMUNIDAD DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;3.579 MADRID, COMUNIDAD DE;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;3.572 MADRID, COMUNIDAD DE;Group 1007 Asthma 4930-4931,4938-4939;Men;1.236 MADRID, COMUNIDAD DE;Group 1007 Asthma 4930-4931,4938-4939;Women;2.336 MADRID, COMUNIDAD DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;24.501 MADRID, COMUNIDAD DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;11.880 MADRID, COMUNIDAD DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;12.621 MADRID, COMUNIDAD DE;Group 1100 Diseases of the digestive system 520-579;Both sexes;82.434 MADRID, COMUNIDAD DE;Group 1100 Diseases of the digestive system 520-579;Men;44.851 MADRID, COMUNIDAD DE;Group 1100 Diseases of the digestive system 520-579;Women;37.583 MADRID, COMUNIDAD DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;2.388 MADRID, COMUNIDAD DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;1.038 MADRID, COMUNIDAD DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;1.350 MADRID, COMUNIDAD DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;1.341 MADRID, COMUNIDAD DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;718 MADRID, COMUNIDAD DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;623 MADRID, COMUNIDAD DE;Group 1103 Diseases of the esophagus 530;Both sexes;1.979 MADRID, COMUNIDAD DE;Group 1103 Diseases of the esophagus 530;Men;1.138 MADRID, COMUNIDAD DE;Group 1103 Diseases of the esophagus 530;Women;840 MADRID, COMUNIDAD DE;Group 1104 Peptic ulcer 531-534;Both sexes;1.203 MADRID, COMUNIDAD DE;Group 1104 Peptic ulcer 531-534;Men;810 MADRID, COMUNIDAD DE;Group 1104 Peptic ulcer 531-534;Women;393 MADRID, COMUNIDAD DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;1.702 MADRID, COMUNIDAD DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;766 MADRID, COMUNIDAD DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;936 MADRID, COMUNIDAD DE;Group 1106 Appendicitis 540-543;Both sexes;7.085 MADRID, COMUNIDAD DE;Group 1106 Appendicitis 540-543;Men;3.953 MADRID, COMUNIDAD DE;Group 1106 Appendicitis 540-543;Women;3.131 MADRID, COMUNIDAD DE;Group 1107 Inguinal hernia 550;Both sexes;9.276 MADRID, COMUNIDAD DE;Group 1107 Inguinal hernia 550;Men;8.167 MADRID, COMUNIDAD DE;Group 1107 Inguinal hernia 550;Women;1.109 MADRID, COMUNIDAD DE;Group 1108 Other abdominal hernia 551-553;Both sexes;7.220 MADRID, COMUNIDAD DE;Group 1108 Other abdominal hernia 551-553;Men;3.454 MADRID, COMUNIDAD DE;Group 1108 Other abdominal hernia 551-553;Women;3.766 MADRID, COMUNIDAD DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;1.286 MADRID, COMUNIDAD DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;642 MADRID, COMUNIDAD DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;644 MADRID, COMUNIDAD DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;4.075 MADRID, COMUNIDAD DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;1.932 MADRID, COMUNIDAD DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;2.144 MADRID, COMUNIDAD DE;Group 1111 Intestinal obstruction without hernia 560;Both sexes;3.236 MADRID, COMUNIDAD DE;Group 1111 Intestinal obstruction without hernia 560;Men;1.554 MADRID, COMUNIDAD DE;Group 1111 Intestinal obstruction without hernia 560;Women;1.681 MADRID, COMUNIDAD DE;Group 1112 Intestinal diverticulosis 562;Both sexes;3.373 MADRID, COMUNIDAD DE;Group 1112 Intestinal diverticulosis 562;Men;1.631 MADRID, COMUNIDAD DE;Group 1112 Intestinal diverticulosis 562;Women;1.741 MADRID, COMUNIDAD DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;5.047 MADRID, COMUNIDAD DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;3.288 MADRID, COMUNIDAD DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;1.759 MADRID, COMUNIDAD DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;2.705 MADRID, COMUNIDAD DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;1.197 MADRID, COMUNIDAD DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1.507 MADRID, COMUNIDAD DE;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1.086 MADRID, COMUNIDAD DE;Group 1115 Alcoholic hepatitis 5710-5713;Men;928 MADRID, COMUNIDAD DE;Group 1115 Alcoholic hepatitis 5710-5713;Women;158 MADRID, COMUNIDAD DE;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;2.904 MADRID, COMUNIDAD DE;Group 1116 Other diseases of the liver 570,5714-573;Men;1.674 MADRID, COMUNIDAD DE;Group 1116 Other diseases of the liver 570,5714-573;Women;1.230 MADRID, COMUNIDAD DE;Group 1117 Cholelithiasis 574;Both sexes;15.235 MADRID, COMUNIDAD DE;Group 1117 Cholelithiasis 574;Men;6.110 MADRID, COMUNIDAD DE;Group 1117 Cholelithiasis 574;Women;9.124 MADRID, COMUNIDAD DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;4.055 MADRID, COMUNIDAD DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;2.054 MADRID, COMUNIDAD DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;2.001 MADRID, COMUNIDAD DE;Group 1119 Pancreatic diseases 577;Both sexes;4.230 MADRID, COMUNIDAD DE;Group 1119 Pancreatic diseases 577;Men;2.232 MADRID, COMUNIDAD DE;Group 1119 Pancreatic diseases 577;Women;1.998 MADRID, COMUNIDAD DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;3.007 MADRID, COMUNIDAD DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1.562 MADRID, COMUNIDAD DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1.445 MADRID, COMUNIDAD DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;6.373 MADRID, COMUNIDAD DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;3.356 MADRID, COMUNIDAD DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;3.017 MADRID, COMUNIDAD DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;3.529 MADRID, COMUNIDAD DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;2.080 MADRID, COMUNIDAD DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;1.449 MADRID, COMUNIDAD DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;380 MADRID, COMUNIDAD DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;196 MADRID, COMUNIDAD DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;184 MADRID, COMUNIDAD DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;2.464 MADRID, COMUNIDAD DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;1.080 MADRID, COMUNIDAD DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;1.383 MADRID, COMUNIDAD DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;59.968 MADRID, COMUNIDAD DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;28.563 MADRID, COMUNIDAD DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;31.405 MADRID, COMUNIDAD DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. MADRID, COMUNIDAD DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. MADRID, COMUNIDAD DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. MADRID, COMUNIDAD DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. MADRID, COMUNIDAD DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. MADRID, COMUNIDAD DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. MADRID, COMUNIDAD DE;Group 1303 Internal derangement of knee 717;Both sexes;9.932 MADRID, COMUNIDAD DE;Group 1303 Internal derangement of knee 717;Men;6.737 MADRID, COMUNIDAD DE;Group 1303 Internal derangement of knee 717;Women;3.194 MADRID, COMUNIDAD DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;18.892 MADRID, COMUNIDAD DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;7.863 MADRID, COMUNIDAD DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;11.029 MADRID, COMUNIDAD DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;941 MADRID, COMUNIDAD DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;315 MADRID, COMUNIDAD DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;626 MADRID, COMUNIDAD DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;3.539 MADRID, COMUNIDAD DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1.615 MADRID, COMUNIDAD DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1.924 MADRID, COMUNIDAD DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;6.782 MADRID, COMUNIDAD DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;3.632 MADRID, COMUNIDAD DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;3.151 MADRID, COMUNIDAD DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;714 MADRID, COMUNIDAD DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;340 MADRID, COMUNIDAD DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;374 MADRID, COMUNIDAD DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;9.235 MADRID, COMUNIDAD DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;4.526 MADRID, COMUNIDAD DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;4.709 MADRID, COMUNIDAD DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;9.932 MADRID, COMUNIDAD DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;3.534 MADRID, COMUNIDAD DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;6.398 MADRID, COMUNIDAD DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;45.367 MADRID, COMUNIDAD DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;21.693 MADRID, COMUNIDAD DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;23.674 MADRID, COMUNIDAD DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;4.813 MADRID, COMUNIDAD DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;1.762 MADRID, COMUNIDAD DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;3.051 MADRID, COMUNIDAD DE;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;3.687 MADRID, COMUNIDAD DE;Group 1402 Renal failure 5836-5837, 584-586;Men;2.090 MADRID, COMUNIDAD DE;Group 1402 Renal failure 5836-5837, 584-586;Women;1.597 MADRID, COMUNIDAD DE;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;5.542 MADRID, COMUNIDAD DE;Group 1403 Urolithiasis 592, 594, 7880;Men;3.327 MADRID, COMUNIDAD DE;Group 1403 Urolithiasis 592, 594, 7880;Women;2.215 MADRID, COMUNIDAD DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;13.349 MADRID, COMUNIDAD DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;6.769 MADRID, COMUNIDAD DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;6.580 MADRID, COMUNIDAD DE;Group 1405 Prostatic hyperplasia 600;Both sexes;4.653 MADRID, COMUNIDAD DE;Group 1405 Prostatic hyperplasia 600;Men;4.653 MADRID, COMUNIDAD DE;Group 1405 Prostatic hyperplasia 600;Women;.. MADRID, COMUNIDAD DE;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;2.694 MADRID, COMUNIDAD DE;Group 1406 Other diseases of the male genital organs 601-608;Men;2.694 MADRID, COMUNIDAD DE;Group 1406 Other diseases of the male genital organs 601-608;Women;.. MADRID, COMUNIDAD DE;Group 1407 Disorders of breast 610-612;Both sexes;2.566 MADRID, COMUNIDAD DE;Group 1407 Disorders of breast 610-612;Men;274 MADRID, COMUNIDAD DE;Group 1407 Disorders of breast 610-612;Women;2.292 MADRID, COMUNIDAD DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;1.077 MADRID, COMUNIDAD DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. MADRID, COMUNIDAD DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;1.077 MADRID, COMUNIDAD DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;370 MADRID, COMUNIDAD DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. MADRID, COMUNIDAD DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;370 MADRID, COMUNIDAD DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;6.615 MADRID, COMUNIDAD DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;124 MADRID, COMUNIDAD DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;6.491 MADRID, COMUNIDAD DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;74.820 MADRID, COMUNIDAD DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. MADRID, COMUNIDAD DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;74.820 MADRID, COMUNIDAD DE;Group 1501 Legally induced abortion 635;Both sexes;135 MADRID, COMUNIDAD DE;Group 1501 Legally induced abortion 635;Men;.. MADRID, COMUNIDAD DE;Group 1501 Legally induced abortion 635;Women;135 MADRID, COMUNIDAD DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;2.720 MADRID, COMUNIDAD DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. MADRID, COMUNIDAD DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;2.720 MADRID, COMUNIDAD DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;48.264 MADRID, COMUNIDAD DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. MADRID, COMUNIDAD DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;48.264 MADRID, COMUNIDAD DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;11.034 MADRID, COMUNIDAD DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. MADRID, COMUNIDAD DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;11.034 MADRID, COMUNIDAD DE;Group 1505 Single spontaneous delivery 650;Both sexes;3.904 MADRID, COMUNIDAD DE;Group 1505 Single spontaneous delivery 650;Men;.. MADRID, COMUNIDAD DE;Group 1505 Single spontaneous delivery 650;Women;3.904 MADRID, COMUNIDAD DE;Group 1506 Other deliveries 6695-6697;Both sexes;2.451 MADRID, COMUNIDAD DE;Group 1506 Other deliveries 6695-6697;Men;.. MADRID, COMUNIDAD DE;Group 1506 Other deliveries 6695-6697;Women;2.451 MADRID, COMUNIDAD DE;Group 1507 Complications related to the puerperium 670-676;Both sexes;584 MADRID, COMUNIDAD DE;Group 1507 Complications related to the puerperium 670-676;Men;.. MADRID, COMUNIDAD DE;Group 1507 Complications related to the puerperium 670-676;Women;584 MADRID, COMUNIDAD DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;5.729 MADRID, COMUNIDAD DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. MADRID, COMUNIDAD DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;5.729 MADRID, COMUNIDAD DE;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;11.470 MADRID, COMUNIDAD DE;Group 1600 Some disorders originating in the perinatal period 760-779;Men;6.329 MADRID, COMUNIDAD DE;Group 1600 Some disorders originating in the perinatal period 760-779;Women;5.141 MADRID, COMUNIDAD DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;2.401 MADRID, COMUNIDAD DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;1.246 MADRID, COMUNIDAD DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;1.154 MADRID, COMUNIDAD DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;9.070 MADRID, COMUNIDAD DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;5.082 MADRID, COMUNIDAD DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;3.987 MADRID, COMUNIDAD DE;Grupo 1700 Congenital abnormalities 740-759;Both sexes;7.541 MADRID, COMUNIDAD DE;Grupo 1700 Congenital abnormalities 740-759;Men;3.883 MADRID, COMUNIDAD DE;Grupo 1700 Congenital abnormalities 740-759;Women;3.658 MADRID, COMUNIDAD DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;24.633 MADRID, COMUNIDAD DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;13.277 MADRID, COMUNIDAD DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;11.356 MADRID, COMUNIDAD DE;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;2.665 MADRID, COMUNIDAD DE;Group 1801 Pain in throat and chest 7841, 7865;Men;1.496 MADRID, COMUNIDAD DE;Group 1801 Pain in throat and chest 7841, 7865;Women;1.169 MADRID, COMUNIDAD DE;Group 1802 Abdominal pain 7890;Both sexes;2.610 MADRID, COMUNIDAD DE;Group 1802 Abdominal pain 7890;Men;1.047 MADRID, COMUNIDAD DE;Group 1802 Abdominal pain 7890;Women;1.563 MADRID, COMUNIDAD DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.804 MADRID, COMUNIDAD DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1.077 MADRID, COMUNIDAD DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;726 MADRID, COMUNIDAD DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;17.555 MADRID, COMUNIDAD DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;9.657 MADRID, COMUNIDAD DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;7.897 MADRID, COMUNIDAD DE;Group 1900 Injuries and poisoning 800-999;Both sexes;53.926 MADRID, COMUNIDAD DE;Group 1900 Injuries and poisoning 800-999;Men;27.779 MADRID, COMUNIDAD DE;Group 1900 Injuries and poisoning 800-999;Women;26.147 MADRID, COMUNIDAD DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;2.433 MADRID, COMUNIDAD DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;1.415 MADRID, COMUNIDAD DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;1.018 MADRID, COMUNIDAD DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1.403 MADRID, COMUNIDAD DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;1.003 MADRID, COMUNIDAD DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;400 MADRID, COMUNIDAD DE;Group 1903 Radius and ulna fracture 813;Both sexes;3.075 MADRID, COMUNIDAD DE;Group 1903 Radius and ulna fracture 813;Men;1.515 MADRID, COMUNIDAD DE;Group 1903 Radius and ulna fracture 813;Women;1.561 MADRID, COMUNIDAD DE;Group 1904 Femur fracture 820-821;Both sexes;7.217 MADRID, COMUNIDAD DE;Group 1904 Femur fracture 820-821;Men;1.944 MADRID, COMUNIDAD DE;Group 1904 Femur fracture 820-821;Women;5.273 MADRID, COMUNIDAD DE;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;3.654 MADRID, COMUNIDAD DE;Group 1905 Leg fracture, including the ankle 823-824;Men;1.952 MADRID, COMUNIDAD DE;Group 1905 Leg fracture, including the ankle 823-824;Women;1.703 MADRID, COMUNIDAD DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;13.851 MADRID, COMUNIDAD DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;8.377 MADRID, COMUNIDAD DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;5.473 MADRID, COMUNIDAD DE;Group 1907 Burns 940-949;Both sexes;487 MADRID, COMUNIDAD DE;Group 1907 Burns 940-949;Men;304 MADRID, COMUNIDAD DE;Group 1907 Burns 940-949;Women;183 MADRID, COMUNIDAD DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;1.524 MADRID, COMUNIDAD DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;699 MADRID, COMUNIDAD DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;825 MADRID, COMUNIDAD DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;18.318 MADRID, COMUNIDAD DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;9.525 MADRID, COMUNIDAD DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;8.793 MADRID, COMUNIDAD DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;115 MADRID, COMUNIDAD DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;70 MADRID, COMUNIDAD DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;45 MADRID, COMUNIDAD DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;1.848 MADRID, COMUNIDAD DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;974 MADRID, COMUNIDAD DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;874 MADRID, COMUNIDAD DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;18.871 MADRID, COMUNIDAD DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;8.311 MADRID, COMUNIDAD DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;10.560 MADRID, COMUNIDAD DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;928 MADRID, COMUNIDAD DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;506 MADRID, COMUNIDAD DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;422 MADRID, COMUNIDAD DE;Group 2102 Contraceptive management V25;Both sexes;141 MADRID, COMUNIDAD DE;Group 2102 Contraceptive management V25;Men;19 MADRID, COMUNIDAD DE;Group 2102 Contraceptive management V25;Women;122 MADRID, COMUNIDAD DE;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. MADRID, COMUNIDAD DE;Group 2103 Living newborns by type of delivery V30-V39;Men;.. MADRID, COMUNIDAD DE;Group 2103 Living newborns by type of delivery V30-V39;Women;.. MADRID, COMUNIDAD DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;6.032 MADRID, COMUNIDAD DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;3.349 MADRID, COMUNIDAD DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;2.683 MADRID, COMUNIDAD DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;11.770 MADRID, COMUNIDAD DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;4.437 MADRID, COMUNIDAD DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;7.333 MURCIA, REGIËN DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;146.541 MURCIA, REGIËN DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;67.458 MURCIA, REGIËN DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;79.083 MURCIA, REGIËN DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3.252 MURCIA, REGIËN DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.796 MURCIA, REGIËN DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.456 MURCIA, REGIËN DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;538 MURCIA, REGIËN DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;294 MURCIA, REGIËN DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;244 MURCIA, REGIËN DE;Group 0102 Imprecise intestinal infections 009;Both sexes;107 MURCIA, REGIËN DE;Group 0102 Imprecise intestinal infections 009;Men;52 MURCIA, REGIËN DE;Group 0102 Imprecise intestinal infections 009;Women;55 MURCIA, REGIËN DE;Group 0103 Tuberculosis 010-018, 137;Both sexes;140 MURCIA, REGIËN DE;Group 0103 Tuberculosis 010-018, 137;Men;86 MURCIA, REGIËN DE;Group 0103 Tuberculosis 010-018, 137;Women;54 MURCIA, REGIËN DE;Group 0104 Septicaemia 038;Both sexes;1.375 MURCIA, REGIËN DE;Group 0104 Septicaemia 038;Men;711 MURCIA, REGIËN DE;Group 0104 Septicaemia 038;Women;664 MURCIA, REGIËN DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;90 MURCIA, REGIËN DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;72 MURCIA, REGIËN DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;18 MURCIA, REGIËN DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.002 MURCIA, REGIËN DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;581 MURCIA, REGIËN DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;421 MURCIA, REGIËN DE;Group 0200 Neoplasms 140-239;Both sexes;12.324 MURCIA, REGIËN DE;Group 0200 Neoplasms 140-239;Men;6.340 MURCIA, REGIËN DE;Group 0200 Neoplasms 140-239;Women;5.984 MURCIA, REGIËN DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.133 MURCIA, REGIËN DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;694 MURCIA, REGIËN DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;439 MURCIA, REGIËN DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;866 MURCIA, REGIËN DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;704 MURCIA, REGIËN DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;162 MURCIA, REGIËN DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;192 MURCIA, REGIËN DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;120 MURCIA, REGIËN DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;72 MURCIA, REGIËN DE;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;986 MURCIA, REGIËN DE;Group 0204 Malignant neoplasm of breast 174-175;Men;9 MURCIA, REGIËN DE;Group 0204 Malignant neoplasm of breast 174-175;Women;977 MURCIA, REGIËN DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;276 MURCIA, REGIËN DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. MURCIA, REGIËN DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;276 MURCIA, REGIËN DE;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;124 MURCIA, REGIËN DE;Group 0206 Malignant neoplasm of ovary 1830;Men;.. MURCIA, REGIËN DE;Group 0206 Malignant neoplasm of ovary 1830;Women;124 MURCIA, REGIËN DE;Group 0207 Malignant neoplasm of prostate 185;Both sexes;412 MURCIA, REGIËN DE;Group 0207 Malignant neoplasm of prostate 185;Men;412 MURCIA, REGIËN DE;Group 0207 Malignant neoplasm of prostate 185;Women;.. MURCIA, REGIËN DE;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.121 MURCIA, REGIËN DE;Group 0208 Malignant neoplasm of bladder 188;Men;971 MURCIA, REGIËN DE;Group 0208 Malignant neoplasm of bladder 188;Women;150 MURCIA, REGIËN DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;4.207 MURCIA, REGIËN DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2.408 MURCIA, REGIËN DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.799 MURCIA, REGIËN DE;Group 0210 Carcinoma in situ 230-234;Both sexes;212 MURCIA, REGIËN DE;Group 0210 Carcinoma in situ 230-234;Men;80 MURCIA, REGIËN DE;Group 0210 Carcinoma in situ 230-234;Women;132 MURCIA, REGIËN DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;134 MURCIA, REGIËN DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;73 MURCIA, REGIËN DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;61 MURCIA, REGIËN DE;Grupo 0212 Leiomyoma of uterus 218;Both sexes;723 MURCIA, REGIËN DE;Grupo 0212 Leiomyoma of uterus 218;Men;.. MURCIA, REGIËN DE;Grupo 0212 Leiomyoma of uterus 218;Women;723 MURCIA, REGIËN DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.938 MURCIA, REGIËN DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;869 MURCIA, REGIËN DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.069 MURCIA, REGIËN DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.319 MURCIA, REGIËN DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;622 MURCIA, REGIËN DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;697 MURCIA, REGIËN DE;Group 0301 Anaemias 280-285;Both sexes;719 MURCIA, REGIËN DE;Group 0301 Anaemias 280-285;Men;354 MURCIA, REGIËN DE;Group 0301 Anaemias 280-285;Women;365 MURCIA, REGIËN DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;600 MURCIA, REGIËN DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;268 MURCIA, REGIËN DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;332 MURCIA, REGIËN DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;3.177 MURCIA, REGIËN DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.314 MURCIA, REGIËN DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.863 MURCIA, REGIËN DE;Group 0401 Diabetes mellitus 249-250;Both sexes;1.066 MURCIA, REGIËN DE;Group 0401 Diabetes mellitus 249-250;Men;667 MURCIA, REGIËN DE;Group 0401 Diabetes mellitus 249-250;Women;399 MURCIA, REGIËN DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2.111 MURCIA, REGIËN DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;647 MURCIA, REGIËN DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.464 MURCIA, REGIËN DE;Group 0500 Mental disorders 290-319;Both sexes;3.464 MURCIA, REGIËN DE;Group 0500 Mental disorders 290-319;Men;1.990 MURCIA, REGIËN DE;Group 0500 Mental disorders 290-319;Women;1.474 MURCIA, REGIËN DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;115 MURCIA, REGIËN DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;54 MURCIA, REGIËN DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;61 MURCIA, REGIËN DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;213 MURCIA, REGIËN DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;171 MURCIA, REGIËN DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;42 MURCIA, REGIËN DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;259 MURCIA, REGIËN DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;199 MURCIA, REGIËN DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;60 MURCIA, REGIËN DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.003 MURCIA, REGIËN DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;661 MURCIA, REGIËN DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;342 MURCIA, REGIËN DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;706 MURCIA, REGIËN DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;333 MURCIA, REGIËN DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;374 MURCIA, REGIËN DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.167 MURCIA, REGIËN DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;572 MURCIA, REGIËN DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;595 MURCIA, REGIËN DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3.487 MURCIA, REGIËN DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.802 MURCIA, REGIËN DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.685 MURCIA, REGIËN DE;Group 0601 Alzheimer's disease 3310;Both sexes;121 MURCIA, REGIËN DE;Group 0601 Alzheimer's disease 3310;Men;37 MURCIA, REGIËN DE;Group 0601 Alzheimer's disease 3310;Women;84 MURCIA, REGIËN DE;Group 0602 Multiple sclerosis 340;Both sexes;90 MURCIA, REGIËN DE;Group 0602 Multiple sclerosis 340;Men;27 MURCIA, REGIËN DE;Group 0602 Multiple sclerosis 340;Women;63 MURCIA, REGIËN DE;Group 0603 Epilepsy 345;Both sexes;777 MURCIA, REGIËN DE;Group 0603 Epilepsy 345;Men;431 MURCIA, REGIËN DE;Group 0603 Epilepsy 345;Women;346 MURCIA, REGIËN DE;Group 0604 Transient cerebral ischemia 435;Both sexes;650 MURCIA, REGIËN DE;Group 0604 Transient cerebral ischemia 435;Men;352 MURCIA, REGIËN DE;Group 0604 Transient cerebral ischemia 435;Women;298 MURCIA, REGIËN DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.849 MURCIA, REGIËN DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;955 MURCIA, REGIËN DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;894 MURCIA, REGIËN DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;450 MURCIA, REGIËN DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;241 MURCIA, REGIËN DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;209 MURCIA, REGIËN DE;Grupo 0701 Cataract 366;Both sexes;24 MURCIA, REGIËN DE;Grupo 0701 Cataract 366;Men;13 MURCIA, REGIËN DE;Grupo 0701 Cataract 366;Women;11 MURCIA, REGIËN DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;426 MURCIA, REGIËN DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;228 MURCIA, REGIËN DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;198 MURCIA, REGIËN DE;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;711 MURCIA, REGIËN DE;Group 0800 Diseases of the ear and the mastoid 380-389;Men;337 MURCIA, REGIËN DE;Group 0800 Diseases of the ear and the mastoid 380-389;Women;374 MURCIA, REGIËN DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;18.340 MURCIA, REGIËN DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;10.312 MURCIA, REGIËN DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;8.028 MURCIA, REGIËN DE;Group 0901 Hypertensive disease 401-405;Both sexes;773 MURCIA, REGIËN DE;Group 0901 Hypertensive disease 401-405;Men;331 MURCIA, REGIËN DE;Group 0901 Hypertensive disease 401-405;Women;442 MURCIA, REGIËN DE;Group 0902 Angina pectoris 4111, 413;Both sexes;1.074 MURCIA, REGIËN DE;Group 0902 Angina pectoris 4111, 413;Men;700 MURCIA, REGIËN DE;Group 0902 Angina pectoris 4111, 413;Women;374 MURCIA, REGIËN DE;Group 0903 Acute myocardial infarction 410;Both sexes;1.811 MURCIA, REGIËN DE;Group 0903 Acute myocardial infarction 410;Men;1.267 MURCIA, REGIËN DE;Group 0903 Acute myocardial infarction 410;Women;544 MURCIA, REGIËN DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.406 MURCIA, REGIËN DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.075 MURCIA, REGIËN DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;331 MURCIA, REGIËN DE;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;406 MURCIA, REGIËN DE;Group 0905 Diseases of the lungs circulation 415-417;Men;191 MURCIA, REGIËN DE;Group 0905 Diseases of the lungs circulation 415-417;Women;215 MURCIA, REGIËN DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.497 MURCIA, REGIËN DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.288 MURCIA, REGIËN DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.209 MURCIA, REGIËN DE;Grupo 0907 Heart failure 428;Both sexes;3.168 MURCIA, REGIËN DE;Grupo 0907 Heart failure 428;Men;1.416 MURCIA, REGIËN DE;Grupo 0907 Heart failure 428;Women;1.752 MURCIA, REGIËN DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3.220 MURCIA, REGIËN DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.787 MURCIA, REGIËN DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.433 MURCIA, REGIËN DE;Grupo 0909 Atherosclerosis 440;Both sexes;280 MURCIA, REGIËN DE;Grupo 0909 Atherosclerosis 440;Men;227 MURCIA, REGIËN DE;Grupo 0909 Atherosclerosis 440;Women;53 MURCIA, REGIËN DE;Group 0910 Varicose veins of lower extremities 454;Both sexes;609 MURCIA, REGIËN DE;Group 0910 Varicose veins of lower extremities 454;Men;199 MURCIA, REGIËN DE;Group 0910 Varicose veins of lower extremities 454;Women;410 MURCIA, REGIËN DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;3.096 MURCIA, REGIËN DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.831 MURCIA, REGIËN DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.265 MURCIA, REGIËN DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;16.041 MURCIA, REGIËN DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;9.115 MURCIA, REGIËN DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6.926 MURCIA, REGIËN DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1.003 MURCIA, REGIËN DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;509 MURCIA, REGIËN DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;494 MURCIA, REGIËN DE;Group 1002 Pneumonia 480-486;Both sexes;3.358 MURCIA, REGIËN DE;Group 1002 Pneumonia 480-486;Men;1.993 MURCIA, REGIËN DE;Group 1002 Pneumonia 480-486;Women;1.365 MURCIA, REGIËN DE;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.361 MURCIA, REGIËN DE;Group 1003 Acute bronchitis and bronchiolitis 466;Men;643 MURCIA, REGIËN DE;Group 1003 Acute bronchitis and bronchiolitis 466;Women;718 MURCIA, REGIËN DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;871 MURCIA, REGIËN DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;498 MURCIA, REGIËN DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;373 MURCIA, REGIËN DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.340 MURCIA, REGIËN DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;832 MURCIA, REGIËN DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;508 MURCIA, REGIËN DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.102 MURCIA, REGIËN DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.715 MURCIA, REGIËN DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;387 MURCIA, REGIËN DE;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;697 MURCIA, REGIËN DE;Group 1007 Asthma 4930-4931,4938-4939;Men;198 MURCIA, REGIËN DE;Group 1007 Asthma 4930-4931,4938-4939;Women;499 MURCIA, REGIËN DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5.309 MURCIA, REGIËN DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.727 MURCIA, REGIËN DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2.582 MURCIA, REGIËN DE;Group 1100 Diseases of the digestive system 520-579;Both sexes;17.308 MURCIA, REGIËN DE;Group 1100 Diseases of the digestive system 520-579;Men;9.597 MURCIA, REGIËN DE;Group 1100 Diseases of the digestive system 520-579;Women;7.711 MURCIA, REGIËN DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;312 MURCIA, REGIËN DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;130 MURCIA, REGIËN DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;182 MURCIA, REGIËN DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;303 MURCIA, REGIËN DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;182 MURCIA, REGIËN DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;121 MURCIA, REGIËN DE;Group 1103 Diseases of the esophagus 530;Both sexes;314 MURCIA, REGIËN DE;Group 1103 Diseases of the esophagus 530;Men;197 MURCIA, REGIËN DE;Group 1103 Diseases of the esophagus 530;Women;117 MURCIA, REGIËN DE;Group 1104 Peptic ulcer 531-534;Both sexes;277 MURCIA, REGIËN DE;Group 1104 Peptic ulcer 531-534;Men;198 MURCIA, REGIËN DE;Group 1104 Peptic ulcer 531-534;Women;79 MURCIA, REGIËN DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;420 MURCIA, REGIËN DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;214 MURCIA, REGIËN DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;206 MURCIA, REGIËN DE;Group 1106 Appendicitis 540-543;Both sexes;1.534 MURCIA, REGIËN DE;Group 1106 Appendicitis 540-543;Men;896 MURCIA, REGIËN DE;Group 1106 Appendicitis 540-543;Women;638 MURCIA, REGIËN DE;Group 1107 Inguinal hernia 550;Both sexes;1.665 MURCIA, REGIËN DE;Group 1107 Inguinal hernia 550;Men;1.465 MURCIA, REGIËN DE;Group 1107 Inguinal hernia 550;Women;200 MURCIA, REGIËN DE;Group 1108 Other abdominal hernia 551-553;Both sexes;1.413 MURCIA, REGIËN DE;Group 1108 Other abdominal hernia 551-553;Men;714 MURCIA, REGIËN DE;Group 1108 Other abdominal hernia 551-553;Women;699 MURCIA, REGIËN DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;379 MURCIA, REGIËN DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;191 MURCIA, REGIËN DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;188 MURCIA, REGIËN DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.176 MURCIA, REGIËN DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;571 MURCIA, REGIËN DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;605 MURCIA, REGIËN DE;Group 1111 Intestinal obstruction without hernia 560;Both sexes;723 MURCIA, REGIËN DE;Group 1111 Intestinal obstruction without hernia 560;Men;363 MURCIA, REGIËN DE;Group 1111 Intestinal obstruction without hernia 560;Women;360 MURCIA, REGIËN DE;Group 1112 Intestinal diverticulosis 562;Both sexes;628 MURCIA, REGIËN DE;Group 1112 Intestinal diverticulosis 562;Men;342 MURCIA, REGIËN DE;Group 1112 Intestinal diverticulosis 562;Women;286 MURCIA, REGIËN DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.025 MURCIA, REGIËN DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;668 MURCIA, REGIËN DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;357 MURCIA, REGIËN DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;489 MURCIA, REGIËN DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;211 MURCIA, REGIËN DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;278 MURCIA, REGIËN DE;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;275 MURCIA, REGIËN DE;Group 1115 Alcoholic hepatitis 5710-5713;Men;232 MURCIA, REGIËN DE;Group 1115 Alcoholic hepatitis 5710-5713;Women;43 MURCIA, REGIËN DE;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;586 MURCIA, REGIËN DE;Group 1116 Other diseases of the liver 570,5714-573;Men;349 MURCIA, REGIËN DE;Group 1116 Other diseases of the liver 570,5714-573;Women;237 MURCIA, REGIËN DE;Group 1117 Cholelithiasis 574;Both sexes;3.366 MURCIA, REGIËN DE;Group 1117 Cholelithiasis 574;Men;1.326 MURCIA, REGIËN DE;Group 1117 Cholelithiasis 574;Women;2.040 MURCIA, REGIËN DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;782 MURCIA, REGIËN DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;442 MURCIA, REGIËN DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;340 MURCIA, REGIËN DE;Group 1119 Pancreatic diseases 577;Both sexes;882 MURCIA, REGIËN DE;Group 1119 Pancreatic diseases 577;Men;506 MURCIA, REGIËN DE;Group 1119 Pancreatic diseases 577;Women;376 MURCIA, REGIËN DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;759 MURCIA, REGIËN DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;400 MURCIA, REGIËN DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;359 MURCIA, REGIËN DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.628 MURCIA, REGIËN DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;888 MURCIA, REGIËN DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;740 MURCIA, REGIËN DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.066 MURCIA, REGIËN DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;629 MURCIA, REGIËN DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;437 MURCIA, REGIËN DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;64 MURCIA, REGIËN DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;26 MURCIA, REGIËN DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;38 MURCIA, REGIËN DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;498 MURCIA, REGIËN DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;233 MURCIA, REGIËN DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;265 MURCIA, REGIËN DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;9.774 MURCIA, REGIËN DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.619 MURCIA, REGIËN DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5.155 MURCIA, REGIËN DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. MURCIA, REGIËN DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. MURCIA, REGIËN DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. MURCIA, REGIËN DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. MURCIA, REGIËN DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. MURCIA, REGIËN DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. MURCIA, REGIËN DE;Group 1303 Internal derangement of knee 717;Both sexes;1.222 MURCIA, REGIËN DE;Group 1303 Internal derangement of knee 717;Men;829 MURCIA, REGIËN DE;Group 1303 Internal derangement of knee 717;Women;393 MURCIA, REGIËN DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3.522 MURCIA, REGIËN DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.459 MURCIA, REGIËN DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.063 MURCIA, REGIËN DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;205 MURCIA, REGIËN DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;69 MURCIA, REGIËN DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;136 MURCIA, REGIËN DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;370 MURCIA, REGIËN DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;183 MURCIA, REGIËN DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;187 MURCIA, REGIËN DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.260 MURCIA, REGIËN DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;685 MURCIA, REGIËN DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;575 MURCIA, REGIËN DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;300 MURCIA, REGIËN DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;127 MURCIA, REGIËN DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;173 MURCIA, REGIËN DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.416 MURCIA, REGIËN DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;690 MURCIA, REGIËN DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;726 MURCIA, REGIËN DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.479 MURCIA, REGIËN DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;577 MURCIA, REGIËN DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;902 MURCIA, REGIËN DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;10.388 MURCIA, REGIËN DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4.793 MURCIA, REGIËN DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;5.595 MURCIA, REGIËN DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.221 MURCIA, REGIËN DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;413 MURCIA, REGIËN DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;808 MURCIA, REGIËN DE;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;902 MURCIA, REGIËN DE;Group 1402 Renal failure 5836-5837, 584-586;Men;539 MURCIA, REGIËN DE;Group 1402 Renal failure 5836-5837, 584-586;Women;363 MURCIA, REGIËN DE;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.625 MURCIA, REGIËN DE;Group 1403 Urolithiasis 592, 594, 7880;Men;953 MURCIA, REGIËN DE;Group 1403 Urolithiasis 592, 594, 7880;Women;672 MURCIA, REGIËN DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;3.053 MURCIA, REGIËN DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.416 MURCIA, REGIËN DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.637 MURCIA, REGIËN DE;Group 1405 Prostatic hyperplasia 600;Both sexes;692 MURCIA, REGIËN DE;Group 1405 Prostatic hyperplasia 600;Men;692 MURCIA, REGIËN DE;Group 1405 Prostatic hyperplasia 600;Women;.. MURCIA, REGIËN DE;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;719 MURCIA, REGIËN DE;Group 1406 Other diseases of the male genital organs 601-608;Men;719 MURCIA, REGIËN DE;Group 1406 Other diseases of the male genital organs 601-608;Women;.. MURCIA, REGIËN DE;Group 1407 Disorders of breast 610-612;Both sexes;605 MURCIA, REGIËN DE;Group 1407 Disorders of breast 610-612;Men;56 MURCIA, REGIËN DE;Group 1407 Disorders of breast 610-612;Women;549 MURCIA, REGIËN DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;274 MURCIA, REGIËN DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. MURCIA, REGIËN DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;274 MURCIA, REGIËN DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;99 MURCIA, REGIËN DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. MURCIA, REGIËN DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;99 MURCIA, REGIËN DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.198 MURCIA, REGIËN DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;5 MURCIA, REGIËN DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.193 MURCIA, REGIËN DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;19.051 MURCIA, REGIËN DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. MURCIA, REGIËN DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;19.051 MURCIA, REGIËN DE;Group 1501 Legally induced abortion 635;Both sexes;13 MURCIA, REGIËN DE;Group 1501 Legally induced abortion 635;Men;.. MURCIA, REGIËN DE;Group 1501 Legally induced abortion 635;Women;13 MURCIA, REGIËN DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;984 MURCIA, REGIËN DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. MURCIA, REGIËN DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;984 MURCIA, REGIËN DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;12.859 MURCIA, REGIËN DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. MURCIA, REGIËN DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;12.859 MURCIA, REGIËN DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2.213 MURCIA, REGIËN DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. MURCIA, REGIËN DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2.213 MURCIA, REGIËN DE;Group 1505 Single spontaneous delivery 650;Both sexes;619 MURCIA, REGIËN DE;Group 1505 Single spontaneous delivery 650;Men;.. MURCIA, REGIËN DE;Group 1505 Single spontaneous delivery 650;Women;619 MURCIA, REGIËN DE;Group 1506 Other deliveries 6695-6697;Both sexes;747 MURCIA, REGIËN DE;Group 1506 Other deliveries 6695-6697;Men;.. MURCIA, REGIËN DE;Group 1506 Other deliveries 6695-6697;Women;747 MURCIA, REGIËN DE;Group 1507 Complications related to the puerperium 670-676;Both sexes;142 MURCIA, REGIËN DE;Group 1507 Complications related to the puerperium 670-676;Men;.. MURCIA, REGIËN DE;Group 1507 Complications related to the puerperium 670-676;Women;142 MURCIA, REGIËN DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.474 MURCIA, REGIËN DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. MURCIA, REGIËN DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.474 MURCIA, REGIËN DE;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.675 MURCIA, REGIËN DE;Group 1600 Some disorders originating in the perinatal period 760-779;Men;967 MURCIA, REGIËN DE;Group 1600 Some disorders originating in the perinatal period 760-779;Women;708 MURCIA, REGIËN DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;548 MURCIA, REGIËN DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;310 MURCIA, REGIËN DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;238 MURCIA, REGIËN DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.127 MURCIA, REGIËN DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;657 MURCIA, REGIËN DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;470 MURCIA, REGIËN DE;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.103 MURCIA, REGIËN DE;Grupo 1700 Congenital abnormalities 740-759;Men;620 MURCIA, REGIËN DE;Grupo 1700 Congenital abnormalities 740-759;Women;483 MURCIA, REGIËN DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;7.816 MURCIA, REGIËN DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4.329 MURCIA, REGIËN DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3.487 MURCIA, REGIËN DE;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.096 MURCIA, REGIËN DE;Group 1801 Pain in throat and chest 7841, 7865;Men;632 MURCIA, REGIËN DE;Group 1801 Pain in throat and chest 7841, 7865;Women;464 MURCIA, REGIËN DE;Group 1802 Abdominal pain 7890;Both sexes;672 MURCIA, REGIËN DE;Group 1802 Abdominal pain 7890;Men;270 MURCIA, REGIËN DE;Group 1802 Abdominal pain 7890;Women;402 MURCIA, REGIËN DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;582 MURCIA, REGIËN DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;313 MURCIA, REGIËN DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;269 MURCIA, REGIËN DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5.466 MURCIA, REGIËN DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;3.114 MURCIA, REGIËN DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.352 MURCIA, REGIËN DE;Group 1900 Injuries and poisoning 800-999;Both sexes;12.345 MURCIA, REGIËN DE;Group 1900 Injuries and poisoning 800-999;Men;6.588 MURCIA, REGIËN DE;Group 1900 Injuries and poisoning 800-999;Women;5.757 MURCIA, REGIËN DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;629 MURCIA, REGIËN DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;358 MURCIA, REGIËN DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;271 MURCIA, REGIËN DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;368 MURCIA, REGIËN DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;261 MURCIA, REGIËN DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;107 MURCIA, REGIËN DE;Group 1903 Radius and ulna fracture 813;Both sexes;689 MURCIA, REGIËN DE;Group 1903 Radius and ulna fracture 813;Men;330 MURCIA, REGIËN DE;Group 1903 Radius and ulna fracture 813;Women;359 MURCIA, REGIËN DE;Group 1904 Femur fracture 820-821;Both sexes;1.765 MURCIA, REGIËN DE;Group 1904 Femur fracture 820-821;Men;523 MURCIA, REGIËN DE;Group 1904 Femur fracture 820-821;Women;1.242 MURCIA, REGIËN DE;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;840 MURCIA, REGIËN DE;Group 1905 Leg fracture, including the ankle 823-824;Men;439 MURCIA, REGIËN DE;Group 1905 Leg fracture, including the ankle 823-824;Women;401 MURCIA, REGIËN DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3.813 MURCIA, REGIËN DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.383 MURCIA, REGIËN DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.430 MURCIA, REGIËN DE;Group 1907 Burns 940-949;Both sexes;117 MURCIA, REGIËN DE;Group 1907 Burns 940-949;Men;70 MURCIA, REGIËN DE;Group 1907 Burns 940-949;Women;47 MURCIA, REGIËN DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;411 MURCIA, REGIËN DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;191 MURCIA, REGIËN DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;220 MURCIA, REGIËN DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3.277 MURCIA, REGIËN DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.792 MURCIA, REGIËN DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.485 MURCIA, REGIËN DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;17 MURCIA, REGIËN DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;12 MURCIA, REGIËN DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;5 MURCIA, REGIËN DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;419 MURCIA, REGIËN DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;229 MURCIA, REGIËN DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;190 MURCIA, REGIËN DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.888 MURCIA, REGIËN DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.188 MURCIA, REGIËN DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.700 MURCIA, REGIËN DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;71 MURCIA, REGIËN DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;37 MURCIA, REGIËN DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;34 MURCIA, REGIËN DE;Group 2102 Contraceptive management V25;Both sexes;66 MURCIA, REGIËN DE;Group 2102 Contraceptive management V25;Men;3 MURCIA, REGIËN DE;Group 2102 Contraceptive management V25;Women;63 MURCIA, REGIËN DE;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. MURCIA, REGIËN DE;Group 2103 Living newborns by type of delivery V30-V39;Men;.. MURCIA, REGIËN DE;Group 2103 Living newborns by type of delivery V30-V39;Women;.. MURCIA, REGIËN DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;869 MURCIA, REGIËN DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;523 MURCIA, REGIËN DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;346 MURCIA, REGIËN DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.882 MURCIA, REGIËN DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;625 MURCIA, REGIËN DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.257 NAVARRA, COMUNIDAD FORAL DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;68.592 NAVARRA, COMUNIDAD FORAL DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;33.408 NAVARRA, COMUNIDAD FORAL DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;35.184 NAVARRA, COMUNIDAD FORAL DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.223 NAVARRA, COMUNIDAD FORAL DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;703 NAVARRA, COMUNIDAD FORAL DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;520 NAVARRA, COMUNIDAD FORAL DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;176 NAVARRA, COMUNIDAD FORAL DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;102 NAVARRA, COMUNIDAD FORAL DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;74 NAVARRA, COMUNIDAD FORAL DE;Group 0102 Imprecise intestinal infections 009;Both sexes;67 NAVARRA, COMUNIDAD FORAL DE;Group 0102 Imprecise intestinal infections 009;Men;31 NAVARRA, COMUNIDAD FORAL DE;Group 0102 Imprecise intestinal infections 009;Women;36 NAVARRA, COMUNIDAD FORAL DE;Group 0103 Tuberculosis 010-018, 137;Both sexes;60 NAVARRA, COMUNIDAD FORAL DE;Group 0103 Tuberculosis 010-018, 137;Men;35 NAVARRA, COMUNIDAD FORAL DE;Group 0103 Tuberculosis 010-018, 137;Women;25 NAVARRA, COMUNIDAD FORAL DE;Group 0104 Septicaemia 038;Both sexes;410 NAVARRA, COMUNIDAD FORAL DE;Group 0104 Septicaemia 038;Men;242 NAVARRA, COMUNIDAD FORAL DE;Group 0104 Septicaemia 038;Women;168 NAVARRA, COMUNIDAD FORAL DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;27 NAVARRA, COMUNIDAD FORAL DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;12 NAVARRA, COMUNIDAD FORAL DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;15 NAVARRA, COMUNIDAD FORAL DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;483 NAVARRA, COMUNIDAD FORAL DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;281 NAVARRA, COMUNIDAD FORAL DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;202 NAVARRA, COMUNIDAD FORAL DE;Group 0200 Neoplasms 140-239;Both sexes;8.144 NAVARRA, COMUNIDAD FORAL DE;Group 0200 Neoplasms 140-239;Men;4.394 NAVARRA, COMUNIDAD FORAL DE;Group 0200 Neoplasms 140-239;Women;3.750 NAVARRA, COMUNIDAD FORAL DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;875 NAVARRA, COMUNIDAD FORAL DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;580 NAVARRA, COMUNIDAD FORAL DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;295 NAVARRA, COMUNIDAD FORAL DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;615 NAVARRA, COMUNIDAD FORAL DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;472 NAVARRA, COMUNIDAD FORAL DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;143 NAVARRA, COMUNIDAD FORAL DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;133 NAVARRA, COMUNIDAD FORAL DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;76 NAVARRA, COMUNIDAD FORAL DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;57 NAVARRA, COMUNIDAD FORAL DE;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;596 NAVARRA, COMUNIDAD FORAL DE;Group 0204 Malignant neoplasm of breast 174-175;Men;5 NAVARRA, COMUNIDAD FORAL DE;Group 0204 Malignant neoplasm of breast 174-175;Women;591 NAVARRA, COMUNIDAD FORAL DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;163 NAVARRA, COMUNIDAD FORAL DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;163 NAVARRA, COMUNIDAD FORAL DE;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;71 NAVARRA, COMUNIDAD FORAL DE;Group 0206 Malignant neoplasm of ovary 1830;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 0206 Malignant neoplasm of ovary 1830;Women;71 NAVARRA, COMUNIDAD FORAL DE;Group 0207 Malignant neoplasm of prostate 185;Both sexes;302 NAVARRA, COMUNIDAD FORAL DE;Group 0207 Malignant neoplasm of prostate 185;Men;302 NAVARRA, COMUNIDAD FORAL DE;Group 0207 Malignant neoplasm of prostate 185;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 0208 Malignant neoplasm of bladder 188;Both sexes;597 NAVARRA, COMUNIDAD FORAL DE;Group 0208 Malignant neoplasm of bladder 188;Men;510 NAVARRA, COMUNIDAD FORAL DE;Group 0208 Malignant neoplasm of bladder 188;Women;87 NAVARRA, COMUNIDAD FORAL DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;3.131 NAVARRA, COMUNIDAD FORAL DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.846 NAVARRA, COMUNIDAD FORAL DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.285 NAVARRA, COMUNIDAD FORAL DE;Group 0210 Carcinoma in situ 230-234;Both sexes;172 NAVARRA, COMUNIDAD FORAL DE;Group 0210 Carcinoma in situ 230-234;Men;81 NAVARRA, COMUNIDAD FORAL DE;Group 0210 Carcinoma in situ 230-234;Women;91 NAVARRA, COMUNIDAD FORAL DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;97 NAVARRA, COMUNIDAD FORAL DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;58 NAVARRA, COMUNIDAD FORAL DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;39 NAVARRA, COMUNIDAD FORAL DE;Grupo 0212 Leiomyoma of uterus 218;Both sexes;306 NAVARRA, COMUNIDAD FORAL DE;Grupo 0212 Leiomyoma of uterus 218;Men;.. NAVARRA, COMUNIDAD FORAL DE;Grupo 0212 Leiomyoma of uterus 218;Women;306 NAVARRA, COMUNIDAD FORAL DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.086 NAVARRA, COMUNIDAD FORAL DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;464 NAVARRA, COMUNIDAD FORAL DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;622 NAVARRA, COMUNIDAD FORAL DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;654 NAVARRA, COMUNIDAD FORAL DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;363 NAVARRA, COMUNIDAD FORAL DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;291 NAVARRA, COMUNIDAD FORAL DE;Group 0301 Anaemias 280-285;Both sexes;410 NAVARRA, COMUNIDAD FORAL DE;Group 0301 Anaemias 280-285;Men;217 NAVARRA, COMUNIDAD FORAL DE;Group 0301 Anaemias 280-285;Women;193 NAVARRA, COMUNIDAD FORAL DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;244 NAVARRA, COMUNIDAD FORAL DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;146 NAVARRA, COMUNIDAD FORAL DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;98 NAVARRA, COMUNIDAD FORAL DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.275 NAVARRA, COMUNIDAD FORAL DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;578 NAVARRA, COMUNIDAD FORAL DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;697 NAVARRA, COMUNIDAD FORAL DE;Group 0401 Diabetes mellitus 249-250;Both sexes;418 NAVARRA, COMUNIDAD FORAL DE;Group 0401 Diabetes mellitus 249-250;Men;259 NAVARRA, COMUNIDAD FORAL DE;Group 0401 Diabetes mellitus 249-250;Women;159 NAVARRA, COMUNIDAD FORAL DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;857 NAVARRA, COMUNIDAD FORAL DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;319 NAVARRA, COMUNIDAD FORAL DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;538 NAVARRA, COMUNIDAD FORAL DE;Group 0500 Mental disorders 290-319;Both sexes;2.036 NAVARRA, COMUNIDAD FORAL DE;Group 0500 Mental disorders 290-319;Men;999 NAVARRA, COMUNIDAD FORAL DE;Group 0500 Mental disorders 290-319;Women;1.037 NAVARRA, COMUNIDAD FORAL DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;268 NAVARRA, COMUNIDAD FORAL DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;108 NAVARRA, COMUNIDAD FORAL DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;160 NAVARRA, COMUNIDAD FORAL DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;113 NAVARRA, COMUNIDAD FORAL DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;85 NAVARRA, COMUNIDAD FORAL DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;28 NAVARRA, COMUNIDAD FORAL DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;78 NAVARRA, COMUNIDAD FORAL DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;50 NAVARRA, COMUNIDAD FORAL DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;28 NAVARRA, COMUNIDAD FORAL DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;542 NAVARRA, COMUNIDAD FORAL DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;314 NAVARRA, COMUNIDAD FORAL DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;228 NAVARRA, COMUNIDAD FORAL DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;474 NAVARRA, COMUNIDAD FORAL DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;208 NAVARRA, COMUNIDAD FORAL DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;266 NAVARRA, COMUNIDAD FORAL DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;561 NAVARRA, COMUNIDAD FORAL DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;234 NAVARRA, COMUNIDAD FORAL DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;327 NAVARRA, COMUNIDAD FORAL DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.797 NAVARRA, COMUNIDAD FORAL DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;943 NAVARRA, COMUNIDAD FORAL DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;854 NAVARRA, COMUNIDAD FORAL DE;Group 0601 Alzheimer's disease 3310;Both sexes;40 NAVARRA, COMUNIDAD FORAL DE;Group 0601 Alzheimer's disease 3310;Men;16 NAVARRA, COMUNIDAD FORAL DE;Group 0601 Alzheimer's disease 3310;Women;24 NAVARRA, COMUNIDAD FORAL DE;Group 0602 Multiple sclerosis 340;Both sexes;23 NAVARRA, COMUNIDAD FORAL DE;Group 0602 Multiple sclerosis 340;Men;6 NAVARRA, COMUNIDAD FORAL DE;Group 0602 Multiple sclerosis 340;Women;17 NAVARRA, COMUNIDAD FORAL DE;Group 0603 Epilepsy 345;Both sexes;186 NAVARRA, COMUNIDAD FORAL DE;Group 0603 Epilepsy 345;Men;84 NAVARRA, COMUNIDAD FORAL DE;Group 0603 Epilepsy 345;Women;102 NAVARRA, COMUNIDAD FORAL DE;Group 0604 Transient cerebral ischemia 435;Both sexes;176 NAVARRA, COMUNIDAD FORAL DE;Group 0604 Transient cerebral ischemia 435;Men;103 NAVARRA, COMUNIDAD FORAL DE;Group 0604 Transient cerebral ischemia 435;Women;73 NAVARRA, COMUNIDAD FORAL DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.372 NAVARRA, COMUNIDAD FORAL DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;734 NAVARRA, COMUNIDAD FORAL DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;638 NAVARRA, COMUNIDAD FORAL DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;383 NAVARRA, COMUNIDAD FORAL DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;195 NAVARRA, COMUNIDAD FORAL DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;188 NAVARRA, COMUNIDAD FORAL DE;Grupo 0701 Cataract 366;Both sexes;28 NAVARRA, COMUNIDAD FORAL DE;Grupo 0701 Cataract 366;Men;16 NAVARRA, COMUNIDAD FORAL DE;Grupo 0701 Cataract 366;Women;12 NAVARRA, COMUNIDAD FORAL DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;355 NAVARRA, COMUNIDAD FORAL DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;179 NAVARRA, COMUNIDAD FORAL DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;176 NAVARRA, COMUNIDAD FORAL DE;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;471 NAVARRA, COMUNIDAD FORAL DE;Group 0800 Diseases of the ear and the mastoid 380-389;Men;245 NAVARRA, COMUNIDAD FORAL DE;Group 0800 Diseases of the ear and the mastoid 380-389;Women;226 NAVARRA, COMUNIDAD FORAL DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;7.913 NAVARRA, COMUNIDAD FORAL DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;4.612 NAVARRA, COMUNIDAD FORAL DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3.301 NAVARRA, COMUNIDAD FORAL DE;Group 0901 Hypertensive disease 401-405;Both sexes;641 NAVARRA, COMUNIDAD FORAL DE;Group 0901 Hypertensive disease 401-405;Men;288 NAVARRA, COMUNIDAD FORAL DE;Group 0901 Hypertensive disease 401-405;Women;353 NAVARRA, COMUNIDAD FORAL DE;Group 0902 Angina pectoris 4111, 413;Both sexes;163 NAVARRA, COMUNIDAD FORAL DE;Group 0902 Angina pectoris 4111, 413;Men;109 NAVARRA, COMUNIDAD FORAL DE;Group 0902 Angina pectoris 4111, 413;Women;54 NAVARRA, COMUNIDAD FORAL DE;Group 0903 Acute myocardial infarction 410;Both sexes;600 NAVARRA, COMUNIDAD FORAL DE;Group 0903 Acute myocardial infarction 410;Men;446 NAVARRA, COMUNIDAD FORAL DE;Group 0903 Acute myocardial infarction 410;Women;154 NAVARRA, COMUNIDAD FORAL DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;553 NAVARRA, COMUNIDAD FORAL DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;448 NAVARRA, COMUNIDAD FORAL DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;105 NAVARRA, COMUNIDAD FORAL DE;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;368 NAVARRA, COMUNIDAD FORAL DE;Group 0905 Diseases of the lungs circulation 415-417;Men;157 NAVARRA, COMUNIDAD FORAL DE;Group 0905 Diseases of the lungs circulation 415-417;Women;211 NAVARRA, COMUNIDAD FORAL DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;987 NAVARRA, COMUNIDAD FORAL DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;581 NAVARRA, COMUNIDAD FORAL DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;406 NAVARRA, COMUNIDAD FORAL DE;Grupo 0907 Heart failure 428;Both sexes;1.296 NAVARRA, COMUNIDAD FORAL DE;Grupo 0907 Heart failure 428;Men;674 NAVARRA, COMUNIDAD FORAL DE;Grupo 0907 Heart failure 428;Women;622 NAVARRA, COMUNIDAD FORAL DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.401 NAVARRA, COMUNIDAD FORAL DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;734 NAVARRA, COMUNIDAD FORAL DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;667 NAVARRA, COMUNIDAD FORAL DE;Grupo 0909 Atherosclerosis 440;Both sexes;361 NAVARRA, COMUNIDAD FORAL DE;Grupo 0909 Atherosclerosis 440;Men;285 NAVARRA, COMUNIDAD FORAL DE;Grupo 0909 Atherosclerosis 440;Women;76 NAVARRA, COMUNIDAD FORAL DE;Group 0910 Varicose veins of lower extremities 454;Both sexes;124 NAVARRA, COMUNIDAD FORAL DE;Group 0910 Varicose veins of lower extremities 454;Men;54 NAVARRA, COMUNIDAD FORAL DE;Group 0910 Varicose veins of lower extremities 454;Women;70 NAVARRA, COMUNIDAD FORAL DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.419 NAVARRA, COMUNIDAD FORAL DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;836 NAVARRA, COMUNIDAD FORAL DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;583 NAVARRA, COMUNIDAD FORAL DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7.771 NAVARRA, COMUNIDAD FORAL DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.350 NAVARRA, COMUNIDAD FORAL DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3.421 NAVARRA, COMUNIDAD FORAL DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;425 NAVARRA, COMUNIDAD FORAL DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;212 NAVARRA, COMUNIDAD FORAL DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;213 NAVARRA, COMUNIDAD FORAL DE;Group 1002 Pneumonia 480-486;Both sexes;1.615 NAVARRA, COMUNIDAD FORAL DE;Group 1002 Pneumonia 480-486;Men;967 NAVARRA, COMUNIDAD FORAL DE;Group 1002 Pneumonia 480-486;Women;648 NAVARRA, COMUNIDAD FORAL DE;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;510 NAVARRA, COMUNIDAD FORAL DE;Group 1003 Acute bronchitis and bronchiolitis 466;Men;251 NAVARRA, COMUNIDAD FORAL DE;Group 1003 Acute bronchitis and bronchiolitis 466;Women;259 NAVARRA, COMUNIDAD FORAL DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;553 NAVARRA, COMUNIDAD FORAL DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;319 NAVARRA, COMUNIDAD FORAL DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;234 NAVARRA, COMUNIDAD FORAL DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;826 NAVARRA, COMUNIDAD FORAL DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;516 NAVARRA, COMUNIDAD FORAL DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;310 NAVARRA, COMUNIDAD FORAL DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.097 NAVARRA, COMUNIDAD FORAL DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;784 NAVARRA, COMUNIDAD FORAL DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;313 NAVARRA, COMUNIDAD FORAL DE;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;339 NAVARRA, COMUNIDAD FORAL DE;Group 1007 Asthma 4930-4931,4938-4939;Men;117 NAVARRA, COMUNIDAD FORAL DE;Group 1007 Asthma 4930-4931,4938-4939;Women;222 NAVARRA, COMUNIDAD FORAL DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.406 NAVARRA, COMUNIDAD FORAL DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.184 NAVARRA, COMUNIDAD FORAL DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.222 NAVARRA, COMUNIDAD FORAL DE;Group 1100 Diseases of the digestive system 520-579;Both sexes;8.539 NAVARRA, COMUNIDAD FORAL DE;Group 1100 Diseases of the digestive system 520-579;Men;4.921 NAVARRA, COMUNIDAD FORAL DE;Group 1100 Diseases of the digestive system 520-579;Women;3.618 NAVARRA, COMUNIDAD FORAL DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;146 NAVARRA, COMUNIDAD FORAL DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;68 NAVARRA, COMUNIDAD FORAL DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;78 NAVARRA, COMUNIDAD FORAL DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;132 NAVARRA, COMUNIDAD FORAL DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;77 NAVARRA, COMUNIDAD FORAL DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;55 NAVARRA, COMUNIDAD FORAL DE;Group 1103 Diseases of the esophagus 530;Both sexes;201 NAVARRA, COMUNIDAD FORAL DE;Group 1103 Diseases of the esophagus 530;Men;130 NAVARRA, COMUNIDAD FORAL DE;Group 1103 Diseases of the esophagus 530;Women;71 NAVARRA, COMUNIDAD FORAL DE;Group 1104 Peptic ulcer 531-534;Both sexes;155 NAVARRA, COMUNIDAD FORAL DE;Group 1104 Peptic ulcer 531-534;Men;108 NAVARRA, COMUNIDAD FORAL DE;Group 1104 Peptic ulcer 531-534;Women;47 NAVARRA, COMUNIDAD FORAL DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;252 NAVARRA, COMUNIDAD FORAL DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;137 NAVARRA, COMUNIDAD FORAL DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;115 NAVARRA, COMUNIDAD FORAL DE;Group 1106 Appendicitis 540-543;Both sexes;755 NAVARRA, COMUNIDAD FORAL DE;Group 1106 Appendicitis 540-543;Men;433 NAVARRA, COMUNIDAD FORAL DE;Group 1106 Appendicitis 540-543;Women;322 NAVARRA, COMUNIDAD FORAL DE;Group 1107 Inguinal hernia 550;Both sexes;787 NAVARRA, COMUNIDAD FORAL DE;Group 1107 Inguinal hernia 550;Men;698 NAVARRA, COMUNIDAD FORAL DE;Group 1107 Inguinal hernia 550;Women;89 NAVARRA, COMUNIDAD FORAL DE;Group 1108 Other abdominal hernia 551-553;Both sexes;703 NAVARRA, COMUNIDAD FORAL DE;Group 1108 Other abdominal hernia 551-553;Men;357 NAVARRA, COMUNIDAD FORAL DE;Group 1108 Other abdominal hernia 551-553;Women;346 NAVARRA, COMUNIDAD FORAL DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;179 NAVARRA, COMUNIDAD FORAL DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;88 NAVARRA, COMUNIDAD FORAL DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;91 NAVARRA, COMUNIDAD FORAL DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;358 NAVARRA, COMUNIDAD FORAL DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;177 NAVARRA, COMUNIDAD FORAL DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;181 NAVARRA, COMUNIDAD FORAL DE;Group 1111 Intestinal obstruction without hernia 560;Both sexes;374 NAVARRA, COMUNIDAD FORAL DE;Group 1111 Intestinal obstruction without hernia 560;Men;193 NAVARRA, COMUNIDAD FORAL DE;Group 1111 Intestinal obstruction without hernia 560;Women;181 NAVARRA, COMUNIDAD FORAL DE;Group 1112 Intestinal diverticulosis 562;Both sexes;342 NAVARRA, COMUNIDAD FORAL DE;Group 1112 Intestinal diverticulosis 562;Men;183 NAVARRA, COMUNIDAD FORAL DE;Group 1112 Intestinal diverticulosis 562;Women;159 NAVARRA, COMUNIDAD FORAL DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;516 NAVARRA, COMUNIDAD FORAL DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;346 NAVARRA, COMUNIDAD FORAL DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;170 NAVARRA, COMUNIDAD FORAL DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;377 NAVARRA, COMUNIDAD FORAL DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;173 NAVARRA, COMUNIDAD FORAL DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;204 NAVARRA, COMUNIDAD FORAL DE;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;206 NAVARRA, COMUNIDAD FORAL DE;Group 1115 Alcoholic hepatitis 5710-5713;Men;172 NAVARRA, COMUNIDAD FORAL DE;Group 1115 Alcoholic hepatitis 5710-5713;Women;34 NAVARRA, COMUNIDAD FORAL DE;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;286 NAVARRA, COMUNIDAD FORAL DE;Group 1116 Other diseases of the liver 570,5714-573;Men;181 NAVARRA, COMUNIDAD FORAL DE;Group 1116 Other diseases of the liver 570,5714-573;Women;105 NAVARRA, COMUNIDAD FORAL DE;Group 1117 Cholelithiasis 574;Both sexes;1.489 NAVARRA, COMUNIDAD FORAL DE;Group 1117 Cholelithiasis 574;Men;690 NAVARRA, COMUNIDAD FORAL DE;Group 1117 Cholelithiasis 574;Women;799 NAVARRA, COMUNIDAD FORAL DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;433 NAVARRA, COMUNIDAD FORAL DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;243 NAVARRA, COMUNIDAD FORAL DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;190 NAVARRA, COMUNIDAD FORAL DE;Group 1119 Pancreatic diseases 577;Both sexes;461 NAVARRA, COMUNIDAD FORAL DE;Group 1119 Pancreatic diseases 577;Men;275 NAVARRA, COMUNIDAD FORAL DE;Group 1119 Pancreatic diseases 577;Women;186 NAVARRA, COMUNIDAD FORAL DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;387 NAVARRA, COMUNIDAD FORAL DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;192 NAVARRA, COMUNIDAD FORAL DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;195 NAVARRA, COMUNIDAD FORAL DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;646 NAVARRA, COMUNIDAD FORAL DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;339 NAVARRA, COMUNIDAD FORAL DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;307 NAVARRA, COMUNIDAD FORAL DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;395 NAVARRA, COMUNIDAD FORAL DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;221 NAVARRA, COMUNIDAD FORAL DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;174 NAVARRA, COMUNIDAD FORAL DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;25 NAVARRA, COMUNIDAD FORAL DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;12 NAVARRA, COMUNIDAD FORAL DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;13 NAVARRA, COMUNIDAD FORAL DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;226 NAVARRA, COMUNIDAD FORAL DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;106 NAVARRA, COMUNIDAD FORAL DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;120 NAVARRA, COMUNIDAD FORAL DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;6.444 NAVARRA, COMUNIDAD FORAL DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3.305 NAVARRA, COMUNIDAD FORAL DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.139 NAVARRA, COMUNIDAD FORAL DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. NAVARRA, COMUNIDAD FORAL DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. NAVARRA, COMUNIDAD FORAL DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 1303 Internal derangement of knee 717;Both sexes;947 NAVARRA, COMUNIDAD FORAL DE;Group 1303 Internal derangement of knee 717;Men;668 NAVARRA, COMUNIDAD FORAL DE;Group 1303 Internal derangement of knee 717;Women;279 NAVARRA, COMUNIDAD FORAL DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.056 NAVARRA, COMUNIDAD FORAL DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.062 NAVARRA, COMUNIDAD FORAL DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;994 NAVARRA, COMUNIDAD FORAL DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;163 NAVARRA, COMUNIDAD FORAL DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;45 NAVARRA, COMUNIDAD FORAL DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;118 NAVARRA, COMUNIDAD FORAL DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;257 NAVARRA, COMUNIDAD FORAL DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;139 NAVARRA, COMUNIDAD FORAL DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;118 NAVARRA, COMUNIDAD FORAL DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;507 NAVARRA, COMUNIDAD FORAL DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;291 NAVARRA, COMUNIDAD FORAL DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;216 NAVARRA, COMUNIDAD FORAL DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;239 NAVARRA, COMUNIDAD FORAL DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;96 NAVARRA, COMUNIDAD FORAL DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;143 NAVARRA, COMUNIDAD FORAL DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.220 NAVARRA, COMUNIDAD FORAL DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;631 NAVARRA, COMUNIDAD FORAL DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;589 NAVARRA, COMUNIDAD FORAL DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.055 NAVARRA, COMUNIDAD FORAL DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;373 NAVARRA, COMUNIDAD FORAL DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;682 NAVARRA, COMUNIDAD FORAL DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.476 NAVARRA, COMUNIDAD FORAL DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.579 NAVARRA, COMUNIDAD FORAL DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.897 NAVARRA, COMUNIDAD FORAL DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;324 NAVARRA, COMUNIDAD FORAL DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;128 NAVARRA, COMUNIDAD FORAL DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;196 NAVARRA, COMUNIDAD FORAL DE;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;288 NAVARRA, COMUNIDAD FORAL DE;Group 1402 Renal failure 5836-5837, 584-586;Men;168 NAVARRA, COMUNIDAD FORAL DE;Group 1402 Renal failure 5836-5837, 584-586;Women;120 NAVARRA, COMUNIDAD FORAL DE;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;316 NAVARRA, COMUNIDAD FORAL DE;Group 1403 Urolithiasis 592, 594, 7880;Men;213 NAVARRA, COMUNIDAD FORAL DE;Group 1403 Urolithiasis 592, 594, 7880;Women;103 NAVARRA, COMUNIDAD FORAL DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.061 NAVARRA, COMUNIDAD FORAL DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;519 NAVARRA, COMUNIDAD FORAL DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;542 NAVARRA, COMUNIDAD FORAL DE;Group 1405 Prostatic hyperplasia 600;Both sexes;310 NAVARRA, COMUNIDAD FORAL DE;Group 1405 Prostatic hyperplasia 600;Men;310 NAVARRA, COMUNIDAD FORAL DE;Group 1405 Prostatic hyperplasia 600;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;212 NAVARRA, COMUNIDAD FORAL DE;Group 1406 Other diseases of the male genital organs 601-608;Men;212 NAVARRA, COMUNIDAD FORAL DE;Group 1406 Other diseases of the male genital organs 601-608;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 1407 Disorders of breast 610-612;Both sexes;201 NAVARRA, COMUNIDAD FORAL DE;Group 1407 Disorders of breast 610-612;Men;23 NAVARRA, COMUNIDAD FORAL DE;Group 1407 Disorders of breast 610-612;Women;178 NAVARRA, COMUNIDAD FORAL DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;98 NAVARRA, COMUNIDAD FORAL DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;98 NAVARRA, COMUNIDAD FORAL DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;37 NAVARRA, COMUNIDAD FORAL DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;37 NAVARRA, COMUNIDAD FORAL DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;629 NAVARRA, COMUNIDAD FORAL DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;6 NAVARRA, COMUNIDAD FORAL DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;623 NAVARRA, COMUNIDAD FORAL DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;6.869 NAVARRA, COMUNIDAD FORAL DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;6.869 NAVARRA, COMUNIDAD FORAL DE;Group 1501 Legally induced abortion 635;Both sexes;2 NAVARRA, COMUNIDAD FORAL DE;Group 1501 Legally induced abortion 635;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1501 Legally induced abortion 635;Women;2 NAVARRA, COMUNIDAD FORAL DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;441 NAVARRA, COMUNIDAD FORAL DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;441 NAVARRA, COMUNIDAD FORAL DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4.131 NAVARRA, COMUNIDAD FORAL DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4.131 NAVARRA, COMUNIDAD FORAL DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.419 NAVARRA, COMUNIDAD FORAL DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.419 NAVARRA, COMUNIDAD FORAL DE;Group 1505 Single spontaneous delivery 650;Both sexes;137 NAVARRA, COMUNIDAD FORAL DE;Group 1505 Single spontaneous delivery 650;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1505 Single spontaneous delivery 650;Women;137 NAVARRA, COMUNIDAD FORAL DE;Group 1506 Other deliveries 6695-6697;Both sexes;268 NAVARRA, COMUNIDAD FORAL DE;Group 1506 Other deliveries 6695-6697;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1506 Other deliveries 6695-6697;Women;268 NAVARRA, COMUNIDAD FORAL DE;Group 1507 Complications related to the puerperium 670-676;Both sexes;46 NAVARRA, COMUNIDAD FORAL DE;Group 1507 Complications related to the puerperium 670-676;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1507 Complications related to the puerperium 670-676;Women;46 NAVARRA, COMUNIDAD FORAL DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;425 NAVARRA, COMUNIDAD FORAL DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;425 NAVARRA, COMUNIDAD FORAL DE;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;622 NAVARRA, COMUNIDAD FORAL DE;Group 1600 Some disorders originating in the perinatal period 760-779;Men;335 NAVARRA, COMUNIDAD FORAL DE;Group 1600 Some disorders originating in the perinatal period 760-779;Women;287 NAVARRA, COMUNIDAD FORAL DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;174 NAVARRA, COMUNIDAD FORAL DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;87 NAVARRA, COMUNIDAD FORAL DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;87 NAVARRA, COMUNIDAD FORAL DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;448 NAVARRA, COMUNIDAD FORAL DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;248 NAVARRA, COMUNIDAD FORAL DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;200 NAVARRA, COMUNIDAD FORAL DE;Grupo 1700 Congenital abnormalities 740-759;Both sexes;534 NAVARRA, COMUNIDAD FORAL DE;Grupo 1700 Congenital abnormalities 740-759;Men;286 NAVARRA, COMUNIDAD FORAL DE;Grupo 1700 Congenital abnormalities 740-759;Women;248 NAVARRA, COMUNIDAD FORAL DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.397 NAVARRA, COMUNIDAD FORAL DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.282 NAVARRA, COMUNIDAD FORAL DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.115 NAVARRA, COMUNIDAD FORAL DE;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;133 NAVARRA, COMUNIDAD FORAL DE;Group 1801 Pain in throat and chest 7841, 7865;Men;74 NAVARRA, COMUNIDAD FORAL DE;Group 1801 Pain in throat and chest 7841, 7865;Women;59 NAVARRA, COMUNIDAD FORAL DE;Group 1802 Abdominal pain 7890;Both sexes;315 NAVARRA, COMUNIDAD FORAL DE;Group 1802 Abdominal pain 7890;Men;115 NAVARRA, COMUNIDAD FORAL DE;Group 1802 Abdominal pain 7890;Women;200 NAVARRA, COMUNIDAD FORAL DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;380 NAVARRA, COMUNIDAD FORAL DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;218 NAVARRA, COMUNIDAD FORAL DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;162 NAVARRA, COMUNIDAD FORAL DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.569 NAVARRA, COMUNIDAD FORAL DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;875 NAVARRA, COMUNIDAD FORAL DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;694 NAVARRA, COMUNIDAD FORAL DE;Group 1900 Injuries and poisoning 800-999;Both sexes;5.595 NAVARRA, COMUNIDAD FORAL DE;Group 1900 Injuries and poisoning 800-999;Men;2.978 NAVARRA, COMUNIDAD FORAL DE;Group 1900 Injuries and poisoning 800-999;Women;2.617 NAVARRA, COMUNIDAD FORAL DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;331 NAVARRA, COMUNIDAD FORAL DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;202 NAVARRA, COMUNIDAD FORAL DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;129 NAVARRA, COMUNIDAD FORAL DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;170 NAVARRA, COMUNIDAD FORAL DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;125 NAVARRA, COMUNIDAD FORAL DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;45 NAVARRA, COMUNIDAD FORAL DE;Group 1903 Radius and ulna fracture 813;Both sexes;392 NAVARRA, COMUNIDAD FORAL DE;Group 1903 Radius and ulna fracture 813;Men;182 NAVARRA, COMUNIDAD FORAL DE;Group 1903 Radius and ulna fracture 813;Women;210 NAVARRA, COMUNIDAD FORAL DE;Group 1904 Femur fracture 820-821;Both sexes;914 NAVARRA, COMUNIDAD FORAL DE;Group 1904 Femur fracture 820-821;Men;273 NAVARRA, COMUNIDAD FORAL DE;Group 1904 Femur fracture 820-821;Women;641 NAVARRA, COMUNIDAD FORAL DE;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;382 NAVARRA, COMUNIDAD FORAL DE;Group 1905 Leg fracture, including the ankle 823-824;Men;187 NAVARRA, COMUNIDAD FORAL DE;Group 1905 Leg fracture, including the ankle 823-824;Women;195 NAVARRA, COMUNIDAD FORAL DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.618 NAVARRA, COMUNIDAD FORAL DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.019 NAVARRA, COMUNIDAD FORAL DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;599 NAVARRA, COMUNIDAD FORAL DE;Group 1907 Burns 940-949;Both sexes;27 NAVARRA, COMUNIDAD FORAL DE;Group 1907 Burns 940-949;Men;16 NAVARRA, COMUNIDAD FORAL DE;Group 1907 Burns 940-949;Women;11 NAVARRA, COMUNIDAD FORAL DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;102 NAVARRA, COMUNIDAD FORAL DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;46 NAVARRA, COMUNIDAD FORAL DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;56 NAVARRA, COMUNIDAD FORAL DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.509 NAVARRA, COMUNIDAD FORAL DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;862 NAVARRA, COMUNIDAD FORAL DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;647 NAVARRA, COMUNIDAD FORAL DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;10 NAVARRA, COMUNIDAD FORAL DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;8 NAVARRA, COMUNIDAD FORAL DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 NAVARRA, COMUNIDAD FORAL DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;140 NAVARRA, COMUNIDAD FORAL DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;58 NAVARRA, COMUNIDAD FORAL DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;82 NAVARRA, COMUNIDAD FORAL DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.803 NAVARRA, COMUNIDAD FORAL DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.001 NAVARRA, COMUNIDAD FORAL DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;802 NAVARRA, COMUNIDAD FORAL DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;82 NAVARRA, COMUNIDAD FORAL DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;44 NAVARRA, COMUNIDAD FORAL DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;38 NAVARRA, COMUNIDAD FORAL DE;Group 2102 Contraceptive management V25;Both sexes;20 NAVARRA, COMUNIDAD FORAL DE;Group 2102 Contraceptive management V25;Men;3 NAVARRA, COMUNIDAD FORAL DE;Group 2102 Contraceptive management V25;Women;17 NAVARRA, COMUNIDAD FORAL DE;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. NAVARRA, COMUNIDAD FORAL DE;Group 2103 Living newborns by type of delivery V30-V39;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 2103 Living newborns by type of delivery V30-V39;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;923 NAVARRA, COMUNIDAD FORAL DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;577 NAVARRA, COMUNIDAD FORAL DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;346 NAVARRA, COMUNIDAD FORAL DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;778 NAVARRA, COMUNIDAD FORAL DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;377 NAVARRA, COMUNIDAD FORAL DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;401 PA═S VASCO;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;245.801 PA═S VASCO;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;122.094 PA═S VASCO;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;123.706 PA═S VASCO;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;4.549 PA═S VASCO;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2.611 PA═S VASCO;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.938 PA═S VASCO;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;562 PA═S VASCO;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;295 PA═S VASCO;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;267 PA═S VASCO;Group 0102 Imprecise intestinal infections 009;Both sexes;266 PA═S VASCO;Group 0102 Imprecise intestinal infections 009;Men;142 PA═S VASCO;Group 0102 Imprecise intestinal infections 009;Women;123 PA═S VASCO;Group 0103 Tuberculosis 010-018, 137;Both sexes;187 PA═S VASCO;Group 0103 Tuberculosis 010-018, 137;Men;118 PA═S VASCO;Group 0103 Tuberculosis 010-018, 137;Women;69 PA═S VASCO;Group 0104 Septicaemia 038;Both sexes;1.942 PA═S VASCO;Group 0104 Septicaemia 038;Men;1.111 PA═S VASCO;Group 0104 Septicaemia 038;Women;831 PA═S VASCO;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;221 PA═S VASCO;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;145 PA═S VASCO;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;75 PA═S VASCO;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.371 PA═S VASCO;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;798 PA═S VASCO;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;573 PA═S VASCO;Group 0200 Neoplasms 140-239;Both sexes;24.210 PA═S VASCO;Group 0200 Neoplasms 140-239;Men;13.165 PA═S VASCO;Group 0200 Neoplasms 140-239;Women;11.045 PA═S VASCO;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;2.635 PA═S VASCO;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;1.621 PA═S VASCO;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;1.014 PA═S VASCO;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.715 PA═S VASCO;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1.318 PA═S VASCO;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;397 PA═S VASCO;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;433 PA═S VASCO;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;224 PA═S VASCO;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;209 PA═S VASCO;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.650 PA═S VASCO;Group 0204 Malignant neoplasm of breast 174-175;Men;13 PA═S VASCO;Group 0204 Malignant neoplasm of breast 174-175;Women;1.637 PA═S VASCO;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;431 PA═S VASCO;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. PA═S VASCO;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;431 PA═S VASCO;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;234 PA═S VASCO;Group 0206 Malignant neoplasm of ovary 1830;Men;.. PA═S VASCO;Group 0206 Malignant neoplasm of ovary 1830;Women;234 PA═S VASCO;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1.376 PA═S VASCO;Group 0207 Malignant neoplasm of prostate 185;Men;1.376 PA═S VASCO;Group 0207 Malignant neoplasm of prostate 185;Women;.. PA═S VASCO;Group 0208 Malignant neoplasm of bladder 188;Both sexes;2.125 PA═S VASCO;Group 0208 Malignant neoplasm of bladder 188;Men;1.733 PA═S VASCO;Group 0208 Malignant neoplasm of bladder 188;Women;392 PA═S VASCO;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;8.856 PA═S VASCO;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;5.242 PA═S VASCO;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;3.614 PA═S VASCO;Group 0210 Carcinoma in situ 230-234;Both sexes;335 PA═S VASCO;Group 0210 Carcinoma in situ 230-234;Men;88 PA═S VASCO;Group 0210 Carcinoma in situ 230-234;Women;247 PA═S VASCO;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;436 PA═S VASCO;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;280 PA═S VASCO;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;155 PA═S VASCO;Grupo 0212 Leiomyoma of uterus 218;Both sexes;945 PA═S VASCO;Grupo 0212 Leiomyoma of uterus 218;Men;.. PA═S VASCO;Grupo 0212 Leiomyoma of uterus 218;Women;945 PA═S VASCO;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;3.040 PA═S VASCO;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.270 PA═S VASCO;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.770 PA═S VASCO;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;2.704 PA═S VASCO;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;1.390 PA═S VASCO;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;1.314 PA═S VASCO;Group 0301 Anaemias 280-285;Both sexes;1.789 PA═S VASCO;Group 0301 Anaemias 280-285;Men;897 PA═S VASCO;Group 0301 Anaemias 280-285;Women;892 PA═S VASCO;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;915 PA═S VASCO;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;493 PA═S VASCO;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;422 PA═S VASCO;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;4.295 PA═S VASCO;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.716 PA═S VASCO;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2.579 PA═S VASCO;Group 0401 Diabetes mellitus 249-250;Both sexes;1.402 PA═S VASCO;Group 0401 Diabetes mellitus 249-250;Men;827 PA═S VASCO;Group 0401 Diabetes mellitus 249-250;Women;575 PA═S VASCO;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2.893 PA═S VASCO;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;889 PA═S VASCO;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;2.004 PA═S VASCO;Group 0500 Mental disorders 290-319;Both sexes;7.512 PA═S VASCO;Group 0500 Mental disorders 290-319;Men;4.052 PA═S VASCO;Group 0500 Mental disorders 290-319;Women;3.460 PA═S VASCO;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;139 PA═S VASCO;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;64 PA═S VASCO;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;75 PA═S VASCO;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;627 PA═S VASCO;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;466 PA═S VASCO;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;161 PA═S VASCO;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;513 PA═S VASCO;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;364 PA═S VASCO;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;149 PA═S VASCO;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;2.513 PA═S VASCO;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;1.581 PA═S VASCO;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;932 PA═S VASCO;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1.818 PA═S VASCO;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;742 PA═S VASCO;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;1.076 PA═S VASCO;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.901 PA═S VASCO;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;834 PA═S VASCO;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;1.067 PA═S VASCO;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;5.542 PA═S VASCO;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.945 PA═S VASCO;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2.597 PA═S VASCO;Group 0601 Alzheimer's disease 3310;Both sexes;110 PA═S VASCO;Group 0601 Alzheimer's disease 3310;Men;45 PA═S VASCO;Group 0601 Alzheimer's disease 3310;Women;65 PA═S VASCO;Group 0602 Multiple sclerosis 340;Both sexes;53 PA═S VASCO;Group 0602 Multiple sclerosis 340;Men;23 PA═S VASCO;Group 0602 Multiple sclerosis 340;Women;30 PA═S VASCO;Group 0603 Epilepsy 345;Both sexes;892 PA═S VASCO;Group 0603 Epilepsy 345;Men;468 PA═S VASCO;Group 0603 Epilepsy 345;Women;424 PA═S VASCO;Group 0604 Transient cerebral ischemia 435;Both sexes;780 PA═S VASCO;Group 0604 Transient cerebral ischemia 435;Men;391 PA═S VASCO;Group 0604 Transient cerebral ischemia 435;Women;389 PA═S VASCO;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.707 PA═S VASCO;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;2.018 PA═S VASCO;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.689 PA═S VASCO;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;769 PA═S VASCO;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;378 PA═S VASCO;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;391 PA═S VASCO;Grupo 0701 Cataract 366;Both sexes;71 PA═S VASCO;Grupo 0701 Cataract 366;Men;33 PA═S VASCO;Grupo 0701 Cataract 366;Women;38 PA═S VASCO;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;698 PA═S VASCO;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;345 PA═S VASCO;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;353 PA═S VASCO;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;1.233 PA═S VASCO;Group 0800 Diseases of the ear and the mastoid 380-389;Men;623 PA═S VASCO;Group 0800 Diseases of the ear and the mastoid 380-389;Women;610 PA═S VASCO;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;32.299 PA═S VASCO;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;18.449 PA═S VASCO;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;13.850 PA═S VASCO;Group 0901 Hypertensive disease 401-405;Both sexes;1.670 PA═S VASCO;Group 0901 Hypertensive disease 401-405;Men;753 PA═S VASCO;Group 0901 Hypertensive disease 401-405;Women;917 PA═S VASCO;Group 0902 Angina pectoris 4111, 413;Both sexes;730 PA═S VASCO;Group 0902 Angina pectoris 4111, 413;Men;451 PA═S VASCO;Group 0902 Angina pectoris 4111, 413;Women;279 PA═S VASCO;Group 0903 Acute myocardial infarction 410;Both sexes;1.957 PA═S VASCO;Group 0903 Acute myocardial infarction 410;Men;1.393 PA═S VASCO;Group 0903 Acute myocardial infarction 410;Women;563 PA═S VASCO;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;2.293 PA═S VASCO;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.776 PA═S VASCO;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;517 PA═S VASCO;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;1.143 PA═S VASCO;Group 0905 Diseases of the lungs circulation 415-417;Men;520 PA═S VASCO;Group 0905 Diseases of the lungs circulation 415-417;Women;623 PA═S VASCO;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;4.826 PA═S VASCO;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;2.729 PA═S VASCO;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;2.097 PA═S VASCO;Grupo 0907 Heart failure 428;Both sexes;6.278 PA═S VASCO;Grupo 0907 Heart failure 428;Men;3.244 PA═S VASCO;Grupo 0907 Heart failure 428;Women;3.034 PA═S VASCO;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;5.323 PA═S VASCO;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;2.857 PA═S VASCO;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;2.465 PA═S VASCO;Grupo 0909 Atherosclerosis 440;Both sexes;1.586 PA═S VASCO;Grupo 0909 Atherosclerosis 440;Men;1.205 PA═S VASCO;Grupo 0909 Atherosclerosis 440;Women;382 PA═S VASCO;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.203 PA═S VASCO;Group 0910 Varicose veins of lower extremities 454;Men;459 PA═S VASCO;Group 0910 Varicose veins of lower extremities 454;Women;744 PA═S VASCO;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;5.291 PA═S VASCO;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;3.063 PA═S VASCO;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;2.228 PA═S VASCO;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;27.612 PA═S VASCO;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;15.911 PA═S VASCO;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;11.701 PA═S VASCO;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1.238 PA═S VASCO;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;647 PA═S VASCO;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;590 PA═S VASCO;Group 1002 Pneumonia 480-486;Both sexes;5.755 PA═S VASCO;Group 1002 Pneumonia 480-486;Men;3.492 PA═S VASCO;Group 1002 Pneumonia 480-486;Women;2.263 PA═S VASCO;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2.692 PA═S VASCO;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1.228 PA═S VASCO;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.465 PA═S VASCO;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1.423 PA═S VASCO;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;751 PA═S VASCO;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;672 PA═S VASCO;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;2.265 PA═S VASCO;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1.443 PA═S VASCO;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;822 PA═S VASCO;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;5.030 PA═S VASCO;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;3.780 PA═S VASCO;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1.250 PA═S VASCO;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1.748 PA═S VASCO;Group 1007 Asthma 4930-4931,4938-4939;Men;587 PA═S VASCO;Group 1007 Asthma 4930-4931,4938-4939;Women;1.160 PA═S VASCO;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;7.462 PA═S VASCO;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;3.983 PA═S VASCO;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;3.479 PA═S VASCO;Group 1100 Diseases of the digestive system 520-579;Both sexes;30.437 PA═S VASCO;Group 1100 Diseases of the digestive system 520-579;Men;17.489 PA═S VASCO;Group 1100 Diseases of the digestive system 520-579;Women;12.948 PA═S VASCO;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;425 PA═S VASCO;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;230 PA═S VASCO;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;194 PA═S VASCO;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;421 PA═S VASCO;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;241 PA═S VASCO;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;179 PA═S VASCO;Group 1103 Diseases of the esophagus 530;Both sexes;615 PA═S VASCO;Group 1103 Diseases of the esophagus 530;Men;399 PA═S VASCO;Group 1103 Diseases of the esophagus 530;Women;216 PA═S VASCO;Group 1104 Peptic ulcer 531-534;Both sexes;623 PA═S VASCO;Group 1104 Peptic ulcer 531-534;Men;445 PA═S VASCO;Group 1104 Peptic ulcer 531-534;Women;177 PA═S VASCO;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;594 PA═S VASCO;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;302 PA═S VASCO;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;293 PA═S VASCO;Group 1106 Appendicitis 540-543;Both sexes;2.534 PA═S VASCO;Group 1106 Appendicitis 540-543;Men;1.395 PA═S VASCO;Group 1106 Appendicitis 540-543;Women;1.139 PA═S VASCO;Group 1107 Inguinal hernia 550;Both sexes;3.794 PA═S VASCO;Group 1107 Inguinal hernia 550;Men;3.377 PA═S VASCO;Group 1107 Inguinal hernia 550;Women;417 PA═S VASCO;Group 1108 Other abdominal hernia 551-553;Both sexes;2.652 PA═S VASCO;Group 1108 Other abdominal hernia 551-553;Men;1.332 PA═S VASCO;Group 1108 Other abdominal hernia 551-553;Women;1.320 PA═S VASCO;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;607 PA═S VASCO;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;323 PA═S VASCO;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;285 PA═S VASCO;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.301 PA═S VASCO;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;616 PA═S VASCO;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;685 PA═S VASCO;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1.724 PA═S VASCO;Group 1111 Intestinal obstruction without hernia 560;Men;906 PA═S VASCO;Group 1111 Intestinal obstruction without hernia 560;Women;818 PA═S VASCO;Group 1112 Intestinal diverticulosis 562;Both sexes;1.439 PA═S VASCO;Group 1112 Intestinal diverticulosis 562;Men;661 PA═S VASCO;Group 1112 Intestinal diverticulosis 562;Women;778 PA═S VASCO;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;2.065 PA═S VASCO;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;1.341 PA═S VASCO;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;724 PA═S VASCO;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;1.114 PA═S VASCO;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;482 PA═S VASCO;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;632 PA═S VASCO;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;547 PA═S VASCO;Group 1115 Alcoholic hepatitis 5710-5713;Men;440 PA═S VASCO;Group 1115 Alcoholic hepatitis 5710-5713;Women;107 PA═S VASCO;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;1.055 PA═S VASCO;Group 1116 Other diseases of the liver 570,5714-573;Men;652 PA═S VASCO;Group 1116 Other diseases of the liver 570,5714-573;Women;403 PA═S VASCO;Group 1117 Cholelithiasis 574;Both sexes;5.019 PA═S VASCO;Group 1117 Cholelithiasis 574;Men;2.136 PA═S VASCO;Group 1117 Cholelithiasis 574;Women;2.883 PA═S VASCO;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1.320 PA═S VASCO;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;739 PA═S VASCO;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;581 PA═S VASCO;Group 1119 Pancreatic diseases 577;Both sexes;1.255 PA═S VASCO;Group 1119 Pancreatic diseases 577;Men;727 PA═S VASCO;Group 1119 Pancreatic diseases 577;Women;528 PA═S VASCO;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1.332 PA═S VASCO;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;744 PA═S VASCO;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;587 PA═S VASCO;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;2.700 PA═S VASCO;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1.481 PA═S VASCO;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1.219 PA═S VASCO;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.889 PA═S VASCO;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;1.102 PA═S VASCO;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;786 PA═S VASCO;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;111 PA═S VASCO;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;59 PA═S VASCO;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;52 PA═S VASCO;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;700 PA═S VASCO;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;320 PA═S VASCO;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;381 PA═S VASCO;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;20.220 PA═S VASCO;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;10.128 PA═S VASCO;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;10.092 PA═S VASCO;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. PA═S VASCO;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. PA═S VASCO;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. PA═S VASCO;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. PA═S VASCO;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. PA═S VASCO;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. PA═S VASCO;Group 1303 Internal derangement of knee 717;Both sexes;3.158 PA═S VASCO;Group 1303 Internal derangement of knee 717;Men;2.161 PA═S VASCO;Group 1303 Internal derangement of knee 717;Women;997 PA═S VASCO;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;7.718 PA═S VASCO;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;3.600 PA═S VASCO;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;4.118 PA═S VASCO;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;278 PA═S VASCO;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;107 PA═S VASCO;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;170 PA═S VASCO;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;1.100 PA═S VASCO;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;538 PA═S VASCO;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;562 PA═S VASCO;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.452 PA═S VASCO;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;773 PA═S VASCO;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;678 PA═S VASCO;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;603 PA═S VASCO;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;269 PA═S VASCO;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;333 PA═S VASCO;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;2.957 PA═S VASCO;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1.655 PA═S VASCO;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;1.302 PA═S VASCO;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;2.955 PA═S VASCO;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;1.024 PA═S VASCO;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.931 PA═S VASCO;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;16.110 PA═S VASCO;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;7.849 PA═S VASCO;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;8.261 PA═S VASCO;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.484 PA═S VASCO;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;540 PA═S VASCO;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;944 PA═S VASCO;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1.292 PA═S VASCO;Group 1402 Renal failure 5836-5837, 584-586;Men;791 PA═S VASCO;Group 1402 Renal failure 5836-5837, 584-586;Women;501 PA═S VASCO;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;2.286 PA═S VASCO;Group 1403 Urolithiasis 592, 594, 7880;Men;1.384 PA═S VASCO;Group 1403 Urolithiasis 592, 594, 7880;Women;902 PA═S VASCO;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;4.620 PA═S VASCO;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;2.387 PA═S VASCO;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;2.233 PA═S VASCO;Group 1405 Prostatic hyperplasia 600;Both sexes;1.585 PA═S VASCO;Group 1405 Prostatic hyperplasia 600;Men;1.585 PA═S VASCO;Group 1405 Prostatic hyperplasia 600;Women;.. PA═S VASCO;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;991 PA═S VASCO;Group 1406 Other diseases of the male genital organs 601-608;Men;991 PA═S VASCO;Group 1406 Other diseases of the male genital organs 601-608;Women;.. PA═S VASCO;Group 1407 Disorders of breast 610-612;Both sexes;1.220 PA═S VASCO;Group 1407 Disorders of breast 610-612;Men;89 PA═S VASCO;Group 1407 Disorders of breast 610-612;Women;1.131 PA═S VASCO;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;391 PA═S VASCO;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. PA═S VASCO;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;391 PA═S VASCO;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;100 PA═S VASCO;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. PA═S VASCO;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;100 PA═S VASCO;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;2.140 PA═S VASCO;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;81 PA═S VASCO;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;2.059 PA═S VASCO;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;21.145 PA═S VASCO;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. PA═S VASCO;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;21.145 PA═S VASCO;Group 1501 Legally induced abortion 635;Both sexes;184 PA═S VASCO;Group 1501 Legally induced abortion 635;Men;.. PA═S VASCO;Group 1501 Legally induced abortion 635;Women;184 PA═S VASCO;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;538 PA═S VASCO;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. PA═S VASCO;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;538 PA═S VASCO;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;12.993 PA═S VASCO;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. PA═S VASCO;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;12.993 PA═S VASCO;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3.581 PA═S VASCO;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. PA═S VASCO;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3.581 PA═S VASCO;Group 1505 Single spontaneous delivery 650;Both sexes;1.866 PA═S VASCO;Group 1505 Single spontaneous delivery 650;Men;.. PA═S VASCO;Group 1505 Single spontaneous delivery 650;Women;1.866 PA═S VASCO;Group 1506 Other deliveries 6695-6697;Both sexes;394 PA═S VASCO;Group 1506 Other deliveries 6695-6697;Men;.. PA═S VASCO;Group 1506 Other deliveries 6695-6697;Women;394 PA═S VASCO;Group 1507 Complications related to the puerperium 670-676;Both sexes;160 PA═S VASCO;Group 1507 Complications related to the puerperium 670-676;Men;.. PA═S VASCO;Group 1507 Complications related to the puerperium 670-676;Women;160 PA═S VASCO;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.430 PA═S VASCO;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. PA═S VASCO;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.430 PA═S VASCO;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.381 PA═S VASCO;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.298 PA═S VASCO;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1.083 PA═S VASCO;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;659 PA═S VASCO;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;333 PA═S VASCO;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;326 PA═S VASCO;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.722 PA═S VASCO;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;965 PA═S VASCO;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;758 PA═S VASCO;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.354 PA═S VASCO;Grupo 1700 Congenital abnormalities 740-759;Men;752 PA═S VASCO;Grupo 1700 Congenital abnormalities 740-759;Women;602 PA═S VASCO;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;13.691 PA═S VASCO;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;7.660 PA═S VASCO;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;6.031 PA═S VASCO;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;2.632 PA═S VASCO;Group 1801 Pain in throat and chest 7841, 7865;Men;1.539 PA═S VASCO;Group 1801 Pain in throat and chest 7841, 7865;Women;1.094 PA═S VASCO;Group 1802 Abdominal pain 7890;Both sexes;1.489 PA═S VASCO;Group 1802 Abdominal pain 7890;Men;656 PA═S VASCO;Group 1802 Abdominal pain 7890;Women;833 PA═S VASCO;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;440 PA═S VASCO;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;230 PA═S VASCO;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;210 PA═S VASCO;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;9.130 PA═S VASCO;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;5.235 PA═S VASCO;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3.895 PA═S VASCO;Group 1900 Injuries and poisoning 800-999;Both sexes;20.949 PA═S VASCO;Group 1900 Injuries and poisoning 800-999;Men;11.059 PA═S VASCO;Group 1900 Injuries and poisoning 800-999;Women;9.890 PA═S VASCO;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1.182 PA═S VASCO;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;679 PA═S VASCO;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;503 PA═S VASCO;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;511 PA═S VASCO;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;352 PA═S VASCO;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;159 PA═S VASCO;Group 1903 Radius and ulna fracture 813;Both sexes;1.413 PA═S VASCO;Group 1903 Radius and ulna fracture 813;Men;587 PA═S VASCO;Group 1903 Radius and ulna fracture 813;Women;826 PA═S VASCO;Group 1904 Femur fracture 820-821;Both sexes;2.946 PA═S VASCO;Group 1904 Femur fracture 820-821;Men;782 PA═S VASCO;Group 1904 Femur fracture 820-821;Women;2.164 PA═S VASCO;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.433 PA═S VASCO;Group 1905 Leg fracture, including the ankle 823-824;Men;723 PA═S VASCO;Group 1905 Leg fracture, including the ankle 823-824;Women;710 PA═S VASCO;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;6.269 PA═S VASCO;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;3.936 PA═S VASCO;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2.333 PA═S VASCO;Group 1907 Burns 940-949;Both sexes;132 PA═S VASCO;Group 1907 Burns 940-949;Men;93 PA═S VASCO;Group 1907 Burns 940-949;Women;39 PA═S VASCO;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;510 PA═S VASCO;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;218 PA═S VASCO;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;291 PA═S VASCO;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;5.728 PA═S VASCO;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;3.267 PA═S VASCO;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;2.461 PA═S VASCO;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;86 PA═S VASCO;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;52 PA═S VASCO;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;34 PA═S VASCO;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;738 PA═S VASCO;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;369 PA═S VASCO;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;370 PA═S VASCO;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;6.087 PA═S VASCO;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;3.139 PA═S VASCO;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2.948 PA═S VASCO;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;254 PA═S VASCO;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;147 PA═S VASCO;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;106 PA═S VASCO;Group 2102 Contraceptive management V25;Both sexes;82 PA═S VASCO;Group 2102 Contraceptive management V25;Men;1 PA═S VASCO;Group 2102 Contraceptive management V25;Women;81 PA═S VASCO;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. PA═S VASCO;Group 2103 Living newborns by type of delivery V30-V39;Men;.. PA═S VASCO;Group 2103 Living newborns by type of delivery V30-V39;Women;.. PA═S VASCO;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1.772 PA═S VASCO;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;1.142 PA═S VASCO;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;629 PA═S VASCO;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;3.979 PA═S VASCO;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1.848 PA═S VASCO;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;2.131 Araba/┴lava;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;36.481 Araba/┴lava;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;18.514 Araba/┴lava;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;17.967 Araba/┴lava;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;568 Araba/┴lava;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;331 Araba/┴lava;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;237 Araba/┴lava;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;77 Araba/┴lava;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;39 Araba/┴lava;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;38 Araba/┴lava;Group 0102 Imprecise intestinal infections 009;Both sexes;21 Araba/┴lava;Group 0102 Imprecise intestinal infections 009;Men;14 Araba/┴lava;Group 0102 Imprecise intestinal infections 009;Women;7 Araba/┴lava;Group 0103 Tuberculosis 010-018, 137;Both sexes;25 Araba/┴lava;Group 0103 Tuberculosis 010-018, 137;Men;10 Araba/┴lava;Group 0103 Tuberculosis 010-018, 137;Women;15 Araba/┴lava;Group 0104 Septicaemia 038;Both sexes;234 Araba/┴lava;Group 0104 Septicaemia 038;Men;143 Araba/┴lava;Group 0104 Septicaemia 038;Women;91 Araba/┴lava;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;18 Araba/┴lava;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;11 Araba/┴lava;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;7 Araba/┴lava;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;193 Araba/┴lava;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;114 Araba/┴lava;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;79 Araba/┴lava;Group 0200 Neoplasms 140-239;Both sexes;3.123 Araba/┴lava;Group 0200 Neoplasms 140-239;Men;1.782 Araba/┴lava;Group 0200 Neoplasms 140-239;Women;1.341 Araba/┴lava;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;313 Araba/┴lava;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;192 Araba/┴lava;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;121 Araba/┴lava;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;155 Araba/┴lava;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;136 Araba/┴lava;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;19 Araba/┴lava;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;26 Araba/┴lava;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;8 Araba/┴lava;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;18 Araba/┴lava;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;219 Araba/┴lava;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Araba/┴lava;Group 0204 Malignant neoplasm of breast 174-175;Women;219 Araba/┴lava;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;36 Araba/┴lava;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Araba/┴lava;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;36 Araba/┴lava;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;31 Araba/┴lava;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Araba/┴lava;Group 0206 Malignant neoplasm of ovary 1830;Women;31 Araba/┴lava;Group 0207 Malignant neoplasm of prostate 185;Both sexes;233 Araba/┴lava;Group 0207 Malignant neoplasm of prostate 185;Men;233 Araba/┴lava;Group 0207 Malignant neoplasm of prostate 185;Women;.. Araba/┴lava;Group 0208 Malignant neoplasm of bladder 188;Both sexes;362 Araba/┴lava;Group 0208 Malignant neoplasm of bladder 188;Men;307 Araba/┴lava;Group 0208 Malignant neoplasm of bladder 188;Women;55 Araba/┴lava;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.106 Araba/┴lava;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;631 Araba/┴lava;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;475 Araba/┴lava;Group 0210 Carcinoma in situ 230-234;Both sexes;35 Araba/┴lava;Group 0210 Carcinoma in situ 230-234;Men;18 Araba/┴lava;Group 0210 Carcinoma in situ 230-234;Women;17 Araba/┴lava;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;88 Araba/┴lava;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;58 Araba/┴lava;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;30 Araba/┴lava;Grupo 0212 Leiomyoma of uterus 218;Both sexes;92 Araba/┴lava;Grupo 0212 Leiomyoma of uterus 218;Men;.. Araba/┴lava;Grupo 0212 Leiomyoma of uterus 218;Women;92 Araba/┴lava;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;427 Araba/┴lava;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;199 Araba/┴lava;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;228 Araba/┴lava;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;496 Araba/┴lava;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;237 Araba/┴lava;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;259 Araba/┴lava;Group 0301 Anaemias 280-285;Both sexes;275 Araba/┴lava;Group 0301 Anaemias 280-285;Men;141 Araba/┴lava;Group 0301 Anaemias 280-285;Women;134 Araba/┴lava;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;221 Araba/┴lava;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;96 Araba/┴lava;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;125 Araba/┴lava;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;727 Araba/┴lava;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;283 Araba/┴lava;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;444 Araba/┴lava;Group 0401 Diabetes mellitus 249-250;Both sexes;237 Araba/┴lava;Group 0401 Diabetes mellitus 249-250;Men;142 Araba/┴lava;Group 0401 Diabetes mellitus 249-250;Women;95 Araba/┴lava;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;490 Araba/┴lava;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;141 Araba/┴lava;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;349 Araba/┴lava;Group 0500 Mental disorders 290-319;Both sexes;935 Araba/┴lava;Group 0500 Mental disorders 290-319;Men;520 Araba/┴lava;Group 0500 Mental disorders 290-319;Women;415 Araba/┴lava;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;17 Araba/┴lava;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;9 Araba/┴lava;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;8 Araba/┴lava;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;76 Araba/┴lava;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;57 Araba/┴lava;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;19 Araba/┴lava;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;42 Araba/┴lava;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;28 Araba/┴lava;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;14 Araba/┴lava;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;312 Araba/┴lava;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;220 Araba/┴lava;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;92 Araba/┴lava;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;205 Araba/┴lava;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;88 Araba/┴lava;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;117 Araba/┴lava;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;283 Araba/┴lava;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;118 Araba/┴lava;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;165 Araba/┴lava;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;941 Araba/┴lava;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;492 Araba/┴lava;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;449 Araba/┴lava;Group 0601 Alzheimer's disease 3310;Both sexes;27 Araba/┴lava;Group 0601 Alzheimer's disease 3310;Men;11 Araba/┴lava;Group 0601 Alzheimer's disease 3310;Women;16 Araba/┴lava;Group 0602 Multiple sclerosis 340;Both sexes;15 Araba/┴lava;Group 0602 Multiple sclerosis 340;Men;4 Araba/┴lava;Group 0602 Multiple sclerosis 340;Women;11 Araba/┴lava;Group 0603 Epilepsy 345;Both sexes;214 Araba/┴lava;Group 0603 Epilepsy 345;Men;117 Araba/┴lava;Group 0603 Epilepsy 345;Women;97 Araba/┴lava;Group 0604 Transient cerebral ischemia 435;Both sexes;136 Araba/┴lava;Group 0604 Transient cerebral ischemia 435;Men;72 Araba/┴lava;Group 0604 Transient cerebral ischemia 435;Women;64 Araba/┴lava;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;549 Araba/┴lava;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;288 Araba/┴lava;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;261 Araba/┴lava;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;101 Araba/┴lava;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;56 Araba/┴lava;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;45 Araba/┴lava;Grupo 0701 Cataract 366;Both sexes;8 Araba/┴lava;Grupo 0701 Cataract 366;Men;4 Araba/┴lava;Grupo 0701 Cataract 366;Women;4 Araba/┴lava;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;93 Araba/┴lava;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;52 Araba/┴lava;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;41 Araba/┴lava;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;174 Araba/┴lava;Group 0800 Diseases of the ear and the mastoid 380-389;Men;81 Araba/┴lava;Group 0800 Diseases of the ear and the mastoid 380-389;Women;93 Araba/┴lava;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4.542 Araba/┴lava;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.615 Araba/┴lava;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1.927 Araba/┴lava;Group 0901 Hypertensive disease 401-405;Both sexes;290 Araba/┴lava;Group 0901 Hypertensive disease 401-405;Men;133 Araba/┴lava;Group 0901 Hypertensive disease 401-405;Women;157 Araba/┴lava;Group 0902 Angina pectoris 4111, 413;Both sexes;120 Araba/┴lava;Group 0902 Angina pectoris 4111, 413;Men;83 Araba/┴lava;Group 0902 Angina pectoris 4111, 413;Women;37 Araba/┴lava;Group 0903 Acute myocardial infarction 410;Both sexes;374 Araba/┴lava;Group 0903 Acute myocardial infarction 410;Men;262 Araba/┴lava;Group 0903 Acute myocardial infarction 410;Women;112 Araba/┴lava;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;199 Araba/┴lava;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;155 Araba/┴lava;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;44 Araba/┴lava;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;179 Araba/┴lava;Group 0905 Diseases of the lungs circulation 415-417;Men;79 Araba/┴lava;Group 0905 Diseases of the lungs circulation 415-417;Women;100 Araba/┴lava;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;663 Araba/┴lava;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;378 Araba/┴lava;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;285 Araba/┴lava;Grupo 0907 Heart failure 428;Both sexes;793 Araba/┴lava;Grupo 0907 Heart failure 428;Men;425 Araba/┴lava;Grupo 0907 Heart failure 428;Women;368 Araba/┴lava;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;702 Araba/┴lava;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;411 Araba/┴lava;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;291 Araba/┴lava;Grupo 0909 Atherosclerosis 440;Both sexes;242 Araba/┴lava;Grupo 0909 Atherosclerosis 440;Men;193 Araba/┴lava;Grupo 0909 Atherosclerosis 440;Women;49 Araba/┴lava;Group 0910 Varicose veins of lower extremities 454;Both sexes;252 Araba/┴lava;Group 0910 Varicose veins of lower extremities 454;Men;84 Araba/┴lava;Group 0910 Varicose veins of lower extremities 454;Women;168 Araba/┴lava;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;728 Araba/┴lava;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;412 Araba/┴lava;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;316 Araba/┴lava;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;3.968 Araba/┴lava;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2.354 Araba/┴lava;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.614 Araba/┴lava;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;163 Araba/┴lava;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;71 Araba/┴lava;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;92 Araba/┴lava;Group 1002 Pneumonia 480-486;Both sexes;886 Araba/┴lava;Group 1002 Pneumonia 480-486;Men;561 Araba/┴lava;Group 1002 Pneumonia 480-486;Women;325 Araba/┴lava;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;539 Araba/┴lava;Group 1003 Acute bronchitis and bronchiolitis 466;Men;272 Araba/┴lava;Group 1003 Acute bronchitis and bronchiolitis 466;Women;267 Araba/┴lava;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;155 Araba/┴lava;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;87 Araba/┴lava;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;68 Araba/┴lava;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;291 Araba/┴lava;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;193 Araba/┴lava;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;98 Araba/┴lava;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;744 Araba/┴lava;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;566 Araba/┴lava;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;178 Araba/┴lava;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;257 Araba/┴lava;Group 1007 Asthma 4930-4931,4938-4939;Men;78 Araba/┴lava;Group 1007 Asthma 4930-4931,4938-4939;Women;179 Araba/┴lava;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;933 Araba/┴lava;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;526 Araba/┴lava;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;407 Araba/┴lava;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.490 Araba/┴lava;Group 1100 Diseases of the digestive system 520-579;Men;2.612 Araba/┴lava;Group 1100 Diseases of the digestive system 520-579;Women;1.878 Araba/┴lava;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;76 Araba/┴lava;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;47 Araba/┴lava;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;29 Araba/┴lava;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;54 Araba/┴lava;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;29 Araba/┴lava;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;25 Araba/┴lava;Group 1103 Diseases of the esophagus 530;Both sexes;138 Araba/┴lava;Group 1103 Diseases of the esophagus 530;Men;94 Araba/┴lava;Group 1103 Diseases of the esophagus 530;Women;44 Araba/┴lava;Group 1104 Peptic ulcer 531-534;Both sexes;88 Araba/┴lava;Group 1104 Peptic ulcer 531-534;Men;59 Araba/┴lava;Group 1104 Peptic ulcer 531-534;Women;29 Araba/┴lava;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;115 Araba/┴lava;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;55 Araba/┴lava;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;60 Araba/┴lava;Group 1106 Appendicitis 540-543;Both sexes;287 Araba/┴lava;Group 1106 Appendicitis 540-543;Men;158 Araba/┴lava;Group 1106 Appendicitis 540-543;Women;129 Araba/┴lava;Group 1107 Inguinal hernia 550;Both sexes;551 Araba/┴lava;Group 1107 Inguinal hernia 550;Men;489 Araba/┴lava;Group 1107 Inguinal hernia 550;Women;62 Araba/┴lava;Group 1108 Other abdominal hernia 551-553;Both sexes;409 Araba/┴lava;Group 1108 Other abdominal hernia 551-553;Men;218 Araba/┴lava;Group 1108 Other abdominal hernia 551-553;Women;191 Araba/┴lava;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;94 Araba/┴lava;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;56 Araba/┴lava;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;38 Araba/┴lava;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;257 Araba/┴lava;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;126 Araba/┴lava;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;131 Araba/┴lava;Group 1111 Intestinal obstruction without hernia 560;Both sexes;292 Araba/┴lava;Group 1111 Intestinal obstruction without hernia 560;Men;156 Araba/┴lava;Group 1111 Intestinal obstruction without hernia 560;Women;136 Araba/┴lava;Group 1112 Intestinal diverticulosis 562;Both sexes;173 Araba/┴lava;Group 1112 Intestinal diverticulosis 562;Men;78 Araba/┴lava;Group 1112 Intestinal diverticulosis 562;Women;95 Araba/┴lava;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;269 Araba/┴lava;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;179 Araba/┴lava;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;90 Araba/┴lava;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;143 Araba/┴lava;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;56 Araba/┴lava;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;87 Araba/┴lava;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;70 Araba/┴lava;Group 1115 Alcoholic hepatitis 5710-5713;Men;55 Araba/┴lava;Group 1115 Alcoholic hepatitis 5710-5713;Women;15 Araba/┴lava;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;153 Araba/┴lava;Group 1116 Other diseases of the liver 570,5714-573;Men;90 Araba/┴lava;Group 1116 Other diseases of the liver 570,5714-573;Women;63 Araba/┴lava;Group 1117 Cholelithiasis 574;Both sexes;686 Araba/┴lava;Group 1117 Cholelithiasis 574;Men;309 Araba/┴lava;Group 1117 Cholelithiasis 574;Women;377 Araba/┴lava;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;206 Araba/┴lava;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;114 Araba/┴lava;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;92 Araba/┴lava;Group 1119 Pancreatic diseases 577;Both sexes;156 Araba/┴lava;Group 1119 Pancreatic diseases 577;Men;96 Araba/┴lava;Group 1119 Pancreatic diseases 577;Women;60 Araba/┴lava;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;273 Araba/┴lava;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;148 Araba/┴lava;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;125 Araba/┴lava;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;378 Araba/┴lava;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;206 Araba/┴lava;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;172 Araba/┴lava;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;291 Araba/┴lava;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;162 Araba/┴lava;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;129 Araba/┴lava;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;19 Araba/┴lava;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;9 Araba/┴lava;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;10 Araba/┴lava;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;68 Araba/┴lava;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;35 Araba/┴lava;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;33 Araba/┴lava;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;3.698 Araba/┴lava;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.956 Araba/┴lava;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.742 Araba/┴lava;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Araba/┴lava;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Araba/┴lava;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Araba/┴lava;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Araba/┴lava;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Araba/┴lava;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Araba/┴lava;Group 1303 Internal derangement of knee 717;Both sexes;639 Araba/┴lava;Group 1303 Internal derangement of knee 717;Men;466 Araba/┴lava;Group 1303 Internal derangement of knee 717;Women;173 Araba/┴lava;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.316 Araba/┴lava;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;691 Araba/┴lava;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;625 Araba/┴lava;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;27 Araba/┴lava;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;9 Araba/┴lava;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;18 Araba/┴lava;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;188 Araba/┴lava;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;87 Araba/┴lava;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;101 Araba/┴lava;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;233 Araba/┴lava;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;123 Araba/┴lava;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;110 Araba/┴lava;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;137 Araba/┴lava;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;52 Araba/┴lava;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;85 Araba/┴lava;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;568 Araba/┴lava;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;329 Araba/┴lava;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;239 Araba/┴lava;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;590 Araba/┴lava;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;199 Araba/┴lava;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;391 Araba/┴lava;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.576 Araba/┴lava;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.393 Araba/┴lava;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.183 Araba/┴lava;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;217 Araba/┴lava;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;75 Araba/┴lava;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;142 Araba/┴lava;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;194 Araba/┴lava;Group 1402 Renal failure 5836-5837, 584-586;Men;117 Araba/┴lava;Group 1402 Renal failure 5836-5837, 584-586;Women;77 Araba/┴lava;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;445 Araba/┴lava;Group 1403 Urolithiasis 592, 594, 7880;Men;287 Araba/┴lava;Group 1403 Urolithiasis 592, 594, 7880;Women;158 Araba/┴lava;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;815 Araba/┴lava;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;427 Araba/┴lava;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;388 Araba/┴lava;Group 1405 Prostatic hyperplasia 600;Both sexes;302 Araba/┴lava;Group 1405 Prostatic hyperplasia 600;Men;302 Araba/┴lava;Group 1405 Prostatic hyperplasia 600;Women;.. Araba/┴lava;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;171 Araba/┴lava;Group 1406 Other diseases of the male genital organs 601-608;Men;171 Araba/┴lava;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Araba/┴lava;Group 1407 Disorders of breast 610-612;Both sexes;111 Araba/┴lava;Group 1407 Disorders of breast 610-612;Men;11 Araba/┴lava;Group 1407 Disorders of breast 610-612;Women;100 Araba/┴lava;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;39 Araba/┴lava;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Araba/┴lava;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;39 Araba/┴lava;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;16 Araba/┴lava;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Araba/┴lava;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;16 Araba/┴lava;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;266 Araba/┴lava;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;3 Araba/┴lava;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;263 Araba/┴lava;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3.100 Araba/┴lava;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Araba/┴lava;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3.100 Araba/┴lava;Group 1501 Legally induced abortion 635;Both sexes;25 Araba/┴lava;Group 1501 Legally induced abortion 635;Men;.. Araba/┴lava;Group 1501 Legally induced abortion 635;Women;25 Araba/┴lava;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;50 Araba/┴lava;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Araba/┴lava;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;50 Araba/┴lava;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;2.102 Araba/┴lava;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Araba/┴lava;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;2.102 Araba/┴lava;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;592 Araba/┴lava;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Araba/┴lava;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;592 Araba/┴lava;Group 1505 Single spontaneous delivery 650;Both sexes;114 Araba/┴lava;Group 1505 Single spontaneous delivery 650;Men;.. Araba/┴lava;Group 1505 Single spontaneous delivery 650;Women;114 Araba/┴lava;Group 1506 Other deliveries 6695-6697;Both sexes;7 Araba/┴lava;Group 1506 Other deliveries 6695-6697;Men;.. Araba/┴lava;Group 1506 Other deliveries 6695-6697;Women;7 Araba/┴lava;Group 1507 Complications related to the puerperium 670-676;Both sexes;1 Araba/┴lava;Group 1507 Complications related to the puerperium 670-676;Men;.. Araba/┴lava;Group 1507 Complications related to the puerperium 670-676;Women;1 Araba/┴lava;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;209 Araba/┴lava;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Araba/┴lava;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;209 Araba/┴lava;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;377 Araba/┴lava;Group 1600 Some disorders originating in the perinatal period 760-779;Men;220 Araba/┴lava;Group 1600 Some disorders originating in the perinatal period 760-779;Women;157 Araba/┴lava;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;91 Araba/┴lava;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;48 Araba/┴lava;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;43 Araba/┴lava;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;286 Araba/┴lava;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;172 Araba/┴lava;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;114 Araba/┴lava;Grupo 1700 Congenital abnormalities 740-759;Both sexes;145 Araba/┴lava;Grupo 1700 Congenital abnormalities 740-759;Men;86 Araba/┴lava;Grupo 1700 Congenital abnormalities 740-759;Women;59 Araba/┴lava;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.361 Araba/┴lava;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.361 Araba/┴lava;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.000 Araba/┴lava;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;294 Araba/┴lava;Group 1801 Pain in throat and chest 7841, 7865;Men;177 Araba/┴lava;Group 1801 Pain in throat and chest 7841, 7865;Women;117 Araba/┴lava;Group 1802 Abdominal pain 7890;Both sexes;272 Araba/┴lava;Group 1802 Abdominal pain 7890;Men;109 Araba/┴lava;Group 1802 Abdominal pain 7890;Women;163 Araba/┴lava;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;4 Araba/┴lava;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;4 Araba/┴lava;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;.. Araba/┴lava;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.791 Araba/┴lava;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.071 Araba/┴lava;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;720 Araba/┴lava;Group 1900 Injuries and poisoning 800-999;Both sexes;3.080 Araba/┴lava;Group 1900 Injuries and poisoning 800-999;Men;1.531 Araba/┴lava;Group 1900 Injuries and poisoning 800-999;Women;1.549 Araba/┴lava;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;400 Araba/┴lava;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;222 Araba/┴lava;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;178 Araba/┴lava;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;80 Araba/┴lava;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;50 Araba/┴lava;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;30 Araba/┴lava;Group 1903 Radius and ulna fracture 813;Both sexes;179 Araba/┴lava;Group 1903 Radius and ulna fracture 813;Men;67 Araba/┴lava;Group 1903 Radius and ulna fracture 813;Women;112 Araba/┴lava;Group 1904 Femur fracture 820-821;Both sexes;362 Araba/┴lava;Group 1904 Femur fracture 820-821;Men;89 Araba/┴lava;Group 1904 Femur fracture 820-821;Women;273 Araba/┴lava;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;189 Araba/┴lava;Group 1905 Leg fracture, including the ankle 823-824;Men;94 Araba/┴lava;Group 1905 Leg fracture, including the ankle 823-824;Women;95 Araba/┴lava;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;738 Araba/┴lava;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;423 Araba/┴lava;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;315 Araba/┴lava;Group 1907 Burns 940-949;Both sexes;4 Araba/┴lava;Group 1907 Burns 940-949;Men;2 Araba/┴lava;Group 1907 Burns 940-949;Women;2 Araba/┴lava;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;161 Araba/┴lava;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;59 Araba/┴lava;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;102 Araba/┴lava;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;864 Araba/┴lava;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;472 Araba/┴lava;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;392 Araba/┴lava;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;9 Araba/┴lava;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;3 Araba/┴lava;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;6 Araba/┴lava;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;94 Araba/┴lava;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;50 Araba/┴lava;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;44 Araba/┴lava;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;701 Araba/┴lava;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;398 Araba/┴lava;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;303 Araba/┴lava;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;12 Araba/┴lava;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;7 Araba/┴lava;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;5 Araba/┴lava;Group 2102 Contraceptive management V25;Both sexes;10 Araba/┴lava;Group 2102 Contraceptive management V25;Men;.. Araba/┴lava;Group 2102 Contraceptive management V25;Women;10 Araba/┴lava;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Araba/┴lava;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Araba/┴lava;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Araba/┴lava;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;194 Araba/┴lava;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;116 Araba/┴lava;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;78 Araba/┴lava;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;485 Araba/┴lava;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;275 Araba/┴lava;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;210 Bizkaia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;126.997 Bizkaia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;62.825 Bizkaia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;64.171 Bizkaia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2.275 Bizkaia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.323 Bizkaia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;952 Bizkaia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;218 Bizkaia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;107 Bizkaia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;111 Bizkaia;Group 0102 Imprecise intestinal infections 009;Both sexes;170 Bizkaia;Group 0102 Imprecise intestinal infections 009;Men;90 Bizkaia;Group 0102 Imprecise intestinal infections 009;Women;79 Bizkaia;Group 0103 Tuberculosis 010-018, 137;Both sexes;100 Bizkaia;Group 0103 Tuberculosis 010-018, 137;Men;66 Bizkaia;Group 0103 Tuberculosis 010-018, 137;Women;34 Bizkaia;Group 0104 Septicaemia 038;Both sexes;910 Bizkaia;Group 0104 Septicaemia 038;Men;532 Bizkaia;Group 0104 Septicaemia 038;Women;378 Bizkaia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;159 Bizkaia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;106 Bizkaia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;52 Bizkaia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;718 Bizkaia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;420 Bizkaia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;298 Bizkaia;Group 0200 Neoplasms 140-239;Both sexes;13.417 Bizkaia;Group 0200 Neoplasms 140-239;Men;7.205 Bizkaia;Group 0200 Neoplasms 140-239;Women;6.212 Bizkaia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.573 Bizkaia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;963 Bizkaia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;610 Bizkaia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;981 Bizkaia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;766 Bizkaia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;215 Bizkaia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;236 Bizkaia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;128 Bizkaia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;108 Bizkaia;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;900 Bizkaia;Group 0204 Malignant neoplasm of breast 174-175;Men;10 Bizkaia;Group 0204 Malignant neoplasm of breast 174-175;Women;890 Bizkaia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;226 Bizkaia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Bizkaia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;226 Bizkaia;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;126 Bizkaia;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Bizkaia;Group 0206 Malignant neoplasm of ovary 1830;Women;126 Bizkaia;Group 0207 Malignant neoplasm of prostate 185;Both sexes;595 Bizkaia;Group 0207 Malignant neoplasm of prostate 185;Men;595 Bizkaia;Group 0207 Malignant neoplasm of prostate 185;Women;.. Bizkaia;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.161 Bizkaia;Group 0208 Malignant neoplasm of bladder 188;Men;939 Bizkaia;Group 0208 Malignant neoplasm of bladder 188;Women;222 Bizkaia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5.105 Bizkaia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3.031 Bizkaia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2.074 Bizkaia;Group 0210 Carcinoma in situ 230-234;Both sexes;180 Bizkaia;Group 0210 Carcinoma in situ 230-234;Men;40 Bizkaia;Group 0210 Carcinoma in situ 230-234;Women;140 Bizkaia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;154 Bizkaia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;94 Bizkaia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;59 Bizkaia;Grupo 0212 Leiomyoma of uterus 218;Both sexes;583 Bizkaia;Grupo 0212 Leiomyoma of uterus 218;Men;.. Bizkaia;Grupo 0212 Leiomyoma of uterus 218;Women;583 Bizkaia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.598 Bizkaia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;639 Bizkaia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;959 Bizkaia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.376 Bizkaia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;726 Bizkaia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;650 Bizkaia;Group 0301 Anaemias 280-285;Both sexes;901 Bizkaia;Group 0301 Anaemias 280-285;Men;463 Bizkaia;Group 0301 Anaemias 280-285;Women;438 Bizkaia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;475 Bizkaia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;263 Bizkaia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;212 Bizkaia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2.158 Bizkaia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;864 Bizkaia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.294 Bizkaia;Group 0401 Diabetes mellitus 249-250;Both sexes;638 Bizkaia;Group 0401 Diabetes mellitus 249-250;Men;365 Bizkaia;Group 0401 Diabetes mellitus 249-250;Women;273 Bizkaia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.520 Bizkaia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;499 Bizkaia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.021 Bizkaia;Group 0500 Mental disorders 290-319;Both sexes;4.547 Bizkaia;Group 0500 Mental disorders 290-319;Men;2.411 Bizkaia;Group 0500 Mental disorders 290-319;Women;2.136 Bizkaia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;49 Bizkaia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;22 Bizkaia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;27 Bizkaia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;358 Bizkaia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;277 Bizkaia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;81 Bizkaia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;346 Bizkaia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;244 Bizkaia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;102 Bizkaia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.530 Bizkaia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;936 Bizkaia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;594 Bizkaia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1.229 Bizkaia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;497 Bizkaia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;732 Bizkaia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.034 Bizkaia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;434 Bizkaia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;600 Bizkaia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.922 Bizkaia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.578 Bizkaia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.344 Bizkaia;Group 0601 Alzheimer's disease 3310;Both sexes;39 Bizkaia;Group 0601 Alzheimer's disease 3310;Men;20 Bizkaia;Group 0601 Alzheimer's disease 3310;Women;19 Bizkaia;Group 0602 Multiple sclerosis 340;Both sexes;22 Bizkaia;Group 0602 Multiple sclerosis 340;Men;14 Bizkaia;Group 0602 Multiple sclerosis 340;Women;8 Bizkaia;Group 0603 Epilepsy 345;Both sexes;397 Bizkaia;Group 0603 Epilepsy 345;Men;200 Bizkaia;Group 0603 Epilepsy 345;Women;197 Bizkaia;Group 0604 Transient cerebral ischemia 435;Both sexes;372 Bizkaia;Group 0604 Transient cerebral ischemia 435;Men;190 Bizkaia;Group 0604 Transient cerebral ischemia 435;Women;182 Bizkaia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;2.092 Bizkaia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.154 Bizkaia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;938 Bizkaia;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;449 Bizkaia;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;216 Bizkaia;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;233 Bizkaia;Grupo 0701 Cataract 366;Both sexes;45 Bizkaia;Grupo 0701 Cataract 366;Men;19 Bizkaia;Grupo 0701 Cataract 366;Women;26 Bizkaia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;404 Bizkaia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;197 Bizkaia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;207 Bizkaia;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;480 Bizkaia;Group 0800 Diseases of the ear and the mastoid 380-389;Men;249 Bizkaia;Group 0800 Diseases of the ear and the mastoid 380-389;Women;231 Bizkaia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;17.089 Bizkaia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;9.808 Bizkaia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;7.281 Bizkaia;Group 0901 Hypertensive disease 401-405;Both sexes;928 Bizkaia;Group 0901 Hypertensive disease 401-405;Men;401 Bizkaia;Group 0901 Hypertensive disease 401-405;Women;527 Bizkaia;Group 0902 Angina pectoris 4111, 413;Both sexes;347 Bizkaia;Group 0902 Angina pectoris 4111, 413;Men;195 Bizkaia;Group 0902 Angina pectoris 4111, 413;Women;152 Bizkaia;Group 0903 Acute myocardial infarction 410;Both sexes;997 Bizkaia;Group 0903 Acute myocardial infarction 410;Men;702 Bizkaia;Group 0903 Acute myocardial infarction 410;Women;294 Bizkaia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.348 Bizkaia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.048 Bizkaia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;300 Bizkaia;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;666 Bizkaia;Group 0905 Diseases of the lungs circulation 415-417;Men;306 Bizkaia;Group 0905 Diseases of the lungs circulation 415-417;Women;360 Bizkaia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.561 Bizkaia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.486 Bizkaia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.075 Bizkaia;Grupo 0907 Heart failure 428;Both sexes;3.503 Bizkaia;Grupo 0907 Heart failure 428;Men;1.826 Bizkaia;Grupo 0907 Heart failure 428;Women;1.677 Bizkaia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.654 Bizkaia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.420 Bizkaia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.233 Bizkaia;Grupo 0909 Atherosclerosis 440;Both sexes;760 Bizkaia;Grupo 0909 Atherosclerosis 440;Men;564 Bizkaia;Grupo 0909 Atherosclerosis 440;Women;197 Bizkaia;Group 0910 Varicose veins of lower extremities 454;Both sexes;428 Bizkaia;Group 0910 Varicose veins of lower extremities 454;Men;171 Bizkaia;Group 0910 Varicose veins of lower extremities 454;Women;257 Bizkaia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.898 Bizkaia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.690 Bizkaia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.208 Bizkaia;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;13.977 Bizkaia;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;7.938 Bizkaia;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6.039 Bizkaia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;613 Bizkaia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;322 Bizkaia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;290 Bizkaia;Group 1002 Pneumonia 480-486;Both sexes;2.631 Bizkaia;Group 1002 Pneumonia 480-486;Men;1.567 Bizkaia;Group 1002 Pneumonia 480-486;Women;1.064 Bizkaia;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.815 Bizkaia;Group 1003 Acute bronchitis and bronchiolitis 466;Men;776 Bizkaia;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.040 Bizkaia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;651 Bizkaia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;332 Bizkaia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;319 Bizkaia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.128 Bizkaia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;698 Bizkaia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;430 Bizkaia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.696 Bizkaia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2.026 Bizkaia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;670 Bizkaia;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;996 Bizkaia;Group 1007 Asthma 4930-4931,4938-4939;Men;289 Bizkaia;Group 1007 Asthma 4930-4931,4938-4939;Women;706 Bizkaia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3.448 Bizkaia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.928 Bizkaia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.520 Bizkaia;Group 1100 Diseases of the digestive system 520-579;Both sexes;16.121 Bizkaia;Group 1100 Diseases of the digestive system 520-579;Men;9.254 Bizkaia;Group 1100 Diseases of the digestive system 520-579;Women;6.867 Bizkaia;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;179 Bizkaia;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;97 Bizkaia;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;81 Bizkaia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;190 Bizkaia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;107 Bizkaia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;82 Bizkaia;Group 1103 Diseases of the esophagus 530;Both sexes;295 Bizkaia;Group 1103 Diseases of the esophagus 530;Men;199 Bizkaia;Group 1103 Diseases of the esophagus 530;Women;96 Bizkaia;Group 1104 Peptic ulcer 531-534;Both sexes;338 Bizkaia;Group 1104 Peptic ulcer 531-534;Men;241 Bizkaia;Group 1104 Peptic ulcer 531-534;Women;96 Bizkaia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;314 Bizkaia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;161 Bizkaia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;154 Bizkaia;Group 1106 Appendicitis 540-543;Both sexes;1.381 Bizkaia;Group 1106 Appendicitis 540-543;Men;761 Bizkaia;Group 1106 Appendicitis 540-543;Women;620 Bizkaia;Group 1107 Inguinal hernia 550;Both sexes;2.168 Bizkaia;Group 1107 Inguinal hernia 550;Men;1.936 Bizkaia;Group 1107 Inguinal hernia 550;Women;232 Bizkaia;Group 1108 Other abdominal hernia 551-553;Both sexes;1.427 Bizkaia;Group 1108 Other abdominal hernia 551-553;Men;722 Bizkaia;Group 1108 Other abdominal hernia 551-553;Women;705 Bizkaia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;309 Bizkaia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;159 Bizkaia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;151 Bizkaia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;528 Bizkaia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;252 Bizkaia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;276 Bizkaia;Group 1111 Intestinal obstruction without hernia 560;Both sexes;806 Bizkaia;Group 1111 Intestinal obstruction without hernia 560;Men;404 Bizkaia;Group 1111 Intestinal obstruction without hernia 560;Women;402 Bizkaia;Group 1112 Intestinal diverticulosis 562;Both sexes;819 Bizkaia;Group 1112 Intestinal diverticulosis 562;Men;374 Bizkaia;Group 1112 Intestinal diverticulosis 562;Women;445 Bizkaia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.033 Bizkaia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;636 Bizkaia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;397 Bizkaia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;654 Bizkaia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;289 Bizkaia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;365 Bizkaia;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;294 Bizkaia;Group 1115 Alcoholic hepatitis 5710-5713;Men;235 Bizkaia;Group 1115 Alcoholic hepatitis 5710-5713;Women;59 Bizkaia;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;658 Bizkaia;Group 1116 Other diseases of the liver 570,5714-573;Men;419 Bizkaia;Group 1116 Other diseases of the liver 570,5714-573;Women;239 Bizkaia;Group 1117 Cholelithiasis 574;Both sexes;2.750 Bizkaia;Group 1117 Cholelithiasis 574;Men;1.142 Bizkaia;Group 1117 Cholelithiasis 574;Women;1.608 Bizkaia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;765 Bizkaia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;436 Bizkaia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;329 Bizkaia;Group 1119 Pancreatic diseases 577;Both sexes;634 Bizkaia;Group 1119 Pancreatic diseases 577;Men;363 Bizkaia;Group 1119 Pancreatic diseases 577;Women;271 Bizkaia;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;578 Bizkaia;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;320 Bizkaia;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;257 Bizkaia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.204 Bizkaia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;672 Bizkaia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;532 Bizkaia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;820 Bizkaia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;490 Bizkaia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;329 Bizkaia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;55 Bizkaia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;29 Bizkaia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;26 Bizkaia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;329 Bizkaia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;153 Bizkaia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;177 Bizkaia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;9.362 Bizkaia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.493 Bizkaia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;4.869 Bizkaia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Bizkaia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Bizkaia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Bizkaia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Bizkaia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Bizkaia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Bizkaia;Group 1303 Internal derangement of knee 717;Both sexes;1.072 Bizkaia;Group 1303 Internal derangement of knee 717;Men;703 Bizkaia;Group 1303 Internal derangement of knee 717;Women;369 Bizkaia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3.982 Bizkaia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.745 Bizkaia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.237 Bizkaia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;163 Bizkaia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;63 Bizkaia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;99 Bizkaia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;424 Bizkaia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;215 Bizkaia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;209 Bizkaia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;626 Bizkaia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;333 Bizkaia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;292 Bizkaia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;216 Bizkaia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;111 Bizkaia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;104 Bizkaia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.435 Bizkaia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;833 Bizkaia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;602 Bizkaia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.445 Bizkaia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;489 Bizkaia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;956 Bizkaia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;8.202 Bizkaia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3.805 Bizkaia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4.397 Bizkaia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;865 Bizkaia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;302 Bizkaia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;563 Bizkaia;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;748 Bizkaia;Group 1402 Renal failure 5836-5837, 584-586;Men;469 Bizkaia;Group 1402 Renal failure 5836-5837, 584-586;Women;279 Bizkaia;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;967 Bizkaia;Group 1403 Urolithiasis 592, 594, 7880;Men;541 Bizkaia;Group 1403 Urolithiasis 592, 594, 7880;Women;426 Bizkaia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2.206 Bizkaia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.133 Bizkaia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.073 Bizkaia;Group 1405 Prostatic hyperplasia 600;Both sexes;720 Bizkaia;Group 1405 Prostatic hyperplasia 600;Men;720 Bizkaia;Group 1405 Prostatic hyperplasia 600;Women;.. Bizkaia;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;559 Bizkaia;Group 1406 Other diseases of the male genital organs 601-608;Men;559 Bizkaia;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Bizkaia;Group 1407 Disorders of breast 610-612;Both sexes;769 Bizkaia;Group 1407 Disorders of breast 610-612;Men;46 Bizkaia;Group 1407 Disorders of breast 610-612;Women;723 Bizkaia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;234 Bizkaia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Bizkaia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;234 Bizkaia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;40 Bizkaia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Bizkaia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;40 Bizkaia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.093 Bizkaia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;34 Bizkaia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.059 Bizkaia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;10.654 Bizkaia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Bizkaia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;10.654 Bizkaia;Group 1501 Legally induced abortion 635;Both sexes;93 Bizkaia;Group 1501 Legally induced abortion 635;Men;.. Bizkaia;Group 1501 Legally induced abortion 635;Women;93 Bizkaia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;280 Bizkaia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Bizkaia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;280 Bizkaia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6.088 Bizkaia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Bizkaia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6.088 Bizkaia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.914 Bizkaia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Bizkaia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.914 Bizkaia;Group 1505 Single spontaneous delivery 650;Both sexes;1.024 Bizkaia;Group 1505 Single spontaneous delivery 650;Men;.. Bizkaia;Group 1505 Single spontaneous delivery 650;Women;1.024 Bizkaia;Group 1506 Other deliveries 6695-6697;Both sexes;221 Bizkaia;Group 1506 Other deliveries 6695-6697;Men;.. Bizkaia;Group 1506 Other deliveries 6695-6697;Women;221 Bizkaia;Group 1507 Complications related to the puerperium 670-676;Both sexes;118 Bizkaia;Group 1507 Complications related to the puerperium 670-676;Men;.. Bizkaia;Group 1507 Complications related to the puerperium 670-676;Women;118 Bizkaia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;917 Bizkaia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Bizkaia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;917 Bizkaia;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.128 Bizkaia;Group 1600 Some disorders originating in the perinatal period 760-779;Men;611 Bizkaia;Group 1600 Some disorders originating in the perinatal period 760-779;Women;517 Bizkaia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;361 Bizkaia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;184 Bizkaia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;177 Bizkaia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;767 Bizkaia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;427 Bizkaia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;341 Bizkaia;Grupo 1700 Congenital abnormalities 740-759;Both sexes;907 Bizkaia;Grupo 1700 Congenital abnormalities 740-759;Men;500 Bizkaia;Grupo 1700 Congenital abnormalities 740-759;Women;407 Bizkaia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;6.655 Bizkaia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3.666 Bizkaia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2.989 Bizkaia;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.351 Bizkaia;Group 1801 Pain in throat and chest 7841, 7865;Men;772 Bizkaia;Group 1801 Pain in throat and chest 7841, 7865;Women;580 Bizkaia;Group 1802 Abdominal pain 7890;Both sexes;691 Bizkaia;Group 1802 Abdominal pain 7890;Men;305 Bizkaia;Group 1802 Abdominal pain 7890;Women;386 Bizkaia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;53 Bizkaia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;18 Bizkaia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;35 Bizkaia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;4.560 Bizkaia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.571 Bizkaia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.989 Bizkaia;Group 1900 Injuries and poisoning 800-999;Both sexes;11.258 Bizkaia;Group 1900 Injuries and poisoning 800-999;Men;6.077 Bizkaia;Group 1900 Injuries and poisoning 800-999;Women;5.181 Bizkaia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;373 Bizkaia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;203 Bizkaia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;170 Bizkaia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;192 Bizkaia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;142 Bizkaia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;50 Bizkaia;Group 1903 Radius and ulna fracture 813;Both sexes;791 Bizkaia;Group 1903 Radius and ulna fracture 813;Men;343 Bizkaia;Group 1903 Radius and ulna fracture 813;Women;448 Bizkaia;Group 1904 Femur fracture 820-821;Both sexes;1.621 Bizkaia;Group 1904 Femur fracture 820-821;Men;445 Bizkaia;Group 1904 Femur fracture 820-821;Women;1.176 Bizkaia;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;808 Bizkaia;Group 1905 Leg fracture, including the ankle 823-824;Men;421 Bizkaia;Group 1905 Leg fracture, including the ankle 823-824;Women;387 Bizkaia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3.636 Bizkaia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.324 Bizkaia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.312 Bizkaia;Group 1907 Burns 940-949;Both sexes;90 Bizkaia;Group 1907 Burns 940-949;Men;65 Bizkaia;Group 1907 Burns 940-949;Women;25 Bizkaia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;204 Bizkaia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;96 Bizkaia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;107 Bizkaia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3.171 Bizkaia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.837 Bizkaia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.334 Bizkaia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;59 Bizkaia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;37 Bizkaia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;22 Bizkaia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;312 Bizkaia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;163 Bizkaia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;150 Bizkaia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.814 Bizkaia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.430 Bizkaia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.384 Bizkaia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;180 Bizkaia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;102 Bizkaia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;77 Bizkaia;Group 2102 Contraceptive management V25;Both sexes;51 Bizkaia;Group 2102 Contraceptive management V25;Men;1 Bizkaia;Group 2102 Contraceptive management V25;Women;50 Bizkaia;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Bizkaia;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Bizkaia;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Bizkaia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;781 Bizkaia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;530 Bizkaia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;250 Bizkaia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.802 Bizkaia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;796 Bizkaia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.006 Gipuzkoa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;82.323 Gipuzkoa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;40.755 Gipuzkoa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;41.568 Gipuzkoa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.706 Gipuzkoa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;957 Gipuzkoa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;749 Gipuzkoa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;267 Gipuzkoa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;149 Gipuzkoa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;118 Gipuzkoa;Group 0102 Imprecise intestinal infections 009;Both sexes;75 Gipuzkoa;Group 0102 Imprecise intestinal infections 009;Men;38 Gipuzkoa;Group 0102 Imprecise intestinal infections 009;Women;37 Gipuzkoa;Group 0103 Tuberculosis 010-018, 137;Both sexes;62 Gipuzkoa;Group 0103 Tuberculosis 010-018, 137;Men;42 Gipuzkoa;Group 0103 Tuberculosis 010-018, 137;Women;20 Gipuzkoa;Group 0104 Septicaemia 038;Both sexes;798 Gipuzkoa;Group 0104 Septicaemia 038;Men;436 Gipuzkoa;Group 0104 Septicaemia 038;Women;362 Gipuzkoa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;44 Gipuzkoa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;28 Gipuzkoa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;16 Gipuzkoa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;460 Gipuzkoa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;264 Gipuzkoa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;196 Gipuzkoa;Group 0200 Neoplasms 140-239;Both sexes;7.670 Gipuzkoa;Group 0200 Neoplasms 140-239;Men;4.178 Gipuzkoa;Group 0200 Neoplasms 140-239;Women;3.492 Gipuzkoa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;749 Gipuzkoa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;466 Gipuzkoa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;283 Gipuzkoa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;579 Gipuzkoa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;416 Gipuzkoa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;163 Gipuzkoa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;171 Gipuzkoa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;88 Gipuzkoa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;83 Gipuzkoa;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;531 Gipuzkoa;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Gipuzkoa;Group 0204 Malignant neoplasm of breast 174-175;Women;528 Gipuzkoa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;169 Gipuzkoa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Gipuzkoa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;169 Gipuzkoa;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;77 Gipuzkoa;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Gipuzkoa;Group 0206 Malignant neoplasm of ovary 1830;Women;77 Gipuzkoa;Group 0207 Malignant neoplasm of prostate 185;Both sexes;548 Gipuzkoa;Group 0207 Malignant neoplasm of prostate 185;Men;548 Gipuzkoa;Group 0207 Malignant neoplasm of prostate 185;Women;.. Gipuzkoa;Group 0208 Malignant neoplasm of bladder 188;Both sexes;602 Gipuzkoa;Group 0208 Malignant neoplasm of bladder 188;Men;487 Gipuzkoa;Group 0208 Malignant neoplasm of bladder 188;Women;115 Gipuzkoa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.645 Gipuzkoa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.580 Gipuzkoa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.065 Gipuzkoa;Group 0210 Carcinoma in situ 230-234;Both sexes;120 Gipuzkoa;Group 0210 Carcinoma in situ 230-234;Men;30 Gipuzkoa;Group 0210 Carcinoma in situ 230-234;Women;90 Gipuzkoa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;194 Gipuzkoa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;128 Gipuzkoa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;66 Gipuzkoa;Grupo 0212 Leiomyoma of uterus 218;Both sexes;270 Gipuzkoa;Grupo 0212 Leiomyoma of uterus 218;Men;.. Gipuzkoa;Grupo 0212 Leiomyoma of uterus 218;Women;270 Gipuzkoa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.015 Gipuzkoa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;432 Gipuzkoa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;583 Gipuzkoa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;832 Gipuzkoa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;427 Gipuzkoa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;405 Gipuzkoa;Group 0301 Anaemias 280-285;Both sexes;613 Gipuzkoa;Group 0301 Anaemias 280-285;Men;293 Gipuzkoa;Group 0301 Anaemias 280-285;Women;320 Gipuzkoa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;219 Gipuzkoa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;134 Gipuzkoa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;85 Gipuzkoa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.410 Gipuzkoa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;569 Gipuzkoa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;841 Gipuzkoa;Group 0401 Diabetes mellitus 249-250;Both sexes;527 Gipuzkoa;Group 0401 Diabetes mellitus 249-250;Men;320 Gipuzkoa;Group 0401 Diabetes mellitus 249-250;Women;207 Gipuzkoa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;883 Gipuzkoa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;249 Gipuzkoa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;634 Gipuzkoa;Group 0500 Mental disorders 290-319;Both sexes;2.030 Gipuzkoa;Group 0500 Mental disorders 290-319;Men;1.121 Gipuzkoa;Group 0500 Mental disorders 290-319;Women;909 Gipuzkoa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;73 Gipuzkoa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;33 Gipuzkoa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;40 Gipuzkoa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;193 Gipuzkoa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;132 Gipuzkoa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;61 Gipuzkoa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;125 Gipuzkoa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;92 Gipuzkoa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;33 Gipuzkoa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;671 Gipuzkoa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;425 Gipuzkoa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;246 Gipuzkoa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;384 Gipuzkoa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;157 Gipuzkoa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;227 Gipuzkoa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;584 Gipuzkoa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;282 Gipuzkoa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;302 Gipuzkoa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.679 Gipuzkoa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;875 Gipuzkoa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;804 Gipuzkoa;Group 0601 Alzheimer's disease 3310;Both sexes;44 Gipuzkoa;Group 0601 Alzheimer's disease 3310;Men;14 Gipuzkoa;Group 0601 Alzheimer's disease 3310;Women;30 Gipuzkoa;Group 0602 Multiple sclerosis 340;Both sexes;16 Gipuzkoa;Group 0602 Multiple sclerosis 340;Men;5 Gipuzkoa;Group 0602 Multiple sclerosis 340;Women;11 Gipuzkoa;Group 0603 Epilepsy 345;Both sexes;281 Gipuzkoa;Group 0603 Epilepsy 345;Men;151 Gipuzkoa;Group 0603 Epilepsy 345;Women;130 Gipuzkoa;Group 0604 Transient cerebral ischemia 435;Both sexes;272 Gipuzkoa;Group 0604 Transient cerebral ischemia 435;Men;129 Gipuzkoa;Group 0604 Transient cerebral ischemia 435;Women;143 Gipuzkoa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.066 Gipuzkoa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;576 Gipuzkoa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;490 Gipuzkoa;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;219 Gipuzkoa;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;106 Gipuzkoa;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;113 Gipuzkoa;Grupo 0701 Cataract 366;Both sexes;18 Gipuzkoa;Grupo 0701 Cataract 366;Men;10 Gipuzkoa;Grupo 0701 Cataract 366;Women;8 Gipuzkoa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;201 Gipuzkoa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;96 Gipuzkoa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;105 Gipuzkoa;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;579 Gipuzkoa;Group 0800 Diseases of the ear and the mastoid 380-389;Men;293 Gipuzkoa;Group 0800 Diseases of the ear and the mastoid 380-389;Women;286 Gipuzkoa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;10.668 Gipuzkoa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;6.026 Gipuzkoa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4.642 Gipuzkoa;Group 0901 Hypertensive disease 401-405;Both sexes;452 Gipuzkoa;Group 0901 Hypertensive disease 401-405;Men;219 Gipuzkoa;Group 0901 Hypertensive disease 401-405;Women;233 Gipuzkoa;Group 0902 Angina pectoris 4111, 413;Both sexes;263 Gipuzkoa;Group 0902 Angina pectoris 4111, 413;Men;173 Gipuzkoa;Group 0902 Angina pectoris 4111, 413;Women;90 Gipuzkoa;Group 0903 Acute myocardial infarction 410;Both sexes;586 Gipuzkoa;Group 0903 Acute myocardial infarction 410;Men;429 Gipuzkoa;Group 0903 Acute myocardial infarction 410;Women;157 Gipuzkoa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;746 Gipuzkoa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;573 Gipuzkoa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;173 Gipuzkoa;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;298 Gipuzkoa;Group 0905 Diseases of the lungs circulation 415-417;Men;135 Gipuzkoa;Group 0905 Diseases of the lungs circulation 415-417;Women;163 Gipuzkoa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.602 Gipuzkoa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;865 Gipuzkoa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;737 Gipuzkoa;Grupo 0907 Heart failure 428;Both sexes;1.982 Gipuzkoa;Grupo 0907 Heart failure 428;Men;993 Gipuzkoa;Grupo 0907 Heart failure 428;Women;989 Gipuzkoa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.967 Gipuzkoa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.026 Gipuzkoa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;941 Gipuzkoa;Grupo 0909 Atherosclerosis 440;Both sexes;584 Gipuzkoa;Grupo 0909 Atherosclerosis 440;Men;448 Gipuzkoa;Grupo 0909 Atherosclerosis 440;Women;136 Gipuzkoa;Group 0910 Varicose veins of lower extremities 454;Both sexes;523 Gipuzkoa;Group 0910 Varicose veins of lower extremities 454;Men;204 Gipuzkoa;Group 0910 Varicose veins of lower extremities 454;Women;319 Gipuzkoa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.665 Gipuzkoa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;961 Gipuzkoa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;704 Gipuzkoa;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;9.667 Gipuzkoa;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;5.619 Gipuzkoa;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;4.048 Gipuzkoa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;462 Gipuzkoa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;254 Gipuzkoa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;208 Gipuzkoa;Group 1002 Pneumonia 480-486;Both sexes;2.238 Gipuzkoa;Group 1002 Pneumonia 480-486;Men;1.364 Gipuzkoa;Group 1002 Pneumonia 480-486;Women;874 Gipuzkoa;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;338 Gipuzkoa;Group 1003 Acute bronchitis and bronchiolitis 466;Men;180 Gipuzkoa;Group 1003 Acute bronchitis and bronchiolitis 466;Women;158 Gipuzkoa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;617 Gipuzkoa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;332 Gipuzkoa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;285 Gipuzkoa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;846 Gipuzkoa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;552 Gipuzkoa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;294 Gipuzkoa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.590 Gipuzkoa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.188 Gipuzkoa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;402 Gipuzkoa;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;495 Gipuzkoa;Group 1007 Asthma 4930-4931,4938-4939;Men;220 Gipuzkoa;Group 1007 Asthma 4930-4931,4938-4939;Women;275 Gipuzkoa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3.081 Gipuzkoa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.529 Gipuzkoa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.552 Gipuzkoa;Group 1100 Diseases of the digestive system 520-579;Both sexes;9.826 Gipuzkoa;Group 1100 Diseases of the digestive system 520-579;Men;5.623 Gipuzkoa;Group 1100 Diseases of the digestive system 520-579;Women;4.203 Gipuzkoa;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;170 Gipuzkoa;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;86 Gipuzkoa;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;84 Gipuzkoa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;177 Gipuzkoa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;105 Gipuzkoa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;72 Gipuzkoa;Group 1103 Diseases of the esophagus 530;Both sexes;182 Gipuzkoa;Group 1103 Diseases of the esophagus 530;Men;106 Gipuzkoa;Group 1103 Diseases of the esophagus 530;Women;76 Gipuzkoa;Group 1104 Peptic ulcer 531-534;Both sexes;197 Gipuzkoa;Group 1104 Peptic ulcer 531-534;Men;145 Gipuzkoa;Group 1104 Peptic ulcer 531-534;Women;52 Gipuzkoa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;165 Gipuzkoa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;86 Gipuzkoa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;79 Gipuzkoa;Group 1106 Appendicitis 540-543;Both sexes;866 Gipuzkoa;Group 1106 Appendicitis 540-543;Men;476 Gipuzkoa;Group 1106 Appendicitis 540-543;Women;390 Gipuzkoa;Group 1107 Inguinal hernia 550;Both sexes;1.075 Gipuzkoa;Group 1107 Inguinal hernia 550;Men;952 Gipuzkoa;Group 1107 Inguinal hernia 550;Women;123 Gipuzkoa;Group 1108 Other abdominal hernia 551-553;Both sexes;816 Gipuzkoa;Group 1108 Other abdominal hernia 551-553;Men;392 Gipuzkoa;Group 1108 Other abdominal hernia 551-553;Women;424 Gipuzkoa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;204 Gipuzkoa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;108 Gipuzkoa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;96 Gipuzkoa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;516 Gipuzkoa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;238 Gipuzkoa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;278 Gipuzkoa;Group 1111 Intestinal obstruction without hernia 560;Both sexes;626 Gipuzkoa;Group 1111 Intestinal obstruction without hernia 560;Men;346 Gipuzkoa;Group 1111 Intestinal obstruction without hernia 560;Women;280 Gipuzkoa;Group 1112 Intestinal diverticulosis 562;Both sexes;447 Gipuzkoa;Group 1112 Intestinal diverticulosis 562;Men;209 Gipuzkoa;Group 1112 Intestinal diverticulosis 562;Women;238 Gipuzkoa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;763 Gipuzkoa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;526 Gipuzkoa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;237 Gipuzkoa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;317 Gipuzkoa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;137 Gipuzkoa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;180 Gipuzkoa;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;183 Gipuzkoa;Group 1115 Alcoholic hepatitis 5710-5713;Men;150 Gipuzkoa;Group 1115 Alcoholic hepatitis 5710-5713;Women;33 Gipuzkoa;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;244 Gipuzkoa;Group 1116 Other diseases of the liver 570,5714-573;Men;143 Gipuzkoa;Group 1116 Other diseases of the liver 570,5714-573;Women;101 Gipuzkoa;Group 1117 Cholelithiasis 574;Both sexes;1.583 Gipuzkoa;Group 1117 Cholelithiasis 574;Men;685 Gipuzkoa;Group 1117 Cholelithiasis 574;Women;898 Gipuzkoa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;349 Gipuzkoa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;189 Gipuzkoa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;160 Gipuzkoa;Group 1119 Pancreatic diseases 577;Both sexes;465 Gipuzkoa;Group 1119 Pancreatic diseases 577;Men;268 Gipuzkoa;Group 1119 Pancreatic diseases 577;Women;197 Gipuzkoa;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;481 Gipuzkoa;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;276 Gipuzkoa;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;205 Gipuzkoa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.118 Gipuzkoa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;603 Gipuzkoa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;515 Gipuzkoa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;778 Gipuzkoa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;450 Gipuzkoa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;328 Gipuzkoa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;37 Gipuzkoa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;21 Gipuzkoa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;16 Gipuzkoa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;303 Gipuzkoa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;132 Gipuzkoa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;171 Gipuzkoa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;7.160 Gipuzkoa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3.679 Gipuzkoa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.481 Gipuzkoa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Gipuzkoa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Gipuzkoa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Gipuzkoa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Gipuzkoa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Gipuzkoa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Gipuzkoa;Group 1303 Internal derangement of knee 717;Both sexes;1.447 Gipuzkoa;Group 1303 Internal derangement of knee 717;Men;992 Gipuzkoa;Group 1303 Internal derangement of knee 717;Women;455 Gipuzkoa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.420 Gipuzkoa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.164 Gipuzkoa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.256 Gipuzkoa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;88 Gipuzkoa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;35 Gipuzkoa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;53 Gipuzkoa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;488 Gipuzkoa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;236 Gipuzkoa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;252 Gipuzkoa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;593 Gipuzkoa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;317 Gipuzkoa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;276 Gipuzkoa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;250 Gipuzkoa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;106 Gipuzkoa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;144 Gipuzkoa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;954 Gipuzkoa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;493 Gipuzkoa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;461 Gipuzkoa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;920 Gipuzkoa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;336 Gipuzkoa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;584 Gipuzkoa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;5.332 Gipuzkoa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.651 Gipuzkoa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2.681 Gipuzkoa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;402 Gipuzkoa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;163 Gipuzkoa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;239 Gipuzkoa;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;350 Gipuzkoa;Group 1402 Renal failure 5836-5837, 584-586;Men;205 Gipuzkoa;Group 1402 Renal failure 5836-5837, 584-586;Women;145 Gipuzkoa;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;874 Gipuzkoa;Group 1403 Urolithiasis 592, 594, 7880;Men;556 Gipuzkoa;Group 1403 Urolithiasis 592, 594, 7880;Women;318 Gipuzkoa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.599 Gipuzkoa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;827 Gipuzkoa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;772 Gipuzkoa;Group 1405 Prostatic hyperplasia 600;Both sexes;563 Gipuzkoa;Group 1405 Prostatic hyperplasia 600;Men;563 Gipuzkoa;Group 1405 Prostatic hyperplasia 600;Women;.. Gipuzkoa;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;261 Gipuzkoa;Group 1406 Other diseases of the male genital organs 601-608;Men;261 Gipuzkoa;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Gipuzkoa;Group 1407 Disorders of breast 610-612;Both sexes;340 Gipuzkoa;Group 1407 Disorders of breast 610-612;Men;32 Gipuzkoa;Group 1407 Disorders of breast 610-612;Women;308 Gipuzkoa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;118 Gipuzkoa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Gipuzkoa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;118 Gipuzkoa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;44 Gipuzkoa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Gipuzkoa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;44 Gipuzkoa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;781 Gipuzkoa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;44 Gipuzkoa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;737 Gipuzkoa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;7.391 Gipuzkoa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Gipuzkoa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;7.391 Gipuzkoa;Group 1501 Legally induced abortion 635;Both sexes;66 Gipuzkoa;Group 1501 Legally induced abortion 635;Men;.. Gipuzkoa;Group 1501 Legally induced abortion 635;Women;66 Gipuzkoa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;208 Gipuzkoa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Gipuzkoa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;208 Gipuzkoa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4.803 Gipuzkoa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Gipuzkoa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4.803 Gipuzkoa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.075 Gipuzkoa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Gipuzkoa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.075 Gipuzkoa;Group 1505 Single spontaneous delivery 650;Both sexes;728 Gipuzkoa;Group 1505 Single spontaneous delivery 650;Men;.. Gipuzkoa;Group 1505 Single spontaneous delivery 650;Women;728 Gipuzkoa;Group 1506 Other deliveries 6695-6697;Both sexes;166 Gipuzkoa;Group 1506 Other deliveries 6695-6697;Men;.. Gipuzkoa;Group 1506 Other deliveries 6695-6697;Women;166 Gipuzkoa;Group 1507 Complications related to the puerperium 670-676;Both sexes;41 Gipuzkoa;Group 1507 Complications related to the puerperium 670-676;Men;.. Gipuzkoa;Group 1507 Complications related to the puerperium 670-676;Women;41 Gipuzkoa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;304 Gipuzkoa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Gipuzkoa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;304 Gipuzkoa;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;876 Gipuzkoa;Group 1600 Some disorders originating in the perinatal period 760-779;Men;467 Gipuzkoa;Group 1600 Some disorders originating in the perinatal period 760-779;Women;409 Gipuzkoa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;207 Gipuzkoa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;101 Gipuzkoa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;106 Gipuzkoa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;669 Gipuzkoa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;366 Gipuzkoa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;303 Gipuzkoa;Grupo 1700 Congenital abnormalities 740-759;Both sexes;302 Gipuzkoa;Grupo 1700 Congenital abnormalities 740-759;Men;166 Gipuzkoa;Grupo 1700 Congenital abnormalities 740-759;Women;136 Gipuzkoa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;4.675 Gipuzkoa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;2.633 Gipuzkoa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2.042 Gipuzkoa;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;987 Gipuzkoa;Group 1801 Pain in throat and chest 7841, 7865;Men;590 Gipuzkoa;Group 1801 Pain in throat and chest 7841, 7865;Women;397 Gipuzkoa;Group 1802 Abdominal pain 7890;Both sexes;526 Gipuzkoa;Group 1802 Abdominal pain 7890;Men;242 Gipuzkoa;Group 1802 Abdominal pain 7890;Women;284 Gipuzkoa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;383 Gipuzkoa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;208 Gipuzkoa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;175 Gipuzkoa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;2.779 Gipuzkoa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.593 Gipuzkoa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.186 Gipuzkoa;Group 1900 Injuries and poisoning 800-999;Both sexes;6.611 Gipuzkoa;Group 1900 Injuries and poisoning 800-999;Men;3.451 Gipuzkoa;Group 1900 Injuries and poisoning 800-999;Women;3.160 Gipuzkoa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;409 Gipuzkoa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;254 Gipuzkoa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;155 Gipuzkoa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;239 Gipuzkoa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;160 Gipuzkoa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;79 Gipuzkoa;Group 1903 Radius and ulna fracture 813;Both sexes;443 Gipuzkoa;Group 1903 Radius and ulna fracture 813;Men;177 Gipuzkoa;Group 1903 Radius and ulna fracture 813;Women;266 Gipuzkoa;Group 1904 Femur fracture 820-821;Both sexes;963 Gipuzkoa;Group 1904 Femur fracture 820-821;Men;248 Gipuzkoa;Group 1904 Femur fracture 820-821;Women;715 Gipuzkoa;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;436 Gipuzkoa;Group 1905 Leg fracture, including the ankle 823-824;Men;208 Gipuzkoa;Group 1905 Leg fracture, including the ankle 823-824;Women;228 Gipuzkoa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.895 Gipuzkoa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.189 Gipuzkoa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;706 Gipuzkoa;Group 1907 Burns 940-949;Both sexes;38 Gipuzkoa;Group 1907 Burns 940-949;Men;26 Gipuzkoa;Group 1907 Burns 940-949;Women;12 Gipuzkoa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;145 Gipuzkoa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;63 Gipuzkoa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;82 Gipuzkoa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.693 Gipuzkoa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;958 Gipuzkoa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;735 Gipuzkoa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;18 Gipuzkoa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;12 Gipuzkoa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;6 Gipuzkoa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;332 Gipuzkoa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;156 Gipuzkoa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;176 Gipuzkoa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.572 Gipuzkoa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.311 Gipuzkoa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.261 Gipuzkoa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;62 Gipuzkoa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;38 Gipuzkoa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;24 Gipuzkoa;Group 2102 Contraceptive management V25;Both sexes;21 Gipuzkoa;Group 2102 Contraceptive management V25;Men;.. Gipuzkoa;Group 2102 Contraceptive management V25;Women;21 Gipuzkoa;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Gipuzkoa;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Gipuzkoa;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Gipuzkoa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;797 Gipuzkoa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;496 Gipuzkoa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;301 Gipuzkoa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.692 Gipuzkoa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;777 Gipuzkoa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;915 RIOJA, LA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;37.009 RIOJA, LA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;18.213 RIOJA, LA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;18.796 RIOJA, LA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;757 RIOJA, LA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;463 RIOJA, LA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;294 RIOJA, LA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;121 RIOJA, LA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;73 RIOJA, LA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;48 RIOJA, LA;Group 0102 Imprecise intestinal infections 009;Both sexes;25 RIOJA, LA;Group 0102 Imprecise intestinal infections 009;Men;12 RIOJA, LA;Group 0102 Imprecise intestinal infections 009;Women;13 RIOJA, LA;Group 0103 Tuberculosis 010-018, 137;Both sexes;20 RIOJA, LA;Group 0103 Tuberculosis 010-018, 137;Men;12 RIOJA, LA;Group 0103 Tuberculosis 010-018, 137;Women;8 RIOJA, LA;Group 0104 Septicaemia 038;Both sexes;338 RIOJA, LA;Group 0104 Septicaemia 038;Men;210 RIOJA, LA;Group 0104 Septicaemia 038;Women;128 RIOJA, LA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;9 RIOJA, LA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;5 RIOJA, LA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;4 RIOJA, LA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;244 RIOJA, LA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;151 RIOJA, LA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;93 RIOJA, LA;Group 0200 Neoplasms 140-239;Both sexes;3.235 RIOJA, LA;Group 0200 Neoplasms 140-239;Men;1.789 RIOJA, LA;Group 0200 Neoplasms 140-239;Women;1.446 RIOJA, LA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;322 RIOJA, LA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;215 RIOJA, LA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;107 RIOJA, LA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;194 RIOJA, LA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;149 RIOJA, LA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;45 RIOJA, LA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;107 RIOJA, LA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;62 RIOJA, LA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;45 RIOJA, LA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;227 RIOJA, LA;Group 0204 Malignant neoplasm of breast 174-175;Men;5 RIOJA, LA;Group 0204 Malignant neoplasm of breast 174-175;Women;222 RIOJA, LA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;57 RIOJA, LA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. RIOJA, LA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;57 RIOJA, LA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;43 RIOJA, LA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. RIOJA, LA;Group 0206 Malignant neoplasm of ovary 1830;Women;43 RIOJA, LA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;104 RIOJA, LA;Group 0207 Malignant neoplasm of prostate 185;Men;104 RIOJA, LA;Group 0207 Malignant neoplasm of prostate 185;Women;.. RIOJA, LA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;357 RIOJA, LA;Group 0208 Malignant neoplasm of bladder 188;Men;293 RIOJA, LA;Group 0208 Malignant neoplasm of bladder 188;Women;64 RIOJA, LA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.155 RIOJA, LA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;719 RIOJA, LA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;436 RIOJA, LA;Group 0210 Carcinoma in situ 230-234;Both sexes;43 RIOJA, LA;Group 0210 Carcinoma in situ 230-234;Men;5 RIOJA, LA;Group 0210 Carcinoma in situ 230-234;Women;38 RIOJA, LA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;45 RIOJA, LA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;26 RIOJA, LA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;19 RIOJA, LA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;158 RIOJA, LA;Grupo 0212 Leiomyoma of uterus 218;Men;.. RIOJA, LA;Grupo 0212 Leiomyoma of uterus 218;Women;158 RIOJA, LA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;423 RIOJA, LA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;211 RIOJA, LA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;212 RIOJA, LA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;700 RIOJA, LA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;396 RIOJA, LA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;304 RIOJA, LA;Group 0301 Anaemias 280-285;Both sexes;493 RIOJA, LA;Group 0301 Anaemias 280-285;Men;266 RIOJA, LA;Group 0301 Anaemias 280-285;Women;227 RIOJA, LA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;207 RIOJA, LA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;130 RIOJA, LA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;77 RIOJA, LA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;623 RIOJA, LA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;284 RIOJA, LA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;339 RIOJA, LA;Group 0401 Diabetes mellitus 249-250;Both sexes;326 RIOJA, LA;Group 0401 Diabetes mellitus 249-250;Men;191 RIOJA, LA;Group 0401 Diabetes mellitus 249-250;Women;135 RIOJA, LA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;297 RIOJA, LA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;93 RIOJA, LA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;204 RIOJA, LA;Group 0500 Mental disorders 290-319;Both sexes;684 RIOJA, LA;Group 0500 Mental disorders 290-319;Men;338 RIOJA, LA;Group 0500 Mental disorders 290-319;Women;346 RIOJA, LA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;36 RIOJA, LA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;18 RIOJA, LA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;18 RIOJA, LA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;34 RIOJA, LA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;16 RIOJA, LA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;18 RIOJA, LA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;33 RIOJA, LA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;24 RIOJA, LA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;9 RIOJA, LA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;200 RIOJA, LA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;100 RIOJA, LA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;100 RIOJA, LA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;138 RIOJA, LA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;58 RIOJA, LA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;80 RIOJA, LA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;243 RIOJA, LA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;122 RIOJA, LA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;121 RIOJA, LA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;655 RIOJA, LA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;310 RIOJA, LA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;345 RIOJA, LA;Group 0601 Alzheimer's disease 3310;Both sexes;15 RIOJA, LA;Group 0601 Alzheimer's disease 3310;Men;3 RIOJA, LA;Group 0601 Alzheimer's disease 3310;Women;12 RIOJA, LA;Group 0602 Multiple sclerosis 340;Both sexes;11 RIOJA, LA;Group 0602 Multiple sclerosis 340;Men;2 RIOJA, LA;Group 0602 Multiple sclerosis 340;Women;9 RIOJA, LA;Group 0603 Epilepsy 345;Both sexes;119 RIOJA, LA;Group 0603 Epilepsy 345;Men;59 RIOJA, LA;Group 0603 Epilepsy 345;Women;60 RIOJA, LA;Group 0604 Transient cerebral ischemia 435;Both sexes;150 RIOJA, LA;Group 0604 Transient cerebral ischemia 435;Men;67 RIOJA, LA;Group 0604 Transient cerebral ischemia 435;Women;83 RIOJA, LA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;360 RIOJA, LA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;179 RIOJA, LA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;181 RIOJA, LA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;243 RIOJA, LA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;121 RIOJA, LA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;122 RIOJA, LA;Grupo 0701 Cataract 366;Both sexes;33 RIOJA, LA;Grupo 0701 Cataract 366;Men;19 RIOJA, LA;Grupo 0701 Cataract 366;Women;14 RIOJA, LA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;210 RIOJA, LA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;102 RIOJA, LA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;108 RIOJA, LA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;180 RIOJA, LA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;81 RIOJA, LA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;99 RIOJA, LA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5.213 RIOJA, LA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.879 RIOJA, LA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.334 RIOJA, LA;Group 0901 Hypertensive disease 401-405;Both sexes;384 RIOJA, LA;Group 0901 Hypertensive disease 401-405;Men;200 RIOJA, LA;Group 0901 Hypertensive disease 401-405;Women;184 RIOJA, LA;Group 0902 Angina pectoris 4111, 413;Both sexes;129 RIOJA, LA;Group 0902 Angina pectoris 4111, 413;Men;88 RIOJA, LA;Group 0902 Angina pectoris 4111, 413;Women;41 RIOJA, LA;Group 0903 Acute myocardial infarction 410;Both sexes;412 RIOJA, LA;Group 0903 Acute myocardial infarction 410;Men;281 RIOJA, LA;Group 0903 Acute myocardial infarction 410;Women;131 RIOJA, LA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;270 RIOJA, LA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;214 RIOJA, LA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;56 RIOJA, LA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;193 RIOJA, LA;Group 0905 Diseases of the lungs circulation 415-417;Men;77 RIOJA, LA;Group 0905 Diseases of the lungs circulation 415-417;Women;116 RIOJA, LA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;570 RIOJA, LA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;306 RIOJA, LA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;264 RIOJA, LA;Grupo 0907 Heart failure 428;Both sexes;1.306 RIOJA, LA;Grupo 0907 Heart failure 428;Men;598 RIOJA, LA;Grupo 0907 Heart failure 428;Women;708 RIOJA, LA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;780 RIOJA, LA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;451 RIOJA, LA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;329 RIOJA, LA;Grupo 0909 Atherosclerosis 440;Both sexes;152 RIOJA, LA;Grupo 0909 Atherosclerosis 440;Men;102 RIOJA, LA;Grupo 0909 Atherosclerosis 440;Women;50 RIOJA, LA;Group 0910 Varicose veins of lower extremities 454;Both sexes;296 RIOJA, LA;Group 0910 Varicose veins of lower extremities 454;Men;113 RIOJA, LA;Group 0910 Varicose veins of lower extremities 454;Women;183 RIOJA, LA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;721 RIOJA, LA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;449 RIOJA, LA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;272 RIOJA, LA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;4.881 RIOJA, LA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2.758 RIOJA, LA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.123 RIOJA, LA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;247 RIOJA, LA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;127 RIOJA, LA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;120 RIOJA, LA;Group 1002 Pneumonia 480-486;Both sexes;951 RIOJA, LA;Group 1002 Pneumonia 480-486;Men;558 RIOJA, LA;Group 1002 Pneumonia 480-486;Women;393 RIOJA, LA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;164 RIOJA, LA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;96 RIOJA, LA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;68 RIOJA, LA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;257 RIOJA, LA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;134 RIOJA, LA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;123 RIOJA, LA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;190 RIOJA, LA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;118 RIOJA, LA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;72 RIOJA, LA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.038 RIOJA, LA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;819 RIOJA, LA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;219 RIOJA, LA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;206 RIOJA, LA;Group 1007 Asthma 4930-4931,4938-4939;Men;44 RIOJA, LA;Group 1007 Asthma 4930-4931,4938-4939;Women;162 RIOJA, LA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.828 RIOJA, LA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;862 RIOJA, LA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;966 RIOJA, LA;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.708 RIOJA, LA;Group 1100 Diseases of the digestive system 520-579;Men;2.688 RIOJA, LA;Group 1100 Diseases of the digestive system 520-579;Women;2.020 RIOJA, LA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;34 RIOJA, LA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;19 RIOJA, LA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;15 RIOJA, LA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;72 RIOJA, LA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;32 RIOJA, LA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;40 RIOJA, LA;Group 1103 Diseases of the esophagus 530;Both sexes;71 RIOJA, LA;Group 1103 Diseases of the esophagus 530;Men;43 RIOJA, LA;Group 1103 Diseases of the esophagus 530;Women;28 RIOJA, LA;Group 1104 Peptic ulcer 531-534;Both sexes;109 RIOJA, LA;Group 1104 Peptic ulcer 531-534;Men;74 RIOJA, LA;Group 1104 Peptic ulcer 531-534;Women;35 RIOJA, LA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;134 RIOJA, LA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;65 RIOJA, LA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;69 RIOJA, LA;Group 1106 Appendicitis 540-543;Both sexes;320 RIOJA, LA;Group 1106 Appendicitis 540-543;Men;186 RIOJA, LA;Group 1106 Appendicitis 540-543;Women;134 RIOJA, LA;Group 1107 Inguinal hernia 550;Both sexes;518 RIOJA, LA;Group 1107 Inguinal hernia 550;Men;464 RIOJA, LA;Group 1107 Inguinal hernia 550;Women;54 RIOJA, LA;Group 1108 Other abdominal hernia 551-553;Both sexes;293 RIOJA, LA;Group 1108 Other abdominal hernia 551-553;Men;147 RIOJA, LA;Group 1108 Other abdominal hernia 551-553;Women;146 RIOJA, LA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;60 RIOJA, LA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;27 RIOJA, LA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;33 RIOJA, LA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;404 RIOJA, LA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;201 RIOJA, LA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;203 RIOJA, LA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;306 RIOJA, LA;Group 1111 Intestinal obstruction without hernia 560;Men;163 RIOJA, LA;Group 1111 Intestinal obstruction without hernia 560;Women;143 RIOJA, LA;Group 1112 Intestinal diverticulosis 562;Both sexes;347 RIOJA, LA;Group 1112 Intestinal diverticulosis 562;Men;159 RIOJA, LA;Group 1112 Intestinal diverticulosis 562;Women;188 RIOJA, LA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;238 RIOJA, LA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;158 RIOJA, LA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;80 RIOJA, LA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;133 RIOJA, LA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;69 RIOJA, LA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;64 RIOJA, LA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;53 RIOJA, LA;Group 1115 Alcoholic hepatitis 5710-5713;Men;42 RIOJA, LA;Group 1115 Alcoholic hepatitis 5710-5713;Women;11 RIOJA, LA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;139 RIOJA, LA;Group 1116 Other diseases of the liver 570,5714-573;Men;78 RIOJA, LA;Group 1116 Other diseases of the liver 570,5714-573;Women;61 RIOJA, LA;Group 1117 Cholelithiasis 574;Both sexes;695 RIOJA, LA;Group 1117 Cholelithiasis 574;Men;327 RIOJA, LA;Group 1117 Cholelithiasis 574;Women;368 RIOJA, LA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;299 RIOJA, LA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;171 RIOJA, LA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;128 RIOJA, LA;Group 1119 Pancreatic diseases 577;Both sexes;290 RIOJA, LA;Group 1119 Pancreatic diseases 577;Men;152 RIOJA, LA;Group 1119 Pancreatic diseases 577;Women;138 RIOJA, LA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;193 RIOJA, LA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;111 RIOJA, LA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;82 RIOJA, LA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;449 RIOJA, LA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;226 RIOJA, LA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;223 RIOJA, LA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;258 RIOJA, LA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;139 RIOJA, LA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;119 RIOJA, LA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;22 RIOJA, LA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;9 RIOJA, LA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;13 RIOJA, LA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;169 RIOJA, LA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;78 RIOJA, LA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;91 RIOJA, LA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.753 RIOJA, LA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.421 RIOJA, LA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.332 RIOJA, LA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. RIOJA, LA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. RIOJA, LA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. RIOJA, LA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. RIOJA, LA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. RIOJA, LA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. RIOJA, LA;Group 1303 Internal derangement of knee 717;Both sexes;530 RIOJA, LA;Group 1303 Internal derangement of knee 717;Men;380 RIOJA, LA;Group 1303 Internal derangement of knee 717;Women;150 RIOJA, LA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;883 RIOJA, LA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;446 RIOJA, LA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;437 RIOJA, LA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;68 RIOJA, LA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;30 RIOJA, LA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;38 RIOJA, LA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;46 RIOJA, LA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;27 RIOJA, LA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;19 RIOJA, LA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;392 RIOJA, LA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;197 RIOJA, LA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;195 RIOJA, LA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;71 RIOJA, LA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;32 RIOJA, LA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;39 RIOJA, LA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;350 RIOJA, LA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;173 RIOJA, LA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;177 RIOJA, LA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;413 RIOJA, LA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;136 RIOJA, LA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;277 RIOJA, LA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.637 RIOJA, LA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.348 RIOJA, LA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.289 RIOJA, LA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;272 RIOJA, LA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;74 RIOJA, LA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;198 RIOJA, LA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;168 RIOJA, LA;Group 1402 Renal failure 5836-5837, 584-586;Men;105 RIOJA, LA;Group 1402 Renal failure 5836-5837, 584-586;Women;63 RIOJA, LA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;386 RIOJA, LA;Group 1403 Urolithiasis 592, 594, 7880;Men;229 RIOJA, LA;Group 1403 Urolithiasis 592, 594, 7880;Women;157 RIOJA, LA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;801 RIOJA, LA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;392 RIOJA, LA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;409 RIOJA, LA;Group 1405 Prostatic hyperplasia 600;Both sexes;250 RIOJA, LA;Group 1405 Prostatic hyperplasia 600;Men;250 RIOJA, LA;Group 1405 Prostatic hyperplasia 600;Women;.. RIOJA, LA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;265 RIOJA, LA;Group 1406 Other diseases of the male genital organs 601-608;Men;265 RIOJA, LA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. RIOJA, LA;Group 1407 Disorders of breast 610-612;Both sexes;90 RIOJA, LA;Group 1407 Disorders of breast 610-612;Men;7 RIOJA, LA;Group 1407 Disorders of breast 610-612;Women;83 RIOJA, LA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;48 RIOJA, LA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. RIOJA, LA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;48 RIOJA, LA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;32 RIOJA, LA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. RIOJA, LA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;32 RIOJA, LA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;325 RIOJA, LA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;26 RIOJA, LA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;299 RIOJA, LA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3.251 RIOJA, LA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. RIOJA, LA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3.251 RIOJA, LA;Group 1501 Legally induced abortion 635;Both sexes;25 RIOJA, LA;Group 1501 Legally induced abortion 635;Men;.. RIOJA, LA;Group 1501 Legally induced abortion 635;Women;25 RIOJA, LA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;162 RIOJA, LA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. RIOJA, LA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;162 RIOJA, LA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.891 RIOJA, LA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. RIOJA, LA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.891 RIOJA, LA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;889 RIOJA, LA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. RIOJA, LA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;889 RIOJA, LA;Group 1505 Single spontaneous delivery 650;Both sexes;96 RIOJA, LA;Group 1505 Single spontaneous delivery 650;Men;.. RIOJA, LA;Group 1505 Single spontaneous delivery 650;Women;96 RIOJA, LA;Group 1506 Other deliveries 6695-6697;Both sexes;4 RIOJA, LA;Group 1506 Other deliveries 6695-6697;Men;.. RIOJA, LA;Group 1506 Other deliveries 6695-6697;Women;4 RIOJA, LA;Group 1507 Complications related to the puerperium 670-676;Both sexes;19 RIOJA, LA;Group 1507 Complications related to the puerperium 670-676;Men;.. RIOJA, LA;Group 1507 Complications related to the puerperium 670-676;Women;19 RIOJA, LA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;165 RIOJA, LA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. RIOJA, LA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;165 RIOJA, LA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;239 RIOJA, LA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;136 RIOJA, LA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;103 RIOJA, LA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;104 RIOJA, LA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;60 RIOJA, LA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;44 RIOJA, LA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;135 RIOJA, LA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;76 RIOJA, LA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;59 RIOJA, LA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;124 RIOJA, LA;Grupo 1700 Congenital abnormalities 740-759;Men;88 RIOJA, LA;Grupo 1700 Congenital abnormalities 740-759;Women;36 RIOJA, LA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.750 RIOJA, LA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;952 RIOJA, LA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;798 RIOJA, LA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;157 RIOJA, LA;Group 1801 Pain in throat and chest 7841, 7865;Men;94 RIOJA, LA;Group 1801 Pain in throat and chest 7841, 7865;Women;63 RIOJA, LA;Group 1802 Abdominal pain 7890;Both sexes;272 RIOJA, LA;Group 1802 Abdominal pain 7890;Men;126 RIOJA, LA;Group 1802 Abdominal pain 7890;Women;146 RIOJA, LA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;2 RIOJA, LA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1 RIOJA, LA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;1 RIOJA, LA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.319 RIOJA, LA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;731 RIOJA, LA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;588 RIOJA, LA;Group 1900 Injuries and poisoning 800-999;Both sexes;2.934 RIOJA, LA;Group 1900 Injuries and poisoning 800-999;Men;1.449 RIOJA, LA;Group 1900 Injuries and poisoning 800-999;Women;1.485 RIOJA, LA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;384 RIOJA, LA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;197 RIOJA, LA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;187 RIOJA, LA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;104 RIOJA, LA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;74 RIOJA, LA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;30 RIOJA, LA;Group 1903 Radius and ulna fracture 813;Both sexes;112 RIOJA, LA;Group 1903 Radius and ulna fracture 813;Men;46 RIOJA, LA;Group 1903 Radius and ulna fracture 813;Women;66 RIOJA, LA;Group 1904 Femur fracture 820-821;Both sexes;486 RIOJA, LA;Group 1904 Femur fracture 820-821;Men;130 RIOJA, LA;Group 1904 Femur fracture 820-821;Women;356 RIOJA, LA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;145 RIOJA, LA;Group 1905 Leg fracture, including the ankle 823-824;Men;74 RIOJA, LA;Group 1905 Leg fracture, including the ankle 823-824;Women;71 RIOJA, LA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;672 RIOJA, LA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;369 RIOJA, LA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;303 RIOJA, LA;Group 1907 Burns 940-949;Both sexes;20 RIOJA, LA;Group 1907 Burns 940-949;Men;13 RIOJA, LA;Group 1907 Burns 940-949;Women;7 RIOJA, LA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;88 RIOJA, LA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;41 RIOJA, LA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;47 RIOJA, LA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;828 RIOJA, LA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;456 RIOJA, LA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;372 RIOJA, LA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;1 RIOJA, LA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. RIOJA, LA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 RIOJA, LA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;94 RIOJA, LA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;49 RIOJA, LA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;45 RIOJA, LA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;993 RIOJA, LA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;486 RIOJA, LA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;507 RIOJA, LA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;14 RIOJA, LA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;10 RIOJA, LA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;4 RIOJA, LA;Group 2102 Contraceptive management V25;Both sexes;6 RIOJA, LA;Group 2102 Contraceptive management V25;Men;.. RIOJA, LA;Group 2102 Contraceptive management V25;Women;6 RIOJA, LA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. RIOJA, LA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. RIOJA, LA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. RIOJA, LA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;165 RIOJA, LA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;89 RIOJA, LA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;76 RIOJA, LA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;808 RIOJA, LA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;387 RIOJA, LA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;421 Ceuta;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;6.769 Ceuta;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;2.423 Ceuta;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;4.346 Ceuta;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;168 Ceuta;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;92 Ceuta;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;76 Ceuta;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;56 Ceuta;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;33 Ceuta;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;23 Ceuta;Group 0102 Imprecise intestinal infections 009;Both sexes;7 Ceuta;Group 0102 Imprecise intestinal infections 009;Men;3 Ceuta;Group 0102 Imprecise intestinal infections 009;Women;4 Ceuta;Group 0103 Tuberculosis 010-018, 137;Both sexes;19 Ceuta;Group 0103 Tuberculosis 010-018, 137;Men;14 Ceuta;Group 0103 Tuberculosis 010-018, 137;Women;5 Ceuta;Group 0104 Septicaemia 038;Both sexes;31 Ceuta;Group 0104 Septicaemia 038;Men;14 Ceuta;Group 0104 Septicaemia 038;Women;17 Ceuta;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;3 Ceuta;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;3 Ceuta;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;.. Ceuta;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;52 Ceuta;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;25 Ceuta;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;27 Ceuta;Group 0200 Neoplasms 140-239;Both sexes;345 Ceuta;Group 0200 Neoplasms 140-239;Men;145 Ceuta;Group 0200 Neoplasms 140-239;Women;200 Ceuta;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;46 Ceuta;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;21 Ceuta;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;25 Ceuta;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;38 Ceuta;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;31 Ceuta;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;7 Ceuta;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;2 Ceuta;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;2 Ceuta;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;.. Ceuta;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;34 Ceuta;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Ceuta;Group 0204 Malignant neoplasm of breast 174-175;Women;34 Ceuta;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;15 Ceuta;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Ceuta;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;15 Ceuta;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;7 Ceuta;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Ceuta;Group 0206 Malignant neoplasm of ovary 1830;Women;7 Ceuta;Group 0207 Malignant neoplasm of prostate 185;Both sexes;10 Ceuta;Group 0207 Malignant neoplasm of prostate 185;Men;10 Ceuta;Group 0207 Malignant neoplasm of prostate 185;Women;.. Ceuta;Group 0208 Malignant neoplasm of bladder 188;Both sexes;9 Ceuta;Group 0208 Malignant neoplasm of bladder 188;Men;6 Ceuta;Group 0208 Malignant neoplasm of bladder 188;Women;3 Ceuta;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;70 Ceuta;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;37 Ceuta;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;33 Ceuta;Group 0210 Carcinoma in situ 230-234;Both sexes;3 Ceuta;Group 0210 Carcinoma in situ 230-234;Men;1 Ceuta;Group 0210 Carcinoma in situ 230-234;Women;2 Ceuta;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;2 Ceuta;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;2 Ceuta;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;.. Ceuta;Grupo 0212 Leiomyoma of uterus 218;Both sexes;33 Ceuta;Grupo 0212 Leiomyoma of uterus 218;Men;.. Ceuta;Grupo 0212 Leiomyoma of uterus 218;Women;33 Ceuta;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;76 Ceuta;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;35 Ceuta;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;41 Ceuta;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;48 Ceuta;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;28 Ceuta;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;20 Ceuta;Group 0301 Anaemias 280-285;Both sexes;22 Ceuta;Group 0301 Anaemias 280-285;Men;13 Ceuta;Group 0301 Anaemias 280-285;Women;9 Ceuta;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;26 Ceuta;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;15 Ceuta;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;11 Ceuta;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;147 Ceuta;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;67 Ceuta;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;80 Ceuta;Group 0401 Diabetes mellitus 249-250;Both sexes;79 Ceuta;Group 0401 Diabetes mellitus 249-250;Men;47 Ceuta;Group 0401 Diabetes mellitus 249-250;Women;32 Ceuta;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;68 Ceuta;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;20 Ceuta;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;48 Ceuta;Group 0500 Mental disorders 290-319;Both sexes;116 Ceuta;Group 0500 Mental disorders 290-319;Men;63 Ceuta;Group 0500 Mental disorders 290-319;Women;53 Ceuta;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;1 Ceuta;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;.. Ceuta;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;1 Ceuta;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;4 Ceuta;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;4 Ceuta;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;.. Ceuta;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;3 Ceuta;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;3 Ceuta;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;.. Ceuta;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;34 Ceuta;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;23 Ceuta;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;11 Ceuta;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;26 Ceuta;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;14 Ceuta;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;12 Ceuta;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;48 Ceuta;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;19 Ceuta;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;29 Ceuta;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;173 Ceuta;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;77 Ceuta;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;96 Ceuta;Group 0601 Alzheimer's disease 3310;Both sexes;1 Ceuta;Group 0601 Alzheimer's disease 3310;Men;1 Ceuta;Group 0601 Alzheimer's disease 3310;Women;.. Ceuta;Group 0602 Multiple sclerosis 340;Both sexes;10 Ceuta;Group 0602 Multiple sclerosis 340;Men;5 Ceuta;Group 0602 Multiple sclerosis 340;Women;5 Ceuta;Group 0603 Epilepsy 345;Both sexes;44 Ceuta;Group 0603 Epilepsy 345;Men;26 Ceuta;Group 0603 Epilepsy 345;Women;18 Ceuta;Group 0604 Transient cerebral ischemia 435;Both sexes;27 Ceuta;Group 0604 Transient cerebral ischemia 435;Men;14 Ceuta;Group 0604 Transient cerebral ischemia 435;Women;13 Ceuta;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;91 Ceuta;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;31 Ceuta;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;60 Ceuta;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;81 Ceuta;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;38 Ceuta;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;43 Ceuta;Grupo 0701 Cataract 366;Both sexes;8 Ceuta;Grupo 0701 Cataract 366;Men;5 Ceuta;Grupo 0701 Cataract 366;Women;3 Ceuta;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;73 Ceuta;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;33 Ceuta;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;40 Ceuta;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;27 Ceuta;Group 0800 Diseases of the ear and the mastoid 380-389;Men;10 Ceuta;Group 0800 Diseases of the ear and the mastoid 380-389;Women;17 Ceuta;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;660 Ceuta;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;335 Ceuta;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;325 Ceuta;Group 0901 Hypertensive disease 401-405;Both sexes;55 Ceuta;Group 0901 Hypertensive disease 401-405;Men;21 Ceuta;Group 0901 Hypertensive disease 401-405;Women;34 Ceuta;Group 0902 Angina pectoris 4111, 413;Both sexes;69 Ceuta;Group 0902 Angina pectoris 4111, 413;Men;35 Ceuta;Group 0902 Angina pectoris 4111, 413;Women;34 Ceuta;Group 0903 Acute myocardial infarction 410;Both sexes;75 Ceuta;Group 0903 Acute myocardial infarction 410;Men;56 Ceuta;Group 0903 Acute myocardial infarction 410;Women;19 Ceuta;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;5 Ceuta;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;2 Ceuta;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;3 Ceuta;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;19 Ceuta;Group 0905 Diseases of the lungs circulation 415-417;Men;10 Ceuta;Group 0905 Diseases of the lungs circulation 415-417;Women;9 Ceuta;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;69 Ceuta;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;32 Ceuta;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;37 Ceuta;Grupo 0907 Heart failure 428;Both sexes;139 Ceuta;Grupo 0907 Heart failure 428;Men;64 Ceuta;Grupo 0907 Heart failure 428;Women;75 Ceuta;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;137 Ceuta;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;64 Ceuta;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;73 Ceuta;Grupo 0909 Atherosclerosis 440;Both sexes;3 Ceuta;Grupo 0909 Atherosclerosis 440;Men;2 Ceuta;Grupo 0909 Atherosclerosis 440;Women;1 Ceuta;Group 0910 Varicose veins of lower extremities 454;Both sexes;7 Ceuta;Group 0910 Varicose veins of lower extremities 454;Men;3 Ceuta;Group 0910 Varicose veins of lower extremities 454;Women;4 Ceuta;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;82 Ceuta;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;46 Ceuta;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;36 Ceuta;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;604 Ceuta;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;338 Ceuta;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;266 Ceuta;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;62 Ceuta;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;29 Ceuta;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;33 Ceuta;Group 1002 Pneumonia 480-486;Both sexes;177 Ceuta;Group 1002 Pneumonia 480-486;Men;89 Ceuta;Group 1002 Pneumonia 480-486;Women;88 Ceuta;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;66 Ceuta;Group 1003 Acute bronchitis and bronchiolitis 466;Men;31 Ceuta;Group 1003 Acute bronchitis and bronchiolitis 466;Women;35 Ceuta;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;7 Ceuta;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;4 Ceuta;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;3 Ceuta;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;34 Ceuta;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;21 Ceuta;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;13 Ceuta;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;84 Ceuta;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;68 Ceuta;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;16 Ceuta;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;7 Ceuta;Group 1007 Asthma 4930-4931,4938-4939;Men;4 Ceuta;Group 1007 Asthma 4930-4931,4938-4939;Women;3 Ceuta;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;167 Ceuta;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;92 Ceuta;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;75 Ceuta;Group 1100 Diseases of the digestive system 520-579;Both sexes;709 Ceuta;Group 1100 Diseases of the digestive system 520-579;Men;356 Ceuta;Group 1100 Diseases of the digestive system 520-579;Women;353 Ceuta;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;3 Ceuta;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;1 Ceuta;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;2 Ceuta;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;2 Ceuta;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;1 Ceuta;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;1 Ceuta;Group 1103 Diseases of the esophagus 530;Both sexes;3 Ceuta;Group 1103 Diseases of the esophagus 530;Men;2 Ceuta;Group 1103 Diseases of the esophagus 530;Women;1 Ceuta;Group 1104 Peptic ulcer 531-534;Both sexes;13 Ceuta;Group 1104 Peptic ulcer 531-534;Men;9 Ceuta;Group 1104 Peptic ulcer 531-534;Women;4 Ceuta;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;17 Ceuta;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;9 Ceuta;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;8 Ceuta;Group 1106 Appendicitis 540-543;Both sexes;91 Ceuta;Group 1106 Appendicitis 540-543;Men;54 Ceuta;Group 1106 Appendicitis 540-543;Women;37 Ceuta;Group 1107 Inguinal hernia 550;Both sexes;16 Ceuta;Group 1107 Inguinal hernia 550;Men;15 Ceuta;Group 1107 Inguinal hernia 550;Women;1 Ceuta;Group 1108 Other abdominal hernia 551-553;Both sexes;67 Ceuta;Group 1108 Other abdominal hernia 551-553;Men;19 Ceuta;Group 1108 Other abdominal hernia 551-553;Women;48 Ceuta;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;13 Ceuta;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;7 Ceuta;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;6 Ceuta;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;87 Ceuta;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;43 Ceuta;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;44 Ceuta;Group 1111 Intestinal obstruction without hernia 560;Both sexes;32 Ceuta;Group 1111 Intestinal obstruction without hernia 560;Men;15 Ceuta;Group 1111 Intestinal obstruction without hernia 560;Women;17 Ceuta;Group 1112 Intestinal diverticulosis 562;Both sexes;21 Ceuta;Group 1112 Intestinal diverticulosis 562;Men;10 Ceuta;Group 1112 Intestinal diverticulosis 562;Women;11 Ceuta;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;45 Ceuta;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;29 Ceuta;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;16 Ceuta;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;21 Ceuta;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;5 Ceuta;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;16 Ceuta;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;22 Ceuta;Group 1115 Alcoholic hepatitis 5710-5713;Men;21 Ceuta;Group 1115 Alcoholic hepatitis 5710-5713;Women;1 Ceuta;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;30 Ceuta;Group 1116 Other diseases of the liver 570,5714-573;Men;16 Ceuta;Group 1116 Other diseases of the liver 570,5714-573;Women;14 Ceuta;Group 1117 Cholelithiasis 574;Both sexes;132 Ceuta;Group 1117 Cholelithiasis 574;Men;51 Ceuta;Group 1117 Cholelithiasis 574;Women;81 Ceuta;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;34 Ceuta;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;14 Ceuta;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;20 Ceuta;Group 1119 Pancreatic diseases 577;Both sexes;37 Ceuta;Group 1119 Pancreatic diseases 577;Men;18 Ceuta;Group 1119 Pancreatic diseases 577;Women;19 Ceuta;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;23 Ceuta;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;17 Ceuta;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;6 Ceuta;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;78 Ceuta;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;30 Ceuta;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;48 Ceuta;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;54 Ceuta;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;21 Ceuta;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;33 Ceuta;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;3 Ceuta;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;1 Ceuta;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;2 Ceuta;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;21 Ceuta;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;8 Ceuta;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;13 Ceuta;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;161 Ceuta;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;73 Ceuta;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;88 Ceuta;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Ceuta;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Ceuta;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Ceuta;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Ceuta;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Ceuta;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Ceuta;Group 1303 Internal derangement of knee 717;Both sexes;7 Ceuta;Group 1303 Internal derangement of knee 717;Men;5 Ceuta;Group 1303 Internal derangement of knee 717;Women;2 Ceuta;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;50 Ceuta;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;26 Ceuta;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;24 Ceuta;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;7 Ceuta;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;5 Ceuta;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;2 Ceuta;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;4 Ceuta;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;3 Ceuta;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1 Ceuta;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;19 Ceuta;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;6 Ceuta;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;13 Ceuta;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;6 Ceuta;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;1 Ceuta;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;5 Ceuta;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;34 Ceuta;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;14 Ceuta;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;20 Ceuta;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;34 Ceuta;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;13 Ceuta;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;21 Ceuta;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;334 Ceuta;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;142 Ceuta;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;192 Ceuta;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;22 Ceuta;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;8 Ceuta;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;14 Ceuta;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;25 Ceuta;Group 1402 Renal failure 5836-5837, 584-586;Men;12 Ceuta;Group 1402 Renal failure 5836-5837, 584-586;Women;13 Ceuta;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;46 Ceuta;Group 1403 Urolithiasis 592, 594, 7880;Men;28 Ceuta;Group 1403 Urolithiasis 592, 594, 7880;Women;18 Ceuta;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;83 Ceuta;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;40 Ceuta;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;43 Ceuta;Group 1405 Prostatic hyperplasia 600;Both sexes;35 Ceuta;Group 1405 Prostatic hyperplasia 600;Men;35 Ceuta;Group 1405 Prostatic hyperplasia 600;Women;.. Ceuta;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;19 Ceuta;Group 1406 Other diseases of the male genital organs 601-608;Men;19 Ceuta;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Ceuta;Group 1407 Disorders of breast 610-612;Both sexes;8 Ceuta;Group 1407 Disorders of breast 610-612;Men;.. Ceuta;Group 1407 Disorders of breast 610-612;Women;8 Ceuta;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;18 Ceuta;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Ceuta;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;18 Ceuta;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;21 Ceuta;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Ceuta;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;21 Ceuta;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;57 Ceuta;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Ceuta;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;57 Ceuta;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.980 Ceuta;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Ceuta;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.980 Ceuta;Group 1501 Legally induced abortion 635;Both sexes;1 Ceuta;Group 1501 Legally induced abortion 635;Men;.. Ceuta;Group 1501 Legally induced abortion 635;Women;1 Ceuta;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;191 Ceuta;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Ceuta;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;191 Ceuta;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.252 Ceuta;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Ceuta;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.252 Ceuta;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;297 Ceuta;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Ceuta;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;297 Ceuta;Group 1505 Single spontaneous delivery 650;Both sexes;91 Ceuta;Group 1505 Single spontaneous delivery 650;Men;.. Ceuta;Group 1505 Single spontaneous delivery 650;Women;91 Ceuta;Group 1506 Other deliveries 6695-6697;Both sexes;12 Ceuta;Group 1506 Other deliveries 6695-6697;Men;.. Ceuta;Group 1506 Other deliveries 6695-6697;Women;12 Ceuta;Group 1507 Complications related to the puerperium 670-676;Both sexes;25 Ceuta;Group 1507 Complications related to the puerperium 670-676;Men;.. Ceuta;Group 1507 Complications related to the puerperium 670-676;Women;25 Ceuta;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;111 Ceuta;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Ceuta;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;111 Ceuta;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;150 Ceuta;Group 1600 Some disorders originating in the perinatal period 760-779;Men;80 Ceuta;Group 1600 Some disorders originating in the perinatal period 760-779;Women;70 Ceuta;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;45 Ceuta;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;21 Ceuta;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;24 Ceuta;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;105 Ceuta;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;59 Ceuta;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;46 Ceuta;Grupo 1700 Congenital abnormalities 740-759;Both sexes;30 Ceuta;Grupo 1700 Congenital abnormalities 740-759;Men;20 Ceuta;Grupo 1700 Congenital abnormalities 740-759;Women;10 Ceuta;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;399 Ceuta;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;206 Ceuta;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;193 Ceuta;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;32 Ceuta;Group 1801 Pain in throat and chest 7841, 7865;Men;21 Ceuta;Group 1801 Pain in throat and chest 7841, 7865;Women;11 Ceuta;Group 1802 Abdominal pain 7890;Both sexes;34 Ceuta;Group 1802 Abdominal pain 7890;Men;11 Ceuta;Group 1802 Abdominal pain 7890;Women;23 Ceuta;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;3 Ceuta;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1 Ceuta;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;2 Ceuta;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;330 Ceuta;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;173 Ceuta;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;157 Ceuta;Group 1900 Injuries and poisoning 800-999;Both sexes;437 Ceuta;Group 1900 Injuries and poisoning 800-999;Men;254 Ceuta;Group 1900 Injuries and poisoning 800-999;Women;183 Ceuta;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;21 Ceuta;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;16 Ceuta;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;5 Ceuta;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;24 Ceuta;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;18 Ceuta;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;6 Ceuta;Group 1903 Radius and ulna fracture 813;Both sexes;35 Ceuta;Group 1903 Radius and ulna fracture 813;Men;21 Ceuta;Group 1903 Radius and ulna fracture 813;Women;14 Ceuta;Group 1904 Femur fracture 820-821;Both sexes;63 Ceuta;Group 1904 Femur fracture 820-821;Men;20 Ceuta;Group 1904 Femur fracture 820-821;Women;43 Ceuta;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;33 Ceuta;Group 1905 Leg fracture, including the ankle 823-824;Men;18 Ceuta;Group 1905 Leg fracture, including the ankle 823-824;Women;15 Ceuta;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;130 Ceuta;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;94 Ceuta;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;36 Ceuta;Group 1907 Burns 940-949;Both sexes;4 Ceuta;Group 1907 Burns 940-949;Men;3 Ceuta;Group 1907 Burns 940-949;Women;1 Ceuta;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;22 Ceuta;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;10 Ceuta;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;12 Ceuta;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;85 Ceuta;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;41 Ceuta;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;44 Ceuta;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;1 Ceuta;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;1 Ceuta;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Ceuta;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;19 Ceuta;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;12 Ceuta;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;7 Ceuta;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;122 Ceuta;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;69 Ceuta;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;53 Ceuta;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;1 Ceuta;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;1 Ceuta;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;.. Ceuta;Group 2102 Contraceptive management V25;Both sexes;.. Ceuta;Group 2102 Contraceptive management V25;Men;.. Ceuta;Group 2102 Contraceptive management V25;Women;.. Ceuta;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Ceuta;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Ceuta;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Ceuta;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;80 Ceuta;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;38 Ceuta;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;42 Ceuta;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;41 Ceuta;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;30 Ceuta;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;11 Melilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;7.213 Melilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;2.053 Melilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;5.160 Melilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;149 Melilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;92 Melilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;57 Melilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;45 Melilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;32 Melilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;13 Melilla;Group 0102 Imprecise intestinal infections 009;Both sexes;1 Melilla;Group 0102 Imprecise intestinal infections 009;Men;.. Melilla;Group 0102 Imprecise intestinal infections 009;Women;1 Melilla;Group 0103 Tuberculosis 010-018, 137;Both sexes;22 Melilla;Group 0103 Tuberculosis 010-018, 137;Men;13 Melilla;Group 0103 Tuberculosis 010-018, 137;Women;9 Melilla;Group 0104 Septicaemia 038;Both sexes;7 Melilla;Group 0104 Septicaemia 038;Men;3 Melilla;Group 0104 Septicaemia 038;Women;4 Melilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;10 Melilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;9 Melilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Melilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;64 Melilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;35 Melilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;29 Melilla;Group 0200 Neoplasms 140-239;Both sexes;324 Melilla;Group 0200 Neoplasms 140-239;Men;146 Melilla;Group 0200 Neoplasms 140-239;Women;178 Melilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;34 Melilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;20 Melilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;14 Melilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;23 Melilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;22 Melilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;1 Melilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;3 Melilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;2 Melilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;1 Melilla;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;28 Melilla;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Melilla;Group 0204 Malignant neoplasm of breast 174-175;Women;28 Melilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;9 Melilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Melilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;9 Melilla;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;2 Melilla;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Melilla;Group 0206 Malignant neoplasm of ovary 1830;Women;2 Melilla;Group 0207 Malignant neoplasm of prostate 185;Both sexes;8 Melilla;Group 0207 Malignant neoplasm of prostate 185;Men;8 Melilla;Group 0207 Malignant neoplasm of prostate 185;Women;.. Melilla;Group 0208 Malignant neoplasm of bladder 188;Both sexes;34 Melilla;Group 0208 Malignant neoplasm of bladder 188;Men;24 Melilla;Group 0208 Malignant neoplasm of bladder 188;Women;10 Melilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;89 Melilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;51 Melilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;38 Melilla;Group 0210 Carcinoma in situ 230-234;Both sexes;7 Melilla;Group 0210 Carcinoma in situ 230-234;Men;.. Melilla;Group 0210 Carcinoma in situ 230-234;Women;7 Melilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;10 Melilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;7 Melilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;3 Melilla;Grupo 0212 Leiomyoma of uterus 218;Both sexes;23 Melilla;Grupo 0212 Leiomyoma of uterus 218;Men;.. Melilla;Grupo 0212 Leiomyoma of uterus 218;Women;23 Melilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;54 Melilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;12 Melilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;42 Melilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;52 Melilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;17 Melilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;35 Melilla;Group 0301 Anaemias 280-285;Both sexes;20 Melilla;Group 0301 Anaemias 280-285;Men;7 Melilla;Group 0301 Anaemias 280-285;Women;13 Melilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;32 Melilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;10 Melilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;22 Melilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;149 Melilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;76 Melilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;73 Melilla;Group 0401 Diabetes mellitus 249-250;Both sexes;71 Melilla;Group 0401 Diabetes mellitus 249-250;Men;42 Melilla;Group 0401 Diabetes mellitus 249-250;Women;29 Melilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;78 Melilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;34 Melilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;44 Melilla;Group 0500 Mental disorders 290-319;Both sexes;125 Melilla;Group 0500 Mental disorders 290-319;Men;97 Melilla;Group 0500 Mental disorders 290-319;Women;28 Melilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;.. Melilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;.. Melilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;.. Melilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;8 Melilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;7 Melilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;1 Melilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;29 Melilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;28 Melilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;1 Melilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;30 Melilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;26 Melilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;4 Melilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;24 Melilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;14 Melilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;10 Melilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;34 Melilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;22 Melilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;12 Melilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;74 Melilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;39 Melilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;35 Melilla;Group 0601 Alzheimer's disease 3310;Both sexes;3 Melilla;Group 0601 Alzheimer's disease 3310;Men;2 Melilla;Group 0601 Alzheimer's disease 3310;Women;1 Melilla;Group 0602 Multiple sclerosis 340;Both sexes;4 Melilla;Group 0602 Multiple sclerosis 340;Men;1 Melilla;Group 0602 Multiple sclerosis 340;Women;3 Melilla;Group 0603 Epilepsy 345;Both sexes;22 Melilla;Group 0603 Epilepsy 345;Men;12 Melilla;Group 0603 Epilepsy 345;Women;10 Melilla;Group 0604 Transient cerebral ischemia 435;Both sexes;11 Melilla;Group 0604 Transient cerebral ischemia 435;Men;6 Melilla;Group 0604 Transient cerebral ischemia 435;Women;5 Melilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;34 Melilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;18 Melilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;16 Melilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;25 Melilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;10 Melilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;15 Melilla;Grupo 0701 Cataract 366;Both sexes;3 Melilla;Grupo 0701 Cataract 366;Men;.. Melilla;Grupo 0701 Cataract 366;Women;3 Melilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;22 Melilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;10 Melilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;12 Melilla;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;7 Melilla;Group 0800 Diseases of the ear and the mastoid 380-389;Men;5 Melilla;Group 0800 Diseases of the ear and the mastoid 380-389;Women;2 Melilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;573 Melilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;325 Melilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;248 Melilla;Group 0901 Hypertensive disease 401-405;Both sexes;9 Melilla;Group 0901 Hypertensive disease 401-405;Men;5 Melilla;Group 0901 Hypertensive disease 401-405;Women;4 Melilla;Group 0902 Angina pectoris 4111, 413;Both sexes;78 Melilla;Group 0902 Angina pectoris 4111, 413;Men;39 Melilla;Group 0902 Angina pectoris 4111, 413;Women;39 Melilla;Group 0903 Acute myocardial infarction 410;Both sexes;83 Melilla;Group 0903 Acute myocardial infarction 410;Men;52 Melilla;Group 0903 Acute myocardial infarction 410;Women;31 Melilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;16 Melilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;12 Melilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;4 Melilla;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;8 Melilla;Group 0905 Diseases of the lungs circulation 415-417;Men;4 Melilla;Group 0905 Diseases of the lungs circulation 415-417;Women;4 Melilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;48 Melilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;31 Melilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;17 Melilla;Grupo 0907 Heart failure 428;Both sexes;149 Melilla;Grupo 0907 Heart failure 428;Men;75 Melilla;Grupo 0907 Heart failure 428;Women;74 Melilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;113 Melilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;62 Melilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;51 Melilla;Grupo 0909 Atherosclerosis 440;Both sexes;3 Melilla;Grupo 0909 Atherosclerosis 440;Men;3 Melilla;Grupo 0909 Atherosclerosis 440;Women;.. Melilla;Group 0910 Varicose veins of lower extremities 454;Both sexes;6 Melilla;Group 0910 Varicose veins of lower extremities 454;Men;3 Melilla;Group 0910 Varicose veins of lower extremities 454;Women;3 Melilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;60 Melilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;39 Melilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;21 Melilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;490 Melilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;269 Melilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;221 Melilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;14 Melilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;7 Melilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;7 Melilla;Group 1002 Pneumonia 480-486;Both sexes;146 Melilla;Group 1002 Pneumonia 480-486;Men;85 Melilla;Group 1002 Pneumonia 480-486;Women;61 Melilla;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;80 Melilla;Group 1003 Acute bronchitis and bronchiolitis 466;Men;39 Melilla;Group 1003 Acute bronchitis and bronchiolitis 466;Women;41 Melilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1 Melilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;.. Melilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1 Melilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;11 Melilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;7 Melilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;4 Melilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;42 Melilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;30 Melilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;12 Melilla;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;22 Melilla;Group 1007 Asthma 4930-4931,4938-4939;Men;10 Melilla;Group 1007 Asthma 4930-4931,4938-4939;Women;12 Melilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;174 Melilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;91 Melilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;83 Melilla;Group 1100 Diseases of the digestive system 520-579;Both sexes;676 Melilla;Group 1100 Diseases of the digestive system 520-579;Men;325 Melilla;Group 1100 Diseases of the digestive system 520-579;Women;351 Melilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;5 Melilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;4 Melilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;1 Melilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;1 Melilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;1 Melilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;.. Melilla;Group 1103 Diseases of the esophagus 530;Both sexes;7 Melilla;Group 1103 Diseases of the esophagus 530;Men;4 Melilla;Group 1103 Diseases of the esophagus 530;Women;3 Melilla;Group 1104 Peptic ulcer 531-534;Both sexes;18 Melilla;Group 1104 Peptic ulcer 531-534;Men;15 Melilla;Group 1104 Peptic ulcer 531-534;Women;3 Melilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;13 Melilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;5 Melilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;8 Melilla;Group 1106 Appendicitis 540-543;Both sexes;85 Melilla;Group 1106 Appendicitis 540-543;Men;47 Melilla;Group 1106 Appendicitis 540-543;Women;38 Melilla;Group 1107 Inguinal hernia 550;Both sexes;53 Melilla;Group 1107 Inguinal hernia 550;Men;43 Melilla;Group 1107 Inguinal hernia 550;Women;10 Melilla;Group 1108 Other abdominal hernia 551-553;Both sexes;55 Melilla;Group 1108 Other abdominal hernia 551-553;Men;22 Melilla;Group 1108 Other abdominal hernia 551-553;Women;33 Melilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;11 Melilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;4 Melilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;7 Melilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;60 Melilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;32 Melilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;28 Melilla;Group 1111 Intestinal obstruction without hernia 560;Both sexes;26 Melilla;Group 1111 Intestinal obstruction without hernia 560;Men;8 Melilla;Group 1111 Intestinal obstruction without hernia 560;Women;18 Melilla;Group 1112 Intestinal diverticulosis 562;Both sexes;10 Melilla;Group 1112 Intestinal diverticulosis 562;Men;5 Melilla;Group 1112 Intestinal diverticulosis 562;Women;5 Melilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;38 Melilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;22 Melilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;16 Melilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;12 Melilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;7 Melilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;5 Melilla;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;9 Melilla;Group 1115 Alcoholic hepatitis 5710-5713;Men;7 Melilla;Group 1115 Alcoholic hepatitis 5710-5713;Women;2 Melilla;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;31 Melilla;Group 1116 Other diseases of the liver 570,5714-573;Men;18 Melilla;Group 1116 Other diseases of the liver 570,5714-573;Women;13 Melilla;Group 1117 Cholelithiasis 574;Both sexes;134 Melilla;Group 1117 Cholelithiasis 574;Men;35 Melilla;Group 1117 Cholelithiasis 574;Women;99 Melilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;29 Melilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;16 Melilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;13 Melilla;Group 1119 Pancreatic diseases 577;Both sexes;50 Melilla;Group 1119 Pancreatic diseases 577;Men;15 Melilla;Group 1119 Pancreatic diseases 577;Women;35 Melilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;29 Melilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;15 Melilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;14 Melilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;41 Melilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;28 Melilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;13 Melilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;34 Melilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;24 Melilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;10 Melilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;.. Melilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;.. Melilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;.. Melilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;7 Melilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;4 Melilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;3 Melilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;94 Melilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;36 Melilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;58 Melilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Melilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Melilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Melilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Melilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Melilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Melilla;Group 1303 Internal derangement of knee 717;Both sexes;5 Melilla;Group 1303 Internal derangement of knee 717;Men;5 Melilla;Group 1303 Internal derangement of knee 717;Women;.. Melilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;36 Melilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;12 Melilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;24 Melilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;4 Melilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;1 Melilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;3 Melilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;10 Melilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;4 Melilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;6 Melilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;11 Melilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;2 Melilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;9 Melilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;1 Melilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;.. Melilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;1 Melilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;8 Melilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;5 Melilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;3 Melilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;19 Melilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;7 Melilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;12 Melilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;374 Melilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;151 Melilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;223 Melilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;27 Melilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;8 Melilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;19 Melilla;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;36 Melilla;Group 1402 Renal failure 5836-5837, 584-586;Men;20 Melilla;Group 1402 Renal failure 5836-5837, 584-586;Women;16 Melilla;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;44 Melilla;Group 1403 Urolithiasis 592, 594, 7880;Men;28 Melilla;Group 1403 Urolithiasis 592, 594, 7880;Women;16 Melilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;104 Melilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;52 Melilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;52 Melilla;Group 1405 Prostatic hyperplasia 600;Both sexes;24 Melilla;Group 1405 Prostatic hyperplasia 600;Men;24 Melilla;Group 1405 Prostatic hyperplasia 600;Women;.. Melilla;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;11 Melilla;Group 1406 Other diseases of the male genital organs 601-608;Men;11 Melilla;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Melilla;Group 1407 Disorders of breast 610-612;Both sexes;13 Melilla;Group 1407 Disorders of breast 610-612;Men;5 Melilla;Group 1407 Disorders of breast 610-612;Women;8 Melilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;9 Melilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Melilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;9 Melilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;36 Melilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Melilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;36 Melilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;70 Melilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;3 Melilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;67 Melilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3.266 Melilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Melilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3.266 Melilla;Group 1501 Legally induced abortion 635;Both sexes;2 Melilla;Group 1501 Legally induced abortion 635;Men;.. Melilla;Group 1501 Legally induced abortion 635;Women;2 Melilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;217 Melilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Melilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;217 Melilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.533 Melilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Melilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.533 Melilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;823 Melilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Melilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;823 Melilla;Group 1505 Single spontaneous delivery 650;Both sexes;246 Melilla;Group 1505 Single spontaneous delivery 650;Men;.. Melilla;Group 1505 Single spontaneous delivery 650;Women;246 Melilla;Group 1506 Other deliveries 6695-6697;Both sexes;24 Melilla;Group 1506 Other deliveries 6695-6697;Men;.. Melilla;Group 1506 Other deliveries 6695-6697;Women;24 Melilla;Group 1507 Complications related to the puerperium 670-676;Both sexes;10 Melilla;Group 1507 Complications related to the puerperium 670-676;Men;.. Melilla;Group 1507 Complications related to the puerperium 670-676;Women;10 Melilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;411 Melilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Melilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;411 Melilla;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;216 Melilla;Group 1600 Some disorders originating in the perinatal period 760-779;Men;117 Melilla;Group 1600 Some disorders originating in the perinatal period 760-779;Women;99 Melilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;61 Melilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;30 Melilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;31 Melilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;155 Melilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;87 Melilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;68 Melilla;Grupo 1700 Congenital abnormalities 740-759;Both sexes;49 Melilla;Grupo 1700 Congenital abnormalities 740-759;Men;28 Melilla;Grupo 1700 Congenital abnormalities 740-759;Women;21 Melilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;134 Melilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;66 Melilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;68 Melilla;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;2 Melilla;Group 1801 Pain in throat and chest 7841, 7865;Men;2 Melilla;Group 1801 Pain in throat and chest 7841, 7865;Women;.. Melilla;Group 1802 Abdominal pain 7890;Both sexes;22 Melilla;Group 1802 Abdominal pain 7890;Men;9 Melilla;Group 1802 Abdominal pain 7890;Women;13 Melilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;4 Melilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;3 Melilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;1 Melilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;106 Melilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;52 Melilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;54 Melilla;Group 1900 Injuries and poisoning 800-999;Both sexes;366 Melilla;Group 1900 Injuries and poisoning 800-999;Men;219 Melilla;Group 1900 Injuries and poisoning 800-999;Women;147 Melilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;21 Melilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;13 Melilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;8 Melilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;18 Melilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;15 Melilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;3 Melilla;Group 1903 Radius and ulna fracture 813;Both sexes;20 Melilla;Group 1903 Radius and ulna fracture 813;Men;14 Melilla;Group 1903 Radius and ulna fracture 813;Women;6 Melilla;Group 1904 Femur fracture 820-821;Both sexes;74 Melilla;Group 1904 Femur fracture 820-821;Men;27 Melilla;Group 1904 Femur fracture 820-821;Women;47 Melilla;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;47 Melilla;Group 1905 Leg fracture, including the ankle 823-824;Men;31 Melilla;Group 1905 Leg fracture, including the ankle 823-824;Women;16 Melilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;98 Melilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;71 Melilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;27 Melilla;Group 1907 Burns 940-949;Both sexes;16 Melilla;Group 1907 Burns 940-949;Men;13 Melilla;Group 1907 Burns 940-949;Women;3 Melilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;7 Melilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;1 Melilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;6 Melilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;56 Melilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;28 Melilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;28 Melilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Melilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Melilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Melilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;9 Melilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;6 Melilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;3 Melilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;29 Melilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;7 Melilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;22 Melilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;3 Melilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;.. Melilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;3 Melilla;Group 2102 Contraceptive management V25;Both sexes;9 Melilla;Group 2102 Contraceptive management V25;Men;.. Melilla;Group 2102 Contraceptive management V25;Women;9 Melilla;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Melilla;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Melilla;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Melilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;6 Melilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;2 Melilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;4 Melilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;11 Melilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;5 Melilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;6